CONTENTS

CROI FOUNDATION ................................................................. 2
IAS–USA ................................................................................. 2
CROI 2017 PROGRAM COMMITTEE ........................................... 3
  Scientific Program Committee ............................................. 3
  Community Liaison Subcommittee .................................... 5
EXTERNAL REVIEWERS ................................................................ 6
SCHOLARSHIP AWARDEES ...................................................... 8
  Young Investigator Awardees ............................................. 8
  International Investigator Awardees ................................... 13
  Community Educator Awardees ........................................... 13
CONTINUING MEDICAL EDUCATION ......................................... 15
GENERAL INFORMATION ........................................................... 17
  Overview ........................................................................ 17
  Americans With Disabilities Act ........................................ 17
  Commercial Support ........................................................ 17
  Emergency Services ........................................................ 17
  Embargo Policies and Social Media ................................... 18
  Welcome Reception .......................................................... 18
  Meals .............................................................................. 18
  Overflow Accommodations for Oral Sessions .................... 19
  USB Flash Drive .............................................................. 19
  Mobile App ..................................................................... 19
  Website ........................................................................... 19
  Webcasts ......................................................................... 20
  Affiliated Activities Policy ................................................. 20
  Wi-Fi Access at the Conference ....................................... 20
  Conference Badges ........................................................... 20
  Child Care ..................................................................... 21
  Conference Etiquette ......................................................... 21
CROI HOTELS .......................................................................... 21
CONFERENCE SERVICES ............................................................ 22
ABSTRACT PROCESS .............................................................. 26
ORAL SESSIONS (including Preconference Sessions) ............ 28
POSTER SESSIONS, BY DAY .................................................... 73
POSTER SESSIONS, BY CATEGORY .......................................... 212
DISCLOSURE OF FINANCIAL RELATIONSHIPS
WITH COMMERCIAL CONCERNS .......................................... 216
INDEX OF STUDIES RELATED TO RESEARCH IN WOMEN .......... 227
AUTHOR INDEX .................................................................... 232
CONFERENCE SCHEDULE OVERVIEW .................................... INSIDE BACK COVER
CONVENTION CENTER FLOOR PLANS ................................... BACK COVER
AREA MAP ........................................................................... BACK COVER

Printed in USA on acid-free paper
© Copyright 2017 CROI Foundation/IAS–USA. All rights reserved.
ISBN #978-0-692-83838-9
CROI FOUNDATION

The CROI Foundation operates exclusively for the charitable and educational purpose of organizing, promoting, and presenting the Conference on Retroviruses and Opportunistic Infections (CROI).

Roles and Responsibilities of the CROI Foundation Volunteer Board of Directors

- Works closely with the CROI Scientific Program Committee (CROI PC) and the CROI Secretariat to accomplish the mission of CROI
- Approves nominations for members of the CROI PC and the CROI PC Chair and Vice Chairs
- Ensures that the CROI PC is responsible for the scientific program content of CROI
- Enters into and oversees the partner agreement with the CROI Secretariat
- Has the sole and absolute discretion to veto any policies, procedures, or actions taken or proposed to be taken by the CROI PC or the CROI Secretariat that would pose a substantial risk of preventing the Foundation at any time from qualifying or continuing to qualify as a 501(c)(3) organization or that might cause the loss of such qualification
- Oversees the long-term financial and administrative integrity of CROI

CROI Foundation Board of Directors

Constance A. Benson, MD
President
University of California San Diego
San Diego, CA, United States

John M. Coffin, PhD
Secretary-Treasurer
Tufts University
Boston, MA, United States

Elaine J. Abrams, MD
ICAP at Columbia University
New York, NY, United States

Susan P. Buchbinder, MD
San Francisco Department of Public Health
San Francisco, CA, United States

Judith S. Currier, MD, MSc
University of California Los Angeles
Los Angeles, CA, United States

Kevin M. De Cock, MD
Centers for Disease Control and Prevention
Nairobi, Kenya

Scott M. Hammer, MD
Columbia University Medical Center/
New York–Presbyterian Hospital
New York, NY, United States

Richard A. Koup, MD
Vaccine Research Center, National Institute of Allergy and Infectious Diseases
Bethesda, MD, United States

John W. Mellors, MD
University of Pittsburgh
Pittsburgh, PA, United States

Julie M. Overbaugh, PhD
Fred Hutchinson Cancer Research Center
Seattle, WA, United States

Robert T. Schooley, MD
University of California San Diego
La Jolla, CA, United States

The International Antiviral Society–USA is a 501(c)(3) not-for-profit professional education organization. The IAS–USA partners with the CROI Foundation to organize CROI. The mission of the IAS–USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

Executive Director: Donna M. Jacobsen
Address: 425 California Street, Suite 1450
San Francisco, CA 94104-2120
Phone: 415-544-9400
Website: www.iasusa.org
The Scientific Program Committee (PC) is a team of experts in their given field who volunteer to organize the scientific program for CROI. Members are selected based on their area of scientific expertise and their commitment to the mission of the conference. Initial terms are up to 3 years; subsequent terms are based on previous participation and interest level. Members are nominated by the PC and approved by the CROI Foundation Board of Directors. The PC members are responsible for identifying topics and speakers that will ensure innovative programming; strategic planning; abstract review and program development; or organizing, conducting, or convening workshops, symposia, and special sessions.

Scientific Program Committee

Elaine J. Abrams, MD  
ICAP at Columbia University  
New York, NY, United States

Adaora Adimora, MD*  
University of North Carolina at Chapel Hill  
Chapel Hill, NC, United States

Galit Alter, PhD  
Ragon Institute of MGH, MIT and Harvard  
Cambridge, MA, United States

Constance A. Benson, MD  
University of California  
San Diego  
San Diego, CA, United States

Paul Bieniasz, PhD*  
The Rockefeller University  
New York, NY, United States

Connie L. Celum, MD, MPH*  
University of Washington  
Seattle, WA, United States

Richard E. Chaisson, MD  
The Johns Hopkins University  
Baltimore, MD, United States

Nicolas Chomont, PhD*  
Université de Montréal  
Montreal, Canada

John M. Coffin, PhD  
Tufts University  
Boston, MA, United States

Kevin M. De Cock, MD  
Centers for Disease Control and Prevention  
Nairobi, Kenya
Community Liaison Subcommittee

The Community Liaison Subcommittee is a group of community educators and advocates that provides feedback to the PC about the content and structure of the scientific program in general and specifically related to scientific topics of interest to the HIV/AIDS-affected community.

Mark Hubbard
Tennessee Association of People With AIDS
Nashville, TN, United States

Morenike Ukpong, FWACS, MBA, BChD
Obafemi Awolowo University
Ile-Ife, Nigeria

Jeff Taylor
Committee Lead
AIDS Treatment Activists Coalition
Palm Springs, CA
United States

Lisa Diane White, MPH*
SisterLove, Inc.
Atlanta, GA, United States

*Joined the Scientific Program Committee or Community Liaison Subcommittee in 2016

The CROI Foundation wishes to thank for their service the following individuals who rotated off the Scientific Program Committee in 2016: Bruce J. Brew, Ellen G. Chadwick, Mario Stevenson, and Amalio Telenti; and from the Community Liaison Subcommittee: Steven F. Wakefield.
EXTERNAL REVIEWERS

We gratefully acknowledge the contributions of the following, who served as volunteer external reviewers of abstracts for CROI 2017.

Edward P. Acosta, PharmD
University of Alabama at Birmingham
Birmingham, AL, United States

Peter L. Anderson, PharmD
University of Colorado
Aurora, CO, United States

Till Baernighausen, MD, PhD, ScD, MSc
Institute of Public Health,
Heidelberg University
Heidelberg, Germany

John M. Blandford, PhD
Centers for Disease Control and Prevention
Atlanta, GA, United States

Marta Boffito, MD, PhD
Chelsea and Westminster NHS Foundation Trust
London, United Kingdom

Jacob Bor, PhD
Boston University
Boston, MA, United States

William Borkowsky, MD
New York University
New York, NY, United States

Bruce J. Brew, MD, MBBS
University of New South Wales
Sydney, Australia

Todd T. Brown, MD, PhD
The Johns Hopkins University
Baltimore, MD, United States

Corey Casper, MD
Fred Hutchinson Cancer Research Center
Seattle, WA, United States

Ellen G. Chadwick, MD
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, IL, United States

David B. Clifford, MD
Washington University
St. Louis, MO, United States

David Evans, PhD
University of Wisconsin Madison
Madison, WI, United States

Charles W. Flexner, MD
The Johns Hopkins University
Baltimore, MD, United States

Patricia M. Flynn, MD
St. Jude Children’s Research Hospital
Memphis, TN, United States

Jennifer Furin, MD, PhD
Case Western Reserve University
Cleveland, OH, United States

Dana H. Gabuzda, MD
Dana Farber Cancer Institute,
Harvard Medical School
Boston, MA, United States

Monica Gandhi, MD, MPH
University of California San Francisco
San Francisco, CA, United States

Gerardo García-Lerma, PhD
Centers for Disease Control and Prevention
Atlanta, GA, United States

Carlo Giaquinto, MD
University of Padova
Padova, Italy

Beatrice H. Hahn, MD
University of Pennsylvania
Philadelphia, PA, United States

James G. Hakim, MD
University of Zimbabwe
Harare, Zimbabwe

P. Richard Harrigan, MD
British Columbia Centre for Excellence in HIV/AIDS
Vancouver, Canada

Priscilla Hsue, MD
University of California San Francisco
San Francisco, CA, United States

Angela Kashuba, PharmD
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States

Susan E. Krown, MD
AIDS Malignancy Consortium
New York, NY, United States

Raphael J. Landovitz, MD
University of California Los Angeles
Los Angeles, CA, United States

Bruno Ledergerber, PhD
University of Zurich
Zurich, Switzerland

Scott L. Letendre, MD
University of California San Diego
San Diego, CA, United States

Sharon R. Lewin, MD
University of Melbourne
Melbourne, Australia

Annie F. Luetkemeyer, MD
University of California San Francisco
San Francisco, CA, United States

Patrick W. G. Mallon, PhD, MBBS
University College Dublin
Dublin, Ireland
Natasha Martin, DPhil
University of California San Diego
San Diego, CA, United States

Grace A. McComsey, MD
Case Western Reserve University
Cleveland, OH, United States

Jonathan Mermin, MD, MPH
Centers for Disease Control and Prevention
Atlanta, GA, United States

Victor Musiime, PhD, MBChB
Makerere University College of Health Sciences
Kampala, Uganda

Susanna Naggie, MD, MHS
Duke University
Durham, NC, United States

Jean-Michel Pawlotsky, MD, PhD
Henri Mondor University Hospital
Creteil, France

Martina Penazzato, MD, PhD
World Health Organization
Geneva, Switzerland

Paul Revill, MSc
University of York
York, United Kingdom

Lesley Scott, MD
National Health Laboratory Service
Johannesburg, South Africa

Kenneth E. Sherman, MD
University of Cincinnati
Cincinnati, OH, United States

James H. Stein, MD
University of Wisconsin
Madison, WI, United States

Mario Stevenson, PhD
University of Miami
Miami, FL, United States

Amalio Telenti, MD, PhD
J. Craig Venter Institute
La Jolla, CA, United States

Timothy Wilkin, MD
Weill Cornell Medicine
New York, NY, United States

David L. Wyles, MD
Denver Health, University of Colorado
Denver, CO, United States

Robert Yarchoan, MD
National Cancer Institute
Bethesda, MD, United States

Clement Zeh, PhD, MPH
Centers for Disease Control and Prevention
Atlanta, GA, United States
CROI is committed to supporting young and early career investigators working in HIV research to help them further their education and to network with other researchers in the field. Young Investigator Scholarship awardees are presenting authors on accepted abstracts and have been highly recommended by their mentors. In addition, CROI offers scholarships to international researchers and community educators working in resource-limited countries who would otherwise be unable to attend CROI. Through their applications and letters of recommendation, these awardees have shown that they will greatly benefit from the opportunity to participate in CROI.

### Young Investigator Awardees

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hadega Aamer</td>
<td>Seattle Children’s Research Institute</td>
</tr>
<tr>
<td>Hosiana Abewe</td>
<td>University of California San Diego</td>
</tr>
<tr>
<td>Rana Abutaima</td>
<td>University of Liverpool</td>
</tr>
<tr>
<td>Emily Adland</td>
<td>The University of Oxford</td>
</tr>
<tr>
<td>Erika Ahlgren</td>
<td>Sahlgrenska Academy, University of Gothenburg</td>
</tr>
<tr>
<td>Giuseppe Ancona</td>
<td>University of Milan</td>
</tr>
<tr>
<td>Nisha Andany</td>
<td>Women’s College Research Institute</td>
</tr>
<tr>
<td>Elizabeth M. Anderson</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>Suvaporn Anugulruengkitt</td>
<td>Chulalongkorn University</td>
</tr>
<tr>
<td>Marília L. Araújo</td>
<td>Universidade de São Paulo</td>
</tr>
<tr>
<td>Nadine Bachmann</td>
<td>University Hospital Zurich</td>
</tr>
<tr>
<td>Anani D. Badje</td>
<td>l’Institut National de la Santé et de la Recherche Médicale</td>
</tr>
<tr>
<td>Francesca Bai</td>
<td>University of Milan</td>
</tr>
<tr>
<td>Samuel Bailin</td>
<td>Vanderbilt University Medical Center</td>
</tr>
<tr>
<td>Kayode Balogun</td>
<td>University Health Network</td>
</tr>
<tr>
<td>Riddhima Banga</td>
<td>Centre Hospitalier Universitaire Vaudois</td>
</tr>
<tr>
<td>Ariola Bardhi</td>
<td>Albert Einstein College of Medicine</td>
</tr>
<tr>
<td>Joshua A. Barocas</td>
<td>Massachusetts General Hospital</td>
</tr>
<tr>
<td>Lisa Bebell</td>
<td>Massachusetts General Hospital</td>
</tr>
<tr>
<td>Angela Bengtson</td>
<td>University of North Carolina at Chapel Hill</td>
</tr>
<tr>
<td>Priya Bhagwat</td>
<td>University of California Los Angeles</td>
</tr>
<tr>
<td>Elisa Biliotti</td>
<td>Sapienza University of Rome</td>
</tr>
<tr>
<td>Anne Boerekamps</td>
<td>Erasmus University Medical Center</td>
</tr>
<tr>
<td>Pauline Bollen</td>
<td>Radboud University Medical Center</td>
</tr>
<tr>
<td>Michal Bonar</td>
<td>Case Western Reserve University</td>
</tr>
<tr>
<td>Kobus Bosman</td>
<td>University Medical Center Utrecht</td>
</tr>
<tr>
<td>Giorgio Bozzi</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>Kirsty Brittain</td>
<td>University of Cape Town</td>
</tr>
<tr>
<td>Jordan Broekhuis</td>
<td>University of Nebraska Medical Center</td>
</tr>
<tr>
<td>Kristina M. Brooks</td>
<td>Clinical Center</td>
</tr>
<tr>
<td>Maria C. Brühl</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>Marcus Buggert</td>
<td>Sahlgrenska University Hospital</td>
</tr>
<tr>
<td>Supranee Buranapraditkun</td>
<td>Chulalongkorn University</td>
</tr>
<tr>
<td>Zahid A. Butt</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Valentina Cambiano</td>
<td>University College London</td>
</tr>
<tr>
<td>Elvira S. Cannizzo</td>
<td>University of Milan</td>
</tr>
</tbody>
</table>
Adam Capoferri
The Johns Hopkins University

Itziar Carrasco Garcia
Puerta de Hierro Research Institute and University Hospital

Heather Carryl
Howard University

Valeria Cento
University of Rome Tor Vergata

Antoine Chaillon
University of California San Diego

Austin W. H. Chan
Duke University

Phillip Chan
SEARCH
The Thai Red Cross AIDS Research Center

Johanna Chapin-Bardales
Emory University

Glen Chew
University of Hawaii

Meredith Clement
Duke University Medical Center

Lauren F. Collins
Duke University

Sarah Dabydeen
University of California San Diego

Raghubendra S. Dagur
University of Nebraska Medical Center

Jennifer M. Dan
University of California San Diego

Michelle L. D’Antoni
University of Hawaii

Mirela D’arc
Universidade Federal do Rio de Janeiro

Thibaut Davy
University of North Carolina at Chapel Hill

Lesley R. de Armas
University of Miami

Davide De Francesco
University College London

Carolina De La Flor
University of Texas Southwestern Medical Center

Heloise M. Delagreverie
Hôpital Saint Louis

Anne Derache
Africa Health Research Institute

Belete A. Desimmie
National Cancer Institute

Amy K. Dickey
Massachusetts General Hospital

Maartje Dijkstra
Public Health Service Amsterdam

Adam Dingens
Fred Hutchinson Cancer Research Center

Horacio A. Duarte
University of Washington

Vanessa El Kamari
Case Western Reserve University

Ceri Evans
Queen Mary University of London

Michelli Faria de Oliveira
University of California San Diego

Carolina Fernández McPhee
Instituto de Investigación Sanitaria Gregorio Marañón
University Hospital Gregorio Marañon

Nina C. Flerin
Albert Einstein College of Medicine

J. Morgan Freiman
Boston Medical Center

Pierre Gantner
Hôpitaux Universitaires de Strasbourg

Erin I. Garcia
University of Washington

Claudia García-Morales
National Institute of Respiratory Diseases

Esther Gathogo
King’s College London

Alexander J. Gill
University of Pennsylvania

Leila B. Giron
Federal University of Sao Paulo

Aleksandr Gorin
University of California Los Angeles

Louise Greathead
Imperial College London

Sharon A. Greene
University of Washington

Diane Gu
University of California Los Angeles

Akshay Gupte
The Johns Hopkins University

Ahmad Haeri Mazanderani
National Institute for Communicable Diseases

Gustaf O. Hammarlund
Sahlgrenska Academy
University of Gothenburg

Nathan Hanan
University of California San Diego

Said Hassounah
Lady Davis Institute, McGill AIDS Centre

Jason M. Hataye
National Institutes of Health
Tiffany Hensley-McBain
University of Washington

Lucas E. Hermans
University Medical Center Utrecht

Sabine Hermans
Amsterdam Institute for Global Health and Development

Linn Hermansson
Sahlgrenska Academy
University of Gothenburg

Raul Ulises Hernandez-Ramirez
Yale University

Bonnie Hiener
The Westmead Institute for Medical Research

Simone H. Hijkema
Erasmus University Medical Center

Akarin Hirsanuthikul
HIV-NAT, The Thai Red Cross AIDS Research Centre

Admire Hlupeni
University of Zimbabwe

Martin Hoeni
University of California San Diego

Malon Van den Hof
Academic Medical Center

Elske Hoornenborg
Public Health Service Amsterdam

Szuhan Huang
George Washington University

Brandon M. Imp
Robert Wood Johnson Medical School

Sergio Ita
University of California San Diego

Watsamon Jantarabenjakul
Chulalongkorn University

Mathew L. Jones
University of Oxford

Claus Kadelka
University of Zurich

Mariah M. Kalmin
The George Washington University

Justin A. Kaplan
National Cancer Institute

Samantha Kaplan
Yale University

Harpreet Kaur
Cleveland Clinic Foundation

Christine Kelly
University College Dublin

Jérôme Kervevan
l’Institut National de la Santé et de la Recherche Médicale

Moliehi Khaketa
University of British Columbia

Zahra Kiani
McGill University

Ditte M. Kirkegaard-Klitbo
Hvidovre Hospital

Astrid R. Krarup
Aarhus University Hospital

Stefanie Kroeze
Amsterdam Institute for Global Health and Development

Steven Lada
University of California San Diego

Camille Lange
National Institutes of Health

Leah T. Le
Yale University

Lorna Leal
Hospital Clinic de Barcelona

Guinevere Q. Lee
Ragon Institute of MGH, MIT and Harvard

Louise Leyre
University of Montreal Hospital Research Centre

Andrea Lisco
National Institutes of Health

Yang Liu
National Cancer Institute

Sarah Lofgren
University of Minnesota

Claire Loiseau
l’Institut National de la Santé et de la Recherche Médicale

Francesca Lombardi
Catholic University of Sacred Heart

Briana Lynch
National Institutes of Health

Christine E. MacBrayne
University of Colorado

João I. Mamede
Northwestern University

Maura Manion
National Institute of Allergy and Infectious Diseases

Madeleine C. P. Mankowski
The Johns Hopkins University

Jennifer Manne-Goehler
Beth Israel Deaconess Medical Center

Alyssa R. Martin
The Johns Hopkins University

Enrique Martin-Gayo
Ragon Institute of MGH, MIT and Harvard

Tafireyi Marukutira
Macfarlane Burnet Institute

Michela Masetti
University of Milan
Aviva Mattingly
National Institutes of Health

Rodrigo Matus Nicodemos
Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health

Allison M. McFall
The Johns Hopkins University

Vanessa McMahan
University of Washington

Luz M. Medrano
Institute of Health Carlos III

Natasha Mehta
University of California San Francisco

Caroline Melhado
University of North Carolina at Chapel Hill

Esther Merlini
University of Milan

Kate Michel
Georgetown University

Brooks I. Mitchell
University of Hawaii

Julie Mitchell
US Military HIV Research Program

Aaloke Mody
University of California San Francisco

Michalina A. Montano
University of Washington

Rocio Montejano
Hospital Universitario La Paz

Caitlin A. Moran
Emory University

Sara Moron-Lopez
IrsiCaixa

Sikhulile Moyo
Botswana Harvard AIDS Institute Partnership

Andrew Musick
National Cancer Institute

Shalena Naidoo
Stellenbosch University

Megan Neary
University of Liverpool

Anne M. Neilan
Massachusetts General Hospital

Kristin N. Nelson
Emory University

Mariia Novikova
National Cancer Institute

Piotr Nowak
Karolinska Institute

Jane A. O’Halloran
University College Dublin

Oluwasolape M. Olawore
The Johns Hopkins University

Lorenzo Onorato
Second University of Naples

Edmund Osei-Kuffour
Heinrich-Heine-University Hospital

Laurence Palk
University of California Los Angeles

Nandagopal Paneerselvam
YR Gaitonde Center for AIDS Research and Education

Nivedha Panneer
Centers for Disease Control and Prevention

Alexander Pasternak
Academic Medical Center

Chansavath Phetsouphanh
University of Oxford

Tamsin Phillips
University of Cape Town

Jillian Pintye
University of Washington

Marilia R. Pinzone
University of Pennsylvania

Timothy Pliotnik
University of Miami

Joan T. Price
University of North Carolina at Chapel Hill

Christina Psomas
University Hospital of Montpellier

Maria Pujantell
IrsiCaixa

Sarah Rasmussen
The Johns Hopkins University

Ludy Registre
Boston University School of Medicine

Michael J. A. Reid
University of California San Francisco

Lindsey Reif
Columbia University

Chiara Resnati
University of Milan

Lara Rheinemann
University of Utah

Owain Roberts
University of Liverpool

Cristina Rodriguez-Hart
The Johns Hopkins University

Anna Joy Rogers
University of Alabama at Birmingham

Julia K. Rohr
Harvard University

Casper Rokx
Erasmus University Medical Center
Charlotte-Paige M. Rolle  
Emory University

Miriam Rosas Umbert  
IrsiCaixa

Jonathan Ross  
Montefiore Medical Center  
Albert Einstein College of Medicine

Kathryn Rough  
Harvard University

Sahar Saeed  
McGill University

Kate Salters  
Simon Fraser University

Ryan Sanford  
Montreal Neurological Institute

Antonella Santoro  
University of Modena and Reggio Emilia

Luca Sardo  
University of the Sciences

Elisabeth Schaffer  
University of North Carolina at Chapel Hill

Stein Schalkwijk  
Radboud University Medical Center

Gundolf Schuettfort  
University Hospital Frankfurt

Jordan A. Schwartz  
University of Toronto

Sergio Serrano-Villar  
Hospital Universitario Ramón y Cajal

Monisha Sharma  
University of Washington

Katie Sharp  
University of California Los Angeles

Leah Shepherd  
University College London

Rupak Shivakoti  
The Johns Hopkins University

Francesco R. Simonetti  
The Johns Hopkins University

Mariya V. Sivay  
The Johns Hopkins University

Robert S. Smith  
Washington University in St. Louis

Victoria P. Strouvelle  
University of Zurich

Hang Su  
University of Nebraska Medical Center

Diya Surie  
University of Washington

Andrew Timmons  
The Johns Hopkins Hospital

Jessie Torgersen  
University of Pennsylvania

Matthew Triplette  
University of Washington

Mattia Trunfio  
University of Torino

Rachel Van Duyne  
National Cancer Institute

Claire E. Van Ommen  
University of British Columbia

Rosan van Zoest  
Amsterdam Institute for Global Health and Development

Rebecca Veenhuis  
The Johns Hopkins University

Jennifer Velloza  
University of Washington

Vinicius A. Vieira  
University of São Paulo

Victor Virlogeux  
L’Institut National de la Santé et de la Recherche Médicale

Thomas Vollbrecht  
Veterans Medical Research Foundation

Alinda Vos  
University Medical Center Utrecht

Elizabeth Wahome  
KEMRI Wellcome Trust

Tomas Raul Wiche Salinas  
Hospital Research Centre  
University of Montreal

Ingeborg Wijting  
Erasmus University Medical Center

Anni Winckelmann  
Aarhus University Hospital

Joanne R. Winter  
University College London

Chun-Shu Wong  
National Institutes of Health

Emily Woolnough  
Alfred Hospital

Vincent Wu  
University of Washington

Guangai Xue  
National Cancer Institute

Jingyan Yang  
Columbia University

Gonzalo Yebra  
University of Edinburgh

Zhe Yuan  
University of Nebraska-Lincoln

Brian C. Zanoni  
Massachusetts General Hospital

Jennifer M. Zerbato  
University of Pittsburgh
Alexander S. Zevin  
University of Washington  
Tian Zhou  
University of Nebraska Medical Center  

**International Investigator Awardees**

Andrew M. Abaasa  
MRC/UVRI Uganda  
Research Unit on AIDS  
Gboglahan Ajibola  
Botswana Harvard AIDS Research Institute Partnership  
 Stable Besa  
Zambart  
Sergio M. de Almeida  
Universidade Federal do Paraná  
Paolo Denti  
University of Cape Town  
Kostyantyn Dumchev  
Ukrainian Institute on Public Health Policy  
Trupti I. Gilada  
Unison Medicare and Research Center  
Ashraf Grimwood  
Kheth’Impilo  
Cheryl J. Hendrickson  
University of the Witwatersrand  
Arvind Kaimal  
Infectious Diseases Institute  
Atupele P. Kapito-Tembo  
University of Malawi College of Medicine  
Margaret P. Kasaro  
University of North Carolina  
Agnes Kiragga  
Makerere University  
Zachary A. Kwena  
Kenya Medical Research Institute  
Kwana Lechiile  
Botswana-UPenn Partnership  
University of Pennsylvania  
Tshepo B. Leeme  
Botswana-UPenn Partnership  
University of Pennsylvania  
Maia Lesosky  
University of Cape Town  
Sekai C. Mathabire  
Epicentre  
Lydia Nakifying  
Infectious Diseases Institute  
Mastula Nanfuka  
The Support Organisation  
McNeil Nongoondo  
University of North Carolina  
Project-Malawi  
Thanh T. Nguyen  
Oxford University  
Thu T. M. Nguyen  
Oxford University  
Harriet Nuwagaba-Biribonwoha  
ICAP at Columbia University  
Moussa Seydi  
Centre Hospitalier Universitaire de Fann  
Tavitiya Sudjaritruk  
Chiang Mai University  
Gaëlle F. Tchouwa  
Virology Laboratory IMPM-IRD, Centre de Recherche Sur les Maladies Emergentes et Reemergentes

**Community Educator Awardees**

Giorgio Barbareschi  
European AIDS Treatment Group  
Tamás Bereczky  
European AIDS Treatment Group  
Aisuluu Bolotbaeva  
Central Asian HIV Foundation  
Giulio M. Corbelli  
AVAC  
Michael Dorosh  
Treatment Educat10n Network  
Florita C. Durueke  
New HIV Vaccine and Microbicides Advocacy Society  
Angel L. Hernández  
University of Puerto Rico  
Andrew H. Kaytes  
Christie’s Place  
Tapiwanashe Kujinga  
Pan-African Treatment Access Movement  
Michael Meulbroek  
Asociación para el Trasplante de Organos a Seropositivos  
Kennedy Mupeli  
Centre for Youth of Hope  
Lillian K. Mworeko  
Makerere University Kampala
Robert Newells
AIDS Project of the East Bay

Adeolu O. Ogunrombi
University of Liverpool

Godfrey O. Okumu
Impact Research and Development Organization

Simon O. Ondiek
Nyanza Reproductive Health Society

David A. Palm
University of North Carolina at Chapel Hill

Julia M. Patterson
University Hospital AIDS Clinical Research Site
Case Western Reserve University

Elias Phiri
Addington Afro Ethnic Health Promotion Group

Ferran Pujol Roca
Projecte dels NOMS-Hispanosida

Jorge Saz Berges
Joves Positius

Cissy Ssuuna
Children's Foundation
Baylor College of Medicine

Moses N. Supercharger
Joint Clinical Research Centre

Manuel A. Venegas
University of Washington

Ntando Yola
Desmond Tutu HIV Foundation
CONTINUING MEDICAL EDUCATION

Accreditation Statement
The International Antiviral Society—USA (IAS—USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS—USA designates this live activity for a maximum of 17.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives
After participating in CROI, learners will be able to:
• Describe results of basic science research on HIV transmission and infection and advances toward a cure
• List the most recent findings from trials related to the clinical aspects of HIV infection and its complications, including relevant coinfections and comorbidities, and implications of these data for treatment strategies
• Describe current epidemiologic data on the prevalence of HIV infection and the biobehavioral approaches to prevention

Statement of Need
Since HIV was identified, the scientific response to the global pandemic has been a coordinated effort among basic researchers, clinical investigators, health care providers, epidemiologists, and community leaders to move information and potential treatment options from research to clinical trials and out to affected communities as quickly as possible. CROI was founded in 1993 by researchers working in the field of HIV/AIDS and its complications, as a science-focused forum for exchanging current research findings among their international peers. CROI continues to focus on scientific exchange, providing an environment in which basic science researchers, translational researchers, clinical investigators, epidemiologists, and public health experts meet to present and discuss the latest research into different facets of HIV and its complications, as well as selected other emerging infections.

CME Credit Information
Physicians (MD, DO, and international equivalents) are eligible to receive CME credit for participation in CROI. CME credits can be claimed for plenary lectures, symposia, opening session lectures, and special sessions. CME credits cannot be claimed for oral abstract sessions, themed discussion sessions, or poster sessions. For physician attendees whose certificate is through the American Board of Internal Medicine (ABIM), Maintenance of Certification (MOC) points are available for participation in CROI. Other researchers, practitioners, and clinicians can receive a Certificate of Participation verifying their attendance, as required by the American Medical Association (AMA).
ABIM MOC Points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17.25 MOC points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Claiming CME Credits, ABIM MOC Points, or a Certificate of Participation

During the conference, daily evaluations will be e-mailed to all CROI participants to the e-mail account used to register for the conference. On the final day of the conference, all CROI participants will receive a final e-mail that will contain their registration confirmation number and a link to the overall CROI evaluation. In addition, a secure web page has been created on the CROI website. The links to to the daily and final evaluation can be found at www.croiconference.org/electronic-materials. You will need your email address and registration ID to access this page. To obtain CME credits, ABIM MOC points, or a Certificate of Participation for CROI, this final evaluation must be completed by March 31, 2017. Once the evaluation is submitted, participants will receive the link to claim and print their certificate.

To determine the number of CME credits, ABIM MOC points, or hours of participation that can be claimed, calculate time spent attending the conference, including opening and plenary lectures, workshops, and symposia. For example, if you attended 2 plenary talks (8:30 AM to 9:30 AM), and a symposium (4:00 PM to 6:00 PM), you would have a total of 3 hours to apply toward CME credits or ABIM MOC points (if applicable) for that day. At the end of CROI, please add the total hours you attended for your certificate. You may claim a maximum of 17.25 AMA PRA Category 1 Credits™ and 17.25 ABIM MOC points for this activity.

ABIM MOC points will only be awarded after the successful completion of the evaluation component demonstrating knowledge gained at all meetings through a series of multiple choice questions. ABIM MOC points are intended for internal medicine physicians, in the United States, who are maintaining their ABIM Board Certification.

A CME/ABIM MOC hour worksheet can be found at www.croiconference.org/sites/default/files/uploads/croi2017-cmeworksheet.pdf

Disclosure of Financial Relationships

It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty members (speakers, presenters, etc) participating in IAS–USA-sponsored activities are required to disclose to the program audience any financial interests within the past 12 months that could be perceived to influence, or give the appearance of potentially influencing, the written or oral presentation. (The ACCME defines a financial interest as an interest in any amount.) The information is intended to make the IAS–USA audience aware of author and contributor interests and commitments with commercial companies or other entities, enabling the audience members to form their own judgments about such associations.

Each author or contributor is required to complete this financial disclosure declaration. In accordance with IAS–USA policy, the IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Disclosure information will be included with the Program and Abstracts eBook on the web.

Drug and Product Disclaimer

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.
GENERAL INFORMATION

Overview
CROI was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. The synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI is the preeminent HIV research meeting in the world and includes up to 4000 HIV research and care leaders internationally. The goal of the conference is to help researchers translate their laboratory and clinical findings into tangible progress against the HIV pandemic. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research.

Americans With Disabilities Act
CROI endeavors to comply fully with the legal requirements of the Americans With Disabilities Act (ADA). If you require assistance on-site, please visit the Seattle Visitor Center and Concierge Services in the Upper Pike Street Lobby during the conference.

Commercial Support
CROI is largely supported by participant registration fees. Please note, CROI registration fees cover all attendee meals (including the welcome reception) and travel expenses for selected invited participants (eg, speakers, leaders, moderators, and CROI PC), as well as selected meeting materials and other conference expenses.

In addition, CROI seeks grants from commercial companies, particularly from companies with competing products. These companies have no input in or control over the selection of faculty or content of the presentations. Commercial support is used to cover some of the costs of the convention center, audiovisual services, and other conference services.

CROI 2017 received grant support commitments from the following commercial companies:

PLATINUM SUPPORTERS
Merck
ViiV Healthcare

GOLD SUPPORTERS
Bristol-Myers Squibb
Gilead Sciences, Inc
Janssen Therapeutics

SILVER SUPPORTER
AbbVie

Emergency Services
In the event of a medical emergency, please contact Security Control immediately. You may contact Security Control by dialing 5127 from any house phone located in the Washington State Convention Center (WSCC). In addition, there are red “hot line” phones located around the WSCC. These phones ring directly into the Security Control office.

IAS–USA staff or any uniformed WSCC personnel with a 2-way radio can also assist you in an emergency. Contacting Security Control will greatly minimize response time in the event an emergency medical unit needs to report to the WSCC. Security personnel can quickly assess the situation and bring emergency personnel directly to the individual in need. For this reason, WSCC requests that our clients and guests NOT contact 911 directly.
Embargo Policies and Social Media

The research presented at CROI 2017 is embargoed until the conclusion of the session in which it is presented. For example, if a study is presented from 1:45 PM to 2:00 PM as part of a session that ends at 2:45 PM, the embargo on that study lifts at 2:45 PM. Embargoes on poster presentations lift at the conclusion of the session in which the poster is presented. If a study to be presented at CROI 2017 is included in an official CROI press conference and that press conference takes place before the official presentation of the study at the conference, the embargo lifts at the conclusion of the press conference in which the study is featured.

CROI embargo policies apply to any public dissemination of research information presented at the conference, including electronic publications (eg, blogs) or social media (eg, Facebook, Twitter). No public dissemination of research information from the conference is permitted prior to the lifting of the conference embargo. Individuals or organizations that violate the conference embargo policy may have their conference credentials revoked and may forfeit the opportunity to participate in future conferences.

Welcome Reception

All registered CROI attendees are invited to join us for a Welcome Reception immediately following the Opening Session on Monday evening. The reception will be held at the Convention Center.

This unique Welcome Reception will offer attendees the opportunity to network with colleagues. Light hor d’oeuvres will be served. Each attendee will be given 2 drink tickets with their registration materials to be used for alcoholic or nonalcoholic beverages.

Meals

Morning coffee and light continental breakfast will be available to conference registrants from 7:30 AM to 8:30 AM, Tuesday, Wednesday, and Thursday, in the 4AB Auditorium. An afternoon snack break will be available at 2:30 PM in the Poster Hall. Attendees are on their own for all other meals, including lunch and dinner, each day. Below is a list of food service options located in the WSCC or within a short walking distance.

Food Service at the Convention Center

820 Pike Street – Pan Asian Cuisine
Crêpes Voilá
Cyber Dogs – Internet Café
Espresso Caffé Dior
Goldberg’s Deli
Subway Sandwiches
Taco Del Mar
The Juicy Café
Tully’s Coffee
Wild Rye Café Bakery

Restaurants Within 4 Blocks of the Convention Center

Blueacre Seafood
Blue C Sushi
Café Yumm!
Daily Grill
Dragonfish Asian Café
FareStart
Gordon Biersch Brewery Restaurant
Il Fornaio
MOD Superfast Pizza
Morton’s Steakhouse
NYC Hyatt Deli Market
Palomino
1700 7th Ave
1510 7th Ave
717 Pine St
629 Pike St
722 Pine St
700 Virginia St
600 Pine St, Ste 401
600 Pine St, Ste 132
1302 6th Ave
1511 6th Ave
1520 7th Ave
6th and Union
206-659-0737
206-467-4022
206-624-9866
206-624-8400
206-467-7777
206-267-7606
206-405-2707
206-264-0994
206-332-0200
206-223-2751
206-682-7011
206-623-1300
206-659-0737
206-467-4022
206-624-9866
206-624-8400
206-467-7777
206-267-7606
206-405-2707
206-264-0994
206-332-0200
206-223-2751
206-682-7011
206-623-1300
Blueacreseafood.com
bluesushi.com
cafeyumm.com
dailygrill.com
dragonfishcafe.com
faresetart.org
gordonbiersch.com
ilfornaio.com
modsuperfast.com
mortons.com
r-u-i.co
Restaurants within 4 Blocks of the Convention Center (continued)

<table>
<thead>
<tr>
<th>Restaurant Name</th>
<th>Address</th>
<th>Phone</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pike Place Chowder</td>
<td>600 Pine St, Ste 404</td>
<td>206-838-5680</td>
<td></td>
</tr>
<tr>
<td>Potbelly Sandwich Shop</td>
<td>1429 4th Ave</td>
<td>206-623-0099</td>
<td>potbelly.com</td>
</tr>
<tr>
<td>RN74</td>
<td>1425 4th Ave</td>
<td>206-456-7474</td>
<td>michaelmina.net</td>
</tr>
<tr>
<td>Rock Bottom Restaurant</td>
<td>1333 5th Ave</td>
<td>206-623-3070</td>
<td>rockbottom.com</td>
</tr>
<tr>
<td>Ruth’s Chris Steak House</td>
<td>727 Pine St</td>
<td>206-624-8524</td>
<td>ruthschris.com</td>
</tr>
<tr>
<td>Soup’s On!</td>
<td>1420 5th Ave</td>
<td>206-625-9976</td>
<td>soupsonusa.com</td>
</tr>
<tr>
<td>Sullivan’s Steakhouse</td>
<td>612 Union St</td>
<td>206-494-4442</td>
<td>sullivansteakhouse.com</td>
</tr>
<tr>
<td>Tango Restaurant &amp; Lounge</td>
<td>1100 Pike St</td>
<td>206-583-0382</td>
<td>tangorestaurant.com</td>
</tr>
<tr>
<td>Tap House Grill</td>
<td>1506 6th Ave</td>
<td>206-816-3314</td>
<td>taphousegrill.com</td>
</tr>
<tr>
<td>Thai Ginger</td>
<td>600 Pine St</td>
<td>206-749-9100</td>
<td><a href="http://www.thaiginger.com">www.thaiginger.com</a></td>
</tr>
<tr>
<td>The Capital Grille</td>
<td>1301 4th Ave</td>
<td>206-382-0900</td>
<td>thecapitalgrille.com</td>
</tr>
<tr>
<td>The Cheesecake Factory</td>
<td>700 Pine St</td>
<td>206-652-5400</td>
<td>thecheesecakefactory.com</td>
</tr>
<tr>
<td>Toss’d Custom Salads</td>
<td>1420 5th Ave</td>
<td>206-682-6700</td>
<td></td>
</tr>
<tr>
<td>Veggie Grill</td>
<td>1427 4th Ave</td>
<td>206-624-1332</td>
<td>veggiegrill.com</td>
</tr>
</tbody>
</table>

Overflow Accommodations for Oral Sessions

There is a simultaneous overflow area located in the Atrium Lobby. There are 6 screens, and each will be live streaming one of the 6 concurrent oral sessions (Oral Abstracts, Themed Discussions, or Symposia). Headsets with an audio switch will be available for easy transitioning between the concurrent sessions.

Overflow monitors for individual session rooms will become available as needed. CROI staff will direct you to these locations.

USB Flash Drive

Any registrant who purchased a USB flash drive with the Abstract eBook preloaded onto it will receive it in their welcome packet at registration. Abstracts can also be found in the Abstract eBook and searchable database on the CROI website after the session in which the abstract is presented.

Mobile App:

The CROI 2017 mobile App has many features to enhance your conference experience:

- View abstracts
- Find information about speakers and other CROI attendees
- Create a personal calendar of the sessions you plan to attend
- E-mail session notes
- Receive the latest changes to the CROI program
- View electronic posters

The mobile App is compatible with iOS and Android devices. Search “CROI 2017” in your mobile device App store. Access is restricted to registered attendees only. Your log-in information and password will be provided with your registration materials.

Website

For additional information about the conference and to access electronic materials please visit the website at www.CROIconference.org.

The final Abstract eBook (flip book and PDF versions) will be available for public download following the conference. Abstracts from CROI 2017 can be viewed and downloaded in the searchable database during the conference. Abstracts and electronic posters from CROI 2014, 2015, 2016 are available at www.croiconference.org/abstracts/search-abstracts/
Webcasts
Plenaries, symposia, scientific overviews, oral abstract sessions, and themed discussions are available as webcasts. Webcasts are also available as streaming video for the Apple iPad and iPhone.
Visit www.CROIconference.org or www.CROIwebcasts.org to access the CROI webcasts. Webcasts will be available within 24 hours of the end of the relevant session.

Affiliated Activities Policy
The goal of CROI is to promote meaningful, high-level scientific interchange of ideas and debate in order to find better ways to prevent, treat, and cure HIV/AIDS. In keeping with this goal, organizations (commercial companies and their agents, not-for-profit groups, government agencies, etc) have been approved to host Affiliated Activities occurring outside CROI session times. Affiliated Activities are not sponsored by, endorsed by, or supported by the IAS—USA, the CROI Foundation, or CROI 2017.
If an affiliated activity is found to have violated the Guidelines for Affiliated Activities, the sponsoring organization, the supporting organization, and the organizer of the meeting may be prohibited from holding an Affiliated Activity at future CROI conferences and may have their current registration revoked. Noncompliance may be subject to fines and damages, and could negatively impact the registration status and attendance of those attending an unapproved affiliated activity.
If you have organized a meeting or activity that includes CROI attendees, as described in the Affiliated Activity guidelines, and have not completed the Affiliated Activity application, please see an IAS—USA staff member in the IAS—USA office (room 603) for assistance.
In the spirit of CROI and the goal of promoting scientific collaboration among colleagues, if you are invited to or are attending a meeting or activity that you feel may not have been approved by CROI, please contact an IAS—USA staff member in the IAS—USA office.

Wi-Fi Access at the Conference
Complimentary Wi-Fi access is provided at the WSCC. Network information is as follows:
Network name: CROI2017
The Wi-Fi password will change daily to prevent devices from automatically connecting to the network. Limiting the number of concurrent devices will assist in maximizing the internet speeds for those devices actively in use. The password for each day of the conference are listed below, and are NOT case sensitive.
Monday password: Monday2017
Tuesday password: Tuesday2017
Wednesday password: Wednesday2017
Thursday password: Thursday2017
If you are having issues with Wi-Fi access, please contact an IAS—USA staff member. Additional Internet hotspots not located in the session rooms are listed in the Convention Center map on the back of the Program.

Conference Badges
Badge pickup is available at the registration lobby; please bring government-issued photo identification that clearly shows your name. You must wear your name badge to gain entry to all official meeting activities, including the poster sessions. DO NOT LOSE YOUR BADGE. Payment of US $850 will be required to replace a lost badge.
Child Care

Children are not permitted entry into any meeting room, including the poster area. If you should require child care, please contact the concierge of your hotel or the Visitor Information Center on Level 1 at the WSCC.

Conference Etiquette

In consideration of the work of presenters at CROI, and the CROI copyright policy, attendees should not photograph posters, record parts of talks, or post other people's data. Please ensure all cell phones and pagers are off or are set on SILENT mode. No photography is permitted in session rooms.

CROI HOTELS

Conference attendees are required to stay in one of the official conference hotels. The few exceptions to this include registrants who live in the Seattle area (ie, within a 50-mile radius of the WSCC) and registrants who are sharing a room with an approved CROI attendee with accommodations booked via the CROI housing system. Please inform the Conference Secretariat if you have inadvertently booked a hotel stay outside of the CROI housing system.

CROI 2017 hotels are listed below.

**Crowne Plaza Seattle Downtown**
1113 6th Avenue
Seattle, WA 98101
PH: 206-464-1980

**The Fairmont Olympic Hotel**
411 University Street
Seattle, WA 98101
PH: 206-621-1700

**Grand Hyatt Seattle**
721 Pine Street
Seattle, WA 98101
PH: 206-774-1234

**Hilton Garden Inn**
1821 Boren Avenue
Seattle, WA 98101
PH: 206-467-7770

**Hilton Seattle**
1301 6th Avenue
Seattle, WA 98101
PH: 206-624-0500

**Mayflower Park Hotel**
405 Olive Way
Seattle, WA 98101
PH: 206-623-8700

**Motif Seattle**
1415 5th Avenue
Seattle, WA 98101
PH: 206-971 8000

**Hyatt at Olive 8**
1635 8th Avenue
Seattle, WA 98101
PH: 206-685-1234

**Renaissance Seattle Hotel**
515 Madison Street
Seattle, WA 98104
PH: 206-583-0300

**Sheraton Seattle Hotel**
1400 6th Avenue
Seattle, WA 98101
PH: 206-621-9000

**W Seattle**
1112 4th Avenue
Seattle, WA 98101
PH: 206-264-6000

**The Westin Seattle**
1900 5th Avenue
Seattle, WA 98101
PH: 206-728-1000
# CONFERENCE SERVICES

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Seattle Visitor Center and Concierge Services</strong></td>
<td>Upper Pike St. Lobby Level 1</td>
<td>Monday to Friday 9:00 AM – 5:00 PM</td>
</tr>
<tr>
<td><strong>Bag and Coat Check</strong></td>
<td>Hall 4C-3, 4 Level 4</td>
<td>Monday: 8:00 AM – 10:30 PM&lt;br&gt;Tuesday: 7:30 AM – 8:00 PM&lt;br&gt;Wednesday and Thursday: 7:30 AM – 6:30 PM</td>
</tr>
<tr>
<td><strong>Cyber Cafe</strong></td>
<td>4D Skybridge Level 4</td>
<td>Sunday: 3:00 AM – 5:00 PM&lt;br&gt;Monday to Wednesday: 7:30 AM – 7:00 PM&lt;br&gt;Thursday: 7:30 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>Media Center</strong></td>
<td>Room 400 Level 4</td>
<td>Monday: 10:00 AM – 7:00 PM&lt;br&gt;Tuesday to Thursday: 8:00 AM – 6:30 PM</td>
</tr>
<tr>
<td><strong>Badge Pickup</strong></td>
<td>Hall 4C-3, 4 Level 4</td>
<td>Sunday: 3:00 PM – 5:00 PM&lt;br&gt;Monday: 8:00 AM – 7:00 PM&lt;br&gt;Tuesday: 7:00 AM – 6:00 PM&lt;br&gt;Wednesday: 8:00 AM – 6:00 PM&lt;br&gt;Thursday: 8:00 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>Attendee Services</strong></td>
<td>Room 620 Level 6</td>
<td>Sunday: 3:00 PM – 6:00 PM&lt;br&gt;Monday to Thursday: 6:00 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>Housing Information</strong></td>
<td>Room 507 Level 5</td>
<td>Sunday: 3:00 PM – 6:00 PM&lt;br&gt;Monday: 9:00 AM – 7:00 PM&lt;br&gt;Tuesday: 8:00 AM – 6:00 PM&lt;br&gt;Wednesday: 8:00 AM – 6:00 PM&lt;br&gt;Thursday: 8:00 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>Scholarship Badge Pickup</strong></td>
<td>Room 416 Level 4</td>
<td>Sunday: 3:00 PM – 6:00 PM&lt;br&gt;Monday: 9:00 AM – 7:00 PM&lt;br&gt;Tuesday: 8:00 AM – 6:00 PM&lt;br&gt;Wednesday: 8:00 AM – 6:00 PM&lt;br&gt;Thursday: 8:00 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>Speaker Ready Room</strong></td>
<td>Room 620 Level 6</td>
<td>Sunday: 3:00 PM – 6:00 PM&lt;br&gt;Monday to Thursday: 6:00 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>Personal Considerations Room</strong></td>
<td>Room 507 Level 5</td>
<td>Sunday: 3:00 PM – 6:00 PM&lt;br&gt;Monday: 9:00 AM – 7:00 PM&lt;br&gt;Tuesday: 8:00 AM – 6:00 PM&lt;br&gt;Wednesday: 8:00 AM – 6:00 PM&lt;br&gt;Thursday: 8:00 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>New Mother’s Room</strong></td>
<td>Room 416 Level 4</td>
<td>Sunday: 3:00 PM – 6:00 PM&lt;br&gt;Monday: 9:00 AM – 7:00 PM&lt;br&gt;Tuesday: 8:00 AM – 6:00 PM&lt;br&gt;Wednesday: 8:00 AM – 6:00 PM&lt;br&gt;Thursday: 8:00 AM – 6:00 PM</td>
</tr>
</tbody>
</table>
CONFERENCE SERVICES

Notes

Full-service concierge assistance, including maps, guides, tickets, restaurant reservations, tours, ground transportation, and personal services is available.

Bag and coat check are free of charge.

Computers with Internet access are available for webcasts and abstract searches.

There is no on-site press registration. Registered press can pick up press kits and obtain location for press conferences at this location.

Badges and conference materials can be picked up at this location.

Oral abstract, invited, and themed discussion session speakers must drop off presentations at least 24 hours before their presentation.

Poster presenters must submit an electronic version of their poster for placement on the CROI website by February 7, 2017.

The Personal Considerations Room is a room set aside for those who require a short-term private space for personal health needs. Use of this room is available on a first-come, first-served basis.

The New Mother’s Room is a room set aside for nursing mothers who require a short-term private room. Use of this room is available on a first-come, first-served basis.
CROI HOTELS

1. Sheraton Seattle Hotel
2. Crowne Plaza Seattle
3. The Fairmont Olympic Hotel
4. Grand Hyatt Seattle
5. Hilton Garden Inn
6. Hilton Seattle
7. Hyatt at Olive 8
8. Mayflower Park Hotel
9. Motif Seattle
10. Renaissance Seattle Hotel
11. W Seattle
12. The Westin Seattle
24th Conference on Retroviruses and Opportunistic Infections
February 13–16, 2017
ABSTRACT PROCESS

Scientific Categories
A. Virology
B. Molecular Epidemiology and HIV/SIV Evolution
C. Pathogenesis: Human Studies and Animal Models
D. Host Immune Responses to Infection, Vaccines, and Immunotherapy
E. HIV Reservoirs, Latency, and All Curative Strategies Including Therapeutic Vaccines and Gene Therapy
F. Neuropathogenesis and CNS HIV Complications
G. Clinical Pharmacology
H. Antiretroviral Therapy: Pre-Clinical and Randomized Trials
I. Antiretroviral Therapy: Efficacy and Effectiveness Studies
J. HIV Drug Resistance
K. HIV Diagnostics
L. Hepatitis Viruses and Liver Complications
M. Malignancies
N. Cardiovascular Complications of HIV Infection and Antiretroviral Therapy
O. Other Complications of HIV Infection and Antiretroviral Therapy
P. Tuberculosis and Other Opportunistic Infections
Q. Maternal/Fetal HIV
R. Pediatrics and Adolescents
S. Epidemiology
T. Prevention Interventions
U. Prevention Scale-Up
V. Contraceptive and Reproductive Health in Women
W. Implementation and Scale-Up of Treatment and Care
X. Population and Cost Modeling
Y. Emerging Viruses: Zika Virus

Abstract Content
Author names, institutions, abstract titles, and abstracts in the Program and Abstracts eBook are generally presented as submitted by the corresponding author.

Abstract Review Process
The PC and a panel of volunteer external reviewers reviewed approximately 2000 submitted abstracts. Each abstract was reviewed by 5 to 10 reviewers selected for each abstract category based upon their individual expertise. PC members and external experts in the field reviewed the abstracts for the quality and originality of the work and scored them numerically. All reviewers were instructed to abstain from scoring any abstract on which they are an author or coauthor, have a financial or personal conflict of interest, or do not have the appropriate expertise to evaluate. Scores ranged from 1 (definite oral presentation) to 5 (rejected). Scores for each abstract were averaged and the standard deviation was calculated to assess variability. If variability was high, outlier scores are identified and censored. Abstracts with high variability in scores were discussed individually during a series of conference calls. Abstracts were accepted for oral presentations, for poster presentations, or rejected. Late-breaking abstract reviews included an assessment of the late-breaking nature of the work (versus just being a late submission).
Common Reasons for Abstract Rejection
- Information is not new enough
- Methodology is inadequate or insufficient to support conclusions
- Background does not summarize the hypothesis
- Submission is poorly written
- Abstract is duplicative of other submissions
- Abstract is not appropriate for CROI
- Controls are absent or inadequate
- Statistical evaluation is inadequate or absent
- Summary of essential results is inadequate or absent
- Data are inadequate or insufficient to support conclusions
- Submission reports clinical trial and data from unplanned analysis or incomplete or ongoing studies
- Format does not follow guidelines (eg, section[s] missing, more than 1 graphic, table, or figure submitted)

Statistics for Abstracts

General abstract submitted ............................... 1751
General abstracts accepted .................................. 948
  General oral abstracts ........................................ 80
  General poster abstracts ...................................... 868
Late-breaking abstracts submitted .......................... 159
Late-breaking abstracts accepted ............................ 53
  Late-breaking oral abstracts ................................. 16
  Late-breaking poster abstracts ............................... 37

Total abstracts submitted .................................. 1910
Total abstract accepted ...................................... 1001

All Authors on Accepted Abstracts

<table>
<thead>
<tr>
<th>Region</th>
<th>N</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Africa</td>
<td>265</td>
<td>14</td>
</tr>
<tr>
<td>Asia</td>
<td>99</td>
<td>5.2</td>
</tr>
<tr>
<td>Australia</td>
<td>35</td>
<td>1.8</td>
</tr>
<tr>
<td>Europe</td>
<td>432</td>
<td>22.5</td>
</tr>
<tr>
<td>Latin and South America</td>
<td>29</td>
<td>1.5</td>
</tr>
<tr>
<td>North America</td>
<td>1050</td>
<td>55</td>
</tr>
</tbody>
</table>

![Pie chart showing distribution of authors by region]
Preconference Sessions • Monday

Program and Agenda
CROI 2017

MONDAY, FEBRUARY 13, 2017

Workshop W1: PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES
Ballroom 6AB 9:00 AM-12:15 PM

Target Audience: This workshop is directed toward new trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows) and new investigators (both international and domestic). It is open to all CROI attendees, however.

Level of Knowledge: It is assumed that participants have been conducting active research in the field for less than 3 years.

Conveners
John W. Mellors, Univ of Pittsburgh, Pittsburgh, PA, USA
Serena S. Spudich, Yale Univ, New Haven, CT, USA

1 PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

MOLECULAR VIROLOGY: ADVANCES IN THE UNDERSTANDING OF HIV-1
Paul Bieniasz, Howard Hughes Medical Center, New York, NY, USA

ADVANCES IN ANTIBODIES
Richard A. Koup, VRC, NIAID, NIH, Bethesda, MD, USA

ADVANCES IN HIV PREVENTION: NEW BIOMEDICAL AND BEHAVIORAL APPROACHES
James A. McIntyre, Anova Health Institute, Johannesburg, South Africa

HIV COMPLICATIONS: PERSISTENT THREAT OR A PROBLEM OF THE PAST?
Judith S. Currier, Univ of California Los Angeles, Los Angeles, CA, USA

HIV RESERVOIRS: OBSTACLES TO AN HIV CURE
Nicolas Chomont, Univ de Montréal, Montreal, QC, Canada
LUNCH AND MARTIN DELANEY PRESENTATION, FROM LAB TO LICENSURE: THE IMPORTANCE OF GOOD PARTICIPATORY PRACTICE IN RESEARCH
Room 6 AB 12:15 PM - 1:45 PM

Description: The Martin Delaney Presentation is held annually during the workshops for Young Investigators, International Investigators, and Community Educators in honor of pioneering HIV/AIDS activist Martin Delaney (1945–2009). It recognizes the important contributions of community advocacy and engagement in research.

Target Audience: This session is directed toward new trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows) and new investigators. Attendance is mandatory for all scholarship recipients. It is open to all CROI attendees.

Level of Knowledge: It is assumed that participants have been conducting active research in the field for less than 1 year.

Objectives: After attending this presentation, participants will be able to:
- List the 6 fundamental principles of Good Participatory Practice (GPP)
- Explain the importance of GPP and describe several practical ways it can be implemented in current and future biomedical HIV treatment and prevention trials
- Explain why GPP principles are important and how they can be applied in future HIV cure research

Moderator
Mark Hubbard, Tennessee Association of People with AIDS, Nashville, TN, USA

2 FROM LAB TO LICENSURE: THE IMPORTANCE OF GOOD PARTICIPATORY PRACTICE IN RESEARCH

HISTORY AND PRINCIPLES OF GOOD PARTICIPATORY PRACTICE GUIDELINES
Stacey Hannah, AIDS Vaccine Advocacy Coalition, New York, NY, USA

GPP AS A GUIDE TO BIOMEDICAL HIV PREVENTION TRIAL DESIGN AND IMPLEMENTATION
Deborah Baron, Wits RHI, Johannesburg, South Africa

APPLYING GPP PRINCIPLES TO CURE RESEARCH
David Evans, Project Inform, San Francisco, CA, USA
Workshop W2: CLINICAL TRIAL DESIGN AND ANALYSIS
Room 6 C  2:15 PM - 4:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in designing or interpreting clinical and epidemiologic studies.

Level of Knowledge: It is assumed that participants are familiar with the basic design of randomized and observational clinical trials and basic HIV epidemiology.

Objectives: At completion of the session, participants will be able to:
- Provide examples of different study designs to assess efficacy of new prevention methods in the era of preexposure prophylaxis (PrEP)
- Describe approaches to designing and evaluating implementation science trials
- Evaluate strengths and limitations of respondent-driven sampling as a method for recruiting and understanding under-studied populations

Conveners
Susan P. Buchbinder, San Francisco Dept of PH, San Francisco, CA, USA
Richard Chaisson, The Johns Hopkins Univ, Baltimore, MD, USA

3  PREVENTION TRIAL DESIGN IN THE ERA OF PREP
Deborah J. Donnell, Fred Hutchinson Cancer Rsr Center, Seattle, WA, USA

4  IMPLEMENTATION SCIENCE TRIALS: DO THE RULES OF RCTS APPLY?
James R. Hargreaves, London Sch of Hygiene and Trop Med, London, United Kingdom

5  RESPONDENT DRIVEN SAMPLING & OTHER METHODS FOR RECRUITING HARD TO REACH POPULATIONS
Carl A. Latkin, The Johns Hopkins Univ, Baltimore, MD, USA

Workshop W3: FRONTIERS IN LABORATORY SCIENCE
Room 611-614  2:15 PM - 4:00 PM

Target Audience: This session is directed to students, researchers and clinicians who are interested in learning about the application of hot new technologies aimed at profiling the immune response to infection and the intracellular molecular mechanisms exploited by HIV during cellular infection.

Level of Knowledge: It is assumed that the participants are familiar with basic immunology and virology.

Objectives:
- Describe how the CRISPR/Cas9 system may be exploited to explore the molecular mechanisms underlying HIV infection
- Describe the role of RNA structure in HIV infection and latency
- Describe how high-dimensional time-of-flight mass spectrometry may be used to explore single cell immune profile dynamics during infection

Conveners
Galit Alter, Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Frank Kirchhoff, Ulm Univ Medical Center, Ulm, Germany

6  HIGH-THROUGHPUT GENOME ENGINEERING IN PRIMARY CD4+ T CELLS
Judd F. Hultquist, Univ of California San Francisco, San Francisco, CA, USA
7 IDENTIFYING AND PROFILING VIRUS-SPECIFIC T CELLS USING MASS CYTOMETRY
Evan William Newell, Singapore Immunol Network, Singapore, Singapore

8 QUANTIFYING HIV-1 MRNA STRUCTURE AND TRANSLATION EFFICIENCY IN CELLS
Silvi Rouskin, Whitehead Institute, Cambridge, MA, USA

Workshop W4: INTERACTIVE CASE-BASED WORKSHOP ON HEPATITIS C
Room 6 E 2:15 PM - 4:00 PM

Target Audience: This session is directed to persons interested in the management of hepatitis C virus (HCV) infection.

Level of Knowledge: It is assumed that participants are familiar with the general principles of HCV treatment and the medications used.

Objectives: At completion of the session, participants will be able to:
• Recognize the limitations of current approaches to fibrosis staging
• Develop a framework for selection of HCV therapy
• Recognize common situations where resistance testing is indicated
• Recognize and manage common drug interactions with coinfection
• Recognize how treatment approaches differ for persons with cirrhosis

Conveners
Susanna Naggie, Duke Univ, Durham, NC, USA
David Wyles, Denver Health, Denver, CO, USA

9 SESSION DESCRIPTION: INTERACTIVE CASE-BASED WORKSHOP ON HEPATITIS C

APPROACHES TO STAGING AND TREATMENT OF EARLY STAGE HCV
John D. Scott, Univ of Washington, Seattle, WA, USA

EFFECT OF RAVs ON DAA TREATMENT AND RE-TREATMENT OF PTS WITH CHRONIC HCV INFECTION
Alessandra Mangia, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy

COMMON DRUG INTERACTIONS WITH HIV/HCV COINFECTION
Debika Bhattacharya, Univ of California Los Angeles, Los Angeles, CA, USA

CIRRHOSIS ISSUES
Sanjay Bhagani, Royal Free Hosp, London, United Kingdom
OPENING SESSION
Auditorium - 4 AB
5:00 PM - 7:00 PM

Session Hosts
Susan P. Buchbinder, San Francisco Dept of PH, CROI 2017 Chair San Francisco, CA, USA
Judith S. Currier, Univ of California Los Angeles, CROI 2017 Vice Chair Los Angeles, CA, USA
Richard A. Koup, VRC, NIAID, NIH, CROI 2017 Vice Chair Bethesda, MD, USA

Bernard Fields Lecture
The Bernard Fields Lecture, named in tribute to the exemplary work of the esteemed microbiologist and virologist Bernard Fields, is given during the Opening Session, usually by a basic scientist recognized for his or her important and relevant contributions to the fields of virology and viral pathogenesis.

10 INSIGHTS INTO HIV PREVENTION, PATHOGENESIS AND TREATMENT FROM NONHUMAN PRIMATE MODELS
Jeffrey D. Lifson, Frederick National Laboratory for Cancer Research, Frederick, MD, USA

N’Galy-Mann Lecture
The N’Galy-Mann Lecture recognizes an HIV/AIDS researcher for his or her important and relevant work in the fields of epidemiology or clinical research. The Lecture is named in honor of Drs Bosenge N’Galy and Jonathan Mann for their crucial, pioneering work in HIV science in Africa.

11 HIV/AIDS RESEARCH IN ZIMBABWE: PROVIDING THE EVIDENCE FOR QUALITY CARE
James G. Hakim, University of Zimbabwe, Harare, Zimbabwe

CROI Foundation Special Event
Musical performance by Zimbabwean human rights activist Oliver Mtukudzi and his band, the Black Spirits.
TUESDAY, FEBRUARY 14, 2017

Plenary PL-1: TUESDAY PLENARY SESSION
Auditorium - 4 AB  8:30 AM - 9:30 AM

12  THE EMERGING POTENTIAL FOR HIV CURE FOR INFANTS, CHILDREN, AND ADULTS
8:30  Jintanat Ananworanich, US Military HIV Rsr Prog, USA and The Thai Red Cross AIDS Rsr Cntr, Thailand

13  ADVANCES IN CELLULAR THERAPY IN CANCER AND HIV
9:00  Carl H. June, Univ of Pennsylvania, Philadelphia, PA, USA

Oral Abstract O-0:1 - GETTING HIV THROUGH THE CELL
Room 611-614  10:00 AM - 12:00 PM

Oral Abstract Moderators
Jaisri Lingappa, Univ of Washington, Seattle, WA, USA
John M. Coffin, Tufts Univ, Boston, MA, USA

14LB  QUATERNARY CONFIGURATION OF THE FUNCTIONAL CD4-BINDING SITE IN THE HIV-1 ENV TRIMER
10:00  Qingbo Liu, Priyamvada Acharya, Michael Dolan, Peng Zhang, Aliaksandru Druz, William Rice, Bridget Carragher, Clinton Potter, Peter D. Kwong, Paolo Luzso
1 NIH, Bethesda, MD, USA, 2 New York Struct Bio Cntr, New York, NY, USA, 3 NIAID, Bethesda, MD, USA

15  EARLY CYTOPLASMIC UNCOATING IS NECESSARY FOR INFECTIVITY OF HIV-1
10:15  João I. Mamede, Gianguido C. Cianci, Meegan R. Anderson, Thomas Hope Northwestern Univ, Chicago, IL, USA

16  ECCENTRIC VIRAL GENOMIC RNA AND INTEGRASE ARE PREMATURELY DEGRADED IN TARGET CELLS
10:45  Michaela Madison, Dana Q. Lawson, Jennifer Elliott, Ayse N. Ozanturk, Pratibha Chowday Koneru, James R. Fuchs, Mamuak Kvaratskhelia, Sebla B. Kutla
1 Washington Univ in St. Louis, St. Louis, MO, USA, 2 Bilkent Univ, Ankara, Turkey, 3 Ohio State Univ, Columbus, OH, USA

17  DYNAMICS OF NUCLEAR ENVELOPE ASSOCIATION AND NUCLEAR IMPORT OF HIV-1 COMPLEXES
11:00  Ryan C. Burdick, Jianbo Chen, Jaya Sastri, Wei-Shau Hu, Vinay K. Pathak NCI, Frederick, MD, USA

18  CYPA REGULATES HIV-1 ACCESS TO AN FG-GUIDED NUCLEAR ENTRY PATHWAY
11:15  Guangai Xue, Vineet KewalRamani, Shih Lin Goh, Hyun Jae Yu, Anna Gres, KyeongEun Lee, Stefan G. Sarafianos, Jeremy Luban
1 NCI, Frederick, MD, USA, 2 Univ of Massachusetts, Worcester, MA, USA, 3 Univ of Missouri, Columbia, MO, USA

19  A COMPREHENSIVE CRISPR SCREEN IDENTIFIES NOVEL HIV RESTRICTION FACTORS
11:30  Molly Ohainle, Louisa Pendergast, Jolien Vermeire, Michael Emerman Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA
Oral Sessions • Tuesday
Program and Agenda
CROI 2017

20
11:30
A RETROTRANSPOSED ESCRT-III FACTOR BLOCKS HIV-1 BUDDING WITHOUT INDUCING CYTOTOXICITY
Lara Rheinemann, Diane Downhour, Gaelee Mercenne, Alesia McKeown, John McCullough, Wes Sundquist, Nels Elde
Univ of Utah, Salt Lake City, UT, USA

21
11:45
DESIGNED PROTEINS INDUCE THE FORMATION OF NANOCAGE-CONTAINING EXTRACELLULAR VESICLES
Joerg Votteler1, Cassie Ogohara2, Sue Yi1, Yang Hsia2, Una Nattermann2, David M Belnap1, Neil P King2, Wes Sundquist1
1Univ of Utah, Salt Lake City, UT, USA, 2Univ of Washington, Seattle, WA, USA

Oral Abstract O-2: CRITICAL ISSUES IN WOMEN’S HEALTH, MTCT, AND HIV TREATMENT IN CHILDREN
Room 606-609
10:00 AM - 12:00 PM

22
10:00
RANDOMIZED TRIAL OFLEEP VS CRYOTHERAPY TO TREAT CIN2/3 IN HIV-INFECTED WOMEN
Sharon A. Greene1, Evans Nyongesa-Malava1, Barbra A. Richardson1, Grace John-Stewart1, Hugo De Vuyst2, Nelly Yatich1, Catherine Kiptinnes1, Sameh Sakr3, Nelly Mugo4, Michael H. Chung1
1Univ of Washington, Seattle, WA, USA, 2Intl Agency for Rsr on Cancer, Lyon, France, 3Coptic Hosp, Nairobi, Kenya, 4KEMRI, Nairobi, Kenya

23
10:15
NATURAL HISTORY OF CERVICAL INTRAEPITHELIAL NEOPLASIA-2 AMONG HIV-INFECTED WOMEN
Christine Colie1, L. Stewart Massad2, Cuiwei Wang1, Kate Michel1, Gysamber D’Souza3, Joel Palefsky4, Howard D. Strickler4, Seble Kassaye1
1Georgetown Univ, Washington, DC, USA, 2Washington Univ, St. Louis, MO, USA, 3The Johns Hopkins Univ, Baltimore, MD, USA, 4Royal Phil Hosp, Sydney, Australia

24
10:30
INTEGRATION OF POSTNATAL SERVICES IMPROVES MCH AND ART OUTCOMES: A RANDOMISED TRIAL
Landon Myer1, Tamsin Phillips2, Allison Zerbe3, Kirsty Brittain1, Stanzi M. Le Roux1, Robert Remien1, Claude A. Mellins2, James A. McIntyre3, Elaine J. Abrams2, for the Maternal Child Health - Antiretroviral Therapy (MCH-ART) study
1Univ of Cape Town, Cape Town, South Africa, 2Columbia Univ, New York, NY, USA, 3New York State Psychiatric Inst, New York, NY, USA, 4Anova Hlth Inst, Johannesburg, South Africa

25
10:45
ADVERSE BIRTH OUTCOMES DIFFER BY ART REGIMEN FROM CONCEPTION IN BOTSWANA
Rebecca Zash1, Denise Jacobson2, Modiegi Disoko3, Gloria Mayondi1, Mompati Mmalane1, Chipo Petlo4, Max Essex2, Shahin Lockman2, Joseph Makhema1, Roger L. Shapiro2
1Beth Israel Deaconess Med Cntr, Boston, MA, USA, 2Harvard Univ, Boston, USA, 3Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana, 4Ministry of Hlth, Botswana, Gaborone, Botswana, 5Brigham and Women’s Hosp, Boston, MA, USA
26
11:00
EFFECT OF POINT-OF-CARE TESTING ON ANTIRETROVIRAL- THERAPY INITIATION RATES IN INFANTS
Ilesh Jani1, Bindiya Meggi1, Osvaldo Loquiha2, Ocean Tobaiwa2, Chishamiso Mudenyanga2, Dadiyai Mutsaka2, Nedio Mabunda1, Adolfo Vubil1, Lara Vojnov2, Trevor Peter4
1Instituto Nacional de Saude, Maputo, Mozambique, 2Clinton Hlth Access Initiative, Maputo, Mozambique
TREATMENT OF ACUTE HIV INFECTION IN NEONATES
11:15
Louise Kuhn1, Karl Technau2, Renate Strehlau2, Stephanie Shiau1, Faeezah Patel2, Gayle G. Sherman1, Caroline Tiemessen1, Grace M. Aldrovandi4, Ashraf Coovadia2, Elaine J. Abrams3
1Columbia Univ, New York, NY, USA, 2Empilweni Service and Rsr Unit, Johannesburg, South Africa, 3Natl Inst of Communicable Diseases, Johannesburg, South Africa, 4Univ of California Los Angeles, Los Angeles, CA, USA, 3ICAP at Columbia Univ, New York, NY, USA
RAPID DECLINE OF TOTAL HIV DNA IN CHILDREN STARTING ART WITHIN 8 DAYS OF BIRTH
11:30
Kirsten A. Veldsman1, Jean Maritz2, Shahieda Isaacs1, Mary Grace K. Katusiime1, Heleen La Grange1, Barbara Laughton1, John Mellors3, Mark Cotton2, Gert U. van Zyl1
1Stellenbosch Univ, Parow, South Africa, 2Stellenbosch Univ, Cape Town, South Africa, 3Univ of Pittsburgh, Pittsburgh, PA, USA
LOPINAVIR/RITONAVIR 1:1 SUPER-BOOSTING OVERCOMES RIFAMPICIN INTERACTIONS IN CHILDREN
11:45
Helena Rabie1, Paolo Denti2, Janice Lee1, Mhleli Masango4, Ashraf Coovadia1, Sandy Pillay3, Afaaf Liberty4, Helen Mcilleron1, Mark Cotton1, Marc Lallemant3
1Stellenbosch Univ, Cape Town, South Africa, 2Univ of Cape Town, Cape Town, South Africa, 3Drug for Neglected Diseases Initiative, Geneva, Switzerland, 4Univ of the Witwatersrand, Johannesburg, South Africa, 5Enhancing Care Foundation, Wentworth Hosp, Durban, South Africa
HIDING IN PLAIN SIGHT: DISCOVERING THE UNDIAGNOSED AND UNDERTREATED HIV EPIDEMIC
10:00 AM - 12:00 PM
Oral Abstract Moderators
Carlos del Rio, Emory Univ, Atlanta, GA, USA
Aleny Couto, Ministry of Health, Maputo, Mozambique
HIV INCIDENCE, PREVALENCE, AND UNDIAGNOSED INFECTIONS IN MEN WHO HAVE SEX WITH MEN
10:00
Sonia Singh, Ruiguang Song, Anna S. Johnson, Eugene McCray, Irene Hall
CDC, Atlanta, GA, USA
VIRAL-LOAD DYNAMICS AMONG PERSONS WITH DIAGNOSED HIV: UNITED STATES, 2014
10:15
Nicole Crepaz1, Tian Tang2, Gary Marks3, Irene Hall4
1CDC, Atlanta, GA, USA, 2ICF Intl, Atlanta, GA, USA
32 TIME SPENT WITH HIV VIRAL LOAD >1500 COPIES/ML AMONG PATIENTS IN HIV CARE, 2000-2014
10:30
Kate Buchacz1, Maria Mendoza1, Carl Armon1, Frank J. Palella1, Charles Rose1, Ellen Tedaldi1, Richard Novak2, Lytt Gardner3, for the the HIV Outpatient Study
1CDC, Atlanta, GA, USA, 2Cerner Corp, Kansas City, MO, USA, 3Northwestern Univ, Chicago, IL, USA, 4Temple Univ, Philadelphia, PA, USA, 5Univ of Illinois, Chicago, IL, USA

33 A RANDOMIZED TRIAL OF NOVEL STRATEGIES TO INCENTIVIZE HIV TESTING AMONG MEN IN UGANDA
10:45
Gabriel Chamie1, Elisabeth Schaffer2, Alex Nyabakira3, Devy Emperador1, Dalsone Kwarisiima4, Diane V. Havlir1, James Kahn1, Moses R. Kamya5, Harsha Thirumurthy6
1Univ of California San Francisco, San Francisco, CA, USA, 2Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 3Makerere Univ and Univ of California San Francisco Rsr Collab, Mbarara, Uganda, 4Makerere Univ Joint AIDS Prog, Kampala, Uganda, 5Makerere Univ Coll of Hlth Scis, Kampala, Uganda

34LB COMBINATION HIV PREVENTION AND HIV INCIDENCE IN RAKAI, UGANDA
11:00
Mary K. Grabowski1, Gertrude Nakigozi2, Fred Nalugoda2, Thomas Quinn1, Godfrey Kigozi3, Ronald H. Gray1, David Serwadda4, Maria Wawer1, Steven J. Reynolds5, Larry W. Chang1
1The Johns Hopkins Univ, Baltimore, MD, USA, 2Rakai Health Sciences Prog, Kalisizo, Uganda, 3Makerere Univ, Kampala, Uganda, 4NIAID, Washington, DC, USA

35 NAMIBIA PILOTS SENTINEL POPULATION SURVEILLANCE OF HIV INCIDENCE AND VIRAL SUPPRESSION
11:15
Tuli Nakanyala1, Andrew D. Maher2, Nicholus Mutenda1, Karen M. Banda2, Anna Jonas3, Charity Ntema4, Ndapewa Hamunime1, David W. Lowrance5, Sadhna V. Patel5, Willi McFarland2
1Ministry of Hlth and Social Services, Windhoek, Namibia, 2Univ of California San Francisco, San Francisco, CA, USA, 3US CDC, Windhoek, Namibia, 4Development Aid from People to People, Windhoek, Namibia, 5CDC, Atlanta, GA, USA

36 SOCIAL NETWORKS AND HIV PREVALENCE IN KENYA IN THE SEARCH STUDY
11:30
Wenjing Zheng1, Norton Sang2, Gabriel Chamie3, Laura B. Balzer4, Craig Cohen1, Tamara D. Clark1, Edwin D. Charlebois5, Moses R. Kamya2, Diane V. Havlir1, Maya L. Petersen1
1Univ of California Berkeley, Berkeley, CA, USA, 2Kenya Med Rsr Inst, Nairobi, Kenya, 3Univ of California San Francisco, San Francisco, CA, USA, 4Harvard Univ, Boston, MA, USA, 5Makerere Univ Coll of Hlth Scis, Kampala, Uganda

37 HIGH RATE OF DISEASE PROGRESSION IN UNTREATED HIV-2 INFECTION
11:45
Joakim Esbjörnsson1, Fredrik Månsson1, Anders Kvist1, Zacarias J. da Silva4, Jacob Lindman1, Angelica Palm1, Marianne Jansson1, Patrik Medstrand1, Hans Norrgren2, for the SWEGUB CORE Group
1Univ of Oxford, Oxford, UK, 2Lund Univ, Malmö, Sweden, 3Lund Univ, Lund, Sweden, 4LNSP, Bissau, Guinea-Bissau
Oral Abstract O-4: NEW HIV DRUGS, FORMULATIONS, COMBINATIONS, AND RESISTANCE

Room 6 AB 10:00 AM - 12:00 PM

Oral Abstract Moderators
Sally Hodder, West Virginia Clinical and Translational Science Inst, Morgantown, WV, USA
Yazdan Yazdanpanah, Inserm, IAME, Paris, France

38 DISCOVERY OF NOVEL POTENT HIV CAPSID INHIBITORS WITH LONG-ACTING POTENTIAL
10:00
Gilead Scis, Inc, Foster City, CA, USA

39 HUMAN CONFIRMATION OF ORAL DOSE REDUCTION POTENTIAL OF NANOPARTICLE ARV FORMULATIONS
10:15
Andrew Owen1, Steve Rannard1, Akil Jackson2, Laura Dickinson1, Marco Giardiello1, Marco Siccardi1, Paul Domanico1, Melynda Watkins1, Yao Cheng2, Marta Boffito3
1Univ of Liverpool, Liverpool, UK, 2Chelsea and Westminster Hosp, London, UK, 3Clinical HIV Access Initiative, Boston, MA, USA

40 CLINICAL PHARMACOLOGY OF THE HIV INTEGRASE STRAND TRANSFER INHIBITOR BICTEGRAVIR
10:30
Heather Zhang, Joseph M. Custodio, Xuelian Wei, Hui Wang, Amanda Vu, John Ling, Hal Martin, Erin Quirk, Brian P. Kearney
Gilead Sci, Foster City, CA, USA

41 RANDOMIZED TRIAL OF BICTEGRAVIR OR DOLUTEGRAVIR WITH FTC/TAF FOR INITIAL HIV THERAPY
10:45
Paul E. Sax1, Edwin DeJesus2, Gordon Crofoot3, Douglas Ward4, Paul Benson5, Xuelian Wei6, Kirsten L. White6, Hal Martin6, Andrew Cheng4, Erin Quirk6
1Brigham and Women’s Hosp, Boston, MA, USA, 2Orlando Immunol Cntr, Orlando, FL, USA, 3The Crofoot Rsr Cntr, Houston, TX, USA, 4Dupont Circle Physicians Group, Washington, DC, USA, 5Be Well Med Cntr, Berkley, MI, USA, 6Gilead Scis, Inc, Foster City, CA, USA

42 PATHWAYS OF RESISTANCE IN SUBJECTS FAILING DOLUTEGRAVIR MONOTHERAPY
11:00
José L. Blanco1, Celia Oldenbuettel2, Réjean Thomas3, Josep Mallolos1, Eva Wolff4, Bluma Brenner5, Christoph D. Spinner6, Mark A. Wainberg2, Esteban Martinez2, for the Redo Group
1Hosp Clinico Barcelona, Barcelona, Spain, 2MVZ Karlplatz, HIV Rsr and Clinical Care Cntr, München, Germany, 3Clinique Médicale l’Actuel, Montreal, QC, Canada, 4MUC Rsr, Munich, Germany, 5McGill Univ, Montreal, Quebec, Canada, 6Univ Klinikum Rechts der Isar, Munich, Germany

43 PREVALENCE AND IMPACT OF PRETREATMENT DRUG RESISTANCE IN THE ANRS 12249 TASP TRIAL
11:15
Anne Derache1, Collins C. Ivuji2, Siva Danaviah1, Anne-Geneviève Marcelin1, Vincent Calvez1, Tulio de Oliveira2, François Dabis3, Deenan Pillay1, for the ANRS 12249 Treatment as Prevention
1Africa Hlth Rsr Inst Mtubatuba, South Africa, 2Univ Coll London, London, UK, 3Pitié-Salpetrière Hosp, Paris, France, 4Univ of KwaZulu-Natal, Durban, South Africa, 5Univ de Bordeaux, Bordeaux, France
44LB PHASE III SWORD 1&2: SWITCH TO DTG+RPV MAINTAINS VIROLOGIC SUPPRESSION THROUGH 48 WKS
38 CROI 2017

10:30

Josep M. Llibre 1, Chien-Ching Hung 2, Cynthia Brinson 1, Francesco Castelli 1, Pierre-Marie Girard 1, Lesley Kahl 1, Elizabeth Blair 1, Brian Wynn 1, Kati Vandermeulen 1, Michael Aboud 1

1Univ Hosp Germans Trias, Badalona, Barcelona, Spain, 2Natl Taiwan Univ Hosp, Taipei, Taiwan, 3Central Texas Clinical Rsr, Austin, TX, USA, 4ASST Spedali Civili di Brescia, Brescia, Italy, 5Saint-Antoine Hosp, Paris, France, 6ViiV Hlthcare, Brentford, Middlesex, UK, 7ViiV Hlthcare, Rsr Triangle Park, NC, USA, 8Viiv Hlthcare, Collegeville, PA, USA, 9Janssen, Beersse, Belgium

45LB DORAVIRINE IS NON-INFERIOR TO DARUNAVIR/R IN PHASE 3 TREATMENT-NAÏVE TRIAL AT WEEK 48
11:45

Jean-Michel Molina 1, Kathleen Squires 2, Paul E. Sax 3, Pedro Cahn 1, Johan Lombaard 1, Edwin DeJesus 4, Xia Xu 5, Bach-Yen T. Nguyen 6, George Hanna 1, Carey Hwang 1

1Hosp St Louis, Paris, France, 2Thomas Jefferson University, Philadelphia, PA, USA, 3Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, 4Fundación Huesped, Buenos Aires, Argentina, 5Josha Research, Bloemfontein, South Africa, 6Orlando Immunology Center, Orlando, FL, USA, 7Merck & Co, Inc, Kenilworth, NJ, USA

Themed Discussion TD-1: CD8 T CELLS: WHERE AND HOW THEY KILL
Room 615-617
1:30 PM - 2:30 PM

Themed Discussion Leader
Nicole Frahm, FHCRC, Seattle, WA, USA

266 LYMPH NODE HIV-SPECIFIC CXCR5+ CTLs ARE ASSOCIATED WITH ENHANCED VIRAL CONTROL

Zaza Ndhlovu 1, Funsho Ogunshola 2, Omolara Baiyegunhi 2, Nikoshia Mewalal 1, Amber Moodley 2, Krista Dong 1, Thumbi Ndung'u 1, Bruce D. Walker 1

1Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA, 2Univ of KwaZulu Natal, Durban, South Africa

267 RESIDENT MEMORY CD8+ T CELLS FORM THE FRONT-LINE DEFENSE IN HIV-INFECTED LYMPH NODES

Marcus Buggert 1, Lalit Beura 1, Son Nguyen 1, David Canaday 3, Ali Najibi 1, Constantinos Petrovas 1, Gustavo Reyes-Terán 3, Steven G. Deeks 1, David Masopust 1, Michael R. Betts 1

1Univ of Pennsylvania, Philadelphia, PA, USA, 2Univ of Minnesota, Minneapolis, MN, USA, 3Case Western Reserve Univ, Cleveland, OH, USA, 4Hosp of the Univ of Pennsylvania, Philadelphia, PA, USA, 5NIH, Bethesda, MD, USA, 6Rsr Cntr in Infectious Diseases, Mexico City, Mexico, 7Univ of California San Francisco, San Francisco, CA, USA

268 HIV-1 ESCAPE FROM CD8+ CYTOTOXIC T-LYMPHOCYTES DEFINED AT CLONAL RESOLUTION

Aleksandr Gorin 1, Yushen Du, Ren Sun, Otto Yang

Univ of California Los Angeles, Los Angeles, CA, USA

269 INVESTIGATING THE ROLE OF TCR STRUCTURE IN FUNCTIONAL ACTIVITY OF HIV-SPECIFIC CTLs

Nina C. Flerin 1, Tynisha Glover 1, Huabiao Chen 2, Jianhua Zheng 1, Harris Goldstein 1

1Albert Einstein Coll of Med, Bronx, NY, USA, 2Ragon Inst of Massachusetts General Hosp, Cambridge, MA, USA
Themed Discussion TD-2: VIRUS AND CELL RNA IN HIV REPLICATION
Room 611-614
1:30 PM - 2:30 PM

Themed Discussion Leader
Kate Bishop, The Francis Crick Inst, London, UK

161 UBP43 (USP18) ABROGATES SAMHD1-MEDIATED RESTRICTION OF HIV-1
Edmund Osei-Kuffour1, Kerstin Schott1, Dieter Häussinger1, Philipp A. Lang1, Karl S. Lang1, Renate König1, Carsten Münk1
1Heinrich Heine Univ Hosp, Düsseldorf, Germany, 2Paul Ehrlich Institut, Fed Inst for Vaccines and BioMeds, Düsseldorf, Germany, 3Univ Hosp, Essen, Düsseldorf, Germany, 4Paul Ehrlich Institut, Langen, Germany

162 LINC RNA DISCOVERY IN THE HIV REPLICATION CYCLE ADDS A NEW LAYER IN HIV-Host INTERPLAY
Wim Trypsteen1, Pejman Mohammadi2, Clarissa Van Hecke1, Pieter Mestdagh1, Steve Lefever1, Pieter De Bleser1, Jo Vandesompele1, Angela Ciuffi2, Ward De Spiegeleere1, Linos Vandekerckhove1
1Ghent Univ, Ghent, Belgium, 2Univ of Lausanne, Lausanne, Switzerland, 3Inflammation Rsr Cntr, Flanders Inst of BioTech, Ghent, Belgium

163 SPlicing IN A PANEL OF HIV-1 TRANSMITTED/FOUNDER VIRUSES
Ann Emery, Ronald Swanstrom
Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

164 THE ROLES OF 5 CONSERVED LENTIVIRAL RNA STRUCTURES IN HIV-1 REPLICATION
Yang Liu1, Olga A. Nikolaitchik1, Belete A. Desimme1, Vinay K. Pathak1, Kevin M. Weeks2, Wei-Shau Hu1
1NCI, Frederick, MD, USA, 2Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

165 EXPONENTIAL GROWTH OF HIV DEPENDENT ON BURST SIZE BREAKTHROUGH OF THE ALLEE THRESHOLD
Jason M. Hataye1, Joseph P. Casazza1, David R. Ambrozek1, Takuya Yamamoto2, Daniel Douek2, Alan S. Perelson3, Richard A. Koup4
1NIH, Bethesda, MD, USA, 2Osaka Univ, Sukta, Osaka, Japan, 3NIAID, Bethesda, MD, USA, 4Los Alamos Natl Lab, Los Alamos, NM, USA
Oral Sessions • Tuesday
Program and Agenda
CROI 2017

Themed Discussion TD-3: HIV, MIGRATION, AND ACCESS TO CARE
Room 606-609
1:30 PM - 2:30 PM

Themed Discussion Leader
Andrea Howard, Columbia Univ, New York, NY, USA

1015 MIGRATION, GENDER, AND HIV INCIDENCE IN RAKAI, UGANDA
Oluwasolape M. Olawore, Aaron Tobian, Fred Nalugoda, Ronald H. Gray, Maria Wawer, Robert Sekekubugu, John Santelli, Larry W. Chang, David Serwadda, Kate Grabowski

The Johns Hopkins Univ, Baltimore, MD, USA, 2 Rakai Hlth Scis Prog, Kalsizo, Uganda, 3 Columbia Univ, New York, NY, USA, 4 Makerere Univ, Kampala, Uganda

1016 OUTCOMES ALONG THE HIV CARE CONTINUUM AMONG UNDOCUMENTED IMMIGRANTS IN CLINICAL CARE
Jonathan Ross, Uriel Felsen, Chinazo Cunningham, Viraj V. Patel, David B. Hanna

Albert Einstein Coll of Med, Bronx, NY, USA

1017 IMMIGRANTS AND BOTSWANA’S ART PROGRAM: POTENTIAL BARRIERS TO EPIDEMIC CONTROL
Tafireyi Marukutira, Mary Grace Alwano, Stephanie Behel, Joseph N. Jarvis, Unoda Chakalisa, Kathleen Powis, William Bapati, Gene Ussery, Refetekele Lebelonyane, Pamela J. Bachanas

US CDC, Gaborone, Botswana, 2 CDC, Atlanta, GA, USA, 3 Botswana Harvard Partnership, Gaborone, Botswana, 4 Harvard Univ, Boston, MA, USA, 5 Tebeloelle Voluntary Counseling and Testing Cntr, Gaborone, Botswana, 6 Northrop Grumman Corporation, Atlanta, GA, USA, 7 Botswana Ministry of Hlth, Gaborone, Botswana

1018 CASCADE OF CARE OF HIV SEROCONVERTERS IN THE CONTEXT OF UNIVERSAL “TEST AND TREAT”
Joseph Larmarange, Mamadou H. Diallo, Collins C. Iwuji, Joanna Orne-Gliemann, Nuala McGrath, Melanie Plazy, Frank Tanser, Rodolphe Thiébaut, Deenan Pillay, François Dabis

IRD, Paris, France, 2 Univ Coll London, UK, London, UK, 3 INSERM, Bordeaux, France, 4 Univ of Southampton, Southampton, UK, 5 Africa Hlth Rsr Inst, Mtubatuba, South Africa, 6 Univ de Bordeaux, Bordeaux, France

Themed Discussion TD-4: OBESITY AND FATTY LIVER DISEASE
Room 6 C
1:30 PM - 2:30 PM

Themed Discussion Leader
John Koethe, MD, Vanderbilt University Medical Center, Nashville, TN, USA

693 BODY MASS INDEX AND THE RISK OF SERIOUS NON-AIDS EVENTS: THE D:A:D STUDY
Amit C. Achhra, Caroline Sabin, Lene Ryom, Antonella d’Arminio Monforte, Stephanie de Wit, Andrew Phillips, Christian Pradier, Jens D. Lundgren, Matthew Law

1 Kirby Inst, Sydney, Australia, 2 Univ Coll London, London, UK, 3 CHIP, Copenhagen, Denmark, 4 Univ of Milan, Milan, Italy, 5 Univ Libre de Bruxelles, Brussels, Belgium, 6 Nice Univ Hosp, Nice, France, 7 Univ of Copenhagen, Copenhagen, Denmark

40 CROI 2017
694 RANDOMIZED TRIAL OF BEHAVIORAL WEIGHT LOSS FOR HIV-INFECTED PATIENTS
Katie Becofsky¹, Edward J. Wing², Jeanne McCaffery³, Matthew Boudreau¹, Rena R. Wing¹
¹Univ of Massachusetts Amherst, Amherst, MA, USA, ²Brown Univ, Providence, RI, USA, ³The Miriam Hosp, Providence, RI, USA

695 PREDICTORS OF SEVERE WEIGHT/BODY MASS INDEX GAIN FOLLOWING ANTIRETROVIRAL INITIATION
Priya Bhagwat¹, Igho Ofotokun², Grace A. McComsey², Todd Brown¹, Carlee Moser², Catherine A. Sugar¹, Judith S. Currier¹
¹Univ of California Los Angeles, Los Angeles, CA, USA, ²Emory Univ, Atlanta, GA, USA, ³Case Western Reserve Univ, Cleveland, OH, USA, ⁴The Johns Hopkins Univ, Baltimore, MD, USA, ⁵Harvard Univ, Boston, MA, USA

696 Raltegravir Switch and Biomarkers of Liver Steatosis and Metabolic Syndrome in Women
David Reynoso¹, Anoma Somasunderam¹, Maitreyee Nigalye¹, Judith S. Currier¹, Netanya S. Utay¹, Jordan E. Lake³
¹Univ of Texas Med Branch at Galveston, Galveston, TX, USA, ²Univ of California Los Angeles, Los Angeles, CA, USA, ³Univ Texas Houston, Houston, TX, USA

697 Changes in Liver Steatosis After Switching Efavirenz to Raltegravir: The Steral Study
Juan Macías¹, Dolores Merino¹, Francisco Téllez³, Federico Pulido¹, Juan González-Garcia¹, Manuel Márquez⁴, Antonio Rivero¹, María Mancebo³, Juan A. Pineda¹, for the RIS-HEP09
¹Hosp Univ de Valme, Sevilla, Spain, ²Complejo Hospitalario Univ de Huelva, Huelva, Spain, ³Hosp Univ de Puerto Real, Cádiz, Spain, ⁴Hosp 12 de Octubre, Madrid, Spain, ⁵Hosp Univ La Paz, Madrid, Spain, ⁶Hosp Virgen de la Victoria, Málaga, Spain, ⁷Hosp Univ Reina Sofia, Cordoba, Spain

Themed Discussion TD-5: PREP WITHOUT BORDERS: NEW DELIVERY OPTIONS
Room 6 E
1:30 PM - 2:30 PM

Themed Discussion Leader
Aaron Siegler, Emory Univ, Atlanta, GA, USA

961 Feasibility of a Pharmacist-Run HIV Prep Clinic in a Community Pharmacy Setting
Elyse Tung¹, Annalisa Thomas¹, Allyson Eichner¹, Peter Shalit³
¹Kelley-Ross Pharm, Seattle, WA, USA, ²Univ of Washington, Seattle, WA, USA

962 Assessing the Efficacy and Feasibility of a Retail Pharmacy-Based HIV Testing Program
Bryan C. Collins, Heather W. Bronson, Elaine G. Martin
Virginia Dept of Hlth, Richmond, VA, USA

963 Midwest Pharmacists’ Knowledge of & Willingness to Provide Preexposure Prophylaxis
Jordan Broekhuis, Kimberly K. Scarsi, Harlan Sayles, Donald Klepser, Joshua Havens, Susan Swindells, Sara H. Bares
Univ of Nebraska, Omaha, NE, USA

964 Text Messaging is Associated with Improved Retention in a Clinic-Based Prep Program
Christine M. Khosropour¹, Richard T. Lester¹, Matthew R. Golden¹, Julia C. Dombrowski¹
¹Univ of Washington, Seattle, WA, USA, ²Univ of British Columbia, Vancouver, British Columbia, Canada
BRIEF BEHAVIORAL INTERVENTION INCREASES PREP DRUG LEVELS IN A REAL-WORLD SETTING

Sarit A. Golub1, Stephanie Pena2, Amy Hilley3, John Pachankis4, Asa Radix2
1City Univ of New York, New York, NY, USA, 2Callen-Lorde Community Hlth Cntr, New York, NY, USA, 3Hunter HIV/AIDS Rsr Team, New York, NY, USA, 4Yale Univ, New Haven, CT, USA

Symposium S-1 VISIONS OF HIV CURE
Room 6 E
4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding the mechanisms of HIV persistence during antiretroviral therapy and the novel strategies developed to cure HIV infection or at least reduce the size of the viral reservoir.

Level of Knowledge: It is assumed that the participants are familiar with the concept of viral reservoirs, HIV latency and cure strategies.

Objectives: At the completion of the session, participants will be able to:
- Describe the methods used to identify and quantify persistently infected cells during antiretroviral therapy
- Evaluate the potential of novel curative strategies
- Describe the mechanism by which an immune intervention (vaccine, immune checkpoint blockers) may reduce the size of the viral reservoir

Conveners
R. Brad Jones, George Washington Univ, Washington, DC, USA
Sharon Lewin, Univ of Melbourne, Melbourne, Australia

46 VISUALIZING PERSISTENT HIV IN CLINICAL SAMPLES
4:00
Daniel E. Kaufmann, Univ of Montreal, Montreal, QC, Canada

47 CHARACTERIZING HIV EXPRESSION IN VIVO
4:30
Mary F. Kearney, NCI, NIH, Frederick, MD, USA

48 IMMUNE-BASED INTERVENTIONS TARGETING INFLAMMATION AND VIRAL PERSISTENCE
5:00
Mirko Paiardini, Emory Univ Sch of Med, Atlanta, GA, USA

49 THERAPEUTIC VACCINATION FOR HIV/SIV: WHAT WILL IT TAKE FOR CURE?
5:30
Louis J. Picker, Oregon Hlth & Sci Univ, Beaverton, OR, USA

**Room 606-609**  
4:00 PM - 6:00 PM

**Target Audience:** This session is directed to clinicians and researchers interested in the pathogenesis, clinical manifestations, diagnosis, treatment and prevention of tuberculosis (TB) and its complications, including HIV and TB co-infection.

**Level of knowledge:** It is assumed that participants are familiar with basic TB biology, epidemiology, clinical features and treatment.

**Objectives:** At the completion of the session, participants will be able to:
- Describe the epidemiology of and factors associated with transmission of multidrug resistant TB (MDR-TB)
- Identify appropriate regimens utilizing new and investigational drugs for treatment of MDR-TB, including the challenges associated with their use in children
- Assess the role of new and existing technologies for diagnosis of MDR-TB

**Conveners**
- Constance Benson, Univ of California San Diego, San Diego, CA, USA
- Roxana Rustomjee, NIAID, NIH, DHHS, Rockville, MD, USA

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>MDR-TB EPIDEMIOLOGY AND TRANSMISSION DYNAMICS</td>
<td>4:00</td>
<td>N. Sarita Shah, CDC, Atlanta, GA, USA</td>
</tr>
<tr>
<td>51</td>
<td>EMERGING TREATMENT ISSUES IN MDR-TB</td>
<td>4:30</td>
<td>Francesca Conradie, Univ of the Witswatersrand, Johannesburg, South Africa</td>
</tr>
<tr>
<td>52</td>
<td>NEW DIAGNOSTIC TECHNOLOGIES FOR MDR-TB</td>
<td>5:00</td>
<td>Catharina C. Boehme, Fndn for Innovative New Diagnostics (FIND), Geneva, Switzerland</td>
</tr>
<tr>
<td>53</td>
<td>THE CHALLENGES OF TREATING MDR-TB IN CHILDREN</td>
<td>5:30</td>
<td>H. Simon Schaaf, Stellenbosch Univ, Cape Town, South Africa</td>
</tr>
</tbody>
</table>
Symposium S-3 STRANGERS IN THE NIGHT: CHALLENGES AND OPPORTUNITIES IN STI CONTROL

Room 6 C  4:00 PM - 6:00 PM

Target audience: This session is directed to clinicians and scientists who are interested in understanding the prevention and management of sexually transmitted infections, and their relationship to HIV.

Level of knowledge: It is assumed that the participants are familiar with basic HIV and STI epidemiology.

Objectives:
At the completion of the session, participants will be able to:
- Describe the role of the vaginal microbiome in susceptibility of HIV acquisition
- Discuss strategies for prevention of sexually transmitted infections
- Identify the promise of point of care tests for sexually transmitted infections

Conveners
Deborah Money, Univ of British Columbia, Vancouver, BC, Canada
Arlene Sena, Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

54  4:00  VAGINAL MICROBIOME AND SUSCEPTIBILITY TO HIV
R. Scott McClelland, Univ of Washington, Seattle, WA, USA

55  4:30  ANTIBIOTIC PROPHYLAXIS FOR STIs: PROMISES OR PERILS
Jean-Michel Molina, Univ of Paris Diderot, Paris, France

56  5:00  SYPHILIS IN THE ERA OF TREATMENT AS PREVENTION AND PRE-EXPOSURE PROPHYLAXIS
Matthew R. Golden, Univ of Washington, Seattle, WA, USA

57  5:30  SCALE-UP OF POINT-OF-CARE TESTS FOR SEXUALLY TRANSMISSIBLE INFECTIONS
Rebecca J. Guy, Kirby Inst, Univ of New South Wales, Sydney, Australia
WEDNESDAY, FEBRUARY 15, 2017

Plenary PL-2 WEDNESDAY PLENARY SESSION
Auditorium - 4 AB 8:30 AM - 9:30 AM

58 8:30 (PREVENTING) THE COMING EPIDEMIC: HIV IN YOUTH
Shannon L. Hader, CDC, Atlanta, GA, USA

59 9:00 ANTIVIRAL VACCINE DEVELOPMENT FROM A (AIDS) TO Z (ZIKA)
Barney S. Graham, NIAID, VRC, NIH, Bethesda, MD, USA

Oral Abstract O-5 ROLE OF HOST AND IMMUNE FACTORS IN HIV INFECTION
Room 611-614 10:00 AM - 12:00 PM

Oral Abstract Moderators
Michael Betts, Univ of Pennsylvania, Philadelphia, PA, USA
Irini Sereti, NIAID, Bethesda, MD, USA

60 10:00 IMMUNE CORRELATES OF HIV ACQUISITION
Krystelle Neganou Makamdog1, Slim Fourati2, Jianfei Hu3, Amy Ransier1, Farida Laboune1, Rafick-Pierre Sekaly1, Daniel Douek1
1NIAID, Bethesda, MD, USA, 2Case Western Reserve Univ, Cleveland, OH, USA

61 10:15 MARKED CHANGES IN CELLULAR BUT NOT VIRUS TRANSCRIPTOME IN CD4-LOW HIV-INFECTED CELLS
Joseph P. Casazza1, Eli Boritz2, David R. Ambrozak3, Amy R. Henry2, Farida Laboune1, Sam Darko1, Jianfei Hu3, Christine Grechi2, Daniel Douek2, Richard A. Koup2
1NIH, Bethesda, MD, USA, 2VRC, NIAID, Bethesda, MD, USA

62LB 10:30 SINGLE CELL TRANSCRIPTIONAL PROFILING REVEALS A NOVEL POPULATION OF MUCOSAL TFH CELLS
Andrew R. Rahmberg1, Premeeala A. Rajakumar1, James M. Billingsley2, Surinder P. Gill1, R. Paul Johnson1
1Emory Univ, Atlanta, GA, USA, 2Yerkes Natl Primate Rsr Cntr, Decatur, GA, USA

63 10:45 HIGH HIV PERMISSIVITY OF T FOLLICULAR REGULATORY CELLS IS RELATED TO Ki67 EXPRESSION
Shannon Miller1, Brodie Miles1, Joy Folkvord2, Amie Meditz1, Martin McCarter1, Mario Santiago1, David N. Levy4, Samantha MaWhinney1, Elizabeth Connick2
1Univ of Colorado Denver, Aurora, CO, USA, 2Univ of Arizona, Tucson, AZ, USA, 3Boulder Community Hosp, Boulder, CO, USA, 4New York Univ Coll of Dentistry, New York, NY, USA

64LB 11:00 VIRION INCORPORATION OF INTEGRIN α4β7: IMPLICATIONS FOR HIV-1 PATHOGENESIS
Christina Guzzo, David Ichikawa, Chung Park, Cathy Rehm, Claudia Cicala, James Arthos, Anthony S. Fauci, John Kehrl, Paolo Lusso
NIAID, Bethesda, MD, USA
DEFINING THE NATURE OF CD8+ T-CELL RESPONSES IN LYMPH NODES OF HIV ELITE CONTROLLER

Son Nguyen1, Marcus Buggert2, Ali Naji3, Perla Del Rio-Estrada3, Gustavo Reyes-Teran4, Steven G. Deeks5, Michael R. Betts1
1Univ of Pennsylvania, Philadelphia, PA, USA, 2Hosp of the Univ of Pennsylvania, Philadelphia, PA, USA, 3Rsr Cntr in Infectious Diseases, Mexico City, Mexico, 4Univ of California San Francisco, San Francisco, CA, USA

HIV-SPECIFIC BINDING ANTIBODY PROFILES ASSOCIATED WITH BROADLY NEUTRALIZING ACTIVITY

Claus Kadelka, Thomas Liechti, Hanna Ebner, Peter Ruset, Roger Kouyos, Huldrych F. Günthard, Alexandra Trkola
Univ of Zurich, Zurich, Switzerland

THE IMPACT OF HIV-GENETICS ON IMPRINTING ANTIBODY RESPONSES: THE SWISS 4.5K SCREEN

Roger Kouyos, Peter Ruset, Claus Kadelka, Alex Marzel, Thomas Liechti, Merle Schanz, Hanna Ebner, Huldrych F. Günthard, Alexandra Trkola, for the Swiss HIV Cohort Study
Univ of Zurich, Zurich, Switzerland

INTENSITY OF SUPPRESSION LINKED WITH SHIFTING COMPARTMENTALIZATION OF CNS HIV DNA

Benjamin B. Gelman1, Joshua G. Lisinicchia1, Lalita D. Singh1, Vipulkumar N. Patel1, Alexander J. Gill2, Colleen E. Kovacsics2, Dennis L. Kolson2
1Univ of Texas Med Branch, Galveston, TX, USA, 2Univ of Pennsylvania, Philadelphia, PA, USA

CNS PARENCHYMA AND CHOROID PLEXUS, NOT CSF, ARE VIRAL RESERVOIRS IN MONKEYS WITH AIDS

Jaclyn Mallard1, Brittany Rife1, Emily Papazian1, Arianna Noggle1, David J. Nolan1, Marco Salemi2, Kenneth C. Williams1
1Boston Coll, Chestnut Hill, MA, USA, 2Univ of Florida, Gainesville, FL, USA

EARLY MACROPHAGE-INDEPENDENT INFLAMMATION AND SHIV-RNA IN CNS IN A RHESUS SHIV MODEL

Denise C. Hsu1, Piyanate Sunyakumthorn2, Matthew Wegner2, Jacob D. Estes2, Claire Deleage3, Robert J. O’Connell2, Victor Valcour1, Serena Spudich5, Nelson L. Michael5, Sandhya Vasan1
1US Military HIV Rsr Prog, Bangkok, Thailand, 2Armed Forces Rsr Inst of Med Scis, Bangkok, Thailand, 3Frederick Natl Lab for Cancer Rsr, Leidos Biomed Rsr Inc, Frederick, MD, USA, 4Univ of California San Francisco, San Francisco, CA, USA, 5Yale Univ, New Haven, CT, USA, 6US Military HIV Rsr Prog, Silver Spring, MD, USA
DEEP SEQUENCING REVEALS RARE CNS
COMPARTMENTALIZATION IN ACUTE HIV-1 INFECTION

Rujipas Sirijatuphat1, James L. Fletcher2, Eric Sanders-Buell3, Jintanat Ananworanich1, Nelson L. Michael1, Victor Valcour3, Sod sai Tovanabutra3, Gustavo Kijak1, Serena Spudich1, for the RV254/SEARCH 010 Team and MHRP Viral Sequencing Core
1Mahidol Univ, Bangkok, Thailand, 2South East Asia Rsr Collab with Hawaii (SEARCH), Bangkok, Thailand, 3US Military HIV Rsr Prog, Silver Spring, MD, USA, 4Univ of California San Francisco, San Francisco, USA, 5Yale Univ, New Haven, CT, USA

CD4/CD8 RATIO ASSOCIATES WITH NEUROPSYCHOLOGIC PERFORMANCE DURING EARLY HIV INFECTION

Leah T. Le1, Kevin Robertson1, Brinda Emu1, Richard W. Price1, Magnus Gisslen1, Henrik Zetterberg1, Roxane Fabre2, Christian Pradier3, Serena Spudich1, Matteo Vassallo2
1Yale Univ, New Haven, CT, USA, 2Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 3Univ of California San Francisco, San Francisco, CA, USA

ASYMPTOMATIC HIV-1 CSF ESCAPE IS UNCOMMON AND IS NOT ASSOCIATED WITH NEURONAL DAMAGE

Sarah Beth Joseph1, Laura P. Kincer1, Natalie M. Bowman1, Henrik Zetterberg2, Magnus Gisslen1, Kevin Robertson1, Serena Spudich1, Joseph J. Eron1, Richard W. Price1, Ronald Swanstrom1
1Univ of North Carolina Chapel Hill, Chapel Hill, NC, USA, 2Sahlgrenska Academy at the Univ of Gothenburg, Gothenburg, Sweden, 3Yale Univ, New Haven, CT, USA, 4Univ of California San Francisco, San Francisco, CA, USA

GENETIC VARIATION IN EIF2AK3 IS ASSOCIATED WITH NEUROCOGNITIVE IMPAIRMENT IN HIV

Scott Letendre1, Cagla Akay-Espinoza2, Ajay Bharti1, Peilin Jia3, Asha R. Kallianpur4, Donald Franklin1, Gerard D. Schellenberg1, Robert K. Heaton4, Igor Grant5, Kelly L. Jordan-Sciutto2
1Univ of California San Diego, San Diego, CA, USA, 2Univ of Pennsylvania, Philadelphia, PA, USA, 3Univ of Texas Houston, Houston, TX, USA, 4Cleveland Clinic Lerner Coll of Med, Cleveland, OH, USA, 5Univ of California San Diego, La Jolla, CA, USA

CEREBRAL SMALL-VESSSEL DISEASE IN HIV-INFECTED PATIENTS WELL CONTROLLED ON CART

Antoine Moulinigrier1, Julien Savatovsky1, Op hélia Godin2, Nadia Valin3, François-Xavier Lescure1, Roland Tubiana2, Ana Canestri3, Cédric Lamirel1, Dominique Costagliola4, for the MICROBREAK ANRS study group
Oral Abstract 0–7 TB AND OTHER OPPORTUNISTIC INFECTIONS
Room 6 C
10:00 AM - 12:00 PM

Oral Abstract Moderators

Haileyesus Getahun, World Health Organization, Geneva, Switzerland
Richard Hafner, NIAID, NIH, Bethesda, MD, USA

76LB A MULTICENTER DIAGNOSTIC ACCURACY STUDY OF THE XPERT ULTRA FOR TUBERCULOSIS DIAGNOSIS
10:00
Samuel G. Schumacher1, Pamela Nabeta2, Catharina C. Boehme1, Jerrold Ellner2, David Alland3, Susan E. Dormann4, Claudia M. Denkinger5, for the TB Clinical Diagnostics Research Consortium and FIND Trial Consortium
1FIND, Geneva, Switzerland, 2Boston Med Cntr, Boston, MA, USA, 3Univ of Med and Dentistry of New Jersey, Newark, NJ, USA, 4The Johns Hopkins Univ, Baltimore, MD, USA

77 WHOLE-GENOME SEQUENCING AND SPATIAL ANALYSIS OF XDR TB TRANSMISSION IN SOUTH AFRICA
10:15
Kristin N. Nelson1, Neel R. Gandhi1, Sara C. Auld1, James C. Brust2, Barun Mathema3, Nazir Ismail4, Pravi Moodley5, Angela Campbell1, Salim Allana6, N. Sarita Shah6
1Emory Univ, Atlanta, GA, USA, 2Albert Einstein Coll of Med, Bronx, NY, USA, 3Columbia Univ, New York, NY, USA, 4NICD, Johannesburg, South Africa, 5Univ of KwaZulu-Natal, Durban, South Africa, 6CDC, Atlanta, GA, USA

78 SIX-MONTH IPT REDUCES MORTALITY INDEPENDENTLY OF ART IN AFRICAN ADULTS WITH HIGH CD4
10:30
Anani D. Badje1, Raoul Moh2, Delphine Gabillard3, Calixte Guehi4, Mathieu Kabran1, Hervé Menan2, André Inwoley3, Christine Danel1, Serge Eholie4, Xavier Anglaret5
1INSERM, Bordeaux, France, 2Prog PAC-CI, ANRS Rsr site, Abidjan, Cote d’Ivoire, 3INSERM, Abidjan, Cote d’Ivoire, 4Service des Maladies Infectieuses et Tropes, Abidjan, Cote d’Ivoire

79 THE ESSENTIALITY OF INH DURING THE FIRST 14 DAYS OF TB THERAPY: THE A5307 EBA TRIAL
10:45
Andreas H. Diacon1, Sachiko Miyahara2, Xin Sun2, Richard Hafner3, Florian von Groote-Bidlingmaier4, Courtney Fletcher5, Evelyn Hogg6, Rodney Dawson7, Susan Swindells1, William Bishai8
1Stellenbosch Univ, Cape Town, South Africa, 2Harvard Univ, Boston, MA, USA, 3NIH, Bethesda, MD, USA, 4TASK Applied Sc, Cape Town, South Africa, 5Univ of Nebraska Med Cntr, Omaha, NE, USA, 6Social &Scientific Systems, Silver Spring, MD, USA, 7Univ of Cape Town, Mowbray, South Africa, 8The Johns Hopkins Univ, Baltimore, MD, USA

80LB THE NIX-TB TRIAL OF PRETOMANID, BEDAQUILINE AND LINEZOLID TO TREAT XDR-TB
11:00
Francesca Conradie1, Andreas H. Diacon2, Daniel Everitt2, Carl Mendel2, Christo van Niekerk3, Pauline Howell4, Kyla Comins5, Mel Spigelman1

81LB RANDOMIZED CONTROLLED TRIAL OF PREDNISONE FOR PREVENTION OF PARADOXICAL TB-IRIS
11:15
Graeme Meintjes1, Cari Stek2, Liz Blumenthal1, Friedrich Thienemann2, Charlotte Schutz1, Jozefien Buyze3, Gary Maartens4, Robert Wilkinson5, Lutgarde Lynen6, for the PredART Trial Team
1Univ of Cape Town, Cape Town, South Africa, 2Inst of Tropical Med, Antwerp, Belgium, 3Imperial Coll, London, UK
82 AMBITION-CM: HIGH-DOSE LIPOSOMAL AMPHOTERICIN FOR HIV-RELATED CRYPTOCOCCAL MENINGITIS

Joseph N. Jarvis1, Tshepo B. Leeme2, Awilly A. Chofle3, Gabriella Bidwell1, Mooketsi Molefi1, Katlego Tshole1, Nametso Lekwape1, Charles Muthoga1, Sile Molloy1, Thomas S. Harrison1


83 A RANDOMISED CONTROLLED TRIAL OF INDUCTION THERAPY OF TALAROMYCES MARNEFFEI INFECTION

Thuy Le1, Nguyen V. Kinh2, Nguyen Le Nhu Tung3, Thanh Thuy Pham Thi4, Pham T. Phuc5, Doan T. Hanh6, Jeremy Day1, Guy Thwaites1, Marcel Wolbers1, for the IVAP Investigators


Oral Abstract O-8 COMMON BEDFELLOWS: PREP, STIs, AND THE MICROBIOME

Room 6 AB

10:00 AM - 12:00 PM

Oral Abstract Moderators

Gita Ramjee, South African Medical Research Council, Tygerberg, South Africa

Hyman Scott, Bridge HIV, San Francisco, CA, USA

84 RESISTANCE EMERGENCE IN MACAQUES ADMINISTERED CABOTEGRAVIR LA DURING ACUTE INFECTION

Jessica Radzio1, Olivia Council1, Mian-er Cong1, James Mitchell1, Shanon Ellis1, Wei Huang1, William Spreen1, Walid Heneine1, Gerardo Garcia-Lerma1

1CDC, Atlanta, GA, USA, 2Monogram BioScis, San Francisco, CA, USA, 3ViiV Healthcare, Rsr Triangle Park, NC, USA

85 DAILY ORAL PREP IS EFFECTIVE AMONG WOMEN WITH ABNORMAL VAGINAL MICROBIOTA

Renee Heffron1, R. Scott McClelland1, Jennifer Balkus1, Connie L. Celum1, Craig Cohen1, Nelly Mugo1, Elizabeth A. Bukusi1, Deborah J. Donnell1, Jared Baeten1, for the Partners PrEP Study Team

1Univ of Washington, Seattle, WA, USA, 2Fred Hutchinson Cancer Rsrs Ctr, Seattle, WA, USA, 3Univ of California San Francisco, San Francisco, CA, USA, 4Kenya Med Rsrs Inst, Nairobi, Kenya

86LB IMPACT OF VAGINAL MICROBIOTA ON GENITAL TISSUE AND PLASMA CONCENTRATIONS OF TENOFOVIR

Sharon L. Hillier1, Leslie A. Meyn1, Katherine Bunge2, Michele Austin1, Bernard J. Moncla1, Charlene S. Dezzutti1, Jill Schwartz1, Mark A. Marzinke1, Craig Hendrix2, Lisa C. Rohan1

1Univ of Pittsburgh, Pittsburgh, PA, USA, 2Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA, 3Magee-Womens Rsrs Inst, Pittsburgh, PA, USA, 4CONRAD, Arlington, VA, USA, 5Johns Hopkins Univ, Baltimore, MD, USA
87  ABDUANCE OF PENILE ANAEROBES, IL-8, AND THE RISK OF HIV ACQUISITION, RAKAI, UGANDA

Cindy M. Liu1, Jessica Prodger2, Aaron Tobian3, Rupert Kaul4, Alison Abraham5, Godfrey Kigozi5, Fred Nalugoda5, David Serwadda2, Lance Price1, Ronald H. Gray6

1George Washington Univ, Washington, DC, USA, 2Johns Hopkins Univ, Baltimore, MD, USA, 3Univ of Toronto, Toronto, Ontario, Canada, 4Rakai Hlth Scis Prog, Kalisizo, Uganda, 5Makerere Univ, Kampala, Uganda

88  DAPIVIRINE RING USE DOES NOT DIMINISH THE EFFECTIVENESS OF HORMONAL CONTRACEPTION

Jennifer Balkus1, Thesla Palanee-Phillips1, Samantha Siva1, Clemensia Nakibiito1, Gonasangrie Nair1, Samuel Kabwigu1, Ishana Harkoo1, Catherine Chappell1, Lydia Soto-Torres1, Jared Baeten1

1Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 2Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa, 3South African Med Rsr Council, Durban, South Africa, 4Makerere Univ-Johns Hopkins Univ Rsr Collab, Kampala, Uganda, 5Emavundleni Rsr Cntr, Cape Town, South Africa, 6CAPRISA, Durban, South Africa, 7Magee-Womens Hosp of UPmc, Pittsburgh, PA, USA, 8NIH, Bethesda, MD, USA, 9Univ of Washington, Seattle, WA, USA

89  STD PARTNER SERVICES TO MONITOR AND PROMOTE PREP USE AMONG MEN WHO HAVE SEX WITH MEN

David A. Katz1, Julia C. Dombrowski1, Teal Bell2, Matthew R. Golden1

1Univ of Washington, Seattle, WA, USA, 2Washington State Dept of Hlth, Olympia, WA, USA

90  CHALLENGES OF TRANSLATING PREP INTEREST INTO UPTAKE AMONG YOUNG BLACK MSM IN ATLANTA

Charlotte-Paige M. Rolle1, Aaron S. Siegler1, Travis Sanchez1, Nicole Luis1, Scott R. Cutro2, Carlos del Rio1, Patrick Sullivan1, Eli Rosenberg1, Colleen F. Kelley1

1Emory Univ, Atlanta, GA, USA, 2Kaiser Permanente, Atlanta, GA, USA

91LB  ON DEMAND POST EXPOSURE PROPHYLAXIS WITH DOXYCYCLINE FOR MSM ENROLLED IN A PREP TRIAL

Jean-Michel Molina1, Isabelle Charreau1, Christian Chidiac1, Gilles Pialoux2, Eric Cua1, Constance Delaugerre1, Catherine Capitant1, Daniela Rojas-Castro1, Laurence Meyer2, for the ANRS IPERGAY Study Group

1St. Louis, Hosp, Paris, France, 2INSERM, Villejuif, France, 3Univ of Lyon, Lyon, France, 4Tenon Hosp, Paris, France, 5CHU de Nice, Nice, France, 6AIDES, Pantin, France, 7AP-HP, Le Kremlin-Bicetre, France

Themed Discussion TD-6 INTRACELLULAR AND TISSUE PHARMACOLOGY

Room 615-617  1:30 PM - 2:30 PM

Themed Discussion Leader
Catia Marzolini, Univ Hosp Basel, Basel, Switzerland

404  LEDIPASVIR/SOFOSBUVIR RAISES TENOFOVIR DIPHOSPHATE CONCENTRATIONS IN RED CELLS

Christine MacBrayne1, Daniel S. Fierer2, Kristen M. Marks3, Peter L. Anderson1, Lane R. Bushman1, Kimberly M. Hollabaugh1, Michael D. Hughes1, Raymond T. Chung3, Susanna Naggie4, Jennifer J. Kiser1

1Univ of Colorado, Aurora, CO, USA, 2Icahn Sch of Med at Mt Sinai, New York, NY, USA, 3Weill Cornell Med, New York, NY, USA, 4Harvard Univ, Boston, MA, USA, 5MGH, Boston, USA, 6Duke Univ, Durham, NC, USA
405 TENOFOVIR DIPHOSPHATE ARISING FROM TAF IS QUANTIFIABLE IN DRIED BLOOD SPOTS
Jose Castillo-Mancilla, Ryan P. Coyle, Jia-Hua Zheng, Lucas Ellison, Laura Roon, Jordan Fey, Lane Bushman, Jennifer J. Kiser, Peter Anderson
Univ of Colorado, Aurora, CO, USA

406 EXTRA/INTRA-CELLULAR NUCLEOSIDE/TIDE SEMEN PHARMACOLOGY: IMPLICATIONS FOR ERADICATION
Julie B. Dumond, Stephen A. Greene, Heather M. Asher Prince, Jingxian Chen, Brian Maas, Craig Sykes, Amanda Schauer, Cynthia L. Gay, Angela Kashuba, Myron S. Cohen
Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

407 INTEGRASE AND PROTEASE INHIBITOR CONCENTRATIONS IN LYMPHOID VS GI TISSUES
Sulggi Lee1, Hiroyu Hatano1, Angela Kashuba2, Mackenzie L. Cottrell2, Teri Liegler1, Sophie Stephenson1, Ma Somsouk1, Peter W. Hunt1, Steven G. Deeks1, Radojka M. Savic3
1Univ of California San Francisco, San Francisco, CA, USA, 2Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

408 PLASMA AND INTRACELLULAR PK OF TENOFOVIR IN PATIENTS SWITCHED FROM TDF TO TAF
Anthony Podany, Sara H. Bares, Joshua Havens, Ravi Dyavar Shetty, Jennifer O’Neill, Sarah Lee, Courtney Fletcher, Susan Swindells, Kimberly K. Scarsi
Univ of Nebraska, Omaha, NE, USA

Themed Discussion TD-7 CNS TREATMENT STRATEGIES: RISK AND BENEFITS
Room 611-614 1:30 PM - 2:30 PM
Themed Discussion Leader
Ned Sacktor, MD, The Johns Hopkins Univ, Baltimore, MD, USA

380 CAN WE AFFORD TO WAIT? ART AND THE CNS
Kevin Robertson1, Javier R. Lama2, Christopher D. Pilcher3, Jessica Rios2, Peter Brandes2, Eduardo Ruiz2, Eline Appelmans4, Serena Spudich5, Ann Duer4, for the SABES Team
1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Asociacion Civil Impacta Salud y Educacion, Lima, Peru, 3Univ of California San Francisco, San Francisco, CA, USA, 4Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 5Yale Univ, New Haven, CT, USA

350 COGNITIVE TRAJECTORIES OVER 4 YEARS AMONG HIV+ WOMEN WITH OPTIMAL VIRAL SUPPRESSION
Leah H. Rubin1, Gayle Springer1, Pauline M. Maki1, Kathryn Anastos1, Deborah Gustafson1, Maria Villacres1, Drenna Waldrop-Valverde1, David Vance1, Hector Bolivar1, Victor Valcour9
1Univ of Illinois at Chicago, Chicago, IL, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA, 3Albert Einstein Coll of Med, Bronx, NY, USA, 4SUNY Downstate Med Cntr, Brooklyn, NY, USA, 5Univ of Southern California, Los Angeles, CA, USA, 6Emory Univ, Atlanta, GA, USA, 7Univ of Alabama at Birmingham, Birmingham, AL, USA, 8Univ of Miami, Miami, FL, USA, 9Univ of California San Francisco, San Francisco, CA, USA
Cenicriviroc Improves Neurocognition and Reduces Monocyte Activation in Treated HIV

Lishomwa C. Ndhlovu1, Michelle L. D’Antoni1, Robert Paul2, Kalpana J. Kallianpur3, Laurent Fischer1, Eric Lefebvre1, Star Seyedkazemi1, Beau K. Nakamoto1, Debra Ogata-Arakaki1, Cecilia Shikuma1

1Univ of Hawaii, Honolulu, HI, USA, 2Univ of Missouri–St. Louis, St. Louis, MO, USA, 3Tobira Therapeutics, Inc, South San Francisco, CA, USA

CSF Inflammatory Markers After Adding Maraviroc to Monotherapy Darunavir/Ritonavir

Tristan Barber1, Arkaitz Imaz2, Marta Boffito1, Daniel Podzamczer2, Anton Pozniak1, Rosa Fortuny2, Nicholas Davies1, Jordi Niubo2, Sundhiya Mandalia1, Brian Gazzard1

1Chelsea and Westminster NHS Fndn Trust, London, UK, 2Hosp Univ de Bellvitge, Barcelona, Spain, 3Imperial Coll London, London, UK

Extensive Efavirenz Metabolism Is Associated With Greater CNS Toxicity

Marijana Vujkovic1, Scarlett Bellamy2, Athena Zuppa1, Marc Gastonguay3, Xiaoyan Han1, Mosepele Mosepele1, Gregory Bisson4, Richard Aplenc5, Robert Gross6

1Children’s Hosp of Philadelphia, Philadelphia, PA, USA, 2Drexel Univ, Philadelphia, PA, USA, 3Metrum Rsr Group, Tariffville, CT, USA, 4Univ of Pennsylvania, Philadelphia, PA, USA, 5Univ of Botswana, Gaborone, Botswana

Themed Discussion TD-8 Screening for HSIL: Alternatives to Cytology

Room 606-609

1:30 PM - 2:30 PM

Themed Discussion Leader

Timothy Wilkin, MD, Weill Cornell Medicine, New York, NY, USA

MULTITEST Screening Strategies Add Value for Predicting Biopsy-Proven HSIL for MSM

Dorothy J. Wiley1, Hilary K. Hsu1, Matthew G. Moran1, Jenny Brook1, David Elashoff1, Martha Ganser1, Stephen Young2, David Morris3, Otoniel Martinez-Maza1, Ronald T. Mitsuyasu1

1Univ of California Los Angeles, Los Angeles, CA, USA, 2Tricore Reference Labs, Albuquerque, NM, USA, 3Desert AIDS Proj, Palm Springs, CA, USA

IMPACT of ART Coverage and Screening on Anal Cancer in HIV+ Men Who Have Sex with Men

Nello Blaser1, Barbara Bertisch1, Manuel Koller1, Marcel Stoeckle2, Matthias Cavassini3, Roger Koyous3, Janne Estill1, Matthias Egger1, Olivia Keiser1, for the Swiss HIV Cohort Study

1Univ of Bern, Bern, Switzerland, 2Univ Hosp Basel, Basel, Switzerland, 3Univ of Lausanne, Lausanne, Switzerland, 4Univ of Zurich, Zurich, Switzerland

Multiple HPV Infections and Anal Precancerous Lesions in HIV-Infected Men

Shu-Hsing Cheng1, Chien-Yu Cheng1, Chi-Chao Wang1, Fang-Yeh Chu2, Yu-Mei Hsieh1

1Taoyuan General Hosp, Taoyuan, Taiwan, 2Far Eastern Memorial Hosp, New Taipei, Taiwan, 3Taipei Med Univ, Taipei, Taiwan
Oral Sessions • Wednesday
Program and Agenda
CROI 2017

595 SCREENING FOR PRECANCEROUS ANAL LESIONS WITH P16/KI67 DUAL STAIN CYTOLOGY IN HIV
Sergio Serrano-Villar1, Beatriz Hernández-Noova2, Amparo de Benito1, Jorge Romero1, Antonio Ocampo3, Laura Pérez-Martínez2, Mar Masia1, Elena Sendagorta2, Gonzalo Sanz2, José Antonio Pérez-Molina1
1Hosp Univ Ramón y Cajal, Madrid, Spain, 2Brystol-Myers-Squibb, Madrid, Spain, 3Centro Sandoval, Madrid, Spain, 4Hosp Xeral de Vigo, Vigo, Pontevedra, 5Hosp San Pedro, Logroño, Spain, 6Hosp General Univ de Elche, Elche, Spain, 7Hosp Univ La Paz, Madrid, Spain, 8Hosp Clinico San Carlos, Madrid, Spain

891 HIV SELF-TEST (HIVST) AWARENESS, EXPOSURE, AND USE, NEW YORK CITY, 2015–2016
Paul M. Salcuni, Zoe R. Edelstein, Demetre C. Daskalakis, Julie Myers
New York City DHMH, Queens, NY, USA

893 PEER-LED ORAL HIV-SELF TESTING FINDS UNDIAGNOSED HIV AMONG MSM IN MALINDI, KENYA
Elisabeth M. van der Elst1, Mahmoud Shally1, Clifford Oduor1, Oscar Chirro1, Fauz Ibrahim2, Bernadette Kombo3, Susan M. Graham4, Eduard Sanders5
1KEMRI Wellcome Trust Rsr Prog, Kilifi, Kenya, 2Kilifi County Dept of Hlth, Kilifi, Kenya, 3Univ of Washington, Seattle, WA, USA, 4Kenya Med Rsr Inst, Kilifi, Kenya

894 ROLE OF PARTNER VIOLENCE IN WOMEN’S ABILITY TO DISTRIBUTE SELF-TESTS TO MALE PARTNERS
Elisabeth Schaffer1, Kawango Agot2, Harsha Thirumurthy1
1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Impact Rsr and Development Org, Kisumu City, Kenya

895 INFORMING HIV SELF-TESTING SERVICES IN MALAWI USING DISCRETE CHOICE EXPERIMENTS
Pitchaya Indravudh1, Marc D’Elbee2, Moses Kumwenda1, Augustine Choko1, Doreen Sakala3, Thokozani Kalua4, Cheryl Johnson4, Karin Hatzold5, Liz Corbett5, Fern Terris-Prestholt2

896 PROVIDING USER SUPPORT FOR HIV SELF-TESTING BEYOND INSTRUCTIONS-FOR-USE IN MALAWI
Pitchaya Indravudh1, Moses Kumwenda1, Melissa Neuman1, Blessings Chisunkha1, Karin Hatzold1, Chiwawa Nkhoma1, Thokozani Kalua2, Cheryl Johnson2, Miriam Taegtmeyer2, Liz Corbett5

Themed Discussion TD-9 HIV SELF-TESTING: KNOW YOURSELF
Room 6 C
1:30 PM - 2:30 PM

Themed Discussion Leader
Joanne Stekler, MD, Univ of Washington, Seattle, WA, USA
**Themed Discussion TD-10 HIV PERSISTENCE: CLONES, CLONES, AND MORE CLONES**

**Room 6 AB**

**1:30 PM - 2:30 PM**

**Themed Discussion Leader**

**Thor Wagner**, *University of Washington/Seattle Children’s, Seattle, WA, USA*

---

**292 CLONAL EXPANSION OF GENOME-INTACT HIV-1 IN FUNCTIONALLY POLARIZED T-CELL SUBSETS**

*Guinevere Q. Lee*, Nina Orlova, Erik Serrao, Xiaoming Sun, Navin F. Chowdhury, Eric Rosenberg, Alan N. Engelman, Xu G. Yu, Mathias Lichterfeld

1Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA; 2Dana-Farber Cancer Inst, Boston, MA, USA; 3Massachusetts General Hosp, Boston, MA, USA; 4Brigham and Women’s Hosp, Boston, MA, USA

---

**293 INTACT PROVIRUSES ARE UNEQUALLY DISTRIBUTED IN T CELL SUBSETS DURING ART**

*Bonnie Hiener*, Bethany A. Horsburgh, John-Sebastian Eden, Kirston Barton, Eunok Lee, Steven G. Deeks, Jeffery Milush, Nicolas Chomont, Rémi Fromentin, Sarah Palmer

1The Westmead Inst for Med Rsr, Westmead, Australia; 2The Univ of Sydney, Sydney, Australia; 3Univ of California San Francisco, San Francisco, CA, USA; 4Univ de Montréal, Montreal, QC, Canada

---

**294 A SMALL FRACTION OF PROVIRUSES IN EXPANDED CLONES EXPRESS UNSPLICED HIV RNA IN VIVO**

*Andrew Musick*, Jonathan Spindler, Brandon Keele, Michael J. Bale, Wei Shao, Ann Wiegand, John Mellors, John Coffin, Frank Maldarelli, Mary F. Kearney

1NCI, Frederick, MD, USA; 2Leidos Biomed, Inc, Frederick, MD, USA; 3Univ of Pittsburgh, Pittsburgh, PA, USA; 4Tufts Univ, Boston, MA, USA

---

**295 PROLIFERATION OF CD4+ T CELLS CONTAINING REPLICATION-COMPETENT HIV-1**

*Zheng Wang*, Ya-Chi Ho, Janet Siliciano, Robert Siliciano

Johns Hopkins Univ, Baltimore, MD, USA

---

**296 CYTOTOXIC T LYMPHOCYTES MAY SHAPE THE HIV-1 PROVIRAL LANDSCAPE**

*R. Brad Jones*, Mihaela Pertea, Katherine Bruner, Ross Pollack, Adam Capoferrer, Robert Siliciano, Ya-Chi Ho

1The George Washington Univ, Washington, DC, USA; 2The Johns Hopkins Univ, Baltimore, MD, USA
Themed Discussion TD-11 INTEGRATION OF SCREENING AND TREATMENT OF NCD INTO HIV CARE IN RESOURCE LIMITED SETTINGS

Room 6 E 1:30 PM - 2:30 PM

Themed Discussion Leader
Matthias Egger, MD, Inst of Social and Preventive Medicine, Univ of Bern, Bern, Switzerland

637 INTEGRATING CARDIOVASCULAR DISEASE RISK-FACTOR SCREENING IN HIV SERVICES IN SWAZILAND
Miriam Rabkin1, Anton M. Palma1, Margaret L. McNairy1, Samkelo Simelane2, Averie B. Gachuhi1, Raymond A. Bitchong2, Harriet Nuwagaba-Biribonwoha3, Pido Bongomin2, Velephi Okello4, Wafaa M. El-Sadr5
1ICAP at Columbia Univ, New York, NY, USA, 2ICAP Swaziland, Mbabane, Swaziland, 3Raleigh Fitkin Memorial Hosp, Manzini, Swaziland, 4Swaziland Ministry of Hlth, Mbabane, Swaziland

638 COMPOSITE “HIV/ HYPERTENSION/ DIABETES CONTROL” OUTCOME IN SEARCH CHRONIC CARE MODEL
Dalsone Kwarisima1, Jeanna Wallenta2, James Ayieko1, Florence Mwangwa1, Asiphas Owaragani3, Tamara D. Clark2, Edwin D. Charlebois1, Maya L. Petersen3, Diane V. Hlavir1, Moses R. Kamya1
1Makerere Univ Joint AIDS Prog, Kampala, Uganda, 2Univ of California San Francisco, San Francisco, CA, USA, 3Kenya Med Res Inst, Nairobi, Kenya, 4Infectious Diseases Rsr Collab, Kampala, Uganda, 5Univ of California Berkeley, Berkeley, CA, USA, 6Makerere Univ Coll of Hlth Scis, Kampala, Uganda

639 THE ART ADVANTAGE: HEALTHCARE UTILIZATION FOR DIABETES & HYPERTENSION IN SOUTH AFRICA
Jennifer Manne-Goehler1, Livia Montana1, Xavier Gomez-Olive2, Guy Harling4, Ryan Wagner2, Alisha Wade1, Julia K. Rohr2, Stephen Tollman5, Till Baernighausen6, Thomas Gaziano1
1Beth Israel Deaconess Med Cntr, Boston, MA, USA, 2Harvard Univ, Cambridge, MA, USA, 3Tintswala Hosp, Acornhoek, South Africa, 4Harvard Univ, Boston, MA, USA, 5Univ of the Witwatersrand, Acornhoek, South Africa, 6MRC/Wits Rural Pub Hlth and Hlth Transitions Rsr Unit, Johannesburg, South Africa, 7Univ of Witwatersrand, Johannesburg, South Africa, 8Heidelberg Univ, Heidelberg, Germany, 9Brigham and Women’s Hosp, Boston, MA, USA

640 CARDIOVASCULAR RISK ASSESSMENT IN A SUB-SAHARAN AFRICA HIV CLINICAL COHORT
Mosepele Mosepele4, Linda C. Hemphill1, Tommy Palai1, Isaac Nkele1, Kara Bennett1, Shahin Lockman5, Virginia Triant1
1Univ of Botswana, Gaborone, Botswana, 2Botswana, 3Massachusetts General Hosp, Boston, MA, USA, 4Harvard AIDS Partnership, Gaborone, Botswana, 5Bennett Statistical Consulting Inc, New York, NY, USA, 6Harvard Univ, Boston, MA, USA

641 HIV AND IMMUNE ACTIVATION ARE RISK FACTORS FOR ENDOTHELIAL DAMAGE IN ADULT MALAWIANS
Christine Kelly1, Henry Mwandumba2, Rob Heyderman1, Raphael Kamng’ona2, Mishek Chammudzi1, Irene Sheha2, Jane E. Malewawa3, Sarah Walker1, Nigel Klein1, Saye Khoo1
1Univ Coll Dublin, Dublin, Ireland, 2Malawi Liverpool Wellcome Clinical Rsr Prog, Blantyre, Malawi, 3Univ Coll London, London, UK, 4Univ of Malawi, Blantyre, Malawi, 5Univ of Liverpool Inst of Translational Med, Liverpool, UK
Symposium S-4 CREATING AND DESTROYING HIV CAPSIDS
Room 611-614 4:00 PM - 6:00 PM

Target audience: This session is directed to clinicians and scientists who are interested in the assembly of HIV-1 particles and mature capsids, viral genome packaging and recognition of the mature HIV-1 capsid by the TRIM5alpha antiviral protein.

Level of knowledge: It is assumed that participants are familiar with basic concepts in HIV-1 particle assembly and structure.

Objectives: At the completion of the session, participants will be able to:
• Describe how HIV-1 Gag assembles into immature particles and then transitions to a mature infectious form
• Describe how variation in HIV-1 genomic RNA structure facilitates packaging of viral RNA into virions
• Describe how RNA interactions with integrase are required for the correct maturation of virions
• Describe how the TRIM5alpha protein recognizes the mature HIV-1 capsid

Conveners
Sebla Kutluay, Washington Univ in St. Louis, St Louis, MO, USA
Victoria D’Souza, Harvard Univ, Cambridge, MA, USA

92 4:00 THE FATES AND FOLDS OF HIV-1 RNA
Alice Telesnitsky, Univ of Michigan, Ann Arbor, MI, USA

93 4:30 STRUCTURE AND FUNCTION OF IMMATURE AND MATURE HIV CAPSIDS
Hans-Georg Kräusslich, Heidelberg Univ, Heidelberg, Germany

94 5:00 A ROLE OF HIV-1 INTEGRASE IN ENCAPSIDATION OF THE VIRAL RNA GENOME
Mamuka Kvaratskhelia, The Ohio State Univ, Columbus, OH, USA

95 5:30 TRIM5ALPHA RECOGNITION OF THE HIV CAPSID
Barbie K. Ganser-Pornillos, Univ of Virginia, Charlottesville, VA, USA
Symposium S-5 HEPATITIS/LIVER
Room 6 E 4:00 PM - 6:00 PM

Target audience: This session is directed to investigators and clinicians who are interested in the epidemiology, basic science, public health impact, and future trends in hepatitis B and hepatitis C therapy.

Level of knowledge: It is assumed that participants are familiar with the general principles of hepatitis B and hepatitis C virology and treatment.

Objectives:
- To identify the limitations and the potential for virologic and immunologic approaches to the cure of HBV infection
- To compare the approach to preventing vertical transmission of HIV to HBV
- To appreciate the opportunities and challenges to achieving the UN HCV elimination goals
- To understand the prevalence of fatty liver disease and recognize the difference between steatosis and steatohepatitis

Conveners
Marion G. Peters, Univ of California San Francisco, San Francisco, CA, USA
Massimo Puoti, ASST GOM Niguarda, Milan, Italy

96  HEPATITIS B: PROGRESS AND PROSPECTS IN HEPATITIS B VIRUS CURE
4:00  Patrick Kennedy, Queen Mary Univ London, London, United Kingdom

97  MANAGEMENT OF CHRONIC HEPATITIS B DURING PREGNANCY
4:30  Mindie H. Nguyen, Stanford Univ Med Cntr, Palo Alto, CA, USA

98  HEPATITIS C VIRUS: GONE BY 2030?
5:00  John W. Ward, CDC, Atlanta, GA, USA

99  FATTY LIVER DISEASE: A GROWING CONCERN
5:30  Rohit Loomba, Univ of California San Diego, La Jolla, CA
Symposium S-6 THE FIRST AGE: INFANTS ON THE WORLD STAGE
Room 606-609
4:00 PM - 6:00 PM

**Target Audience:** This session is directed to clinicians and scientists who are interested in understanding the impact of HIV and ART on newborns and infants

**Level of Knowledge:** It is assumed that the participants are familiar with the basic concepts of HIV acquisition, prevention, and treatment in infants and newborns

**Objectives:** At the completion of the session, participants will be able to:
- Describe the impact of HIV and ART on pregnancy outcomes among women with HIV infection
- Discuss the short- and long-term outcomes of ART-exposure in uninfected infants and children born to women with HIV
- Review approaches to early diagnosis of HIV in newborns and infants
- Describe experiences with, and outcomes of, early ART in HIV infected infants

**Conveners**

Mutsa Bwakura-Dangarembizi, Univ of Zimbabwe, Harare, Zimbabwe

Thanyawee Puthanakit, Chulalongkorn Univ, Bangkok, Thailand

---

100 4:00 MTCT: EVOLVING EPIDEMIOLOGY AND PREGNANCY OUTCOMES
Roger L. Shapiro, Harvard Schl of Pub Hlth, Boston, MA, USA

101 4:30 THE ART AND SCIENCE OF INFANT DIAGNOSIS
Martina Penazzato, WHO, Geneva, Switzerland

102 5:00 THE HIV-EXPOSED AND UNINFECTED CHILD: WHAT’S TO WORRY?
Claire Thorne, Univ College London, London, United Kingdom

103 5:30 THE TREATMENT OF NEWBORNS AND INFANTS LIVING WITH HIV
Elizabeth Maleche Obimbo, Univ of Nairobi, Nairobi, Kenya
Symposium S-7 GETTING TO THE THIRD 90
Room 6 C  4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding progress and challenges in maximizing the percentage of people on antiretroviral therapy who have viral load suppression, particularly in low and middle income settings, and how global targets for viral suppression can be achieved in the future.

Level of Knowledge: It is assumed that the participants are familiar with effects of antiretroviral treatment on HIV viral load, the basic concepts of viral load measurement, and the influences of adherence and drug resistance.

Objectives: At the completion of the session, participants will be able to:
- Describe the issues related to implementation of monitoring of ART in low and middle income settings
- Describe challenges in achieving the target of 90% virally suppressed

Conveners
Laura Broyles, Centers for Disease Control and Prevention, Atlanta, GA, USA
Velephi Okello, Swaziland Ministry of Health, Mbabane, Swaziland

104  ACTING OR NOT ACTING ON VIRAL LOAD
4:00  Steven J. Reynolds, NIAID, NIH, Washington, DC, USA

105  MEASURING VIRAL LOAD: INNOVATIONS AND TAKING TO SCALE
4:30  Rosanna W. Peeling, London Sch of Hygiene and Trop Medicine, London, United Kingdom

106  USING TECHNOLOGY TO IMPROVE ADHERENCE
5:00  Richard T. Lester, Univ of British Columbia, Vancouver, Canada

107  REACHING KEY AND VULNERABLE POPULATIONS TO ACHIEVE THE THIRD 90
5:30  Ruanne V. Barnabas, Univ of Washington, Seattle, USA
THURSDAY, FEBRUARY 16, 2017

Plenary PL-3 THURSDAY PLENARY SESSION
Auditorium - 4 AB 8:30 AM - 9:30 AM

108 IF YOU CAN MAKE IT THERE: ENDING THE HIV EPIDEMIC IN NEW YORK
8:30
Demetre C. Daskalakis, NYC DHMH, New York, NY, USA

109 HTLV-1: THE OTHER HUMAN RETROVIRUS
9:00
Charles R. Bangham, Imperial Coll London, London, UK

Oral Abstract 0-10 IMPROVING THE HIV CARE CASCADE
Room 6 C 10:00 AM - 12:00 PM

Oral Abstract Moderators
Loice Achieng, Univ of Nairobi, Nairobi, Kenya
Valdilea Veloso, Oswaldo Cruz Foundation - Fiocruz, Rio de Janeiro, Brazil

110 A COMBINATION INTERVENTION STRATEGY FOR HIV LINKAGE AND RETENTION IN MOZAMBIQUE
10:00
Batya Elul1, Matthew R. Lamb1, Maria Lahuerta1, Fatima Abacassamo1, Laurence Ahoua1, Stephanie Kujawski1, Maria Tomo2, Ilesh Jani4
1Columbia Univ, New York, NY, USA, 2Cntr for Collab in Hlth, Maputo City, Mozambique, 3ICAP at Columbia Univ, Maputo City, Mozambique, 4Inst Nacional de Saude, Maputo, Mozambique

111 PEER NAVIGATION ENHANCES HIV CARE RETENTION: AN RCT IN SOUTH AFRICAN PRIMARY CLINICS
10:15
Wayne T. Steward1, Emily Agnew1, Julia DeKadt1, Hailey Gilmore2, Mary-Jane Ratlhagana2, Jessica Grignon1, Starley B. Shade1, John Tumbo2, Scott Barnhart1, Sheri A Lippman1
1Univ of California San Francisco, San Francisco, CA, USA, 2Intl Training and Educ Cntr for Hlth–South Africa, Pretoria, South Africa, 3Univ of Washington, Seattle, WA, USA, 4Rustenburg Sub-District Office, Rustenburg, South Africa

112 COST-EFFECTIVENESS OF POLICY OPTIONS WHEN PRETREATMENT NNRTI DRUG RESISTANCE IS HIGH
10:30
Andrew Phillips1, Valentina Cambi2, Michael Jordan2, Fumiyo Nakagawa3, Marco Vitoria1, Meg Doherty1, Paul Revill4, Elliot Raizes3, Silvia Bertagnolio4, for the Working Group on Modelling Drug Resistance in Sub-Saharan Africa
1Univ Coll London, London, UK, 2Tufts Univ, Boston, MA, USA, 3WHO, Geneva, Switzerland, 4Univ of York, York, UK, 5CDC, Atlanta, GA, USA

113 INCREASED RISK OF CART FAILURE AFTER LOW-LEVEL VIREMIA UNDER WHO GUIDELINES
10:45
Lucas E. Hermans1, Michelle A. Moorhouse2, Sergio Carmona2, Diederick Grobbee1, Laura Marije Hofstra1, Douglas D. Richman3, Hugo Tempelman2, Willem D. Venter4, Annemarie Wensing4, for the Ndlovu Research Consortium
1Univ Med Cntr Utrecht, Utrecht, Netherlands, 2Univ of Witwatersrand, Johannesburg, South Africa, 3Univ Med Cntr Utrecht, Utrecht, Netherlands, 4Univ of California San Diego, San Diego, California, USA, 5Ndlovu Care Group, Groblersdal, South Africa
Oral Abstract O-11 HIV PERSISTENCE AND REACTIVATION
Room 6 E 10:00 AM - 12:00 PM

Oral Abstract Moderators
Ann Chahroudi, Emory University School of Medicine, Atlanta, GA, USA
Davey Smith, Univ of California, San Diego, La Jolla, CA, USA

118 TLR7 AGONIST GS-9620 INCREASES IMMUNE-MEDIATED CLEARANCE OF HIV-INFECTED CELLS
10:00

Alivelu Irrinki1, Angela Tsai1, Jasmine Kaur1, Jay Lalezari2, Tomas Cihlar4, George Kuol1, Derek D. Sloan3, Jeffrey Murry1

1Gilead Sciences, Inc, Foster City, CA, USA, 2Quest Clinical Rsr, San Francisco, CA, USA, 3Agenovir, South San Francisco, CA, USA

119LB VIRAL CONTROL INDUCED BY HIVONCSV VACCINES & ROMIDEPSIN IN EARLY TREATED INDIVIDUALS
10:15

Beatriz Muthe1, José Moltó2, Christian Manzardo1, Josep Coll1, Maria C. Puertas1, Javier Martínez-Picado1, Tomas Hanke2, Bonaventura Clotet1, Christian Brander1, for the BCN02-Romi Study Group

1IrsiCaixa AIDS Rsr Inst, Badalona, Spain, 2Fundació Lluita Contra la Sida, Badalona, Spain, 3Univ of Barcelona, Barcelona, Spain, 4The Jenner Inst, Oxford, UK

REAL PROGRESS IN THE HIV EPIDEMIC: PHIA FINDINGS FROM ZIMBABWE, MALAWI, AND ZAMBIA
11:00

Jessica E. Justman1, David Hoos1, Graham Kalton2, Rose Nyirenda3, Crispin Moyo4, Owen Mugurungi5, Andrew Voetsch6, Hetal Patel6, Laura Porter6, for the PHIA Project Teams for Malawi, Zambia and Zimbabwe


STRATEGIES TO ACHIEVE 90-90-90: MODELING INSIGHTS FROM ZIMBABWE
11:15

Jack Olney, Jeffrey Eaton, Ellen McRobie, Timothy B. Hallett

IMPERIAL COLLEGE LONDON, LONDON, UK

HIV CASCADE OF CARE INTERVENTIONS IN KENYA: CLINICAL IMPACT AND COST-EFFECTIVENESS
11:30

Liem Binh Luong Nguyen1, Yazdan Yazdanpanah2, David Maman3, Stephen Wanjala4, Alexandra Vandenbulcke4, Elisabeth Szumilin3, William Hennequin4, Robert Parker2, Pierre Mendiharat2, Kenneth Freedberg3

1INSERM, Paris, France, 2Epicentre, Cape Town, South Africa, 3MSF, Nairobi, Kenya, 4MSF, Paris, France, 5Massachusetts General Hosp, Boston, MA, USA

A RANDOMIZED TRIAL OF READY-TO-USE SUPPLEMENTARY FOOD AT ART INITIATION IN AFRICA
11:45

Jane E. Mallewa1, Alexander J. Szubert2, Jay Berkley3, Sanele Nkomani4, Abraham Silika5, Peter Muyenyi3, Andrew Prendergast3, Sarah Walker3, Diana Gibb3, for the REALITY Trial Team


TLR7 AGONIST GS-9620 INCREASES IMMUNE-MEDIATED CLEARANCE OF HIV-INFECTED CELLS
1:00

Alivelu Irrinki1, Angela Tsai1, Jasmine Kaur1, Jay Lalezari2, Tomas Cihlar4, George Kuol1, Derek D. Sloan3, Jeffrey Murry1

1Gilead Sciences, Inc, Foster City, CA, USA, 2Quest Clinical Rsr, San Francisco, CA, USA, 3Agenovir, South San Francisco, CA, USA

VIRAL CONTROL INDUCED BY HIVONCSV VACCINES & ROMIDEPSIN IN EARLY TREATED INDIVIDUALS
10:15

Beatriz Muthe1, José Moltó2, Christian Manzardo1, Josep Coll1, Maria C. Puertas1, Javier Martínez-Picado1, Tomas Hanke2, Bonaventura Clotet1, Christian Brander1, for the BCN02-Romi Study Group

1IrsiCaixa AIDS Rsr Inst, Badalona, Spain, 2Fundació Lluita Contra la Sida, Badalona, Spain, 3Univ of Barcelona, Barcelona, Spain, 4The Jenner Inst, Oxford, UK
120  
10:30

NO EVIDENCE OF ONGOING HIV REPLICATION AFTER 7 YEARS ON ART

Mary Grace K. Katusiime¹, Gert U. van Zyl¹, Ann Wiegand², Elias K. Halvas³, Valerie F. Boltz⁴, Barbara Laughton⁴, Susan Engelbrecht⁴, Mark Cotton⁴, John W. Mellors⁵, Mary F. Kearney¹

¹Stellenbosch Univ, Parow, South Africa, ²NIH, Frederick, MD, USA, ³Univ of Pittsburgh, Pittsburgh, PA, USA

121  
10:45

A PROPORTION OF LATENT HIV IS MISSED BY ASSAYING ONLY RESTING CD4 T CELLS

Anthony R. Cillo, Michele Sobolewski, Taylor Buckley, John Bui, Joshua C. Cyktor, John W. Mellors

Univ of Pittsburgh, Pittsburgh, PA, USA

122  
11:00

CTLs PARE DEFECTIVE HIV PROVIRUSES WITHOUT IMPACTING INFECTIOUS LATENT RESERVOIRS

Szuhan Huang¹, Allison S. Thomas¹, Sara Karandish¹, Dora Chan¹, Adam Ward¹, Ya-Chi Ho¹, Erika Benko¹, Colin Kovacs², R. Brad Jones¹

¹The George Washington Univ, Washington, DC, USA, ²Boston Univ, Boston, MA, USA, ³The Johns Hopkins Univ, Baltimore, MD, USA, ⁴Maple Leaf Med Clinic, Toronto, Ontario, Canada, ⁵Univ of Toronto, Toronto, Ontario, Canada

123  
11:15

DEVELOPMENT OF A PKC AGONIST DERIVED FROM INGENOL FOR HIV LATENCY DISRUPTION IN VIVO

Jessica Brehm¹, Vincent Tai¹, David Irlbeck¹, Robert Ferris¹, Nancie Archin², Matt Kanke², Jean-Pierre Routy², David M. Margolis², Jun Tang¹, David Favre¹

¹GlaxoSmithKline, Durham, NC, USA, ²Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ³McGill Univ Hlth Cntre, Glen Site, Montréal, QC, Canada

124  
11:30

HIV RNA REBOUND POST INTERRUPTION IN PERSONS SUPPRESSED IN FIEBIG I ACUTE HIV

Donn Colby¹, Nicolas Chomont¹, Eugene Kroon¹, Louise Leyre², Suteeraporn Pinyakorn³, Nelson L. Michael¹, Merlin L. Robb³, Nittaya Phanuphak³, Jintanat Ananworanich¹, for the RV411 and RV254/SEARCH010 Study Groups

¹SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ²Cntr de Rsr du Cntr Hosp de l’Univ de Montréal, Montréal, QC, Canada, ³US Military HIV Rsr Prog, Bethesda, MD, USA

125  
11:45

EARLY DETECTION OF HIV REBOUND BY INNATE SENSORS POST ART INTERRUPTION

Julie Mitchell¹, Eugene Kroon¹, Khunthalee Benjaporpong², Suteeraporn Pinyakorn³, Praphan Phanuphak⁴, Sharon R. Lewin⁴, Jintanat Ananworanich¹, Mark de Souza¹, Lydia Trautmann¹, for the Search 019 Study Group

¹Henry M. Jackson Fndn, Silver Spring, MD, USA, ²SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ³Henry M. Jackson Fndn, Bethesda, MD, USA, ⁴Doherty Inst for Infection and Immunity, Melbourne, Australia
Oral Abstract O-12

INFLAMMATION AND AGE-RELATED COMPLICATIONS

Room 6 AB

10:00 AM - 12:00 PM

Oral Abstract Moderators

Jason Baker, HCMC / Univ of Minnesota, Minneapolis, MN, USA
Heidi Crane, Univ of Washington, Seattle, WA, USA

126

IL-β INHIBITION SIGNIFICANTLY REDUCES ATHEROSCLEROTIC INFLAMMATION IN TREATED HIV

10:00

Priscilla Hsu1, Steven G. Deeks1, Amorina E. Ishaii, Sophia Hur1, Danny Li1, Felicia Sterman1, Jay Lalezari4, Adam Rupert5, Peter Ganz5, Ahmed Tawakol2
1Univ of California San Francisco, San Francisco, CA, USA, 2Massachusetts General Hosp, Boston, MA, USA, 3California Pacific Med Cntr, San Francisco, CA, USA, 4Quest Clinical Rsr, San Francisco, CA, USA, 5Natl Inst of Hlth, Frederick, MD, USA

127

HYPERBILIRUBINEMIA PREVENTS CARDIOVASCULAR DISEASE FOR HIV+ AND HIV- INDIVIDUALS

10:15

Vincent C. Marconi1, Kaku So-Armah2, Janet Tate3, Joseph Lim4, Vincent Lo Re3, Adeel A. Butt4, Matthew B. Goetz5, Maria Rodriguez-Barradas7, Amy Justice5, Matthew Freiberg9
1Emory Univ, Atlanta, GA, USA, 2Boston Univ, Boston, MA, USA, 3VA Connecticut Hlthcare System, West Haven, CT, USA, 4Yale Univ, New Haven, CT, USA, 5Univ of Pennsylvania, Philadelphia, PA, USA, 6Weil Cornell Med Coll, New York, NY, USA, 7VA Greater Los Angeles Hlth Care System, Los Angeles, CA, USA, 8Baylor Coll of Med, Houston, TX, USA, 9Vanderbilt Univ, Nashville, TN, USA

128LB

ASSOCIATION BETWEEN CARDIOVASCULAR DISEASE & CONTEMPORARILY USED PROTEASE INHIBITORS

10:30

Lene Ryom1, Jens D. Lundgren1, Wafa M. El-Sadr1, Peter Reiss4, Andrew Phillips5, Ole Kirk5, Rainer Weber5, Caroline Sabin5, Amanda Mcroft5, for the D:A:D Study Group
1CHIP, Copenhagen, Denmark, 2Univ of Copenhagen, Copenhagen, Denmark, 3ICAP at Columbia Univ, New York, NY, USA, 4Stichting HIV Monitoring and Academic Med Cntr Amsterdam, Amsterdam, Netherlands, 5Univ Coll London, London, UK, 6Rigshosp, Copenhagen, Denmark, 7Univ of Zurich, Zurich, Switzerland, 8Univ Coll London, London, UK

129

CARDIOVASCULAR PREVENTION POLICY IN HIV: RECOMMENDATIONS FROM A MODELING STUDY

10:45

Rosan van Zoest1, Mikaela Smit2, Brooke Nichols3, Ilonca Vaartjes4, Colette Smit5, Marc van der Valk6, Ferdinand Wit7, Timothy B. Hallett2, Peter Reiss2, for the Netherlands ATHENA Observational HIV Cohort
1Amsterdam Inst for Global Hlth and Development and Academic Med Cntr, Amsterdam, Netherlands, 2Imperial Coll London, London, UK, 3Erasmus Univ Med Cntr, Rotterdam, Netherlands, 4Univ Med Cntr Utrecht, Utrecht, Netherlands, 5Stichting HIV Monitoring, Amsterdam, Netherlands, 6Academic Med Cntr, Amsterdam, Netherlands

130

IMPACT OF SMOKING, HYPERTENSION & CHOLESTEROL ON MYOCARDIAL INFARCTION IN HIV+ ADULTS

11:00

Keri N. Althoff1, Frank J. Palella2, Kelly Gebo3, Stephen J. Gange1, Charles Rabkin1, Jennifer E. Thorne1, Micheal A. Horberg2, Daniel B. Klein3, Mari Kitahata2, Richard D. Moore4
1The Johns Hopkins Univ, Baltimore, MD, USA, 2Northwestern Univ, Chicago, IL, USA, 3NCI, Rockville, MD, USA, 4Kaiser Permanente Mid-Atlantic States, Rockville, MD, USA, 5Kaiser Hosp, San Leandro, CA, USA, 6Univ of Washington, Seattle, WA, USA
CESSION OF CIGARETTE SMOKING AND THE IMPACT ON CANCER INCIDENT IN THE D:A:D STUDY

Leah Shepherd1, Lene Ryom2, Kathryn Petoumenos3, Camilla Ingrid Hatleberg3, Antonella d’Arminio Monforte4, Fabrice Bonnet5, Peter Reiss6, Jens D. Lundgren7, Amanda Mocroft8, for the D:A:D study group

1Univ Coll London, London, UK, 2CHIP, Copenhagen, Denmark, 3Kirby Inst, Sydney, Australia, 4Univ of Milan, Milan, Italy, 5CHU de Bordeaux, Bordeaux, France, 6Stichting HIV Monitoring and Academic Med Cntr, Amsterdam, Netherlands

BONE DENSITY AND TRABECULAR BONE SCORE IMPROVE FRACTURE PREDICTION IN HIV+ WOMEN

Jingyan Yang1, Anjali Sharma2, Josh Aschheim3, Kathryn Anastos4, Mardge H. Cohen4, Elizabeth T. Golub5, Deborah Gustafson6, Daniel Merenstein7, Phyllis Tien8, Michael T. Yin1

1Columbia Univ Med Cntr, New York, NY, USA, 2Albert Einstein Coll of Med, Bronx, NY, USA, 3Arcadia Hlth, New York, USA, 4John H.Stroger Jr. Hosp of Cook County, Chicago, IL, USA, 5The Johns Hopkins Univ, Baltimore, MD, USA, 6SUNY Downstate Med Cntr, Brooklyn, NY, USA, 7Georgetown Univ, Washington, DC, USA, 8Univ of California San Francisco, San Francisco, CA, USA

FRAILTY PROGRESSION AND RECOVERY AMONG PERSONS AGING WITH HIV AND SUBSTANCE USE

Damani A. Piggott, Karen Bandeen-Roche, Shruti H. Mehta, Todd Brown, Huanle Yang, Jeremy D. Walston, Sean X. Leng, Gregory D. Kirk

The Johns Hopkins Univ, Baltimore, MD, USA

Oral Abstract O-9 HEPATITIS C: PROBLEMS AND PROGRESS
Room 606-609
10:00 AM - 12:00 PM

INCIDENCE OF HEPATITIS C AMONG HIV-INFECTED MEN WHO HAVE SEX WITH MEN, 2000–2015

Antoine Chaillon1, Christy M. Anderson1, Thomas C. Martin1, Edward R. Cachay2, David L. Wyles2, Davey M. Smith3, Susan J. Little3, Richard S. Garfein1, Natasha Martin1

1Univ of California San Diego, San Diego, CA, 2Denver Health, Denver, CO, USA

MODELING HIV-HCV EPIDEMIOLOGY IN THE DAA ERA: THE ROAD TO ERADICATION

Victor Virlogeux1, Laurent Cotte1, Pascal Pugièse1, Isabelle Poizot-Martin1, Marc-Antoine Valantin1, Lise Cuzin1, Jacques Reynes1, Eric Billault1, Thomas Huleux1, for the DatAIDS Study Group

1INSERM, Lyon, France, 2Hospices Civils de Lyon, Lyon, France, 3CHU de Nice, Nice, France, 4Assistance Publique–Hôpitaux de Marseille, Marseille, France, 5Assistance Publique–Hôpitaux de Paris, Paris, France, 6CHU Toulouse, Toulouse, France, 7CHU de Montpellier, Montpellier, France, 8CHU de Nantes, Nantes, France, 9Cntr Hosp de Tourcoing, Tourcoing, France
136  UNRESTRICTED DAA ACCESS IN THE NETHERLANDS: RAPID THERAPY UPTAKE IN HIV+HCV+ PATIENTS
10:30
Anne Boerekamps¹, Astrid Newsum², Colette Smit³, Peter Reiss³, Clemens Richter³, Marc van der Valk⁴, Joop Arends⁵, Kees Brinkman⁶, Bart Rijnders⁵, for the Netherlands ATHENA HIV observational cohort and the NVHB-SHM Hepatitis Working Group

¹Erasmus Univ Med Cntr, Rotterdam, Netherlands, ²Pub Hlth Service of Amsterdam and Academic Med Cntr, Amsterdam, Netherlands, ³Stichting HIV Monitoring, Amsterdam, Netherlands, ⁴Stichting HIV Monitoring and Academic Med Cntr, Amsterdam, Netherlands, ⁵Rijnstate Hosp, Arnhem, Netherlands, ⁶Academic Med Cntr, Amsterdam, Netherlands, ⁷Univ Med Cntr Utrecht, Utrecht, Netherlands, ⁸OLVG, Amsterdam, Netherlands

137LB  SUBSTANTIAL DECLINE IN ACUTE HCV INFECTIONS AMONG DUTCH HIV+MSM AFTER DAA ROLL OUT
10:45
Anne Boerekamps¹, Guido van den Berk², Fanny Lauw³, Eliane Leyten⁴, Joop Arends¹, Marjo Kasteren⁵, Mark Claassen⁶, Charles Boucher⁷, Bart Rijnders¹, for the Dutch Acute HCV in HIV (DAHHS) study group

¹Erasmus Univ Med Cntr, Rotterdam, Netherlands, ²OLVG, Amsterdam, Netherlands, ³Slotervaart MC, Amsterdam, Netherlands, ⁴MC Haaglanden, The Hague, Netherlands, ⁵Univ Med Cntr Utrecht, Utrecht, Netherlands, ⁶St. Elizabeth Ziekenhuis, Tilburg, Netherlands, ⁷Rijnstate Hosp, Arnhem, Netherlands

138  CORRELATION OF RENAL BIOMARKERS AND TENOFOVIR AUC IN THE ION-4 STUDY COHORT
11:00
Austin W. Chan¹, Larry Park¹, Lauren F. Collins¹, Curtis Cooper¹, Michael Saag¹, Douglas Dieterich¹, Mark Sulkowski³, Susanna Naggie¹, for the ION-4 Study Group

¹Duke Univ, Durham, NC, USA, ²Ottawa General Rsr Inst, Ottawa, Ontario, ³Univ of Alabama at Birmingham, Birmingham, AL, USA, ⁴Icahn Sch of Med at Mt Sinai, New York, NY, USA, ⁵The Johns Hopkins Univ, Baltimore, MD, USA

139  HEPATOCELLULAR CARCINOMA AFTER SVR WITH IFN-FREE REGIMENS IN HIV/HCV COINFECTION
11:15
Nicolás Merchante¹, Boris Revollo², Francisco Rodríguez-Arrondo², Esperanza Merino³, Maria J. Galindo³, Marta Montero³, Antonio Rivero-Juárez³, Marcial Delgado-Fernández³, María J. Rios-Villegas³, Juan A. Pineda¹

¹Hosp Univ de Valme, Sevilla, Spain, ²Hosp German Trias i Pujol, Badalona, Spain, ³Hosp Univ de Donostia, San Sebastián, Spain, ⁴Hosp General Univ de Alcalá, Alcalá, Spain, ⁵Hosp Clinico de Valencia, Valencia, Spain, ⁶Hosp Univ y Politécnico La Fe, Valencia, Spain, ⁷Hosp Univ Reina Sofia, Córdoba, Spain, ⁸Hosp Regional Univ de Málaga, Málaga, Spain, ⁹Hosp Univ Virgen Macarena, Sevilla, Spain

140  IDENTIFICATION OF HCV INTER-SUBTYPE RECOMBINANT STRAINS WITH BREAKPOINTS IN NSSA
11:30
Suqin Cai¹, Alicia Newton, Wei Huang, Jeannette Whitcomb
Monogram BioScis, South San Francisco, CA, USA

141  SYNERGY BETWEEN COMBINATIONS OF ANTI-HCV BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES
11:45
Madeleine C. Mankowski¹, Andrew I. Flyak¹, Stuart C. Ray³, James E. Crowe¹, Justin R. Bailey³

¹Johns Hopkins Univ, Severna Park, MD, USA, ²Vanderbilt Univ, Nashville, TN, USA, ³Johns Hopkins Univ, Baltimore, MD, USA
Themed Discussion TD-12 THE IMPOSSIBLE DREAM: POPULATION PERSPECTIVES ON 90:90:90 IN ADOLESCENTS AND YOUNG ADULTS
Room 615-617
1:30 PM - 2:30 PM

Themed Discussion Leader
Mary-Ann Davies, University of Cape Town Faculty of Health Sciences, Cape Town, South Africa

834 COMMUNITY INTERVENTION IMPROVES ADOLESCENT HIV STATUS KNOWLEDGE:HPTN 071 STUDY ZAMBIA

Kwame Shanaube1, Mwate J. Chaila1, David Macleod2, Ab Schaap1, Sian Floyd3, Conred Jani1, Graeme Hoddinott4, Richard Hayes1, Sarah Fidler4, Helen Ayles3


835 A NOVEL MODEL OF COMMUNITY COHORT CARE FOR HIV-INFECTED ADOLESCENTS IMPROVES OUTCOMES

Lindsey Reif1, Rachel Bertrand2, Vanessa Rivera3, Bernadette Jospeh2, Benedict Anglade2, Jean W. Pape1, Daniel Fitzgerald3, Margaret McNairy1

1Columbia Univ, New York, NY, USA, 2GHESKIO, Port-au-Prince, Haiti, 3Weill Cornell Med, New York, NY, USA

836 LOCAL SOCIAL NETWORKS PREDICT RETENTION & SUPPRESSION IN YOUNG WOMEN IN SEARCH TRIAL

Lillian Brown1, Wenjing Zheng1, James Ayieko3, Asiphas Owaraganise1, Florence Mwangwa4, Tamara D. Clark1, Edwin D. Charlebois1, Moses R. Kamya1, Diane V. Havlir1, Maya L. Petersen2

1Univ of California San Francisco, San Francisco, CA, USA, 2Univ of California Berkeley, Berkeley, CA, USA, 3Kenya Med Rsr Inst, Nairobi, Kenya, 4Infectious Diseases Rsr Collab, Kampala, Uganda, 5Makerere Univ, Kampala, Uganda

837 TEENAGE PREGNANCY: A CRITICAL BARRIER TO RETENTION ON ANTIRETROVIRAL THERAPY

Harriet Nuwagaba-Biribonwoha1, Agnes Kiragga2, Constantin Yiannoutsos1, Beverly Music1, Kara K. Wools-Kaloustian1, Elaine J. Abrams3, Batya Elul4, for the International Epidemiologic Databases to Evaluate AIDS (IeDEA) East Africa Collaboration

1ICAP at Columbia Univ, New York, NY, USA, 2Makerere Univ, Kampala, Uganda, 3Indiana Univ, Indianapolis, IN, USA, 4Columbia Univ, New York, NY, USA

838 IMPACT OF SUBSTANCE USE, MENTAL HEALTH, AND AGE ON RETENTION AND VIRAL SUPPRESSION

Brian C. Zanoni1, Sara Lammert1, Jessica Haberer1, Gregory K. Robbins1, Heidi M. Crane2, Michael J. Mugavero1, Katerina Christopoulos4, Kenneth H. Mayer1

1Massachusetts General Hosp, Boston, MA, USA, 2Univ of Washington, Seattle, WA, USA, 3Univ of Alabama at Birmingham, Birmingham, AL, USA, 4Univ of California San Francisco, San Francisco, CA, USA, 5Fenway Hlth, Boston, MA, USA
Themed Discussion Leader

**Oral Sessions • Thursday**

**Program and Agenda**

**CROI 2017**

---

### Themed Discussion TD-13 HOT FLUSHES: HORMONAL CONTRACEPTION AND HIV RISK

**Room 611-614**

1:30 PM - 2:30 PM

**Themed Discussion Leader**

**Laneta Dorflinger**, Contraceptive Technology Innovation, FHI360, Durham, NC, USA

#### 944 DEPOT MEDROXYPROGESTERONE ACETATE INCREASES HIV-1 REPLICATION IN MUCOSAL TISSUE

Charlene S. Dezzutti¹, Seo Young Park¹, Ingrid Macio², Kenneth Marks³, Sidney Lawlor³, Catherine Chappell⁴, Katherine Bunge⁴

¹Univ of Pittsburgh, Pittsburgh, PA, USA, ²Univ of Pittsburgh Med Cntr, Pittsburgh, PA, USA, ³Magee-Womens Rsr Inst, Pittsburgh, PA, USA, ⁴Magee-Womens Hosp of UPMC, Pittsburgh, PA, USA

#### 943 CHANGES IN GENITAL-TRACT HIV TARGET CELLS WITH THREE PROGESTIN-BASED CONTRACEPTIVES

Lisa B. Haddad¹, Alison S. Kohlmeier², Richard Haaland², Nakita Brown¹, David Lupo², Christina Mehta¹, Anandi N. Sheth¹, Khemia Titanji¹, Clyde Hart¹, Igho Ofotokun¹

¹Emory Univ, Atlanta, GA, USA, ²CDC, Atlanta, GA, USA

#### 945 ZIM-Chic: Impact of Contraceptive Initiation on Immune Cells in the Cervix and PBMCs

Sharon L. Achilles¹, Feliz Mhlanga¹, Leslie A. Meyn¹, Kevin A. Stoner³, Allen T. Matubu¹, Zvavahera M. Chirenje¹, Sharon L. Hillier¹

¹Univ of Pittsburgh, Pittsburgh, PA, USA, ²Univ of Zimbabwe, Harare, Zimbabwe, ³Magee–Womens Rsr Inst, Pittsburgh, PA, USA

#### 946 HIV GENITAL-TRACT SHEDDING WHILE ON PROGESTIN CONTRACEPTION

Julie A. Nelson¹, Jeff Wiener¹, Jennifer H. Tang¹, Lamechin Chinula¹, Stacey Hurst¹, Gerald Tegha¹, Albans Msika³, Mina C. Hosseinipour¹, Lisa B. Haddad¹, Athena Kourtis³

¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ²CDC, Atlanta, GA, USA, ³Univ of North Carolina Proj–Malawi, Lilongwe, Malawi, ⁴Emory Univ, Atlanta, GA, USA

#### 947 HORMONAL CONTRACEPTION DOES NOT AFFECT ART EFFECTIVENESS OR GENITAL HIV SHEDDING

Rena Patel¹, Jared Baeten¹, Renee Heffron¹, Ting Hong¹, Nicole Davis², Kavita Nanda¹, Robert Coombs¹, Elizabeth A. Bukusi¹, Athena Kourtis³, Nelly Mugo³

¹Univ of Washington, Seattle, WA, USA, ²CDC, Atlanta, GA, USA, ³FHI 360, Durham, NC, USA, ⁴Kenya Med Rsr Inst, Nairobi, Kenya, ⁵KEMRI, Nairobi, Kenya

---

### Themed Discussion TD-14 HIV AND SUBSTANCE ABUSE: DOUBLE TROUBLE

**Room 606-609**

1:30 PM - 2:30 PM

**Themed Discussion Leader**

**Steven Shoptaw**, Univ of California Los Angeles, Los Angeles, CA, USA

#### 869 “HOOKED ON PAINKILLERS” PRIOR TO FIRST INJECTION AMONG PWID IN 16 U.S. CITIES

Dita Broz¹, Maria Zlotorzynska², Michael Spiller¹, Gabriela Paz-Bailey¹, for the NHBS Study Group

¹CDC, Atlanta, GA, USA, ²Emory Univ, Atlanta, GA, USA

---

**CROI 2017**
870 **OPIOID SUBSTITUTION THERAPY AND INITIATION INTO INJECTION DRUG USE IN SAN DIEGO, CA**

Maria Luisa Mittal1, Devesh Vashishtha1, Xiaoying Sun1, Sonia Jain1, Richard S. Garfein1, Steffanie A. Strathdee2, Dan Werb1

1Univ of California San Diego, La Jolla, CA, USA, 2Univ of California San Diego, San Diego, CA, USA

871 **CHANGES IN PRESCRIPTION OPIOID, METH, AND COCAINE USE AMONG MSM IN 20 US CITIES**

Brooke Hoots, Dita Broz, Lina Nerlander, Gabriela Paz-Bailey

CDC, Atlanta, GA, USA

872 **CHANGING PATTERN OF CRYSTAL METH USE IN BLACK & WHITE MSM, WASHINGTON, DC, 2008–2014**

Irene Kuo1, Rudy Patrick1, Jenevieve Opoku2, Anthony Rawls1, Manya Magnus1, James Peterson1, Michael Kharfen2, Alan Greenberg1

1The George Washington Univ, Washington, DC, USA, 2District of Columbia Dept of Hlth, Washington, DC, USA

873 **INCREASING METHAMPHETAMINE USE AMONG NON-MSM WHO INJECT DRUGS IN KING COUNTY, WA**

Sara N. Glick1, Richard Burt2, Kim Kummer1, Joe Tinsley2, Caleb Banta-Green1, Matthew R. Golden1

1Univ of Washington, Seattle, WA, USA, 2Pub Hlth - Seattle & King County, Seattle, WA, USA

---

Themed Discussion TD-15 I WANT A NEW DRUG

**Room 6 C**

**1:30 PM - 2:30 PM**

**Themed Discussion Leader**

Karl Salzwedel, National Institutes of Health, Bethesda, MD, USA

433 **NOVEL HIV PI WITH HIGH RESISTANCE BARRIER AND POTENTIAL FOR UNBOOSTED QD ORAL DOSING**

John O. Link, Darryl Kato, Michael Moore, Andrew Mulato, Bernard Murray, Judy Mwangi, Nathan D. Shapiro, George Stepan, Yujin Wang, Zheng-Yu Yang

Gilead Scis, Inc, Foster City, CA, USA

434 **NOVEL NON-CATALYTIC SITE INTEGRASE INHIBITOR WITH IMPROVED RESISTANCE PROFILE**

Michael L. Mitchell, Mini Balakrishnan, Gediminas Brizgys, Ruby Cai, Eric Lansdon, Andrew Mulato, Mark Osier, Jianhong Wang, Helen Yu, Roman Sakowicz

Gilead Scis, Inc, Foster City, CA, USA

435 **MK-8591 CONCENTRATIONS AT SITES OF HIV TRANSMISSION AND REPLICATION**

Jay Grobler, Carolyn McHale, Carol Freddo, Dan Dreyer, Li Sun, Marissa Vavrek, Sheila Breidinger, Kerry Fillgrove, Daria Hazuda, Ming-Tain Lai

Merck & Co, Inc, West Point, PA, USA

436 **GS-9131 IS A NOVEL NRTI WITH ACTIVITY AGAINST NRTI-RESISTANT HIV-1**

Kirsten L. White, Nicolas Margot, Kirsten Stray, Helen Yu, George Stepan, Constantine Boojamra, Richard Mackman, Adrian Ray, Michael D. Miller, Tomas Cihlar

Gilead Scis, Inc, Foster City, CA, USA
437 PRO140 SINGLE-AGENT MAINTENANCE THERAPY FOR HIV-1 INFECTION: A 2-YEAR UPDATE

Jay Lalezari1, Kush Dhody2, Ula Kowalczyk1, Kazem Kazempour1, Nader Pourhassan1, Paul J. Maddon4
1Quest Clinical Rsr, San Francisco, CA, USA, 2Amarex Clinical Rsr, LLC, Germantown, MD, USA, 3CytoDyn, Inc, Vancouver, WA, USA, 4Maddon Advisors LLC, Scarsdale, NY, USA

Themed Discussion TD-16 HOW DOES THE MICROBIOME AFFECT HIV INFECTION?

Room 6 E 1:30 PM - 2:30 PM

Themed Discussion Leader
Cara Wilson, MD, Univ of Colorado-Anschutz Medical Campus, Aurora, CO, USA

207 IMPACT OF MSM-ASSOCIATED MICROBIOTA ON IMMUNE ACTIVATION AND IN VITRO HIV INFECTION

Sam Li, Abigail Armstrong, Charles P. Neff, Catherine Lozupone, Brent E. Palmer
Univ of Colorado, Aurora, CO, USA

208 FECAL MICROBIOTA FROM HIV-INFECTED SUBJECTS INCREASES IMMUNE ACTIVATION AND INFECTION

Charles P. Neff, Sam Li, Abigail Armstrong, Catherine Lozupone, Brent E. Palmer
Univ of Colorado, Aurora, CO, USA

209 MARAVIROC INHIBITS HIV TARGET T-CELL TRAFFICKING INTO THE FEMALE GENITAL LUMEN

Alison S. Kohlmeier1, Sean McMaster2, Jessica Radzio1, Mian-er Cong1, Chuong Dinh1, Amy Martin1, Jacob E. Kohlmeier1, Gerardo Garcia-Lerma2
1CDC, Atlanta, GA, USA, 2Emory Univ, Atlanta, GA, USA

210 INVESTIGATING THE EFFECT OF PH ON CERVICOVAGINAL MUCUS BARRIER PROPERTIES TO HIV

Julie K. Shade, Thuy Hoang, Kevin Delong, Justin Hanes, Richard Cone, Laura Ensign
The Johns Hopkins Univ, Baltimore, MD, USA

Themed Discussion TD-17 EMERGING VIRUSES: THE ZIKA VIRUS

Room 6 AB 1:30 PM - 2:30 PM

Themed Discussion Leader
Robert T. Schooley, Univ of California San Diego, La Jolla, CA, USA

1054 CHARACTERIZATION OF MORE THAN 10,000 ZIKA VIRUS TEST RESULTS IN THE US

Joseph M. Volpe1, Dajie Luo1, Arren Fisher1, Mindy Nye1, Barbara Body1, Marcia Eisenberg1
1LabCorp, Durham, NC, USA, 2LabCorp, Burlington, NC, USA

1055LB ZIKA VIRUS PERSISTENCE IN BODY FLUIDS

Gabriela Paz-Bailey1, Eli Rosenberg2, Katherine Doyle1, Jorge Munoz-Jordan1, Gilberto Santiago1, Liore Klein1, Janice Perez3, Stephen Waterman1, Luisa Alvarado1, Tyler Sharp1
1CDC, Atlanta, GA, USA, 2Emory Univ, Atlanta, GA, USA, 3Caduceus Healthcare, Inc, Ponce, PR, USA, 4Ponce Univ, Ponce, PR, USA
1056LB NEUROLOGIC CONSEQUENCES OF POSTNATAL ZIKA VIRUS INFECTION IN INFANTS

Maud Mavigner1, Justin O’Neal1, Siddhartha Bhaumik1, Jakob Habib1, Cameron Robinson1, Maria Alvarado3, Xiaodong Zhang1, Jens Wrammert1, Mehul Suthar2, Ann Chahroudi1

1Emory Univ, Atlanta, GA, USA, 2Emory Vaccine Center, Atlanta, GA, USA, 3Yerkes Natl Primate Rsr Cntr, Atlanta, GA, USA

1057LB ZIKA VIRUS PROTECTION BY A SINGLE LOW-DOSE NUCLEOSIDE-MODIFIED mRNA VACCINATION

Michael J. Hogan1, Norbert Pardi1, Rebecca S. Pelc2, Hanne Anderson1, Charles McGee1, Michael J. Hope1, Mark G. Lewis1, Theodore C. Pierson1, Barton F. Haynes2, Drew Weissman1

1Univ of Pennsylvania, Philadelphia, PA, USA, 2NIAID, Bethesda, MD, USA, 3Bioqual, Inc, Rockville, MD, USA, 4Duke Univ, Durham, NC, USA, 5Acuitas Therapeutics, Vancouver, BC, Canada

Symposium S-8 PATHS INTERTWINED: BROADLY NEUTRALIZING ANTIBODIES AND THE HIV-1 ENVELOPE TRIMER

Room 606-609 4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding how broadly neutralizing antibody responses in HIV-1 infection develop, how they may be harnessed for preventive vaccines, and exploited for HIV cure.

Level of Knowledge: It is assumed that the participants are familiar with the basic principles of how antibodies function.

Objectives:
- Describe how broadly neutralizing antibodies are stimulated during infection and following vaccination
- Describe the structural properties of broadly neutralizing antibodies and their interaction with the HIV Envelope
- Describe the potential of exploiting broadly neutralizing antibodies for functional cure

Conveners
Nicole Doria-Rose, National Institutes of Health, Bethesda, MD, USA
Gabriella Scarlatti, Global HIV Vaccine Enterprise, New York, NY, USA

142 NEUTRALIZING ANTIBODY DEVELOPMENT DURING HIV-1 INFECTION

Penelope Moore, Univ of the Witwatersrand, Johannesburg, South Africa

143 IMMUNOGEN DESIGN TO INDUCE HIV NEUTRALIZING ANTIBODIES

William R. Schief, Scripps Rsr Inst, La Jolla, CA, USA

144 STRUCTURAL STUDIES OF HIV NEUTRALIZING ANTIBODIES

Andrew B. Ward, Scripps Rsr Inst, La Jolla, CA, USA

145 CLINICAL STUDIES WITH BROADLY NEUTRALIZING ANTIBODIES

Michel Nussenzweig, Rockefeller Univ, New York, NY, USA
Symposium S-9 MODERN ART
Room 6 E 4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding contemporary antiretroviral therapy and HIV drug resistance.

Level of Knowledge: It is assumed that the participants are familiar with the principles of HIV drug resistance and antiretroviral therapy.

Objectives: At the completion of the session, participants will be able to:

- Describe trends in transmitted HIV drug resistance and resistance emergence on ART.
- Compare strategies for simplification of antiretroviral therapy in patients suppressed on therapy.
- Summarize the challenges in developing an initial antiretroviral regimen for the global HIV epidemic.

Conveners
Ying-Ru Lo, World Health Organization, Geneva, Switzerland
Paul E. Sax, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

0146 HIV-1 DRUG RESISTANCE IN RESOURCE-LIMITED SETTINGS
4:00
Ravindra K. Gupta, Univ College London, London, UK

0147 LONG-ACTING ANTIRETROVIRAL THERAPY: A SHOT IN THE DARK OR A PARADIGM SHIFT?
4:30
Charles W. Flexner, The Johns Hopkins Univ, Baltimore, MD, USA

148 SIMPLE ART: MORE COMPLEX THAN THOUGHT
5:00
Jose R. Arribas, Hospital La Paz, Madrid, Spain

149 TOWARD AN IDEAL ANTIRETROVIRAL REGIMEN FOR THE GLOBAL EPIDEMIC
5:30
Beatriz Grinsztejn, Oswaldo Cruz Foundation - Fiocruz, Rio de Janeiro, Brazil
Symposium S-10 LEVERAGING THE PLATFORM: RESPONDING TO NONCOMMUNICABLE DISEASES

Room 6 C 4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding the potential for synergies between global efforts to reduce premature mortality from noncommunicable diseases and global efforts to improve the quality and length of life of people living with HIV.

Level of Knowledge: It is assumed that participants are familiar with basic clinical management of HIV and a range of noncommunicable diseases, including prevention, care and treatment. Some familiarity with health care systems in low resource settings will enhance the value of this session.

Objectives: At the completion of the session, participants will be able to:

- Understand the global burden of noncommunicable diseases associated with HIV
- Understand the use of HIV treatment infrastructure to address noncommunicable diseases
- Understand the benefits and challenges of integrating services for HIV and noncommunicable diseases at different levels of the health system

Conveners
Peter Godfrey-Faussett, UNAIDS, Geneva, Switzerland
Irene Mukui, National AIDS and STI Control Program, Nairobi, Kenya

150 OVERVIEW OF THE GLOBAL BURDEN OF NONCOMMUNICABLE DISEASES IN HIV INFECTION
4:00 Pragna Patel, CDC, Atlanta, GA, USA

151 CARDIOVASCULAR DISEASE AMONGST PEOPLE LIVING WITH HIV IN AFRICA
4:30 Gerald Yonga, Aga Khan Univ, Nairobi, Kenya

152 CAN WE LEVERAGE HIV PLATFORMS FOR PREVENTION OF CERVICAL CANCER IN LMICs IN SSA?
5:00 Doreen Ramogola-Masire, Univ of Botswana-Univ of Pennsylvania Collaboration, Gaborone, Botswana

153 MINIMIZING MORBIDITY: INTEGRATING CARE FOR DEPRESSION & HIV IN LOW RESOURCE SETTINGS
5:30 Pamela Collins, NIMH, Bethesda, MD, USA
### Poster Sessions by Day

**Tuesday, February 14, 2017**

<table>
<thead>
<tr>
<th>Poster P-A1: VIROLOGY TRAFFICKING</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Poster Hall - 4 EF</strong></td>
</tr>
<tr>
<td>2:30 PM - 4:00 PM</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>154</strong></th>
<th>PHENOTYPING AND SORTING OF INDIVIDUAL FREE INFECTIOUS HIV PARTICLES BY FLOW CYTOMETRY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michal Bonar, John Tilton</td>
<td></td>
</tr>
<tr>
<td>Case Western Reserve Univ, Cleveland, OH, USA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>155</strong></th>
<th>SINGLE VIRUS IMAGING OF HIV-1 WITH FLUORESCENTLY LABELED CA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zeger Debyser, Irena Zurnic, Lieve Dirix, Veerle Lemmens, Veerle Lemmens, Susana Rocha, Johan Hofkens, Jelle Hendrix, Frauke Christ</td>
<td></td>
</tr>
<tr>
<td>Katholieke Univ Leuven, Leuven, Belgium</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>156</strong></th>
<th>CHARACTERIZING CELLULAR FACTORS INVOLVED IN HIV-1 GAG TRAFFICKING TO ASSEMBLY SITES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rachel Van Duyne, Philip R. Tedbury, Eric O. Freed</td>
<td></td>
</tr>
<tr>
<td>NCI, Frederick, MD, USA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>157</strong></th>
<th>HIV-1 RESISTANCE TO KF116 REVEALS INTEGRASE’S ROLE DURING POLYPEPTIDE PROCESSING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashley C. Hoyte¹, Augusta V. Jamin², Pratibha Chowdary Koneru³, Stephanie Rebensburg⁴, Jason Anderson⁴, Matthew Kobe⁴, Emma N. Ivanauskas⁴, James R. Fuchs⁴, Alan N. Engelmann⁴, Mamuka Kvaratskhelia⁴</td>
<td></td>
</tr>
<tr>
<td>¹The Ohio State Univ, Columbus, OH, USA, ²Dana-Farber Cancer Inst, Boston, MA, USA, ³The Ohio State Univ, Columbus, OH, USA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>158</strong></th>
<th>ROLE OF MA TRIMERIZATION IN HIV-1 ENVELOPE GLYCOPROTEIN INCORPORATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mariia Novikova, Philip R. Tedbury, Eric O. Freed</td>
<td></td>
</tr>
<tr>
<td>NCI, Frederick, MD, USA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>159</strong></th>
<th>PRODUCTION OF HIV-1 PROTEINS FROM “DEFECTIVE” HIV-1 PROVIRUS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hiromi Imamichi¹, Joseph Adelsberger², H. Clifford Lane³</td>
<td></td>
</tr>
<tr>
<td>¹NIADD, Bethesda, MD, USA, ²Leidos Biomed Rsr, Inc, Frederick, MD, USA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>160LB</strong></th>
<th>NUCLEAR PORE HETEROGENEITY AFFECTS HIV-1 INFECTION AND THE ANTIVIRAL ACTIVITY OF MX2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melissa Kane¹, Stephanie Rebensburg², Matthew Takata¹, Trinity Zang¹, Masahiro Yamashita¹, Mamuka Kvaratskhelia¹, Paul Bieniasz³</td>
<td></td>
</tr>
<tr>
<td>¹The Rockefeller Univ, New York, NY, USA, ²The Ohio State Univ, Columbus, OH, USA, ³Aaron Diamond AIDS Rsr Cntr, New York, NY, USA, ⁴Howard Hughes Med Cntr, New York, NY, USA</td>
<td></td>
</tr>
</tbody>
</table>
**Poster P-B1: UNDERSTANDING NETWORKS AND LINKED INFECTIONS: FROM LOCAL TO GLOBAL**

**Poster Hall - 4 EF**

**2:30 PM - 4:00 PM**

**182 IDENTIFICATION OF MAJOR ROUTES OF HIV TRANSMISSION THROUGHOUT MESOAMERICA**

Antoine Chaillon¹, Joel O. Wertheim¹, Santiago Avila-Rios¹, Ann M. Dennis¹, Claudia García-Morales², Carlos Mejía-Villatoro³, Elsa Y. Palou⁴, Gustavo Reyes-Terán⁵, Sanjay R. Mehta⁶, for the The Mesoamerican Project Group

¹Univ of California, San Diego, San Diego, CA, USA, ²Natl Inst of Respiratory Diseases, Mexico City, Mexico, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴Roosevelt Hosp, Guatemala City, Guatemala, ⁵ Hosp Escuela Univ, Tegucigalpa, Honduras, ⁶Rsr Cntr in Infectious Diseases, Mexico City, Mexico

**183 REVEALING THE MOLECULAR EPIDEMIOLOGY OF THE COLOGNE, GERMANY, HIV EPIDEMIC**

Melanie Stecher¹, Martin Hoenigl², Joerg Janne Vehreschild¹, Clara Lehmann¹, Gerd Fätkenheuer¹, Rolf Kaiser¹, Sanjay R. Mehta², Antoine Chaillon²

¹Univ of Cologne, Cologne, Germany, ²Univ of California San Diego, San Diego, CA, USA, ³Cologne Univ Hosp, Cologne, Germany

**184 STRUCTURE OF HIV-1C TRANSMISSION NETWORK IN SOUTHERN BOTSWANA, 2016**

Vlad Novitsky¹, Sikhulile Moyo², Melissa Zahralban-Steele¹, Baitshepi Mokaleng¹, Dorcas Maruapula², Mary F. McLane¹, Kathleen Wirth¹, Lisa A. Mills¹, Simani Gaseitsiwe², Max Essex¹

¹Harvard Univ, Boston, MA, USA, ²Botswana Harvard AIDS Rsr Inst Partnership, Gaborone, Botswana, ³CDC Botswana, Gaborone, Botswana

**185 PHYLOGENETICS OF A RECENT HIV OUTBREAK AMONG PEOPLE WHO INJECT DRUGS IN SCOTLAND**

Manon Ragonnet-Cronin¹, Celia Jackson², Amanda Bradley-Stewart³, Celia Aitken³, Andrew McAuley³, Norah Palmateer³, David Goldberg¹, Catriona Milosevic², Andrew Leigh Brown¹

¹Univ of Edinburgh, Edinburgh, UK, ²NHS Greater Glasgow and Clyde, Glasgow, UK, ³Hlth Protection Scotland, Glasgow, UK

**186 NONDISCLOSED MSM LINK TOGETHER IN HIV TRANSMISSION NETWORKS**

Manon Ragonnet-Cronin¹, Stéphane Hué², Anna Tostevin², Anton Pozniak², Tracy Fawcett², Alison E. Brown², David Dunn³, Andrew Leigh Brown², for the UK HIV Drug Resistance Database


**187 MATING THE EFFECT OF COMPLETENESS OF HIV SEQUENCING DATA ON TRANSMISSION NETWORKS**

Sharoda Dasgupta¹, Anne Marie France¹, Mary-Grace Brandt², M Cheryl B. Ocfemia¹, Tianchi Zhang¹, Nivedha Panneer¹, Angela Hernandez², Alexandra Oster¹

¹CDC, Atlanta, GA, USA, ²Michigan Dept of Community Hlth, Detroit, MI, USA
188 TEMPORAL CHANGES IN HIV TRANSMISSION PATTERNS AMONG YOUNG MEN WHO HAVE SEX WITH MEN
Nivedha Panneer¹, Y. O. Whiteside², Anne Marie France², Joel O. Wertheim³, Alexandra Oster⁴
¹Oak Ridge Inst for Sci and Educ, Atlanta, GA, USA, ²CDC, Atlanta, GA, USA, ³Univ of California San Diego, San Diego, CA, USA

189 PHYLODYNAMIC ANALYSIS AIDS PARTNER SERVICES BY IDENTIFYING UNREPORTED TRANSMISSION
Ellsworth Campbell¹, Anupama Shankar¹, Emily Westheimer², Cynthia L. Gay³, Stephanie E. Cohen⁴, Jin-Fen Li⁴, Jeffrey A. Johnson¹, Philip J. Peters¹, William M. Switzer⁴
¹CDC, Atlanta, GA, USA, ²New York City DHMH, New York, NY, USA, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴San Francisco Dept of Pub Hlth, San Francisco, CA, USA

190 NEUTRALIZING ANTIBODIES IN HUMANS INFECTED WITH ZOONOTIC SIMIAN FOAMY VIRUSES
Caroline Lambert, Julie Gouzil, Léa Richard, Réjane Rua, Edouard Betsem, Antoine Gessain, Florence Buseyne
Inst Pasteur, Paris, France

Poster P-C4: ANIMAL MODELS OF HIV INFECTION
Poster Hall - 4 EF 2:30 PM - 4:00 PM

216 ANTIBIOTICS DISRUPT GASTROINTESTINAL BACTERIA AND HOST IMMUNITY IN Rhesus Macaques
Alexander S. Zevin, Jennifer A. Manuzak, Tiffany Hensley-McBain, Ryan Cheu, Charlene Miller, Jacob Modesitt, Jeremy Smedley, Nichole Klatt
Univ of Washington, Seattle, WA, USA

217 ALCOHOL CONSUMPTION INCREASES SIV FOUNDER VIRUS DIVERSITY TO ALTER DISEASE COURSE
Spencer Robichaux, Angela M. Amedee
Louisiana State Univ, New Orleans, LA, USA

218 GORILLA ENTERIC VIROME DYNAMICS IN ASSOCIATION WITH SIV INFECTION
Mirela D’arc¹, Carolina Furtado¹, Juliana D. Siqueira¹, Ahidjo Ayouba¹, Martine Peeters¹, Marcelo A. Soares²
¹Univ Fed do Rio de Janeiro, Rio de Janeiro, Brazil, ²Inst Nacional de Câncer, Rio de Janeiro, Brazil, ³IRD, Montpellier, France

219 EARLY HIV-1 DETECTION IN HUMANIZED MICE
Hang Su, Prasanta Dash, Larisa Y. Poluektova, Santhi Gorantla, Howard E. Gendelman
Univ of Nebraska, Omaha, NE, USA

220 AN ENGINEERED RNA VIRUS CAUSES ACUTE AIDS IN HUMAN CD4,CCR5 TRANSGENIC MICE
Rachel A. Liberatore, Emily J. Mastrocara, Elena Cassella, Jessie Willen, Fabian Schmidt, Dennis Voronin, Trinity Zang, Theodora Hatzioannou, Paul Bieniasz
The Rockefeller Univ, New York, NY, USA
221 RAPID T FOLLICULAR HELPER CELL RECONSTITUTION IN LYMPH NODES AFTER ART INITIATION
Chun-Shu Wong1, Afroditi Boulougoura1, Angela Kibi2, Jeremy Davis3, Stefania Pittaluga3, Maura Manion1, Andrea Lisco1, Virginia Sheikh4, JoAnn Mican1, Irini Sereti1
1NIAID, Bethesda, MD, USA, 2Leidos Biomed Rsr, Bethesda, MD, USA, 3NCI, Bethesda, MD, USA, 4FDA, Silver Spring, MD, USA

222 INFLAMMASOME AND PYROPTOSIS ARE INVOLVED IN THE LACK OF IMMUNE RESPONSE DURING CART
Michela Masetti1, Massimiliano Fabbiani2, Mara Bais3, Antonio Muscatello1, Nicola Squilace1, Elisa Colella1, Mario Clerici1, Andrea Gori1, Daria Trabattoni1, Alessandra Bander4
1Univ of Milan, Milan, Italy, 2San Gerardo Hosp, Monza, Italy, 3Univ of Milan, Segrate, Milan, Italy

223 INCREASED IL-18/IL-1B RATIO BLUNTS CCL20 PRODUCTION AND TH17 GUT HOMING DURING CART
Claire Loiseau1, Mary Requena1, Anne Laure Iscache1, Michelle Cazabat1, Nicolas Carrere1, Bertrand Suc2, Bruno Marchou4, Jacques Izopet1, Pierre Delobel2
1INSERM, Toulouse, France, 2CHU Toulouse, Toulouse, France

224 GENITAL HIV SHEDDING WHEN ANTIRETROVIRAL THERAPY (ART) SUPPRESSES PLASMA HIV RNA
Marta E. Bull1, Caroline Mitchell1, Corey Williams1, Jaime Soria1, Eduardo Ticona2, Eduardo Ticona3, Alberto M. La Rosa2, Joan Dragavon1, Robert Coombs1, Lisa Frenkel1
1Univ of Washington, Seattle, WA, USA, 2Massachusetts General Hosp, Boston, MA, USA, 3Seattle Children's Rsr Inst, Seattle, WA, USA, 4Hosp Nacional Dos de Mayo, Lima, Peru, 5Hosp Dos de Mayo, Lima, Peru, 6Asociación Civil Impacta Salud y Educación, Lima, Peru

225 PREDICTORS OF IMMUNE RECOVERY AFTER ART IN VERY ADVANCED DISEASE
Pablo F. Belaunzaran-Zamudio1, Alejandro Olmedo1, Irini Sereti1, Yanink Caro-Vega1, Adam Rupert1, Alondra Lopez1, Ian Sanne1, Juan Sierra-Madero1, Michael M. Lederman1
1Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zuiran, Mexico, Mexico, 2NIAID, Bethesda, MD, USA, 3Leidos Biomed Rsr, Inc, Frederick, VA, USA, 4Univ of the Witwatersrand, Johannesburg, South Africa, 5Case Western Reserve Univ, Cleveland, OH, USA

226 PARADOXICAL CD4 DECLINE ON ART: A NOVEL, RARE, AND PERPLEXING IMMUNOLOGIC OUTCOME
Andrea Lisco1, Itzhak Levy1, Jason Brophy4, Claire Deleage4, Chun-Shu Wong1, Adam Rupert1, Caryn G. Morse4, Shanna Chan1, Jacob D. Estes4, Irini Sereti1
1NIAID, Bethesda, MD, USA, 2Academic Med Cntr Hosp, Tel Aviv, Israel, 3Children's Hosp of Eastern Ontario, Ottawa, Canada, 4Frederick Natl Lab for Cancer Rsr, Frederick, USA, 5Leidos Biomed Rsr, Inc, Frederick, MD, USA, 6NIH, Bethesda, MD, USA, 7Winnipeg Regional Hlth Authority, Manitoba, Canada
EFFECT OF EXOGENOUS INTERFERON ALPHA ON HIV VIRAL POPULATIONS IN VIVO

Giorgio Bozzi, Wei Shao, Robin L. Dewar, Vinay K. Pathak, Belete A. Desimmie, Ryan C. Burdick, Sara Jones, Claudia Balotta, Mary E. Wright, Frank Maldarelli

1NCI, Frederick, MD, USA, 2Leidos Biomed Rsr, Inc, Frederick, MD, USA, 3Leidos Biomed Rsr, Inc, Bethesda, MD, USA, 4Univ of Milan, Milan, Italy, 5NIAID, Bethesda, MD, USA

Poster P-D1: HIV-SPECIFIC ANTIBODIES AND HOW TO INDUCE THEM
Poster Hall - 4 EF
2:30 PM - 4:00 PM

A BROAD POLyclonal RESPONSE IS MEDIATED BY SUPERINFECTION WITH 2 DISTINCT VIRUSES

Bingjie Wang, Katherine L. Williams, Valerite Cortez, James A. Williams, Kelly K. Lee, R. Scott McClelland, Julie Overbaugh

1Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 2Univ of Washington, Seattle, WA, USA

HIGH-RESOLUTION MAPPING OF AN ENV EPITOPE BY COMPREHENSIVE ESCAPE MUTANT SELECTION

Adam Dingens, Hugh Haddox, Julie Overbaugh, Jesse Bloom

Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA

INITIAL HIV DIVERSITY & NEUTRALIZING ANTIBODY DEVELOPMENT IN PEOPLE WHO INJECT DRUGS

Andrew D. Redd, Nicole Doria-Rose, Matthew Seivers, Stephen Schmidt, Oliver Laeyendecker, Stephen Porcella, Gregory D. Kirk, John R. Mascola, Shruti H. Mehta, Thomas C. Quinn

1NIAID, Bethesda, MD, USA, 2NIH, Bethesda, MD, USA, 3The Johns Hopkins Univ, Baltimore, MD, USA, 4NIAID, Hamilton, MT, USA, 5Vaccine Rsr Cntr, Bethesda, MD, USA

ELITE NEUTRALIZATION AND UNIQUE EPITOPE SPECIFICITY OF A VIREMIC NONPROGRESSOR

Nandagopal Paneerselvam, Chinnambedu Ravichandran Swathirajan, Sunil S. Solomon, Jayantha Bhattacharya, Bimal K. Chakrabarti, Rajat Goyal, Aylur K. Srikrishnan, Kailapuri G. Murugavel

1YRG CARE, Chennai, India, 2HIV Vaccine Translational Rsr Lab, Faridabad, India, 3Intl AIDS Vaccine Initiative, New York, NY, USA

USING EMPIRIC SATURATION MUTAGENESIS TO IDENTIFY NOVEL ENV TRIMERS FOR VACCINES

Maria Jose Duenas Decamp, Li Jiang, Dan Bolon, Paul Clapham

1Univ of Massachusetts, Worcester, MA, USA, 2Harvard Univ, Boston, MA, USA

OLEANOLIC ACID DERIVATIVE OKS3-019 AS A NOVEL BIFUNCTIONAL HIV-1 ENTRY INHIBITOR

Shigeyoshi Harada, Kasumi Ogihara, Yuta Hikichi, Tetsuro Matano, Tetsuo Narumi, Kazuhiara Yoshimura

1Nat Inst of Infectious Diseases, Shinjuku-ku, Tokyo, Japan, 2Shizuoka Univ, Hamamatsu, Shizuoka, Japan

GP41 ANTIGENIC RECOGNITION AND RESPONSE IN HIV-NEGATIVE MEN WHO HAVE SEX WITH MEN

Katie McFaul, Jia Guo, Elizabeth Atkins, Xiao-Ning Xu, Peter Kelleher, for the Centre for Immunology and Vaccinology
Imperial Coll London, London, UK
249 B-CELL RESPONSES POST-ART INTERRUPTION IN PERSONS TREATED IN FIEBIG I
Supranee Buranapraditkun1, Donn Colby2, Suwanna Pattamasavin1, Suteeraporn Pinyakorn1, Rapeech Trichaviroj3, Nelson L. Michael4, Merlin L. Robb3, Jintanat Ananworanich1, Lydie Trautmann1, for the RV411 and RV254/SEARCH010 study groups
1Henry M. Jackson Fndn for the Advancement of Military Med, Bethesda, MD, USA, 2SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 3U.S Military HIV Rsr Prog, Bethesda, MD, USA, 4Armed Forces Rsr Inst of Med Sci, Bangkok, Thailand, 5Walter Reed Army Inst of Rsr, Silver Spring, MD, USA

250 DC FUNCTIONALITY DISTINGUISHES HIV-1 CONTROLLERS WITH NEUTRALIZING ANTIBODY BREADTH
Enrique Martin-Gayo1, Zhengyu Ouyang1, Dho hyung Kim1, Kellie E. Kolb2, Bruce D. Walker1, Alex K Shalek2, Xu G. Yu1
1Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA, 2MIT Inst for Med Engineering & Sci (IMES), Cambridge, MA, USA

Poster P-E1: PERSISTENT VIREMIA AND IMMUNITY ON ART
Poster Hall - 4 EF
2:30 PM - 4:00 PM

277 RESIDUAL LOW-LEVEL VIREMIA ON ART NOT ASSOCIATED WITH LOWER SYSTEMIC EXPOSURE TO ARVs
Monica Gandhi1, Andrei Stefanescu2, Ronald Bosch3, Rajesh T. Gandhi3, Joshua C. Cyktor3, Howard Hornig1, Joseph J. Eron4, John W. Mellors4, Deborah McMahon4
1Univ of California San Francisco, San Francisco, CA, USA, 2Harvard Univ, Boston, MA, USA, 3Massachusetts General Hosp, Boston, MA, USA, 4Univ of Pittsburgh, Pittsburgh, PA, USA, 5Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

278 ANTIGP41 TITERS REFLECT RESIDUAL REPLICATION IN VIROLOGICALLY SUPPRESSED ART PATIENTS
Heloise M. Delagreverie1, Maxime Grudé2, Sidonie Lambert2, François Raffi1, Catherine Leport2, Cécile Goujard3, Lorraine Plessis3, Christine Katlama4, Francis Barin5, Constance Delaugerre10
1Hôpital Saint Louis, PARIS, France, 2INSERM, Paris, France, 3Institut Pierre Louis d’Épidémiologie et de Santé, Paris, France, 4CHU Hotel-Dieu Nantes, Nantes, France, 5Hôpital Bichat, Paris, France, 6AP-HP, Le Kremlin-Bicêtre, France, 7INSERM, Villejuif, France, 8Pierre and Marie Curie Univ, Paris, France, 9INSERM, Tours, France, 10Hôpital Saint Louis, Paris, France

279 ANTIBODY LEVELS CORRELATE WITH THE INFECTED CELL POPULATION IN HIV PATIENTS ON ART
Sheila Keating1, Christina Lalama2, Ronald Bosch1, Deborah McMahon1, Joshua Cyktor1, John Mellors1, Joseph J. Eron4, Rajesh T. Gandhi3, Michael P. Busch1, for the ACTG 5321 team
1Blood Systems Rsr Inst, San Francisco, CA, USA, 2Harvard Univ, Boston, MA, USA, 3Univ of Pittsburgh, Pittsburgh, PA, USA, 4Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 5Massachusetts General Hosp and Ragon Inst, Boston, MA, USA

280 PERSISTENT IMMUNE ACTIVATION DESPITE ART: THE “DIE IS CAST” BEFORE ART INITIATION
Rajesh T. Gandhi1, Deborah McMahon1, Ronald Bosch1, Christina Lalama2, Bernard Macatangay2, Joshua Cyktor3, Ann Collier1, Charles Rinaldo2, Joseph J. Eron1, John Mellors2
1Massachusetts General Hosp and Ragon Inst, Boston, MA, USA, 2Univ of Pittsburgh, Pittsburgh, PA, USA, 3Harvard Univ, Boston, MA, USA, 4Univ of Washington, Seattle, WA, USA, 5Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA
281  SEX-BASED DIFFERENCES IN HIV RESERVOIR ACTIVITY AND RESIDUAL IMMUNE ACTIVATION
Eileen Scully¹, Monica Gandhi², Rowena Johnston², Rob Gorelick⁴, Jeffrey D. Lifson¹, Sharon R. Lewin³, Jonathan Kari¹, Nicolas Chomont⁸, Peter Bacchetti⁵, Steven G. Deeks³

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Univ of California San Francisco, San Francisco, CA, USA, ³amfAR, New York, NY, USA, ⁴Leidos Biomed Rsr, Inc, Frederick, MD, USA, ⁵Frederick Natl Lab, Frederick, MD, USA, ⁶Univ of Melbourne, Melbourne, Australia, ⁷Case Western Reserve Univ, Cleveland, OH, USA, ⁸Univ de Montréal, Montréal, QC, Canada

300  NOVEL ASSAY TO MEASURE INTEGRATED HIV DNA IN PBMC FROM ART-SUPPRESSED PERSONS
Steven Lada¹, Jake VanBelzan¹, Caroline Ignacio¹, Matthew Strain¹, Una O’Doherty¹, Douglas D. Richman¹

¹Univ of California San Diego, La Jolla, CA, USA, ²Univ of Pennsylvania, Philadelphia, PA, USA

301  PARALLEL NEXTGEN FULL-LENGTH HIV PROVIRAL DNA SEQUENCE AND INTEGRATION SITE ANALYSIS
Mathew L. Jones, Emanuele Marchi, Jacob Hurst, Nicola Robinson, John Frater
Univ of Oxford, Oxford, UK

302  HIV-1 INTEGRATION SITES ANALYSIS REVEALS DIFFERENT COMPARTMENTS OF THE HIV RESERVOIR
Eva Malatinkova¹, Wei Wang¹, Stephanie Laufs¹, Ward De Spiegeelaere¹, Ning Wu¹, Saira Afzal¹, Raffaele Fronza¹, Sabine Kinloch-de Loes¹, Manfred Schmidt¹, Linos Vandekerckhove¹

¹HIV Cure Rsr Cntr, Ghent Univ, Ghent, Belgium, ²German Cancer Rsr Cntr and Natl Cntr for Tumor Diseases, Heidelberg, Germany, ³Royal Free Hosp, London, UK

303  ENRICHMENT OF DEFECTIVE PROVIRUSES LACKING TAT-REV DURING LONG-TERM ART
Francesco R. Simonetti¹, Paolo Cattaneo¹, Alessia Lai¹, Elizabeth M. Anderson¹, Stefano Rusconi¹, Melissa Tosiano¹, John Mellors², Frank Maldarelli¹, Massimo Galli¹, Claudia Balotta¹

¹Univ of Milan, Milan Italy, ²NCI, Frederick, MD, USA, ³Univ of Pittsburgh, Pittsburgh, PA, USA, ⁴Luigi Sacco Univ Hosp, Milan, Italy

304  HIV INTEGRATION SITE/ORIENTATION CONFERENCE SELECTIVE ADVANTAGE FOR PERSISTENCE ON ART
Hadega Aamer¹, Malika Aid¹, Sherry McLaughlin¹, Thomas R. Sibley¹, Evan J. Silberman¹, Wenjie Deng³, Paul Edlefsen¹, Rafick-Pierre Sekaly⁵, Lisa Frenkel¹, James Mullins³

¹Seattle Children’s Rsr Inst, Seattle, WA, USA, ²Harvard Univ, Boston, USA, ³Univ of Washington, Seattle, WA, USA, ⁴Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ⁵Case Western Reserve Univ, Cleveland, OH, USA
305 ROMIDEPSIN-INDUCED HIV-1 VIREMIA IS OLIGOCLONAL WITH LIMITED DELETERIOUS MUTATIONS
Anni Winckelmann1, Kirsten Barton2, Bonnie Hiener2, Timothy E. Schlb1, Wei Shao1, Thomas A. Rasmussen1, Lars Østergaard1, Ole S. Søgaard1, Martin Tolstrup1, Sarah Palmer1
1Aarhus Univ Hosp, Aarhus, Denmark, 2Univ of Sydney, Westmead, Australia, 3Univ of Sydney, Camperdown, New South Wales, Australia, 4Leidos Biomed Rsr, Inc, Frederick, MD, USA

Poster Sessions • Tuesday
Program and Agenda
CROI 2017

317 INDUCIBLE HIV-1 LATENT RESERVOIR INCREASES AFTER HIV- OR HIV- SOLID ORGAN TRANSPLANT
Alyssa R. Martin1, Andrew D. Redd2, Gregory Laird1, Robert Siliciano1, Diane Brown1, Darin Ostrander1, Thomas Quinn1, Dorry Segev1, Aaron Tobian1, Christine Durand1
1The Johns Hopkins Univ, Baltimore, MD, USA, 2NIAID, Bethesda, MD, USA

318 PERSISTENCE OF A MINORITY HIV VARIANT DESPITE ALLOGBM T WITH COMPLETE DONOR CHIMERMISM
Adam Capoferri1, Andrew D. Redd2, Daniel I. Rosenbloom1, Roberto Ramirez1, Subul Beg1, Andrew Timmons4, Christopher Gocke1, Robert Siliciano1, Richard Ambinder1, Christine Durand1
1The Johns Hopkins Univ, Baltimore, MD, USA, 2NIAID, Bethesda, MD, USA, 3Columbia Univ, New York, NY, USA, 4Univ of Minnesota, Minneapolis, MN, USA

319 TWO HUNDRED EIGHTY-EIGHT—DAY DRUG-FREE REMISSION FROM HIV REBOUND BY ALLOGENEIC PBSCT
Nathan Cummins1, Stacey Rizza1, Jason Baker2, Nicolas Chomont3, Tae-Wook Chun1, Mathias Lichterfeld1, Douglas D. Richman1, Timothy Schacker1, Joseph D. Yao1, Andrew Badley1
1Mayo Clinic, Rochester, MN, USA, 2Univ of Minnesota, Minneapolis, MN, USA, 3Univ de Montréal, Montreal, QC, Canada, 4NIH, Bethesda, MD, USA, 5Massachusetts General Hosp, Boston, MA, USA, 6Univ of California San Diego, La Jolla, CA, USA, 7Univ of Minnesota, Minneapolis, MN, USA

320 PERSISTENCE OF HIV DNA IN TISSUES EARLY AFTER TRANSPLANTATION WITH CCR5Δ32 STEM CELLS
Kobus Bosman1, Monique Nijhuis1, Anke Bruns1, Maria Salgado2, Gero Hüttler1, Lodewijk Brosens1, Javier Martinez-Picado3, Jürgen Kuball1, Annemarie Wensing1, for the IciStem consortium
1Univ Med Cntr Utrecht, Utrecht, Netherlands, 2AIDS Rsr Inst IrsiCaixa, Badalona, Spain, 3Cellex, Dresden, Germany, 4ICREA, Barcelona, Spain

321 IMMUNE DYSREGULATION DICTATES SHIV REBOUND AFTER STEM-CELL TRANSPLANTATION IN MACAQUES
Christopher Peterson1, Clarisse Benne1, Patricia Polacino1, Keith Jerome1, Shi-Lok Hu1, Nichole Klatt1, Stephen DeRosa2, Rafick-Pierre Sekaly3, Hans-Peter Kiem1
1Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 2Case Western Reserve Univ, Cleveland, OH, USA, 3Washington Natl Primate Rsr Cntr, Seattle, WA, USA, 4Univ of Washington, Seattle, WA, USA
322 CONTROL OF PATHOGENIC SHIV INFECTION IN TRANSPLANTED MACAQUES
Christopher Peterson1, Kevin G. Haworth1, Bryan P. Burke2, Patricia Polacino1, Shiu-Lok Hu4, Brandon Keele2, Jeffrey S. Bartlett2, Geoff P. Symonds2, Hans-Peter Kiem1
1Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 2Calimmune, Inc, Pasadena, CA, USA, 3Washington Natl Primate Rsr Cntr, Seattle, WA, USA, 4Univ of Washington, Seattle, WA, USA, 5NCI, Frederick, MD, USA

Poster Sessions • Tuesday
Program and Agenda
CROI 2017

Poster P-F5 VIROLOGY/BASIC NEUROSCIENCE
Poster Hall - 4 EF
2:30 PM - 4:00 PM

373 PROGRESSIVE HIPPOCAMPAL NEURONAL LOSS IN PEDIATRIC SIV INFECTION
Heather Carryl1, Koen Van Rompuy2, Kristina De Paris1, Mark W. Burke1
1Howard Univ, Washington, DC, USA, 2Univ of California Davis, Davis, CA, USA, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

374 HIV GENE VARIANTS ALTERING CORECEPTOR BINDING & DRUG RESISTANCE PREDICT CNS PHENOTYPES
Debashis Sahoo, Sarah Dabydeen, Kumud K. Singh
Univ of California San Diego, La Jolla, CA, USA

375 IFNy-INDUCED PROTEASOMAL DEGRADATION OF ASTROCYTIC HO-1 IN HIV NEUROPATHOGENESIS
Alexander J. Gill1, Colleen E. Kovacsics1, Suren A. Ambegaokar1, Benjamin B. Gelman1, Dennis L. Kolson1
1Univ of Pennsylvania, Philadelphia, PA, USA, 2Ohio Wesleyan Univ, Delaware, OH, USA, 3Univ of Texas Med Branch, Galveston, TX, USA

376 IFN-β REDUCES MACROPHAGE HEME OXYGENASE-1 EXPRESSION: ROLE IN HIV NEUROPATHOGENESIS
Fiorella P. Rossi1, Alexander J. Gill1, Rolando Garza2, Dennis L. Kolson1
1Univ of Pennsylvania, Philadelphia, PA, USA, 2Univ of Texas at San Antonio, San Antonio, TX, USA

377 CNS IRON STATUS IS ASSOCIATED WITH NEUROCOGNITIVE FUNCTION OVER TIME IN HIV+ ADULTS
Harpreet Kaur1, William S. Bush2, Scott Letendre3, Ronald J. Ellis3, Robert K. Heaton4, Stephanie M. Patton5, James R. Connor4, David C. Samuels6, Todd Hulgan7, Asha R. Kallianpur1
1Cleveland Clinic, Cleveland, OH, USA, 2Case Western Reserve Univ, Cleveland, OH, USA, 3Univ of California San Diego, San Diego, CA, USA, 4Penn State, Hershey, PA, USA, 5Vanderbilt Univ, Nashville, TN, USA

378 DIFFERENTIAL IN VITRO NEUROTOXICITY OF ANTIRETROVIRAL DRUGS
Cagla Akay-Espinoza1, Anna L. Stern1, Rebecca I. Nara1, Nina Panvelker1, Jiean Li1, Kelly L. Jordan-Sciutto1
1Univ of Pennsylvania, Philadelphia, PA, USA

379 DISCORDANT HIV RNA IN OLFATORY MUCOSA OF HIV-POSITIVE PATIENTS
Andrea Calcagno1, Tiziano Allice1, Luca Bertero1, Mattia Trunfio1, Maria Enrica Amasio1, Daniele Imperiale1, Valeria Ghisetti2, Giovanni Di Perri1, Paola Cassoni1, Stefano Bonora1
1Univ of Torino, Torino, Italy, 2Ospedale Amedeo di Savoia, Torino, Italy, 3Ospedale Maria Vittoria, Torino, Italy
**Poster P-F6 INTERVENTION-FOCUSED**

**Poster Hall - 4 E**  
2:30 PM - 4:00 PM

380  **CAN WE AFFORD TO WAIT? ART AND THE CNS**

Kevin Robertson1, Javier R. Lama2, Christopher D. Pilcher3, Jessica Rios2, Peter Brandes1, Eduardo Ruiz2, Eline Appelmans4, Serena Spudich5, Ann Duer5, for the SABES Team

1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Assocacion Civil Impacta Salud y Educacion, Lima, Peru, 3Univ of California San Francisco, San Francisco, CA, USA, 4Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 5Yale Univ, New Haven, CT, USA

381  **Cenicriviroc improves neurocognition and reduces monocyte activation in treated HIV**

Lishomwa C. Ndhlovu1, Michelle L. D’Antoni2, Robert Paul2, Kalpana J. Kallianpur3, Laurent Fischer3, Eric Lefebvre3, Star Seyedkazemi3, Beau K. Nakamoto3, Debra Ogata-Arakaki4, Cecilia Shikuma1

1Univ of Hawaii, Honolulu, HI, USA, 2Univ of Missouri–St. Louis, St. Louis, MO, USA, 4Tobira Therapeutics, Inc, South San Francisco, CA, USA

382  **CSF inflammatory markers after adding maraviroc to monotherapy darunavir/ritonavir**

Tristan Barber1, Arkaitz Imaz1, Marta Boffito2, Daniel Podzamczer2, Anton Pozniak1, Rosa Fortuny2, Nicholas Davies1, Jordi Niubo2, Sundhya Mandal1a, Brian Gazzard2

1Chelsea and Westminster NHS Fndn Trust, London, UK, 2Hosp Univ de Bellvitge, Barcelona, Spain, 3Imperial Coll London, London, UK

383  **CSF levels of the glial marker YKL-40 strongly associated with neuronal injury in HIV**

Linn Hermansson1, Markus Axelsson1, Kaj Blennow1, Dietmar Fuchs1, Lars Hagberg1, Jan Lycke1, Henrik Zetterberg1, Magnus Gisslén1

1 Sahlgrenska Academy at the Univ of Gothenburg, Gothenburg, Sweden, 2Sahlgrenska Univ Hosp, Gothenburg, Sweden, 3Innsbruck Med Univ, Innsbruck, Austria

384  **Extensive efavirenz metabolism is associated with greater CNS toxicity**

Marijana Vujkovic1, Scarlett Bellamy2, Athena Zuppa1, Marc Gastonguay3, Xiaoyan Han1, Mosepele Mosepele1, Gregory Bisson4, Richard Aplenc1, Robert Gross4

1Children’s Hosp of Philadelphia, Philadelphia, PA, USA, 2Drexel Univ, Philadelphia, PA, USA, 3Metrum Rsr Group, Tariffville, CT, USA, 4Univ of Pennsylvania, Philadelphia, PA, USA, 5Univ of Botswana, Gaborone, Botswana

385  **Exhausted T cells and inflammatory monocytes are linked to brain atrophy in HIV**

Brooks I. Mitchell1, Glen Chew1, Kalpana J. Kallianpur1, Mary Margaret Byron1, Robert Paul2, Beau K. Nakamoto3, Dominic Chow4, Scott A. Souza1, Cecilia Shikuma1, Lishomwa C. Ndhlovu1

1Univ of Hawaii, Honolulu, HI, USA, 2Univ of Missouri–St. Louis, St. Louis, MO, USA
CSF AND SERUM BIOMARKERS OF NEURONAL INJURY AND AGING IN HIV-INFECTED PARTICIPANTS

Sergio M. de Almeida, Clea E. Ribeiro, Indianara Rotta, Mauro Plovesan, Sonia M. Raboni, Scott Letendre, Bin Tang, Florin Vaida, Ronald J. Ellis

1Univ Fed do Paraná, Curitiba, Brazil, 2Univ of California San Diego, San Diego, CA, USA

CSF S100B AND CX3CR1 MONOCYTES IN ACUTE HIV INFECTION PREDICT PUTAMEN ATROPHY

Lishomwa C. Ndhlovu, Kalpana J. Kallianpur, Eugene Kroom, Thep Chalermchai, Khunthalee Benjapornpong, Shelly J. Krebs, Serena Spudich, Jintanat Ananworanich, Victor Valcour, for the RV254/SEARCH010 Study Group

1Univ of Hawaii, Honolulu, HI, USA, 2Search, The Thai Red Cross AIDS Rsr Ctrn, Bangkok, Thailand, 3Search, Bangkok, Thailand, 4Thai Red Cross AIDS Rsr Ctrn, Bangkok, Thailand, 5US Military HIV Rsr Prag, Silver Spring, MD, USA, 6Yale Univ, New Haven, CT, USA, 7Univ of California San Francisco, San Francisco, CA, USA

TELOMERE LENGTH: NEUROCOGNITIVE BIOMARKER IN HIV-1–INFECTED SUBJECTS

Marília L. Araújo, Maria Rita. P Gascón, Raquel Paiva, Bárbara Santana, Rodrigo Calado, Wellington Duarte, Luiz A. Fonseca, Augusto César P. Oliveira, Jorge Casseb

1Univ de São Paulo, São Paulo, Brazil, 2Inst de Infectologia Emílio Ribas, São Paulo, Brazil, 3Univ de São Paulo Ribeirão Preto, Ribeirão Preto, Brazil

CEREBROSPINAL FLUID CONCENTRATION OF THE SYNAPTIC MARKER NEUROGRANIN IN HIV

Maria C. Brühl, Aylin Yilmaz, Lars Hagberg, Dietmar Fuchs, Kaj Blennow, Henrik Zetterberg, Richard W. Price, Magnus Gisslén

1Sahlgrenska Univ Hosp, Gothenburg, Sweden, 2Sahlgrenska Academy at the Univ of Gothenburg, Gothenburg, Sweden, 3Innsbruck Med Univ, Innsbruck, Austria, 4San Francisco General Hosp, San Francisco, CA, USA

THE HUMAN GUT MICROBIOME AND HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS

Josue Perez-Santiago, Sara Gianella, Ajay Bharti, Debralee Cookson, Robert K. Heaton, Igor Grant, Scott Letendre, Scott N. Peterson

1Univ of California San Diego, San Diego, CA, USA, 2Univ of California San Diego, La Jolla, CA, USA, 3Sanford Burnham Prebys Med Discovery Inst, La Jolla, CA, USA

HIV ANTIBODIES IN CSF AND SERUM IN UNTREATED AND TREATED INFECTION

Magnus Gisslén, Richard W. Price, Serena Spudich, Lars Hagberg, Steven G. Deeks, Peter Burbelo

1Sahlgrenska Academy at the Univ of Gothenburg, Gothenburg, Sweden, 2Univ of California San Francisco, San Francisco, CA, USA, 3Yale Univ, New Haven, CT, USA, 4NIDCR, Bethesda, MD, USA

NUCLEAR-MITOCHONDRIAL INTERACTIONS AND NEUROCOGNITIVE IMPAIRMENT IN HIV+ ADULTS

Sandra P. Smieszek, Asha R. Kallianpur, David C. Samuels, Donald Franklin, Robert K. Heaton, Scott Letendre, Ronald J. Ellis, Todd Hulgan, William S. Bush

1Case Western Reserve Univ, Cleveland, OH, USA, 2Case Western Clinic Lerner Coll of Med, Cleveland, OH, USA, 3Vanderbilt Univ, Nashville, TN, USA, 4Univ of California San Diego, San Diego, CA, USA, 5Univ of California San Diego, La Jolla, CA, USA
393 GENETICALLY PREDICTED GENE EXPRESSION AND HIV-ASSOCIATED NEUROCOGNITIVE DISORDER

Sandra Smieszek1, William S. Bush1, Todd Hulgan2, David C. Samuels2, Donald Franklin3, Robert K. Heaton4, Scott Letendre1, Ronald J. Ellis3, Asha R. Kallianpur

1Case Western Reserve Univ, Cleveland, OH, USA, 2Vanderbilt Univ, Nashville, TN, USA, 3Univ of California San Diego, San Diego, CA, USA, 4Univ of California San Diego, La Jolla, CA, USA, 5Cleveland Clinic Lerner Coll of Med, Cleveland, OH, USA

---

404 LEDIPASVIR/SOFOSBUVIR RAISES TENOFOVIR DIPHOSPHATE CONCENTRATIONS IN RED CELLS

Christine MacBrayne1, Daniel S. Fierer2, Kristen M. Marks3, Peter L. Anderson1, Lane R. Bushman1, Kimberly M. Hollabaugh1, Michael D. Hughes1, Raymond T. Chung3, Susanna Naggie6, Jennifer J. Kiser1

1Univ of Colorado, Aurora, CO, USA, 2Columbia Sch of Med at Mt Sinai, New York, NY, USA, 3Weill Cornell Med, New York, NY, USA, 4Harvard Univ, Boston, MA, USA, 5MGH, Boston, USA, 6Duke Univ, Durham, NC, USA

405 TENOFOVIR DIPHOSPHATE ARISING FROM TAF IS QUANTIFIABLE IN DRIED BLOOD SPOTS

Jose Castillo-Mancilla, Ryan P. Coyle, Jia-Hua Zheng, Lucas Ellison, Laura Roon, Jordan Fey, Lane Bushman, Jennifer J. Kiser, Peter Anderson

Univ of Colorado, Aurora, CO, USA

406 EXTRA/INTRA-CELLULAR NUCLEOSIDE/TIDE SEMEN PHARMACOLOGY: IMPLICATIONS FOR ERADICATION

Julie B. Dumond, Stephen A. Greene, Heather M. Asher Prince, Jinxian Chen, Brian Maas, Craig Sykes, Amanda Schauer, Cynthia L. Gay, Angela Kashuba, Myron S. Cohen

Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

407 INTEGRASE AND PROTEASE INHIBITOR CONCENTRATIONS IN LYMPHOID VS GI TISSUES

Sulggi Lee1, Hiroyu Hatano1, Angela Kashuba1, Mackenzie L. Cottrell2, Teri Liedler1, Sophie Stephenson1, Ma Somsouk1, Peter W. Hunt1, Steven G. Deeks1, Radjoka M. Savic1

1Univ of California San Francisco, San Francisco, CA, USA, 2Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

408 PLASMA AND INTRACELLULAR PK OF TENOFOVIR IN PATIENTS SWITCHED FROM TDF TO TAF

Anthony Podany, Sara H. Bares, Joshua Havens, Ravi Dyavar Shetty, Jennifer O’Neill, Sarah Lee, Courtney Fletcher, Susan Swindells, Kimberly K. Scarsi

Univ of Nebraska, Omaha, NE, USA
### Poster P-G3 PHARMACOKINETICS AND PHARMACOGENETICS: NEW AND EXISTING DRUGS AND FORMULATIONS

<table>
<thead>
<tr>
<th>Poster Hall - 4 EF</th>
<th>2:30 PM - 4:00 PM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>415</strong></td>
<td><strong>PHARMACOKINETICS ANALYSIS OF VRC01, A BROADLY NEUTRALIZING HIV-1 MONOCLONAL ANTIBODY</strong></td>
</tr>
<tr>
<td><strong>Yunda Huang</strong></td>
<td><strong>Lily Zhang</strong>, Nicole Grunenberg, Robert Bailor, Abby Isaacs, Julie Ledgerwood, Kelly Seaton, Kenneth Mayer, Larry Corey, Peter Gilbert</td>
</tr>
<tr>
<td>1Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 2NIAID, Gaithersburg, MD, USA, 3NIAID, Bethesda, MD, USA, 4Duke Human Vaccine Inst, Durham, NC, USA, 5The Fenway Inst, Boston, MA, USA</td>
<td></td>
</tr>
<tr>
<td><strong>416</strong></td>
<td><strong>EFFECT OF CYP3A4*22 ON ORAL RILPIVIRINE PLASMA CONCENTRATIONS</strong></td>
</tr>
<tr>
<td><strong>Rana Abutaima</strong></td>
<td><strong>Marta Boffito</strong>, Andrea Calcagno, Jessica Cusato, Antonio D’Avolio, Laura Else, Chris Higgs, Saye Khoo, Marco Siccardi, Andrew Owen</td>
</tr>
<tr>
<td>1Univ of Liverpool, Liverpool, UK, 2St. Stephen’s AIDS Trust, Chelsea and Westminster Hosp, London, UK, 3Univ of Turin, Turin, Italy</td>
<td></td>
</tr>
<tr>
<td><strong>417</strong></td>
<td><strong>EFFECT OF CYP3A5 GENOTYPE ON THE PK OF MARAVIROC AND METABOLITES IN HEALTHY SUBJECTS</strong></td>
</tr>
<tr>
<td><strong>Manoli Vourvahis</strong></td>
<td><strong>Sunil Nepal</strong>, Annie Fang, Gwendolyn Fate, Linda S. Wood, Jean-Claude Marshall, Andrew Clark, Jayvant Heera</td>
</tr>
<tr>
<td>1Pfizer, New York, NY, USA, 2Pfizer, Biostatistics, Colville, PA, USA, 3Pfizer, Groton, CT, USA, 4ViiV Hlthcare, London, UK</td>
<td></td>
</tr>
<tr>
<td><strong>418</strong></td>
<td><strong>ABCG2 RS2231142 INFLUENCES TFV CONCENTRATIONS IN PLASMA AND URINE</strong></td>
</tr>
<tr>
<td><strong>Margherita Bracchi</strong></td>
<td><strong>Megan Neary</strong>, Nicole Pagani, Laura Else, Saye Khoo, Zaheer Abbas, David Hawkins, Graeme Moyle, Andrew Owen, Marta Boffito</td>
</tr>
<tr>
<td>1Chelsea and Westminster Hosp, London, UK, 2Univ of Liverpool, Liverpool, UK, 3Chelsea and Westminster NHS Fndn Trust, London, UK</td>
<td></td>
</tr>
<tr>
<td><strong>419</strong></td>
<td><strong>TFV-DP IN DRIED BLOOD SPOTS (DBS) FOLLOWING DIRECTLY OBSERVED THERAPY: DOT-DBS STUDY</strong></td>
</tr>
<tr>
<td><strong>Peter Anderson</strong></td>
<td><strong>Albert Y. Liu</strong>, Jose Castillo-Mancilla, Sharon Seifert, Cricket McHugh, Theresa Wagner, Susan Buchbinder, Lane Bushman, Jennifer J. Kiser, Samantha MaWhinney</td>
</tr>
<tr>
<td>1Univ of Colorado Denver, Aurora, CO, USA, 2San Francisco Dept of Pub Hlth, San Francisco, CA, USA</td>
<td></td>
</tr>
<tr>
<td><strong>420</strong></td>
<td><strong>IN VITRO AND IN VIVO EVALUATION OF BIODEGRADABLE IMPLANT CONTAINING TAF FOR HIV PREP</strong></td>
</tr>
<tr>
<td><strong>Phillip G. Durham</strong></td>
<td><strong>Greg Gatto</strong>, Leah Johnson, Mark A. Marzinke, Stephanie Swarner, Ginger Rothrock, Tejal Desai, Ian McGowan, Ida Washington, Ariane van der Straten</td>
</tr>
<tr>
<td>1RTI Intl, Durham, NC, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA, 3Univ of California San Francisco, San Francisco, CA, USA, 4Univ of Pittsburgh, Pittsburgh, PA, 5Magee-Womens Rsr Inst, Pittsburgh, PA, USA, 6RTI Intl, San Francisco, CA, USA</td>
<td></td>
</tr>
</tbody>
</table>
421LB  HPTN 076: TMC278 LA SAFE, TOLERABLE, AND ACCEPTABLE FOR HIV PRE-EXPOSURE PROPHYLAXIS

Linda-Gail Bekker¹, Shuying S. Li², Betsy Tolley³, Mark A. Marzinke⁴, Nyaradzo Mgodi⁵, Jessica E. Justman⁶, Shobha Swaminathan⁷, Adeola Adeye⁸, Jennifer H. Farrior⁹, Nirupama Sista¹

¹Univ of Cape Town, Cape Town, South Africa, ²FRCHC, Seattle, WA, USA, ³FHI 360, Durham, NC, USA, ⁴Johns Hopkins Univ, Baltimore, MD, USA, ⁵Univ of Zimbabwe, Harare, Zimbabwe, ⁶ICAP at Columbia Univ, New York, NY, USA, ⁷Rutgers Univ, Newark, NJ, USA, ⁸NIH, Rockville, MD, USA

422LB  TRANSCUTANEOUS REFILLABLE NONFLUIDIC IMPLANT FOR CONSTANT DELIVERY OF HIV PREP

Corrine Xuan Chua¹, Priya Jain¹, Ming Hu¹, Peter L. Anderson¹, Jason T. Kimata¹, Jagannadha Sastry¹, Roberto Arduino¹, Alessandro Grattoni¹

¹Houston Methodist Rsr Inst, Houston, TX, USA, ²Univ of Houston, Houston, TX, USA, ³Univ of Colorado Denver, Aurora, CO, USA, ⁴Baylor Coll of Med, Houston, TX, USA, ⁵Univ of Texas, Houston, TX, USA

Poster P-H2 ANTIRETROVIRAL CLINICAL TRIALS
Poster Hall - 4 EF 2:30 PM - 4:00 PM

441  WITHDRAWN

442  LONG-TERM SAFETY AND EFFICACY OF CAB AND RPV AS 2-DRUG ORAL MAINTENANCE THERAPY

David A. Margolis¹, Cynthia Brinson², Graham H. Smith³, Joseph J. Eron⁴, Gary J. Richmond⁵, Roger P. LeBlanc⁶, Peter E. Williams⁷, William Spreen⁸, Kenneth Sutton⁹, Britt S. Stancil¹⁰

¹ViiV Hlthcare, Rsr Triangle Park, NC, USA, ²Central Texas Clinical Rsr, Austin, TX, USA, ³Maple Leaf Med Clinic, Toronto, Ontario, Canada, ⁴Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁵Gary J Richmond MD PA, Ft Lauderdale, FL, USA, ⁶Clinique OPUS, Montréal, Québec, Canada, ⁷Janssen Rsr and Development, Beerse, Belgium, ⁸ViiV Hlthcare, Raleigh, NC, USA, ⁹PAREXEL Intl, Durham, NC, USA

443  EFFICACY & SAFETY OF SWITCHING TO EVG/COBI/FTC/TAF IN VIROLOGICALLY SUPPRESSED WOMEN

Sally Hodder¹, Kathleen Squires², Cissy Kityo³, Debbie Hagins⁴, Anchalee Avihingsanon⁵, Yulia Plotnikova⁶, Shuping Jiang⁷, Rima Kulkarni⁷, Andrew Cheng⁸, Huyen Cao⁹

¹West Virginia Clinical and Translational Sci Inst, Morgantown, WV, USA, ²Thomas Jefferson Univ, Philadelphia, PA, USA, ³Joint Clinical Rsr Cntr, Kampala, Uganda, ⁴Chatham CARE Cntr, Savannah, GA, USA, ⁵HIV-NAT, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ⁶Irkutsk Regional Cntr for Prevention and Control of AIDS and Infectious Diseases, Irkutsk, Russian Federation, ⁷Gilead Scis, Inc, Foster City, CA, USA

444  THE FDA SNAPSHOT ALGORITHM MAY OVERESTIMATE THE EFFICACY OF INITIAL ART

Stephen J. Kerr¹, Andrew Carr²

¹The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ²St. Vincent’s Hosp, Sydney, Australia
445 CELLULAR HIV-1 DNA LEVELS AFTER 96 WEEKS OF SWITCH TO ATV/R +3TC IN THE ATLAS-M TRIAL
Francesca Lombardi1, Simone Belmonti1, Eugenia Quirios-Roldan2, Alessandra Latini1, Chiara Picarello1, Arianna Emilizzio1, Massimiliano Fabbiani1, Roberto Cauda1, Andrea De Luca1, for the ATLAS-M study group
1Catholic Univ of Sacred Heart, Rome, Italy, 2Spedali Civili di Brescia, Brescia, Italy, 3IFO S. Gallicano Inst (IRCCS), Rome, Italy, 4Univ of Milan, Milan, Italy, 5Siena Univ Hosp, Siena, Italy

446 DYNAMICS OF VIRAL LOAD AND CYTOKINES WHEN ART IS INITIATED SOON AFTER HIV ACQUISITION
Trupti I. Gilada1, Javier R. Lama2, Rachel A. Bender Ignacio3, Ricardo Alfaro2, Carmela Ganoza2, Angela K. Ulrich4, Socorro M. Harb5, Rogelio M. Valdez6, Robert Coombs1, Ann Duerd
1Unison Medicare and Rsr Cntr, Mumbai, India, 2Asociacion Civil Impacta Salud y Educacion, Lima, Peru, 3Univ of Washington, Seattle, WA, USA, 4Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA

447 VALACYCLOVIR DOES NOT ATTENUATE CD4 COUNT DECLINE IN CART-UNTREATED HIV INFECTION
Darrell H. Tan1, Janet M. Raboud2, Leah Szadkowski3, Beatriz Grinsztejn4, Jose Valdez Madruga5, Pedro Cahn6, Simon Barton1, Amanda Clarke6, Wendy Zubyk6, Sharon Walmsley7
1St. Michael's Hosp, Toronto, Ontario, Canada, 2Univ of Toronto, Toronto, Ontario, Canada, 3Toronto General Rsr Inst, Toronto, Ontario, Canada, 4Inst Nacional de Infectologia (INI-Fiocruz), Rio de Janeiro, Brazil, 5Centro de Referencia e Treinamento em DST/AIDS-SP, Sao Paulo, Brazil, 6Fundacion Huesped, Buenos Aires, Argentina, 7St. Stephen's AIDS Trust, London, UK, 8Brighton & Sussex Univ Hosps NHS Trust, Brighton, UK, 9Canadian HIV Trials Network, Vancouver, British Columbia, Canada, 10Univ of Toronto, Toronto, Ontario, Canada

448 RALTEGRAVIR/EMTRICITABINE/TENOFOVIR IN HIV-2 INFECTION (ANRS 159 VIH-2 PILOT TRIAL)
Sophie Matheron1, Diane Descamps1, Sébastien Gallien2, Amel Besseghir2, Roland Tubiana3, Florence Diamond4, Fideline Collin5, Françoise Brun-Vezinet6, Genevieve Chene1, for the ANRS 159 VIH2 trial Study Group
1Hopital Bichat-Claude Bernard, AP-HP, Paris, France, 2Hopital Saint Louis, AP-HP, Paris, France, 3INSERM, Bordeaux, France, 4Hopital Pitié-Salpêtrière, AP-HP, Paris, France

449LB LONG-ACTING IBALIZUMAB IN PATIENTS WITH MULTI-DRUG RESISTANT HIV-1: A 24-WEEK STUDY
Stanley Lewis1, Jeffry Fessel1, Brinda Emu2, Shannon Schrader3, Princy Kumar4, Gary J. Richmond5, Steven Weinheimer1, Christian Marsolais7
1TaiMed Biologics USA, Irvine, CA, USA, 2Kaiser Permanent Med Cntr, San Francisco, CA, USA, 3Yale Univ, New Haven, CT, USA, 4Schrader Clinic, Houston, TX, USA, 5Georgetown Univ, Washington, DC, 6Gary J Richmond MD PA, Ft Lauderdale, FL, USA, 7Tetheratechnologies, Inc, Montreal, Canada

450LB A PHASE 2 OPEN-LABEL TRIAL OF ANTIBODY UB-421 MONOTHERAPY AS A SUBSTITUTE FOR HAART
Chang-Yi Wang1, Wingwai Wong2, Hung-Chin Tsai3, Yen-Hsu Chen4, Mei-June Liao5, Shugene Lynn6, for the United BioPharma UB-421 Clinical and Research Team
1United Biomed, Inc, Hauppauge, NY, USA, 2Taipei Veterans General Hosp, Taipei, Taiwan, 3Kaohsiung Veterans General Hosp, Kaohsiung, Taiwan, 4Kaohsiung Med Univ and Hosp, Kaohsiung, Taiwan, 5United Biopharma, Inc, Hsinchu, Taiwan, 6UBI Asia, Hsinchu, Taiwan
451LB DOLUTEGRAVIR AS MAINTENANCE MONOTHERAPY FOR HIV-1: A RANDOMIZED CLINICAL TRIAL

Ingeborg Wijting1, Casper Rokx1, Charles Boucher1, Dorine de Vries-Slujs1, Karin Schuurink1, Elzoey Andrinopoulou1, EricvanGorp1, Wouter Bierman1, Bart Rijnders1, for the DOMONO study-group

1Erasmus Univ Med Ctr Rotterdam, Rotterdam, Netherlands, 2Univ Med Ctr Groningen, Groningen, Netherlands

452LB ELSULFAVIRINE AS COMPARED TO EFAVirenz IN COMBINATION WITH TDF/FTC: 48-WEEK STUDY

Robert Murphy1, Alexey V. Kravchenko2, Elena Orlova-Morozova3, Firaya Nagimova4, Oleg Kozirev5, Tatyana Shimonava6, Marina Deulina7, Natalia Vostokova8, Olga Zozulya9, Vadim Bichko10

1Northwestern Univ, Chicago, IL, USA, 2Russia AIDS Federal Ctr, Moscow, Russian Federation, 3Moscow Region AIDS Ctr, Moscow, Russian Federation, 4Republic Tartarstan AIDS Ctr, Kazan, Russian Federation, 5Volgograd Region AIDS Ctr, Volgograd, Russian Federation, 6Moscow City AIDS Ctr, Moscow, Russian Federation, 7IPharma Moscow, Moscow, Russian Federation, 8Virion, Inc, San Diego, CA, USA

453 SIGNIFICANT EFFICACY & LONG-TERM SAFETY DIFFERENCE WITH TAF-BASED STR IN NAÏVE ADULTS

Jose R. Arribas1, Melanie Thompson2, Paul E. Sax3, Bernhard Haas4, Cheryl McDonald5, David Wohl6, Edwin DeJesus7, Amanda Clarke8, Moupalui Das9, Scott McCallister9

1Hosp Univ La Paz, Madrid, Spain, 2AIDS Rsr Consortium of Atlanta, Atlanta, GA, USA, 3Brigham and Women's Hosp, Boston, MA, USA, 4Hosp Graz West, Graz, Austria, 5Tarrant County Infectious Disease Associates, Fort Worth, TX, USA, 6Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 7Univ of California San Diego, San Diego, CA, USA, 8Brighton & Sussex Univ Hosps NHS Trust, Brighton, UK, 9Gilead Scis, Inc, Foster City, CA, USA

454 PATTERNS OF EFAVIRENz USE AS FIRST-LINE THERAPY IN THE UNITED STATES: 1999–2015

Angela Bengston1, Brian W. Pence1, Ellen F. Eaton1, Jessie K. Edwards1, Joseph J. Eron2, W. C. Mathews3, Katie Mollan4, Richard D. Moore5, Connall O’Cleirigh6, Michael J. Mugavero2

1Univ of Alabama at Birmingham, Birmingham, AL, USA, 2Univ of California San Diego, San Diego, CA, USA, 3Johns Hopkins, Baltimore, MD, USA, 4Massachusetts General Hosp, Boston, MA, USA

455 ART INITIATION, REGARDLESS OF COMPOSITION, IMPROVES PATIENT-REPORTED DEPRESSION

Ellen Eaton, Ashutosh Tamhane, Michael J. Mugavero

Univ of Alabama at Birmingham, Birmingham, AL, USA

456 THE CLINICAL AND ECONOMIC IMPACT OF DOLUTEGRAVIR-BASED FIRST-LINE ART IN INDIA

Amy Zheng1, Nagalingeswaran Kumasamy2, Mingshu Huang1, A. David Paltiel3, Kenneth H. Mayer4, Bharat Bhushan Rewari5, Rochelle P. Walensky, Kenneth Freedberg

1Massachusetts General Hosp, Boston, MA, USA, 2YR Gaitonde Ctr for AIDS Rsr and Educ, Chennai, India, 3Yale Univ, New Haven, CT, USA, 4Fenway Hlth, Boston, MA, USA, 5WHO, New Delhi, India
Poster Sessions • Tuesday
Program and Agenda
CROI 2017

457 QUALITY OF LIFE IMPROVEMENT DURING SECOND-LINE THERAPY IN RESOURCE-LIMITED SETTINGS
Thiago S. Torres1, Linda J. Harrison1, Alberto M. La Rosa2, Lu Zheng3, Sandra W. Cardoso4, Selvamuthu Poongulali4, McNeil Ngongondo4, Ann Collier5, Michael D. Hughes1, for the AIDS Clinical Trials Group (ACTG) A5273 Study Group
1Harvard Univ, Boston, MA, USA, 2Asociación Civil Impacta Salud y Educación, Lima, Peru, 3Inst Nacional de Infectologia (INI/Fiocruz), Rio de Janeiro, Brazil, 4YRCARE Med Cntr, Chennai, India, 5UNC-Proj Malawi, Lilongwe, Malawi, 6Univ of Washington, Seattle, WA, USA

458 PROMISING RESULTS OF DOLUTEGRAVIR + LAMIVUDINE MAINTENANCE IN ANRS 167 LAMIDOL TRIAL
Veronique Joly1, Charles Burdet2, Roland Landman3, François Raffi4, Christine Katlama3, André Cabié5, Aida Benalycherif6, Gilles Peytavin7, Diane Descamps8, Yazdan Yazdanpanah9
1Hôpital Bichat, Paris, France, 2INSERM, Paris, France, 3IMEA, Paris, France, 4CHU Hotel-Dieu Nantes, Nantes, France, 5Pierre and Marie Curie Univ, Paris, France, 6CHU Fort de France, Fort de France, Martinique, France

459 ADVERSE DRUG REACTIONS AMONG PATIENTS RECEIVING SECOND-LINE ART IN SOUTH AFRICA
Dorina Onoya1, Kamban Hirasen1, Lawrence Long1, Matthew Fox2
1Univ of the Witwatersrand, Johannesburg, South Africa, 2Boston Univ, Boston, MA, USA

460 LONG-TERM EFFICACY OF DOLUTEGRAVIR 50 MG BID IN INI-RESISTANT FAILING HIV-1 SUBJECTS
Antonella Castagna1, Micol Ferrara2, Laura Galli3, Laura Comi4, Gaetana Sterrantino5, Giovanni Cenderello5, Mauro Zaccarelli5, Emanuele Focà6, Andrea Roncadori1, Adriano Lazzarin10
1Univ Vita-Salute San Raffaele, Milan, Italy, 2Univ di Torino, Torino, Italy, 3Ospedale San Raffaele, Milano, Italy, 4Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy, 5Azienda Ospedaliero Univ Careggi, Firenze, Italy, 6Galliera Hosp, Genoa, Italy, 7Natl Inst for Infectious Diseases, Rome, Italy, 8ASST Spedali Civili di Brescia, Brescia, Italy, 9CINECA, Casalecchio di Reno, Italy, 10San Raffaele Vita-Salute Univ, Milan, Italy

Poster P-J3 INTEGRASE STRAND TRANSFER INHIBITOR RESISTANCE
Poster Hall - 4 EF

495 EVOLUTION OF ARCHIVED HIV-1 QUASISPECIES IN INDIVIDUALS TREATED WITH DOLUTEGRAVIR
Pierre Gantner1, Guinevere Q. Lee2, David Rey1, Thibault Mesplede3, Marialuisa Partisani4, Geneviève Beck-Wirth5, Jean-Pierre Faller6, Martin Martinot5, Mark Wainberg3, Samira Fafi-Kremer1
1Hôpitaux Univ de Strasbourg, Strasbourg, France, 2BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, 3McGill Univ, Montreal, Quebec, Canada, 4Groupe Hosp Regional—Mulhouse Sud Alsace, Mulhouse, France, 5Hôpital Nord Franche Comté, Belfort, France, 6Hôpital Civil de Colmar, Colmar, France
496 IMPACT OF CLINICALLY OBSERVED INTEGRASE MUTATIONS ON DOLUTEGRAVIR RESISTANCE
Atsuko Hachiya, Masaaki Nakashima, Yoko Ido, Urara Shigemi, Masakazu Matsuda, Reiko Okazaki, Junji Imamura, Yoshiyuki Yokomaku, Yasumasa Iwatanii
Natl Hosp Org Nagoya Med Cntr, Nagoya, Japan

497 BICTEGRAVIR DISSOCIATION HALF-LIFE FROM HIV-1 G140S+Q148H INTEGRASE/DNA COMPLEXES
Kirsten L. White, Anita Niedziela-Majka, Nikolai Novikov, Michael D. Miller, Haolun Jin, Scott E. Lazerwith, Manuel Tsiang
Gilead Scis, Inc, Foster City, CA, USA

498 PHENOTYPIC SUSCEPTIBILITY OF SIV AND HIV-1 VARIANTS TO BICTEGRAVIR, A NOVEL INSTI
Said Hassounah, Thibault Mesplede, Bonnie Spira, Nathan Osman, Mark A. Wainberg
McGill Univ, Montréal, Quebec, Canada

499 A HIGH-LEVEL RESISTANCE TO INTEGRASE INHIBITORS SELECTED OUTSIDE INTEGRASE HIV-1 GENE
Isabelle Malet1, Frédéric Subra2, Charlotte Charpentier1, Gilles Collin1, Diane Descamps1, Vincent Calvez1, Anne-Geneviève Marcellin1, Olivier Delelis2
1Pitié-Salpêtrière Hosp, Paris, France, 2École Normale Supérieure de Cachan, Cachan, France

500LB EMERGENCE OF INTEGRASE RESISTANCE MUTATIONS DURING INITIAL THERAPY WITH TDF/FTC/DTG
Jennifer A. Fulcher1, Yushen Du1, Ren Sun1, Raphael J. Landovitz2
1Univ of California Los Angeles, Los Angeles, CA, USA, 2UCLA Cntr for Clinical AIDS Rsr & Educ, Los Angeles, CA, USA

501 CROSS-RESISTANCE PROFILES OF THE NNRTIS IN DEVELOPMENT TO PREVENT HIV-1 INFECTION
Nicholas S. Giacobbi, Nicolas Sluis-Cremer
Univ of Pittsburgh, Pittsburgh, PA, USA

502 DRUG RESISTANCE AFTER CESSATION OF EFAVIRENZ-BASED ANTIRETROVIRAL TREATMENT
Gbolahan Ajibola1, Christopher Rowley2, Kathleen M. Powis1, Suhailulie Moyo1, Jean Leidner1, Kara Bennett1, Florence Chilisa1, Joseph Makhema1, Roger L. Shapiro1, Shahin Lockman2
1Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana, 2Harvard Univ, Boston, MA, USA

503 4’-MODIFIED NRTIS’ POTENT ANTI-HIV ACTIVITY STEMS FROM STRONG RT ACTIVE-SITE BINDING
Kenji Maeda1, Yuki Takamatsu2, Debananda Das3, Satoru Kohgo1, Shinichiro Hattori1, Hironori Hayashi1, Kouki Matsuda1, Stefan G. Sarafianos1, Hiroaki Mitsuya2
1Natl Cntr for Global Hlth and Med Rsr Inst, Shinjuku, Tokyo, Japan, 2NIH, Bethesda, MD, USA, 3Sojo Univ, Kumamoto, Japan, 4Univ of Missouri, Columbia, MO, USA
504LB RISING TRANSMITTED RESISTANCE FORCES ABANDONMENT OF WHO RECOMMENDED THERAPY IN ARUBA

Laura Marije Hofstra¹, Elena Sánchez Rivas², Monique Nijhuis¹, Eduan Wilkinson¹, Karina Kelly², Tania Mudrikova¹, Rob Schuurman¹, Tulio de Oliveira¹, Jaclyn De Kort¹, Annemarie Wensing¹

¹Univ Med Cntr Utrecht, Utrecht, Netherlands; ²Dr. Horacio E. Oduber Hosp, Oranjestad, Aruba; ³Univ of KwaZulu-Natal, Durban, South Africa

505 LOW HIV-1 RESISTANCE IN SUBJECTS USING DARUNAVIR ONCEDAILY REGIMENS ACROSS STUDIES

Erkki Lathouwers¹, Eric Y. Wong², Donghan Luo³, Sareh Seyedkazemi², Sandra De Meyer¹, Kimberley Brown²

¹Janssen Infectious Diseases BVBA, Beerse, Belgium; ²Janssen Scientific Affairs, LLC, Titusville, NJ, USA

506 EVOLUTION OF GAG AND GP41 IN PATIENTS RECEIVING FIRSTLINE PI AND NNRTI REGIMENS

Justen Manasa¹, Vici Varghese¹, Soo-Yon Rhee¹, Jeffrey Fessel¹, Karen S. Jang¹, Elizabeth White¹, David Katzenstein¹, Robert Shafer¹

¹Stanford Univ, Stanford, CA, USA; ²Kaiser Permanent Med Cntr, San Francisco, CA, USA

507 RESISTANCE TO POTENT AND BROADLY ACTIVE HIV-1 MATURATION INHIBITORS

Justin A. Kaplan¹, Emiko Urano¹, Sherimay Ablan¹, Nishani Kuruppu¹, David Martinº, T.J. Nitz², Ritu Gaur³, Carl Wild³, Eric Freed¹

¹NCI, Frederick, MD, USA; ²DFH Pharma, Inc, Gaithersburg, MD, USA; ³South Asian Univ, Akbar Bhawan, Chanakyapuri, New Delhi, India

508 CLINICAL VALIDATION OF A NOVEL DIAGNOSTIC HIV-2 TOTAL NUCLEIC ACID QUALITATIVE ASSAY

Ming Chang¹, Audrey J. Wong¹, Dana Raugi¹, Robert Smith¹, Jose Ortega¹, Selly Ba², Moussa Seydii², Geoffrey Gottlieb², Robert Coombs¹, for the University of Washington-Dakar HIV-2 Study Group

¹Univ of Washington, Seattle, WA, USA; ²CHU de Fann, Dakar, Senegal

509 EVALUATION OF FDA-APPROVED RAPID HIV TESTS FOR LABORATORY DIAGNOSIS OF HIV INFECTION

Kevin P. Delaney, Steven Ethridge, Hongwei Jia, Silvina Masciotra, Laura Wesolowski

CDC, Atlanta, GA, USA

510 PERFORMANCE OF DRIED BLOOD SPOTS AS A SAMPLE TYPE FOR HIV AG/AB COMBO ASSAY

Vera Holzmayer, Kelly Coller, Jill Fuhrman, Mary Rodgers, Gavin Cloherty

Abbott Labs, Abbott Park, IL, USA
511 Recency Staging of HIV Infections Through Routine Diagnostic Testing
Eduard Grebe1, Alex Welte1, Jake Hall1, Michael P. Busch1, Shelley Facente4, Sheila Keating1, Kara Marson5, Christopher D. Pilcher5, Gary Murphy2, for the CEPHIA
1Stellenbosch Univ, Stellenbosch, South Africa, 2Pub Hlth England, London, UK, 3Blood Systems Rsr Inst, San Francisco, CA, USA, 4Univ of California San Francisco, San Francisco, USA

512 Development of a High-Throughput Multiplex Assay for Measuring HIV Incidence
Martin Stengelin1, Daisy Roy1, Sudeep Kumar1, Kara Marson1, Steven G. Deeks2, Gary Murphy2, Michael P. Busch4, Christopher D. Pilcher2
1Meso Scale Diagnostics, LLC, Rockville, MD, USA, 2Univ of California San Francisco, San Francisco, CA, USA, 3Pub Hlth England, London, UK, 4Blood Systems Rsr Inst, San Francisco, CA, USA

513 Identifying Recent HIV Infections: An Individualized Assessment of Risk
Jaythoon Hassan1, Joanne Moran1, Kate O’Donnell1, Gary Murphy3, Derval Igoe3, Cillian De Gascun1, for the Monitoring Recently Acquired HIV Infection Group
1Univ Coll Dublin, Dublin, Ireland, 2Hlth Protection Surveillance Cntr, Dublin, Ireland, 3Pub Hlth England, London, UK

514 The HIV Genomic Incidence Assay Meets FRR and MDRI Performance Standards
Sung Yong Park1, Tanzy Love1, Kathryn Anastos1, Jack DeHovitz4, Chenglong Liu5, Kord Kobert6, Mardeg Cohen7, Wendy Mack8, Elizabeth T. Golub8, Ha Youn Lee9
1Univ Southern California, Los Angeles, CA, USA, 2Univ of Rochester, Rochester, NY, USA, 3Albert Einstein Coll of Med, Bronx, NY, USA, 4SUNY Downstate Med Cntr, Brooklyn, NY, USA, 5Georgetown Univ, Washington, DC, USA, 6Univ of California San Francisco, San Francisco, CA, USA, 7Stroger Hosp, Chicago, IL, USA, 8Johns Hopkins Univ, Baltimore, MD, USA

Poster P-L1 HCV Transmission: The Cascade is Not Running Dry
Poster Hall - 4 EF
2:30 PM - 4:00 PM

515 Duration of Acute Hepatitis C Infection and Implications for Incidence Estimation
Eshan Patel1, Anna Eisenberg2, Jeffrey Quinn1, Thomas C. Quinn1, Aaron Tobian1, Oliver Laeyendecker1
1Johns Hopkins Univ, Baltimore, MD, USA, 2NIAID, Baltimore, MD, USA, 3NIAID, Bethesda, MD, USA

516 Hepatitis C Virus Genotype and Ig-G Avidity Response During Recent Infection
Veronica Bruce1, Eshan Patel1, Andrea Cox1, Shruti H. Mehta1, Denali Boon2, Jacob Konikoff2, David Thomas2, Thomas C. Quinn1, Kimberly Page1, Oliver Laeyendecker1
1Univ of New Mexico, Albuquerque, NM, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA, 3NIAID, Bethesda, MD, USA

517 Identification of Risk Factors for Hepatitis-C Testing in Non-Birth Cohort Patients
Amanda E. Smart1, Alexander Gebo2, Peter Basch1, Whitney Nichols2, Alexander Zeymo2, Idene Perez3, Maria Hafeez2, Ilan Fleisher2, Stephen Fernandez2, Dawn Fishbein2
1Georgetown Univ, Washington, DC, USA, 2MedStar Hlth Rsr Inst, Hyattsville, MD, USA
518  ESTABLISHING EPIDEMIOLOGICAL LINKAGE WITHIN HCV NETWORKS USING GENETIC DISTANCE

Rebecca Rose¹, Susanna Lamers², Guido Massaccesi³, William Osburn¹, Stuart C. Ray¹, Andrea Cox¹, Oliver Laeyendecker¹

¹BioInfoExperts, Norfolk, VA, USA, ²BioInfoExperts, Thibodaux, LA, USA, ³Johns Hopkins Univ, Baltimore, MD, USA, ¹NIADDK, Baltimore, MD, USA

519  HIGH PREVALENCE OF HEPATITIS-C VIRUS AMONG HIV NEGATIVE MSM IN AMSTERDAM PREP PROJECT

Elske Hoornenborg¹, Maria Prins¹, Roel C.A. Achterbergh¹, Maarten F. Schim van der Loeff¹, Udi Davidovich¹, Arjan Hogewoning¹, Henry J.C. de Vries¹, Janke Schinkel¹, Thijs J.W. van der Laar¹, for the Amsterdam PrEP Project team in the HIV Transmission Elimination Amsterdam Consortium (H-team)

¹Pub Hlth Service Amsterdam, Amsterdam, Netherlands, ²Academic Med Cntr, Amsterdam Zuidoost, Netherlands, ³Stichting Sanquin Bloedvoorziening, Amsterdam, Netherlands

520  HIGH CLUSTERING OF ACUTE HCV INFECTIONS AMONG HIV-POSITIVE MEN WHO HAVE SEX WITH MEN

Eve Todesco¹, Nesrine Day², Corinne Amiel³, Veronique Schneider⁴, Georges Kreplak², Laurent Roudière¹, Stéphane Hué², Christine Katlama¹, Anne-Geneviève Marcelin¹, Marc-Antoine Valantin¹


521  SYSTEMATIC HCV-RNA SCREEN IN HIV+ MSM REVEALS HIGH NUMBERS OF POTENTIAL TRANSMITTERS

Dominique L. Braun¹, Roger Koyousov¹, Benjamin H. Hampel¹, Christina Grube¹, Huldrych F. Günthard¹, Jürg Böni², Jan S. Fehr², for the Swiss HIV Cohort Study

¹Univ Hosp Zurich, Zurich, Switzerland, ²Univ of Zurich, Zurich, Switzerland


Gavin Cloherty¹, Vera Holzmayer¹, Jacques Pepin², Eric H. Frost², Michael Fried³, Anto Tshefu², Franck Fwamba², Jérémie Muwanga³, Steven R. Meshnick¹, Jonathan Parr¹

¹Abbott Labs, Abbott Park, IL, USA, ²Univ of Sherbrooke, Sherbrooke, Quebec, Canada, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴Univ of Kinshasa, Kinshasa, Democratic Republic of the Congo, ⁵Natl AIDS Control Prog (PNLS), Kinshasa, Democratic Republic of the Congo

523  LOW HCV PREVALENCE AMONG HIV+ INDIVIDUALS IN SUB-SAHARAN AFRICA

Anne Loarec¹, Lucas Molfino², Kizito Walter², Winnie Muyindike³, Valentina Carmimeo¹, Isabelle Andrieux-Meyer¹, Sune Balkan⁴, Yvonne Nzomukunda¹, David Maman¹, Juliet Mwanga-Amumpaire⁴

¹MSF, Epicentre, Paris, France, ²MSF, Maputo, Mozambique, ³MSF, Nairobi, Kenya, ⁴Mbarara Univ of Sci and Tech, Mbarara, Uganda, ⁵MSF, Geneva, Switzerland, ⁶MSF, Paris, France, ⁷Epicentre, Cape Town, South Africa, ²MSF, Epicentre, Mbarara, Uganda

524  EFFECT OF OST AND PSYCHOTHERAPY ON HIV RISK AMONG HCV INFECTED INDIVIDUALS

Zahid A. Butt¹, Nabin Shrestha¹, Naveed Z. Janjua², for the The BC-HTC Team

¹Univ of British Columbia, Vancouver, British Columbia, Canada, ²BC Cntr for Disease Control, Vancouver, British Columbia, Canada
525 PROGRESSION OF LIVER FIBROSIS IN HIV-MONoinfected adults with elevated transaminases

Rebecca Krakora,1 Mary McLaughlin,2 David E. Kleiner,1 Nina Kvaratskhelia,1 Raisa Canales Santos,3 Colleen Hadigan,1 Joseph A. Kovacs,1 Theo Heller,4 Caryn G. Morse1
1NIH, Bethesda, MD, USA, 2NIAID, Bethesda, MD, USA, 3NCI, Bethesda, MD, USA, 4NIDDK, Bethesda, MD, USA

526 GUT EPITHELIAL DAMAGE, IMMUNE ACTIVATION & LIVER FIBROSIS IN HIV AND HCV INFECTION

Michael J. Reid,1 Yifei Ma,1 Rebecca Scherzer,1 Jennifer Price,1 Audrey French,1, Michael Plankey,1 Carl Grunfeld,1 Phyllis Tien1
1Univ of California San Francisco, San Francisco, CA, USA 2Rush Univ, Chicago, IL, USA, 3Georgetown Univ, Washington, DC, USA

527 VERTICALLY HIV/HCV- VS HCV-INFECTED CHILDREN: HCV TREATMENT & PROGRESSION TO FIBROSIS

Carolina Fernández McPhee,1 Talía Sainz,1 Loreto Hierro,1 Antoni Noguera-Julian,1 María José Mellado,1 Marta Montero,2 María Isabel González-Tome,3 Paloma Jara,1 Carmen Díaz,1 María Luisa Navarro1
1Univ Hosp Gregorio Marañon, Madrid, Spain, 2Hosp La Paz and IDiPaz, Madrid, Spain, 3Univ Hosp La Paz, Madrid, Spain, 4Univ de Barcelona, Barcelona, Spain, 5Hosp Unv y Politécnico La Fe, Valencia, Spain, 6Univ Hosp 12 de Octubre, Madrid, Spain

528 THE ASSOCIATION BETWEEN HIV AND COMORBID CONDITIONS IN 2 LARGE PATIENT COHORTS

Sarah E. Rowan,1 Joshua Durfee,1 David C. Tabano,2 Suzanne Dircksen,1 Edward Havranek,1 Aimee Truesdale,1 Arthur Davidson,1
1Denver Hlth and Hosp Authority, Denver, CO, USA, 2Kaiser Permanente Colorado, Denver, CO, USA

529 CAUSE & PREDICTORS OF MORTALITY IN AN HIV/HEPATITIS-C–COINFECTED COHORT IN SCOTLAND

Rebecca Metcalfe,1 Gordon Proctor,1 Joe Schofield,1 Emma Thomson2
1Brownlee Cntr for Infectious Diseases, NHS Greater Glasgow and Clyde, Glasgow, UK, 2Univ of Glasgow, Glasgow, UK, 3Pub Hlth Protection Unit, NHS Greater Glasgow and Clyde, Glasgow, UK

530 ADAR1 SNPS INVOLVED IN SEVERITY OF LIVER DISEASE IN HIV/HCV-COINFECTED PATIENTS

Luz M. Medrano,1 Amanda Fernández-Rodriguez,1 Juan Berenguer,1 María A. Jimenez-Sousa,1 Teresa Aldamiz-Echevarria2, Francisco Tejerina2, Cristina Diez,1 Lorna Vigón,1 Salvador Resino3, for the Institute of Health Carlos III (ISCIII)
1Inst of Hlth Carlos III, Madrid, Spain, 2Hosp Gregorio Marañon, Madrid, Spain

531 CB2-RR VARIANT, LINKED TO LIVER DAMAGE IN HIV/HCV CASES, MAY FAVOR HIV ACQUISITION

Caterina Sagnelli,1 Marco Merli,1 Caterina Uberti-Foppa,2 Giulia Bellini,1 Hamid Hasson2, Nicola Coppola,2 Adriano Lazzarin2, Evangelista Sagnelli1, Francesca Rossi1
1Second Univ of Naples, Naples, Italy, 2San Raffaele Scientific Inst, Milan, Italy
PNPLA3_RS738409 VARIANT INFLUENCES PROGRESSION TO CIRRHOSIS IN HIV/HCV COINFECTION

Luis M. Real¹, Juan Macías¹, María Mancebo¹, Mario Frías², Giovanni Dolci¹, Francisco Téllez³, Dolores Merino², Giovanni Guaraldi², Antonio Rivero-Juárez², Juan A. Pineda¹

¹Hosp Univ de Valme, Sevilla, Spain, ²Hosp Univ Reina Sofia, Córdoba, Spain, ³Univ of Modena and Reggio Emilia, Modena, Italy, ⁴Hosp de La Línea, La Línea de la Concepción, Spain, ⁵Complejo Hospital Univ de Huelva, Huelva, Spain

FIB-4 CUTOFFS FOR PREDICTION OF LIVER-RELATED EVENTS IN HIV/HCV COINFECTION

Leire Pérez Latorre¹, Marisa Montes², Miguel A. Von Wichmann², Manuel Crespo³, Marta Montero³, Carmen Quereda³, María J. Téllez³, José M. Bellón³, Juan González-García³, Juan Berenguer¹

¹Hosp General Univ Gregorio Marañón, Madrid, Spain, ²Hosp Univ La Paz, Madrid, Spain, ³Hosp Univ Donostia, San Sebastián, Spain, ⁴Complejo Hospital Univ de Vigo, Vigo, Pontevedra, Spain, ⁵Hosp Univ y Politécnico La Fe, Valencia, Spain, ⁶Hosp Ramon y Cajal, Madrid, Spain, ⁷Hosp Clínico de San Carlos, Madrid, Spain

EFFECTIVENESS OF DAA s IN HIV/HCV-COINFECTED PATIENTS WITH DECOMPENSATED CIRRHOSIS

Juan Berenguer¹, Lourdes Domínguez-Domínguez², Ángela Gil-Martín³, Carmen Quereda⁴, Teresa Aldámar-Echevarría⁴, Ignacio Santos⁵, Pablo Ryan⁶, Gabriel Gaspar⁶, Inma Jarrín⁶, Juan González-García⁶

¹Gregorio Maranon Hosp, Madrid, Spain, ²Hosp Univ 12 de Octubre, Madrid, Spain, ³Servicio Madrileño de Salud, Madrid, Spain, ⁴Hosp Ramon y Cajal, Madrid, Spain, ⁵Hosp Univ de La Princesa, Madrid, Spain, ⁶Infanta Leonor Hosp, Madrid, Spain, ⁷Hosp Univ de Getafe, Getafe, 28905, ⁸Inst of Hlth Carlos III, Madrid, Spain, ⁹Hosp Univ La Paz, Madrid, Spain

EFFICACY AND SAFETY OF DAA s IN CIRRHOTIC HCV/HIV COINFECTED PATIENTS

Jordi Navarro¹, Montse Laguno², Helem Haydee Vilchez³, Josep M. Guardiola⁴, Jose A. Carrion⁵, Luis Force⁶, Mireia Cairo⁶, Carmen Cifuentes⁷, Manuel Crespo⁸, for the Catalano-Balear Study Group

¹Hosp Univ Vall d’Hebron, Barcelona, Spain, ²Hosp Clinic i Provincial de Barcelona, Barcelona, Spain, ³Hosp Univ de San Espases, Palma de Mallorca, Spain, ⁴Hosp de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵Hosp del Mar, Barcelona, Spain, ⁶Hosp de Mataró, Mataró, Spain, ⁷Hosp Univ Mútua de Terrassa, Terrassa, Spain, ⁸Hosp de Son Llàtzer, Palma de Mallorca, Spain, ⁹Hosp Univ de la Vall d’Hebron, Barcelona, Spain

INFLUENCE OF HIV ON CHANGES IN LIVER FUNCTION IN CIRRHOSIS AFTER ANTI-HCV TREATMENT

Juan Macías¹, Luis E. Morano-Amado², Francisca Cuenca-Lopez², Dolores Merino³, Manuel Márquez³, Karin Neukam¹, María J. Rios-Villegas⁴, Francisco Téllez⁵, Juan A. Pineda¹

¹Hosp Univ de Valme, Sevilla, Spain, ²Hosp Univ Alvaro Cunqueiro, Vigo, Spain, ³Hosp Univ Reina Sofia, Córdoba, Spain, ⁴Complejo Hospital Univ de Huelva, Huelva, Spain, ⁵Hosp Virgen de la Victoria, Málaga, Spain, ⁶Hosp Univ Virgen Macarena, Sevilla, Spain, ⁷Hosp de La Línea, La Línea de la Concepción, Spain
537  LIVER MICRORNA HSA-MIR-125A-5P MAY EXERT AN ONCOSUPPRESSOR EFFECT ON HCC

Lorenzo Onorato1, Giorgio de Stefano1, Valentina Lodice2, Nunzia Farella3, Nicoletta Potenza3, Evangelista Sagnelli3, Aniello Russo3, Carmine Minichini3, Mario Starace3, Nicola Coppola1
1Second Univ of Naples, Naples, Italy, 2AORN dei Colli, PO Cotugno, Naples, Italy, 3Second Univ of Naples, Caserta, Italy

538  REAL-LIFE TREATMENT RATES FOR HEPATOCELLULAR CARCINOMA IN HIV-INFECTED PATIENTS

Nicolás Merchante1, Francisco Rodríguez-Arrondo1, Esperanza Merino1, Boris Revollo1, Sofia Ibarra2, Miguel Garcia-Deltoro2, Francisco Téllez2, Joseba Portu3, Alberto Romero-Palacios3, Juan A. Pineda3
1Hosp Univ de Valme, Sevilla, Spain, 2Hosp Univ de Donostia, San Sebastián, Spain, 3Hosp Univ de Alicante, Alicante, Spain, 4Hosp German Trias i Pujol, Badalona, Spain, 5Hosp de Basurto, Basurto, Spain, 6Hosp General de Valencia, Valencia, Spain, 7Hosp de La Línea, La Línea de la Concepción, Spain, 8Hosp de Txagorritxu, Vitoria, Spain, 9Hosp de Puerto Real, Puerto Real, Spain

539  PREDICTORS OF HEPATOCELLULAR CARCINOMA IN HIV/HCV COINFECTED PATIENTS WITH CIRRHOSIS

Aaron P. Thrift, Kathryn E. Royse, Christine Hartman, Jennifer R. Kramer, Elizabeth Chiao
Baylor Coll of Med, Houston, TX

540  IFN-FREE THERAPY IS EFFECTIVE AND SAFE FOR HCV RECURRENT IN LT HCV/HIV COINFECTION

Christian Manzardo1, Maria Carlota Londoño2, Ana Moreno2, Lluis Castells3, Victoria Aguiler4, Jose R. Fernandez2, Jorge Calvo-Pulido4, Judith Peñafiel4, Antoni Rimola4, Jose M. Miro1
1Univ of Barcelona, Barcelona, Spain, 2Hosp Ramon y Cajal, Madrid, Spain, 3Hosp Univ Vall d’Hebron, Barcelona, Spain, 4Hosp Univ La Fe, Valencia, Spain, 5Hosp Univ de Cruces, Barakaldo, Spain, 6Hosp 12 de Octubre, Madrid, Spain

541  RISK FACTORS OF ACUTE REJECTION AFTER LIVER TRANSPLANTATION IN HIV+/HCV+ PATIENTS

Christian Manzardo1, Sandra Silva Arrieta2, Antonio Rafecas3, Sandra Franco1, Santos del Campo4, Elisa Cordero4, Judith Peñafiel4, Antoni Rimola4, Christian Brande2, Jose M. Miro1
1Univ of Barcelona, Barcelona, Spain, 2IrsiCaixa Inst for AIDS Rsr, Badalona, Spain, 3L’Hosp de Llobregat, Spain, 4Hosp Ramon y Cajal, Madrid, Spain, 5Univ de Sevilla, Sevilla, Spain

542LB  HCC DEVELOPMENT IN HCV PATIENTS AFTER DAA: THE EXPERIENCE OF THE SCOLTA PROJECT

Barbara Menzaghi1, Carlo Magni1, Laura A. Nicolini1, Giovanni Cenderello1, Vito Fiore2, Maria Gussio2, Roberto Gulminetti3, Francesca Vichi3, Paolo Bonfanti3
1Busto Arsizio Hosp, Busto Arsizio, Italy, 2ASST Fatebenefratelli, Milan, Italy, 3Univ of Genova, Genova, Italy, 4Galliera Hosp, Genoa, Italy, 5Unit of Infectious Diseases, Sassari, Italy, 6Garbaldi Hosp, Catania, Italy, 7IRCCS Policlinico San Matteo Fdhn Univ of Pavia, Pavia, Italy, 8Maria Annunziata Hosp, Milan, Italy, 9A. Manzoni Hospital, Lecco, Italy
591 MULTIPLE-TEST SCREENING STRATEGIES IMPROVE BIOSPY-PROVEN HSIL-DETECTION IN HIV+ WOMEN

Dorothy J. Wiley1, Elizabeth Chiao1, Jeanette Lee2, Ashish A. Deshmukh2, Scott B. Cantor2, Joel Palefsky2, Elizabeth A. Stier2

1Univ of California Los Angeles, Los Angeles, CA, USA, 2Baylor Coll of Med, Houston, TX, USA, 3Univ of Arkansas for Med Scis, Little Rock, AR, USA, 4Univ of Florida, Gainesville, FL, USA, 5Univ of Texas MD Anderson Cancer Ctr, Houston, TX, USA, 6Univ of California San Francisco, San Francisco, CA, USA, 7Boston Univ, Boston, MA, USA

592 SCREENING STRATEGIES ADD VALUE FOR PREDICTING BIOSPY-PROVEN HSIL FOR MSM

Dorothy J. Wiley1, Hilary K. Hsu1, Matthew G. Moran1, Jenny Brook1, David Elashoff1, Martha Ganser1, Stephen Young1, David Morris1, Otoniel Martinez-Maza1, Ronald T. Mitsuyasu1

1Univ of California Los Angeles, Los Angeles, CA, USA, 2Tricore Reference Labs, Albuquerque, NM, USA, 3Desert AIDS Proj, Palm Springs, CA, USA

593 ANAL HIGH-RISK HPV ASSOCIATIONS WITH SERUM CYTOKINES/CHEMOKINES AND FREE TESTOSTERONE

Dorothy J. Wiley1, Hilary K. Hsu2, Sitram Vangala1, David Elashoff1, Xiang Lu1, Todd Brown1, Gysamber D’Souza2, Elizabeth Breen1, Stephen Young1, Nancy Joste1

1Univ of California Los Angeles, Los Angeles, CA, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA, 3Tricore Reference Labs, Albuquerque, NM, USA, 4Univ of New Mexico Hlth Scs Ctr, Albuquerque, NM, USA

594 MULTIPLE HPV INFECTIONS AND ANAL PRECANCEROUS LESIONS IN HIV-INFECTED MEN

Shu-Hsing Cheng1, Chien-Yu Cheng1, Chi-Chao Wang1, Fang-Yeh Chu1, Yu-Mei Hsu1

1Taoyuan General Hosp, Taoyuan, Taiwan, 2Far Eastern Memorial Hosp, New Taipei, Taiwan, 3Taipei Med Univ, Taipei, Taiwan

595 SCREENING FOR PRECANCEROUS ANAL LESIONS WITH P16/KI67 DUAL STAIN CYTOLOGY IN HIV

Sergio Serrano-Villar1, Beatriz Hernández-Novoa2, Amparo de Benito1, Jorge Romero1, Antonio Ocampo1, Laura Pérez-Martinez2, Mar Masia6, Elena Sendagorta1, Gonzalo Sanz1, José Antonio Pérez-Molina1

1Hosp Univ Ramón y Cajal, Madrid, Spain, 2Brystol-Myers-Squibb, Madrid, Spain, 3Centro Sandoval, Madrid, Spain, 4Hosp Xeral de Vigo, Vigo, Pontevedra, 5Hosp San Pedro, Logroño, Spain, 6Hosp General Univ de Elche, Elche, Spain, 7Hosp Univ La Paz, Madrid, Spain, 8Hosp Clínico San Carlos, Madrid, Spain

596 IMPACT OF ART COVERAGE AND SCREENING ON ANAL CANCER IN HIV+ MEN WHO HAVE SEX WITH MEN

Nello Blaser1, Barbara Bertisch1, Manuel Koller1, Marcel Stoeckle2, Matthias Cavassini1, Roger Koyou1, Janne Estill1, Matthias Egger1, Olivia Keiser1, for the Swiss HIV Cohort Study

1Univ of Bern, Bern, Switzerland, 2Univ Hosp Basel, Basel, Switzerland, 3Univ of Lausanne, Lausanne, Switzerland, 4Univ of Zurich, Zurich, Switzerland

597 PREVALENCE OF HPV TYPES COVERED BY CURRENT VACCINES IN HIV-INFECTED MEN, SUN STUDY

Pragna Patel1, Tim Bush1, Lois Conley1, Elizabeth Unger1, Teresa Darragh1, Keith Henry1, Gerome Escota4, Joel Palefsky4, John T. Brooks4, Erna M. Kojic4

1CDC, Atlanta, GA, USA, 2Univ of California San Francisco, San Francisco, CA, USA, 3Hennepin County Med Ctr, Minneapolis, MN, USA, 4Washington Univ, St. Louis, MO, USA, 5Brown Univ, Providence, RI, USA
Poster Sessions • Tuesday
Program and Agenda
CROI 2017

Poster P-N5 INFLAMMATION, BIOMARKERS, AND RISK FACTORS FOR VASCULAR DISEASE
Poster Hall - 4 EF
2:30 PM - 4:00 PM

623 ASSOCIATION OF INFLAMMATION AND COAGULATION WITH CLINICAL RISK IN THE START TRIAL
Jason Baker, Shweta Sharma, Birgit Grund, for the INSIGHT START (Strategic Timing of Antiretroviral Treatment) Study Group
Univ of Minnesota, Minneapolis, MN, USA

624 HIV VIRAL BURDEN ASSOCIATED WITH SUBCLINICAL CORONARY ARTERY DISEASE IN HIV+ MEN
Sabina Haberlen, Ruibin Wang, Frank J. Palella, Lisa Jacobson, Todd Brown, Mallory Witt, Kathryn Berlacher, Matthew Budoff, Alison Abraham, Wendy Post
The Johns Hopkins Univ, Baltimore, MD, USA, Northwestern Univ, Chicago, IL, USA, Los Angeles Biomed Res Inst at Harbor—UCLA Med Ctr, Torrance, CA, USA, Univ of Pittsburgh, Pittsburgh, PA, USA, Harbor—UCLA Med Ctr, Torrance, CA, USA

625 HIGHER CARNITINE LEVELS ARE ASSOCIATED WITH SUBSEQUENT MYOCARDIAL INFARCTIONS IN HIV
Arjun Sinha, Peter W. Hunt, Jeffrey N. Martin, Yifei Ma, Heidi M. Crane, Daniel Drozd, Peter Ganz, Stanley Hazen, Priscilla Hsue
Univ of California San Francisco, San Francisco, CA, USA, Univ of Washington, Seattle, WA, USA, Cleveland Clinic, Cleveland, OH, USA

626 VACS INDEX IS SUPERIOR TO NADIR CD4 COUNT FOR PREDICTING AMI AND MORTALITY
Christopher Rentsch, Janet Tate, Vincent C. Marconi, Matthew Budoff, Adee A. Butt, Matthew Freiberg, Matthew Goetz, Maria Rodriguez-Barradas, David Rimland, Amy Justice
VA Connecticut Hlthcare System, West Haven, CT, USA, Emory Univ, Atlanta, GA, USA, Harbor—UCLA Med Ctr, Torrance, CA, USA, Mount Sinai Med Ctr, New York, NY, USA, Vanderbilt Univ, Nashville, TN, USA, VA Greater Los Angeles Hlth Care System, Los Angeles, CA, USA, Baylor Coll of Med, Houston, TX, USA, Atlanta VA Med Ctr, Decatur, GA, USA, VA Connecticut Hlthcare System, West Haven, CT, USA

627 EPICARDIAL FAT, IMMUNE ACTIVATION, AND CORONARY PLAQUE AMONG HIV+ AND HIV- WOMEN
Suman Srinivasa, Michael Lu, Kathleen V. Fitch, Travis R. Hallett, Tricia H. Burdo, Janet Lo, Sara E. Looby, Udo Hoffmann, Steven K. Grinspoon, Markella V. Zanni
Massachusetts General Hosp, Boston, MA, USA, Temple Univ, Philadelphia, PA, USA

628 DIVERGENT EFFECTS OF HIV AND SMOKING ON AORTIC INFLAMMATION
Chris T. Longenecker, Claire E. Sullivan, Justin T. Morrison, Corrilyn O. Hileman, David A. Zidar, Robert Gilkeson, James O’Donnell, Grace A. McComsey
Case Western Reserve Univ, Cleveland, OH, USA, Univ Hosps of Cleveland Med Ctr, Cleveland, OH, USA
629 CRP PREDICTS SUBCLINICAL CVD PROGRESSION IN HIV- BUT NOT HIV+ WOMEN
Caitlin A. Moran1, Aswani Vunnava1, Anandi N. Sheth1, Christina Mehta1, Phyllis Tien1, Michael Plankey1, Elizabeth T. Golub1, Ashred Quyyumi1, Robert C. Kaplan1, Igho Ofotokun1
1Emory Univ, Atlanta, GA, USA, 2Univ of California San Francisco, San Francisco, CA, USA, 3Georgetown Univ, Washington, DC, USA, 4The Johns Hopkins Univ, Baltimore, MD, USA, 5Albert Einstein Coll of Med, Bronx, NY, USA

630 SERUM ST2 IS AN INDEPENDENT PREDICTOR OF ALL-CAUSE MORTALITY IN HIV-INFECTED PATIENTS
Rodolphe Thiébaut1, Sophie Hue2, Fabien LeMarec1, Jean Daniel Lelièvre2, Michel Dupon3, Emilie Foucat2, Isabelle Pellegrin3, Christine Lacabartez2, Fabrice Bonnet1, Yves Levy3
1INSERM, Bordeaux, France, 2INSERM, Créteil, France, 3CHU de Bordeaux, Bordeaux, France

631 A LOWER CD COUNT PREDICTS MOST CAUSES OF DEATH EXCEPT CARDIOVASCULAR DEATHS
Gisela Leierer1, Armin Rieger2, Brigitte Schmied3, Mario Sarcletti1, Maria Geit1, Bernhard Haas5, Ninon Taylor4, Michaela Rappold1, Bruno Ledegerber1, Robert Zangerle1
1Med Univ of Innsbruck, Innsbruck, Austria, 2Med Univ of Vienna, Vienna, Austria, 3Med Univ of Vienna, Vienna, Austria, 4Otto-Wagner Hosp, Vienna, Austria, 5Keppler Univ Hosp Linz, Linz, Austria, 6General Hosp Graz South-West, Graz, Austria, 7Paracelsus Med Univ, Salzburg, Austria, 8Univ of Zurich, Zurich, Switzerland

632 ASSOCIATIONS BETWEEN HIV CONTROLLER STATUS AND SUBCLINICAL CAROTID ATHEROSCLEROSIS
Rebeccah McKibben1, David B Hanna2, Sabina Haberlen3, Robert C Kaplan2, Frank J Palella1, Elizabeth T Golub1, Peter Bacchetti5, Ruth Greenblatt5, Todd Brown6, Wendy Post1
1Johns Hopkins Univ, Baltimore, MD, USA, 2Albert Einstein Coll of Med, Bronx, NY, USA, 3Johns Hopkins Bloomberg SPH, Baltimore, MD, USA, 4Northwestern Univ, Chicago, IL, USA, 5Univ of California, San Francisco, San Francisco, CA, USA, 6Johns Hopkins Univ, Baltimore, MD, USA

633 ASSOCIATION BETWEEN CARDIOVASCULAR EVENTS AND HIV-SPECIFIC RISK FACTORS
Stefan Esser1, Norbert H. Brockmeyer2, Martin Hower3, Volker Holzendorf6, Christina Schulze2, Marina Arendt5, Till Neumann5, Nico Reinsch7, for the HIV HEART Study Group
1Univ Hosp Duisburg-Essen, Essen, Germany, 2Ruhr-Univ Bochum, Bochum, Germany, 3City Hosp Dortmund, Dortmund, Germany, 4Univ Leipzig, Leipzig, Germany, 5Univ Hosp Essen, Essen, Germany, 6Cardiologic Outpatient Clinic Staubach, Bochum, Germany, 7Alfried Krupp Hosp, Essen, Germany

634 IMPAIRED ANTIVASCULAR CONTRACTION OF PERIVASCULAR ADIPOSE TISSUE IN HIV INDIVIDUALS
Dan Wang, Cheng Wang, Cuiwei Wang, Chenglong Liu, Jennifer Verbesey, Phileen Sun, Seble Kassay, Mary Young, Christopher Wilcox, for the Hypertension, Kidney and Vascular Research Center and DC Women's Interagency HIV Study
Georgetown Univ, Washington, DC, USA
635LB NOVEL IMAGING STRATEGY SHOWS HIGH-LEVEL AORTIC CD206+ MACROPHAGE INFILTRATION IN HIV
Markella V. Zanni1, Mabel Toribio1, Moses Q. Wilks1, Michael T. Lu1, Tricia H. Burdo2, Fred Cope2, Udo Hoffmann3, Kenneth C. Williams4, Georges El-Fakhri1, Steven K. Grinspoon1
1Massachusetts General Hosp, Boston, MA, USA, 2Temple Univ, Philadelphia, PA, USA, 3Navidea Biopharmaceuticals, Dublin, OH, USA, 4Boston Coll, Chestnut Hill, MA, USA

636LB GUT MICROBIOTA, TRYPTOPHAN CATABOLISM AND ATHEROSCLEROSIS IN HIV INFECTION
Qibin Qi1, Simin Hua1, David B. Hanna1, Clary Clish2, Jason Lazar1, Wendy Post3, Kathryn Anastos1, Robert Burk1, Robert C. Kaplan1
1Albert Einstein Coll of Med, Bronx, NY, USA, 2Broad Inst of MIT and Harvard, Cambridge, MA, USA, 3SUNY Downstate Med Cntr, Brooklyn, NY, USA, 4Johns Hopkins Univ, Baltimore, MD, USA

637 INTEGRATING CARDIOVASCULAR DISEASE RISK-FACTOR SCREENING IN HIV SERVICES IN SWAZILAND
Miriam Rabkin1, Anton M. Palma1, Margaret L. McNairy1, Samkelo Simelane2, Averie B. Gachuhi2, Raymond A. Bitchong2, Harriet Nuwagaba-Biribonwoha3, Pido Bongomin2, Velephi Okello4, Wafa M. El-Sadr1
1ICAP at Columbia Univ, New York, NY, USA, 2ICAP Swaziland, Mbabane, Swaziland, 3Raleigh Fitkin Memorial Hosp, Manzini, Swaziland, 5Swaziland Ministry of Hlth, Mbabane, Swaziland

638 COMPOSITE “HIV/ HYPERTENSION/ DIABETES CONTROL” OUTCOME IN SEARCH CHRONIC CARE MODEL
Dalsone Kwariisima1, Jeanne Wallenta2, James Ayieko2, Florence Mwangwa3, Asiphas Owaragani4, Tamara D. Clark2, Edwin D. Charlebois5, Maya L. Petersen2, Diane V. Havliir2, Moses R. Kamya6
1Makerere Univ Joint AIDS Prog, Kampala, Uganda, 2Univ of California San Francisco, San Francisco, CA, USA, 3Kenya Med Rsr Inst, Nairobi, Kenya, 4Infectious Diseases Rsr Collab, Kampala, Uganda, 5Univ of California Berkeley, Berkeley, CA, USA, 6Makerere Univ Coll of Hlth Scis, Kampala, Uganda

639 THE ART ADVANTAGE: HEALTHCARE UTILIZATION FOR DIABETES & HYPERTENSION IN SOUTH AFRICA
1Beth Israel Deaconess Med Cntr, Boston, MA, USA, 2Harvard Univ, Cambridge, MA, USA, 3Tintswalo Hosp, Acornhoek, South Africa, 4Harvard Univ, Boston, MA, USA, 5Univ of the Witwatersrand, Acornhoek, South Africa, 6MRC/Wits Rural Pub Hlth and Hlth Transitions Rsr Unit, Johannesburg, South Africa, 7Univ of Witwatersrand, Johannesburg, South Africa, 8Heidelberg Univ, Heidelberg, Germany, 9Brigham and Women’s Hosp, Boston, MA, USA

640 CARDIOVASCULAR RISK ASSESSMENT IN A SUB-SAHaran AFRICA HIV CLINICAL COHORT
Mosepele Mosepele1, Linda C. Hempfling1, Tommy Palai1, Isaac Nkele3, Kara Bennett2, Shahin Lockman2, Virginia Triant2
1Univ of Botswana, Gaborone, Botswana, 2Massachusetts General Hosp, Boston, MA, USA, 3Botswana--Harvard AIDS Partnership, Gaborone, Botswana, 4Bennett Statistical Consulting Inc, New York, NY, USA, 5Harvard Univ, Boston, MA, USA
**Poster Sessions • Tuesday**

**Program and Agenda**

**CROI 2017**

---

**Poster P-01 IMMUNOLOGIC PREDICTORS OF MORBIDITY AND MORTALITY**

**Poster Hall - 4 EF**

**2:30 PM - 4:00 PM**

---

**641 HIV AND IMMUNE ACTIVATION ARE RISK FACTORS FOR ENDOTHELIAL DAMAGE IN ADULT MALAWIANS**

Christine Kelly¹, Henry Mwandumba², Rob Heyderman³, Raphael Kamng‘ona⁴, Mishek Chammudzi⁵, Irene Sheha⁶, Jane E. Mallewa⁶, Sarah Walker⁶, Nigel Klein⁷, Saye Khoo⁸

¹Univ Coll Dublin, Dublin, Ireland, ²Malawi Liverpool Wellcome Clinical Rsr Prog, Blantyre, Malawi, ³Univ Coll London, London, UK, ⁴Univ of Malawi, Blantyre, Malawi, ⁵Univ of Liverpool Inst of Translational Med, Liverpool, UK

---

**642 INCREASING PREVALENCE OF HYPERTENSION AMONG HIV-POSITIVE ADULTS IN SENEGAL, 1994–2015**

Noelle A. Benzekri¹, Papa Salif Sow², Moussa Seydi², Stephen E. Hawes¹, Geoffroy Gottlieb¹

¹Univ of Washington, Seattle, WA, ²CHU de Fann, Dakar, Senegal

---

**Poster P-O1 IMMUNOLOGIC PREDICTORS OF MORBIDITY AND MORTALITY**

**Poster Hall - 4 EF**

**2:30 PM - 4:00 PM**

---

**643 MITOCHONDRIAL D-LOOP SNPs ASSOCIATED WITH AGE-RELATED COMORBIDITIES IN HIV PATIENTS**

Rumi Minami, Soichiro Takahama, Yasunori Koga, Masahiro Yamamoto

Natl Hosp Org, Kyushu Med Cntr, Fukuoka, Japan

---

**644 IMMUNOLOGIC AND VIROLOGIC MEASURES AND MORTALITY AFTER NCD IN HIV+ ADULTS**


Vanderbilt Univ, Nashville, TN, USA

---

**645 VITAMIN D METABOLITES AND MORTALITY RISK AMONG HAART-TREATED HIV-INFECTED MEN**

Long Zhang¹, Todd Brown¹, Joseph B. Margolick¹, Sabina Haberlen¹, Mallory Witt¹, Frank J. Palella², Lawrence Kingsley³, Andrew Hoofnagle³, Lisa Jacobson¹, Alison Abraham¹

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Los Angeles Biomed Rsr Inst at Harbor–UCLA Med Ctr, Torrance, CA, USA, ³Northwestern Univ, Chicago, IL, USA, ⁴Univ of Pittsburgh, Pittsburgh, PA, USA, ⁵Univ of Washington, Seattle, WA, USA

---

**646 LONGITUDINAL HIV VIRAL TRAJECTORIES AND COMORBIDITIES IN THE WIHS**

Seble Kassaye¹, Cuimei Wang¹, Jeff Collmann¹, Tracey Wilson¹, Kathryn Anastos², Mardge H. Cohen³, Ruth Greenblatt¹, Joel Milam¹, Stephen J. Gange¹, Michael Plankey¹

¹Georgetown Univ, Washington, DC, USA, ²SUNY Downstate Med Ctr, Brooklyn, NY, USA, ³Albert Einstein Coll of Med, Bronx, NY, USA, ⁴John H.Stroger Jr. Hosp of Cook County, Chicago, IL, USA, ⁵Univ of California San Francisco, San Francisco, CA, USA, ⁶Univ of Southern California, Los Angeles, CA, USA, ⁷The Johns Hopkins Univ, Baltimore, MD, USA
647 OXIDATIVE STRESS PREDICTS SERIOUS NON-AIDS EVENTS IN HIV-INFECTED PATIENTS

Mar Masia1, Sergio Padilla2, Marta Fernández2, Xavier Barber1, Santiago Moreno1, Jose A. Iribarren3, Joaquin Portilla2, Alejandro Peña4, Francesc Vidal1, Félix Gutiérrez2

1Hosp General Univ de Elche, Elche, Spain, 2Univ Miguel Hernández, Elche, Spain, 3Hosp Ramon y Cajal, Madrid, Spain, 4Hospital Donostia, San Sebastián, Spain, 5Hosp General Univ de Alicante, Alicante, Spain, 6Hosp Univ San Cecilio, Granada, Spain, 7Hosp Univ de Tarragona Joan XXIII, Tarragona, Spain

648 INFLAMMATION BIOMARKERS PREDICT CLINICAL TREATMENT FAILURE IN HIV-INFECTED ADULTS

Rupak Shivakoti1, Nikhil Gupte2, Sandy Pillay3, Cynthia Riviere4, Sandra W. Cardoso5, Ashwin Balagopal5, Richard Sembal1, Thomas Campbell2, Amita Gupta2, for the NCWS 319 and ACTG 5175 PEARLS Study Team

1The Johns Hopkins Univ, Baltimore, MD, USA, 2BJGMC Clinical Trials Unit, Pune, India, 3Durban Univ of Techn, Durban, South Africa, 4Les Cnrs GHESKIO, Port-Au-Prince, Haiti, 5Inst Nacional de Infectologia (INI/Fiocruz), Rio de Janeiro, Brazil, 6Univ of Colorado Denver, Aurora, CO, USA

649 ART EFFECTS ON RENAL AND BONE HEALTH IN LIFELONG HIV SURVIVORS

Aviva Mattingly1, Sara Jones2, Aylin Unsal1, Julia Purdy1, James Reynolds1, Jeffrey Kopp1, Rohan Hazra1, Colleen Hadigan1

1NIAID, Bethesda, MD, USA, 2Liedos Biomed Rsr Inc, Frederick, MD, USA, 3NIH, Bethesda, MD, USA, 4NIDDK, Bethesda, MD, USA, 5NICHD, Bethesda, MD, USA

650 FACTORS ASSOCIATED WITH RAPID EGFR DECLINE IN PATIENTS RECEIVING TDF AND/OR ATV

Lisa Hamzah1, Sophie Jose1, Rachael Jones2, Deborah Williams4, David Chadwick3, Andrew Phillips2, Caroline Sabin1, Frank Post6


651 DISCONTINUATION OF DTG, EVG/C, AND RAL DUE TO TOXICITY IN A PROSPECTIVE COHORT

Josep M. Llibre1, Anna Esteve1, Jose M. Miro1, Gracia Mateo1, Adrià Curran1, Daniel Podzamczer1, Melchor Riera1, Francesc Homar1, Luis Force1

1Univ Hosp Germans Trias, Barcelona, Spain, 2Cntr d’Estudis Epidemiològics Sobre les ITS i Sida de Catalunya, Barcelona, Spain, 3Univ of Barcelona, Barcelona, Spain, 4Hosp Sant Pau, Barcelona, Spain, 5Hosp Vall d’Hebró, Barcelona, Spain, 6Hosp Univ de Bellvitge, Barcelona, Spain, 7Hosp Univ Son Espases, Palma de Mallorca, Spain, 8Hosp Son Llàtzer, Palma de Mallorca, Spain, 9Hosp de Mataró, Mataró, Spain

652 IMPACT OF TENOFIVIR DIFUMARATE ON TELOMERE LENGTH OF AVIREMIC HIV-INFECTED PATIENTS

Rocio Montejano1, Natalia Stella-Ascariz2, Susana Monge2, Jose I. Bernardino1, Ignacio Pérez-Valero1, Laura Pintado1, Marisa Montes1, Jesus Mingorance1, Rosario Perona1, Jose R. Arribas1

1Inst de Investigación Hosp Univ La Paz, Madrid, Spain, 2Univ de Alcalá de Henares, Madrid, Spain, 3Inst of Biomed Rsr “Alberto Sols,” Madrid, Spain

Poster Sessions • Tuesday
Program and Agenda
CROI 2017
653  DARUNAVIR/R USE AND INCIDENT CHRONIC KIDNEY DISEASE IN HIV-POSITIVE PERSONS

Lene Ryom¹, Jens D. Lundgren¹, Peter Reiss², Ole Kirk¹, Matthew Law³, Michael Ross⁴, Philippe Morlat¹, Christoph A. Fux⁴, Amanda Mocroft¹, for the D:A:D Study Group

¹CHIP, Rigshosp, Copenhagen, Denmark, ²Stichting HIV Monitoring and Academic Med Ctr Amsterdam, Amsterdam, Netherlands, ³Kirby Inst, Sydney, Australia, ⁴Mt Sinai Sch of Med, New York, NY, USA, ⁵CHU Bordeaux, Bordeaux, France, ⁶Clinic for Infectious Diseases and Hosp Hygiene, Kantonsspital Aarau, Aarau, Switzerland, ⁷Univ Coll London, London, UK

Poster P-P1 TB PREVENTION
Poster Hall - 4 EF 2:30 PM - 4:00 PM

705  CO-TRIMOXAZOLE PROPHYLAXIS DECREASES TUBERCULOSIS RISK AMONG ASIAN PATIENTS WITH HIV

Wen-Wei Ku¹, Awachana Jiamsakul¹, Kedar Joshi³, Mark Kristoffer Ungos Pasayana¹, Alvina Widhani¹, Romaneke Chaiwarith³, Saiasopin Kiertiburanakul¹, Kiat Ruxrungtham³, Ly Penh Sun³, Wingwai Wong¹

¹Taipei Veterans General Hosp, Taipei, Taiwan, ²Kirby Inst, Sydney, Australia, ³Inst of Infectious Diseases, Pune, India, ⁴Rsr Inst for Trop Med, Manila, Philippines, ⁵Cipto Mangunkusumo Hospital, Univ of Indonesia, Jakarta, Indonesia, ⁶Rsr Inst for Hlth Scis, Chiang Mai Univ, Chiang Mai, Thailand, ⁷Mahidol Univ, Bangkok, Thailand, ⁸HIV-NAT, Thai Red Cross AIDS Rsr Ctrn, Bangkok, Thailand, ⁹Univ of Hlth Scis, Phnom Penh, Cambodia

706  ISONIAZID PREVENTIVE THERAPY INITIATION, COMPLETION, & RETENTION IN CARE IN ETHIOPIA

Andrea Howard¹, Katharine Yuengling¹, Yael Hirsch-Moverman¹, Suzue Saito¹, Tsigereda Gadisa², Wafa M. El-Sadr¹, Zenebe Melaku³

¹ICAP at Columbia Univ, New York, NY, USA, ²ICAP at Columbia Univ, Maseru, Lesotho, ³ICAP at Columbia Univ, Addis Ababa, Ethiopia

707  IPT COVERAGE IN NURSE-LED SCREENING OF CHILD TUBERCULOSIS CONTACTS

Nicole Salazar-Austin¹, Silvia Cohn¹, Grace Barnes¹, Molefi Tladi², Katlego Matlaelo², Neil Martinson², Richard Chaisson¹

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Perinatal HIV Rsr Unit, Soweto, South Africa

708  PROVISION OF IPT TO PEOPLE LIVING WITH HIV IN SWAZILAND: A RETROSPECTIVE COHORT STUDY

Munyaradzi Pasipamire¹, Batsabile Simelane², Kikanda Kindandi², Arnold Mafukidze³, Marianne Calnan³, Samson Haumba³

¹Ministry of Hlth–Swaziland Natl AIDS Prog, Mbabane, Swaziland, ²URC Swaziland, Mbabane, Swaziland, ³Ministry of Hlth, Mbabane, Swaziland

709  DOES THE BENEFIT OF IPT FOR PERSONS WITH HIV WHO CONSUME ALCOHOL OUTWEIGH THE RISK?

J. Morgan Freiman¹, Winnie Muyindike², Karen Jacobson¹, C. Robert Horsburgh¹, Jerrold Elmir³, Judith Hahn³, Benjamin Linas³

¹Boston Med Ctr, Boston, MA, USA, ²Mbarara Univ of Sci and Tech, Mbarara, Uganda, ³Boston Univ, Boston, MA, USA, ⁴Univ of California San Francisco, San Francisco, CA, USA
HEPATOTOXICITY DURING IPT AND ART IN SEVERELY IMMUNOSUPPRESSED PEOPLE

McNeil Ngongondo1, Sachiko Miyahara2, Michael D. Hughes2, Xin Sun1, Anita Gupta1, Johnstone Kumwenda1, Thiago S. Torres3, Gregory Bisson6, Mina C. Hosseinipour4, for the Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team

1UNC Proj-Malawi, Lilongwe, Malawi, 2Harvard Univ, Boston, MA, USA, 3The Johns Hopkins Univ, Baltimore, MD, USA, 4Coll of Med-Johns Hopkins Rsr Proj, Blantyre, Malawi, 5Inst Nacional de Infectologia (INI-Fiocruz), Rio de Janeiro, Brazil, 6Univ of Pennsylvania, Philadelphia, PA, USA

THE SENSITIVITY OF QUANTIFERON-TB GOLD PLUS IS NOT AFFECTED BY HIV STATUS

L. Telisinghe1, M. Amofa-Sekyi2, K. Maluzi2, D. Kaluba-Milimo2, M. Cheeba-Lengwe2, K. Chiwele2, B. Kosloff3, S. Floyd1, S. L. Bailey1, H. Ayles4


LOOP-MEDIATED ISOTHERMAL AMPLIFICATION ASSAY TO DIAGNOSE TUBERCULOSIS IN RURAL UGANDA

Lydia Nakiyinyi1, Prossy Nakwanagi1, Tifu Agaba1, Mark Mugenyi1, Frank Mubiru1, Moses L. Joloba1, Yukari C. Manabe3

1Infectious Diseases Inst, Kampala, Uganda, 2Baylor Coll of Med Children’s Fndn, Kampala, Uganda, 3Kiboga Hosp, Kiboga, Uganda, 4Makerere Univ, Kampala, Uganda, 5The Johns Hopkins Univ, Baltimore, MD, USA

THE DIAGNOSIS OF EXTRAPULMONARY TUBERCULOSIS BY GENEXPERT MTB/RIF ASSAY IN ETHIOPIA

Mulualem Tadesse1, Dossegnaw Aragaw1, Alemayehu Bekele1

1Jimma Univ, Jimma, Ethiopia

EXTRAPULMONARY TB AT ART PROGRAMS IN LOWER-INCOME COUNTRIES: DIAGNOSTICS AND OUTCOMES

Kathrin Zürcher1, Marie Ballif1, Sasisopin Kiertiburanakul2, Marcel Yotebieng3, Beatrix Grinsztejn1, Denna Michael1, Henri Chenal4, Matthias Egger1, April C. Pettit2, Lukas Fenner1

1Inst of Social and Preventive Med, Univ of Bern, Bern, Switzerland, 2Mahidol Univ, Bangkok, Thailand, 3The Ohio State Univ, Columbus, OH, USA, 4Inst Nacional de Infectologia (INI-Fiocruz), Rio de Janeiro, Brazil, 5Natl Inst for Med Rsr, Kisesa HDSS, Mwanza, Tanzania, United Republic of, 6CIRBA, Abidjan, Côte d’Ivoire, 7Vanderbilt Univ, Nashville, TN, USA

LOW-LEVEL M. TB GENOTYPIC HETERORESISTANCE PREDICTS PHENOTYPIC DRUG RESISTANCE

John Z. Metcalfe1, Elizabeth Streicher1, Christopher Allender1, Darrin Lemmer1, Rebecca Colman1, Grant Theron2, Rob Warren1, David M. Engelthaler1

1Univ of California San Francisco, San Francisco, CA, USA, 2Stellenbosch Univ, Tygerberg, South Africa, 3Translational Genomics Rsr Inst, Flagstaff, AZ, USA, 4Univ of California San Diego, San Diego, CA, USA
716B  HUMAN AND MOUSE HEMATOPOIETIC STEM CELLS ARE A DEPOT FOR DORMANT M. TUBERCULOSIS

Julia Tornack1, Stephen Reece1, Wolfgang Bauer1, Alexis Vogelzang1, Silke Bandermann1, Ulrike Zedler1, Georg Stingl2, Stefan Kaufmann1, Fritz Melchers1

1Max Planck Inst for Infection Bio, Berlin, Germany, 2Med Univ of Vienna, Vienna, Austria

Poster P-P3 TB TREATMENT, OUTCOMES, AND MORTALITY
Poster Hall - 4 EF
2:30 PM - 4:00 PM

717  RISK FACTORS FOR DEATH IN ADVANCED HIV-INFECTED ADULTS IN AN EMPIRIC TB THERAPY TRIAL

Gregory Bisson1, Ritesh Ramchandani2, Sachiko Miyahara2, Xin Sun2, Jing Bao3, Amita Gupta4, Mina C. Hosseinipour2, Johnstone Kumwenda4, for the Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team

1Univ of Pennsylvania, Philadelphia, PA, USA, 2Harvard Univ, Boston, MA, USA, 3NIH, Bethesda, MD, USA, 4Johns Hopkins Univ, Baltimore, MD, USA, 5Univ of North Carolina Proj–Malawi, Lilongwe, Malawi, 6Malawi Coll of Med–Johns Hopkins Univ Rsr Proj, Blantyre, Malawi

718  DOES TIME TO ART INITIATION IMPACT EARLY RESPONSES TO DR-TB TREATMENT?

Erika K. Mohr1, Johnny Daniels1, Odelia Muller1, Bongani Chabalala1, Jennifer Hughes1, Virginia de Azevedo2, Amir Shroufi3, Sarah Jane Steele3, Gabriella Ferlazzo3, Laura Trivino Duran1

1MSF, Khayelitsha, Cape Town, South Africa, 2City of Cape Town Dept of Hlth, Cape Town, South Africa, 3MSF, Cape Town, South Africa

719  HIV-RELATED TB TREATMENT INTERMITTENCY IN THE CONTINUATION PHASE AND MORTALITY

Brenda Crabtree-Ramirez1, Cathy Jenkins2, Bryan E. Shepherd3, Karu Jayathilake1, Valdilea Veloso2, Eduardo Gotuzzo3, Claudia P. Cortes1, Denis Padgett1, Catherine McGowan1, Timothy R. Sterling1

1Inst Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico, Mexico, 2Vanderbilt Univ, Nashville, TN, USA, 3Oswaldo Cruz Fndn–Fiocruz, Rio de Janeiro, Brazil, 4Univ Peruana Cayetano Heredia, Lima, Peru, 5Univ of Chile, Santiago, Chile, 6Hosp Seguro Social, Tegucigalpa, Honduras

720  IMPACT OF INH ADHERENCE ON TB INCIDENCE AND MORTALITY BY WEEK 96 IN ACTG 5274 TRIAL

Amita Gupta1, Xin Sun2, Sachiko Miyahara2, Mitch Matoga3, Deborah Langat4, Cynthia Riviere5, Gregory Bisson6, Johnstone Kumwenda7, Mina C. Hosseinipour8, for the ACTG A5274/REMEMBER Study Team

1Johns Hopkins Univ, Baltimore, MD, USA, 2Harvard Univ, Boston, MA, USA, 3Univ of North Carolina Proj–Malawi, Lilongwe, Malawi, 4KEMRI/Walter Reed Proj, Kericho, Kenya, 5Les Cntrs GHSKIO, Port-Au-Prince, Haiti, 6Univ of Pennsylvania, Philadelphia, PA, USA, 7Malawi Coll of Med–Johns Hopkins Univ Rsr Proj, Blantyre, Malawi

721  WITHDRAWN
722 OUTCOMES ACROSS THE TUBERCULOSIS TREATMENT CASCADE AMONG ADOLESCENTS IN HAITI

Lindsey Reif1, Rachel Bertrand2, Eric Kutscher3, Vanessa Rivera3, Pierrot Julma4, Serena Koenig5, Jean W. Pape1, Daniel Fitzgerald1, Margaret McNairy3

1Columbia Univ, New York, NY, USA, 2GHESKIO, Port-au-Prince, Haiti, 3Weill Cornell Med, New York, NY, USA, 4Harvard Univ, Boston, MA, USA

723LB WITHDRAWN

724LB EFFICACY OF BEDAQUILINE, PRETOMANID, MOXIFLOXACIN & PZA (BPAMZ) AGAINST DS- & MDR-TB

Rodney Dawson1, Kendra Harris1, Almari Conradie3, Divan Burger1, Stephen Murray1, Carl Mendel2, Mel Spigelman2

1Univ of Cape Town, Mowbray, South Africa, 2Global Alliance for TB Drug Development, New York, NY, USA, 3QuintilesIMS, Bloemfontein, South Africa, 4Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA

Poster P-Q2 THE PMTCT CASCADE: TRANSMISSION, TESTING, AND VIRAL SUPPRESSION

Poster Hall - 4 EF 2:30 PM - 4:00 PM

761 MOTHER-TO-CHILD TRANSMISSION OF HIV IN KENYA: A MULTIYEAR NATIONAL EVALUATION

Lucy Ng’ang’a1, Christine J. McGrath1, Agnes Langat1, Jillian Pintye1, Mary Schmitz2, Abraham Katana1, Rose Wafula3, John Kinuthia3, Grace John-Stewart1, Kevin De Cock1

1US CDC, Nairobi, Kenya, 2Univ of Texas Med Branch, Galveston, TX, USA, 3Univ of Washington, Seattle, WA, USA, 4Natl AIDS and STD Control Prog, Ministry of Hlth, Nairobi, Kenya, 5Kenyatta Natl Hosp, Nairobi, Kenya

762 MISSED OPPORTUNITIES FOR REPEAT HIV TESTING AND EARLY ART INITIATION IN PREGNANCY

Anna Joy Rogers1, Eliud Akama2, Elly Weke3, Justin Blackburn1, George Owino4, Elizabeth A. Bukusi1, Patrick Oyaro2, Zachary A. Kwenza1, Craig Cohen3, Janet M. Turan1


763 LOW HIV INCIDENCE IN SOUTH AFRICAN PREGNANT WOMEN RECEIVING A PREVENTION INTERVENTION

Geoffrey Fatti1, Ashraf Grimwood1, Bon Egbujie1, Eula Mothibi1, Najma Shaikh1, Debra Jackson2, Brian Eley1

1Kheth’Impilo, Cape Town, South Africa, 2UNICEF, New York, NY, USA, 3Univ of Cape Town, Cape Town, South Africa

764 HIV INCIDENCE, CASCADE, AND TESTING AMONG MOTHERS IN WESTERN KENYA

Alliance Nikuze1, Stephen Wanjala2, Jihane Ben-Farhat1, Willis Omwoyo1, Laura Oyiengo1, Elisabeth Szumilin3, Leon Salumu4, Alexandra Vandenbulcke3, Valarie S. Opolo5, David Maman7

765 DETECTION OF HIV IN BREAST MILK AMONG PREGNANT/POSTPARTUM WOMEN WITH RECENT HIV
Alison L Drake¹, John Kinuthia², Daniel Matemo³, Barbara A. Richardson¹, Sandy Emery³, Vrasha Chohan³, Julie Overbaugh⁴, Grace John-Stewart¹
¹Univ of Washington, Seattle, WA, USA, ²Kenyatta Natl Hosp, Nairobi, Kenya, ³Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA

766 UPTAKE AND RETENTION IN CARE OF PREGNANT WOMEN STARTING OPTION B+ IN MAPUTO
Esmeralda Karajeanes¹, Dulce Bila¹, Orvalho Augusto², Maria Lain¹, Basilio Muiaanga¹, Chadreque Mulunya¹, Nello Macuacua¹, Victorino Chavane¹, Paula Vaz¹
¹Fundação Ariel Glaser Contra o Sida Pediatrico, Maputo, Mozambique, ²Univ Eduardo Mondlane, Maputo, Mozambique, ³Direcção Provincial de Saúde de Maputo, Maputo Provincia, Mozambique

767 STRATEGIES FOR VIRAL-LOAD MONITORING DURING PREGNANCY IN RESOURCE-LIMITED SETTINGS
Maia Lesosky¹, Elaine J. Abrams², Nei-Yuan M. Hsiao³, Landon Myer¹, for the Maternal Child Health - Antiretroviral Therapy (MCH-ART) study
¹Univ of Cape Town, Cape Town, South Africa, ²Columbia Univ, New York, NY, USA, ³NHLS, Cape Town, South Africa

768 VIRAL SUPPRESSION AMONG HIV+ PREGNANT WOMEN ENTERING ANTENATAL CARE ON ART IN UGANDA
Catherine A. Koss¹, Paul Natureeba², Deborah Cohan¹, Teddy Ochieng², Theodore Ruel¹, Miriam Nakalembe³, Tamara D. Clark¹, Edwin D. Charlebois³, Moses R. Kamya¹, Diane V. Havlir¹
¹Univ of California San Francisco, San Francisco, CA, USA, ²Makerere Univ–Univ of California San Francisco Rsr Collab, Kampala, Uganda, ³Makerere Univ Coll of Hlth Scis, Kampala, Uganda

769 MEASURES OF ENGAGEMENT IN ROUTINE HIV CARE TO PREDICT ELEVATED VIRAL LOAD ON ART
Tamsin Phillips¹, Allison Zerbe², Agnes Ronan³, Nei-Yuan M. Hsiao³, Greg Petro³, James A. McIntyre³, Andrew Boulle¹, Elaine J. Abrams³, Landon Myer¹, for the Maternal Child Health - Antiretroviral Therapy (MCH-ART) study
¹Univ of Cape Town, Cape Town, South Africa, ²ICAP at Columbia Univ, New York, NY, USA, ³Natl Hlth Lab Service, Cape Town, South Africa, ⁴Anova Hlth Inst, Johannesburg, South Africa

770 SELF-REPORT AND DRY BLOOD SPOTS AS MARKERS OF ANTIRETROVIAL ADHERENCE IN PREGNANCY
Maria L. Alcaide¹, Shandir Ramlagan², Violeta Rodriguez³, Ryan Cook³, Karl Pelzter², Stephen Weiss¹, Deborah Jones¹
¹Univ of Miami, Miami, USA, ²HIV/AIDS, STIs, and TB Rsr Prog, Pretoria, South Africa, ³Univ of California Los Angeles, Los Angeles, CA, USA

771 UNINTENDED PREGNANCY PREDICTS SUBSEQUENT RAISED VIRAL LOAD IN THE POSTNATAL PERIOD
Kirsty Brittain¹, Tamsin Phillips¹, Allison Zerbe², Agnes Ronan¹, Greg Petro³, Nei-Yuan M. Hsiao³, James A. McIntyre¹, Elaine J. Abrams³, Landon Myer¹, for the Maternal Child Health - Antiretroviral Therapy (MCH-ART) Study
¹Univ of Cape Town, Cape Town, South Africa, ²Columbia Univ, New York, NY, USA, ³NHLS, Cape Town, South Africa, ⁴Anova Hlth Inst, Johannesburg, South Africa, ⁵ICAP at Columbia Univ, New York, NY, USA
780 MITOCHONDRIAL DNA CONTENT IN HIV-EXPOSED UNINFECTED INFANTS IN CAMEROON

Jennifer Jao1, Kathleen M. Powis2, Brian Kirmmse3, Chunli Yu4, Fanny Epie5, Elaine J. Abrams6, Derek LeRoith7, Mitchell Geffner7, Irwin J. Kurland7, Helene C. Cote8

1Icahn Sch of Med at Mt Sinai, New York, NY, USA, 2Massachusetts General Hosp, Boston, MA, USA, 3Univ of Mississippi, Jackson, MS, USA, 4Cameroon Baptist Convention Hlth Services, Bamenda, Cameroon, 5Cameroon Univ, New York, NY, USA, 6Univ of Southern California, Los Angeles, CA, USA, 7Albert Einstein Coll of Med, Bronx, NY, USA, 8Univ of British Columbia, Vancouver, Canada

781 LOPINAVIR/RITONAVIR INITIATED AT 7 DAYS OF LIFE IMPAIRS INFANT GROWTH

Nicolas Nagot1, Thorkild Tylleskär2, Chipepo Kankasa3, Nicolas MEDA4, James Tumwine5, Mandisa Singata6, Marianne Periès7, Philippe Van de Perre1, Stephane Blanché2, for the ANRS 12174 Trial Group

1INSERM, Montpellier, France, 2Univ of Bergen, Bergen, Norway, 3Univ Teaching Hosp, Lusaka, Zambia, 4Cntr MURAZ, Bobo-Doulasso, Burkina Faso, 5Univ of Makerere, Kampala, Uganda, 6Univ of Fort Hare, East London, South Africa, 7Necker Hosp, Paris, France

782 GROWTH OUTCOMES OF HIV-EXPOSED UNINFECTED CHILDREN BY BIRTH PERIOD IN MALAWI

Malango T. Msukwa1, Andreas Haas2, Lyson Tenthani1, Cristina B. Hofer1, Janne Estill2, Frank M. Chimbwandira1, Adrian Spoerri2, Joep J. van Oosterhout2, Olivia Keiser3, for the Umoyo Study Group

1Univ of Bern, Lilongwe, Malawi, 2Univ of Bern, Bern, Switzerland, 3Lighthouse Trust, Lilongwe, Malawi

783 GROWTH IN INFANTS EXPOSED TO EFV AND TDF THROUGH BREASTMILK: MALAWI PMTCT OPTION B+

Atupele P. Kapito-Tembo1, Austin Wesevich2, Andy Bauleni2, Mina C. Hosseinipour1, Dennis Ongubo2, Queen Dube1, Amanda Corbett2, Don Mathanga1, Victor Mwapasa1, Sam Phiri1, for the CHF Team on Cellular Aging and HIV Comorbidities in Women and Children (CARMA)

1Univ of Malawi, Blantyre, Malawi, 2Harvard Univ, Boston, MA, USA, 3Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana, 4Independent Consultant, Nairobi, Kenya, 5Boston Children’s Hosp, Boston, MA, USA, 6Lighthouse Trust, Lilongwe, Malawi

784 PREDICTORS OF NEURODEVELOPMENT IN CHILDREN OF HIV-INFECTED AND -UNINFECTED WOMEN

Jean Leidner1, Paige L. Williams2, Gloria Mayondi3, Penny Holding4, Adam Cassidy5, Joseph Makhema3, Charlotte Mdulu6, Shahin Lockman7, Betsy Kammerer2

1Goodtables Consulting, Oklahoma, OK, USA, 2Harvard Univ, Boston, MA, USA, 3Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana, 4Independent Consultant, Nairobi, Kenya, 5Boston Children’s Hosp, Boston, MA, USA, 6Lighthouse Trust, Lilongwe, Malawi

785 B-CELL SUBSETS PROFILE AND VACCINE RESPONSE IN HIV-EXPOSED UNINFECTED (HEU) CHILDREN

Laurence Raymond Marchand1, Catherine Gravel1, Armelle Le Campion2, Marc Boucher2, Normand Lapointe2, Valerie Lamarre2, Fatima Kakkar3, Helene C. Cote1, Hugo Soudeyns3, for the CHF Team on Cellular Aging and HIV Comorbidities in Women and Children (CARMA)

1CHU Sainte Justine, Montreal, Canada, 2Univ of Montreal, Montreal, Canada, 3Univ of British Columbia, Vancouver, Canada
786 INFLAMMATORY RESPONSES ASSOCIATED WITH CMV AND MATERNAL HIV IN ZIMBABWEAN INFANTS
Ceri Evans, Bernard Chasekwa, Sandra Rukobo, Margaret Ghova, Kuda Mutasa, Robert Ntozini, Jean Humphrey, Andrew Prendergast
1Queen Mary Univ of London, London, UK, 2Zvitambo Inst for Maternal and Child Hlth Rsr, Harare, Zimbabwe

787 MATERNAL ART ASSOCIATED WITH IMPROVED PROTECTIVE TRANSPLACENTAL ANTIBODY TRANSFER
Scott Dryden-Peterson, Elize de Bruyn, Gloria Mayondo, Betsy Kammerer, Jean Leidner, Roger L. Shapiro, Haruna Jibril, Shabir Madhi, Shahin Lockman
1Brigham and Women's Hosp, Boston, MA, USA, 2Respiratory and Meningeal Pathogens Rsr Unit, Soweto, South Africa, 3Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana, 4Boston Children's Hosp, Boston, MA, USA, 5Goodtables Consulting, Norman, OK, USA, 6Harvard Univ, Boston, MA, USA, 7Botswana Ministry of Hlth, Gaborone, Botswana

Poster P-R5 COMORBIDITIES AND COMPLICATIONS IN CHILDREN AND YOUTH
Poster Hall - 4 EF 2:30 PM - 4:00 PM

818 TREATMENT OUTCOMES OF KAPOSI SARCOMA IN HIV-1–INFECTED CHILDREN IN MOZAMBIQUE
Faizana Amodo, Yolanda Cachomba, Dalila Rego, Orvalho Augusto, Dulce Bila, Paula Vaz
1Hosp Central de Maputo, Maputo, Mozambique, 2Univ Eduardo Mondlane, Maputo, Mozambique, 3Fundação Ariel Glaser Contra o Sida Pediatrico, Maputo, Mozambique

819 DURABLE GAINS IN BONE MASS AMONG SOUTH AFRICAN CHILDREN SWITCHING TO EFAVIRENZ
Stephen M. Arpadi, Stephanie Shiau, Renate Strehlau, Faeezah Patel, Ndileka Mbete, Louise Kuhn, Ashraf Coovadia, Michael T. Yin
1Columbia Univ, New York, NY, USA, 2Empilweni Service and Rsr Unit, Johannesburg, South Africa

820 EFFECTS OF CALCIUM AND VITAMIN D SUPPLEMENTATION ON BONE HEALTH IN HIV-INFECTED YOUTH
Tavitiya Sudjaritruk, Linda Urpibul, Torsak Bunupuradah, Suparat Kanjanavarnit, Tawalchaya Chotecharoentanani, Sineenart Taejaroenkul, Pradthana Ounchanum, Piyaarat Suntarattiwong, Thanyawee Puthanakit, for the CAL-D Study Group
1Chiang Mai Univ, Chiang Mai, Thailand, 2HIV Netherlands Australia Thailand Rsr Collab (HIV-NAT), 3Nakornping Hosp, Chiang Mai, Thailand, 4Chiang Rai Prachanukroh Hosp, Chiang Rai, Thailand, 5Queen Sirikit Natl Inst of Child Hlth, Bangkok, Thailand, 6Chulalongkorn Univ, Bangkok, Thailand

821 METABOLIC PROFILES OF ADULTS VERTICALLY INFECTED WITH HIV AND THE GENERAL POPULATION
Elise Arrivé, Jean-Paul Viard, Elisa Arezes, Feriel Ayat, Benoit Salanave, Sophie Matheron, Véronique Reliquet, Corinne Vigouroux, Josiane Warszawski, for the ANRS CO19 COVERTE Study Group
1Univ of Bordeaux, Bordeaux, France, 2Hôtel-Dieu de Paris, Paris, France, 3INSERM, Le Kremlin-Bicêtre, France, 4Equipe de Surveillance et d'Epidémiologie Nutritionnelle/Agence Natl de Santé Publique, Bobigny, France, 5Bichat-Claude Bernard Hosp, Paris, France, 6CHU Hôtel Dieu, Nantes, France, 7INSERM, Paris, France
**Poster Sessions • Tuesday**

**Program and Agenda**

CROI 2017

---

822  
**EFFECTS OF VITAMIN D SUPPLEMENTATION ON CAROTID INTIMA-MEDIA THICKNESS IN HIV+ YOUTH**

Allison R. Eckard¹, Paolo Raggi², Mary Ann O’Riordan³, Julia C. Rosebush⁴, Danielle Labbato¹, Ann Chahroudi⁴, Joshua H. Ruff⁴, Chris T. Longenecker⁴, Vin Tangpricha⁴, Grace A. McComsey⁴

¹Med Univ of South Carolina, Charleston, SC, USA, ²Mazankowski Alberta Heart Inst, Edmonton, Canada, ³Case Western Reserve Univ, Cleveland, OH, USA, ⁴Emory Univ, Atlanta, GA, USA

---

823  
**DOES PREMATURE VASCULAR STIFFNESS SLOWLY IMPROVE FOLLOWING EARLY ART? DATA FROM CHER**

Steve Innes¹, Mark Cotton¹, Kennedy N. Otowmbe¹, Barbara Laughton¹, Sara H Browne¹

¹Stellenbosch Univ, Cape Town, South Africa, ²Univ of the Witwatersrand, Johannesburg, South Africa, ³Univ of California San Diego, San Diego, CA, USA

---

824  
**SV CAM AND MCP-1 INVOLVED IN PREMATURE ARTERIAL-WALL STIFFNESS IN PREPUBERTAL CHILDREN**

Steve Innes¹, Richard Glashoff², Shalena Naidoo¹, Kennedy N. Otowmbe¹, Barbara Laughton¹, Maile Karris¹, Mark Cotton¹, Sara H Browne¹

¹Stellenbosch Univ, Cape Town, South Africa, ²Univ of the Witwatersrand, Johannesburg, South Africa, ³Univ of California San Diego, San Diego, CA

---

825  
**VASCULAR HEALTH AND CEREBRAL BLOOD FLOW IN PERINATALLY HIV-INFECTED CHILDREN**

Charlotte Blokhuis¹, Sophie Cohen¹, Henriëtte J. Scherpbie², Henk-Jan M. Mutsaerts³, Joost C. Meijers³, Neeltje A. Kootstra³, Peter Reiss³, Ferdinand Wit¹, Charlotte E. Teunissen¹, Dasja Pajkrt¹

¹Emma Children’s Hosp/Academic Med Cntr, Amsterdam, Netherlands, ²Academic Med Cntr, Amsterdam, Netherlands, ³Sanquin Rsr, Amsterdam, Netherlands, ⁴Stichting HIV Monitoring and Academic Med Cntr, Amsterdam, Netherlands, ⁵VU Univ Med Ctr, Amsterdam, Netherlands

---

826  
**NEUROPSYCHOLOGICAL OUTCOMES IN A TWO YEAR AFRICAN-BASED PEDIATRIC OBSERVATIONAL STUDY**

Michael J. Boivin¹, Miriam Chernoff², Barbara Laughton³, Mutsa Bwakura-Dangarembizi⁴, Portia Kamthunzi⁵, Linda Barlow-Mosha⁶, Avy Violar³, Mark Cotton³, Paul Palumbo⁴, for the IMPAACT P1104s Study Team

¹Michigan State Univ, East Lansing, MI, USA, ²Harvard Univ, Boston, MA, USA, ³Stellenbosch Univ, Cape Town, South Africa, ⁴Univ of Zimbabwe, Harare, Zimbabwe, ⁵Univ of North Carolina Proj–Malawi, Lilongwe, Malawi, ⁶Makerere Univ–Johns Hopkins Univ Rsr Collab, Kampala, Uganda, ⁷Univ of the Witwatersrand, Johannesburg, South Africa, ⁸Dartmouth-Hitchcock Med Cntr, Lebanon, NH, USA

---

827  
**PLASMA HEME OXYGENASE-1 IS ASSOCIATED WITH COGNITIVE DECLINE IN CHILDREN WITH HIV**

David Bearden¹, Alexander J. Gill², Paige L. Williams³, Dennis L. Kolson², Laura Schankel¹, Allison Agwu¹, Russell B. Van Dyke⁵, Steven D. Douglas⁴, for the Pediatric HIV/AIDS Cohort Study (PHACS) network and the IMPAACT 219C Study Team

¹Univ of Rochester, Rochester, NY, USA, ²Univ of Pennsylvania, Philadelphia, PA, USA, ³Harvard Univ, Boston, MA, USA, ⁴Children’s Hosp of Philadelphia, Philadelphia, PA, USA, ⁵The Johns Hopkins Univ, Baltimore, MD, USA, ⁶Tulane Univ, Metairie, LA, USA
828 BIOMARKERS OF COGNITIVE DECLINE IN PERINATALLY INFECTED CHILDREN WITH HIV
David Bearden¹, Alexander J. Gill², Paige L. Williams³, Dennis L. Kolson², Laura Schankel⁴, Allison Agwu⁵, Russell B. Van Dyke⁶, Steven D. Douglas⁷, for the The Pediatric HIV/AIDS Cohort Study (PHACS) network and the IMPAACT 219C study team
¹Univ of Rochester, Rochester, NY, USA, ²Univ of Pennsylvania, Philadelphia, PA, USA, ³Harvard Univ, Boston, MA, USA, ⁴Children’s Hosp of Philadelphia, Philadelphia, PA, USA, ⁵The Johns Hopkins Univ, Baltimore, MD, USA, ⁶Tulane Univ, Metairie, LA, USA

829 MONOCYTES MAY BE ANTIVIRAL TARGETS TO LIMIT PEDIATRIC HIV-RELATED CNS MANIFESTATIONS
Erica L. Johnson, Dominika Swieboda, Christina Gavegnano, Rana Chakraborty, Raymond F. Schinazi
Emory Univ, Atlanta, GA, USA

830 CENTRAL NERVOUS SYSTEM PENETRATION OF ANTIRETROVIRAL THERAPY IN HIV-INFECTED CHILDREN
Malon V. Hof⁸, Charlotte Blokhuis¹, Sophie Cohen⁹, Henriëtte J. Scherpier¹, Ferdinand Wit¹, Marcel Pistorius¹, Neeltje A. Kootstra¹, Charlotte E. Teunissen¹, Ron Mathot¹, Dasja Pajkr¹
¹Academic Med Cntr, Amsterdam, Netherlands, ²Emma Children’s Hosp/ Academic Med Cntr, Amsterdam, Netherlands, ³Stichting HIV Monitoring and Academic Med Cntr, Amsterdam, Netherlands, ⁴VU Univ Med Cntr, Amsterdam, Netherlands

Poster P-S5 MEASURING HIV INCIDENCE AND PREVALENCE
Poster Hall - 4 EF 2:30 PM - 4:00 PM

876 ASSESSINGUTILITY OF HIV INCIDENCE ASSAYS IN ESTIMATING INDIVIDUAL INFECTION TIMES
Christopher D. Pilcher¹, Shelley Facente¹, Eduard Grebe², Sheila Keating³, Reshma Kassanjee⁴, Matt A. Price⁵, Michael P. Busch³, Gary Murphy⁶, Alex Welte³, Travis C. Porco³

877 A MULTIPLEX ASSAY FOR MONITORING RECENT HIV-1 TRANSMISSION IN LOCALIZED OUTBREAKS
Kelly Curtis, Ellsworth Campbell, Krystin A. Price, William M. Switzer
CDC, Atlanta, GA, USA

878 INFERENCE OF HIV-1 INFECTION DATES IN AN OUTBREAK USING ANTIBODY-BASED RECENCY ASSAYS
Ellsworth Campbell¹, Kelly Curtis¹, Krystin A. Price¹, Debra Hanson¹, Sara J. Blosser¹, Joan Duwve¹, Pam Pontones¹, Philip J. Peters¹, William M. Switzer¹
¹CDC, Atlanta, GA, USA, ²Indiana State Hlth Dept, Indianapolis, IN, USA, ³Indiana Univ, Indianapolis, IN, USA
879 IDENTIFICATION AND VALIDATION OF AN INCIDENCE-TESTING ALGORITHM FOR HIV-1 SUBTYPE C
Oliver Laeyendecker1, Jacob Konikoff2, Douglas Morrison3, Ronald Brookmeyer1, Jing Wang4, Connie L. Celum5, Charles S. Morrison6, Quarraisha Abdool Karim7, Audrey Pettifor4, Susan H. Eshleman8
1NIAID, NIH, Baltimore, MD, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA, 3Univ of California Los Angeles, Los Angeles, CA, USA, 4Fred Hutchinson Cancer Res Ctr, Seattle, WA, USA, 5Univ of Washington, Seattle, WA, USA, 6FHI 360, Durham, NC, USA, 7CAPRISA, Durban, South Africa, 8Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 9The Johns Hopkins Univ, Baltimore, MD, USA

880 VALIDATION OF LIMITING ANTIGEN AVIDITY ASSAY TO ESTIMATE HIV INCIDENCE IN EAST AFRICA
Oliver Laeyendecker1, Ronald H. Gray2, Kate Grabowski2, Steven Reynolds1, Anthony Ndyanabo3, Joseph Ssekasanvu2, Gilad Bismut2, Maria Wawer2, David Serwadda3, Thomas C. Quinn1
1NIAID, Baltimore, MD, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA, 3Rakai Hlth Scis Prog, Kalisizo, Uganda, 4Makerere Univ, Kampala, Uganda

881 MISCLASSIFICATION RATE OF HIV ANTIBODY AVIDITY ASSAYS IN INDIVIDUALS FROM CAMEROON
Briana Lynch1, Eshan Patel2, Colleen R. Courtney1, Aubin J. Nanfack3, Thomas Quinn1, Oliver Laeyendecker4, Phillipe N. Nyambi3, Ralf Duerr4, Andrew D. Redd5, for the Medical Diagnostic Center, Yaoundé, Cameroon
1NIH, Bethesda, MD, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA, 3New York Univ, New York, NY, USA, 4NIAID, Baltimore, MD, USA, 5NIAID, Bethesda, MD, USA

882 WITHDRAWN

883 HIGH HIV INCIDENCE AMONG PWID AND MSM ATTENDING INTEGRATED CARE CENTERS IN INDIA
Allison M. McFall1, Sunil S. Solomon1, Gregory M. Lucas1, Aylur K. Srikrishnan2, Muniratnam S. Kumar2, Santhanam Anand2, Canjeevaram K. Vasudevan2, David D. Celentano1, Shruti H. Mehta1
1The Johns Hopkins Univ, Baltimore, MD, USA, 2YR Gaitonde Ctrr for AIDS Rsr and Educ, Chennai, India

884 TRENDS IN HIV INCIDENCE AMONG PWID, MSM AND CSW USING PREVENTION SERVICES IN UKRAINE
Kostyantyn Dumchev1, Olga Varetska2, Yana Sazonova3, Pavlo Smyrnov2
1Ukrainian Inst on Pub Hlth Policy, Kyiv, Ukraine, 2`Alliance for Pub Hlth, Kyiv, Ukraine

885 IMPROVED EVALUATION OF HIV PREVALENCe ADJUSTING FOR INFORMATIVE NONPARTICIPATION
Linbo Wang1, Erik VanWidenfelt1, Chloe Auletta-Young1, Nealia Khan1, Etienne Kadima1, Unoda Chakalisa1, Tendani Gaolathe1, Eric Tchetgen Tchetgen1, Kathleen Wirth1
1Harvard Univ, Boston, MA, 2Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana
113
CROI 2017

Poster Sessions • Tuesday
Program and Agenda

Poster P-S7 HIV SELF TESTING: KNOW YOURSELF
Poster Hall - 4 EF
2:30 PM - 4:00 PM

891 HIV SELF-TEST (HIVST) AWARENESS, EXPOSURE, AND USE, NEW YORK CITY, 2015–2016
Paul M. Salcuni, Zoe R. Edelstein, Demetre C. Daskalakis, Julie Myers
New York City DHMH, Queens, NY, USA

892 ETEST: A “SMART” HOME HIV TESTING SYSTEM ENABLING REAL-TIME FOLLOW-UP AFTER TESTING
Tyler B. Wray1, Philip A. Chan2, Don Operario1, Erik Simpanen1
1Brown Univ, Providence, RI, USA, 2The Miriam Hosp, Providence, RI, USA

893 PEER-LED ORAL HIV-Self Testing Finds Undiagnosed HIV Among MSM in Malindi, Kenya
Elisabeth M. van der Elst1, Mahmoud Shally1, Clifford Oduor1, Oscar Chirro1, Fauz Ibrahim1, Bernadette Kombo1, Susan M. Graham1, Eduard Sanders1
1KEMRI Wellcome Trust Rsr Prog, Kilifi, Kenya, 2Kilifi County Dept of Hlth, Kilifi, Kenya, 3Univ of Washington, Seattle, WA, USA, 4Kenya Med Rsr Inst, Kilifi, Kenya

894 ROLE OF PARTNER VIOLENCE IN WOMEN’S ABILITY TO DISTRIBUTE SELF-TESTS TO MALE PARTNERS
Elisabeth Schaffer1, Kawango Agot2, Harsha Thirumurthy1
1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Impact Rsr and Development Org, Kisumu City, Kenya

895 INFORMING HIV SELF-TESTING SERVICES IN MALAWI USING DISCRETE CHOICE EXPERIMENTS
Pitchaya Indravudh1, Marc D’Elbee1, Moses Kumwenda1, Augustine Choko1, Doreen Sakala1, Thokozani Kalua1, Cheryl Johnson1, Karin Hatzold1, Liz Corbett1, Fern Terris-Prestholt1

896 PROVIDING USER SUPPORT FOR HIV SELF-TESTING BEYOND INSTRUCTIONS-FOR-USE IN MALAWI
Pitchaya Indravudh1, Moses Kumwenda1, Melissa Neuman1, Blessings Chisunkha1, Karin Hatzold1, Chiwawa Nkhoma1, Thokozani Kalua1, Cheryl Johnson1, Miriam Taegtmeyer1, Liz Corbett1

897 ACCEPTABILITY OF SELF-COLLECTED RECTAL SWABS FOR HIV EXPOSURE TESTING AMONG MSM/TGW
Hong Van Tieu1, Maria Lemos1, Michele Andrasik2, Ira Fleming3, Vijay Nandi4, Geneva Ortiz4, Debbie Lucy5, Martin Musuruana1, Julie McElrath5, Beryl A. Koblin1
1New York Blood Cntr, New York, NY, USA, 2Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 3Univ of Illinois, Peoria, IL, USA

898 FEASIBILITY AND REACH OF A HOME-TEST GIVEAWAY IN NEW YORK CITY, 2015–2016
Zoe R. Edelstein1, Paul M. Salcuni1, Benjamin Tsoi1, Paul Kobrak1, Adriana Andaluz1, David A Katz2, Demetre C. Daskalakis1, Julie Myers1
1New York City DHMH, Queens, NY, USA, 2Univ of Washington, Seattle, WA, USA
Poster Sessions • Tuesday
Program and Agenda
CROI 2017

899  STATE-LEVEL ESTIMATES OF HIV INCIDENCE, PREVALENCE, AND UNDIAGNOSED INFECTIONS
   Anna S. Johnson, Ruiguang Song, Irene Hall
   CDC, Atlanta, GA, USA

900  ESTIMATING THE UNDIAGNOSED FRACTION: A COMPARISON OF NEW METHODS
   Jeanette Birnbaum1, Jason Carr2, Martina Morris1
   1Univ of Washington, Seattle, WA, USA, 2Washington State Dept of Hlth, Olympia, USA

901  HIV TESTING MOTIVATIONS OF US MEN WHO HAVE SEX WITH MEN IN A NATIONAL ONLINE SURVEY
   David A. Katz1, Patrick Sullivan2, Robert C. Sineath2, Jennie McKenney2, Maria Zlotorzynska3, Susan Cassels1, Joanne Stekler1
   1Univ of Washington, Seattle, WA, USA, 2Emory Univ, Atlanta, GA, USA, 3Univ of California Santa Barbara, Santa Barbara, CA, USA

902  INCREASES IN HIV TESTING FREQUENCY AMONG MEN WHO HAVE SEX WITH MEN, UNITED STATES
   Qian An, Ruiguang Song, Teresa Finlayson, Cyprian Weinert, Gabriela Paz-Bailey
   CDC, Atlanta, GA, USA

903  UNDIAGNOSED HIV AND HCV IN A NEW YORK CITY EMERGENCY ROOM, 2015
   Lucia V. Torian1, Uriel Felsen2, Qiang Xia3, Eric Rude1, Herbert Rose4, Angelica Bocour5, Gary J. Williams6, Bob F. Bridgforth7, Lisa A. Forgione1, Barry S. Zingman1
   1New York City DHMH, New York, NY, USA, 2Albert Einstein Coll of Med, Bronx, NY, USA, 3New York City DHMH, Long Island City, NY, USA, 4Montefiore Med Cntr, Bronx, NY, USA, 5Quest Diagnostics, San Clemente, CA, USA

904  EXAMINATION OF UNRECOGNIZED AND MISREPORTED HIV STATUS IN BALTIMORE MSM AND PWID
   Danielle German1, Kate Shearer1, Colin Flynn2, Carl A. Latkin1, Oliver Laeyendecker1, Thomas Quinn1, William Clarke1
   1The Johns Hopkins Univ, Baltimore, MD, USA, 2Maryland DHMH, Baltimore, MD, USA, 3NIAID, Baltimore, MD, USA

905  SPATIAL VARIATION ALONG THE HIV CARE CONTINUUM IN WASHINGTON, DC, 2014–2015
   Arpi Terzian1, Naji Younes1, Jenevieve Opoku1, Johnathan Hubbard1, Rena R. Jones2, Princy Kumar3, Amanda D. Castel4, for the The DC Cohort Executive Committee
   1The George Washington Univ, Washington, DC, USA, 2District of Columbia Dept of Hlth, Washington, DC, USA, 3NCI, Bethesda, MD, USA

906  TRENDS AND DISPARITIES IN ART USE AMONG PERSONS WITH HIV IN SAN FRANCISCO, 2006–2015
   Ling Hsu1, Sandy Schwarcz2, Susan Scheer1
   1San Francisco Dept of Pub Hlth, San Francisco, CA, USA

907  CARE CONSTANCY AND VIRAL SUPPRESSION AMONG ADULTS IN HIV CLINICAL CARE, UNITED STATES
   Heather Bradley, Kate Buchacz, Yunfeng Tie, Oluwatosin Olayi, R. L. Shouse
   CDC, Atlanta, GA, USA
908 BEYOND THE STATIC HIV CONTINUUM: CAPTURING THE DYNAMIC PROCESS OF RETENTION

Hana Lee1, Xiaotian Wu1, Michael J. Mugavero2, Stephen R. Cole3, Bryan Lau1, Becky L. Genberg1, Joseph Hogan1
1Brown Univ, Providence, RI, USA, 2Univ of Alabama at Birmingham, Birmingham, AL, USA, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4The Johns Hopkins Univ, Baltimore, MD, USA

909 ASSOCIATION BETWEEN 4 MEASURES OF RETENTION IN CARE AND VIROLOGIC FAILURE

Mariah M. Kalmin, Amanda D. Castel, Alan Greenberg, Heather Young, Heather Hoffman, for the DC Cohort Executive Committee
George Washington Univ, Washington, DC, USA

910 USING SURVEILLANCE DATA TO MEASURE PROGRESS ALONG THE HIV CARE CONTINUUM

Nancy A. Hessol1, Ling Hsu2, Sharon Pipkin2, Susan Scheer2
1Univ of California San Francisco, San Francisco, CA, USA, 2San Francisco Dept of Pub Hlth, San Francisco, CA, USA

911 IMPROVED HIV CARE OUTCOMES FOR INMATES REFERRED TO COMMUNITY PROGRAMS IN PHILADELPHIA

Makeda Carroll1, Tanner Nassau1, Melissa Miller1, Cody Poerio2, Hannah Zellman1, Bruce Herdman1, Coleman Terrell1, Kathleen Brady1

912 HEALTH LITERACY AND DEMOGRAPHIC DISPARITIES IN HIV-1 VIRAL SUPPRESSION

Peter F Rebeiro1, Tristan McPherson2, Kathryn Goggins1, Megan M. Turner1, Sally S. Bebawy1, Lauren Brinkley-Rubinstein1, Anna K. Person1, Timothy R. Sterling1, Sunil Kripalani3, April C. Pettit1
1Vanderbilt Univ, Nashville, TN, USA, 2Columbia Univ, New York, NY, USA, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

913 FOOD INSECURITY AND HIV TREATMENT OUTCOMES IN THE WOMEN’S INTERAGENCY HIV STUDY

Sheri Weiser1, Lila A. Sheira1, Kartika Palar1, Tracey Wilson1, Lisa Metsch3, Adaora Adimora4, Igbo Ofotokun1, Eryka Wentz4, Phyllis Tien3, Edward A. Frongillo3
1Univ of California San Francisco, San Francisco, CA, USA, 2SUNY Downstate Med Cntr, Brooklyn, NY, USA, 3Columbia Univ, New York, NY, USA, 4Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 5Emory Univ, Atlanta, GA, USA, 6The Johns Hopkins Univ, Baltimore, MD, USA, 7Univ of South Carolina, Columbia, SC, USA

914 HIV STATUS AWARENESS AND ART COVERAGE AMONG FEMALE SEX WORKERS IN JUBA, SOUTH SUDAN

Avi Hakim1, Victoria Achut1, Alfred Okiria2, Alex Bolo1, Jennifer Wesson4, Joel Katoro1, Golda Caeser1, Acaga Taban1, Lee Hundley7
1South Sudan Ministry of Hlth, Juba, South Sudan, 2IntraHlth Intl, Juba, South Sudan, 3CDC–South Sudan, Juba, South Sudan, 4IntraHlth Intl, Chapel Hill, NC, USA, 5Emory Univ, Atlanta, USA
915 “TEST AND TREAT” ANTIRETROVIRAL THERAPY AMONG FEMALE SEX WORKERS IN KAMPALA, UGANDA
Yunia Mayanja, Onesmus Kamacooko, Daniel Bagiire, Gertrude Namale, Janet Seeley
MRC/UVRI Uganda Rsr Unit on AIDS, Entebbe, Uganda

916 VALIDATING SELF-REPORTED USE OF ANTIRETROVIRAL THERAPY IN AGINCOURT, SOUTH AFRICA
1Beth Israel Deaconess Med Cntr, Boston, MA, USA, 2Harvard Univ, Cambridge, MA, USA, 3Tshwane Hosp, Pretoria, South Africa, 4Univ of the Witwatersrand, Johannesburg, South Africa, 5Univ of the Witwatersrand, Johannesburg, South Africa, 6Heidelberg Univ, Heidelberg, Germany

917 REDUCING THE DEMAND FOR VIRAL-LOAD MONITORING IN THE CONTEXT OF TREATMENT FOR ALL
Denise Evans1, Mouhamed Abdou Salam Mbengue1, Dorina Onoya1, Charles Chasela1, Matthew Fox1
1Univ of the Witwatersrand, Johannesburg, South Africa, 2Boston Univ, Boston, MA, USA

Poster P-U1 STRATEGIES TO INCREASE HIV TESTING
Poster Hall - 4 EF
2:30 PM - 4:00 PM

956 A PRAGMATIC RANDOMIZED CLINICAL TRIAL OF RAPID HIV SCREENING IN EMERGENCY DEPARTMENTS
Jason Haukoos1, Michael S. Lyons2, Douglas A. White2, Emily Hopkins1, Meggan Buossi1, Sarah Pfeifer1, Andrew Ruffner1, Danielle Signer1, Richard Rothman1, for the HIV TESTED Trial Investigators
1Denver Hlth Med Cntr, Denver, CO, USA, 2Univ of Cincinnati Coll of Med, Cincinnati, OH, USA

957 OPT-OUT HIV/HCV TESTING AMONG JAIL INMATES
Carolina De La Flor1, Esmaeil Porsa2, Ank E. Nijhawan1
1Univ of Texas Southwestern Med Cntr, Dallas, TX, USA, 2Parkland Hlth and Hosp Systems, Dallas, TX, USA

958 STRENGTHENING MALE-PARTNER TESTING IN ANTENATAL CARE: FINDINGS FROM SOUTH AFRICA
Amy M. Medley1, Nienke van Schaik3, Carlos Toledo3, Makungureyi Mlambo1, Sello Moremi2, Kabelo Baloyi1, Nompumelelo Khanyile3, Sphindile Magwaza3, Cila Kabongo4, John Tumbo4
1CDC, Atlanta, GA, USA, 2Hlth Systems Trust, Durban, South Africa, 3US CDC, Pretoria, South Africa, 4Rustenburg Sub-District Office, Rustenburg, South Africa

959 HPTN 071 HOME-BASED TESTING IMPROVES UPTAKE OF HCT AMONG PREGNANT WOMEN IN ZAMBIA
Stable Besa1, Ab Schaap1, Mwate J. Chaila1, S. Floyd2, Richard Hayes2, Sarah Fidler3, Kwame Shanaube1, H. Ayles4, for the Zambart Study Group
DOES HIV TREATMENT AVAILABILITY ENCOURAGE PEOPLE TO LEARN THEIR HIV STATUS?

Ellen Moscoe¹, Jacob Bor², Frank Tanser³, Deenan Pillay⁴, Till Baernighausen⁵

¹Harvard Univ, Boston, MA, USA, ²Boston Univ, Boston, MA, USA, ³Africa Cntr for Pop Hlth, Mtubatuba, South Africa, ⁴Africa Hlth Rsr Inst, Mtubatuba, South Africa, ⁵Heidelberg Univ, Heidelberg, Germany

997 HIV TESTING, LINKAGE TO CARE, AND VIRAL SUPPRESSION AMONG GAY MEN IN NIGERIA

Habib R. Omari¹, Uchenna Ononaku², Rebecca G. Nowak¹, Ifeanyi Orazulike¹, Trevor Crowell¹, Nicaise Ndembì¹, Hongjie Liu¹, Stefan Baral⁶, Man Charurat¹

¹Univ of Maryland, Baltimore, MD, USA, ²Inst of Human Virology Nigeria, Abuja, Nigeria, ³Univ of California Berkeley, Berkeley, CA, USA, ⁴US Military HIV Rsr Prog, Bethesda, MD, USA, ⁵Univ of California Berkeley, Berkeley, CA, USA, ⁶The Johns Hopkins Univ, Baltimore, MD, USA

998 ART INITIATION AND RETENTION IN AFTER-HOUR VERSUS DAILY MALE HEALTH CLINICS

Tali Cassidy¹, Amir Shroufi¹, Sarah Jane Steele¹, Morna Cornell¹, Virginia de Azevedo¹, David Binza¹, Rodd Gerstenhaber¹

¹Médecins Sans Frontières, Cape Town, South Africa, ²Univ of Cape Town, Cape Town, South Africa, ³City of Cape Town Dept of Hlth, Cape Town, South Africa, ⁴Western Cape Provincial Dept of Hlth, Cape Town, South Africa

999 THE IMPACT OF CARE NAVIGATORS ON ENGAGEMENT IN HIV CARE IN WESTERN KENYA

Becky L. Genberg¹, Violet Naanyu¹, Alfred Keter¹, Anthony Ngeresa³, Juddy Wachira¹, Joseph Hoganc¹, Paula Braitsb¹

¹Brown Univ, Providence, RI, USA, ²Moi Univ, Eldoret, Kenya, ³Academic Model Providing Access to Hlthcare, Eldoret, Kenya, ⁴Univ of Toronto, Toronto, Canada

1000 IMPROVED RETENTION WITH LONGER FOLLOW-UP INTERVALS FOR STABLE PATIENTS IN ZAMBIA

Aaloke Mody¹, Nancy Padian¹, Nancy Czaicki¹, Monika Roy¹, Carolyn Bolton Moore¹, Charles Holmes¹, Elvin Geng¹, Izuokanj Sikazwe⁵

¹Univ of California San Francisco, San Francisco, CA, USA, ²Univ of California Berkeley, Berkeley, CA, USA, ³Univ of Alabama at Birmingham—CIDRZ, Lusaka, Zambia, ⁴The Johns Hopkins Univ—CIDRZ, Bethesda, MD, USA, ⁵Cntr for Infectious Disease Rsr in Zambia, Lusaka, Zambia

1001 EXPERIENCES WITH RETENTION IN CARE AND VIRAL SUPPRESSION IN A PHARMACY REFILL PROGRAM

Arvind Kaimal¹, Barbara Castelnuovo¹, Martha Atwine¹, Rachel Musomba¹, Maria S. Nabaggala¹, Rosalind P. Rтанshti¹, Mohammed Lamorde¹

¹Makerere Univ, Kampala, Uganda, ²Univ of Cambridge, Cambridge, UK

1002 VIROLOGIC OUTCOMES WHEN ANTIRETROVIRAL THERAPY IS USED FOR PREVENTION: HPTN 052

Jessica M. Fogel¹, Xinyi C. Zhang¹, Estelle Piwowar-Manning¹, Nagalingeswaran Kumarasamy¹, James G. Hakim¹, Beatriz Grinsztejn¹, Ying Q. Chen¹, Myron S. Cohen¹, Susan H. Eshleman¹, for the HPTN 052 Study Team

¹The Johns Hopkins Univ Sch of Med, Baltimore, MD, USA, ²Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ³YRG CARE, Chennai, India, ⁴Univ of Zimbabwe, Harare, Zimbabwe, ⁵Inst de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil, ⁶Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1003 USERS MAY LACK CONFIDENCE IN ART FOR HIV PREVENTION: A QUALITATIVE ANALYSIS

Monique A. Wyatt1, Emily E Pisarski1, Jared Baeten2, Renee Heffron2, Edith Nakku-Joloba3, Timothy R. Muwonge4, Elly T Katabira1, Connie L. Celum5, Norma C. Ware6

1Harvard Univ, Boston, MA, USA, 2Univ of Washington, Seattle, WA, USA, 3Makerere Univ, Kampala, Uganda, 4Infectious Diseases Inst, Kampala, Uganda

1004 UPTAKE AND ADAPTATION OF COMMUNITY ADHERENCE GROUPS IN ZAMBIA

Monika Roy1, Mpande Mukumbwa-Mwenechanya1, Emilie Efronson2, Mwansa Lumpa3, Anjali Sharma2, Izukanji Sikazwe2, Nancy Padian3, Carolyn Bolton Moore4, Elvin Geng1, Charles Holmes5

1Univ of California San Francisco, San Francisco, CA, USA, 2Univ of Washington, Seattle, WA, USA, 3Univ of California Berkeley, Berkeley, CA, USA, 4Cntr for Infectious Disease Rsr in Zambia, Lusaka, Zambia, 5Johns Hopkins Univ, Baltimore, MD, USA

1005 ASSESSING RETENTION IN A CLUSTER RANDOMIZED TRAIL TO ACCELERATE ART INITIATION

Richard Katuramu1, Fred Semitala2, Gideon Amanyire1, Jennifer Namusobya1, Leatitia Kampiire1, Jeanna Wallenta1, David Glidden2, Moses R. Kamya3, Diane V. Havlir2, Elvin Geng3

1Makerere Univ Joint AIDS Prog, Kampala, Uganda, 2Makerere Univ Coll of Hlth Scis, Kampala, Uganda, 3Univ of California San Francisco, San Francisco, CA, USA

1006 LOWER RETENTION IN CARE WHEN ART IS INITIATED WITH CD4 ≥ 500 CELLS/ML

Isabelle A. Meyer-Andrieux1, Jim Todd2, Robert Keango1, Elisabeth Poulet1, Prince Nkhoma3, Elisabeth Szumilin4, David Maman5, Leon Salumu4

1MSF, Geneva, Switzerland, 2London Sch of Hygiene & Trop Med, London, UK, 3MSF, Lilongwe, Malawi, 4MSF, Paris, France, 5Epicentre, Cape Town, South Africa

1007 ART INITIATION FOR NEWLY DIAGNOSED PLHIV: IMPLICATIONS FOR TEST & TREAT, SOUTH AFRICA

Anna Larsen1, Mireille Cheyip1, Abraham Tesfay1, Peter Vranken1, Henry Fomundam2, Anthony Wuoth3, Getahun Aynalem4

1US CDC, Pretoria, South Africa, 2Howard Univ, Pretoria, South Africa

1008 TREATMENT NEED AND FAST-TRACK ART IN THE BOTSWANA COMBINATION PREVENTION PROJECT

Refeletswe Lebelonyane1, Lisa A. Mills3, Joe Theu1, Lisa Block1, Michael Kasonde1, Tony Chebani1, Shenaz el-Halabi1, Elliot Raizes1, Shahin Lockman1, Joseph N. Jarvis2

1Botswana Ministry of Hlth, Gaborone, Botswana, 2CDC Botswana, Gaborone, Botswana, 3CDC Atlanta, Atlanta, USA, 4Harvard Univ, Boston, MA, USA
1009 LINKAGE TO CARE OUTCOMES IN THE BOTSWANA COMBINATION PREVENTION PROJECT
Mary Grace Alwano1, Pamela J. Bachanas1, Catherine Motswere1, Tafireyi Marukutira1, Baraedi W Sento1, Nokuthula Majingo1, Shahin Lockman1, Molly Pretorius Holme1, Huisheng Wang2, Janet Moore3
1US CDC, Gaborone, Botswana, 2CDC, Atlanta, GA, USA, 3Tebelapele HIV Testing and Counseling Ctr, Gaborone, Botswana, 4Ministry of Hlth, Gaborone, Botswana, 5Harvard Univ, Boston, MA, USA, 6Northrup Grumman, Atlanta, GA, USA

1010 ART COVERAGE AFTER 2 YEARS OF A UTT INTERVENTION IN ZAMBIA: FINDINGS FROM HPTN071
Sian Floyd1, Mwelwa Phiri2, Ab Schaap3, David Macleod3, Kwame Shanaube2, Sam Griffith1, Nulda Beyers3, Richard Hayes1, Sarah Fidler1, Helen Ayles2

1011 REACHING 90-90-90? FINDINGS AFTER 2 YEARS OF HPTN 071 (PopART) INTERVENTION IN ZAMBIA
Richard Hayes1, S. Floyd1, Ab Schaap2, Kwame Shanaube3, Peter Bock3, Sam Griffith1, Nulda Beyers1, H. Ayles2, Sarah Fidler4, for the HPTN 071 (PopART) Study Team

1012 HEALTH CARE COVERAGE AND VIRAL SUPPRESSION PRE- AND POST-ACA IMPLEMENTATION
Heather Bradley1, Joseph Prejean1, Lindsey Dawson2, Antigone Dempsey1, Jennifer Kates3, Pamela W. Klein4, R. L. Shouse5
1CDC, Atlanta, GA, USA, 2Kaiser Family Fndn, Washington, DC, USA, 3HRSA, HIV/ AIDS Bureau, Rockville, MD, USA

1013 HOUSING STABILITY IS ASSOCIATED WITH HIV VIRAL SUPPRESSION IN A HOUSING PLACEMENT RCT
Yaoyu Zhong1, Ellen Wiewel1, Vivian L. Towe2, Rachel Johnson1, Laura McAllister-Hollod1, Joanne Hsu1, Sarah Braunstein1, John Rojas1
1New York City DHMH, Long Island City, NY, USA, 2RAND Corporation, Arlington, VA, USA

1014 ADVANCING “TASP” USING A MEDICAL-CARE COORDINATION MODEL IN LOS ANGELES COUNTY
Wendy H. Garland, Sonali P. Kulkarni
Los Angeles County, Los Angeles, CA, USA

Poster P-W4 ADVANCED HIV AND LONG-TERM CARE
Poster Hall - 4 EF 2:30 PM - 4:00 PM

1019 FACTORS ASSOCIATED WITH LATE PRESENTATION FOR HIV CARE IN SOUTH AFRICA
Henry Fomundam1, Abraham Tesfay1, Shelter Mushipe1, Myriam Mosina1, Carol Boshiele1, Hanson Tebe1, Anna Larsen2, Mireille Cheyip2, Getahun Aynalem2, Yogan Pillay3
1Howard Univ, Pretoria, South Africa, 2US CDC, Pretoria, South Africa, 3South African Natl Dept of Hlth, Pretoria, South Africa
1020 SOUTH AFRICA’S NATIONAL THIRD-LINE ART COHORT: DESCRIPTIVE ANALYSIS
Francesca Conradie1, Matthew Fox2, Michelle A. Moorhouse1, Gary Maartens1, Willem D. Venter1, Mahomed-Yunus Moosa4, Khadija Jamaloodien6
1Univ of the Witwatersrand, Johannesburg, South Africa, 2Boston Univ, Boston, MA, 3Univ of Cape Town, Cape Town, South Africa, 4Univ of KwaZulu-Natal, Durban, South Africa, 5South African Natl Dept of Hlth, Pretoria, South Africa

1021 “I WON’T DIE WITH THE CAUSE OF AIDS”: 10 YEARS ON ART IN SOUTH AFRICA’S HIV PROGRAM
Cheryl J. Hendrickson1, Sophie Pascoe1, Aneesa Moolla1, Mhairi Maskew1, Matthew Fox2
1Univ of the Witwatersrand, Johannesburg, South Africa, 2Boston Univ, Boston, MA

1022 OUTCOMES OF AHI SCREENING AND IMMEDIATE ART INITIATION IN COASTAL KENYA
Edward Sanders1, Oscar Chirro2, Juma Mangi2, Elizabeth Wahome2, Matt A. Price1, Huub C. Gelderblom3, Elisabeth M. van der Elst4, Susan M. Graham5

1023 TEN YEARS OF SUPPORTING SCALE-UP OF HIV CARE AND EXPANSION OF ART IN 4 COUNTRIES
Chloe A. Teasdale1, Chunhui Wang, Jessica E. Justman, David Hoos, Mark Hawken, Zenebe Melaku, Antonio Mussa, Wafaa M. El-Sadr, Elaine J. Abrams
ICAP at Columbia Univ, New York, NY, USA

Poster P-X2 COST-EFFECTIVENESS OF HIV TESTING AND SCREENING STRATEGIES
Poster Hall - 4 EF 2:30 PM - 4:00 PM

1028 EFFECTIVENESS AND COST-EFFECTIVENESS OF HIV SCREENING STRATEGIES ACROSS EUROPE
Guillaume Mabileau1, Julia Del Amo2, Kristi Rüütel1, A. David Paltiel1, Liis Lemsalu1, Asunción Díaz2, Jesús Martín Fernández2, Rochelle P. Walensky3, Kenneth Freedberg4, Yazdan Yazdanpanah5
1INSERM, Paris, France, 2Inst of Hlth Carlos III, Madrid, Spain, 3Natl Inst for Hlth Development, Tallinn, Estonia, 4Yale SPH, New Haven, CT, USA, 5Univ Rey Juan Carlos, Madrid, Spain, 6Massachusetts General Hosp, Boston, MA, USA

1029 COST-EFFECTIVENESS OF HIV SCREENING OF HETEROSEXUALS IN THE UNITED STATES
Angela B. Hutchinson1, Katherine A. Hicks2, Emine Yaylali1, Emily Tucker1, Evin Jacobson1, Stephanie L. Sansom1
1CDC, Atlanta, GA, USA, 2RTI Hlth Solutions, Rsr Triangle Park, NC, USA, 3Univ of Michigan, Ann Arbor, MI, USA
1030  COST-EFFECTIVENESS OF DIFFERENT DELIVERY APPROACHES FOR HIV SELF-TESTING
Valentina Cambiano\textsuperscript{1}, Cheryl Johnson\textsuperscript{1}, Carmen Figueroa\textsuperscript{2}, Paul Revill\textsuperscript{3}, Rachel Baggage\textsuperscript{2}, Elizabeth L. Corbett\textsuperscript{2}, Tsitsi Apollo\textsuperscript{2}, Karin Hatzold\textsuperscript{2}, Frances Cowan\textsuperscript{2}, Andrew Phillips\textsuperscript{1}
\textsuperscript{1}Univ Coll London, London, UK, \textsuperscript{2}WHO, Geneva, Switzerland, \textsuperscript{3}Univ of York, York, UK, \textsuperscript{4}London Sch of Hygiene & Trop Med, London, UK, \textsuperscript{5}Zimbabwe Ministry of Hlth and Child Care, Harare, Zimbabwe, \textsuperscript{6}Pop ServicesIntl, Harare, Zimbabwe, \textsuperscript{7}Cntr for Sexual Hlth and HIV/AIDS Rsr, Harare, Zimbabwe

1031  THE COST OF NOT RETESTING: HIV MISDIAGNOSIS IN THE ART “TEST-AND-OFFER” ERA
Jeffrey Eaton\textsuperscript{1}, Cheryl Johnson\textsuperscript{2}, Simon Gregson\textsuperscript{1}
\textsuperscript{1}Imperial Coll London, London, UK, \textsuperscript{2}WHO, Geneva, Switzerland

1032  MODELING THE COST-EFFECTIVENESS OF ASSISTED PARTNER NOTIFICATION FOR HIV IN KENYA
Monisha Sharma\textsuperscript{1}, Jennifer Smith\textsuperscript{2}, Carey Farquhar\textsuperscript{1}, Roger Ying\textsuperscript{1}, Peter Cherutich\textsuperscript{1}, Beatrice Wamuti\textsuperscript{1}, Matthew R. Golden\textsuperscript{1}, Felix Abuna\textsuperscript{2}, Ruanne V. Barnabas\textsuperscript{2}
\textsuperscript{1}Univ of Washington, Seattle, WA, USA, \textsuperscript{2}Imperial Coll London, London, UK

1054  CHARACTERIZATION OF MORE THAN 10,000 ZIKA VIRUS TEST RESULTS IN THE US
Joseph M. Volpe\textsuperscript{1}, Dajie Luo\textsuperscript{1}, Arren Fisher\textsuperscript{1}, Mindy Nye\textsuperscript{1}, Barbara Body\textsuperscript{1}, Marcia Eisenberg\textsuperscript{1}
\textsuperscript{1}LabCorp, Durham, NC, USA, \textsuperscript{2}LabCorp, Burlington, NC, USA

1055LB  ZIKA VIRUS PERSISTENCE IN BODY FLUIDS
Gabriela Paz-Bailey\textsuperscript{1}, Eli Rosenberg\textsuperscript{1}, Katherine Doyle\textsuperscript{1}, Jorge Munoz-Jordan\textsuperscript{1}, Gilberto Santiago\textsuperscript{1}, Liore Klein\textsuperscript{2}, Janice Perez\textsuperscript{2}, Stephen Waterman\textsuperscript{1}, Luisa Alvarado\textsuperscript{1}, Tyler Sharp\textsuperscript{1}
\textsuperscript{1}CDC, Atlanta, GA, USA, \textsuperscript{2}Emory Univ, Atlanta, GA, USA, \textsuperscript{3}Caduceus Healthcare Inc, Ponce, PR, USA, \textsuperscript{4}Ponce Univ, Ponce, PR, USA

1056LB  NEUROLOGIC CONSEQUENCES OF POSTNATAL ZIKA VIRUS INFECTION IN INFANTS
Maud Mavigner\textsuperscript{1}, Justin O’Neal\textsuperscript{2}, Siddhartha Bhamuk\textsuperscript{1}, Jakob Habib\textsuperscript{1}, Cameron Robinson\textsuperscript{1}, Maria Alvarado\textsuperscript{1}, Xiaodong Zhang\textsuperscript{1}, Jens Wrammert\textsuperscript{1}, Mehul Suthar\textsuperscript{1}, Ann Chahroudi\textsuperscript{1}
\textsuperscript{1}Emory Univ, Atlanta, GA, USA, \textsuperscript{2}Emory Vaccine Center, Atlanta, GA, USA, \textsuperscript{3}Yerkes Natl Primate Rsr Ctr, Atlanta, GA, USA

1057LB  ZIKA VIRUS PROTECTION BY A SINGLE LOW-DOSE NUCLEOSIDE-MODIFIED mRNA VACCINATION
Michael J. Hogan\textsuperscript{1}, Norbert Pardi\textsuperscript{1}, Rebecca S. Pelc\textsuperscript{1}, Hanne Anderson\textsuperscript{1}, Charles McGee\textsuperscript{1}, Michael J. Hope\textsuperscript{1}, Mark G. Lewis\textsuperscript{1}, Theodore C. Pierson\textsuperscript{1}, Barton F. Haynes\textsuperscript{1}, Drew Weissman\textsuperscript{1}
\textsuperscript{1}Univ of Pennsylvania, Philadelphia, PA, USA, \textsuperscript{2}NIADC, Bethesda, MD, USA, \textsuperscript{3}Bioqual, Inc, Rockville, MD, USA, \textsuperscript{4}Duke Univ, Durham, NC, USA, \textsuperscript{5}Acuitas Therapeutics, Vancouver, BC, Canada
161  UBP43 (USP18) ABROGATES SAMHD1-MEDIATED RESTRICTION OF HIV-1

Edmund Osei-Kuffour1, Kerstin Schott2, Dieter Häussinger3, Philipp A Lang1, Karl S. Lang1, Renate König1, Carsten Münk1
1Heinrich Heine Univ Hosp, Düsseldorf, Germany, 2Paul Ehrlich Institut, Fed Inst for Vaccines and BioMeds, Düsseldorf, Germany, 3Univ Hosp, Essen, Düsseldorf, Germany, 2Paul Ehrlich Institut, Langen, Germany

162  LNCRNA DISCOVERY IN THE HIV REPLICATION CYCLE ADDS A NEW LAYER IN HIV-HOST INTERPLAY

Wim Tryptsteen1, Pejman Mohammadi2, Clarissa Van Hecke1, Pieter Mestdagh1, Steve Lefever1, Pieter De Bleser1, Jo Vandesompele1, Angela Ciuffi1, Ward De Spieghelaere3, Linos Vandekerckhove1
1Ghent Univ, Ghent, Belgium, 2Univ of Lausanne, Lausanne, Switzerland, 3Inflammation Rsr Cntr, Flanders Inst of BioTech, Ghent, Belgium

163  SPlicing in a panel of HIV-1 transmitted/founder viruses

Ann Emery, Ronald Swanstrom
Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

164  the roles of 5 conserved lentiviral RNA structures in HIV-1 replication

Yang Liu1, Olga A. Nikolaitchik1, Belete A. Desimmie1, Vinay K. Pathak1, Kevin M. Weeks2, Wei-Shau Hu1
1NCI, Frederick, MD, USA, 2Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

165  exponential growth of HIV dependent on burst size breakthrough of the Allee threshold

Jason M. Hataye1, Joseph P. Casazza1, David R. Ambrozak1, Takuya Yamamoto1, Daniel Douek1, Alan S. Perelson2, Richard A. Koup1
1NIH, Bethesda, MD, USA, 2Osaka Univ, Sukta, Osaka, Japan, 3NIAID, Bethesda, MD, USA, 4Los Alamos Natl Lab, Los Alamos, NM, USA

172  characterizing APOBEC3H function and evolution in African green monkeys

Erin I. Garcia1, Michael Emerman2
1Univ of Washington, Seattle, WA, USA, 2Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA

173  mapping the HIV-1 VIF-CBFβ interaction interface and identification of determinants

Belete A. Desimmie1, Jessica Smith1, Hiroshi Matsuo1, Wei-Shau Hu1, Vinay K. Pathak1
1NCI, Frederick, MD, USA, 2Univ of Minnesota, Minneapolis, MN, USA

174  the ability of HIV-1 to evade SAMHD1-mediated restriction in macrophage

Timothy Plitnik, Mark Sharkey, Mario Stevenson
Univ of Miami, Miami, FL, USA
175 MHC DOWN-MODULATION IN HIV-INFECTED CELLS OCCURS LATE IN THE VIRUS REPLICATIVE CYCLE
Rodrigo Matus Nicodemos, Daniel Douek, Richard A. Koup
Vaccine Rsr Cntr, NIAID, Bethesda, MD, USA

Poster P-B2 VIRAL DIVERSITY
Poster Hall - 4 EF
2:30 PM - 4:00 PM

191 ESTIMATING THE HERITABILITY OF AN HIV-1 TRAIT IN A CLINICAL SETTING
Nadine Bachmann1, Teja Turk1, Alex Marzel1, Claus Kadelka2, Thomas Klimkait3, Vincent Aubert1, Jürg Böni2, Huldrych F. Günthard1, Roger Koyou2
1Univ Hosp Zurich, Zurich, Switzerland, 2Univ of Zurich, Zurich, Switzerland, 3Dept of Biomed, Basel, Switzerland, 4Univ Hosp Lausanne, Lausanne, Switzerland

192 NGS ANALYSIS OF HIV-1 GROUP O RT RESIDUE 181C PREVALENCE AND EVOLUTION OVER TIME
Marie Leoz1, Myriam Vezain2, Elodie Alessandri3, Sophie Coutant4, Guillelmette Unal1, Isabelle Tournier3, Francois Simon5, Jean-Christophe Plantier1
1Rouen Univ Hosp, Rouen, France, 2Normandie Univ, Rouen, France, 3COREVIH Haute-Normandie, Rouen, France, 4Saint Louis Hosp, Paris, France

193 ANALYSIS OF NEARLY FULL-GENOME HIV-1 SEQUENCES FROM UGANDA: RESULTS FROM PANGEA_HIV
Gonzalo Yebra1, Deogratius Ssemwanga2, Dan Frampton3, Brian Magambo4, Nicholas Bbosa4, Frederick Lyagoba2, Rebecca N. Nsubuga2, Pontiano Kaleebu1, Andrew Leigh Brown4, for the PANGEA HIV Consortium
1Univ of Edinburgh, Edinburgh, UK, 2MRC Uganda Virus Rsr Inst, Entebbe, Uganda, 3Farr Inst of Hlth Informatics Rsr, London, UK

194 LTR GENETIC DIVERSITY AMONG HIV-2 ARV-NAÏVE PATIENTS IN THE ANRS CO5 HIV-2 COHORT
Quentin Le Hingrat1, Benoit Visseaux1, Melanie Bertine1, Fideline Collin2, Florence Damond1, Olivier Schwartz1, Sophie Matheron1, Diane Descamps1, Charlotte Charpentier1, for the ANRS HIV-2 CO5 Cohort
1Bichat Hosp, Paris, France, 2INSM, Bordeaux, France, 3Inst Pasteur, Paris, France

195 PHYLOGEOGRAPHIC STUDY OF HIV-2 GROUPS A AND B EARLY EPIDEMICS IN WESTERN AFRICA
Benoit Visseaux1, Stéphane Hue2, Florence Damond1, Fideline Collin2, Alexandre Storto1, Genevieve Chene1, Sophie Matheron1, Charlotte Charpentier1, Diane Descamps1, for the French ANRS COS HIV-2 Cohort
202 FEW ACUTE HIV-1 SYMPTOMS AND HIGH SET-POINT VIRAL LOAD IN SUBTYPE-C INFECTIONS

Amin S. Hassan1, Jonathan Hare2, Matt A. Price3, Per Bjorkman4, Susan Allen5, Jill Gilmour6, Thumbi Ndung’u7, Sarah Rowland-Jones8, Eduard Sanders9, Joakim Esbjörnsson10


203 GRANULOCYTIC MYELOID-DERIVED SUPPRESSOR CELLS IN PRIMARY HIV INFECTION

Nicola Tumino, Maria Teresa Bilotta, Adriana Ammassari, Annalisa Mondi, Casetti Rita, Veronica Bordoni, Eleonora Cimini, Federico Martini, Chiara Agrati, Sacchi Alessandra

Nat I Inst for Infectious Diseases Lazzaro Spallanzani, Rome, Italy

204 HIV-1 EXPLOITS THE INTERPLAY BETWEEN EPITHELIAL AND TH17 CELLS FOR DISSEMINATION

Tomas Raul Wiche Salinas1, Annie Gosselin1, Dragos Vlad1, Yuwei Zhang1, Huicheng Chen1, Cécile Tremblay1, Jean-Pierre Routy1, Petronela Ancuta1

1Cntr de Rsr du Cntr Hosp de l’Univ de Montréal, 2McGill Univ Hlth Cntr, Glen site, Montréal, Canada

205 PLASMA-SOLUBLE CD163 IS SUPPRESSED UPON EARLY ART INITIATION IN ACUTE HIV INFECTION

Michelle L. D’Antoni1, Somporn Tipsuk2, Shelly J. Krebs3, Thep Chalermchai4, Duangthai Suttichom5, Nittaya Phanuphak6, Victor Valcour6, Jintanat Ananworanich1, Lishomwa C. Ndhlouvi7, for the RV254/SEARCH 010, SEARCH013, and SEARCH011 Study Groups

1Univ of Hawaii, Honolulu, HI, USA, 2search, South East Asia Rsr Collab with Hawaii, Bangkok, Thailand, 3US Military HIV Rsr Prog, Silver Spring, MD, USA, 4Univ of California San Francisco, San Francisco, CA, USA

206 CMV REPLICATION DURING PRIMARY HIV INFECTION IS ASSOCIATED WITH T-CELL DYSFUNCTION

Jennifer M. Dan1, Antoine Chaillon2, Masato Nakazawa1, Davey M. Smith1, Milenka Vargas2, Rachel Schrier3, Susan J. Little1, Sara Gianella2

1Univ of California San Diego, La Jolla, CA, USA, 2Univ of California San Diego, San Diego, CA, USA

Poster P-C2 HOW DOES THE MICROBIOME AFFECT HIV INFECTION?

Poster Hall - 4 EF 2:30 PM - 4:00 PM

207 IMPACT OF MSM-ASSOCIATED MICROBIOTA ON IMMUNE ACTIVATION AND IN VITRO HIV INFECTION

Sam Li, Abigail Armstrong, Charles P. Neff, Catherine Lozupone, Brent E. Palmer

Univ of Colorado, Aurora, CO, USA

208 FECAL MICROBIOTA FROM HIV-INFECTED SUBJECTS INCREASES IMMUNE ACTIVATION AND INFECTION

Charles P. Neff, Sam Li, Abigail Armstrong, Catherine Lozupone, Brent E. Palmer

Univ of Colorado, Aurora, CO, USA
209 \textbf{MARAVIROC INHIBITS HIV TARGET T-CELL TRAFFICKING INTO THE FEMALE GENITAL LUMEN}
\textbf{Alison S. Kohlmeier}, \textsuperscript{1} Sean McMaster, \textsuperscript{1} Jessica Radzio, \textsuperscript{1} Mian-er Cong, \textsuperscript{1} Chuong Dinh, \textsuperscript{1} Amy Martin, \textsuperscript{1} Jacob E. Kohlmeier, \textsuperscript{1} Gerardo Garcia-Lerma
\textsuperscript{1}CDC, Atlanta, GA, USA, \textsuperscript{1}Emory Univ, Atlanta, GA, USA

210 \textbf{INVESTIGATING THE EFFECT OF PH ON CERVICOVAGINAL MUCUS BARRIER PROPERTIES TO HIV}
\textbf{Julie K. Shade}, Thuy Hoang, Kevin Delong, Justin Hanes, Richard Cone, Laura Ensign
\textit{The Johns Hopkins Univ, Baltimore, MD, USA}

\textbf{Poster P-C3 HIV INFECTION AND THE MICROBIOME}
\textbf{Poster Hall - 4 EF} 2:30 PM - 4:00 PM

211 \textbf{INFLAMMATORY GUT ILCs ASSOCIATE WITH DYSBIOSIS DURING UNTREATED HIV-1 INFECTION}
\textbf{Stephanie Dillon}, \textsuperscript{1} Daniel N. Frank, \textsuperscript{1} Gregory Austin, \textsuperscript{1} Sara Gianella, \textsuperscript{1} Moriah Castleman, \textsuperscript{1} Andrew Cogswell, \textsuperscript{1} Alan Landay, \textsuperscript{1} Edward Barker, \textsuperscript{1} Cara Wilson
\textsuperscript{1}Univ of Colorado Anschutz Med Campus, Aurora, CO, USA, \textsuperscript{1}Univ of California San Diego, La Jolla, CA, USA, \textsuperscript{1}Rush Univ, Chicago, IL, USA

212 \textbf{GUT-MICROBIOTA–RELATED METABOLIC PATHWAYS IN ELITE CONTROLLERS AND HIV PROGRESSORS}
\textbf{Piotr Nowak}, \textsuperscript{1} Javier Rivera, \textsuperscript{2} Jan Vesterbacka, \textsuperscript{1} Marc Noguera-Julian, \textsuperscript{1} Kaja Novaan, \textsuperscript{1} Maria L. Calle, \textsuperscript{1} Roger Paredes, \textsuperscript{4} Anders Sönnerborg
\textsuperscript{1}Karolinska Inst, Stockholm, Sweden, \textsuperscript{2}IrsiCaixa Inst for AIDS Rsr, Badalona, Spain, \textsuperscript{3}Univ of Vic—Central Univ of Catalonia, Barcelona, Spain, \textsuperscript{4}Karolinska Univ Hosp, Stockholm, Sweden

213 \textbf{CHANGES IN THE ORAL MICROBIOME WITH ART INITIATION}
\textbf{Rachel Presti}, \textsuperscript{1} Scott Handley, \textsuperscript{1} Lindsay Droit, \textsuperscript{1} Mahmoud Ghannoum, \textsuperscript{1} Mark Jacobson, \textsuperscript{1} Caroline H. Shiboski, \textsuperscript{1} Jennifer Webster-Cyriaque, \textsuperscript{1} Todd Brown, \textsuperscript{1} Michael T. Yin, \textsuperscript{2} Edgar T. Overton
\textsuperscript{1}Washington Univ in St. Louis, St. Louis, MO, USA, \textsuperscript{2}Washington Univ, St. Louis, MO, USA, \textsuperscript{3}Case Western Reserve Univ, Cleveland, OH, USA, \textsuperscript{4}Univ of California San Francisco, San Francisco, CA, USA, \textsuperscript{5}Univ of North Carolina at Chapel Hill, NC, USA, \textsuperscript{6}The Johns Hopkins Univ, Baltimore, MD, USA, \textsuperscript{7}Columbia Univ, New York, NY, USA, \textsuperscript{8}Univ of Alabama at Birmingham, Birmingham, AL, USA

214 \textbf{ACUTE HIV INFECTION AND HUMAN GUT MICROBIOME BEFORE AND AFTER ANTIRETROVIRAL THERAPY}
\textbf{Ornella Sortino}, \textsuperscript{1} Nittaya Phanuphak, \textsuperscript{1} Nitiya Chomchey, \textsuperscript{1} Yasmine Belkaid, \textsuperscript{1} Jacquice Davis, \textsuperscript{1} Mariam Quinones, \textsuperscript{1} Suteaporn Pinyakorn, \textsuperscript{1} Jintanat Ananworanich, \textsuperscript{1} Jason Brenchley, \textsuperscript{1} Irini Sereti
\textsuperscript{1}Leidos Biomed Rsr, Inc, Frederick, MD, USA, \textsuperscript{2}SEARCH, Thai Red Cross AIDS Rsr Ctr, Bangkok, Thailand, \textsuperscript{3}SEARCH, Bangkok, Thailand, \textsuperscript{4}NIAID, Bethesda, MD, USA, \textsuperscript{5}Henry M. Jackson Fndn for the Advancement of Military Med, Bethesda, MD, USA

215 \textbf{TWO-YEAR CART DOES NOT RESTORE PERIPHERAL BLOOD AND INTESTINAL HIV-RELATED DYSBIOSIS}
\textbf{Camilla Tincati}, \textbf{Giuseppe Ancona}, Esther Merlini, Antonella d’Arminio Monforte, Giulia Marchetti
\textit{Univ of Milan, Milan, Italy}
Poster Sessions • Wednesday

Program and Agenda

CROI 2017

Poster Sessions • Wednesday

126

Poster Hall - 4 EF

2:30 PM - 4:00 PM

266 LYMPH NODE HIV-SPECIFIC CXCR5+ CTLs ARE ASSOCIATED WITH ENHANCED VIRAL CONTROL

Zaza Ndhlovu1, Funsho Ogunshola2, Omolara Baiyegunhi2, Nikoshia Mewalal2, Amber Moodley2, Krista Dong1, Thumi Ndungu1, Bruce D. Walker1

1Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA, 2Univ of KwaZulu Natal, Durban, South Africa

267 RESIDENT MEMORY CD8+ T CELLS FORM THE FRONT-LINE DEFENSE IN HIV-INFECTED LYMPH NODES

Marcus Buggert1, Lalit Beura2, Son Nguyen1, David Canaday3, Ali Naji4, Constantinos Petras5, Gustavo Reyes-Terán4, Steven G. Deeks2, David Masopust6, Michael R. Betts1

1Univ of Pennsylvania, Philadelphia, PA, USA, 2Univ of Minnesota, Minneapolis, MN, USA, 3Case Western Reserve Univ, Cleveland, OH, USA, 4Hosp of the Univ of Pennsylvania, Philadelphia, PA, USA, 5NIH, Bethesda, MD, USA, 6Rsr Cntr in Infectious Diseases, Mexico City, Mexico, 7Univ of California San Francisco, San Francisco, CA, USA

268 HIV-1 ESCAPE FROM CD8+ CYTOTOXIC T-LYMPHOCYTES DEFINED AT CLONAL RESOLUTION

Aleksandr Gorin, Yushen Du, Ren Sun, Otto Yang

Univ of California Los Angeles, Los Angeles, CA, USA

269 INVESTIGATING THE ROLE OF TCR STRUCTURE IN FUNCTIONAL ACTIVITY OF HIV-SPECIFIC CTLs

Nina C. Flerin1, Tynisha Glover1, Huabiao Chen2, Jianhua Zheng1, Harris Goldstein1

1Albert Einstein Coll of Med, Bronx, NY, USA, 2Ragon Inst of Massachusetts General Hosp, Cambridge, MA, USA

270 HIV-SPECIFIC CD8 T CELLS IN PERSONS TREATED IN FIEBIG I ACUTE INFECTION WHO STOP ART

Hiroshi Takata1, Donn Colby2, Eugene Kroon1, Suteearporn Pinyakorn1, Nelson L. Michael1, Merlin L. Robbi1, Jintana Intasan2, Jintanat Anaworanich3, Lydie Trautmann1, for the RV411 and RV254/SEARCH010 Study Groups

1Walter Reed Army Inst of Rsr, Silver Spring, MD, USA, 2SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 3Walter Reed Army Inst of Rsr, Silver Spring, MD, USA, 4US Military HIV Rsr Prog, Silver Springs, MD, USA

271 EARLY CART OF HIV-1 INFECTED SUBJECTS PRESERVES ANTIVIRAL FUNCTION OF CD8+ T CELLS

Miriam Rosas Umbert1, Beatriz Mothe1, Gemma Hancock1, Hongbing Yang1, Christian Manzardo4, Josep Coll1, Christian Brander1, Lucy Dorrell1

1IrsiCaixa AIDS Rsr Inst, Badalona, Spain, 2Hosp Germans Trias i Pujol, Badalona, Spain, 3Univ of Oxford, Oxford, UK, 4Univ of Barcelona, Barcelona, Spain

272 ROLE OF CTL IN PEDIATRIC HIV CURE STRATEGIES FOLLOWING EARLY WIDESPREAD VIRAL ESCAPE

Ellen M. Leitman1, Christina F. Thobakgale2, M. Azim Ansari1, Jayna Raghwani3, Emily Adland1, Oliver Pybus1, Paul Kellam1, Philippa C. Matthews1, Astrid Gall1, Philip J. Goulder1

273 TRAIL-SHORT REDUCES THE CYTOTOXIC CAPACITY OF NK CELLS
Fatma Aboulnasr, Nathan Cummins, Zilin Nie, Stephen Burke, Andrew Badley
Mayo Clinic, Rochester, MN, USA

274 OF THE TB01 MOTIF KIR GENES, KIR3DS1 PLAYS ROLE IN HIV RESISTANCE & NK CELL FUNCTION
Zahra Kiani1, Elise Jackson1, Xin Yu Zhang1, Irene Lisovsky1, Benjamin Tallon1, Julie Bruneau1, Jean-Pierre Routy2, Nicole Bernard4
1McGill Univ, Montreal, Quebec, 2Univ of Montreal, Montreal, Canada, 3McGill Univ Hlth Cntr, Glen site, Montréal, Canada, 4Rsr Inst, McGill Univ Hlth Cntr, Montreal, Canada

275 NO RECOVERY OF VA7.2 MAIT CELLS AFTER THERAPEUTIC IMMUNISATION PLUS IL-2/GM-CSF/RHGH
Louise Greathed, Alexander Cocker, Anna Herasimtschuk, Sundhiya Mandalia, Peter Kelleher, Nesrina Imami
Imperial Coll London, London, UK

276 REDUCED CD161 EXPRESSION ON MAIT CELLS IN HIV-INFECTED SUBJECTS WITH IMMUNE FAILURE
Michael L. Freeman, Michael M. Lederman
Case Western Reserve Univ, Cleveland, OH, USA

288 CCR6+ RECTAL CD4+ T-CELLS ARE A SIGNIFICANT RESERVOIR ON ART
Jenny L. Anderson1, Gabriela Khoury1, Rémi Fromentin2, Nicolas Chomont1, Ma Somsouk1, Wendy Hartogensis1, Peter Bacchetti1, Paul Cameron1, Steven G. Deeks1, Sharon R. Lewin1
1Univ of Melbourne, Melbourne, Australia, 2Univ de Montréal, Montréal, Canada, 3Univ of California San Francisco, San Francisco, CA, USA

289 BLOOD CXCR3+ CD4 T CELLS ARE ENRICHED IN INDUCTIBLE REPLICATION-COMPETENT HIV
Riddhima Banga, Francesco Procopio, Matthias Cavassini, Giuseppe Pantaleo, Matthieu Perreau
Lausanne Univ Hosp, Lausanne, Switzerland

290 SKEWED DISTRIBUTION OF HIV-2 RESERVOIR WITH LIMITED INPUT OF CENTRAL MEMORY T CELLS
Assia Samri1, Charlotte Charpentier1, Mélanie Bertine2, Mariama Diallo1, Sophie Even1, Sophie Matheron1, Rodolphe Thiébaut1, Brigitte Autran2, Françoise Brun-Vezinet3, for the ANRS COS IMMUNOVOIR-2 Study Group
291 ALTERED STABILITY OF HIV-INFECTED MEMORY CELLS FOLLOWING VERY EARLY ART
Louise Leyre1, Jintanat Ananworanich2, Claire Vandergeeten3, Eugene Kroon4, Nittiya Chomchey5, Srijayat Akapirat5, Merlin L. Robb2, Nittaya Phanuphak1, Nicolas Chomont6, for the RV234/SEARCH010 and RV304 Study Groups
1Cntr de Rsr du Cntr Hosp de l’Univ de Montréal, Montréal, Québec, Canada 2US Military HIV Rsr Prgr, Silver Spring, MD, USA, 3Vaccine and Gene Therapy Inst, Port St Lucie, FL, US, 4SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 5Armed Forces Rsr Inst of Med Sci, Bangkok, Thailand, 6Univ de Montréal, Montreal, QC, Canada

Poster Sessions • Wednesday
Program and Agenda
CROI 2017

128

128 CR01 2017
312 STIMULATING THE RIG-I PATHWAY TO KILL LATENT HIV-INFECTED CELLS USING ACITRETIN

Peilin Li1, Philipp Kaiser1, Harry Lampiris1, Peggy Kim2, Steven A. Yukl1, Diane V Havlir1, Warner C. Greene4, Joseph K. Wong1

1San Francisco VA Med Cntr/Univ of California San Francisco, San Francisco, CA, USA, 2San Francisco VA Med Cntr, San Francisco, CA, USA, 3San Francisco General Hosp, Univ of California San Francisco, San Francisco, CA, USA, 4Gladstone Inst of Virology and Immunol, San Francisco, CA, USA

313 TLR7 AGONIST GS-986 MARKEDLY ACTIVATES T & B CELLS FROM ART-SUPPRESSED DONORS

Joshua C. Cyktor1, Anthony R. Cillo1, John Bui1, Joseph Hesselgesser2, Tomas Chilar1, Jeffrey Murry3, John Mellors1

1Univ of Pittsburgh, Pittsburgh, PA, USA, 2Gilead Scis, Foster City, PA, USA

314 TLR9 AGONIST TRIGGERS POTENT INTESTINAL ANTVIRAL RESPONSE IN HIV+ INDIVIDUALS ON ART

Astrid R. Krarup1, Mariane H. Schleimann1, Line K. Vibholm1, Mohamed Abdel Mohsen2, Anders K. Dige1, Lars Østergaard1, Thomas Benfield1, Satish K. Pillai2, Ole S. Søgaard1, Paul W. Denton1

1Aarhus Univ Hosp, Aarhus, Denmark, 2Blood Systems Rsr Inst, San Francisco, CA, USA, 3Copenhagen Univ Hosp, Hvidovre, Denmark

315 SMALL-MOLECULE INHIBITION OF INTRINSIC STRESS PATHWAYS REDUCES HIV TRANSCRIPTION

Andrew Timmons, Robert Siliciano, Cynthia K. Bullen
The Johns Hopkins Hosp, Baltimore, MD, USA

316 NNRTIS DECREASE HIV-1 PRODUCTION FROM RCD4+ T CELLS FOLLOWING LATENCY REVERSAL

Jennifer M. Zerbato1, Gilda Tachedjian2, Nicolas Sluis-Cremer1

1Univ of Pittsburgh, Pittsburgh, PA, USA, 2Burnet Inst, Melbourne, Australia

Poster P-E9 NEW TREATMENTS TO MODIFY THE HIV RESERVOIR
Poster Hall - 4 EF 2:30 PM - 4:00 PM

331 ENHANCEMENT OF THE CD4 CHIMERIC ANTIGEN RECEPTOR AGAINST HIV INFECTION

Anjie Zhen, Mayra A. Carrillo, Valerie Rezek, Scott G. Kitchen
Univ of California Los Angeles, Los Angeles, CA, USA

332 HEMATOPOIETIC STEM-CELL–BASED CHIMERIC ANTIGEN RECEPTOR THERAPY FOR HIV INFECTION

Anjie Zhen1, Christopher Peterson2, Mayra A. Carrillo1, Valerie Rezek1, Masakazu Kamata1, Jerome Zack1, Hans-Peter Kiern1, Scott G. Kitchen1

1Univ of California Los Angeles, Los Angeles, CA, USA, 2Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA

333 LENTIVIRAL DENDRITIC CELL VACCINE RAISES PROTECTIVE CTLS AND TARGETS LATENT HIV

Thomas D. Norton1, Anjie Zhen2, Takuya Tada1, Scott G. Kitchen2, Nathaniel R. Landau1

1New York Univ, New York, NY, USA, 2Univ of California Los Angeles, Los Angeles, CA, USA
**Self-activating vectors that express Vif-resistant APOBEC3G for HIV-1 gene therapy**

Krista Delviks-Frankenberry¹, Daniel Ackerman¹, Nina Timberlake², Maria Hamscher³, Olga A Nikolaitchik⁴, Wei-Shau Hu⁵, Bruce E. Torbett⁶, Vinay K. Pathak⁷

¹NCI, Frederick, MD, USA, ²The Scripps Rsr Inst, La Jolla, CA, USA

**Engineering HIV-resistant anti-HIV chimeric antigen receptor (CAR) T cells**

Malika Hale¹, Taylor Mesojednik¹, Guillermo Romano Ibarra¹, Jaya Sahni¹, Bryan Sands¹, Karen Sommer¹, Andrew M. Scharenberg², David J. Rawlings¹, Thor Wagner²

¹Seattle Children’s Rsr Inst, Seattle, WA, USA, ²Univ of Washington, Seattle, WA, USA

**Viral outcomes after antiretroviral therapy interruptions to evaluate a functional cure**

Lorna Leal¹, Constanza Lucero¹, Montserrat Plana¹, Nuria Climent¹, Esteban Martinez¹, Pedro Castro¹, Beatriz Mothe², Juan Carlos López-Bernaldo¹, Jose M. Gatell¹, Felipe García¹

¹IDIBAPS, Barcelona, Spain, ²IrsiCaixa Inst for AIDS Rsr, Badalona, Spain, ³Hosp Gregorio Marañón, Madrid, Spain

**A bispecific approach for targeting IMRS in HIV-1 latency**

Debbie S. Ruelas¹, Yanyan Zheng¹, Fahimeh Raoufi¹, Laurence Fayadat-Dilman¹, Yuan Li¹, Julie Strizki², Richard Barnard², Mohammad Tabrizifard¹, Daniel Gorman¹

¹Merck & Co, Palo Alto, CA, USA, ²Merck & Co, Inc, West Point, PA, USA

**TLR7 agonist treatment of SIV+ monkeys on ART can lead to complete viral remission**

So-Yon Lim¹, Christa Osuna¹, Joseph Hesselgesser¹, Alison Hill¹, Michael D. Miller¹, Tomas Cihlar², Romas Geleziunas², William Lee², James Whitney¹

¹Beth Israel Deaconess Med Ctr, Boston, MA, USA, ²Gilead Scis, Inc, Foster City, PA, USA, ³Boston College, Chestnut Hill, MA, USA

**The role of prestroke immune status in stroke mechanisms in HIV+ individuals**

Jose Gutierrez¹, Camilla Ingrid Hatleberg², Henry W. Evans³, Michael T. Yin¹

¹Columbia Univ, New York, NY, USA, ²CHIP, Copenhagen, Denmark

**Types of ischemic strokes among HIV-infected individuals across the United States**

Heidi M. Crane¹, Robin M. Nance¹, Felicia C. Chow¹, Christina Marra¹, Joseph Zunt¹, Emily Ho¹, Richard D. Moore¹, Daniel Drozd¹, Mari Kitahata¹, David Tirschwell¹

¹Univ of Washington, Seattle, WA, USA, ²Univ of California San Francisco, San Francisco, CA, USA, ³Harborview Med Ctr, Seattle, WA, USA, ⁴The Johns Hopkins Univ, Baltimore, MD, USA

**Association of HIV and opportunistic infections with incident stroke**

Yung-Feng Yen¹, I-An Jen², Yi-Ming A. Chen¹

¹Taipei City Hosp, Taipei, Taiwan, ²Natl Yang-Ming Univ, Taipei, Taiwan, ³Kaohsiung Med Univ, Kaohsiung, Taiwan
363 CNS MONITORING OF CART INTERRUPTION IN INDIVIDUALS TREATED DURING FIEBIG I ACUTE HIV
Phillip Chan, Donn Colby, Victor Valcour, Napaporn Sailasuta, Shelly J. Krebs, Linda Jaqzdzinski, Robert Paul, Jintanat Ananworanich, for the RV411 and RV254/SEARCH 010 Study Groups

1SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 2Univ of California San Francisco, San Francisco, USA, 3Univ of Hawaii, Honolulu, HI, USA, 4US Military HIV Rsr Prog, Silver Spring, MD, USA, 5Univ of Missouri–St. Louis, St. Louis, MO, USA, 6Yale Univ, New Haven, CT, USA

364 CSF HIV-1 COMPARTMENTALIZATION BY ENV DEEP SEQUENCING: RELATION TO NEURONAL INJURY
Richard W. Price, Magnus Gisslén, Laura P. Kincer, Ean Spielvogel, Amy Lin, Jaser Eusuff, Serena Spudich, Ronald Swanstrom, Sarah Beth Joseph, for the THINC Study Group

1Univ of California San Francisco, San Francisco, CA, USA, 2Sahlgenska Academy at the Univ of Gothenburg, Gothenburg, Sweden, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4Univ of California Berkeley, Berkeley, CA, USA, 5Yale Univ, New Haven, CT, USA

365 EARLY EMERGENCE OF MAC-TROPIC HIV VARIANTS IN BRAIN OF PATIENTS WITH NORMAL NEUROLOGY
Maria Paz Gonzalez-Perez, Paul P. Peters, Paul Clapham
Univ of Massachusetts, Worcester, MA, USA

366 BLOOD BRAIN BARRIER FUNCTION, ART NEUROACTIVITY, AND RISK OF CSF HIV ESCAPE
Carmela Pinnetti, Massimo Tempestilli, Patrizia Lorenzini, Valentina Fedele, Stefania Carta, Valentina Mazzotta, Chiara Agrati, Adriana Ammassari, Carlo F. Perno, Andrea Antinori
Nati Inst for Infectious Diseases, Rome, Italy

367 SEX-BASED DIFFERENCES IN HIV RESERVOIRS IN BRAIN AND NEUROCognition
Michelle Faria de Oliveira, Masato Nakazawa, Andrej Vitomirov, Mitchell Zhao, Ben Gouaux, David Moore, Ronald J. Ellis, Davey M. Smith, Sara Gianella

1Univ of California San Diego, La Jolla, CA, USA, 2Univ of California San Diego, San Diego, CA, USA

368 THE EFFECT OF CRYPTOCOCCAL MENINGITIS ON THE HIV RESERVOIR IN THE CNS
Maura Manion, Camille Lange, Kathy Huppler Hullsiek, Brandon Keele, Helene Highbarger, David Meyà, Frank Maldarelli, David Boulware, Irini Sereti

1NIAID, Bethesda, MD, USA, 2NIH, Frederick, MD, USA, 3Univ of Minnesota, Minneapolis, MN, USA, 4NCI, Frederick, MD, USA, 5Leidos Biomed, Inc, Frederick, MD, USA, 6Makerere Univ, Kampala, Uganda

369 HIV CNS COMPARTMENTALIZATION AMONG SUBJECTS WITH HIV-1 SUBTYPES G AND CRF02_AG
Olubusuyi M. Adewumi, Elena Dukhovlinova, Nathan Shehu, Shuntai Zhou, Maxwell Akanbi, Babafemi Taiwo, Adesola Oggunniyi, Kevin Robertson, Ronald Swanstrom

1Univ of Ibadan, Ibadan, Nigeria, 2Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 3Jos Univ Teaching Hosp, Jos, Nigeria, 4Northwestern Univ Feinberg Sch of Med, Chicago, IL, USA
**Expression of Unique and Diverse HIV Variants in Cerebrospinal Fluid During ART**

Jeffrey A. Johnson, Sarah Malik, Sam Nightingale, Jin-fen Li, Apostolos Beloukas, Tom Solomon, Saye Khoo, Anna Maria Geretti

1CDC, Atlanta, GA, USA, 2Univ of Liverpool, Liverpool, UK, 3Univ of Liverpool Inst of Translational Med, Liverpool, UK

---

**CSF Escape in Treated HIV Infection Shows X4 Tropism and Defective Viral Sequences**

Bryan Smith, Guahan Li, Hiromi Imamichi, Brad Sherman, Manori De Alwis, Govind Nair, Joseph Snow, Daniel S. Reich, H. Clifford Lane, Avindra Nath

1NIH, Bethesda, MD, USA, 2NIH, Frederick, MD, USA, 3NIAID, Bethesda, MD, USA

---

**Neuropsychiatric Adverse Events Associated with Integrase Strand Transfer Inhibitors**

Prabha Viswanathan, Elande Baro, Guoxing Soon, Adam Sherwat, Kimberly Struble

FDA, Silver Spring, MD, USA

---

**MRS Measures Associate with Impaired Neuropsychological Performance in Acute HIV**

Joanna Hellmuth, James L. Fletcher, Victor Valcour, Napapon Sailasuta, Somporn Tipsuk, Jintanat Ananworanich, Bonnie Slika, Robert Paul, Serena Spudich, for the SEARCH 010/RV254 Study Group

1Univ of California San Francisco, San Francisco, CA, USA, 2SEARCH, Bangkok, Thailand, 3Univ of Hawaii, Honolulu, HI, USA, 4US Military HIV Rsr Prgr, Silver Spring, MD, USA, 5Univ of Missouri-St. Louis, St. Louis, MO, USA, 6Yale Univ, New Haven, USA

---

**Circulating HIV DNA is Associated with Weaker Intrinsic Brain Connectivity**

Kalpana J. Kallianpur, Bruce Shiramizu, Melissa Agsalda-Garcia, Robert Paul, Cecilia Shikuma, Gregory Kirk, Rasmus Birn

1Univ of Hawaii—Manoa, Honolulu, HI, USA, 2Univ of Missouri-St. Louis, St. Louis, MO, USA, 3Univ of Wisconsin Madison, Madison, WI, USA

---

**Retinal Layers Thickness as Marker of Accelerated Neurocognitive Decay in HIV Disease**

Chiara Resnati, Alessandro Invernizzi, Alessandra Acquistapace, Marta Ferrari, Sara Bochicchio, Valentina Leta, Cristina Gervasoni, Stefano Rusconi, Simone Pomati, Agostino Riva

1Univ of Milan, Milano, Italy, 2Luigi Sacco Univ Hosp, Milano, Italy

---

**Longitudinal Assessment of Regionally Specific Brain Volumes in Treated HIV+ Patients**

Ryan Sanford, Lesley K. Fellows, Louis Collins, Beau M. Ances

1Montreal Neuro Inst, Montreal, Canada, 2Washington Univ, St. Louis, MO, USA

---

**Brain HIV Latency Leads to a Complex Pattern of Neurochemical Dysregulation**

Lucette Cysique, Michael V. Tobia, Thomas Gates, Lauriane Juge, Simon Jones, Caroline Rae, Bruce Brew

1NeuroSci Rsr Australia, Randwick, Australia, 2Univ of New South Wales, Randwick, Australia, 3St. Vincent’s Hosp, Sydney, Australia, 4Univ of New South Wales, Darlinghurst, Australia
**CEREBRAL ENDOTHELIAL FUNCTION CORRELATES WITH PERFORMANCE ON COGNITIVE SCREENING TEST**

Natasha Mehta¹, Yanling Li², Yinghuan Hu², Huanling Wang², Weihai Xu², Taisheng Li¹, Felicia C Chow¹

¹Univ of California San Francisco, San Francisco, CA, USA, ²Peking Union Med Coll Hosp, Beijing, China

**RANDOMIZED TRIAL OF BRAIN FUNCTION CHANGE AFTER STARTING TDF/FTC+ATV/R OR ABC/3TC+EFV**

Ignacio Pérez-Valero¹, Alicia Gonzalez-Baeza¹, Lucia Bailon¹, Belén Alejos¹, Rocío Montejano¹, Victor Hontanon¹, Helena Melero¹, Marisa Montes¹, Carmen Bayon¹, Jose R. Arribas¹

¹Hosp Univ La Paz, Madrid, Spain, Spain, ²Instituto de Salud Carlos III, Madrid, Spain, ³Univ Rey Juan Carlos, Alcorcón, Spain

**RESTING CEREBRAL BLOOD FLOW AND RISKY DECISION-MAKING IN HIV+ AND HIV– YOUNG ADULTS**

Robert S. Smith¹, Anika Guha², Aaron Tanenbaum¹, Florin Vaida³, Robert Paul⁴, Beau M. Ances¹

¹Washington Univ in Saint Louis, Saint Louis, MO, USA, ²Univ of California Los Angeles, Los Angeles, CA, USA, ³Univ of California San Diego, San Diego, USA, ⁴Univ of Missouri–St. Louis, St. Louis, MO, USA

**MRI REVEALS ENLARGED INTRACRANIAL ARTERIES IN HIV-ASSOCIATED NEUROCognitive DISORDER**

Govind Nair, Angela Summers, Joseph Snow, Daniel S. Reich, Sally Steinbach, Paba M. DeAlwis, Bryan Smith, Avindra Nath

NIH, Bethesda, MD, USA

**WORKING MEMORY IN HIV+ YOUNG ADULTS: FUNCTIONAL IMAGING USING MAGNETOENCEPHALOGRAPHY**

Sharon Nichols¹, Ashley R. Swan¹, Annemarie A. Quinto², Chris Fennema-Notestine², Mingxiong Huang³

¹Univ of California San Diego, La Jolla, CA, USA, ²Univ of California San Diego, San Diego, USA

**COBICISTAT, BUT NOT RITONAVIR, INCREASES DABIGATRAN EXPOSURE**

Kristina M. Brooks¹, Lori A. Gordon³, Scott Penzak¹, Anela Kellogg³, Maryellen McManus¹, Khanh Nghiem¹, Jay Lozier¹, Jomy M. George¹, Colleen Hadigan², Parag Kumar¹

¹NIH, Bethesda, MD, USA, ²Xavier Univ of Louisiana, New Orleans, LA, USA, ³Univ of North Texas, Fort Worth, TX, USA, ⁴Leidos Biomed Rsr, Inc, Bethesda, MD, USA, ⁵NIAID, Bethesda, MD, USA

**EARLY TERMINATION OF A PK STUDY BETWEEN DOLUTEGRAVIR AND WEEKLY ISONIAZID/RIFAPENTINE**

Kristina M. Brooks¹, Alice K. Pau¹, Jomy M. George³, Raul Alfaró¹, Anela Kellogg¹, Mary McLaughlin³, Maryellen McManus¹, Colleen Hadigan¹, Joseph A. Kovacs¹, Parag Kumar¹

¹NIH Clinical Center, Bethesda, MD, USA, ²NIAID, NIH, Bethesda, MD, USA, ³Leidos Biomedical Research, Inc, Bethesda, MD, USA
410  INCREASED Dolutegravir Exposure in HIV Patients Switched from Ritonavir to Cobicistat
Cristina Gervasoni, Agostino Riva, Amedeo Capetti, Valeria Cozzi, Giuliano Rizzardi, Massimo Galli, Emilio Clementi, Dario Cattaneo
Luigi Sacco Univ Hosp, Milan, Italy

411  EFFECT OF COBICISTAT ON TENOFOVIR PLASMA CONCENTRATION: A CROSS-SECTIONAL STUDY
Cristina Gervasoni1, Davide Minisci1, Sara Baldelli1, Cristina Mazzali2, Andrea Giacomelli1, Laura Milazzo1, Paola Meraviglia1, Emilio Clementi1, Massimo Galli1, Dario Cattaneo1
1Luigi Sacco Univ Hosp, Milano, Italy, 2Politecnico di Milano, Italy, Milano, Italy

412  MULTIPLE-DOSE TREATMENT WITH RITONAVIR INCREASES THE EXPOSURE OF DORAVIRINE
Sauzanne Khalilieh1, Matt Anderson1, Tine Laethem2, Kelly Yee3, Rosa Sanchez1, Li Fan1, Monali Sura1, Luc Van Bortel1, Greit Van Lancker1, Marian Iwamoto1
1Merck & Co, Inc, Kenilworth, NJ, USA, 2MSD Belgium, Brussels, Belgium, 3Ghent Univ Hosp, Ghent, Belgium

413  GLECAPREVIR AND PIBRENTASVIR INTERACTIONS WITH COMBINATION ANTIRETROVIRAL REGIMENS
Matthew P. Koslowski, Sandeep Dutta, Rolando M. Viani, Xin Qi, Roger Trinh, Andrew Campbell, Wei Liu
AbbVie, North Chicago, IL, USA

414  EFFECT OF LOW-DOSE METHOTREXATE ON THE PHARMACOKINETICS OF TENOFOVIR
David Gingich1, Heather Ribaudo1, Amy Kantor1, James H. Stein1, Judith S. Currier1, Priscilla Hsue1, Francesca Aweeka1
1Univ of California San Francisco, San Francisco, CA, USA, 2Harvard Univ, Boston, MA, USA, 3Univ of Wisconsin, Madison, WI, USA, 4Univ of California Los Angeles, Los Angeles, CA, USA

Poster P-G4  EXPOSURE-RESPONSE RELATIONSHIPS OF ANTIRETROVIRAL DRUGS
Poster Hall - 4 EF  2:30 PM - 4:00 PM

423  AN IN VITRO–IN SILICO STUDY OF REDUCED-DOSE Efavirenz Interaction with Levonorgestrel
Owain Roberts1, Paul Curley1, Rajith Kumar Reddy Rajoli1, Darren M. Moss1, Mohammed Lamorde2, Andrew Owen2, Kimberly K. Scarsil3, Marco Siccardi1
1Univ of Liverpool, Liverpool, UK, 2Infectious Diseases Inst Ltd, Kampala, Uganda, 3Univ of Nebraska, Omaha, NE, USA

424  PHARMACOKINETICS, SAFETY & EFFICACY OF E/C/F/TAF IN HIV-INFECTED CHILDREN (6-12 YRS)
Aditya Gaur1, Eva Natukunda1, Pope Kosalkarska1, Jag Batra2, Natella Rakhmanina2, Amy Coluci2, Yongwu Shao2, Heather Zhang2, Cheryl Pikora2, Martin Rhee3
1St. Jude Children’s Rsr Hosp, Memphis, TN, USA, 2Joint Clinical Rsr Cntr, Kampala, Uganda, 3Khon Kaen Univ, Khon Kaen, Thailand, 4Miller Children’s Hosp, Long Beach, CA, USA, 5Children’s Rsr Inst–Children’s Natl Med Cntr, Washington, DC, USA, 6Gilead Scis, Inc, Foster City, CA, USA
**PHARMACOKINETICS, SAFETY, AND EFFICACY OF ATV OR DRV WITH COBI IN ADOLESCENTS**

Elizabeth J. McFarland1, Gloria P. Heresi2, Jag Batra3, Torsak Bunupuradatham1, Kulkanya Chekephaibulkit1, Pope Kosalarksa2, Pamela Wong1, Heather Zhang2, Cheryl Pikora2, Martin Rhee2

1Univ of Colorado, Aurora, CO, USA, 2Univ of Texas, Houston, TX, USA, 3Miller Children’s Hosp, Long Beach, CA, USA, 4HIV-NAT, Thai Red Cross AIDS Rsr, Bangkok, Thailand, 5Mahidol Univ, Bangkok, Thailand, 6Khon Kaen Univ, Khon Kaen, Thailand, 7Gilead Scis, Inc, Foster City, CA, USA

**EFFECT OF DOLUTEGRAVIR PLASMA CONCENTRATION ON CENTRAL NERVOUS SYSTEM SIDE EFFECTS**

Hiroki Yagura1, Dai Watanabe1, Takao Nakauchi1, Kosuke Tomishima1, Daisuke Kasai1, Yasuharu Nishida1, Munehiro Yoshino2, Tomoko Uehira1, Kunio Yamazaki1, Takuma Shirasaka2

1Natl Hosp, Osaka, Japan, 2Natl Hosp Org Osaka Minami Med Cntr, Osaka, Japan

**EVALUATION OF RPV/FTC/TAF EXPOSURE-EFFICACY AND EXPOSURE-SAFETY RELATIONSHIPS**

Sophia R. Majeed1, Kavitha Bhasi1, Yongwu Shao1, William Garner1, Jenna Scott1, Carlos P. Ruixo2, Devi SenGupta1, Huyen Cao1, Brian P. Kearney1, Joseph M. Custodio1

1Gilead Scis, Foster City, CA, USA, 2Janssen Rsr and Development, Beerse, Belgium
437 PRO140 SINGLE-AGENT MAINTENANCE THERAPY FOR HIV-1 INFECTION: A 2-YEAR UPDATE

Jay Lalezari1, Kush Dhody1, Ula Kowalczyk1, Kazem Kazempour1, Nader Pourhassan1, Paul J. Madden2
1Quest Clinical Rsr, San Francisco, CA, USA, 2Amarex Clinical Rsr, LLC, Germantown, MD, USA, 3CytoDyn Inc, Vancouver, WA, USA, 4Maddon Advisors LLC, Scarsdale, NY, USA

438 INTRAMUSCULAR IBALIZUMAB: PHARMACOKINETICS, SAFETY, AND EFFICACY VS IV ADMINISTRATION

Hsi-Hsun Lin1, Susan Shin-Jung Lee2, Ning-Chi Wang3, Ying-An Lai4, Kwei-Ling Kuo4, Steven Weinheimer5, Stanley Lewis6
1E-Da Hosp, Kaohsiung City, Taiwan, 2Kaohsiung Veterans General Hosp, Kaohsiung, Taiwan, 3Tri-Service General Hosp, Taipei City, Taiwan, 4TaiMed Biologics, Taipei City, Taiwan, 5TaiMed Biologics USA, Irvine, CA, USA

439 A LONG-ACTING NANOFORMULATED CABOTEGRAVIR PRODRUG FOR IMPROVED ANTIRETROVIRAL THERAPY

Tian Zhou, Benson Edagwa, JoEllyn McMillan, Howard E. Gendelman
Univ of Nebraska, Omaha, NE, USA

440 ANTIVIRAL ACTIVITY OF EFDA AGAINST NRTI-SENSITIVE AND -RESISTANT STRAINS OF HIV-2

Vincent Wu1, Robert Smith1, Sara Masoum1, Dana Raugi1, Selly Ba2, Moussa Seydi3, Jay Grobler4, Geoffrey Gottlieb5, for the University of Washington—Dakar HIV-2 Study Group
1Univ of Washington, Seattle, WA, USA, 2CHU de Fann, Dakar, Senegal, 3Merck & Co, West Point, PA, USA

Poster P-I3 ART: VIRAL RESPONSE OVER THE LONG TERM

Poster Hall - 4 EF 2:30 PM - 4:00 PM

461 VIROLOGICAL RESPONSE TO ANTIRETROVIRAL TREATMENT IN AN EASTERN EUROPEAN COHORT STUDY

Radko Avi, Merit Pauskar, Heli Rajasaar, Ene-Ly Jõgeda, Pillerin Soodla, Irja Lutsar, Kristi Huik, for the Estonian HIV Positive Patients Database
Univ of Tartu, Tartu, Estonia

462 DURABILITY OF NNRTI BASED REGIMENS AFTER 7 YEARS OF TREATMENT IN RURAL UGANDA

Mastula Nanfuka1, Zishan Cui1, Stephen Okoibo1, Josephine Birungi1, Pontiano Kaleebu1, Julia Zhu2, Samuel Tibengana3, David Moore4
1The AIDS Support Organization, Kampala, Uganda, 2BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, 3Med Rsr Council, Entebbe, Uganda, 4Univ of British Columbia, Vancouver, British Columbia, Canada

463 LONG-TERM VIRAL SUPPRESSION DURING INITIAL ANTIRETROVIRAL THERAPY IN HANOI, VIETNAM

Junko Tanuma1, Shoko Matsumoto1, Sebastien Haneuze2, Cuong Do Duy3, Thanh Thuy Pham Thi4, Dung T. Nguyen4, Kinh V. Nguyen4, Shinichi Oka5
1Natl Cntr for Global Hlth and Med, Tokyo, Japan, 2Harvard Univ, Boston, MA, USA, 3Bach Mai Hosp, Hanoi, Vietnam, 4Natl Hosp for Trop Diseases, Hanoi, Vietnam
OUTCOMES AND SIDE EFFECTS OF PATIENTS ON ART FOR MORE THAN 10 YEARS IN MALAWI

Sekai C. Mathabire1, Alia Tayea1, Joseph Bitilinyu-Bangoh2, Elkin H. Bermudez2, Leon Salumu1, Isabel A. Quiles3, Elisabeth Szumilin3, Zengani Chirwa4, Fernanda Rick1, David Maman4
1MSF France, Chiradzulu, Malawi, 2Queen Elizabeth Central Hosp, Blantyre, Malawi, 3MSF France, Paris, France, 4MSF France, Lilongwe, Malawi, 5Ministry of Hlth, Malawi, Lilongwe, Malawi, 6Epicentre, Cape Town, South Africa

INCREASED PERSISTENCE OF INITIAL ART WITH INSTI-CONTAINING REGIMENS

Thibaut Davy, Sonia Napravnik, Oksana Zakharova, Joseph J. Eron
Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

DYNAMICS OF ULTRA-DEPTH SUPPRESSED HIV VIREMIA (<=5 CP/ML) IN CART-TREATED PATIENTS

Alessandra Amendola, Adriana Ammassari, Assunta Navarra, Giulia Bibbolino, Carmela Pinnetti, Isabella Abbate, Gabriella Rozera, Annalisa Mondi, Enrico Girardi, Maria R. Capobianchi
Natl Inst for Infectious Diseases Lazzaro Spallanzani, Rome, Italy

SUBOPTIMAL IMMUNE RECOVERY DESPITE SUPPRESSIVE ANTIRETROVIRAL THERAPY IN AFRICA

Stefanie Kroeze1, Pascale Ondoa1, Cissy Kityo2, Margaret Siwale1, Sonia Boender1, Peter Reiss2, Ferdinand Wit3, Tobias F. Rinke de Wit4, Raph L. Hamers2, for the PASER Study Group
1Amsterdam Inst for Global Hlth and Development, Amsterdam, Netherlands, 2Joint Clinical Rsr Cntr, Kampala, Uganda, 3Lusaka Trust Hosp, Lusake, Zambia, 4Stichting HIV Monitoring and Academic Med Cntr Amsterdam, Amsterdam, Netherlands

CURRENT STATIN USE REDUCES RISK OF VIRAL REBOUND ON SUPPRESSIVE CART

Henning J. Drechsler1, Colby Ayers2, James Cutrell2, Naim Maalouf3, Pablo Tebas4, Roger Bedimo4
1VA North Texas Hlth Care Cntr, Dallas, TX, USA, 2Univ of Texas Southwestern, Dallas, TX, USA, 3Univ of Texas Southwestern Med Cntr, Dallas, TX, USA, 4Univ of Pennsylvania, Philadelphia, PA, USA

HIV-RELATED PILL AVERSION: CHARACTERIZING A NOVEL BARRIER TO ADHERENCE

Robin Dorman, Sarah H. Sutton, Lynn M. Yee
Northwestern Univ, Chicago, IL, USA

HEPATITIS C CASCADE OF CARE IN NON-BIRTH COHORT PATIENTS WITHIN A LARGE HEALTH SYSTEM

Chinyere Ukaegbu1, Alexander Geboy1, Whitney Nichols1, Amanda E. Smart2, Stephen Fernandes2, Peter Basch3, Dawn Fishbein1
1MedStar Hlth Rsr Inst, Washington, DC, USA, 2Georgetown Univ, Washington, DC, USA, 3MedStar Hlth Rsr Inst, Hyattsville, MD, USA
544 STRATEGIES FOR UTILIZING EHR TO IMPROVE BIRTH COHORT TESTING IN THE HOSPITAL SETTING
Lorlette Moir, Shuchin Shukla, Uriel Felsen, Jeffrey Weiss, Kimberly Cartmill, Jonathan M. Schwartz, Paul Meissner, Kimberly Yu, Yuming Ning, Alain H. Litwin
Montefiore Med Cntr, Bronx, NY, USA

545 IMPLEMENTATION OF AN EHR PROMPT REVEALS LOW ADHERENCE TO HCV TESTING RECOMMENDATIONS
Alexander Geboy1, Whitney Nichols1, Chinnyere Ukaegbu1, Stephen Fernandez2, Peter Basch1, Dawn Fishbein1
1MedStar Hlth Rsr Inst, Washington, DC, USA, 2MedStar Hlth Rsr Inst, Hyattsville, MD, USA

546 DEVELOPMENT OF AN EMR-BASED ALGORITHM TO PLACE PATIENTS IN THE HCV CARE CASCADE
Jason Zucker, Justin Aaron, Henry W. Evans, Peter Gordon, Michael T. Yin
Columbia Univ, New York, NY, USA

547 COST-EFFECTIVENESS OF HCV SCREENING AND LINKAGE IN MMT: RELEVANCE OF HIV COINFECTION
Bruce R. Schackman1, Jared A. Leff1, Jake R. Morgan2, Sarah Gutkind1, Czarina N. Behrendsf, Kevin L. Delucchif, Courtney McNight4, David C. Perlman4, Carmen L. Masson5, Benjamin Linas6
1Weill Cornell Med Coll, New York, NY, USA, 2Boston Med Cntr, Boston, MA, USA, 3Univ of California San Francisco, San Francisco, CA, USA, 4Icahn Sch of Med at Mt Sinai, New York, NY, USA, 5Boston Univ, Boston, MA, USA

548 PROVIDING HCV CURES IN THE MEDICAL HOME: TRAINING A NEW GENERATION OF PROVIDERS
Sarah Rojas, Christian B. Ramers, Stephanie Constantino
Family Hlth Cntrs of San Diego, San Diego, CA, USA

549 HCV RNA DETECTION IN SMALL VOLUME CAPILLARY BLOOD FOR POINT-OF-CARE APPLICATIONS
Mark Hopkins1, Rachael Dagnall2, Athanassios Papadimitropoulos1, Paula Davies1, Jillian William1, Eimear Railton1, Sarah Sarah Hau1, Apostolos Beloukas2, Anna Maria Geretti2
1Royal Liverpool Univ Hosp, Liverpool, UK, 2Univ of Liverpool, Liverpool, UK

550 HIV/HCV COINFECTION IN THE DAA ERA: “EN ROUTE FOR ERADICATION”?
Laurent Cotte1, Pascal Pugièse2, Isabelle Poizot-Martin3, Marc-Antoine Valantin4, Lise Cuzin1, Jacques Reynes5, Eric Billaud2, Thomas Huleux3, Pierre Pradat4, for the DataAIDS Study Group
1Hospices Civils de Lyon, Lyon, France, 2CHU de Nice, Nice, France, 3Assistance Publique – Hôpitaux de Marseille, Marseille, France, 4Assistance Publique - Hôpitaux de Paris, Paris, France, 5CHU Toulouse, Toulouse, France, 6CHU de Montpellier, Montpellier, France, 7CHU de Nantes, Nantes, France, 8Cntr Hosp de Tourcoing, Tourcoing, France
551 SAME SAME BUT DIFFERENT? RISK OF DAA THERAPY FAILURE IN
REAL-LIFE HCV/HIV COINFECTION
Christoph Boesecke1, Patrick Ingiliz2, Florian Berger3, Thomas Lutz4,
Knud Schewe5, Julian Schulze zur Wisch6, Axel Baumgarten7, Stefan
Christensen1, Jürgen K. Rockstroh1, Stefan Mauss1
1 Univ Hosp Bonn, Bonn, Germany, 2 Ctr For Infectiology, Berlin, Germany, 3 Ctr
For HIV and Hepatogastroenterology, Dusseldorf, Germany, 4 Infektiologikum,
Frankfurt, Germany, 5 dagana e.V., Berlin, Germany, 6 Univ Med Ctr,
Hamburg—Eppendorf, Hamburg, Germany, 7 CIM Infectious Diseases, Münster,
Germany

552 DIRECT-ACTING ANTIVIRALS IMPROVE ACCESS TO CARE AND
CURE FOR PATIENTS WITH HIV-HCV
Lauren F. Collins, Austin Chan, Jiayin Zheng, Shein-Chung Chow, Julius M.
Wildcr, Andrew J. Mui, Susanna Naggie
Duke Univ, Durham, NC, USA

553 DIRECT ACTING ANTIVIRAL UPTAKE DISPARITIES IN HIV/HCV–
COINFECTED POPULATIONS
Sahar Saeed1, Erin C. Strumpf2, Sharon Walmsley2, Curtis Cooper1, Brian
Conway3, Valerie-Martel Laferriere4, Neora Pick5, Alexander Wong2, Marina
Klein4, for the Canadian Co-Infection Cohort Study
1 McGill Univ, Montreal, Canada, 2 Univ of Toronto, Toronto, Ontario, Canada,
3 Ottawa General Rsr Inst, Ottawa, Ontario, Canada, 4 Vancouver Infectious
Diseases Ctr, Vancouver, Canada, 5 Ctr Hosp de l’Univ de Montréal, Montreal,
Canada, 6 Oak Tree Clinic, Vancouver, Canada, 7 Regina Qu’Appelle Hlth Region,
Regina, Canada, 8 McGill Univ Hlth Ctr Rsr Inst, Montreal, Ontario, Canada

554 HCV TREATMENT IN PEOPLE WHO INJECT DRUGS COLOCATED
WITHIN NEEDLE AND SYRINGE PROGRAM
Benjamin Eckhardt1, Kristen M. Marks2, Brian Edlin3
1 New York Univ, New York, NY, USA, 2 Weill Cornell Med, New York, NY, USA,
3 Natl Development and Rsr Insts, New York, NY, USA

555 HIGH EFFICACY OF IFN-FREE ANTI-HCV REGIMENS FOR
INDIVIDUALS ON OPIATE AGONIST THERAPY
Juan Macias1, Luis E. Morano-Amado2, Francisca Cuenca-Lopez2, Miriam
Serrano3, Karin Neukam1, Francisco Téllez3, Manuel Márquez2, Dolores
Merino1, Juan A. Pineda1
1 Hosp Univ de Valme, Sevilla, Spain, 2 Hosp Univ Alvaro Cunqueiro, Vigo, Spain,
3 Hosp Univ Reina Sofia, Cordoba, Spain, 4 Hosp Univ de Gran Canaria Dr Negrín,
Las Palmas, Gran Canaria, 5 Hosp de La Línea, La Línea de la Concepción,
Spain, 6 Hosp Virgen de la Victoria, Málaga, Spain, 7 Complejo Hospario Univ de
Huelva, Huelva, Spain

556 SVR12 FOR PATIENTS WITH BEHAVIORAL HEALTH CONDITIONS
TREATED FOR HEPATITIS C IN FQHCS
Sophy S. Wong, Megan Crowley, Jan Diamond
Alameda Hlth Consortium, San Leandro, CA, USA

557 REAL-WORLD OUTCOMES OF HCV TREATMENT IN HOMELESS
AND MARGINALLY HOUSED ADULTS
Joshua A. Barocas1, Marguerite Beiser1, Casey Leon2, Molly Ingemi2, Paul
McCabe1, Lena Cardoso2, Benjamin Linas3, James O’Connell2
1 Massachusetts General Hosp, Boston, MA, USA, 2 Boston Hlth Care for the
Homeless, Boston, MA, USA, 3 Quinnipiac Univ, North Haven, CT, USA, 4 Boston
Univ, Boston, MA, USA
558  TREATMENT READINESS FOR HEPATITIS C INFECTION AMONG PWID IN CHENNAI, INDIA
Eshan U. Patel1, Sunil S. Solomon2, Allison M. McFall1, Aylur K. Srikrishnan1, Amrose Pradeep1, Jungen Yi1, Oliver Laeyendecker1, David Thomas1, Mark Sulkowski1, Shruti H. Mehta1
1Johns Hopkins Univ, Baltimore, MD, USA, 2YRG CARE, Chennai, India, 3NIAID, Baltimore, MD, USA

559  FIELD-BASED DELIVERY OF HCV THERAPY WITH MINIMAL MONITORING TO PWID IN CHENNAI, INDIA
Sunil S. Solomon1, Amrose Pradeep1, Mark Sulkowski1, Aylur K. Srikrishnan1, Nandagopal Paneerselvam1, Shanmugam Saravanan2, Santhanam Anand2, Muniratnam S. Kumar1, David Thomas1, Shruti H. Mehta1
1Johns Hopkins Univ Sch of Med, Baltimore, MD, USA, 2YRG Gaitonde Cntr for AIDS Rsr and Educ, Chennai, India, 3Johns Hopkins Univ, Baltimore, USA

560  HIGH RATES OF HCV CURE AMONG URBAN BLACK AND NON-BLACK HIV-INFECTED PATIENTS
Oluwaseun Falade-Nwulia1, Juhi Moon1, Geetanjali Chander1, Tanyaporn Wansom2, Catherine Sutcliffe1, Shruti H. Mehta1, David Thomas1, Richard D. Moore1, Mark Sulkowski1
1Johns Hopkins Univ, Baltimore, MD, USA, 4US Military HIV Rsr Prog, Bethesda, MD, USA

---

Poster Sessions • Wednesday
Program and Agenda
CROI 2017

561  GLOBAL ORIGINS OF RESISTANCE-ASSOCIATED VARIANTS IN THE NSSA REGION OF HCV
Bradley R. Jones1, Jeffrey Joy2
1BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, 2Univ of British Columbia, Vancouver, British Columbia, Canada

562  IMPACT OF HCV NSSA RESISTANCE ON TREATMENT RESPONSE IN HIV AND HIV/HCV PATIENTS
Itziar Carrasco Garcia1, Ana Arias2, Laura Benitez2, Silvia Requena1, Miriam Cuesta1, Luis Otero2, Valentin Cuervas-Mons2, Carmen de Mendoza Fernandez2, for the Internal Medicine Department
1Puerta de Hierro Rsr Inst and Univ Hosp, Madrid, Spain, 2Hosp Puerta de Hierro, Madrid, Spain, 3Hosp de Cabueñas, Asturias, Spain

563  CATALOGING THE IMPACT OF Y93 SUBSTITUTIONS ON HCV NSSA INHIBITOR SUSCEPTIBILITY
Alicia Newton, Charity Ting, Arne Frantzell, Jennifer Cook, Christos Petropoulos, Wei Huang
Monogram BioScis, South San Francisco, CA, USA

564  NATURAL HCV RESISTANCE IS COMMON IN ITALY AND DIFFERENTLY ASSOCIATED TO GENOTYPES
Valeria Cento1, Ada Bertoli1, Giustino Parrutti1, Giuliano Rizzardini1, Gloria Taliani2, Caterina Pasquazzi2, Massimo Andreoni1, Carlo F. Perno1, Francesca Ceccherini Silberstein2, for the Vironet Cohort
1Univ of Rome Tor Vergata, Rome, Italy, 2Pescara Hosp, Pescara, Italy, 3Luigi Sacco Univ Hosp, Milan, Italy, 4Sapienza Univ of Rome, Rome, Italy
565  OPTIMAL EFFICACY OF HCV-RESISTANCE–BASED RETREATMENTS AFTER PI FAILURE

Valeria Cento1, Silvia Barbaliscia1, Stefano Bonora2, Sergio Babudieri3, Alessia Ciancio1, Giuliano Rizzardi1, Mario Angelico1, Carlo F. Perno1, Francesca Ceccherini Silberstein1, for the Vironet Cohort

1Univ of Rome Tor Vergata, Rome, Italy, 2Univ degli Studi di Torino, Torino, Italy, 3Univ of Sassari, Sassari, Italy, 4City of Hlth and Sci of Turin, Turin, Italy, 5Luigi Sacco Univ Hosp, Milano, Italy, 4Hosp of Rome Tor Vergata, Rome, Italy

566  RETREATMENT OPTIONS AFTER FAILING A FIRST LINE OF DAA AGAINST HEPATITIS C VIRUS

Ana B. Perez1, Natalia Chueca1, Miguel García-Deltoro2, Ana María Martínez-Sapiña1, Daniel Navarro3, Dolores Merino3, Miguel Jiménez4, Juan Manuel Pascasio5, Antonio Rivero6, Federico García7

1Complejo Hospario Univ de Granada, Granada, Spain, 2Hosp General de Valencia, Valencia, Spain, 3Hosp Univ Miguel Servet, Zaragoza, Spain, 4Complejo Hospario Univ de Santiago, Santiago de Compostela, Spain, 5Complejo Hospario Univ de Huelva, Huelva, Spain, 6Hosp Regional Carlos Haya, Málaga, Spain, 7Hosp Univ Virgen del Rocío, Sevilla, Spain, 8Hosp Univ Reina Sofia, Cordoba, Spain

567  HCV REINFECTION AFTER SUCCESSFUL DAA TREATMENT: A GECCO ANALYSIS

Patrick Ingiliz1, Stefan Christensen2, Florian Berger1, Torben Kimhofer3, Knud Schewe4, Christoph Boesecke5, Dietrich Hueppe6, Julian Schulze zur Wiesch1, Thomas Lutz7, Stefan Mauss8

1Cntr for Infectiology, Berlin, Germany, 2CIM Infectious Diseases, Münster, Germany, 3Cntr for HIV and Hepatogastroenterology, Duesseldorf, Germany, 4Imperial Coll London, London, UK, 5dagnae e.V., Berlin, Germany, 6Univ Hosp Bonn, Bonn, Germany, 7Gastroenterology Practice, Herne, Germany, 8Univ Med Cntr, Hamburg-Eppendorf, Germany, Hamburg, Germany, 9Infektiologikum, Frankfurt, Germany

568LB  LEDIPASVIR/SOFOSBUVIR±RIBAVIRIN IN HCV AND HCV/HIV PRIOR SOF-BASED VIROLOGIC FAILURES

Edward Tam1, Robert S. Brown, Jr2, Sanjaya Satapathy3, Gregory Camus4, Amanda Copans5, Lorenzo Rossaro5, William D. Guyer5, Richard Haubrich5, Minhee Kang2, Annie Luetkemeyer2

1LAIR Cntr, Vancouver, Canada, 2Weill Cornell Med, New York, NY, USA, 3Univ of Tennessee, Memphis, TN, USA, 4Gilead Scis, Inc, Foster City, CA, USA, 5Harvard Univ, Boston, MA, USA, 6Univ of California San Francisco, San Francisco, CA

Poster Sessions: Wednesday

Poster P-L6 DAAs: TREATMENT AND ITS COMPLEXITIES
Poster Hall - 4 EF
2:30 PM - 4:00 PM

569  NINETY-SIX % SVR RATES USING IMPORTED GENERIC DAA FOR PATIENTS WITH HEPATITIS C

Andrew Hill1, Giten Khwairakpam2, James Wang1, Sergey Golovin2, Julia Dragunova1, Rachel Smith1, Vicky Houghton-Price1, Roxanna S Kologoul-Linden1, Anton Pozniak2, Greg Jefferys9

570 VIRAL KINETICS PREDICT RESPONSE TO ALL-ORAL THERAPY AGAINST HCV GENOTYPE 3 INFECTION
Juan A. Pineda1, Luis E. Morano-Amado2, Rafael Granados3, Juan Macías4, Francisco Téllez2, Miguel García-Deltoro2, María J. Rios-Villegas2, Antonio Collado2, Karin Neukam3, for the GEHEP-MONO/HEPAVIR-DAA, RIS-HEP07 and RIS-HEP13 Study Groups
1Hosp Univ de Valme, Seville, Spain, 2Hosp Univ Alvaro Cunqueiro, Vigo, Spain, 3Hosp Univ de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, 4Hosp Univ de Valme, Sevilla, Spain, 5Hosp de La Línea, La Línea de la Concepción, Spain, 6Hosp General de Valencia, Valencia, Spain, 7Hosp Univ Virgen Macarena, Sevilla, Spain, 8Hosp Univ Torrecárdenas, Almería, Spain

571 ALL ORAL DAA THERAPY IN HCV GENOTYPE 4 INFECTION WITH AND WITHOUT HIV COINFECTION
Juan A. Pineda1, Luis E. Morano-Amado2, Francisco Téllez2, Blanca Figueruela López2, Marcial Delgado-Fernández2, Antonio Rivero-Juárez2, Dolores Merino3, Montserrat Pérez-Pérez3, Karin Neukam3, for the GEHEP-MONO/HEPAVIR-DAA, RIS-HEP07 and RIS-HEP13 Study Groups
1Hosp Univ de Valme, Seville, Spain, 2Hosp Univ Alvaro Cunqueiro, Vigo, Spain, 3Hosp de La Línea, La Línea de la Concepción, Spain, 4Hosp Univ de Valme, Seville, Spain, 5Hosp Regional Univ de Málaga, Málaga, Spain, 6Hosp Univ Reina Sofia, Córdoba, Spain, 7Complejo Hospario Univ de Huelva, Huelva, Spain, 8Hosp La Línea, AGS Campo de Gibraltar, La Línea de la Concepción, Spain

572 EFFECTIVENESS OF ALL-ORAL DAA S FOR HCV GENOTYPE 3 IN HIV/HCV-COINFECTED PATIENTS
Juan González-García1, Ana Moreno2, Encarnnnacion Cruz2, Lourdes Domínguez-Dominguez3, Victoria Moreno4, Jorge Vergas5, Jose Sanz5, Laura Benítez4, Beatriz Álvarez4, Juan Berenguer4
1Hosp Univ La Paz, Madrid, Spain, 2Hosp Ramon y Cajal, Madrid, Spain, 3Subdirección General de Farmacia, Madrid, Spain, 4Hosp Univ 12 de Octubre, Madrid, Spain, 5Hosp Clinico San Carlos, Madrid, Spain, 6Hosp Principe de Asturias, Alcalá de Henares (Madrid), Spain, 7Clinica Puerta de Hierro, Majadahonda (Madrid), Spain, 8Hosp Univ Fundación Jiménez Díaz, Madrid, Spain, 9Hosp General Univ Gregorio Marañón, Madrid, Spain

573 SOFOSBUVIR/LEDIPASVIR AS CHOLESTEROL-INCREASE RISK FACTOR IN HIV SUBJECTS
Hosp Univ Reina Sofia, Cordoba, Spain

574 LIPID LEVELS AND THE RISK OF ACUTE MYOCARDIAL INFARCTION AMONG HCV+ AND HCV- PERSONS
Adeel A. Butt1, Peng Yan2, Kara Chew2, Judith S. Currier3, Kathleen Corey4, Raymond Chung5, Abdul-Badi Abou-Samra4, Javed Butler4, Matthew Freiberg4, for the ERCHIVES
1Hamad Hlthcare Quality Inst and Hamad Med Corporation, Doha, Qatar, 2VA Pittsburgh Hlthcare System, Pittsburgh, PA, USA, 3Univ of California Los Angeles, Los Angeles, CA, USA, 4Massachusetts General Hosp, Boston, USA, 5Hamad Medica Corporation, Doha, Qatar, 6SUNY Stonybrook, Stony Brook, NY, USA, 7Vanderbilt Univ Sch of Med, Nashville, TN, USA

575 EFFECT OF INTERFERON-FREE TREATMENT ON LIPID AND GLUCOSE METABOLISM IN HEPATITIS C
Elisa Biliotti, Donatella Palazzo, Marco Serani, Rozenn Esvan, Paola Maidà, Paola Perinelli, Martina Spaziante, Alessandro Maria Silvestri, Lorenzo Volpicelli, Gloria Taliani
Sapienza Univ of Rome, Rome, Italy
576 INFLUENCE OF DAA THERAPY ON ALT LEVELS IN HCV- AND HIV/HCV-INFECTED PATIENTS (GECCO)

Stefan Mauss1, Christoph Boesecke2, Florian Berger3, Patrick Ingiliz1, Thomas Lutz2, Knud Schewe4, Malte Wehmeyer5, Axel Baumgarten1, Jürgen K Rockstroh1, Stefan Christensen6

1Cnr for HIV and Hepatogastroenterology, Duesseldorf, Germany, 2Univ Hosp Bonn, Bonn, Germany, 3Cnr for Infectiology, Berlin, Germany, 4Infektiologikum, Frankfurt, Germany, 5dagnae e. V., Berlin, Germany, 6i. Univ Hosp Hamburg—Eppendorf, Hamburg, Germany, 7Bonn Univ Hosp, Bonn, Germany, 8CIM Infectious Diseases, Münster, Germany

Poster P-M2 AIDS-RELATED CANCER: ART, RISK,INCIDENCE, AND BURDEN
Poster Hall - 4 EF 2:30 PM - 4:00 PM

598 EARLIER VERSUS DELAYED ANTIRETROVIRAL THERAPY INITIATION AND RISK OF CANCER

Michael J. Silverberg1, Wendy Leyden1, Haiqun Lin2, Li Qin2, Chad J. Achenbach1, Gysamber D’Souza3, Eric A. Engels1, Charles Rabkin1, Keri N. Althoff4, Romain Neugebauer1

1Kaiser Permanente, Oakland, CA, USA, 2Yale Univ, New Haven, CT, USA, 3Northwestern Univ, Chicago, IL, USA, 4Johns Hopkins Univ, Baltimore, MD, USA, 5NCI, Rockville, MD, USA

599 TIMING OF CART INITIATION INFLUENCES CANCER RISK AMONG WOMEN LIVING WITH HIV

Kate Salters1, Monica Ye2, Neora Pick3, Angela Kaida4, Sam Wiseman4, Shahab Jabbari5, Mark Hull1, Jean A. Shoveller1, Julio S. Montaner7, Robert S. Hogg7

1Simon Fraser Univ, Burnaby, British Columbia, Canada, 2BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, 3Oak Tree Clinic, Vancouver, British Columbia, Canada, 4St. Paul’s Hosp, Vancouver, British Columbia, Canada

600 CANCER RISK AMONG HIV-INFECTED PEOPLE IN THE US DURING THE MODERN TREATMENT ERA

Raul Ulises Hernandez-Ramirez1, Meredith S. Shiels2, Robert Dubrow1, Eric A. Engels2

1Yale Univ, New Haven, CT, USA, 2NCI, Rockville, MD, USA

601 CANCER INCIDENCE AMONG PERSONS ON MODERN SUPPRESSIVE ART, 2000–2012

Ann N. Burchell1, Kate Salters1, Oghenowode Eyawo2, Joanne Lindsay4, Jason Chia5, Michelle Cotterchio6, Mark Hull1, Monica Ye1, Janet M. Raboud6, Robert S. Hogg6

1St. Michael's Hosp, Toronto, Ontario, Canada, 2Simon Fraser Univ, Vancouver, British Columbia, Canada, 3BC Cnr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, 4St. Michael's Hosp, Toronto, Canada, 5Cancer Care Ontario, Toronto, Canada, 6Univ of Toronto, Toronto, Ontario, Canada

602 CANCER BURDEN AMONG HIV+ INDIVIDUALS ON ART IN MALAWI: A RECORD LINKAGE STUDY

Marie-Josephe Horner1, Steady Chasimpha2, Adrian Spoerri3, Julia Bohlius1, Hannock Tweya1, Eddie Moffo Phipi2, Sam Phipi1, Kennedy Malisita2, Charles Dzamalala2, Satish Gopal7

1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Malawi Cancer Registry, Blantyre, Malawi, 3Univ of Bern, Bern, Switzerland, 4Lighthouse Trust Clinic, Lilongwe, Malawi, 5Queen Elizabeth Hosp ART Clinic, Blantyre, Malawi, 6Lighthouse Trust, Lilongwe, Malawi, 7Univ of North Carolina Proj–Malawi, Lilongwe, Malawi
Poster P-N1 CARDIOVASCULAR RISK AND ART EFFECTS
Poster Hall - 4 EF 2:30 PM - 4:00 PM

608 THE EFFECT OF ART ON INFLAMMATION, COAGULATION, AND VASCULAR INJURY IN START
Jason Baker, Shweta Sharma, Birgit Grund, for the INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group
Univ of Minnesota, Minneapolis, MN, USA

609 PROTHROMBOTIC EFFECTS OF ABACAVIR IN AN IN VIVO MODEL
Isabel Andujar, Victor Collado-Díaz, Samuel Orden, Airinho Sanchez-Lopez, Maria Angeles Martinez-Cuesta, Angeles Alvarez, Juan V. Esplugues
1FISABIO, Valencia, Spain, 2Univ of Valencia, Valencia, Spain

610 A SWITCH TO RALTEGRAVIR DOES NOT LOWER PLATELET REACTIVITY IN HIV-INFECTED ADULTS
Wouter A. van der Heijden, Marjolein Bosch, Reinout van Creveld, Monique Keuter, Andre van der Ven, Quirijn de Mast
Radboud Univ Med Cntr, Nijmegen, Netherlands

Poster P-N2 DYSLIPIDEMIA AND HDL FUNCTION
Poster Hall - 4 EF 2:30 PM - 4:00 PM

611 DYSFUNCTIONAL HDL FROM HIV+ INDIVIDUALS PROMOTES FOAM-CELL FORMATION IN VITRO
Thomas A. Angelovich, Anna Hearps, Margaret D. Shi, Theodoros Kelesidis, Anthony Jaworowski
1Burnet Inst, Melbourne, Australia, 2Univ of California Los Angeles, Los Angeles, CA, USA

612 HDL CHOLESTEROL EFFLUX CAPACITY IS INVERSELY RELATED TO CLASSICAL MONOCYTE NUMBER
Santhosh R. Mannem, Dominic Chow, Martin Playford Playford, Beau K. Nakamoto, Kalpana J. Kallianpur, Mary Margaret Byron, Brooks I. Mitchell, Cecilia Shikuma, Nehal N. Mehta
1Univ of Hawaii, Honolulu, HI, USA, 2Natl Heart, Lung and Blood Inst, Bethesda, MD, USA

613 EFFECT OF ART INITIATION ON MONOCYTE AND HDL FUNCTION
1Univ Coll Dublin, Dublin, Ireland, 2Univ of California Los Angeles, Los Angeles, CA, USA, 3Mater Misericordiae Univ Hosp, Dublin, Ireland

614 CHOLESTEROL EFFLUX RESPONDS TO THE IMMUNE STATUS IN PROGRESSION OF HIV INFECTION
Olivia Tort, Roque Pastor, Felipe García, Esteban Martínez, Montserrat Plana, Tuixent Escrivá, Montserrat Cofán, Emma Fernández, Jose M. Gatell, Mireia Arnedo
1IDIBAPS, Barcelona, Spain, 2Hosp Clinic of Barcelona, Barcelona, Spain
615  LOWER RATES OF CVD PROCEDURES IN HIV-INFECTED PATIENTS WITH ACUTE CORONARY SYNDROME
Meredith Clement1, Li Lin2, Ann M. Navar1, Nwora L. Okeke1, Susanna Naggie1, Pamela Douglas1
1Duke Univ, Durham, NC, USA, 2Duke Clinical Rsr Inst, Durham, NC, USA

616  EXERCISE, OXIDATIVE STRESS, AND FIBRINOLYTIC FUNCTION IN HIV-1 INFECTED ADULTS
Elizabeth Connick1, Jared Greiner2, Caitlin Dow1, Kyle Diehl1, Brian Stauffer1, Christopher DeSouza1
1Univ of Arizona, Tucson, AZ, USA, 2Univ of Colorado Boulder, Boulder, CO, USA,
Univ of Colorado Denver, Aurora, CO, USA

617  VITAMIN D DEFICIENCY IMPAIRS THE BENEFICIAL EFFECTS OF STATIN IN TREATED HIV
Corrilynn O. Hileman1, Vin Tangpricha2, Abdus Sattar1, Grace A. McComsey1
1Case Western Reserve Univ, Cleveland, OH, USA, 2Emory Univ, Atlanta, GA, USA

618  EFFECT OF STATIN ON ARGinine METABOLITES IN TREATED HIV INFECTION
Sahera Dirajlal-Fargo1, Vanessa El Kamari1, Abdus Sattar2, Nicholas Funderburg1, W. H. Wilson Tang4, Grace A. McComsey2
1Rainbow Babies and Children's Hosp—Case Western Sch of Med, Cleveland, OH, USA,
Case Western Reserve Univ, Cleveland, OH, USA, Ohio State Univ, Columbus, OH, USA,
Cleveland Clinic, Cleveland, OH, USA

619  THE LARGE GAP BETWEEN STATIN ELIGIBILITY AND PRESCRIPTION AMONG HIV+ IN NORTH AMERICA
Keri N. Althoff1, Micheal A. Horberg2, Joseph J. Eron1, Stephen J. Gange1, Heidi M. Crane4, Amy Justice6, Mari Kitahata4, Joseph B. Margolick1, Oghenowede Eyawo6, Richard D. Moore1
1The Johns Hopkins Univ, Baltimore, MD, USA, 2Kaiser Permanente Mid-Atlantic States, Rockville, MD, USA,
Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, Univ of Washington, Seattle, WA, USA,
VA Connecticut Hlthcare System, West Haven, CT, USA, BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada

620  FIRST AND RECURRENT VENOUS THROMBOSIS IN HIV PATIENTS OF THE DUTCH ATHENA COHORT
Casper Rokx1, Jaime Borjas Howard1, Colette Smit1, Ferdinand Wit1, Elise D Pieterman1, Karina Meijer1, Wouter Bierman2, Vladimir Tichelaar2, Bart Rijnders1
1Erasmus Univ Med Cntr, Rotterdam, Netherlands, 2Univ Med Cntr Groningen, Groningen, Netherlands, Stichting HIV Monitoring, Amsterdam, Netherlands

621  PREVALENCE AND PROGNOSTIC IMPACT OF PULMONARY HYPERTENSION IN HIV-INFECTED ADULTS
Courtney Zola, John R. Koethe, Meng Xu, Quinn S. Wells, Eric Farber-Eger, Evan L. Brittian
Vanderbilt Univ, Nashville, TN, USA
622 **BODY-MASS INDEX AND ADJUDICATED HEART FAILURE IN A LARGE ELECTRONIC HIV COHORT**
Matthew J. Feinstein, Alexandra B. Stevenson, Anna Pawlowski, Daniel Schneider, Prasanth Nannapaneni, Sadiya S. Khan, Mercedes Carnethon, Chad J. Achenbach, Sanjiv J. Shah, Donald M Lloyd-Jones
Northwestern Univ, Chicago, IL, USA

654 **HIV AS A RISK FACTOR OF AIRWAY OBSTRUCTIVE DISEASE**
Alain Makinson1, Sabrina Eymard-Duverney2, Céline Ribet3, Lucie Marchand4, Maurice Hayot4, Gilles Pialoux5, Jacques Reynolds3, Marie Zins1, Vincent Le Moing4, for the ANRS EP48 HICHEST Study Team
1Univ Hosp Montpellier, Montpellier, France, 2INSERM, Montpellier, France, 3INSERM, Villejuif, France, 4France Recherche Nord et Sud Sida-HIV et Hépatites, Paris, France, 5Tenon Hosp, Paris, France, 6CHU de Montpellier, Montpellier, France

655 **CHRONIC HIV PULMONARY DISEASE (CHPD) IN NEVER-SMOKING HIV PATIENTS**
Antonella Santoro1, Riccardo Scaglioni1, Giulia Besutti1, Andrea Malagoli1, Jonathon Leipsic2, Janice Leung2, Gabriella Orlando1, Stefano Zona1, Guido Ligabue1, Giovanni Guaraldi1
1Univ of Modena and Reggio Emilia, Modena, Italy, 2Univ of British Columbia, Vancouver, British Columbia, Canada

656 **THE INFLUENCE OF HIV INFECTION ON PULMONARY FUNCTION IN A RURAL AFRICAN POPULATION**
Alinda Vos1, Meri Varkila2, Hugo Tempelman1, Walter Devillé1, Roos Barth1, Diederick Grobbee1, Roel Coutinho1, Kerstin Klipstein-Grobusch1, for the Ndlovu Research Group
1Univ Med Cntr Utrecht, Utrecht, Netherlands, 2Ndlovu Care Group, Groblersdal, South Africa

657 **FACTORS ASSOCIATED WITH PULMONARY IMPAIRMENT IN HIV-INFECTED SOUTH AFRICAN ADULTS**
Akshay Gupte1, Michelle Wong2, Reginah Msandiwa3, Grace Barnes1, Jonathan Golub1, Richard Chaissong1, Chris Hoffmann1, Neil Martinson1
1The Johns Hopkins Univ, Baltimore, MD, USA, 2Univ of the Witwatersrand, Soweto, South Africa, 3Perinatal HIV Rsr Unit, Soweto, South Africa

658 **CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND MORTALITY IN HIV**
Matthew Triplette1, Sheldon T. Brown1, Matthew B. Goetz2, Joon W. Kim2, Maria Rodriguez-Barradas2, Guy W. Soo Hoo2, Cherry Wongtrakool6, Kathleen Akgün3, Amy Justice4, Kristina Crothers1
1Univ of Washington, Seattle, WA, USA, 2James J. Peters VA Med Cntr, Bronx, NY, NY, USA, 3VA Greater Los Angeles Hlth Care System, Los Angeles, CA, USA, 4James J. Peters VA Med Cntr, Bronx, NY, USA, 5Baylor Coll of Med, Houston, TX, USA, 6Emory Univ, Atlanta, GA, USA, 7Yale Univ, New Haven, CT, USA, 8VA Connecticut Hlthcare System, West Haven, CT, USA

659 **SPIROMETRIC AND RADIOLOGICAL PREDICTORS OF INCIDENT COPD IN A SPANISH COHORT**
Francisco Fanjul, Gloria Sampériz, Javier Verdú, Helem Haydee Vilchez, Antoni Campins, Luisa Martin, Maria Peñaranda, Maria Angeles Ribas, Maria Leyes, Melchor Riera
Hosp Univ Son Espases, Palma de Mallorca, Spain
660  **EFFECT OF HIV INFECTION ON ALPHA-1 ANTITRYPSIN FUNCTION: ROLE IN EMPHYSEMA?**
Sarah E. Stephenson1, Engi F. Attia2, Carole L. Wilson1, Cherry Wongtrakool3, Kristina Crothers1, Irina Petraceh4, Lynn M. Schnapp5
1Med Univ of South Carolina, Charleston, SC, USA, 2Univ of Washington, Seattle, WA, USA, 3Emory Univ, Atlanta, GA, USA, 4Natl Jewish Hlth, Univ of Colorado, Denver, CO, USA

661  **HIV AND CIRCULATING LEVELS OF PRO-SURFACTANT PROTEIN B AND SURFACTANT PROTEIN D**
Meredith S. Shiels1, Gregory D. Kirk2, M. Brad Drummond3, Dilsher Dhillon4, Samir Hanash4, Ayumu Taguchi4, Eric A. Engels1
1NCI, Rockville, MD, USA, 2Johns Hopkins Univ, Baltimore, MD, USA, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4MD Anderson Cancer Cntr, Houston, TX, USA

---

**Poster P-O4 FRAILTY AND MULTIMORBIDITY**
**Poster Hall - 4 EF**

---

662  **TREND IN MULTIMORBIDITY AMONG HIV+ ADULTS IN CLINICAL CARE IN THE US**
Cherise Wong1, Stephen J. Gange2, Richard D. Moore2, Amy Justice3, Alison Abraham4, Kelly Gebo1, Jeffrey N. Martin4, Angel Althoff5
1The Johns Hopkins Univ, Baltimore, MD, USA, 2VA Connecticut Hlthcare System, West Haven, CT, USA, 3Univ of Calgary, Calgary, Canada, 4Univ of California San Francisco, San Francisco, CA, USA, 5Univ Central del Caribe, Bayamon, Puerto Rico

663  **NON-AIDS ILLNESS BURDEN DIFFERS BY SEX, RACE, AND INSURANCE TYPE IN AGING HIV+ ADULTS**
Frank J. Palella1, Rachel Hart2, Carl Armon3, Ellen Tedaldi4, Bienvenido Yangco5, Richard Novak5, Linda Battalora6, Douglas Ward1, Bonnie Dean2, Kate Buchacz7
1Northwestern Univ, Chicago, IL, USA, 2Cerner Corporation, Kansas City, MO, USA, 3Temple Univ, Philadelphia, PA, USA, 4Infectious Disease Rsr Inst, Tampa, FL, USA, 5Univ of Illinois, Chicago, IL, USA, 6Colorado Sch of Mines, Golden, CO, USA, 7Dupont Circle Physicians Group, Washington, DC, USA, 8CDC, Atlanta, GA, USA

664  **PSYCHIATRIC DISORDERS OBSERVED IN HIV+ PATIENTS USING 6 COMMON THIRD AGENTS IN OPERA**
Ricky Hsu1, Jennifer Fusco2, Cassidy Henegar2, Felix Carpio3, Karam Mounzer4, Michael Wohlfeiler5, Vani Vannappagari6, Michael Aboud7, Lloyd Curtis8, Gregory Fusco2
1New York Univ, New York, NY, USA, 2Epividian, Durham, NC, USA, 3Altamed Hlth Services, Los Angeles, CA, USA, 4Philadelphia FIGHT, Philadelphia, PA, USA, 5AIDS Hlthcare Fndn, Los Angeles, CA, USA, 6ViiV Hlthcare, Rsr Triangle Park, NC, USA, 7ViiV Hlthcare, Brentford, UK, 8GlaxoSmithKline, Uxbridge, UK

665  **FRAILTY HAS A STRONGER ASSOCIATION THAN NEUROCOGNITIVE IMPAIRMENT WITH POOR OUTCOMES**
Kristine Erlanson1, Mona Abdo2, Kevin Robertson3, Susan L. Koletar4, Robert Kalayjian5, Babafemi Taiwo6, Frank J. Palella7, Katherine Tassiopoulos1, for the A5322 Study Team
1Univ of Colorado, Aurora, CO, USA, 2Harvard Univ, Boston, USA, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4Ohio State Univ, Columbus, OH, USA, 5MetroHlth Med Cntr, Cleveland, OH, USA, 6Northwestern Univ, Chicago, IL, USA
666  FRAILTY STATUS AND RISK OF FALLS IN HIV-INFECTED OLDER ADULTS IN THE ACTG A5322 STUDY
Katherine Tassiopoulos, Mona Abdo, Susan L. Koletar, Frank J. Paella, Babafemi Taiwo, Kristine Erlandson, for the A5322 Study Team
1Harvard Univ, Boston, MA, USA, 2Ohio State Univ, Columbus, OH, USA, 3Northwestern Univ, Chicago, IL, USA, 4Univ of Colorado, Aurora, CO, USA

667  PHYSICAL FUNCTION AND INFLAMMATION IN OLDER HIV-INFECTED MEN
Hillary McClintic, Matthew Freiberg, Stephen Crystal, David Leaf, Julie A. Womack, Karen Nieves-Lugo, Janet Tate, Kristina Crothers, Amy Justice, Krisann Oursler
1Virginia Tech, Roanoke, VA, USA, 2Vanderbilt Univ, Nashville, TN, USA, 3Rutgers, The State Univ of New Jersey, New Brunswick, NJ, USA, 4VA Greater Los Angeles Hlthcare System, Los Angeles, CA, USA, 5VA Connecticut Hlthcare System, Branford, CT, USA, 6The George Washington Univ, Washington, DC, USA, 7VA Connecticut Hlthcare System, West Haven, CT, USA, 8Univ of Washington, Seattle, WA, USA, 9Salem VA Med Cntr, Salem, VA, USA

668  VACS INDEX AS A PREDICTOR FOR NON-AIDS DEFINING CONDITIONS IN A LONGITUDINAL COHORT
Brian K. Agan, Seung Hyun Won, Christina Schofield, Anuradha Ganesan, Margaret Glancey, Jason Okulicz, Edmund C. Tramont, Julie Pavlin, for the IDCRP HIV Working Group
1Uniformed Services Univ of the Hlth Scis, Bethesda, MD, USA, 2Madigan Army Med Cntr, Tacoma, WA, USA, 3San Antonio Military Med Cntr, Fort Sam Houston, TX, USA, 4NIAID, Bethesda, MD, USA

669  AMERICAN GINSENG FOR THE TREATMENT OF HIV FATIGUE: A RANDOMIZED CLINICAL TRIAL
Adriana Andrade, Jeff Sloan, Chun-Su Yuan, Brent Bauer, Paul Novotny, Judith Rabkin, Jeffrey Hsu, Adrian Dobs, Todd Brown
1The Johns Hopkins Univ, Baltimore, MD, USA, 2Mayo Clinic, Rochester, MN, USA, 3Univ of Chicago Med, Chicago, IL, USA, 4Columbia Univ, New York, NY, USA

670  APPLES—THE AUSTRALIAN POSITIVE & PEERS LONGEVITY EVALUATION STUDY
Kathy Petoumenos, Robin Huang, Jennifer Hoy, Mark Bloch, David J. Templeton, David Baker, Michelle Giles, Matthew Law, David A. Cooper
1Kirby Inst, Sydney, Australia, 2The Alfred Hosp and Monash Univ, Melbourne, Australia, 3Hawthorne House Med Practice, Sydney, Australia, 4RPA Sexual Hlth, Camperdown, Australia, 5East Sydney Doctors, Darlinghurst, Australia, 6Monash Hlth, Melbourne, Australia

671  PATIENTS’ BELIEFS ABOUT THEIR HAART IN COMPARISON WITH THEIR CHRONIC COTREATMENTS
Susan Kamal, Olivier Bugnon, Matthias Cavassini, Marie-Paule Schneider, for the Swiss HIV Cohort Study
1Univ of Lausanne, Lausanne, Switzerland, 2Univ of Geneva, Univ of Lausanne, Lausanne, Switzerland
725 TUBERCULOSIS IN SOUTH AFRICA IS MORE CONCENTRATED BY RACE THAN POVERTY
Stanford Univ, Stanford, CA, USA

726 HIGH TB INFECTION RATE IN CHILDREN & YOUNG ADULTS IN RURAL UGANDA IN THE SEARCH TRIAL
Carina Marquez1, Atukunda Mucunqizi2, Gabriel Chamie3, Dalsone Kwarriisma3, Theodore Ruel1, Laura B. Balzer2, Tamara D. Clark1, Edwin D. Charlebois1, Maya L. Petersen3, Diane V. Havlir3
1Univ of California San Francisco, San Francisco, CA, USA, 2Infectious Diseases Rsr Collab, Kampala, Uganda, 3Makerere Univ Joint AIDS Prog, Kampala, Uganda, *Harvard Univ, Boston, MA, USA, *Univ of California Berkeley, Berkeley, CA, USA

727 THE HIV-ASSOCIATED BURDEN OF RECURRENT TB DISEASE IN CAPE TOWN, SOUTH AFRICA
Sabine Hermans1, Nesbert Zinyakatira2, Judy Caldwell2, Frank Cobelens4, Andrew Boule3, Robin Wood2
1Amsterdam Inst for Global Hlth and Development, Amsterdam, Netherlands, 2Univ of Cape Town, Cape Town, South Africa, 3City Hlth, Cape Town, South Africa, 4Univ of Amsterdam, Amsterdam Zuidoost, Netherlands

728 HIV TESTING UPTAKE AMONG HOUSEHOLD CONTACTS OF MDR-TB INDEX CASES IN 8 COUNTRIES
Valarie S. Opollo1, Xingye Wu2, Richard Lando1, Susan Swindells4, Amita Gupta2, Anneke Hesseling5, Rodney Dawson4, Michael D. Hughes4, N. Sarita Shah5, for the A5300/I2003 Study Team
1Kenya Med Rsr Inst, Kisumu, Nyanza, Kenya, 2Harvard Univ, Boston, MA, USA, 3Kenya Med Rsr Inst, Kisumu, Kenya, 4Univ of Nebraska, Omaha, NE, USA, 5The Johns Hopkins Univ, Baltimore, MD, USA, 6Stellenbosch Univ, Tygerberg, South Africa, 7Univ of Cape Town, Mowbray, South Africa, 8CDC, Atlanta, GA, USA

729 HIV CONTINUUM AND EXPEDITED TB DIAGNOSIS IN TB/HIV COINFECTED PATIENTS IN BOTSWANA
Diane Gu1, Sanghyuk S Shin2, Chawangwa Modongo2, Cynthia Caiphus1, Othusitse Fan2, Matsiri Ogopotse2, Mbatsi Dima2, Nicola M Zetola4
1Univ of California Los Angeles, Los Angeles, CA, USA, 2Botswana–UPenn Partnership, Gaborone, Botswana, 3Princess Marina Hosp, Gaborone, Botswana, 4Univ of Pennsylvania, Gaborone, Botswana

730 IMPROVEMENT OF HIV/TB CARE: TIME-SERIES ANALYSIS OF HEALTH FACILITY DATA
Nehaben Ramanlal1, Dulce Bila1, Orvalho Augusto2, Nello Macuacua1, Victorino Chavane1, Leonel Zevo1, Chadreque Muluna3, Esmeralda Karajeanes1, Paula Vaz1
1Fundação Ariel Glaser Contra o Sida Pediatrico, Maputo, Mozambique, 2Univ Eduardo Mondlane, Maputo, Mozambique, 3Direccção Provincial de Saúde de Maputo, Maputo Provincia, Mozambique
731 INTEGRASE INHIBITORS ARE AN INDEPENDENT RISK FACTOR FOR IRIS: AN ATHENA COHORT STUDY

Ingeborg Wijting1, Casper Rokx1, Ferdinand Wit2, Anneloes Postma1, Andy Hoepelman1, Ineke van der Ende1, Peter Reiss1, Bart Rijnders1

1Erasmus Univ Med Cntr, Rotterdam, Netherlands, 2Stichting HIV Monitoring, Amsterdam, Netherlands, 3Univ Med Cntr Utrecht, Utrecht, Netherlands

732 INITIATION OF ART BASED ON INTEGRASE INHIBITORS INCREASES THE RISK OF IRIS

Marine Dutertre1, Lise Cuzin2, Pascal Puglièse3, Veronica Joly4, Marc-Antoine Valantin5, Laurent Cotte6, Thomas Huleux7, Pierre Delobel2, Guillaume Martin-Blondel1, for the Dat’AIDS

1Toulouse Univ Hosp, Toulouse, France, 2CHU Toulouse, Toulouse, France, 3CHU de Nice, Nice, France, 4Bichat Hosp, Paris, France, 5AP–HP, Paris, France, 6Hospices Civils de Lyon, Lyon, France, 7Cntr Hosp de Tourcoing, Tourcoing, France

733 INFLAMMASOMES PLAY A MAJOR ROLE IN TB IRIS PATHOGENESIS

Denise C. Hsu1, Daniel Sturdevant2, Eleanor Wilson1, Virginia Sheikh1, Ornella Sortino3, Silvia Lage1, Timothy G. Myers1, Stephen Porcella1, Irini Sereti1

1NIAID, Bethesda, MD, USA, 2NIAID, Hamilton, MT, USA, 3Leidos Biomed Rsr Inc, Frederick, MD, USA

734 THE DIABETES-TUBERCULOSIS COMORBIDITY AMONG PERSONS WITH HIV

Monica Sane Schepsi1, Jalal Miah2, Anna Kaluzhenina3, Katerina Manika Manika4, Emanuele Pontali5, Monica Rios Prego6, Maria Nieves Altet Altet7, Diana Sanchez Mellado Sanchez Mellado8, Enrico Girardi9, for the TB NET

1Natl Inst for Infectious Diseases L. Spallanzani, Rome, Italy, 2Newham Univ Hosp Barts NHS Trust, London, UK, 3Volgograd State Med Univ, Volgograd, Russian Federation, 4Aristotle Univ of Thessaloniki, Thessaloniki, Greece, 5Galliera Hosp, Genova, Italy, 6EComplexo Hspario Univ de Pontevedra, Pontevedra, Spain, 7Unidad de Prevención y Control de la TB de Barcelona, Barcelona, Spain, 8IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain

735 RISK PROFILES IN MONOINFECTED TB PATIENTS AND THOSE COINFECTED WITH HCV AND/OR HIV

David Roth1, James Johnston1, Jason Wong1, Mel Krajden1, Zahid A. Butt1, Nabin Shrestha2, Mark Gilbert1, Victoria Cook1, Naveed Z. Janjua1

1BC Cntr for Disease Control, Vancouver, British Columbia, Canada, 2Univ of British Columbia, Vancouver, British Columbia, Canada

736 PROBLEM DRUG USE PREDICTS HIGHER HIV PREVALENCE IN UK TUBERCULOSIS CASES, 2010–2014

Joanne R. Winter1, Helen R. Stagg2, Colette J. Smith1, Maeve K. Lalar1, Alison E. Brown2, H. L. Thomas2, Valerie Delpech2, Ibrahim Abubakar1

878 EVALUATION OF MATERNAL AND INFANT HIV POINT-OF-CARE DIAGNOSTICS AT BIRTH IN TANZANIA

Issa Sabi, Hellen Mahiga, Jimson Mgaya, Otto Geisenberger, John France, Michael Hoelscher, Arne Kroidi

1NIMR–Mbeya Med Rsr Cnt (MMRC), Mbeya, Tanzania, 2Univ of Munich, Munich, Germany, 3Mbeya Referral Hosp, Mbeya, Tanzania

879 EVALUATION OF THE CEPHEID HIV-1 QUAL POINT-OF-CARE TEST FOR HIV DIAGNOSIS AT BIRTH

Maryanne R. Ibrahim, Sikhulile Moyo, Terence Mohammed, Kenneth Maswabi, Gbolahan Ajibola, Rebecca Gelman, Chloé Aulettta-Young, Shahin Lockman, Joseph Makhema, Roger L. Shapiro

1Doris Duke Intl Clinical Rsr Fellowship, Los Angeles, CA, USA, 2Botswana Harvard AIDS Rsr Inst Partnership, Gaborone, Botswana, 3Dana–Farber Cancer Inst, Boston, MA, USA

879 TARGETED HIV SCREENING AT BIRTH CAN IDENTIFY THE MAJORITY OF IN UTERO TRANSMISSIONS

Maryanne R. Ibrahim, Kenneth Maswabi, Gbolahan Ajibola, Sikhulile Moyo, Michael D. Hughes, Chloé Aulettta-Young, Daniel R. Kuritzkes, Mathias Lichterfeld, Joseph Makkema, Roger L. Shapiro

1Doris Duke Intl Clinical Rsr Fellowship, Los Angeles, CA, USA, 2Botswana Harvard AIDS Rsr Inst Partnership, Gaborone, Botswana, 3Harvard Univ, Boston, MA, USA, 4Brigham and Women's Hosp, Boston, MA, USA, 5Massachusetts General Hosp, Boston, MA, USA

879 IMPACT OF BIRTH PCR ON RETENTION IN CARE OF HIV-EXPOSED INFANTS IN PRIMARY CARE

Aurelie Nelson, Laura Trivino Duran, Tali Cassidy, Gilles van Cutsem, Sarah Jane Steele, Mark Cotton, Janet Giddy, Jean Maritz

1MSF, Khayelitsha, South Africa, 2MSF, Cape Town, South Africa, 3Stellenbosch Univ, Cape Town, South Africa, 4KESS, Cape Town, South Africa

879 IMPACT OF EXPANDED SCREENING AND POC ON INFANT DIAGNOSIS AND ART INITIATION

Alliance Nikuze, Stephen Wanjala, Jihane Ben-Farhat, Willis Omwoyo, Laura Oyiengo, Elisabeth Szumilin, Leon Salumu, Alexandra Vandenbulcke, Valarie S. Opollo, David Maman


879 DELAYED HIV DNA PCR DETECTION AMONG INFANTS WHO RECEIVED COMBINATION ART PROPHYLAXIS

Thanyawee Puthanakit, Archawin Rojanawiwat, Tanawan Samleeat, Hansa Thaisri, Jiratchaya Sophonphan, Sarawut Boonsuk, Sunet Ongwande, Varunee Jinarat, for the Thailand ACC Program

1Chulalongkorn Univ, Bangkok, Thailand, 2Ministry of Pub Hlth, Nonthaburi, Thailand, 3Chiang Mai Univ, Chiang Mai, Thailand, 4HIV Netherlands Australia Thailand Rsr Collab, Thai Red Cross AIDS Rsr, Bangkok, Thailand, 5Ministry of Pub Hlth, Nonthaburi, Thailand

879 HIV VIRAL-LOAD TRENDS WITHIN SOUTH AFRICA'S EARLY INFANT DIAGNOSIS PROGRAM, 2010–2015

Ahmad Haeri Mazanderani, Faith Moyo, Tendesayi Kufa-Chakezha, Gayle G. Sherman

1NCID, Johannesburg, South Africa, 2Univ of the Witwatersrand, Johannesburg, South Africa
795 DETECTION OF INDUCIBLE HIV IN CHILDREN ON ART DESPITE LOW HIV-1 DNA

Shalena Naidoo1, Michele Sobolewski2, Taylor Buckley2, Joshua C. Cyktor2, Melissa Tosiano2, Mary Grace K. Katusiime1, Gert U. van Zyl1, Mark Cotton1, Richard Glashoff1, John Mellors1

1Stellenbosch Univ, Cape Town, South Africa, 2Univ of Pittsburgh, Pittsburgh, PA, USA, 3Stellenbosch Univ, Parow, South Africa

796 HIV RESERVOIR SIZE IS NOT INCREASED BY SHORT ART INTERRUPTION IN KENYAN INFANTS

Mark D. Pankau1, Dalton Walamwana2, Sarah Benki-Nugent3, Agnes Langat2, Ken Tapia3, Elizabeth Maleche-Obimbo2, Julie Overbaugh1, Grace John-Stewart2, Dara Lehman1

1FRCHC, Seattle, WA, USA, 2Univ of Nairobi, Nairobi, Kenya, 3Univ of Washington, Seattle, WA, USA, 4US CDC, Nairobi, Kenya, 5Kenyatta Nati Hosp, Nairobi, Kenya

797 HIV SUBTYPE D IS ASSOCIATED WITH INCREASED LATENT RESERVOIR SIZE IN CHILDREN

Leila B. Giron1, Jane Achan4, Paul Bangirana1, Moses R. Kamya3, Diane V. Havlir3, Joseph K. Wong4, Theodore Ruel3, Satish K. Pillai5

1Fed Univ of Sao Paulo/Blood Systems Rsr Inst, Sao Paulo, Brazil, 2Disease Control and Elimination Theme, Med Rsr Unit, Fajara, Gambia, 3Makerere Univ, Kampala, Uganda, 4Univ of San Francisco, San Francisco, USA, 5Blood Systems Rsr Inst/UCSF, San Francisco, CA, USA

798 B-CELL RESPONSES IN EARLY TREATED LONG TERM VIRAL SUPPRESSED SERONEG HIV+ CHILDREN

Paolo Palma1, Paola Zangari1, Nicola Cotugno2, Eleni Nastoulia1, Laura McCoy3, Salvatore Rocca2, Bridget Ferns1, Savita Pahwa2, Paolo Rossi1, for the EPIICAL Consortium


799 RAPID RESTORATION OF EFFECTIVE ANTI-HIV CD4+ T-CELL ACTIVITY IN ART-TREATED CHILDREN

Emily Adland1, Luisa Mori2, Leana Laker1, Alice Swordy2, Anna Csala1, Masahiko Mori1, Philippa C. Matthews1, Pieter Jooste1, Philip J. Boulder1


800 PD-1+ MEMORY CD4 T CELLS, PROLIFERATIVE CAPACITY, AND INFLAMMATION IN HIV+ CHILDREN

Julia Foldi1, Lina Kozhaya1, Max Kilberg1, Mussa Mwamzuka2, Fatma Marshed2, Aabid Ahmed2, William Borkowsky1, Derya Unutmaz2, Alka Khaitan1

1New York Univ, New York, NY, USA, 2Bomu Hosp, Mombasa, Kenya
801 MICROBIAL TRANSLLOCATION DOES NOT DRIVE IMMUNE ACTIVATION IN UGANDAN CHILDREN WITH HIV
Felicity Fitzgerald1, Edouard Lhomme2, Kathryn Harris3, Julia Kenny1, Ronan Doyle1, Cissy Kityo1, Sarah Walker3, Rodolphe Thiébaut3, Nigel Klein4, for the CHAPAS-3 Trial Team

802 TARGETING IMMUNOACTIVATION IN HIV+ CHILDREN BY MODIFICATION OF THE GUT MICROBIOTA
Talia Sainz1, Nuria Jiménez-Hernández2, Laura Diaz3, Sergio Serrano-Villar4, María José Mellado1, Luis Prieto1, Jose Tomas Ramos5, M. Ángeles Muñoz-Fernández1, María José Gosalbes1, Maria Luisa Navarro1
1Hosp La Paz Inst for Hlth Rsr, Madrid, Spain, 2FISABIO–Salud Pública, Valencia, Spain, 3Gregorio Maranon Hosp, Madrid, Spain, 4Hosp Univ Ramón y Cajal, Madrid, Spain, 5Hosp de Getafe, Madrid, Spain

803 B- AND T-CELL SUBSETS AND IMMUNOGENICITY OF ROTAVIRUS VACCINE IN PHIV & PHEU INFANTS
Adriana Weinberg1, Jane Lindsey2, Ronald Bosch2, Deborah Persaud3, Paul Sato4, Barbara Heckman4, Kelly Richardson1, Amanda Zadzilka1, Margaret Nelson1, Myron Levin1
1Univ of Colorado, Aurora, CO, USA, 2Harvard Univ, Boston, MA, USA, 3The Johns Hopkins Univ, Baltimore, MD, USA, 4DAIDS, NIAID, Bethesda, MD, USA, 5Data Mgmt Cntr, Amherst, NY, USA, 6Frontier Sci and Tech Rsr Fndn, Amherst, NY, USA, 7Merck & Co, Inc, Upper Gwynedd, PA, USA

804 IMMUNOLOGICAL RESPONSE AFTER A BOOSTER DOSE OF HBV VACCINE IN HIV-INFECTED YOUTH
Vania Giacomet1, Daria Trabattoni2, Pilar Nannini2, Michela Masetti2, Federica Forlanini1, Mario Clerici1, Gian Vincenzo Zuccotti4
1L. Sacco Hosp, Milan, Italy, 2Univ of Milan, Milan, Italy, 3Univ of Milan, Segrate, Milan, Italy, 4Ospedale dei Bambini V. Buzzi, Milan, Italy

805 HPV4 VACCINE IMMUNOGENICITY/EFFECTIVENESS IN PERINATALLY HIV-INFECTED (PHIV) YOUTH
Anna-Barbara Moscicki1, Brad Karalius2, Katherine Tassiopoulos2, Denise Jacobson1, Kunjal Patel2, Murli U. Purswani1, George R. Seage3, Tzy-Jyun Yao4
1Univ of California Los Angeles, Los Angeles, CA, USA, 2Harvard Univ, Boston, MA, USA, 3Bronx Lebanon Hosp, Bronx, NY, USA

Poster P-R6 APPROACHING 90:90:90 IN ADOLESCENTS AND YOUNG ADULTS
Poster Hall - 4 EF
2:30 PM - 4:00 PM

831 CURRENT TRENDS IN CHILDREN WITH HIV DIAGNOSED IN THE UK AND IRELAND
Helen Peters, Kate Francis, Intira J. Collins, Ali Judd, Claire Thorne
Univ Coll London, London, UK
832 BASELINE POPULATION HIV CASCADE AND 2-YR OUTCOME OF HIV+ CHILDREN IN THE SEARCH TRIAL

Laura B. Balzer¹, Norton Sang¹, Albert Plenty¹, Teri Liegler¹, Craig Cohen¹, Elizabeth A. Bukusi², Moses R. Kamya³, Maya L. Petersen⁴, Diane V. Havlir⁵, Theodore Ruel⁶

¹Univ of California San Francisco, San Francisco, CA, USA, ²Kenya Med Rsr Inst, Nairobi, Kenya, ³Makerere Univ, Kampala, Uganda, ⁴Univ of California Berkeley, Berkeley, CA, USA

833 COST-EFFECTIVENESS OF HIV SCREENING: US ADOLESCENTS AND YOUNG ADULTS (AYA) AGED 13–24

Anne M. Neilan¹, Richard Dunville², Cheryl B. Ocfemia³, Joshua A. Salomon¹, Li Yan Wang², Katherine K. Hsu³, Elizabeth DiNenno⁴, Rochelle P. Walensky⁵, Robert A. Parker⁶, Andrea I. Ciarennolo⁷

¹Massachusetts General Hosp, Boston, MA, USA, ²CDC, Atlanta, GA, USA, ³Harvard SPH, Boston, MA, USA, ⁴Massachusetts Dept of Pub Hlth, Boston, MA, USA

834 COMMUNITY INTERVENTION IMPROVES ADOLESCENT HIV STATUS KNOWLEDGE: HPTN 071 STUDY ZAMBIA

Kwame Shanaube¹, Mwate J. Chaila¹, David Macleod², Ab Schaap³, Sian Floyd², Conred Jani¹, Graeme Hoddinott¹, Richard Hayes², Sarah Fidler³, Helen Ayles³


835 A NOVEL MODEL OF COMMUNITY COHORT CARE FOR HIV-INFECTED ADOLESCENTS IMPROVES OUTCOMES

Lindsey Reif¹, Rachel Bertrand², Vanessa Rivera³, Bernadette Jospeh⁴, Benedict Anglade⁵, Jean W. Pape¹, Daniel Fitzgerald¹, Margaret McNairy³

¹Columbia Univ, New York, NY, USA, ²ICAP at Columbia Univ, New York, NY, USA, ³GHESKIO, Port-au-Prince, Haiti, ⁴Weill Cornell Med, New York, NY, USA

836 LOCAL SOCIAL NETWORKS PREDICT RETENTION & SUPPRESSION IN YOUNG WOMEN IN SEARCH TRIAL

Lillian Brown¹, Wenjing Zheng¹, James Ayiekó¹, Asiphas Owaraganise¹, Florence Mwangwa², Tamara D. Clark¹, Edwin D. Charlebois³, Moses R. Kamya³, Diane V. Havlir¹, Maya L. Petersen²

¹Univ of California San Francisco, San Francisco, CA, USA, ²Univ of California Berkeley, Berkeley, CA, USA, ³Kenya Med Rsr Inst, Nairobi, Kenya, ⁴Infectious Diseases Rsr Collab, Kampala, Uganda, ⁵Makerere Univ, Kampala, Uganda

837 TEENAGE PREGNANCY: A CRITICAL BARRIER TO RETENTION ON ANTIRETROVIRAL THERAPY

Harriet Nuwagaba-Biribonwaho¹, Agnes Kiragga³, Constantin Yiannoutos¹, Beverly Musick¹, Kara K. Wools-Kaloustian², Elaine J. Abrams³, Batya Elul¹, for the International Epidemiologic Databases to Evaluate AIDS (IeDEA) East Africa Collaboration

¹ICAP at Columbia Univ, New York, NY, USA, ²Makerere Univ, Kampala, Uganda, ³Indiana Univ, Indianapolis, IN, USA, ⁴Columbia Univ, New York, NY, USA
IMPACT OF SUBSTANCE USE, MENTAL HEALTH, AND AGE ON RETENTION AND VIRAL SUPPRESSION

Brian C. Zanoni1, Sara Lammert1, Jessica Haberer1, Gregory K. Robbins1, Heidi M. Crane2, Michael J. Mugavero2, Katerina Christopoulos3, Kenneth H. Mayer4
1Massachusetts General Hosp, Boston, MA, USA, 2Univ of Washington, Seattle, WA, USA, 3Univ of Alabama at Birmingham, Birmingham, AL, USA, 4Univ of California San Francisco, San Francisco, CA, USA, 5Fenway Hlth, Boston, MA, USA

THE MACARTI STUDY: CLOSING THE GAPS IN HIV CARE AMONG YOUTH IN ATLANTA, GA

Andres Camacho-Gonzalez1, Scott Gillespie1, Lateshia Thomas-Seaton2, Krystal Frieson1, Sophia A. Hussen3, Ashley Murray4, Zaneta Gaul4, Madeline Sutton5, Chanda Graves, Rana Chakraborty
1Emory Univ, Atlanta, GA, USA, 2Children’s Hlthcare of Atlanta, Atlanta, GA, USA, 3Atlanta VA Med Cntr, Decatur, GA, USA, 4Emory Univ, Atlanta, GA, USA, 5CDC, Atlanta, GA, USA

RETENTION, ART USE, AND VIRAL SUPPRESSION AMONG YOUNG ADULTS NEWLY LINKED TO HIV CARE

Fidel A. Desir1, Peter F. Rebeiro2, Richard D. Moore1, Heidi M. Crane3, Karyn Gabler4, Joseph B. Margolick1, Michael A. Horberg5, Michael J. Silverberg6, Keri N. Althoff7
1The Johns Hopkins Univ, Baltimore, MD, USA, 2Vanderbilt Univ, Nashville, TN, USA, 3Univ of Washington, Seattle, WA, USA, 4BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, 5Harvard Univ, Boston, MA, USA, 6Kaiser Permanente Mid-Atlantic States, Rockville, MD, USA, 7Kaiser Permanente Northern California, Oakland, CA, USA

WITHDRAWN

“HOOKED ON PAINKILLERS” PRIOR TO FIRST INJECTION AMONG PWID IN 16 U.S. CITIES

Dita Broz1, Maria Zlotorzynska2, Michael Spiller1, Gabriela Paz-Bailey1, for the NHBS Study Group
1CDC, Atlanta, GA, USA, 2Emory Univ, Atlanta, GA, USA

OPIOID SUBSTITUTION THERAPY AND INITIATION INTO INJECTION DRUG USE IN SAN DIEGO, CA

Maria Luisa Mittal1, Devesh Vashishta1, Xiaoying Sun1, Sonia Jain1, Richard S. Garfein1, Steffanie A. Strathdee2, Dan Werb1
1Univ of California San Diego, La Jolla, CA, USA, 2Univ of California San Diego, San Diego, CA, USA

CHANGES IN PRESCRIPTION OPIOID, METH, AND COCAINE USE AMONG MSM IN 20 US CITIES

Brooke Hoots, Dita Broz, Lina Nerlander, Gabriela Paz-Bailey
CDC, Atlanta, GA, USA

Poster P-S4 HIV AND SUBSTANCE USE: DOUBLE TROUBLE
Poster Hall - 4 EF 2:30 PM - 4:00 PM
872  CHANGING PATTERN OF CRYSTAL METH USE IN BLACK & WHITE MSM, WASHINGTON, DC, 2008–2014
Irene Kuo1, Rudy Patrick1, Jenevieve Opoku2, Anthony Rawls1, Manya Magnus1, James Peterson1, Michael Kharfen2, Alan Greenberg1
1The George Washington Univ, Washington, DC, USA, 2District of Columbia Dept of Hlth, Washington, DC, USA

873  INCREASING METHAMPHETAMINE USE AMONG NON-MSM WHO INJECT DRUGS IN KING COUNTY, WA
Sara N. Glick1, Richard Burt1, Kim Kummer1, Joe Tinsley2, Caleb Banta-Green1, Matthew R. Golden1
1Univ of Washington, Seattle, WA, USA, 2Pub Hlth - Seattle & King County, Seattle, WA, USA

874  REDUCING ALCOHOL CONSUMPTION IMPROVED HIV VIRAL SUPPRESSION IN WOMEN
Robert L. Cook1, Zhi Zhou1, Maria J. Miguez2, Babette Brumback1, John Lewis1, Luis Espinoza1, Kendall J. Bryant4
1Univ of Florida, Gainesville, FL, USA, 2Florida Intl Univ, Miami, FL, USA, 3Univ of Miami, Miami, FL, USA, 4Natl Inst on Alcohol Abuse and Alcoholism, Bethesda, MD, USA

875  THE RELATIVE IMPACTS OF ART AND HARM REDUCTION ON HIV INCIDENCE IN BRITISH COLUMBIA
Bohdan Nosyk, Xiao Zang, Jeong E. Min, Emanuel Krebs, Viviane D. Lima, M-J Milloy, Jean A. Shoveller, Rolando Barrios, Evan Wood, Julio S. Montaner
BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada

934  PREP USED IN PREGNANCY DOES NOT INCREASE POOR BIRTH OUTCOMES
Renee Heffron1, Nelly Mugo2, Ting Hong1, Elizabeth A. Bukusi2, Elly T. Katabira1, Stephen Asiimwe2, Mark A. Marzinke2, Connie L. Celum1, Jared Baeten1, for the Partners Demonstration Project and Partners PrEP Study Teams
1Univ of Washington, Seattle, WA, USA, 2Kenya Med Rsr Inst, Nairobi, Kenya, 3Makerere Univ, Kampala, Uganda, 4Kabwohe Clinical Rsr Cntr, Kabwohe, Uganda, 5The Johns Hopkins Univ, Baltimore, MD, USA

935  PREGNANCY INCIDENCE AND OUTCOMES AMONG WOMEN USING THE DAPIVIRINE VAGINAL RING
Bonus Makanani1, Jennifer Balkus1, Thesla Palane-Phillips1, Yamikani Mbilizi1, Jeanna Piper1, Kenneth Kintu1, Tchangani Tembo2, Lisa Noguchi1, Helen Rees1, Jared Baeten1
1Malawi Coll of Med–Johns Hopkins Univ Rsr Proj, Blantyre, Malawi, 2Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 3Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa, 4NIH, Bethesda, MD, USA, 5Makerere Univ—Johns Hopkins Univ Rsr Collab, Kampala, Uganda, 6Univ of North Carolina Proj—Malawi, Lilongwe, Malawi, 7The Johns Hopkins Univ, Baltimore, MD, USA, 8Univ of Washington, Seattle, WA, USA
PREFERENCE AND CHOICE OF MULTIPURPOSE PREVENTION TECHNOLOGIES IN YOUNG AFRICAN WOMEN
Ariane van der Straten 1, Helen Cheng 1, Kawango Agot 2, Khatija Ahmed 3, Rachel Weinrib 1, Kghlisho Manenzhe 1, Fredrick Owino 2, Alexandra Minnis 1, for the Trio Study Team
1RTI Intl, San Francisco, CA, USA, 2Impact Rsr and Development Org, Kisumu, Kenya, 3Setshaba Rsr Cntr, Pretoria, South Africa

MODERN CONTRACEPTIVE USE AND UNPROTECTED SEX IN HIGH-RISK HIV-POSITIVE WOMEN IN KENYA
Diya Surie 1, Krista Yuhas 1, Kate Wilson 1, Linnet N. Masese 1, Juma Shafi 2, John Kinuthia 3, Walter Jaako 2, R. Scott McClelland 1
1Univ of Washington, Seattle, WA, USA, 2Univ of Nairobi, Nairobi, Kenya, 3Kenyatta Natl Hosp, Nairobi, Kenya

INTERACTION BETWEEN ETONOGESTREL-RELEASING IMPLANT AND 3 ANTIRETROVIRAL REGIMENS
Regis Kreitchmann 1, Alice Stek 2, Brookie Best 1, Edmund Capparelli 2, Jiajia Wang 3, David E. Shapiro 3, Edmund Capparelli 3, Jiajia Wang 4, David E. Shapiro 4, Nahida Chakhtoura 5, Sandra Burchett 6, Mark Mirochnick 7, for the IMPAACT P1026s Protocol Team
1Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil, 2Univ of Southern California, Los Angeles, CA, USA, 3Univ of California San Diego, La Jolla, CA, USA, 4Harvard Univ, Boston, MA, USA, 5NICHD, Bethesda, MD, USA, 6Boston Children’s Hosp, Boston, MA, USA, 7Boston Med Cntr, Boston, MA, USA

FERTILITY AND REPRODUCTIVE OUTCOMES OF HIV+ AND HIV-WOMEN IN THE CARMA COHORT STUDY
Clara E. Van Ommen 1, Ariane Y. Albert 2, Ariel Nesbitt 1, Shelana Gordon 1, Evelyn J. Maan 1, Helene C. Cote 1, Neora Pick 1, Deborah M. Money 1, Melanie C. Murray 1, for the CHF Team on Cellular Aging and HIV Comorbidities in Women and Children (CARMA)
1Univ of British Columbia, Vancouver, Canada, 2Women’s Hlth Rsr Inst, Vancouver, Canada, 3Oak Tree Clinic, Vancouver, Canada

EARLY ONSET MENOPAUSE AMONG WOMEN LIVING WITH HIV IN CANADA
Nisha Andany 1, Angela Kaida 2, Alexandra de Pokomandy 1, Lu Wang 1, V. Logan Kennedy 1, Mark Yudin 1, Kath Webster 1, Anita Benoit 1, Mona Loutfy 1, for the CHIWOS Research Team
1Women’s Coll Rsr Inst, Toronto, Ontario, Canada, 2Simon Fraser Univ, Burnaby, British Columbia, Canada, 3McCill Univ, Montreal, Canada, 4BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, 5St. Michael’s Hosp, Toronto, Ontario, Canada, 6CHIWOS Study, Vancouver, Canada, 7Univ of Toronto, Toronto, Ontario, Canada

COST-EFFECTIVENESS OF 2 METHODS TO TREAT CERVICAL DYSPLASIA IN HIV-POSITIVE WOMEN
Naomi Lince-Deroche 1, Craig Van Rensburg 1, Jane Phiri 1, Pamela Michelow 1, Jennifer Smith 1, Cindy Finnhaber 1
1Hlth Economics and Epi Rsr Office, Johannesburg, South Africa, 2NHLS, Johannesburg, South Africa, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4Right to Care, Johannesburg, South Africa

FERTILITY DESIRES OF HIV-POSITIVE MEN AND WOMEN IN THE US
Susan E. Cohn 1, Lisa B. Haddad 1, Christina S. Hayford 1, Anandi N. Sheth 2, Justin A. Schmandt 1, Joan S. Chmiel 1
1Northwestern Univ, Chicago, IL, USA, 2Emory Univ, Atlanta, GA, USA
CROI 2017
Poster Sessions • Wednesday
Program and Agenda

Poster P-T2 HOT FLASHES: HORMONAL CONTRACEPTION AND HIV RISK
Poster Hall - 4 EF 2:30 PM - 4:00 PM

943 CHANGES IN GENITAL-TRACT HIV TARGET CELLS WITH THREE PROGESTIN-BASED CONTRACEPTIVES
Lisa B. Haddad 1, Alison S. Kohlmeier 2, Richard Haaland 1, Nakita Brown 1, David Lupo 1, Christina Mehta 1, Anandi N. Sheth 1, Kehmia Titanji 1, Clyde Hart 1, Igho Ofotokun 1
1 Emory Univ, Atlanta, GA, USA, 2 CDC, Atlanta, GA, USA

944 DEPOT MEDROXYPROGESTERONE ACETATE INCREASES HIV-1 REPLICATION IN MUCOSAL TISSUE
Charlene S. Dezzutti 1, Seo Young Park 1, Ingrid Macio 1, Kenneth Marks 3, Sidney Lawlor 1, Catherine Chappell 1, Katherine Bunge 1
1 Univ of Pittsburgh, Pittsburgh, PA, USA, 2 Univ of Pittsburgh Med Ctr, Pittsburgh, PA, USA, 3 Magee-Womens Rsr Inst, Pittsburgh, PA, USA, 4 Magee-Womens Hosp of UPMC, Pittsburgh, PA, USA

945 ZIM-CHIC: IMPACT OF CONTRACEPTIVE INITIATION ON IMMUNE CELLS IN THE CERVIX AND PBMCs
Sharon L. Achilles 1, Feliz Mhlanga 2, Leslie A. Meyn 1, Kevin A. Stoner 3, Allen T. Matubu 2, Zvavahera M. Chirenje 2, Sharon L. Hillier 1
1 Univ of Pittsburgh, Pittsburgh, PA, USA, 2 Univ of Zimbabwe, Harare, Zimbabwe, 3 Magee–Womens Rsr Inst, Pittsburgh, PA, USA

946 HIV GENITAL-TRACT SHEDDING WHILE ON PROGESTIN CONTRACEPTION
Julie A. Nelson 1, Jeff Wiener 2, Jennifer H. Tang 1, Lameck Chinula 3, Stacey Hurst 2, Gerald Tegha 1, Albans Msika 1, Mina C. Hosseinipour 1, Lisa B. Haddad 4, Athena Kourtis 2
1 Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2 CDC, Atlanta, GA, USA, 3 Univ of North Carolina Proj–Malawi, Lilongwe, Malawi, 4 Emory Univ, Atlanta, GA, USA

947 HORMONAL CONTRACEPTION DOES NOT AFFECT ART EFFECTIVENESS OR GENITAL HIV SHEDDING
Rena Patel 1, Jared Baeten 1, Renee Heffron 1, Ting Hong 1, Nicole Davis 2, Kavita Nanda 3, Robert Coombs 1, Elizabeth A. Bukusi 1, Athena Kourtis 2, Nelly Mugo 1
1 Univ of Washington, Seattle, WA, USA, 2 CDC, Atlanta, GA, USA, 3 FHI 360, Durham, NC, USA, 4 Kenya Med Rsr Inst, Nairobi, Kenya, 5 KEMRI, Nairobi, Kenya

Poster P-T3 GENITAL INFECTIONS: MISHAPS AT THE MUCOSA
Poster Hall - 4 EF 2:30 PM - 4:00 PM

948 ASYMPTOMATIC CHLAMYDIA AND GONORRHEA ARE ASSOCIATED WITH CD8+ T-CELL ACTIVATION
Vinicius A. Vieira 1, Natalia B. Cerqueira 1, Dayane A. Costa 1, Priscilla R. Costa 1, Vivian I. Avelino-Silva 1, Ricardo D. Vasoncelos 1, Jose Valdez Madruga 1, Valdirea Veloso 1, Beatriz Grinsztejn 1, Esper G. Kallas 1
1 Univ of Sao Paulo, Sao Paulo, Brazil, 2 Centro de Referência e Treinamento DST/AIDS–SP, Sao Paulo, Brazil, 3 Oswaldo Cruz Fdn–Fiocruz, Rio de Janeiro, Brazil
949 MUCOSAL INFLAMMATION ABROGATES TENOFOVIR-GEL–
MEDIATED PROTECTION FROM HIV INFECTION
Lyle McKinnon¹, Lenine Liebenberg², Nonhlanhla Yende², Lindi Masson³,
Angela Kashuba¹, Derseree Archary⁴, Quarraisha Abdool Karim⁵, Salim
Abdool Karim⁵, Jo-Ann Passmore⁴, for the CAPRISA Mucosal Immunology
Collaboration
¹Univ of Manitoba, Winnipeg, Manitoba, Canada, ²CAPRISA, Durban, South
Africa, ³Univ of Cape Town, Cape Town, South Africa, ⁴Univ of North Carolina at
Chapel Hill, Chapel Hill, NC, USA

950 IS SYNDROMIC DIAGNOSIS OF REPRODUCTIVE TRACT
INFECTIONS ANTIQUATED IN THE HIV ERA?
Harriet Nuwagaba-Biribonwoha¹, Hannah Chung¹, Asungushe
Kayombo², Deodatha Mugisha³, Kokuhumbya Kazaoura³, Oscar Ernest¹,
Gissenge J. Lija⁴, Deborah Kajoka⁴, Jessica E. Justman⁵, Elaine J. Abrams⁵
¹ICAP at Columbia Univ, New York, NY, USA, ²Natl Inst of Med Rsr, Mwanza,
Tanzania, United Republic of, ³CDC Tanzania, Dar es Salaam, Tanzania,
⁴Tanzania Ministry of Hlth, Community Development, Gender, Elderly and
Children, Dar es Salaam, Tanzania

Poster P-U2 PREP WITHOUT BORDERS: NEW DELIVERY OPTIONS
Poster Hall - 4 EF 2:30 PM - 4:00 PM

961 FEASIBILITY OF A PHARMACIST–RUN HIV PREP CLINIC IN A
COMMUNITY PHARMACY SETTING
Elyse Tung¹, Annalisa Thomas¹, Allyson Eichner¹, Peter Shalit²
¹Kelley-Ross Pharm, Seattle, WA, USA, ²Univ of Washington, Seattle, WA, USA

962 ASSESSING THE EFFICACY AND FEASIBILITY OF A RETAIL
PHARMACY-BASED HIV TESTING PROGRAM
Bryan C. Collins, Heather W. Bronson, Elaine G. Martin
Virginia Dept of Hlth, Richmond, VA, USA

963 MIDWEST PHARMACISTS’ KNOWLEDGE OF & WILLINGNESS TO
PROVIDE PREEXPOSURE PROPHYLAXIS
Jordan Broekhuis, Kimberly K. Scarsi, Harlan Sayles, Donald Klepser,
Joshua Havens, Susan Swindells, Sara H. Bares
Univ of Nebraska, Omaha, NE, USA

964 TEXT MESSAGING IS ASSOCIATED WITH IMPROVED RETENTION
IN A CLINIC-BASED PREP PROGRAM
Christine M. Khosropour¹, Richard T. Lester², Matthew R. Golden², Julia
C. Dombrowski¹
¹Univ of Washington, Seattle, WA, USA, ²Univ of British Columbia, Vancouver,
British Columbia, Canada

965 BRIEF BEHAVIORAL INTERVENTION INCREASES PREP DRUG
LEVELS IN A REAL-WORLD SETTING
Sarit A. Golub¹, Stephanie Pena², Amy Hilley³, John Pachankis⁴, Asa Radix²
¹City Univ of New York, New York, NY, USA, ²Callen-Lorde Community Hlth Cntr,
New York, NY, USA, ³Hunter HIV/AIDS Rsr Team, New York, NY, USA, ⁴Yale Univ,
New Haven, CT, USA
**Poster P-U3 PREP AWARENESS, TARGETING, AND UPTAKE**  
Poster Hall - 4 EF  
2:30 PM - 4:00 PM

### 966  
**FOUR-YEAR TRENDS IN AWARENESS AND USE OF HIV PREP AMONG GBMSM IN VANCOUVER, CANADA**

Moliehi Khaketla¹, Nathan J. Lachowsky², Heather L. Armstrong³, Zishan Cui³, Mark Hull³, Paul Sereda⁴, Robert S. Hogg⁵, Julio S. Montaner⁶, Eric Roth⁷, David Moore⁸

¹Univ of British Columbia, Vancouver, Canada, ²Univ of Victoria, Victoria, Canada, ³BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada

### 967  
**KNOWLEDGE ABOUT PREP AMONG MSM AND TRANS* METHAMPHETAMINE USERS IN SEATTLE**

Vanessa McMahan¹, Aleks Martin², Lindsay Garske³, Jared Baeten¹, Caleb Banta-Green⁴, Joanne Stekler⁴

¹Univ of Washington, Seattle, WA, USA, ²Proj NEON, Seattle, WA, USA

### 968  
**A CLINICAL HIV PREEXPOSURE PROPHYLAXIS EDUCATION INTERVENTION AMONG MSM**

Julia Raifman¹, Catherine E. Oldenburg², Amy Nunn³, Madeline C. Montgomery⁴, Alexi Almonte⁵, Allison Agwu⁶, Renata Arrington-Sanders⁷, Philip A. Chan⁸

¹The Johns Hopkins Univ, Baltimore, MD, ²Univ of California San Francisco, San Francisco, CA, USA, ³Brown Univ, Providence, RI, USA, ⁴Miriam Hosp, Providence, RI, USA

### 969  
**PREP GUIDELINES HAVE LIMITED ACCURACY IDENTIFYING YOUNG MSM PRIOR TO SEROCONVERSION**

Nicola Lancki, Ellen Almirol, Leigh Alon, Moira McNulty, John A. Schneider

Univ of Chicago, Chicago, IL, USA

### 970  
**IDENTIFYING PREGNANT WOMEN FOR PREP USING ROUTINE ANTENATAL CARE INDICATORS IN KENYA**

Jillian Pintye¹, Benson Singa², Kennedy Wanyonyi², Janet Itindi², John Kinuthia³, Lucy Ng’ang’a³, Agnes Langat³, Abraham Katana³, Christine J. McGrath³, Grace John-Stewart¹

¹Univ of Washington, Seattle, WA, USA, ²Kenya Med Rsr Inst, Nairobi, Kenya, ³Kenyatta Natl Hosp, Nairobi, Kenya, ⁴US CDC, Nairobi, Kenya, ⁵Univ of Texas Med Branch, Galveston, TX, USA

### 971  
**PREP UPTAKE DISPARITIES IN A DIVERSE ON-LINE SAMPLE OF US MEN WHO HAVE SEX WITH MEN**

Kenneth H. Mayer¹, Katie Biello², David S. Novak³, Douglas Krakower⁴, Matthew J. Mimiaga⁵

¹Fenway Hlth, Boston, MA, USA, ²Brown Univ, Providence, RI, USA, ³On-Line Buddies, Inc, Cambridge, MA, USA, ⁴Beth Israel Deaconess Med Cntr, Boston, MA, USA
972 IMPACT OF INSURANCE COVERAGE ON PREEXPOSURE PROPHYLAXIS FOR HIV PREVENTION

Rupa R. Patel1, Leandro Mena2, Amy Nunn3, Timothy McBride1, Laura C. Harrison2, Catherine E. Oldenburg3, Jingxia Liu3, Kenneth H. Mayer3, Philip A. Chan4

1Washington Univ in St. Louis, St. Louis, MO, USA, 2Univ of Mississippi, Jackson, MS, USA, 3Brown Univ, Providence, RI, USA, 4Univ of California San Francisco, San Francisco, USA, 5Fenway Hlth, Boston, USA, 6The Miriam Hosp, Providence, RI, USA

973 CONCORDANT POPULATION-LEVEL INCREASES IN PREP FOUND WITH NOVEL PUBLIC HEALTH METHODS

Susan Buskin1, Julia Hood1, Sara N. Glick2, Warren Dinges1, Matthew R. Golden1

1Pub Hlth–Seattle & King County, Seattle, WA, USA, 2Univ of Washington, Seattle, WA, USA, 3Seattle Infectious Disease Clinic, Seattle, WA, USA

974 RACIAL/ETHNIC DISPARITIES IN PERSISTENCE AMONG PREP USERS IN SAN FRANCISCO

Hyman Scott1, Miranda Nordell1, Anne Hirozawa1, Monica Gandhi2, Catherine James1, Hali Hamner1, Susan Buchbinder1, Susan Scheer1

1San Francisco Dept of Pub Hlth, San Francisco, CA, USA, 2Univ of California San Francisco, San Francisco, CA, USA

975 URINE TENOFOVIR TESTING TO MEASURE PREP ADHERENCE AMONG YOUTH IN A REAL WORLD SETTING

Linden Lalley-Chareczko1, Devon Clark1, Ganesh S. Moorothy1, Athena Zuppa2, Caitlin Conyngham1, Karam Mounzer1, Pablo Tebas1, Helen C. Koenig1

1Philadelphia FIGHT, Philadelphia, PA, USA, 2Univ of Pennsylvania, Philadelphia, PA, USA, 3Children’s Hosp of Philadelphia, Philadelphia, PA, USA

976 COMBINING MEASURES OF ADHERENCE CAN ASSESS PATTERNS OF PREP DRUG-TAKING

Andrew M. Abaasa1, Craig Hendrix2, Monica Gandhi2, Peter Anderson3, Anatoli Kamali3, Eduard Sanders4, Gaudensia Mutua4, Frances Priddy5, Haberer Jessica6

1MRC/UVRI Uganda Rsr Unit on AIDS, Entebbe, Uganda, 2The Johns Hopkins Univ, Baltimore, MD, USA, 3Univ of California San Francisco, San Francisco, CA, USA, 4Univ of Colorado, Aurora, CO, USA, 5Intl AIDS Vaccine Initiative, New York, NY, USA, 6Kenya Med Rsr Inst, Kilifi, Kenya, 7Univ of Nairobi, Nairobi, Kenya, 8Cntr for Global Hlth, Massachusetts General Hosp, Boston, MA, USA

977 SUBSTANCE-USING MSM ON HIV PREEXPOSURE PROPHYLAXIS HAVE BETTER ADHERENCE

Martin Hoenigl1, Sonia Jain2, David J Moore3, Deborah Collins1, Xiaoying Sun1, Peter L. Anderson4, Katya Calvo5, Michael Dubé6, Sheldon Morris1, for the California Collaborative Treatment Group (CCTG) 595 Team

1Univ of California San Diego, San Diego, CA, USA, 2Univ of California San Diego, La Jolla, CA, USA, 3Long Beach HHS, Long Beach, CA, USA, 4Univ of Colorado Denver, Aurora, CO, USA, 5Los Angeles Biomed Rsr Inst at Harbor–UCLA Med Cntr, Torrance, CA, USA, 6Univ of Southern California, Los Angeles, CA, USA
978 OLDER AGE ASSOCIATED WITH BOTH ADHERENCE AND RENAL DECLINE IN THE PREP DEMO PROJECT

Monica Gandhi1, Peter Bacchetti1, Catherine A. Koss1, Chengshin Jin1, Howard Horng1, Richard Elion1, Michael Kolber1, Stephanie E. Cohen1, Susan Buchbinder4, Albert Y. Liu4
1Univ of California San Francisco, San Francisco, CA, USA, 2The George Washington Univ, Washington, DC, USA, 3Univ of Miami, Miami, FL, USA, 4San Francisco Dept of Pub Hlth, San Francisco, CA, USA

979 CHANGES IN SEXUAL BEHAVIOR AND STI DIAGNOSES AMONG MSM USING PREP IN SEATTLE, WA

Michalina A. Montano, Julia C. Dombrowski, Lindley A. Barbee, Matthew R. Golden, Christine M. Khosropour
Univ of Washington, Seattle, WA, USA


Ya-Lin A. Huang, Guoyu Tao, Taraz Samandari, Karen W. Hoover
CDC, Atlanta, GA, USA

981 BONE CHANGES WITH TDF-CONTAINING AND NON–TDF-CONTAINING PREP IN US MEN AND WOMEN

Todd Brown1, Timothy Wilkin2, Kenneth H. Mayer3, Raphael J. Landovitz4, Ying Q. Chen5, Alicia Young6, Mark A. Marzinke7, Wairimu Chege8, Marybeth McCauley9, Roy M. Gulick10
1The Johns Hopkins Univ, Baltimore, MD, USA, 2Weill Cornell Med, New York, NY, USA, 3Fenway Hlth, Boston, MA, USA, 4Univ of California Los Angeles Cntr for Clinical AIDS Rsr & Educ, Los Angeles, CA, USA, 5Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 6Statistical Cntr for HIV/AIDS Rsr and Prevention, Seattle, WA, USA, 7NIAID, Bethesda, MD, USA, 8FHI 360, Washington, DC, USA

Poster P-W1 MEASURING THE GLOBAL HIV CARE CASCADE
Poster Hall - 4 EF 2:30 PM - 4:00 PM

988 BOTSWANA'S PROGRESS TOWARDS THE THIRD “90”: VIRAL SUPPRESSION IN THE MASA PROGRAM

Madisa Mine1, Julia Ngidi1, Lesego Gabaititi2, Joseph N. Jarvis3, Modiri Tau1, Ava Avalos1, Tendani Gaolathe1, Dinah Ramabaya4, Bornaparte Nkomo5
1Natl Hlth Lab, Gaborone, Botswana, 2Univ of Botswana, Gaborone, Botswana, 3CDC Botswana, Gaborone, Botswana, 4Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana, 5Ministry of Hlth, Gaborone, Botswana

989 POPULATION-LEVEL VIRAL-LOAD MONITORING TO MEASURE PROGRESS TOWARDS THE “THIRD 90”

Maia Lesosky1, Nei-Yuan M. Hsiao1, Wolfgang Preiser2, Jean Maritz3, Landon Myer4
1Univ of Cape Town, Cape Town, South Africa, 2Stellenbosch Univ, Cape Town, South Africa, 3NHLS, Cape Town, South Africa, 4NHL, Cape Town, South Africa

990 CONTEMPORARY DISENGAGEMENT FROM ANTIRETROVIRAL THERAPY IN KHAYELITSHA, SOUTH AFRICA

Samantha Kaplan1, Christa Oosthuizen2, Kathryn Stinson2, Francesca Little1, Jonathan Euvrard3, Meg Osler4, Katherine Hilderbrand5, Andrew Boule2, Graeme Meintjes2
1Yale Univ Sch of Med, New Haven, CT, USA, 2Univ of Cape Town, Cape Town, South Africa
991 **SELF-REPORTED AND BIOMARKER HIV TREATMENT CASCADES FOR OLDER SOUTH AFRICAN ADULTS**

Julia K. Rohr¹, Jennifer Manne-Goehler², Xavier Gomez-Olive³, Joshua A. Salomon⁴, Pascal Geldsetzer⁵, Ryan Wagner⁶, Molly Rosenberg⁷, Chodziwadiwa Kabudula⁴, Kathleen Kahn⁴, Till Baernighausen⁷

¹Harvard Univ, Cambridge, MA, USA, ²Beth Israel Deaconess Med Ctr, Boston, MA, USA, ³Tintswalo Hosp, Acornhoek, South Africa, ⁴Univ of the Witwatersrand, Acornhoek, South Africa, ⁵Indiana Univ, Bloomington, IN, USA, ⁶Univ of the Witwatersrand, Johannesburg, South Africa, ⁷Heidelberg Univ, Heidelberg, Germany

992 **MISDIAGNOSED HIV INFECTION IN PREGNANT WOMEN INITIATING UNIVERSAL ART IN SOUTH AFRICA**

Allison Zerbe¹, Nei-yuan Hsiao², Tamsin Phillips¹, Kirsty Brittain¹, Elaine J. Abrams¹, Landon Myer³, for the Maternal Child Health - Antiretroviral Therapy (MCH-ART) Study

¹ICAP at Columbia Univ, New York, NY, USA, ²Div of Med Virology, Cape Town, South Africa, ³Univ of Cape Town, Cape Town, South Africa

993 **ACCURACY OF HIV AND CD4 FIELD TESTING IN THE BOTSWANA COMBINATION PREVENTION PROJECT**

Ebi Bile¹, Pamela J. Bachanas², Fiona Maurice¹, Sylvia Modise¹, Liziwe Chebani¹, Vongai Makovore¹, Peter Fonjungo¹, Mary Grace Alwano¹, William Bapati¹, Joseph N. Jarvis¹

¹US CDC Botswana, Gaborone, Botswana, ²CDC, Atlanta, GA, USA, ³Botswana Ministry of Hlth, Gaborone, Botswana, ¹Tebelopele Voluntary Counseling and Testing Ctr, Gaborone, Botswana

994 **PATIENTS’ OUT-OF-POCKET EXPENDITURES FOR ART IN SWAZILAND**

Maria Vaikath¹, Shaukat Khan², Emma Mafara², Ndumiso Dlamini², Phiwayinkhosi Dlamini², Nothando Ndzinisa², Njabulo Simelane², Velephi Okello¹, Till Baernighausen⁷, Pascal Geldsetzer¹

¹Harvard Univ, Boston, MA, ²Clinton Hlth Access Initiative, Mbabane, Swaziland, ³Swaziland Ministry of Hlth, Mbabane, Swaziland, ⁴Heidelberg Univ, Heidelberg, Germany

995 **MARKED MORTALITY AND RETENTION UNDER-REPORTING IN A LARGE HIV PROGRAM IN ZAMBIA**

Charles Holmes¹, Izuankanji Sikazwe¹, Ingrid Eshun-Wilson², Nancy Czaicki³, Kombatende Sikombe¹, Sandra Simbeza¹, Carolyn Bolton Moore⁴, Cardinal Hantuba¹, Nancy Padian³, Elvin Geng³

¹Cntr for Infectious Disease Rsr in Zambia, Lusaka, Zambia, ²Stellenbosch Univ, Cape Town, South Africa, ³Univ of California Berkeley, Berkeley, USA, ⁴Univ of Alabama at Birmingham in Lusaka, Zambia, ⁵Univ of California San Francisco, San Francisco, CA, USA

996 **DIFFERENTIAL UPTAKE OF HIV CARE AND TREATMENT BY SEXUAL RISK BEHAVIORS**

Veena G. Billioux¹, Larry W. Chang¹, Kate Grabowski¹, Steven Reynolds², Gertrude Nakigozi³, Joseph Seakasanu¹, Robert Ssekubugu³, Ronald H. Gray¹, Maria Wawer¹, for the Rakai Health Sciences Program

¹The Johns Hopkins Univ, Baltimore, MD, USA, ²NIAID, Washington, DC, USA, ³Rakai Hlth Scis Prog, Kalisizo, Uganda
1015 MIGRATION, GENDER, AND HIV INCIDENCE IN RAKAI, UGANDA
Oluwasolape M. Olawore1, Aaron Tobian2, Fred Nagaluda2, Ronald H. Gray1, Maria Wawer1, Robert Sekekubugu1, John Santelli3, Larry W. Chang1, David Serwadda4, Kate Grabowski1
1The Johns Hopkins Univ, Baltimore, MD, USA, 2Rakai Hlth Scis Prog, Kalisizo, Uganda, 3Columbia Univ, New York, NY, USA, 4Makerere Univ, Kampala, Uganda

1016 OUTCOMES ALONG THE HIV CARE CONTINUUM AMONG UNDOCUMENTED IMMIGRANTS IN CLINICAL CARE
Jonathan Ross, Uriel Felsen, Chinazo Cunningham, Viraj V. Patel, David B. Hanna
Albert Einstein Coll of Med, Bronx, NY, USA

1017 IMMIGRANTS AND BOTSWANA’S ART PROGRAM: POTENTIAL BARRIERS TO EPIDEMIC CONTROL
Tafireyi Marukutira1, Mary Grace Alwano2, Stephanie Behel3, Joseph N. Jarvis1, Unoda Chakalisa3, Kathleen Powis4, William Bapati5, Gene Ussery6, Refeletswe Lebelonyane7, Pamela J. Bachanas2
1US CDC, Gaborone, Botswana, 2CDC, Atlanta, GA, USA, 3Botswana Harvard Partnership, Gaborone, Botswana, 4Harvard Univ, Boston, MA, USA, 5Tebelopele Voluntary Counseling and Testing Cntr, Gaborone, Botswana, 6Northrop Grumman Corporation, Atlanta, GA, USA, 7Botswana Ministry of Hlth, Gaborone, Botswana

1018 CASCADE OF CARE OF HIV SEROCONVERTERS IN THE CONTEXT OF UNIVERSAL “TEST AND TREAT”
Joseph Larmarange1, Mamadou H. Diallo2, Collins C. Iwuji2, Joanna Orne-Gliemann3, Nuala McGrath3, Mélanie Plazy4, Frank Tanser5, Rodolphe Thiébaut6, Deenan Pillay6, François Dabis6
1IRD, Paris, France, 2Univ Coll London, UK, London, UK, 3INSERM, Bordeaux, France, 4Univ of Southampton, Southampton, UK, 5Africa Hlth Rsr Inst, Mtubatuba, South Africa, 6Univ de Bordeaux, Bordeaux, France

1033 PREP TARGETING STRATEGIES FOR US ADOLESCENT SEXUAL MINORITY MALES: A MODELING STUDY
Steven M. Goodreau1, Deven T. Hamilton1, Patrick Sullivan2, Samuel Jenness3, Rachel A. Kearns3, Li Yan Wang4, Richard Dunville3, Lisa C. Barrios3, Eli Rosenberg2
1Univ of Washington, Seattle, WA, USA, 2Emory Univ, Atlanta, GA, USA, 3CDC, Atlanta, GA, USA

1034 STI INCIDENCE AMONG MSM FOLLOWING HIV PREEXPOSURE PROPHYLAXIS: A MODELING STUDY
Samuel Jenness1, Kevin Weiss1, Steven M. Goodreau2, Thomas Gift1, Harrell Chesson3, Karen W. Hoover5, Dawn K. Smith3, Patrick Sullivan1, Eli Rosenberg1
1Emory Univ, Atlanta, GA, USA, 2Univ of Washington, Seattle, WA, USA, 3CDC, Atlanta, GA, USA
1035  **ANTICIPATED ADHERENCE, EFFICACY, AND IMPACT OF WEEKLY ORAL PREEXPOSURE PROPHYLAXIS**

Christian Selinger¹, Ameya Kirtane², Omar Abouzid³, Robert Langer⁴, Carlo G. Traverso⁵, Anna Bershteyn⁶

¹Inst for Disease Modeling, Bellevue, WA, USA, ²Massachusetts Inst of Tech, Cambridge, MA, USA, ³Brigham and Women’s Hosp, Boston, MA, USA

1036  **POPULATION-LEVEL IMPACT AND COST-EFFECTIVENESS OF AN HIV VACCINE IN SOUTH AFRICA**

Christian Selinger¹, Anna Bershteyn¹, Dobromir Dimitrov⁷, Timothy B. Hallett¹, Linda-Gail Bekker⁸, Helen Rees⁹, Glenda Gray⁹, for the Pox-Protein Public-Private Partnership Global Access Committee

¹Inst for Disease Modeling, Bellevue, WA, USA, ²Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ³Imperial Coll London, London, UK, ⁴Univ of Cape Town, Cape Town, South Africa, ⁵Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa, ⁶Perinatal HIV Rsr Unit, Soweto, South Africa

1037  **COST-EFFECTIVENESS OF PREEXPOSURE PROPHYLAXIS ACROSS COUNTIES IN WESTERN KENYA**

Anna Bershteyn¹, Daniel J. Klein¹, Adam N. Akullian¹, Zindoga Mukandavire², Graham F. Medley³, Wanjiru Mukoma³, Michael K. Kiragu³, Kennedy Mutai¹, Katharine Kripke², for the OPTIONS Consortium

¹Inst for Disease Modeling, Bellevue, WA, USA, ²London Sch of Hygiene and Trop Med, London, United Kingdom, ³LVCT Hlth, Nairobi, Kenya, ⁴National AIDS Control Council, Ministry of Hlth, Nairobi, Kenya, ⁵Avenir Hlth, Washington, DC, USA

1038  **THE POTENTIAL IMPACT AND COST-EFFECTIVENESS OF MULTIPURPOSE PREVENTION TECHNOLOGIES**

Ide Cremin¹, Jennifer Smith¹, Rebecca Geary², Timothy B. Hallett¹


1039  **THE IMPORTANCE OF A LOCAL PERSPECTIVE IN MONITORING THE SUCCESS OF HIV PREVENTION**

Sarah-Jane Anderson¹, Joanne Enstone², Geoff P. Garnett³, Timothy B. Hallett¹

¹Imperial Coll London, London, UK, ²Univ of Nottingham, Nottingham, UK, ³Bill and Melinda Gates Fndn, Seattle, WA, USA
**Poster P-A3 HIV CELL INTERACTION**

**Poster Hall - 4 EF**

2:30 PM - 4:00 PM

166 **DETECTION AND CHARACTERIZATION OF CELLS EXPRESSING HIV RNA BY FLOW CYTOMETRY**

Aaron Christensen-Quick1, Amey Mukim2, Celsa A. Spina2, Sara Gianella3, Davey M. Smith1

1Univ of California San Diego, San Diego, CA, USA, 2VA San Diego Hlthcare System, San Diego, CA, USA, 3Univ of California San Diego, La Jolla, CA, USA

167 **INFLAMMASOME-REGULATED CYTOKINE IL-37 INHIBITS HIV-1 REPLICATION IN PRIMARY HUMAN CD4**

Neel Sangal, Guido Massaccesi, Jeffrey Quinn, Andrea Cox, Matthew Winter, Michael Chattergoon

Johns Hopkins Univ, Baltimore, MD, USA

168 **BCA2 INTERFERES WITH HIV-1 TRANSCRIPTION BY ENHANCING THE SUMOYLATION OF IKBA**

Marta Colomer-Lluch, Ruth Serra-Moreno

Texas Tech Univ, Lubbock, TX, USA

169 **RHO FAMILY GTPASES ENHANCE HIV-1 INFECTION**

Mark Lucera1, Zach Fleissner2, Caroline Tabler2, Daniela Schlatzer3, Zach Troyer1, John Tilton1

1Univ of Colorado, Aurora, CO, USA, 2Case Western Reserve Univ, Cleveland, OH, USA

170 **SEmen FACTORS ASSOCIATED WITH SEMen VIRAL LOAD AND INFECTION-ENHANCING ACTIVITY**

Christopher D. Pilcher1, Kara Marson1, Peter Bacchetti2, Sheila Keating3, Wendy Hartogensis1, Teri Liegler1, H. Ewa Wittkowska1, Satish K. Pillai2, Frederick M. Hecht1, Nadia R. Roan1

1Univ of California San Francisco, San Francisco, CA, USA, 2Blood Systems Rsr Inst, San Francisco, CA, USA, 3Gladstone Inst of Virology, San Francisco, CA, USA

171LB **STRUCTURAL BASIS FOR INHIBITOR-INDUCED AGGREGATION OF HIV INTEGRASE**

Kushol Gupta1, Vesa Turkki1, Scott Sherrill-Mix1, Young Hwang1, Grant Eilers1, Robert T. Nolte1, Emile Velthuisen1, Jerry Jeffrey1, Gregory Van Duyne1, Frederic Bushman1

1Univ of Pennsylvania, Philadelphia, PA, USA, 1Glaxosmithkline, Rsr Triangle Park, NC, USA

**Poster P-AS VIRUS ADAPTATION TO IMMUNITY**

**Poster Hall - 4 EF**

2:30 PM - 4:00 PM

176 **HLA-B27–RESTRICTED CTL-ESCAPE MUTATIONS INCREASE SENSITIVITY OF HIV-1 TO INTERFERON ?**

Philipp Schommers1, Christopher Ford1, Angelique Hölzemer1, Gerd Fäktenheuer1, Marcus Attfled2

1Univ of Cologne, Cologne, Germany, 2Heinrich Pette Inst, Hamburg, Germany

177 **CXCR4 VARIANTS ARE NEUTRALIZATION-RESISTANT COMPARED TO CCR5-USING VIRUSES IN HIV-1B**

Ludy Registre1, Yvetane Moreau1, Sila Ataca1, Manish Sagar1

1Boston Univ, Boston, MA, USA, 2Boston Med Cntr, Boston, MA, USA
178  MEASURING FITNESS OF IN VIVO ESCAPE MUTATIONS IN SIV ENV BY FITSEQ
Sergio Ita¹, Alison Hill², Evan Lam³, Ismael B. Fofana³, Welkin E. Johnson⁴
¹Univ of California San Diego, La Jolla, CA, USA, ²Boston Coll, Chestnut Hill, MA, USA

179  SIV ESCAPE FROM A VACCINE TARGETING CLEAVAGE SITES IS ASSOCIATED WITH A FITNESS LOSS
So-Yon Lim¹, David Tang², David La³, Shaun Tyler³, Ben Liang⁴, Francis Plummer⁵, Ma Luo⁶, James Whitney⁷
¹Beth Israel Deaconess Med Cntr, Boston, MA, USA, ²Natl MicroBio Lab, Winnipeg, Canada

180  MUTATIONS IN HIV-1 ENV RESCUE Replication DEFECTS DESPITE POOR CELL-FREE INFECTIVITY
Rachel Van Duyne, Lillian Kuo, Ken Fujii, Eric O. Freed
NCI, Frederick, MD, USA

181LB RESISTANCE TO TYPE I INTERFERONS IS A MAJOR DETERMINANT OF HIV-1 TRANSMISSION FITNESS
Shilpa S. Iyer¹, Frederic Bibollet-Ruche¹, Scott Sherill-Mix¹, Gerald H. Learn¹, Lindsey J. Plenderleith², Andrew G. Smith¹, Ronnie M. Russell³, Paul M. Sharp⁴, Persephone Borrow⁴, Beatrice H. Hahn⁵

Poster P-B3 TIMING INFECTION AND DEFINING FOUNDER SEQUENCES AND DUAL INFECTIONS
Poster Hall - 4 EF  2:30 PM - 4:00 PM

196  BLIND DATING: PHYLOGENETIC DETERMINATION OF LATENT HIV SEQUENCE AGES WITHIN HOST
Bradley R. Jones¹, Joshua Horacsek¹, Jeffrey Joy¹, Zabrina Brumme¹, Art Poon²
¹Simon Fraser Univ, Burnaby, British Columbia, Canada, ²Univ of British Columbia, Vancouver, British Columbia, Canada

197  HIV-1 SEQUENCES FROM EARLY INFECTION PREDICT THE AGE OF THE INFECTION
Morgane Rolland¹, Christopher L. Owen¹, Sodsai Tovanabutra¹, Eric Sanders-Buell¹, Lucas Maganga¹, Hannah Kibuuka¹, Sorachai Nitayaphan¹, Fredrick Sawe¹, Merlin L. Robbi³, Nelson L. Michael³
¹US Military HIV Rsr Prog, Silver Spring, MD, USA, ²MMRP, Mbeya, Tanzania, ³United Republic of, ⁴AFRIMS, Bangkok, Thailand, ⁵Kenya Med Reseach Inst/Walter Reed Proj, Kericho, Kenya

198  USING PRIMER ID DEEP SEQUENCING TO IDENTIFY RECENT HIV INFECTION IN NORTH CAROLINA
Shuntai Zhou¹, Christopher Sellers¹, Marc Potempa¹, Scott J. Zimmerman¹, Erkia Samoff¹, William C. Miller¹, Joseph J. Eron¹, Myron S. Cohen¹, Ronald Swanstrom¹, Ann M. Dennis¹
¹Univ of North Carolina at Chapel Hill, Chapel, NC, USA, ²North Carolina State Lab of Pub Hlth, Raleigh, NC, USA, ³North Carolina Div of Pub Hlth, Raleigh, NC, USA, ⁴Ohio State Univ, Columbus, OH, USA
199 CHARACTERIZATION OF RECTAL TRANSMISSION BOTTLENECK USING SIV-MACAQUE MODEL

Zhe Yuan1, Fangrui Ma1, Andrew J. Demers1, Dong Wang2, Jianqing Xu2, Mark G. Lewis3, Qingsheng Li4
1Univ of Nebraska—Lincoln, Lincoln, NE, USA, 2Dow AgroScis, LLC, Indianapolis, IN, USA, 3Fudan Univ, Shanghai, China, 4BIOQUAL, Inc, Rockville, MD, USA

200 HIV-1 SUPERINFECTION AFTER RECENT INFECTION IS UNCOMMON IN SUB-SAHARAN AFRICA

Gabriel A. Wagner1, Parris S. Jordan1, Sergei L. Kosakovsky Pond2, Matt A. Price2, Eric Hunter2, Susan Allen2, William Kilembe2, Douglas D. Richman1, Antoine Chaillou1, for the IAVI
1Univ of California San Diego, La Jolla, CA, USA, 2Temple Univ, Philadelphia, PA, USA, 3Intl AIDS Vaccine Initiative, New York, NY, USA, 4Emory Univ, Atlanta, GA, USA, 5Zambia—Emory HIV Rsr Proj, Atlanta, GA, USA

201 FREQUENT INTRASUBTYPE HIV DUAL INFECTION IN TREATED CHRONICALLY INFECTED INDIVIDUALS

Gabriel A. Wagner1, Antoine Chaillou1, Gemma Caballero2, Donald Franklin1, Sergei L. Kosakovsky Pond2, Robert K. Heaton1, Douglas D. Richman1, Davey M. Smith1, for the CHARTER
1Univ of California San Diego, La Jolla, CA, USA, 2VA San Diego Hlthcare System, La Jolla, CA, USA, 3Temple Univ, Philadelphia, PA, USA

Poster P-C6 CORRELATES OF HIV DISEASE
Poster Hall - 4 EF 2:30 PM - 4:00 PM

228 GENOME-WIDE METHYLATION IS ASSOCIATED WITH HIV-1 INFECTION AND DISEASE PROGRESSION

Sara Moron-Lopez1, Judith Dalmau1, Victor Urrea1, Miguel Lopez2, Maria C. Puertas2, Beatriz Mothe2, Christian Brander1, Manel Esteller1, Maria Berdasco2, Javier Martinez-Picado1
1IrsiCaixa Inst for AIDS Rsr, Badalona, Spain, 2Bellvitge Biomed Rsr Inst, L'Hosp de Llobregat, Spain

229 MITOCHONDRIAL HAPLOGROUP AND HLA-B MAY JOINTLY INFLUENCE HIV VIRAL LOAD AND CD4 COUNT

Samuel Bailin, Mark Pilkinton, David C. Samuels, Silvana Gaudieri, Spyros Kalams, Todd Hulgan
Vanderbilt Univ, Nashville, TN, USA

230 T-CELL PHENOTYPE AND RECEPTOR DIVERSITY IN BLOOD & ADIPOSE TISSUE FROM HIV+ PERSONS

Vanderbilt Univ, Nashville, TN, USA

231 REDUCED APOPTOSIS CONTRIBUTES TO GASTROINTESTINAL NEUTROPHIL INFILTRATION IN HIV

Tiffany Hensley-McBain1, Jennifer Manuzak1, Charlene Miller1, Alexander S. Zevin1, Eric Lee2, Cara Wilson2, Thomas Hope3, Adam Burgener4, Nichole Klatt1
1Univ of Washington, Seattle, WA, USA, 2Univ of Colorado Anschutz Med Campus, Aurora, CO, USA, 3Northwestern Univ, Evanston, IL, USA, 4Pub Hlth Agency of Canada, Winnipeg, Canada
232 HIV INDUCES LIPID ACCUMULATION IN ALVEOLAR MACROPHAGES IN VITRO
Amy K. Dickey1, Bjorn Corleis2, Abigail Schiff2, Antonella Lisante2, Benjamin Medoff3, Josyalyn Cho1, Douglas Kwon2
1Massachusetts General Hosp, Boston, MA, USA, 2Ragon Inst of MGH, MIT, and Harvard, Cambridge, MA, USA, 3Harvard Univ, Boston, MA, USA

233 TIM-3 IS A MARKER OF PDC DYSFUNCTION IN HIV INFECTION
Jordan A. Schwartz1, Kiera L. Clayton1, Shariq Mujib1, Hongliang Zhang1, Nur-ul-ur Rahman1, Jun Liu2, Feng Yun Yue2, Erika Benko2, Colin Kovacs2, Mario Ostrowski1
1Univ of Toronto, Toronto, Canada, 2Maple Leaf Med Clinic, Toronto, Canada

234 IMMUNE CHECKPOINT MOLECULES IN HIV AND AGING
Lesley R. de Armas, Suresh Pallikkuth, Sidney Lane, Rajendra Pahwa, Varghese George, Stefano Rinaldi, Margaret Fischl, Gordon Dickinson, Allan Rodriguez, Savita Pahwa
Univ of Miami, Miami, FL, USA

235 SOLUBLE UPAR PREDICTS ALL-CAUSE MORTALITY FROM HIV-1 INFECTION
Ditte M Kirkegaard-Klitbo, Anne Langkilde, Niels Mejer, Ove Andersen, Jesper Eugen-Olsen, Thomas Benfield
Hvidovre Hosp, Hvidovre, Denmark

236 R5-TROPIC HIV RESISTANCE IN A SUBSET OF ELITE AND VIREMIC CONTROLLERS
Elena Gonzalo-Gil, Patrick Rapuano, Jimmy Auer, Zach Porterfield, Uchenna Ikediobi, Ayse Coskun, Richard Sutton
Yale Univ, New Haven, CT, USA

237LB MULTI-ANCESTRY GWAS IDENTIFIES NOVEL VARIANTS ASSOCIATED WITH HIV-1 VIRAL LOAD
Eric O. Johnson1, Dana B. Hancock1, Nathan C. Gaddis1, Christina A Markunas1, Yuelong Guo1, Elizabeth T. Golub2, Mardge H. Cohen1, Kathryn Anastos4, Ruth Greenblatt2, Bradley E. Aouizerat6
1RTI Intl, Rsr Triangle Park, NC, USA, 2Johns Hopkins Univ, Baltimore, MD, USA, 3Stroger Hosp, Chicago, IL, USA, 4Albert Einstein Coll of Med, Bronx, NY, USA, 5Univ of California San Francisco, San Francisco, CA, USA, 6New York Univ, New York, NY, USA

Poster P-C7 INTERACTIONS OF HIV WITH OTHER INFECTIONS
Poster Hall - 4 EF
2:30 PM - 4:00 PM

238 18F-FDG-PET/CT ABNORMALITIES ARE ASSOCIATED WITH HIGHER RISK OF IRIS IN HIV
Dima A. Hammoud1, Georgios Z. Papadakis1, Afrodit Boulougoura2, Virginia Sheikh1, Lori E. Dodd4, Jing Wang2, Angela Kibiy6, JoAnn Mican2, Corina Milo1, Irini Sereti2
1NIH, Bethesda, MD, USA, 2NIAID, Bethesda, MD, USA, 3FDA, Silver Spring, MD, USA, 4NIAID, Rockville, MD, USA, 5Leidos Biomed Rsr, Rockville, MD, USA, 6Leidos Biomed Rsr, Bethesda, MD, USA

239 MAIT CELLS, MICROBIAL TRANSLOCATION AND THE MICROBIOME IN HIV/HCV CHRONIC INFECTIONS
Esther Merlini1, Maddalena Cerrone1, Bonnie van Wilgenburg2, Leo Swadling3, Camilla Tincati1, Elvira S. Cannizzo1, Antonella d’Arminio Monforte1, Paul Klereman1, Giulia Marchetti1
1Univ of Milan, Milan, Italy, 2Univ of Oxford, Oxford, UK
240 IMPACT OF MUCOSAL CMV AND EBV REPLICATION ON ENTERIC MICROBIOME DURING HIV INFECTION
Antoine Chaillon¹, Sara Gianella², Ece A. Mutlu³, Phillip A. Engen⁴, Robin M. Voigt⁵, Ali Keshavarzian⁶, John Losurdo⁶, Steven Lada⁶, Masato Nakazawa⁶, Alan Landay⁸
¹Univ of California San Diego, San Diego, CA, USA, ²Univ of California San Diego, La Jolla, CA, ³Rush Univ Med Cntr, Chicago, IL, USA

241 EFFECT OF HIV STATUS, CMV, AND EBV REPLICATION ON MUCOSAL GENE EXPRESSION IN THE GUT
Sara Gianella¹, Antoine Chaillon², Ece A. Mutlu³, Phillip A. Engen⁴, Robin M. Voigt⁵, Ali Keshavarzian⁶, John Losurdo⁶, Steven Lada⁶, Masato Nakazawa⁶, Alan Landay⁸
¹Univ of California San Diego, San Diego, CA, USA, ²Univ of California San Diego, La Jolla, CA, USA, ³Rush Univ, Chicago, IL, USA

251 TELMISARTAN DOES NOT IMPROVE LYMPH NODE OR FAT FIBROSIS IN TREATED HIV INFECTION
Netanya S. Utay¹, Douglas Kitch¹, Carl Fichtenbaum¹, Michael M. Lederman¹, Jacob D. Estes¹, Clara Magyar², Karin Klingman², Judith S. Currier¹, Jordan E. Lake¹, for the A5317 Team
¹Univ of Texas, Galveston, TX, USA, ²Harvard Univ, Boston, MA, USA, ³Univ of Cincinnati, Cincinnati, OH, USA, ⁴Case Western Reserve Univ, Cleveland, OH, USA, ⁵Frederick Natl Lab for Cancer Rsr, Frederick, MD, USA, ⁶Univ of California Los Angeles, Los Angeles, CA, USA, ⁷DAIDS, NIAID, Bethesda, MD, USA

252 PHARMACOLOGIC INHIBITION OF IDO BLUNTS FEATURES OF SIV-RELATED CHRONIC INFLAMMATION
Richard M. Dunham¹, Kevin W. Brown¹, James M. Billingsley², Zhong-Min Ma¹, Gregory K. Tharp², Christopher J. Miller², Steven E. Bosingher³, Brian A. Johns¹, David Favre¹
¹GlaxoSmithKline, Durham, NC, USA, ²Yerkes Natl Primate Rsr Cntr, Atlanta, GA, USA, ³Univ of California Davis, Davis, CA, USA

253 HIV-SPECIFIC ANTIBODIES ENHANCE TYPE I INTERFERON PRODUCTION FROM PLASMACYTOTID DCS
Rebecca Veenhuis¹, Zachary Freeman¹, Jack Korleski¹, Alessandra Tomasi¹, Austin Boesch², Margaret Ackerman², Joseph B. Margolick¹, Joel Blankson¹, Michael Chattergoon¹, Andrea Cox¹
¹The Johns Hopkins Univ, Baltimore, MD, USA, ²Dartmouth Coll, Hanover, NH, USA

254 TARGETING TYPE I INTERFERON-MEDIATED IMMUNE ACTIVATION TO CONTROL HIV INFECTION
Anjie Zhen¹, Mayra A. Carrillo¹, Valerie Rezek¹, David Brooks², Scott G. Kitchen¹
¹Univ of California Los Angeles, Los Angeles, CA, USA, ²Princess Margaret Cancer Cntr, Toronto, Ontario, Canada

255 METFORMIN REDUCES T-CELL EXHAUSTION IN A CLINICAL TRIAL OF HIV-INFECTED ADULTS ON ART
Glen Chew¹, Dominic Chow¹, Scott A. Souza¹, Lindsay Kohorn¹, Richard M. Watanabe¹, Ivo Sah Bandar¹, Eun-Young Park¹, Mary Margaret Byron¹, Lishomwa C. Ndhlovu¹, Cecilia Shikuma¹
¹Univ of Hawaii, Honolulu, HI, USA, ²Univ of Southern California, Los Angeles, CA, USA
256 P2X PURINERGIC RECEPTORS AS THERAPEUTIC TARGETS OF HIV-1 INFECTION AND INFLAMMATION
Talia Swartz¹, Natasha Durham¹, Alexandra Soare¹, Meagan O’Brien¹, Nina Bhardwaj¹, Benjamin K. Chen¹
²Icahn Sch of Med at Mt Sinai, New York, NY, USA, ³Tufts Univ, Boston, MA, USA

257 AGE AND HIV DO NOT SYNERGISTICALLY IMPACT T-CELL MATURATION OR ACTIVATION
Shelli Farhadian¹, Emilie Jalbert², Yanhong Deng³, Matthew B. Goetz⁴, Lesley Park⁵, Amy Justice⁶, Robert Dubrow⁷, Brinda Emu⁸, for the VACS Project Team
¹Yale Univ, New Haven, CT, USA, ²Univ of Colorado, Aurora, CO, USA, ³VA Greater Los Angeles Hlth Care System, Los Angeles, CA, USA, ⁴Stanford Med, Stanford, CA, USA, ⁵VA Connecticut Hlthcare System, West Haven, CT, USA

258 CELLULAR IMMUNE ACTIVATION IN THE ERA OF CART AND AN AGING HIV+ POPULATION
Lesley R. de Armas¹, Suresh Pallikkuth, Rajendra Pahwa, Stefano Rinaldi, Varghese George, Li Pan, Allan Rodriguez, Margaret Fischl, Gordon Dickinson, Savita Pahwa
Univ of Miami, Miami, FL, USA

259 ADAR1, A TARGET TO BOOST HIV-1 IMMUNE RESPONSE
Maria Pujantell, Ester Ballana, Eva Riveira-Muñoz, Bonaventura Clotet, Jose A. Este
IrsiCaixa Inst for AIDS Rsr, Badalona, Spain

260LB LIVER INFLAMMATION CORRELATES WITH SIV LEVELS AND IS ONLY PARTLY REVERSED WITH CART
Bridget Fisher¹, Rachel Brown¹, Matthew Wood¹, Richard Green², Cole Fisher¹, Michael Gale³, Guido Silvestri³, Ann Chahroudi³, Nichole Klatt², Donald Sodora³
¹Cntr for Infectious Disease Rsr, Seattle, WA, USA, ²Univ of Washington, Seattle, WA, USA, ³Emory Univ, Atlanta, GA, USA

261 CD57+ CYTOTOXIC CD4+ EFFECTOR T CELLS INCREASE IN CHRONIC HIV INFECTION
Chansavath Phetsouphanh¹, Jodi Meyerowitz¹, Lyle Murray¹, Dominique Goedhals², Cloete Van Vuuren², Sarah Fidler³, Paul Klenerman¹, John Frater¹

262 TARGETING LC WITH ANTI-LANGERIN HIV FUSION MONOCLONAL AB PROMOTES TFH DIFFERENTIATION
Jérôme Kervevan¹, Aurélie Chaigneau¹, Sandy Zuwarski², Marion Bonnet³, Romain Marlin¹, Marie-Thérèse Nugeyre¹, Elisabeth Menu¹, Gerard Zuwarski², Yves Levy¹, Sylvain Cardinaud¹
¹INSERM, Créteil, France, ²Baylor Inst for Immunol Rsr, Dallas, TX, USA, ³Univ of Cardiff, Cardiff, UK, ¹Inst Pasteur, Paris, France

263 HIV-1-INFECTION–ASSOCIATED CHANGES IN THE HUMAN CD4+ T-CELL PROTEOME
Johannes Nemeth¹, Valentina Vongrad¹, Karin Metzner¹, Victoria P. Strouvelle², Rainer Weber², Patrick Pedrioli³, Ruedi Aebersold¹, Huldrych F. Günthard¹, Ben Collins¹
¹Cntr for Infectious Disease Rsr, Seattle, WA, USA, ²Univ of Zürich, Zürich, Switzerland, ³ETH Zürich, Zürich, Switzerland
CHARACTERIZATION OF PREEXISTING HIV-SPECIFIC CD4 T CELLS IN UNINFECTED INDIVIDUALS

Audrey Daigneault1, Nathalie Brassard2, Amy E. Baxter1, Lucie Barblu1, Colin Havenar-Daughton1, Roxanne Charlebois1, Jean-Pierre Routy1, Shane Crotty1, Daniel E. Kaufmann1

1Cntr de Rsr du Cntr Hosp de l’Univ de Montréal, 2La Jolla Inst for Allergy and Immunol, La Jolla, CA, USA, 3McGill Univ Hlth Cntr, Glen site, Montréal, Canada

TFH CELLS FUNCTIONAL PROFILE DRIVES ABNORMAL B CELL MATURATION IN HIV INFECTION

Giuseppe Pantaleo1, Alessandra Noto1, Andrew McDavid2, Phu Van3, Agostino Riva1, Guy Cavet3, Song Ding1, Raphael Gottardo1, Craig Fenwick1

1Univ Hosp of Lausanne, Lausanne, Switzerland, 2FRCHC, Seattle, WA, USA, 3Luigi Sacco Univ Hosp, Milan, Italy, Milano, Italy, *Areca, Redwood City, CA, USA, 1Eurovacc Foundation, Amstterdam, Netherlands

SOLUBLE BIOMARKERS IN ACUTE HIV INFECTION REVEAL INSIGHT INTO HIV RESERVOIR

Jeffrey E. Teigler1, Bonnie Silke1, Nicolas Chomont3, Eugene Kroon1, Merlin L. Robb3, Jintanat Ananworanich1, Nelson L. Michael1, Hendrik Streeck2, Shelly J. Krebs1

1US Military HIV Rsr Prog, Silver Spring, MD, USA, 2Univ de Montréal, Montreal, QC, Canada, 3SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 4Inst for HIV Rsr, Essen, Germany

FAST VALIDATION TO STUDY THE BASELINE AND INDUCIBLE HIV RESERVOIR

Marilia R. Pinzone1, Xiaohe Liu2, Lidia Sambucetti3, Giuseppe Nunnari3, Una O’Doherty1

1Univ of Pennsylvania, Philadelphia, PA, USA, 2SRI Intl, Menlo Park, USA, 3Univ of Messina, Messina, Italy

HOST TRANSCRIPTOMIC DETERMINANTS OF HIV PERSISTENCE IN VIVO

Mohamed Abdel Mohsen1, Xutao Deng3, Sheila Keating1, Andrew Worlock1, Christopher D. Pilcher1, Michael P. Busch1, Steven G. Deeks1, Satish K. Pillai1

1Blood Systems Rsr Inst, San Francisco, CA, USA, 2Hologic Corporation, Bedford, MA, USA, 3Univ of California, San Francisco, San Francisco, CA, USA

LOW INDUCIBILITY OF THE HIV RESERVOIR IN EARLY ART-TREATED THAI CHILDREN

Marta Massanella1, Jintanat Ananworanich2, Louise Leyre3, Thidarat Jupimai4, Mark de Souza2, Piyarat Suntarattiwong3, Pope Kosalaraka2, Thanyawee Puthanakit4, Nicolas Chomont3, for the HIVNAT209 and HIVNAT194 Study Groups

1Cntr de Rsr du Cntr Hosp de l’Univ de Montréal, Montréal, Canada, 2Henry M. Jackson Fndn for the Advancement of Military Med, Bethesda, MD, USA, 3HIV—NAT Rsr Collab, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 4SEARCH, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 5Queen Sirikit Natl Inst of Child Hlth, Bangkok, Thailand, 6Khon Kaen Univ, Khon Kaen, Thailand, 7Chulalongkorn Univ, Bangkok, Thailand

CELL-ASSOCIATED HIV RNA PREDICTS POSTTREATMENT HIV CONTROL AND CD4+ T-CELL LOSS

Alexander Pasternak, Jan Prins, Ben Berkhout

Univ of Amsterdam, Amsterdam, Netherlands
287 PRE-ART TUBERCULOSIS AND TB-IRIS AFFECT THE HIV-1 RESERVOIR
Camille Lange1, Maura Manion2, Gregg Roby1, Rob Gorelick2, Virginia Sheikh3, Joseph Adelsberger4, Frank Maldarelli5, Irini Sereti6
1NCI, Frederick, MD, USA, 2NIH, Bethesda, MD, USA, 3NIH, Rockville, MD, USA, 4AIDS and Cancer Virus Prog, Frederick, MD, USA, 5FDA, Silver Spring, MD, USA, 6Leidos Biomed Rsr, Inc, Frederick, MD, USA

Poster P-E4 HIV PERSISTENCE: SEND IN THE CLONES
Poster Hall - 4 EF 2:30 PM - 4:00 PM

292 CLONAL EXPANSION OF GENOME-INTACT HIV-1 IN FUNCTIONALLY POLARIZED T-CELL SUBSETS
Guinevere Q. Lee1, Nina Orlova1, Erik Serra2, Xiaoming Sun1, Navin F. Chowdhury1, Eric Rosenberg1, Alan N. Engelman2, Xu G. Yu1, Mathias Lichterfeld3
1Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA, 2Dana-Farber Cancer Inst, Boston, MA, USA, 3Massachusetts General Hosp, Boston, MA, USA, 4Brigham and Women's Hosp, Boston, MA, USA

293 INTACT PROVIRUSES ARE UNEQUALLY DISTRIBUTED IN T CELL SUBSETS DURING ART
Bonnie Hiener1, Bethany A. Horsburgh1, John-Sebastian Eden2, Kirston Barton1, Eunok Lee1, Steven G. Deeks1, Jeffery Milush1, Nicolas Chomont3, Rémi Fromentin4, Sarah Palmer1
1The Westmead Inst for Med Rsr, Westmead, Australia, 2The Univ of Sydney, Sydney, Australia, 3Univ of California San Francisco, San Francisco, CA, USA, 4Univ de Montréal, Montreal, QC, Canada

294 A SMALL FRACTION OF PROVIRUSES IN EXPANDED CLONES EXPRESS UNSPLICED HIV RNA IN VIVO
Andrew Musick1, Jonathan Spindler1, Brandon Keele2, Michael J. Bale3, Wei Shao3, Ann Wiegand3, John Mellors3, John Coffin4, Frank Maldarelli5, Mary F. Kearney1
1NCI, Frederick, MD, USA, 2Leidos Biomed, Inc, Frederick, MD, USA, 3Univ of Pittsburgh, Pittsburgh, PA, USA, 4Tufts Univ, Boston, MA, USA

295 PROLIFERATION OF CD4+ T CELLS CONTAINING REPLICATION-COMPETENT HIV-1
Zheng Wang1, Ya-Chi Ho, Janet Siliciano, Robert Siliciano
1Johns Hopkins Univ, Baltimore, MD, USA

296 CYTOTOXIC T LYMPHOCYTES MAY SHAPE THE HIV-1 PROVIRAL LANDSCAPE
R. Brad Jones1, Mihaela Pertea1, Katherine Bruner1, Ross Pollack1, Adam Capoferrer2, Robert Siliciano1, Ya-Chi Ho
1The George Washington Univ, Washington, DC, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA

297 DYNAMICS OF HIV CLONAL EXPANSION AND PERSISTENCE DURING ART
Elizabeth M Anderson1, Shawn Hill1, Jennifer Bell1, Francesco R. Simonetti2, Cathy Rehm1, Sara Jones1, Rob Gorelick1, John Coffin3, Frank Maldarelli4
1NCI, Frederick, MD, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA, 3NIH, Bethesda, MD, USA, 4Leidos Biomed Rsr, Inc, Frederick, MD, USA, 5Tufts Univ, Boston, MA, USA
298 CLONES OF HIV-INFECTED CELLS ARISE IN VIVO IN THE FIRST FEW WEEKS FOLLOWING INFECTION

David Wells¹, Jennifer M. Zerbato², Joann D. Kuruc³, Joseph J. Eron³, Mary F. Kearney⁴, John Coffin⁵, Frank Maldarelli¹, Xiaolin Wu⁶, John W. Mellors⁷, Stephen H. Hughes⁸

¹Liedos Biomed Rsr, Inc, Frederick, MD, USA, ²Univ of Pittsburgh, Pittsburgh, PA, USA, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴NCI, Frederick, MD, USA, ⁵Tufts Univ, Boston, MA, USA

299LB RESURGENCE OF HIV-1 FOUNDERS FOLLOWING ANTIRETROVIRAL TREATMENT INTERRUPTION

Morgane Rolland¹, Eric Sanders-Buell¹, Meera Bose¹, Nittaya Phanuphak¹, Mark de Souza¹, Nelson L. Michael¹, Merlin L. Robb¹, Jintanat Ananworanich¹, Sodsai Tovanabutra¹, for the RV254/SEARCH 010 Study Groups

¹US Military HIV Rsr Prog, Silver Spring, MD, USA, ²Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ³SEARCH, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand

323 HIV-1 DNA BLOOD RESERVOIRS ARE NOT ALTERED BY HIGH-DOSE CHEMOTHERAPY FOR LYMPHOMA

Heloise M. Delagreverie¹, Antoine Chaillon², Laurence Gerard¹, Marie-Laure Nérel³, Romain Palich³, Sylvain Chawk³, Lionel Galicier¹, Eric Oksenhendler¹, Marie-Laure Chaux Baudier¹, Constance Delaugerre¹

¹Saint Louis Hosp, Paris, France, ²Univ of California San Diego, San Diego, CA, USA, ³Pitié-Salpêtrière Hosp, Paris, France

324 THE IMPACT OF IMMUNOGLOBULIN IN PRIMARY HIV INFECTION ON THE HIV RESERVOIR

Juan Tiraboschi¹, Prabhjeet Phalora², Nicola Robinson², Emily Hopkins², Steve Kaye¹, Jeremy Sanderson¹, Sarah Fidler³, Paul Klejnerman³, John Frater⁴, Julie Fox⁴


325 RATES OF VIRAL DECAY IN HIV-1 CONTROLLERS INITIATING ANTIRETROVIRAL THERAPY

Jonathan Li¹, Heloise M. Delagreverie², Rachel Getz³, Christina Lalama³, Ronald Bosch³, Daniel R. Kuritzkes¹, Alan Landay⁴, Florencia Pereyra¹, Paul E. Sax¹, for the AIDS Clinical Trials Group A5308 Study Team

¹Brigham and Women’s Hosp, Harvard Med Sch, Boston, MA, USA, ²Saint Louis Hosp, Paris, France, ³Harvard Univ, Boston, MA, USA, ⁴Rush Univ Med Cntr, Chicago, IL, USA

326 PEGYLATED IFN-ALPHA-2B DECREASES LATENT HIV MEASURES IN ART-SUPPRESSED SUBJECTS

Livio Azzoni¹, Emmanouil Papasavvas², Nicolas Chomont², Qingsheng Li³, Bonnie J. Howell⁴, Douglas D. Richman³, Pablo Tebas³, Karam Mounzer⁴, Jay Kostman⁵, Luis Montaner¹

¹Wistar Inst, Philadelphia, PA, USA, ²Univ de Montréal, Montreal, QC, Canada, ³Univ of Nebraska, Lincoln, NE, USA, ⁴Merck & Co, Inc, West Point, PA, USA, ⁵Univ of California San Diego, La Jolla, CA, USA, ⁶Univ of Pennsylvania, Philadelphia, PA, USA, ⁷Philadelphia FIGHT, Philadelphia, PA, USA, ⁸Philadelphia FIGHT Community Hlth Cntrs, Philadelphia, PA, USA
327 EFFECTS OF PEG-IFNα ON THE HIV-1 DNA LEVELS IN HIV-1/HCV COINFECTED INDIVIDUALS
Victoria P. Strouvelle, Valentina Vongrad, Dominique L. Braun, Yik Lim Kok, Roger Kouyos, Karin Metzner, Huldrych F. Günthard, for the Swiss HIV Cohort Study
Univ of Zürich, Zürich, Switzerland

328 IN VIVO CONTROL OF HIV INFECTION BY AN ENGINEERED BI-SPECIFIC ANTI-HIV FUSION PROTEIN
Ariola Bardhi1, Weizao Chen2, Yanping Wang3, Jennifer Jones1, John C. Kappes1, Christina Ochsenbauer1, Dimitr S. Dimitrov1, Harris Goldstein1
1Albert Einstein Coll of Med, Bronx, NY, USA, 2NIH, Frederick, MD, USA, 3Univ Alabama at Birmingham, Birmingham, AL, USA

329 PGT121 ANTIBODY ENGINEERING: ENHANCED INFECTED CELL KILLING AND DRUG-LIKE PROPERTIES
Mini Balakrishnan, Nathan D. Thomesen, Craig S. Pace, Xue Zhang, Magdeleine Hung, Mark R. Nagel, Brian A. Carr, Y. E. Hu, Helen Yu, John A. Corbin
Gilead Scis, Inc, Foster City, CA, USA

330LB VRC01 INFUSION HAS NO EFFECT ON HIV-1 PERSISTENCE IN ART-SUPPRESSED CHRONIC INFECTION
Sharon Riddler1, Christine Durand1, Lu Zheng2, Justin Ritz3, Richard A. Koup4, Julie Ledgerwood5, Bernard Macatangay5, Joshua C. Cyktor4, John W. Mellors1, for the ACTG A5342 Protocol Team
1Univ of Pittsburgh, Pittsburgh, PA, USA, 2Johns Hopkins Univ, Baltimore, MD, USA, 3Harvard Univ, Boston, MA, USA, 4NIAID, Bethesda, MD, USA

339 HEIGHTENED SYSTEMIC AND CNS IMMUNE ACTIVATION IN ACUTE HIV INFECTION WITH SYPHILIS
Phillip Chan1, Donn Colby1, Eugene Kroon1, Victor Valcour2, Napapon Sailsatua1, Joanna Hellmuth1, Shelly J. Krebs1, Jintanat Ananworanich1, Serena Spudich1, for the RV254/SEARCH 010 Study Group
1SEARCH, The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 2Univ of California San Francisco, San Francisco, USA, 3Univ of Hawaii, Honolulu, HI, USA, 4US Military HIV Rsr Prog, Silver Spring, MD, USA, 5Yale Univ, New Haven, CT, USA

340 CNS INFLAMMATION STILL PRESENT AFTER >10 YEARS OF EFFECTIVE ANTIRETROVIRAL THERAPY
Gustaf O. Hammarlund1, Arvid Edén1, Åsa Mellgren2, Dietmar Fuchs1, Henrik Zetterberg1, Lars Hagberg1, Staffan Nilsson1, Aylin Yilmaz1, Magnus Gisslén1
1Univ of Gothenburg, Gothenburg, Sweden, 2South Älvsborgs Hosp, Börs, Sweden, 3Innsbruck Med Univ, Innsbruck, Austria, 4Chalmers Univ of Tech, Gothenburg, Sweden

341 MONOCYTE ACTIVATION IS ASSOCIATED WITH COGNITION IN SUPPRESSED HIV-INFECTED WOMEN
Brandon M. Imp1, Leah H. Rubin2, Phyllis Tien3, Michael Plankey4, Elizabeth T. Golub1, Audrey French1, Victor Valcour1, for the Women’s Interagency HIV Study (WIHS)
1Rutgers Robert Wood Johnson Med Sch, Piscataway, NJ, USA, 2Univ of Illinois at Chicago, Chicago, IL, USA, 3Univ of California San Francisco, San Francisco, CA, USA, 4Georgetown Univ, Washington, DC, 5The Johns Hopkins Univ, Baltimore, MD, USA, 6Rush Univ, Chicago, IL, USA
342  SYSTEMIC INFLAMMATORY AND IMMUNE BIOMARKERS IN NEUROCOGNITIVE CHANGE WITH INITIAL ART

Kevin Robertson1, Sachiko Miyahara2, Alan Landay3, Todd Brown4, Carl Fichtenbaum5, Joseph J. Eron6, Athié Tsibris7, Babafemi Taiwo8, for the ACTG 5303 team

1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Harvard Univ, Boston, MA, USA, 3Rush Univ, Chicago, IL, USA, 4The Johns Hopkins Univ, Baltimore, MD, USA, 5Univ of Cincinnati, Cincinnati, OH, USA, 6Massachusetts General Hosp, Cambridge, MA, USA, 7Northwestern Univ, Chicago, IL, USA

343  IMPACT OF ADVANCING AGE ON COGNITION IN HIV+ PERSONS ON A FIRST SUPPRESSIVE REGIMEN

Hamza Coban1, Kevin Robertson2, Kunling Wu3, Ronald Bosch4, Ronald J. Ellis1

1Univ of California San Diego, La Jolla, CA, USA, 2Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 3Harvard Univ, Boston, MA, USA, 4Univ of California, San Diego, CA, USA

344  CNS IMMUNE ACTIVATION PERSISTS IN ACUTE AND CHRONIC HIV DESPITE EXTENDED CART

Joanna Hellmuth1, John Best2, Carlo Sacdalan1, Shelly J. Krebs3, Duangthai Suttichom1, Serena Spudich4, Nisakorn Ratnaratorn1, Jintanat Ananworanich5, Victor Valcour4, for the SEARCH 010/RV254 Study Group

1Univ of California San Francisco, San Francisco, CA, USA, 2Univ of Pennsylvania, Philadelphia, PA, USA, 3SEARCH, Thai Red Cross AIDS Rsr Ctr, Bangkok, Thailand, 4US Military HIV Rsr Prog, Silver Spring, MD, USA, 5SEARCH, South East Asia Rsr Collab with Hawaii, Bangkok, Thailand, 6Yale Univ, New Haven, CT, USA

345  IMMUNE MARKERS OF CRYPTOCOCCAL REACTIVATION IN HIV INFECTION

Admire Hlupeni1, Kathryn F. Boyd2, Azure T. Makadzange3, Chiratidzo E. Ndhlovu1

1Univ of Zimbabwe, Harare, Zimbabwe, 2Infectious Disease Rsr Lab, Harare, Zimbabwe, 3Massachusetts General Hosp, Cambridge, MA, USA

Poster P-F3 NEUROCOGNITIVE FUNCTIONING, VIRAL SUPPRESSION, AND ASSOCIATED RISKS

Poster Hall - 4 EF 2:30 PM - 4:00 PM

349  HIV NEUROLOGICAL DISORDERS CAN OCCUR IN PATIENTS WITH SUPPRESSED HIV-1 VL IN PLASMA

Cathia Soulie1, Maxime Grudé2, Corinne Amiel3, Laurence Morand-Joubert4, Stephanie Raymond5, Coralie Pallier4, Pantxika Bellecave4, Diane Descamps5, Anne-Geneviève Marcellin1, for the ANRS Resistance ACT11 Group

350 COGNITIVE TRAJECTORIES OVER 4 YEARS AMONG HIV+ WOMEN WITH OPTIMAL VIRAL SUPPRESSION
Leah H. Rubin, Gayle Springer, Pauline M. Maki, Kathryn Anastos, Deborah Gustafson, Maria Villacres, Drena Waldrop-Valverde, David Vance, Hector Bolivar, Victor Valcour
1Univ of Illinois at Chicago, Chicago, IL, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA, 3Albert Einstein Coll of Med, Bronx, NY, USA, 4SUNY Downstate Med Cntr, Brooklyn, NY, USA, 5Univ of Southern California, Los Angeles, CA, USA, 6Emory Univ, Atlanta, GA, USA, 7Univ of Alabama at Birmingham, Birmingham, AL, USA, 8Univ of Miami, Miami, FL, USA, 9Univ of California San Francisco, San Francisco, CA, USA

351 COGNITIVE TRAJECTORIES IN SUPPRESSED HIV INFECTION INDICATE EVOLVING DISEASE ACTIVITY
Chloe Gott, Thomas Gates, Nadene Dermody, Bruce Brew, Lucette Cysique
1Macquarie Univ, North Ryde, NSW, Australia, 2St Vincent’s Hosp, Sydney, Darlinghurst, NSW, Australia, 3Univ of New South Wales, Darlinghurst, NSW, Australia, 4NeuroSci Rsr Australia, Randwick, NSW, Australia

352LB LONGITUDINAL ANALYSIS SHOWS NO EVIDENCE FOR ACCELERATED BRAIN AGING IN TREATED HIV
1Imperial College London, London, United Kingdom, 2Academic Medical Center Amsterdam, Amsterdam, Netherlands, 3Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands, 4UCL, London, UK, 5Stichting HIV Monitoring and Academic Medical Center Amsterdam, Amsterdam, Netherlands

353 DECREASE IN EXECUTIVE FUNCTION IS ASSOCIATED WITH DETECTABLE PLASMA HIV DURING CART
Albert Anderson, Josue Perez-Santiago, Andrea Knezevic, Xiaohu Yang, Eugene Huang, Jennifer Judicello, David Moore, Ronald J. Ellis, Robert K. Heaton, Scott Letendre
1Emory Univ, Atlanta, GA, USA, 2Univ of California San Diego, San Diego, CA, USA, 3Univ of California at San Diego, La Jolla, CA, USA

354 DAAs IMPROVE VACS BUT DO NOT INFLUENCE COGNITIVE IMPAIRMENT IN HIV/HCV COINFECTED
Ilaria Mastrorosa, Patrizia Lorenzini, Martina Ricottini, Gabriele Fabbri, Pietro Balestra, Alessandra Vergori, Carmela Pinnetti, Mauro Zaccarelli, Adriana Ammassari, Andrea Antinori
Natl Inst for Infectious Diseases, Rome, Italy

355 LIMITATIONS OF THE INTERNATIONAL HIV DEMENTIA SCALE IN THE CURRENT ERA
Benedetta Milanini, Emmanuel Bahamena, Babajide Keshinro, Francis Kiweewa, Rither Langat, Winnie Rehema, Isabel E. Allen, Christina Polyak, Julie Ake, Victor Valcour
1Univ of California San Francisco, San Francisco, CA, USA, 2Walter Reed Proj—Tanzania, Mbeya, Tanzania, United Republic of, 3Walter Reed Proj—Nigeria, Abuja, Nigeria, 4Makerere Univ Walter Reed Proj, Kampala, Uganda, 5KEMRI/Walter Reed Proj, Kericho, Kenya, 6KEMRI/Walter Reed Proj, Kisumu, Kenya, 7US Military HIV Rsr Proj, Bethesda, MD, USA
EFFECTS OF AGE AND OBESITY ON NEUROCOGNITIVE PERFORMANCE IN THE MACS COHORT

Kristine Erlandson1, Long Zhang2, Lisa Jacobson2, James T. Becker1, Cynthia Munro3, Jordan E. Lake1, Eileen Martin4, Andrew Levine5, Todd Brown5, Ned Sacktor6

1Univ of Colorado, Aurora, CO, USA, 2The Johns Hopkins Univ, Baltimore, MD, USA, 3Univ of Pittsburgh, Pittsburgh, PA, USA, 4Univ Texas Houston, Houston, USA, 5Rush Univ, Chicago, USA, 6Univ of California Los Angeles, Los Angeles, CA, USA

CSF TO PLASMA HIV-RNA RATIO ≥1 IS ASSOCIATED WITH HAND IN UNTREATED HIV PATIENTS

Francesca Bai, Francesca Iannuzzi, Esther Merlini, Lidia Borghi, Teresa Bini, Giulia Marchetti, Antonella d’Arminio Monforte

Univ of Milan, Milan, Italy

POST-TRAUMATIC STRESS AND NEUROCOGNITIVE IMPAIRMENT IN A US MILITARY COHORT

Robert Deiss1, Raeanne Moore2, Nancy Crum-Cianflone1, Scott Letendre2, Anuradha Ganesan1, Jason Okulicz2, Mary F. Bavaro3, David J. Moore4, Brian K. Agan1

1Uniformed Services Univ of the Hlth Scis, Rockville, MD, USA, 2Univ of California San Diego, San Diego, CA, USA, 3Infectious Disease Service, San Antonio, TX, USA, 4Naval Med Cntr of San Diego, San Diego, CA, USA

ANTIRETROVIRALS IMPROVE HAND STAGE IN HIV+ PATIENTS WITH SUBTYPE D AND A IN UGANDA

Ned Sacktor1, Deanna Saylor1, Gertrude Nakigozi2, Kevin Robertson1, Noeline Nakasujja1, Ronald H. Gray1, Maria Wawer1

1The Johns Hopkins Univ, Baltimore, MD, USA, 2Rakai Hlth Scis Prog, Kalisizo, Uganda, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4Makarere Univ, Kampala, Uganda

ADDITIONAL SCREENING TESTS FOR HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS

Mattia Trunfio1, Chiara Montrucchio1, Daniela Vai2, Daniele Imperiale2, Alessandro Livelli2, Giancarlo Orofino2, Alice Trentalange2, Stefano Bonora1, Giovanni Di Perri1, Andrea Calcagno1

1Univ of Torino, Torino, Italy, 2Maria Vittoria Hosp, Torino, Italy, 3Amedeo di Savoia Hosp, Torino, Italy

COGNITIVE COMPLAINTS AND DEVELOPMENT OF FALLS AMONG HIV+ AND HIV- WOMEN

Anjali Sharma1, Donald R. Hoover2, Qiuhu Shi3, Michael Plankey4, Phyllis Tien5, Kathleen M. Weber2, Michelle Floris-Moore5, Hector Bolivar2, Marica M. Holstad2, Michael T. Yin10

1Albert Einstein Coll of Med, Bronx, NY, USA, 2Rutgers, the State Univ of New Jersey, Piscataway, NJ, USA, 3New York Med Coll, Valhalla, NY, USA, 4Georgetown Univ, Washington DC, USA, 5Univ of California San Francisco, San Francisco, CA, USA, 6Cook County Hlth & Hosps System, Chicago, IL, USA, 7Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 8Univ of Miami, Miami, FL, USA, 9Emory Univ, Atlanta, GA, USA, 10Columbia Univ, New York, NY, USA
362 PREVALENCE OF NEUROCOGNITIVE DISORDERS IN A WELL-TREATED AND AGING SWISS HIV-COHORT
Melanie Metral$, Isabella Locatelli$, Peter Brugger$, Klemens Gutbrod$, Ursula Kunze$, Isaura Nadin$, Marc Schwind$, Riccardo Pignatti$, Matthias Cavassini$, Renaud Du Pasquier$
$Univ of Lausanne, Lausanne, Switzerland, $Univ Hosp of Zürich, Zürich, Switzerland, $Univ Hosp of Bern, Bern, Switzerland, $Felix Platter Hosp, Basel, Switzerland, $Univ Hosp of Geneva, Geneva, Switzerland, $Klinik für Neuro, St. Gallen, Switzerland, $Servizio di Malattie Infettive, Lugano, Switzerland

Poster P-G5 ANTIRETROVIRAL PHARMACOKINETICS: SPECIAL PROBLEMS AND POPULATIONS
Poster Hall - 4 EF
2:30 PM - 4:00 PM

428 EFFECT OF SORBITOL ON 3TC PK AFTER ADMINISTRATION OF LAMIVUDINE SOLUTION IN ADULTS
Kimberly K. Adkison$, Cynthia McCoig$, Allen Wolstenholme$, Yu Lou$, Zhiping Zhang$, Amy Eld$, Katy Hayward$, Mark Shafer$
$ViiV Hlthcare, Rsr Triangle Park, NC, USA, $ViiV Hlthcare, Tres Cantos, Madrid, Spain, $GloxoSmithKline, Collville, PA, USA, $PAREXEL Intl, Durham, NC, USA, $ViiV Hlthcare, Brentford, UK$

429 CRUSHING OF DOLUTEGRAVIR COMBINATION TABLETS INCREASES DOLUTEGRAVIR EXPOSURE
Marieke Roskam-Kwint$, Pauline Bollen$, Angela Colbers$, Marijolijn Duijser-van Essenberger$, Veroniek Harbers$, Reinout van Crevel$, David M. Burger$
$Radboud Univ Med Cntr, Nijmegen, Netherlands, $Elisabeth–TweeSteden Ziekenhuis, Tilburg, Netherlands$

430 EFFECT OF SEVERE RENAL IMPAIRMENT ON DORAVIRINE PHARMACOKINETICS
Wendy Ankrom$, Kelly Yee$, Rosa Sanchez$, Adedayo Abedoyin$, Li Fan$, Thomas Marbury$, Richard A. Preston$, Sauzanne Khalilieh$, Marian Iwamoto$
$Merck & Co, Inc, Kenilworth, NJ, USA, $Orlando Clinical Rsr Cntr, Orlando, FL, USA, $Univ of Miami, Miami, FL, USA$

431 HIGHER PLASMA LEVELS AND MORE SIDE EFFECTS IN ELDERLY DARUNAVIR-TREATED PATIENTS

432 PHARMACOKINETICS OF DOLUTEGRAVIR IN PEOPLE LIVING WITH HIV OVER THE AGE OF 60
Emilie Elliot$, Xinzhui Wang$, Nicole Pagani$, Alison Jenkin$, Jaime Vera-Rojas$, Isaac Day-Weber$, Graeme Moyle$, Myra McClure$, Marta Boffito$
**Poster P-15 IMMEDIATE VS DELAYED ART**

**Poster Hall - 4 EF**

**2:30 PM - 4:00 PM**

---

**470** LONG-TERM EFFECTS OF IMMEDIATE VERSUS DEFERRED C-ART IN PRIMARY HIV INFECTION (PHI)

Kees Brinkman, Sebastian Tawil, Guido van den Berk, Daoud Ait Moha, Willem Blok

OLVG, Amsterdam, Netherlands

**471** IL-6 AND D-DIMER PREDICT MORTALITY AND ARE ELEVATED AFTER DELAYED HIV TREATMENT

Ashita S. Batavia, Myung Hee Lee, Patrice Severe, Julie Reust, Yuan-Shan Zhu, Marc Antoine Jean Juste, Kathryn Dupnik, Jean W. Pape, Daniel Fitzgerald

1Weill Cornell Med Coll, New York, NY, USA, 2GHESKIO, Port-au-Prince, Haiti

**472** EARLY TREATMENT IS LIKELY MORE IMPORTANT THAN PREVIOUSLY THOUGHT

Katherine E. Schlusser, Shweta Sharma, Julia A. Metcalf, Angie N. Pinto, Rika Draenert, Pola de la Torre, Giuseppe Tambussi, James Neaton, Oliver Laeyendecker

1The Johns Hopkins Univ, Baltimore, MD, USA, 2Univ of Minnesota, Minneapolis, MN, USA, 3NIAID, Bethesda, MD, USA, 4Kirby Inst, Sydney, Australia, 5Klinikum der Univ Munich, Munich, Germany, 6Cooper Univ Hosp, Camden, NJ, USA, 7Ospedale San Raffaele, Milano, Italy, 8NIAID, Bethesda, MD, USA

**473** ART IN HIV PERSONS WITH PRETREATMENT VIREMIA ≤3000 C/ML: THE START STUDY

Irini Sereti, Roy M. Gulick, Sonya Krishnan, Stephen A. Migueles, Adrian Palfreeman, Veronique Touzeau-Römer, Waldo Belloso, Sean Emery, Matthew Law

1NIAID, Bethesda, MD, USA, 2Weill Cornell Med, New York, NY, USA, 3Leicester Royal Infirmary, Leicester, UK, 4Med Univ of Vienna, Vienna, Austria, 5Hosp Italiano de Buenos Aires, Buenos Aires, Argentina, 6Kirby Inst, Sydney, Australia

**474** BENEFIT OF CONTINUOUS/IMMEDIATE ART ON DISEASE RISK: SMART & START COMBINED ANALYSIS

Álvaro H. Borges, Jacqueline Neuhaus, Shweta Sharma, James Neaton, Keith Henry, Olga Anagnostou, Therese Staab, Sean Emery, Jens D. Lundgren, for the INSIGHT SMART & START Study Groups

1RigsHosp, Copenhagen, Denmark, 2Univ of Minnesota, Minneapolis, MN, USA, 3Hennepin County Med Cntr, Minneapolis, MN, USA, 4Univ of Athens, Athens, Greece, 5Cnr Hosp de Luxembourg, Luxembourg, Luxembourg, 6Kirby Inst, Sydney, Australia

**475** NO PER-PATIENT COST INCREASE UNDER IMMEDIATE ART FOR ALL: EVIDENCE FROM SWAZILAND

Shaukat Khan, Emma Mafara, Pascal Geldsetzer, Salinda Phanitsiri, Cebele Wong, Charlotte Lejeune, Fiona Walsh, Velephi Okello, Till Baernighausen

1Clinton Hlth Access Initiative, Mbabane, Swaziland, 2Harvard Univ, Boston, MA, USA, 3Clinton Hlth Access Initiative, Boston, MA, USA, 4Swaziland Ministry of Hlth, Mbabane, Swaziland, 5Heidelberg Univ, Heidelberg, Germany
181 COST-EFFECTIVENESS AND BUDGET IMPACT OF IMMEDIATE ART INITIATION IN CÔTE D’IVOIRE
Eric N. Ouattara1, Rachel L. MacLean2, Christine Daniel1, Ethan D. Borre3, Delphine Gabillard4, Mingshu Huang5, A. David Paltiel1, Xavier Anglaret6, Serge Eholie7, Kenneth Freedberg8
1Prog PAC-CI, ANRS Rsr site, Abidjan, Côte d’Ivoire, 2Massachusetts General Hosp, Boston, MA, USA, 3INSERM, Bordeaux, France, 4Yale Univ, New Haven, CT, USA, 5Service des Maladies Infectieuses et Tropes, Abidjan, Côte d’Ivoire

Poster Sessions • Thursday
Program and Agenda
CROI 2017

Poster P-J1 PREVALENCE AND INCIDENCE OF HIV DRUG RESISTANCE
Poster Hall - 4 EF 2:30 PM - 4:00 PM

476 CORRELATES OF DRUG RESISTANCE MUTATIONS IN ART-NAIVE INDIVIDUALS WITH HIV INFECTION
Sarah E. Porter1, Ellsworth Campbell1, Emily Westheimer1, Cynthia L. Gay1, Stephanie E. Cohen1, Anupama Shankar1, Jin-Fen Li1, Jeffrey A. Johnson1, William M. Switzer1, Philip J. Peters1
1CDC, Atlanta, GA, USA, 2New York City DHMH, New York, NY, USA, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4San Francisco Dept of Pub Hlth, San Francisco, CA, USA

477 HIV INTEGRASE GENOTYPIC TESTING AND RESISTANCE IN THE UNITED STATES—9 JURISDICTIONS
Angela L. Hernandez1, M. Cheryl B. Ocfemia1, Neeraja Saduvala2, Alexandra Oster1, Walid Heneine1, Jeffrey A. Johnson1, Irene Hall1
1CDC, Atlanta, GA, USA, 2ICF Intl, Atlanta, GA, USA

478 PREDICTORS OF HIV GENOTYPING AMONG NEW DIAGNOSES LINKED TO CARE IN PHILADELPHIA
Melissa Miller, Tanner Nassau, Makeda Carroll, Coleman Terrell, Kathleen Brady
Philadelphia Dept of Pub Hlth, Philadelphia, PA, USA

479 PRETREATMENT DRUG-RESISTANCE INCREASE IN 3 FOCAL POINTS OF MEXICO, 2012–2015
Claudia García-Morales1, Santiago Avila-Rios1, Daniela Tapia-Trejo1, Verónica S. Quiroz-Morales1, Samuel Navarro2, Carlos A. Barrera-Arellano2, Jesús Casillas-Rodríguez2, Akio Murakami-Ogasawara1, Gustavo Reyes-Terán1, for the HIV MexNet Group
1Natl Inst of Respiratory Diseases, Mexico City, Mexico, 2Hosp General Tijuana, Tijuana, Baja California, USA, 3Capsitats Cancín, Cancín, Quintana Roo, Mexico, 4Clínica Especializada Condesa, Mexico City, Mexico

480 HIV DRUG RESISTANCE: A UNIQUE PERSPECTIVE ACROSS 4 AFRICAN COUNTRIES
Brook Danboise1, Christina Polyak1, Alex Kasembeli2, Samoel Khamadi3, Babajide Keshinro Keshinro1, Hannah Kibuuka1, John Owuoth1, Sheila A. Peel1, Julie Ake1, Trevor Crowell1
1US Military HIV Rsr Prog, Bethesda, MD, USA, 2Walter Reed Prog—Kericho, Kericho, Kenya, 3Walter Reed Prog—Tanzania, Mbeya, Tanzania, 4Walter Reed Prog—Nigeria, Abuja, Nigeria, 5Makerere Univ Walter Reed Prog, Kampala, Uganda, 6Walter Reed Prog, Kisumu, Kenya
482 HIV PRETREATMENT DRUG RESISTANCE IN CAMEROON: FIRST NATIONWIDE STUDY
Gaëlle F. Tchouwa¹, Jenny Domuyeum¹, Sabrina Eymard-Duverny², Amandine Cournil³, Eric Delaporte³, Martine Peeters³, Elliot Raizes³, Eitel Mpoudi-Ngole¹, Avelin F. Aghokeng¹
¹CREMER, Yaoundé, Cameroon, ²Univ de Montpellier, Montpellier, France, Montpellier, France, ³CDC, Atlanta, GA, USA, ⁴IRD, Yaoundé, Cameroon

483 LOW PREVALENCE OF HIV DRUG RESISTANCE WITH MODERN AGENTS
Thibaut Davy, Laurence Brunet, Sonia Napravnik, Oksana Zakharova, Ann M. Dennis, Joseph J. Eron
Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

484 LOW PREVALENCE OF NRTI, NNRTI, AND PI DRUG RESISTANCE MUTATIONS IN BOTSWANA
Sikhulile Moyo¹, Simani Gaseitsiwe¹, Melissa Zahralban-Steele³, Dorcas Maruapula¹, Phillimon P. Sebogodi¹, Madisa Mine¹, Elliot Raizes⁴, Shahin Lockman³, Max Essex², Vlad Novitsky²
¹Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana, ²Harvard Univ, Boston, MA, ³Natl Hlth Lab, Gaborone, Botswana, ⁴CDC, Atlanta, GA, USA

485 ARV RESISTANCE MUTATIONS IN PATIENTS RECEIVING A WHO TDF-CONTAINING 1ST-LINE REGIMEN
Soo-Yon Rhee¹, John Gregson², Ravindra K. Gupta¹, Robert Shafer³, for the TenoRes Study Group

486 VIRAL SUPPRESSION AND ACQUIRED HIV DRUG RESISTANCE IN CAMEROON: A NATIONWIDE STUDY
Gaëlle F. Tchouwa¹, Jenny Domuyeum¹, Sabrina Eymard-Duverny², Amandine Cournil³, Eric Delaporte³, Martine Peeters³, Eitel Mpoudi-Ngole¹, Elliot Raizes³, Avelin F. Aghokeng¹
¹CREMER, Yaoundé, Cameroon, ²Univ de Montpellier, Montpellier, France, Montpellier, France, ³CDC, Atlanta, GA, USA, ⁴IRD, Yaoundé, Cameroon

487 HIGH HIV DRUG RESISTANCE OF FIRST-LINE ART TREATMENT IN BENIN PEDIATRIC POPULATION
Djenèba Bocar Fofana¹, Marcelline d’Almeida¹, Pierre–Marie Girard¹, Bernabé Lafia¹, Sidonie Lambert¹, Lutecia Zohoun-Guidigbi¹, Rene Kekeh², Cathia Soulé², Anne–Geneviève Marcellin¹, Laurence Morand-Joubert¹
¹Saint-Antoine Hosp, Paris, France, ²Univ d’Abomey–Calavi, Benin, ³CNHU–HCM, Cotonou, Benin, ⁴Reference Lab of the Natl Cntr for the Treatment of HIV, Cotonou, Benin, ⁵Pitie-Salpetriere Hosp, Paris, France

488 DRUG-RESISTANT HIV-1 DURING LONG-TERM SECOND-LINE ANTIRETROVIRAL TREATMENT IN KENYA
Seth Inzaule¹, Raph L. Hamers¹, Irene Mukui³, Kennedy Were¹, Preston Owiiti¹, Daniel Kwaro¹, Tobias R. de Wit¹, Clement Zehª
¹Academic Med Cntr of the Univ of Amsterdam, Amsterdam, Netherlands, ²Natl AIDS and STI Control Prog, Nairobi, Kenya, ³Kenya Med Rsr Inst, Kisumu, Kenya, ⁴US CDC, Kisumu, Kenya

489 ELIMINATING DRUG RESISTANCE IN SOUTH AFRICA BY USING DOLUTEGRAVIR
Katie Sharp¹, Thibault Mesplede², Mark A. Wainberg³, Sally Blower¹
¹Univ of California Los Angeles, Los Angeles, CA, USA, ²McGill Univ, Montreal, Quebec, Canada
490 IMPACT OF PRETREATMENT HIV-DRUG RESISTANCE ON VIROLOGIC OUTCOME OF FIRST-LINE ART
Ingrid A. Beck, Molly Levine, Ross Milne, Isaac So, Nina Andersen, Michael Watling, Michael H. Chung, James Munyao, Catherine Kiptinness, Lisa Frenkel

1Seattle Children’s Rsr Inst, Seattle, WA, USA, 2Univ of Washington, Seattle, WA, USA, 3Coptic Hope Cntr, Nairobi, Kenya

491 RESPONSE TO FIRST-LINE ART IN ADULTS WITH DRUG RESISTENT HIV, ANRS 12249 TASp TRIAL
Collins C. Iwuji, Anne Derache, Kathy Baisley, Siva Danaviah, Tulio de Oliveira, François Dabis, Kholoud Porter, Deenan Pillay, for the ANRS 12249 TasP Study Group

1Univ Coll London, London, UK, 2Africa Hlth Rsr Inst, Mtubatub, South Africa, 3London Sch of Hygiene and Trop Med, London, UK, 4Africa Cntr for Pop Heath, Mtubatub, South Africa, 5Univ of KwaZulu-Natal, Durban, South Africa, 6Univ de Bordeaux, Bordeaux, France

492 ASSOCIATION BETWEEN HIV DRUG RESISTANCE AND BASELINE FAILURE IN THE ACTG PEARLS STUDY
Rami Kantor, Saran Vardhanabhuti, Srikanth Tripathy, Mariza Morgado, Shanmugam Saravanan, Carole Wallis, Sarah E. Hudelson, Susan H. Eshleman, Thomas Campbell

1Brown Univ, Providence, RI, USA, 2Harvard Univ, Cambridge, MA, USA, 3Natl Inst for Rsr in TB, Chennai, India, 4Oswaldo Cruz Inst, Rio de Janeiro, Brazil, 5YRG CARE, Chennai, Tamilnadu, 6Lancet Labs and BARC-SA, Johannesburg, South Africa, 7The Johns Hopkins Univ, Baltimore, MD, USA, 8Univ of Colorado Denver, Aurora, CO, USA

493 SHOULD WE BE TESTING FOR BASELINE INTEGRASE RESISTANCE?
Yiannis Koullias, Paul E. Sax, Rochelle P. Walensky, Emily P. Hyle

1Brigham and Women’s Hosp, Boston, MA, USA, 2Massachusetts General Hosp, Boston, MA, USA

494 COST-EFFECTIVENESS ANALYSIS OF PRE-ART HIV DRUG RESISTANCE TESTING IN KENYA

1Univ of Washington/Seattle Children's Rsr Inst, Seattle, WA, USA, 2Stanford Univ, Stanford, CA, USA, 3Seattle Children's Rsr Inst, Seattle, WA, USA

577 HIGH PREVALENCE OF HEPATITIS DELTA VIRUS AMONG CAMEROONIAN HBsAG-POSITIVE SPECIMENS
Mary Rodgers, Kelly Coller, Ka-Cheung Luk, Emily Butler, Jill Fuhrman, Elizabeth Krilich, Devin Barnaby, Nicolea Ndembli, Lazare Raptue, Gavin Cloherty

1Abbott Labs, Abbott Park, IL, USA, 2Franciscan Univ of Steubenville, Steubenville, OH, USA, 3Inst for Human Virology, Abuja, Nigeria, 4Univ of Montagnes, Bangangté, Cameroon
**Poster Sessions • Thursday**

**Program and Agenda**

**CROI 2017**

184

---

578 **DECLINE AND CHANGING PROFILE OF HEPATITIS DELTA AMONG INJECTION DRUG USERS IN SPAIN**

Antonio Aguilera¹, Vincent Soriano², Pablo Barreiro³, Jose M. Peña³, Rocio Trastoy⁴, Jose J. Costa⁵

¹Complexo Hospitalar Univ Santiago, Santiago, Spain, ²La Paz Univ Hosp, Madrid, Spain

---

579 **UNCONVENTIONAL T CELLS IN A PEG-INF-2α ADD-ON STRATEGY FOR SUPPRESSED HBV INFECTION**

Camilla Tincati¹, Elvira S. Cannizzo¹, Francesca Binda², Paola Ronzi², Federico A. Cazzaniga³, Antonella d’Arminio Monforte¹, Giulia Marchetti¹, Laura Milazzo²

¹Univ of Milan, Milan, Italy, ²Luigi Sacco Univ Hosp, Milan, Italy

---

580 **INCREASED RATES OF HBV SEROCONVERSION UNDER LONG-TERM HBV ACTIVE THERAPY IN HBV/HIV**

Christoph Boesecke¹, Fabian Busch¹, Clara Lehmann¹, Carolynne Schwarze-Zander¹, Jakob Malin¹, Joerg Janne Vehreschild², Jan-Christian Wasmuth¹, Gerd Fätkenheuer¹, Jürgen K. Rockstroh¹, for the Cologne Bonn Cohort

¹Bonn Univ Hosp, Bonn, Germany, ²Cologne Univ Hosp, Cologne, Germany

---

581 **MORTALITY OF HIV/HBV COINFECTED PATIENTS ON ART IN URBAN AND RURAL SOUTHERN AFRICA**

Jonas Hector¹, Michael J. Vinikoor², Kalo Musukuma³, Roma Chilengi³, Laura Jefferys³, Michael A. Hobbins¹, Mary-Ann Davies⁴, Matthias Egger⁵, Gilles Wandelier³

¹SolidarMed, Luzern, Switzerland, ²Cntr for Infectious Disease Rsr in Zambia, Lusake, Zambia, ³SolidarMed, Pemba, Mozambique, ⁴Univ of Cape Town, Cape Town, South Africa, ⁵Univ of Bern, Bern, Switzerland

---

582 **EFFECTIVENESS OF HAV VACCINATION AMONG HIV-POSITIVE PATIENTS DURING AN HAV OUTBREAK**

Kuan-Yin Lin¹, Szu-Min Hsieh¹, Hsin-Yun Sun¹, Yi-Chun Lo¹, Wang-Huei Sheng¹, Yu-Chung Chuang¹, Sung-Ching Pan¹, Chien-Ching Hung¹, Shan-Chwen Chang¹

¹Natl Taiwan Univ Hosp, Taipei, Taiwan, ²Taiwan Ctrs for Disease Control, Taipei, Taiwan

---

583 **ACTIVE HPGV-2 INFECTION IS RESTRICTED TO COCIRCULATING HCV INFECTION**

Kelly Coller, Michael Berg, Matthew Frankel, Kenn Forberg, John Hackett, Gavin Cloherty, George Dawson

Abbott Labs, Abbott Park, IL, USA

---

584LB **TDF TO PREVENT PERINATAL HEPATITIS B VIRUS TRANSMISSION: A RANDOMIZED TRIAL (ITAP)**

Gonzague Jourdain¹, Nicole Ngo-Giang-Huong¹, Linda J. Harrison², Luc Decker¹, Camlin Tierney³, Tim R. Cressey³, Jullapong Achalapong⁴, George K. Siberry³, Noelle Nelson⁵, Nantasak Chotivanich³

¹IRD, Chiang Mai, Thailand, ²Harvard Univ, Boston, MA, USA, ³Prog for HIV Prevention and Treatment, Chiang Mai, Thailand, ⁴Chiangrai Prachanukroh Hosp, Chiang Rai, Thailand, ⁵NIH, Bethesda, MD, USA, ⁶CDC, Atlanta, GA, USA, ⁷Chonburi Hospital, Chonburi, Thailand
**Poster Sessions • Thursday
Program and Agenda
CROI 2017**

**Poster Hall - 4 EF**

**2:30 PM - 4:00 PM**

---

**585**

**EFFECTS OF TREATMENT WITH MARAVIROC—A CCR5 INHIBITOR ON HUMAN HEPATIC STELLATE CELLS**

Salvatore Martini¹, Angelica Perna¹, Angela Lucariello¹, Margherita Macera¹, Maria Aurora Carleo¹, Germano Guerra¹, Vincenzo Esposito², Antonio De Luca¹, Nicola Coppola¹

¹Second Univ of Naples, Naples, Italy, ²AORN dei Colli, Naples, Italy, ³Univ of Molise, Campobasso, Italy

---

**586**

**CORRELATION OF BLOOD TRANSCRIPTOME WITH OUTCOME AFTER DAA TREATMENT FOR HCV INFECTION**

Cody Orr¹, Paul Nietert¹, Shyam Kottilil², Gary Hardiman¹, Eric G. Meissner¹

¹Med Univ of South Carolina, Charleston, SC, USA, ²Univ of Maryland, Baltimore, MD, USA

---

**587**

**DO MAIT CELLS IMPACT FIBROSIS IN HCV AND HIV/HCV COINFECTED PATIENTS?**

Boris J. Beudeker¹, Gertine van Oord¹, Joop Arends², Julian Schulze zur Wiesch³, Marieke van Heide – Mulder¹, Robert de Knecht¹, Annelies Verbon², Andre Boonstra¹, Mark Claassen¹

¹Erasmus Univ Med Cntr, Rotterdam, Netherlands, ²Univ Med Cntr Utrecht, Utrecht, Netherlands, ³Univ Med Cntr Hamburg-Eppendorf, Hamburg, Germany, ⁴Rijnstate Hosp, Arnhem, Netherlands

---

**588**

**PATHOGENESIS OF HIV-INDUCED LIVER DISEASE IN DUAL IMMUNE AND LIVER HUMANIZED MICE**

Raghubendra S. Dagur, Weimin Wang, Yan Cheng, Weizhe Li, Edward Makarov, Natalia Osna, Santhi Gorantla, Larisa Y. Poluektova

Univ of Nebraska, Omaha, NE, USA

---

**589**

**PERIPHERAL ENDO THELIAL FUNCTION IS SUBOPTIMAL IN HCV-UNTREATED, HIV-SUPPRESSED ADULTS**

Kara W. Chew¹, Eric Daar², Jordan E. Lake¹, Chrisandra L. Shufelt¹, Zhaoping Li¹, Diana Liao¹, Wilbert Jordan³, C. Noel Bairey Merz⁴, Judith S. Currier¹, Debika Bhattacharya¹

¹Univ of California Los Angeles, Los Angeles, CA, USA, ²Los Angeles Biomed Rsr Inst at Harbor–UCLA Med Cntr, Torrance, CA, USA, ³Univ Texas Houston, Houston, TX, USA, ⁴Cedars-Sinai Med Cntr, Los Angeles, CA, USA, ⁵Charles R. Drew Univ of Med and Sci, Los Angeles, CA, USA

---

**590**

**LEUKOCYTE TELOMERE ATTRITION IS RAPID FOLLOWING HIV BUT NOT HCV SEROCONVERSION**

Alejandro Gonzalez-Serna¹, Abhinav Ajaykumar², Izabelle Gadawski², M. Angeles Muñoz-Fernández³, Kanna Hayashi¹, M.J. Milloy¹, P. Richard Harrigan¹, Helene C. Cote²

¹BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, ²Univ of British Columbia, Vancouver, British Columbia, Canada, ³General Univ Hosp Gregorio Marañon, Madrid, Spain
**Poster P-M3 AIDS-RELATED CANCER: LYMHPHOMA, KAPOSI SARCOMA, LUNG, AND LIVER**

**Poster Hall - 4 EF**

2:30 PM - 4:00 PM

**603** LYMHPHOMA IN HIV-2-INFECTED PATIENTS IN CART ERA: A 15-PATIENT SINGLE-CENTER SERIES
Anne-Marie Ronchetti, Sophie Matheron, Lionel Galicier, Florence Damond, Nadia Mahjoub, Amel Besseghir, Veronique Meignin, Francois Simon, Eric Oksenhendler, Laurence Gerard
1Saint Louis Hosp, Paris, France, 2Bichat-Claude Bernard Hosp, Paris, France, 3INSERM, Bordeaux, France

**604** EPSTEIN-BARR VIRUS DNA LOAD: A POSSIBLE PREDICTOR OF AIDS-RELATED LYMPHOMA
Simone H. Hijlkema, Jeroen J. van Kampen, David van de Vijver, Ineke van der Ende
Erasmus Univ Med Ctr, Rotterdam, Netherlands

**605** THE IMMUNE ACTIVATION PROFILE LINKED TO KAPOSI SARCOMA IN HIV-1-POSITIVE ADULTS
Christina Psomas, Mehwish Younas, Jacques Reynes, Pierre Portales, Jean-François Eliaou, Pierre Corbeau
1Univ Hosp of Montpellier, Montpellier, France, 2Inst of Human Genetics, Montpellier, France

**606** TREATMENT AND OUTCOMES OF NON–SMALL-CELL LUNG CANCER IN LATER ART-ERA HIV INFECTION
Keith M. Sigel, Kristina Crothers, Sheldon T. Brown, Cynthia L. Gibert, Matthew B. Goetz, Roger Bedimo, Roxanne Wadia, Maria Rodriguez-Barradas, Fatma Shebl, Lesley Park
1Icahn Sch of Med at Mt Sinai, New York, NY, USA, 2Univ of Washington, Seattle, WA, USA, 3James J. Peters VA Med Ctr, Bronx, NY, USA, 4Washington, DC, VA Med Ctr, Washington, DC, USA, 5VA Greater Los Angeles Hlth Care System, Los Angeles, CA, USA, 6VA North Texas Hlth Care Ctr, Dallas, TX, USA, 7VA Connecticut Hlthcare System, West Haven, CT, USA, 8Baylor Coll of Med, Houston, TX, USA, 9Yale Univ, New Haven, CT, USA, 10Stanford Med, Stanford, CA, USA

**607** ETIOLOGY OF HEPATOCELLULAR CARCINOMA IN WEST AFRICA: THE HIV CONTRIBUTION
Antoine Jaquet, Boris Tchounga, Aristophane Tanon, Aklesso Bagny, Didier K. Ekouevi, Hamar A. Traore, Annie J. Sasco, Moussa Maiga, Francois Dabis, for the IeDEA West Africa Collaboration
1Univ de Bordeaux, Bordeaux, France, 2CHU de Treichville, Abidjan, Cote d’Ivoire, 3CHU Campus, Lomé, Togo, 4Univ de Lomé, Lomé, Togo, 5CHU du Point G, Bamako, Mali, 6Hôpital Gabriel Touré, Bamako, Mali

**Poster P-O10 ORGAN TRANSPLANTATION**

**Poster Hall - 4 EF**

2:30 PM - 4:00 PM

**688** KIDNEY TRANSPLANT OUTCOMES IN HIV-POSITIVE AND HIV-NEGATIVE RECIPIENT PAIRS
Esther Gathogo, Frank Post
1King’s Coll London, London, UK, 2King’s Coll Hosp NHS Fndn Trust, London, UK

**689** PLANNED PRACTICE OF HIV POSITIVE-TO-POSITIVE TRANSPLANTS IN US TRANSPLANT CENTERS
Sarah Rasmussen, Mary Grace Bowring, Ashton Shaffer, Allan Massie, Aaron Tobian, Dorry Segev, Christine Durand
The Johns Hopkins Univ, Baltimore, MD, USA

186 CROI 2017
690  FOOD INSECURITY IS ASSOCIATED WITH POOR DIABETES CONTROL IN THE WIHS

Kartika Palar1, Edward A. Frongillo2, Tracey Wilson3, Margde Cohen4, Eryka Wentz2, Adaora Adimora5, Daniel Merenstein6, Janet M. Turan6, Phyllis Tien7, Sheri Weiser1

1Univ of California at San Francisco, San Francisco, CA, USA, 2Univ of South Carolina, Columbia, SC, USA, 3SUNY Downstate Med Cntr, Brooklyn, NY, USA, 4Stroger Hosp, Chicago, IL, USA, 5The Johns Hopkins Univ, Baltimore, MD, USA, 6Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 7Georgetown Univ, Washington, DC, USA

691  ADIPOSE MITOCHONDRIAL FUNCTION, ADIPONECTIN, AND INSULIN RESISTANCE IN ACTG A5224S

Todd Hulgan1, Benjamin Ramsey2, John R. Koethe3, David C. Samuels3, Mariana Gerschenson3, Daniel Libutti3, Grace A. McComsey4, Paul E. Sax5, Todd Brown6, for the AIDS Clinical Trials Group Study A5224S Team

1Vanderbilt Univ, Nashville, TN, USA, 2Univ of South Carolina, Greenville, SC, USA, 3Univ of Hawaii-Manoa, Honolulu, HI, USA, 4Case Western Reserve Univ, Cleveland, OH, USA, 5Bingham and Women’s Hosp, Boston, MA, USA, 6The Johns Hopkins Univ, Baltimore, MD, USA

692  PLASMINOGEN ACTIVATOR INHIBITOR-1 PREDICTS REDUCED INSULIN SENSITIVITY IN HIV

Kamonkiat Wirunsawanya1, Dominic Chow1, Loni Belyea1, Cecilia Shikuma1, Richard M Watanabe2, Lindsay Kohorn1, Bruce Shiramizu1, Brooks Mitchell1, Scott A. Souza1, Lishomwa Ndhlovu1

1Univ of Hawaii, Honolulu, HI, USA, 2Univ of Southern California, Los Angeles, CA, USA

693  BODY MASS INDEX AND THE RISK OF SERIOUS NON-AIDS EVENTS: THE D:A:D STUDY

Amit C. Achhra1, Caroline Sabin2, Lene Ryom2, Antonella d’Arminio Monforte1, Stephane de Wit1, Andrew Phillips2, Christian Pradier3, Jens D. Lundgren1, Matthew Law2, for the the DAD Study Group

1Kirby Inst, Sydney, Australia, 2Univ Coll London, London, UK, 3CHIP, Copenhagen, Denmark, 4Univ of Milan, Milan, Italy, 5Univ Libre de Bruxelles, Brussels, Belgium, 6Nice Univ Hosp, Nice, France, 7Univ of Copenhagen, Copenhagen, Denmark

694  RANDOMIZED TRIAL OF BEHAVIORAL WEIGHT LOSS FOR HIV-INFECTED PATIENTS

Katie Becofsky1, Edward J. Wing2, Jeanne McCaffery3, Matthew Boudreau1, Rena R. Wing4

1Univ of Massachusetts Amherst, Amherst, MA, USA, 2Brown Univ, Providence, RI, USA, 3The Miriam Hosp, Providence, RI, USA

695  PREDICTORS OF SEVERE WEIGHT/BODY MASS INDEX GAIN FOLLOWING ANTIRETROVIRAL INITIATION

Priya Bhagwat1, Igbo Ofotokun2, Grace A. McComsey3, Todd Brown4, Carlee Moser5, Catherine A. Sugar6, Judith S. Currier4

1Univ of California Los Angeles, Los Angeles, CA, USA, 2Emory Univ, Atlanta, GA, USA, 3Case Western Reserve Univ, Cleveland, OH, USA, 4The Johns Hopkins Univ, Baltimore, MD, USA, 5Harvard Univ, Boston, MA, USA
**Poster Sessions • Thursday**

**Program and Agenda**

**CROI 2017**

**696 RALTEGRAVIR SWITCH AND BIOMARKERS OF LIVER STEATOSIS AND METABOLIC SYNDROME IN WOMEN**

David Reynoso¹, Anoma Somasunderam¹, Maitreyee Nigalye¹, Judith S. Currier⁴, Netanya S. Uty¹, **Jordan E. Lake**¹

¹Univ of Texas Med Branch at Galveston, Galveston, TX, USA, ²Univ of California Los Angeles, Los Angeles, CA, USA, ³Univ Texas Houston, Houston, TX, USA

**697 CHANGES IN LIVER STEATOSIS AFTER SWITCHING EFAVIRENZ TO RALTEGRAVIR: THE STERAL STUDY**

Juan Macías¹, Dolores Merino², Francisco Téllez¹, Federico Pulido¹, Juan González-García¹, Manuel Márquez³, Antonio Rivero¹, María Mancebo¹, Juan A. Pineda¹, for the RIS-HEP09

¹Hosp Univ de Valme, Sevilla, Spain, ²Complejo Hospitalario Univ de Huelva, Huelva, Spain, ³Hosp Univ de Puerto Real, Cádiz, Spain, ⁴Hosp 12 de Octubre, Madrid, Spain, ⁵Hosp Univ La Paz, Madrid, Spain, ⁶Hosp Virgen de la Victoria, Málaga, Spain, ⁷Hosp Univ Reina Sofia, Cordoba, Spain

**698 OBESITY IN ANTIRETROVIRAL-TREATED HIV-INFECTED ADULTS: PREDICTORS AND COMORBIDITIES**

Anchalee Avihingsanon¹, Sivaporn Gatechompol¹, Opas Putcharoen², Jiratchaya Sophophon¹, Supalak Phophinthak¹, Sasawimol Ubolyam¹, Stephen J. Kerr¹, Kiat Ruxrungtham², Praphan Phanunphak¹, for the HIV-NAT 006 Study Group

¹HIV-NAT, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, ²Chulalongkorn Univ, Bangkok, Thailand

**699 WOMEN GAIN MORE WEIGHT THAN MEN FOLLOWING INITIATION OF ANTIRETROVIRAL THERAPY**

Sara H. Bares¹, Laura M. Smeaton¹, Ai Xu¹, Catherine Godfrey¹, Grace A. McComsey¹

¹Univ of Nebraska, Omaha, NE, USA, ²Harvard Univ, Cambridge, MA, USA, ³DAIDS, NIAID, Bethesda, MD, USA, ⁴Case Western Reserve Univ, Cleveland, OH, USA

**700 CT FAT DENSITY REFLECTS HISTOLOGIC FAT QUALITY IN ART-TREATED, HIV-1-INFECTED ADULTS**

Jordan E. Lake¹, Carlee Moser², Liz Johnston³, Clara Magyar³, Scott D. Nelson¹, Kristine Erlandson⁴, Todd Brown⁵, Grace A. McComsey⁶

¹Univ of Texas, Houston, TX, USA, ²Harvard Univ, Boston, MA, USA, ³Univ of California Los Angeles, Los Angeles, CA, ⁴Univ of Colorado, Aurora, CO, USA, ⁵The Johns Hopkins Univ, Baltimore, MD, USA, ⁶Case Western Reserve Univ, Cleveland, OH, USA

**701 ASSOCIATION OF NAFLD WITH ADIPOKINE AND INFLAMMATORY MARKERS DIFFERS BY HIV STATUS**

Jennifer Price¹, Ruibin Wang¹, Eric Seaberg², Matthew Budoff³, Lawrence Kingsley¹, Frank J. Palella², Mallory Witt¹, Wendy Post¹, Chloe Thio¹

¹Univ California San Francisco, San Francisco, CA, USA, ²The Johns Hopkins Univ, Baltimore, MD, USA, ³Harbor–UCLA Med Cntr, Torrance, CA, USA, ⁴Univ of Pittsburgh, Pittsburgh, PA, USA, ⁵Northwestern Univ, Chicago, IL, USA, ⁶Los Angeles Biomed Rsr Inst, Harbor–UCLA Med Cntr, Torrance, CA, USA
702 PREVALENCE AND RISK FACTORS FOR HEPATIC STEATOSIS IN HIV+ PERSONS
Jessie Torgersen1, Kaku So-Armah2, Matthew Freiberg3, Matthew Budoff4, Joseph Lim5, Adeel Butt6, Maria Rodriguez-Barradas7, Amy Justice8, Jay Kostman9, Vincent Lo Re1
1Univ of Pennsylvania, Philadelphia, PA, USA, 2Boston Univ, Boston, MA, USA, 3Vanderbilt Univ, Nashville, TN, USA, 4Harbor–UCLA Med Ctr, Torrance, CA, USA, 5Yale Univ, New Haven, CT, USA, 6Univ of Pittsburgh, Pittsburgh, PA, USA, 7Baylor Coll of Med, Houston, TX, USA, 8VA Connecticut Hlthcare System, West Haven, CT, USA, 9Philadelphia FIGHT Community Hlth Cntrs, Philadelphia, PA, USA

703 LIVER STEATOSIS AND FIBROSIS IN AT-RISK EUROPEAN HIV-MONOINFECTED PATIENTS
Maud Lemoine1, Lambert Assoumou2, Patrick Ingiliz3, Pierre-Marie Girard4, Stephane de Wit5, Marc-Antoine Valantin6, Anja Huefner7, Jacqueline Capeau8, Dominique Costagliola9, Georg Behrens10

704 CHANGES IN LIVER FIBROSIS AND STEATOSIS IN HIV MONOINFECTED PATIENTS OVER 24 MONTHS
Raphael Mohr, Christoph Boesecke, Carolyne Schwarze-Zander, Jan-Christian Wasmuth, Jonel Trebicka, Jürgen K. Rockstroh
Univ Hosp Bonn, Bonn, Germany

Poster P-05 PREDATORS OF INFLAMMATION OR ART
Poster Hall - 4 EF 2:30 PM - 4:00 PM

672 BIOMARKERS OF AGING IN HIV-POSITIVE INDIVIDUALS AND MATCHED CONTROLS
Davide De Francesco1, Sebastian Oehlke2, Alexander Bürkle3, Ferdinand Witt4, Claudio Franceschi5, Neeltje A. Kootstra6, Claude Libert7, Peter Reiss8, Caroline Sabin9, for the Co-morBidity in Relation to AIDS (COBRA) Collaboration
1Univ Coll London, London, UK, 2Univ of Konstanz, Konstanz, Germany, 3Stichting HIV Monitoring and Academic Med Ctr, Amsterdam, Netherlands, 4Alma Mater Studiorum Univ di Bologna, Bologna, Italy, 5Academic Med Ctr, Amsterdam, Netherlands, 6VIB, Ghent, Belgium

673 LONGITUDINAL ASSOCIATION BETWEEN ALCOHOL USE AND INFLAMMATORY BIOMARKERS
Kaku So-Armah1, Matthew Freiberg2, Debbie Cheng3, Gregory Patts1, Russell Tracy1, Margaret Doyle1, Natalia Gnatienko1, Kendall J. Bryant4, Evgeny Krupitsky5, Jeffrey H. Samet1
1Boston Univ, Boston, MA, USA, 2Vanderbilt Univ, Nashville, TN, USA, 3Univ of Vermont, Colchester, VT, USA, 4Boston Med Ctr, Boston, MA, USA, 5Natl Inst on Alcohol Abuse and Alcoholism, Bethesda, MD, USA, 6St.Petersburg Pavlov State Med Univ, St. Petersburg, Russia

674 ASSOCIATION OF ANISOCYTOSIS WITH MARKERS OF INFLAMMATION AND IMMUNE EXHAUSTION IN HIV
Sadeer Al-Kindi, David A. Zidar, Grace A. McComsey, Chris T. Longenecker
Case Western Reserve Univ, Cleveland, OH, USA
**Poster P-O6 BONE DISEASE: RISK PREDICTION**

**Poster Hall - 4 EF**

**2:30 PM - 4:00 PM**

### 677 BONE MICROARCHITECTURAL CHANGES AND FRACTURE-RISK PREDICTION IN HIV AND HCV

**Roger Bedimo**¹, Beverley Adams-Huet², John Poindexter³, Irfan Farukhi³, Rosinda Castanon³, Geri Brown³, Diana Turner³, Teresa Moore³, Pablo Tebas³, Naim Maalouf²

¹VA North Texas Hlth Care Cntr, Dallas, TX, ²Univ of Texas Southwestern Med Cntr, Dallas, TX, ³VA North Texas Hlthcare System, Dallas, TX, ⁴Univ of Pennsylvania, Philadelphia, PA

### 678 FRAX-TOOL FRACTURE-RISK COMPARISON: HAVE A LITTLE BACKBONE!

**Linda Battalora**¹, Carl Armon², Kate Buchacz³, John Hammer⁴, John Spear⁵, John T. Brooks⁶, Benjamin Young⁴, Edgar T. Overton⁶

¹Colorado Sch of Mines, Golden, CO, USA, ²Cerner Corporation, Kansas City, MO, USA, ³CDC, Atlanta, GA, USA, ⁴Denver Infectious Disease Consultants, Denver, CO, USA, ⁵APEX Family Med, Denver, CO, USA, ⁶Univ of Alabama at Birmingham, Birmingham, AL, USA

### 679 FRACTURE-RISK ESTIMATES IN HIV-POSITIVE AND -NEGATIVE SUBJECTS: DATA FROM HIV UPBEAT

**Aoife G. Cotter**¹, Dylan Shannon¹, Tara McGinty¹, Alan Macken¹, Eoin Kavanagh², Geraldine McCarthy³, Jennifer J. Brady⁴, Juliet Compston⁴, Caroline Sabin⁴, Patrick W. Mallon¹

Poster P-O7 BONE DISEASE: MECHANISMS
Poster Hall - 4 EF
2:30 PM - 4:00 PM

680 SOCS-1/TRAFF-6 UP-REGULATION IN BONE IMPAIRMENT IN HIV+ PATIENTS ON EFFECTIVE CART
Elvira S. Cannizzo, Federico A. Cazzaniga, Esther Merlini, Camilla Tincati, Lidia Gazzola, Nathalie Iannotti, Angelo Del Sole, Antonella d’Arminio Monforte, Giulia Marchetti
Univ of Milan, Milan, Italy

681 BONE DENSITY, MICROARCHITECTURE, AND BONE STRENGTH AFTER 1 YEAR OF TDF
Robert Güerri-Fernández, Hernando Knobel, Judit Villar, Alicia González-Mena, Ana Guelar, Ludovic Humbert, Elisabet Lerma-Chipirraz, Marta Trenchs-Rodríguez, Adolfo Diez-Pérez
1Hosp del Mar, Barcelona, Spain, 2Galgo Med, Inc, Barcelona, Spain, 3CAP Passeig de Sant Joan, Barcelona, Spain

Poster P-O8 BONE DISEASE: INTERVENTIONS
Poster Hall - 4 EF
2:30 PM - 4:00 PM

682 A RANDOMIZED TRIAL OF VITAMIN D3 (3000 VERSUS 1000 IU) IN HIV+ POSTMENOPAUSAL WOMEN
Michael T. Yin, Chengchen Zhang, Mariana Bucovsky, David Ferris, Susan Olender, Arindam Roy Choudhury, Anjali Sharma, Cosmina Zeana, Barry S. Zingman, Elizabeth Shane
1Columbia Univ, New York, NY, USA, 2Columbia Univ, New York, NY, USA, 3Icahn Sch of Med at Mt Sinai, New York, NY, USA, 4Albert Einstein Coll of Med, Bronx, NY, USA, 5Bronx Lebanon Hosp Cntr, Bronx, NY, USA, 6Montefiore Med Cntr, Bronx, NY, USA

683 SWITCHING FROM TDF TO TAF IN HIV-INFECTED ADULTS WITH LOW BMD: A POOLED ANALYSIS
Todd Brown, Michael T. Yin, Samir Gupta, Christine Katlama, Adriano Lazzarin, Kathy Melbourne, Calvin Cohen, YaPei Liu, Thai Nguyen-Cleary, Scott McCallister
1The Johns Hopkin Univ, Baltimore, MD, USA, 2Columbia Univ, New York, NY, USA, 3Indiana Univ, Indianapolis, IN, USA, 4Pierre and Marie Curie Univ, Paris, France, 5Vita-Salute San Raffaele Univ, Milan, Italy, 6Gilead Scis, Inc, Foster City, CA, USA

684 ANTIRETROVIRAL BONE LOSS IS DURABLY SUPPRESSED BY A DOSE OF ZOLEDRONIC ACID
Igho Ofotokun, Kehmia Titanji, Aswani Vunnava, Antonina Foster, Anandi N. Sheth, Cecile D. Lahiri, Jeffrey J. Lennox, Andrea Knezevic, Kirk A. Easley, M. N. Weitzmann
Emory Univ, Atlanta, GA, USA

685LB HIGH DOSE VITAMIN D3 INCREASES SPINE BONE DENSITY IN HIV+ YOUTH ON TENOFOVIR (TDF)
Peter L. Havens, Charles Stephensen, Marta Van Loan, Brandy Rutledge, Bob Harris, Patricia M. Flynn, Catherine Gordon, Bill Kapogiannis, Kathleen Mulligan, for the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 109 Study Team
1Med Coll of Wisconsin, Wauwatosa, WI, USA, 2USDA, Davis, CA, USA, 3Westat, Rockville, MD, USA, 4St. Jude Children’s Rsr Hosp, Memphis, TN, USA, 5Univ of Cincinnati, Cincinnati, OH, USA, 6Nichd, Bethesda, MD, USA, 7Univ of California San Francisco, San Francisco, CA, USA
Poster Sessions • Thursday
Program and Agenda
CROI 2017

Poster P-O9 RENAL DISEASE
Poster Hall - 4 EF
2:30 PM - 4:00 PM

192
PREVALENCE AND RISK FACTORS OF RENAL INJURY IN OPTION B+ DURING THE FIRST 6 MONTHS
Caroline Melhado, Jacob Phulusa, Mathius John, Allan Jumbe, Bryna Harrington, Bryan Mthiko, Mina C. Hosseinipour, for the S4 Team
Univ of North Carolina Proj–Malawi, Lilongwe, Malawi

Poster P-P10 NEUROSYPHILIS
Poster Hall - 4 EF
2:30 PM - 4:00 PM

749
HOW WELL DO NEUROLOGIC SYMPTOMS IDENTIFY HIV-INFECTED INDIVIDUALS WITH NEUROSYPHILIS?
Arielle P. Davis1, Joshua Stern2, Sheila Dunaway1, Lauren Tantalo1, Sharon Sahi1, Abigail Crooks1, Claire Stevens1, Sarah Holte1, Christina Marra1
1Harborview Med Cntr, Seattle, WA, USA, 2Univ of Washington, Seattle, WA, USA

Poster P-P11 PROTOZOAL OIs
Poster Hall - 4 EF
2:30 PM - 4:00 PM

751
STOPPING SECONDARY TE PROPHYLAXIS IN SUPPRESSED PATIENTS WITH CD4 100-200 IS NOT SAFE
Jose M. Miro, for the Opportunistic Infection Team of the COHERE in EuroCoord
IDIBAPS, Barcelona, Spain

752
ASYMTOMATIC INFECTION IN AN HIV COHORT: LEISHMANIASIS OUTBREAK IN FUENLABRADA, SPAIN
Alicia Castro1, Eugenia Carrillo2, Juan V. San Martin1, Laura Botana1, Laura Molina1, Laura Fernandez2, Belen Matia1, Carmen Sanchez2, Jose Manuel Ruiz-Giardin1, Javier Moreno2
1Hosp Univ de Fuenlabrada, Fuenlabrada, Madrid, Spain, 2Inst de Salud Carlos III, Majadahonda, Spain

Alejandro Pérez, John Weiser, Heather Bradley
CDC, Atlanta, GA, USA

738 SIGNIFICANT HIGHER CMV-REACTIVATION IN PJP PATIENTS WITH ADJUNCTIVE CORTICOSTEROIDS

Gundolf Schuettfort, Sarah Tomasini, H.R. Brodt, Philipp De Leuw, Siri Goepel, Gerrit Kann, Annette E. Haberl, Eva Herrmann, Timo Wolf, Christoph Stephan
Univ Hosp Frankfurt, Frankfurt, Germany

739 HIV COINFECTION HAS A SIGNIFICANT IMPACT ON TRANSCRIPTIONAL RESPONSE TO TUBERCULOSIS

Hanif Esmail1, Rachel Lai2, Christine Graham2, Anne O’Garra2, Robert Wilkinson1

740 PREVALENCE OF ADVANCED HIV DISEASE AND CRYPTOCOCCAL INFECTION IN GABORONE, BOTSWANA

Kwana Lechiile1, Hannah K. Mitchell1, Fredah Mulenga2, Irene Goercke3, Martin S. Azama2, Mooketsi Molefi3, Tshepo B. Leeme3, Mark W. Tenforde4, Madisa Mine5, Joseph N. Jarvis6
1Botswana—UPenn Partnership, Gaborone, Botswana, 2Ministry of Hlth, Gaborone, Botswana, 3Univ of Washington, Seattle, WA, USA, 4Univ of Botswana, Gaborone, Botswana, 5Natl Hlth Lab, Gaborone, Botswana, 6US CDC, Gaborone, Botswana

741 CRYPTOCOCCAL ANTIGEN SCREENING AMONG PATIENTS WITH ADVANCED HIV INFECTION IN VIETNAM

Dat Q. Vu1, Kinh V. Nguyen2, Dung T. Nguyen2, Moses Bateganya3, Sheryl Lyss4, Anh T. Ho5, Jonathan Kaplan5, Presented by Hanzhu Qian, for the CRICS Team
1Hanoi Med Univ, Hanoi, Vietnam, 2Natl Hosp for Trop Diseases, Hanoi, Vietnam, 3CDC, Atlanta, GA, USA, 4CDC, Hanoi, Vietnam

742 CHANGES IN CRAG TITERS AMONG ASYMPTOMATIC HIV-POSITIVE PATIENTS

Agnes Kiragga1, Francis Kakooza1, Bozena M. Morawski2, Elizabeth Nalintya1, Radha Rajasingham2, David Boulware2, David Meya3, Yukari C. Manabe4
1Infectious Diseases Inst, Kampala, Uganda, 2Univ of Minnesota, Minneapolis, MN, USA, 3Makerere Univ, Kampala, Uganda, 4The Johns Hopkins Univ, Baltimore, MD, USA

743 HIGH PREVALENCE OF CNS DISSEMINATION WITH ASYMPTOMATIC CRYPTOCOCCAL ANTIGENEMIA

Azure T. Makadzange1, Admire Hlupeni1, Kathryn F. Boyd1, Takudzwa Chagumaira2, Christine Ross3, Snigdha Vallabhaneni4, Shirish Balachandra4, Moses Bateganya4, Chiratidzo E. Ndhlou2
1Massachusetts General Hosp, Cambridge, MA, USA, 2Univ of Zimbabwe, Harare, Zimbabwe, 3Infectious Disease Rsr Lab, Harare, Zimbabwe, 4CDC, Atlanta, GA, USA
744 SERTRALINE AND HIGH-DOSE FLUCONAZOLE TREATMENT OF CRYPTOCOCCAL MENINGITIS IN TANZANIA
Katende Andrew, Gladys Mbwanji, Diana Faini, Aneth Kalinjuma, Katherine Hullsiek, Josh Rhein, Maja Weisser, David Meya, David Boulware, Emilio Letang
1Hakara Hlth Ins, Morogoro, Tanzania, 2Univ of Minnesota, Minneapolis, MN, USA, 3Infectious Disease Inst, Kampala, Uganda

745 MORTALITY DUE TO HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS IN BOTSWANA IN THE ART ERA
Tshepo B. Leeme, Raju K. Patel, Caitlin Azzo, Nametso Lekwape, Katlego Tsholo, Ephraim Tawanana, Mooketsi Molefi, Margaret Mokomane, Mark W. Tenforde, Joe N. Jarvis
1Botswana–UPenn Partnership, Gaborone, Botswana, 2Univ of Pennsylvania, Philadelphia, USA, 3Botswana Ministry of Hlth, Gaborone, Botswana, 4Univ of Botswana, Gaborone, Botswana, 5Univ of Washington, Seattle, WA, USA, 6US CDC, Gaborone, Botswana

746 CSF IMMUNE RESPONSES ASSOCIATED WITH DEPRESSION FOLLOWING CRYPTOCOCCAL MENINGITIS
Sarah Lofgren, Kathy Huppler Hullsiek, Bozema M. Morawski, Josh Rhein, David Meya, Mahsa Abassi, Noeline Nakasujja, Abdu Musubire, David Boulware, for the Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis (ASTRO-CM) Study Group
1Univ of Minnesota, Minneapolis, MN, USA, 2Infectious Disease Inst, Kampala, Uganda, 3Makarere Univ, Kampala, Uganda

747 CLINICAL PERFORMANCE OF THE MP1P IMMUNOASSAY FOR RAPID DIAGNOSIS OF TALAROMYCOSIS
1Oxford Univ Clinical Rsr Unit, Ho Chi Minh, Vietnam, 2Univ of Hong Kong, Hong Kong, 3Hosp for Trop Diseases, Ho Chi Minh City, Vietnam

748 PREDICTING THE RISK OF DEATH IN HIV-ASSOCIATED TALAROMYCYES MARNEFFEI INFECTION
Thanh T. Nguyen, Thu T. Nguyen, Nguyen Le Nhu Tung, Jeremy Day, Cecilia Shikuma, Chau V. Nguyen, Guy Thwaites, Thuy Le
1Oxford Univ Vietnam Collaboration, Ho Chi Minh City, Vietnam, 2Hosp for Trop Diseases, Ho Chi Minh City, Vietnam, 3Univ of Hawaii, Honolulu, HI, USA

Poster P-Q1 PK AND SAFETY OF ARVs AND MONOCLONAL ANTIBODIES FOR PMTCT
Poster Hall - 4 EF 2:30 PM - 4:00 PM

753 DOSING FOR TWO: PLACENTAL TRANSFER OF DARUNAVIR AND SIMULATION OF FETAL EXPOSURE
Stein Schalkwijk, Aaron O. Buaben, Angela Colbers, David M. Burger, Rick Greupink, Frans G. Russel
Radboud Univ Med Cntr, Nijmegen, Netherlands
754  SUBSTANTIALLY LOWER RILPIVIRINE PLASMA CONCENTRATIONS DURING PREGNANCY

Angela Colbers1, Stein Schalkwijk1, Deborah Konopnicki2, Andrea Ginglemaier1, John Lambert1, Ineke van der Ende1, José Moltó6, David M. Burger1, for the PANNA Network
1Radboud Univ Med Cntr, Nijmegen, Netherlands, 2Saint-Pierre Univ Hosp, Brussels, Belgium, 3Klinikum der Univ München, München, Germany, 4Mater Misericordiae Univ Hosp Dublin, Dublin, Ireland, 5Erasmus Univ Med Cntr, Rotterdam, Netherlands, 6Fundació Lluita Contra la Sida, Badalona, Spain

755  ELVITEGRAVIR/COBICISTAT PHARMACOKINETICS IN PREGNANCY AND POSTPARTUM

Brookie Best1, Edmund Capparelli1, Alice Stek2, Edward Acosta3, Elizabeth Smith4, Nahida Chakhtoura5, Jiayia Wang6, Adrian Hernandez7, Mark Mirochnick8, for the IMPAACT P1026s Protocol Team
1Univ of California San Diego, La Jolla, CA, USA, 2Univ of Southern California, Los Angeles, CA, USA, 3Univ of Alabama at Birmingham, Birmingham, AL, USA, 4DAIDS, NIAID, Rockville, MD, USA, 5NICHD, Bethesda, MD, USA, 6Harvard Univ, Boston, MA, USA, 7Frontier Sci & Tech Rsr, Amherst, NY, USA, 8Boston Med Cntr, Boston, MA, USA

756  PROTEASE-INHIBITOR–BASED CART IS ASSOCIATED WITH HIGH ESTRADIOL LEVELS IN PREGNANCY

Kayode Balogun1, Monica Guzman1, Eszter Papp1, Mona Loutfy2, Mark Yudin3, Jay MacGillivray4, Kellie Murphy5, Sharon Walmsley6, Michael Silverman7, Lena Serghides8
1Univ Hlth Network, Toronto, Ontario, Canada, 2Women’s Coll Rsr Inst, Toronto, Ontario, Canada, 3St. Michael’s Hosp, Toronto, Ontario, Canada, 4Mt Sinai Hosp, Toronto, Ontario, Canada, 5Univ of Toronto, Toronto, Ontario, Canada, 6Univ of Western Ontario, London, Ontario, Canada

757  RALTEGRAVIR PHARMACOKINETICS AND SAFETY IN HIV-1 EXPOSED NEONATES: DOSE-FINDING STUDY

Diana F. Clarke1, Edward Acosta2, Anne Chain1, Mae Cababasay3, Jiayia Wang4, Hedy Teppier5, Elizabeth Smith6, Rohan Hazra7, Mark Mirochnick8, for the IMPAACT P1110 Protocol Team
1Stellenbosch Univ, Cape Town, South Africa, 2Univ of Witwatersrand, Johannesburg, South Africa, 3Harvard Univ, Boston, MA, USA, 4Univ of Cape Town, Cape Town, South Africa, 5Univ of California San Diego, La Jolla, CA, USA, 6Boston Med Cntr, Boston, MA, USA

758  PHARMACOKINETICS OF NEVIRAPINE PROPHYLAXIS IN HIV-EXPOSED LOW BIRTH WEIGHT INFANTS

Adrie Bekker1, Avy Violari1, Mae Cababasay2, Jiayia Wang3, Lubbe Wiesner4, Edmund Capparelli5, Mark Cotton6, Firdose Naka6, Mark Mirochnick7, for the IMPAACT P1106 Team
1Stellenbosch Univ, Cape Town, South Africa, 2Univ of Witwatersrand, Johannesburg, South Africa, 3Harvard Univ, Boston, MA, USA, 4Univ of Cape Town, Cape Town, South Africa, 5Univ of California San Diego, La Jolla, CA, USA, 6Boston Med Cntr, Boston, MA, USA
759 SAFETY OF 6-WEEK TRIPLE ANTIRETROVIRAL PROPHYLAXIS IN HIGH-RISK HIV-EXPOSED INFANTS

Suvaporn Anugulruengkitt1, Piyarat Sunantarattiwong2, Pradhana Ounchanum1, Ussanee Srimongpotng1, Watsamon Jantaranabekkul1, Jiratchaya Sophonphan2, Tim R. Cressey3, Chitsanu Parcharoen3, Thanaywee Puthanakhan1, for the CIPHER_AEPPEP Study Team

1Chulalongkorn Univ, Bangkok, Thailand, 2Queen Sirikit Natl Inf of Child Hlth, Bangkok, Thailand, 3Chiang Rai Prachanukroh Hosp, Chiang Rai, Thailand, 4Khon Kaen Hosp, Khon Kaen, Thailand, 5HIV Netherlands Australia Thailand Rsr Collab, Thai Red Cross AIDS Rsr, Bangkok, Thailand, 6Prog for HIV Prevention and Treatment, Chiang Mai, Thailand

760 SAFETY & PHARMACOKINETICS OF THE MONOCLONAL ANTIBODY, VRC01, IN HIV-EXPOSED NEWBORNS

Coleen K. Cunningham1, Elizabeth J. McFarland2, Edmund V. Capparelli3, Petronella Muresan4, Charlotte Perlowski5, Megan Valentine6, Elizabeth Smith7, John R. Mascola8, Barney S. Graham9, for the IMPAACT P1112 Team

1Duke Univ, Durham, NC, USA, 2Univ of Colorado, Aurora, CO, USA, 3Univ of California San Diego, La Jolla, CA, USA, 4Harvard Univ, Boston, MA, USA, 5FHI360, Durham, NC, USA, 6DAIDS, NIAID, Rockville, MD, USA, 7Vaccine Rsr Cntr, NIAID, Bethesda, MD, USA

772 SUBSEQUENT PREGNANCY OUTCOMES IN WOMEN DURING FOLLOW-UP IN PROMISE 1077HS

Jose H. Pilotto1, Sean Brummel3, Lisa M. Hoffman4, Paula Britto5, Gaerolwe Msheto6, Linda Aurpibul7, Nahida Chakhtoura8, Karin Klingman9, Judith S. Currier10, for the 1077HS Team

1Fiocruz, Rio de Janeiro, Brazil, 2Harvard Univ, Boston, MA, USA, 3Univ of California Los Angeles, Los Angeles, CA, USA, 4Harvard Univ-Botswana Collaboration, Gaberone, Botswana, 5Chiang Mai Univ, Chiang Mai, Thailand, 6NICHD, Bethesda, MD, USA, 7DAIDS, NIAID, Bethesda, MD, USA

773 HIV AND RISK OF POSTPARTUM INFECTION, COMPLICATIONS, AND MORTALITY IN RURAL UGANDA

Lisa Bebell1, Joseph Ngonzi2, Mark J. Siedner3, Winnie Muyindike4, Bosco M. Bwana5, Laura E. Riley6, Yop Boum7, David Bangsberg8, Ingrid V. Bassett9

1Massachusetts General Hosp, Boston, MA, USA, 2Mbarara Univ of Sci and Tech, Mbarara, Uganda, 3Epicentre, MSF, Mbarara, Uganda, 4MGH-Ragon Inst, Boston, MA, USA

774 CMV VIREMIA IN HIV-POSITIVE AND -NEGATIVE PREGNANT WOMEN IN BOTSWANA

Natasha O. Moraka1, Maryanne R. Ibrahim2, Sikhulile Moyo3, Prisca Thami4, Gloria Mayondi5, Christiana Smith6, Adria Weinberg7, Rosemary Musonda8, Simani Gaseitsiwe9, Shahin Lockman10

1Botswana Harvard AIDS Inst Partnership, Gaberone, Botswana, 2Doris Duke Intl Clinical Rsr Fellowship, Los Angeles, CA, USA, 3Univ of Colorado, Denver, CO, USA, 4Univ of Colorado, Aurora, CO, USA, 5Harvard Univ, Boston, MA, USA
775 PREGNANCIES IN WOMEN WHO ACQUIRED HIV PERINATALLY
Mira Hleyhel1, Catherine Dollfus2, Roland Tubiana3, Christine Rouzioux4, Pierre Frange4, Stéphane Blanche5, Jérôme Le Chenadec4, Albert Faye5, Laurent Mandelbrot4, József Warszawski3

776 ANTENATAL ANTIRETROVIRAL THERAPY AND ADVERSE BIRTH OUTCOMES: THE PROMISE TRIAL
Benjamin H. Chi1, Mona Farhad2, Maxensia Owor2, Tsungai Chipato4, Min Qin3, Sufia Dadabhia3, Devasena Gnanashanmugam4, Nahida Chakhtoura5, Mary Glenn Fowler6, Jeffrey S. Stringer1
1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Harvard Univ, Boston, MA, USA, 3Makerere Univ–Johns Hopkins Univ Rsr Collab, Kampala, Uganda, 4Univ of Zimbabwe, Harare, Zimbabwe, 5The Johns Hopkins Univ, Baltimore, MD, USA, 6DAIDS, NIAID, Bethesda, MD, USA, 7NICHD, Bethesda, MD, USA

777 RISK FACTORS FOR LOW BIRTH WEIGHT AND PRETERM DELIVERY IN THE PROMISE TRIAL
Dorothy Sebikari1, Min Qin2, Maxensia Owor2, Jeffrey S. Stringer1, Mona Farhad2, Nahida Chakhtoura3, Benjamin H. Chi1, Karin Klingman4, Gerhard Theron5, Mary Glenn Fowler6
1Makerere Univ–Johns Hopkins Univ Rsr Collab, Kampala, Uganda, 2Harvard Univ, Boston, MA, USA, 3Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4NICHD, Bethesda, MD, USA, 5DAIDS, NIAID, Bethesda, MD, USA, 6Stellenbosch Univ, Cape Town, South Africa, 7The Johns Hopkins Univ, Baltimore, MD, USA

778 DO HIV+ WOMEN ON PROTEASE INHIBITORS DELIVER PRETERM? FINDINGS FROM A UK STUDY
Graziella Favarato1, Claire Townsend, Heather Bailey, Claire Thorne, for the UK and Ireland National Study of HIV in Pregnancy and Childhood (NSHPC)
Univ Coll London, London, UK

779 TDF/FTC IN PREGNANCY SHOWS NO INCREASE IN ADVERSE INFANT BIRTH OUTCOMES IN US COHORTS
Kathryn Rough1, George R. Seage1, Paige L. Williams1, Sonia Hernandez-Diaz2, Yanling Huo2, Ellen G. Chadwick2, Lisa M. Hoffman2, Emily Barr2, David E. Shapiro3, Kunjal Patel1
1Harvard Univ, Boston, MA, USA, 2Ann & Robert H. Lurie Children’s Hosp of Chicago, Chicago, IL, USA, 3Univ of California Los Angeles, Los Angeles, CA, USA, 4Children’s Hosp Colorado, Aurora, CO, USA

Poster P-R3 PHARMACOKINETICS AND DOSING OF ARVs AND COTREATMENTS IN CHILDREN AND YOUTH
Poster Hall - 4 EF
2:30 PM - 4:00 PM

806 DOLUTEGRAVIR PHARMACOKINETICS, SAFETY AND EFFICACY IN HIV+ CHILDREN 2 TO <6 YEARS OLD
Theodore Ruel1, Edward Acosta2, Rajendra P. Singh3, Carmelita Alvero3, Kathleen George2, Stephanie Popson3, Cindy Vavro2, Rohan Hazra4, Andrew Wiznia5, for the P1093 Team
1Univ of California, San Francisco, San Francisco, CA, USA, 2Univ of Alabama at Birmingham, Birmingham, AL, USA, 3GlaxoSmithKline, King of Prussia, PA, USA, 4Harvard Univ, Boston, MA, USA, 5FHI 360, Durham, NC, USA, 6Frontier Sci & Tech Rsr Fndn, Inc., Amherst, NY, USA, 7ViiV Hlthcare, Rsr Triangle Park, NC, USA, 8Univ of Alabama at Birmingham, Birmingham, AL, USA, 9Albert Einstein Coll of Med, Bronx, NY, USA
**Pharmacokinetics of Rilpivirine After Switching from Efavirenz in Adolescents**

Watsamon Jantaranbenjakul¹, Narukjapon Thammajaruk², Torsak Bunupurudah³, Jiratchara Sophonphan¹, Tim R. Cressey¹, Angela Colbers⁴, David M. Burger⁵, Wanapatreea Phongsamart¹, Thanyawee Puthanakit¹, Chitsanu Pancharoen¹

¹Chulalongkorn Univ, Bangkok, Thailand, ²HIV Netherlands Australia Thailand Rsr Collab, Thai Red Cross AIDS Rsr, Bangkok, Thailand, ³Prog for HIV Prevention and Treatment, Chiang Mai, Thailand, ⁴Radboud Univ, Nijmegen, Netherlands, ⁵Mahidol Univ, Bangkok, Thailand

**Nevirapine PK, Virological Outcome, and AEs in African Children on Paediatric FDCs**

Andrzej Bienczak¹, Paolo Denti¹, Adrian Cook⁵, Lubbe Wiesner¹, Diana Gibb², David M. Burger³, Sarah Walker, Helen Mcilleron¹, for the CHAPAS-3 Study Team

¹Univ of Cape Town, Cape Town, South Africa, ²Univ Coll London, London, UK, ³Radboud Univ Med Cntr, Nijmegen, Netherlands

**An Easy-to-Use Paediatric Dosing Tool: One mg/kg Dose Does Not Fit All**

Paolo Denti¹, Nandita Sugandhi², Tim R. Cressey¹, Mark Mirochnick³, Edmund V. Capparelli², Martina Penazzato³, for the Paediatric ARV Working Group

¹Univ of Cape Town, Cape Town, South Africa, ²Clinton Hlth Access Initiative, New York, NY, USA, ³Prog for HIV Prevention and Treatment, Chiang Mai, Thailand, ⁴Boston Med Cntr, Boston, MA, USA, ⁵Univ of California San Diego, La Jolla, CA, USA

**Sertraline Pharmacokinetics in HIV-Infected on ARV and Uninfected Youth**

Nathan Hanan¹, Mary Paul¹, Yanling Huo³, Edmund Capparelli², Suad Kapetanovic³, J. L. Ariens¹, Elizabeth Smith¹, Pim Brouwers³, Brookie Best¹, for the IMPAACT P1080 Protocol Team

¹Univ of California San Diego, La Jolla, CA, USA, ²Baylor Coll of Med, Houston, TX, USA, ³Harvard Univ, Boston, MA, USA, ⁴NIMH, Rockville, MD, USA, ⁵FHI 360, Durham, NC, USA, ⁶NIH, Rockville, MD, USA

**Suboptimal Cotrimoxazole Prophylactic Concentrations in Children**

Claire Pressiat¹, Véronique Mea-Assande², Caroline Yonaba³, Jean-Marc Treluyer¹, Désiré Lucien Dahourou¹, Madeleine Amorissani-Folquet⁶, Stéphane Blanche¹, Valeriane Leroy⁶, Déborah Hirt⁶, for the MONOD Study Group

Poster P-R4 ART STRATEGIES AND OUTCOMES IN CHILDREN AND YOUTH

Poster Hall - 4 EF  2:30 PM - 4:00 PM

812  Dolutegravir-based CART in Vertically HIV-1–Infected Adolescents, Real-world Setting

Coralie Briand1, Catherine Dollfus2, Marion Caseris3, Elie Kantor4, Veronique Avettand-Fenoël1, Diane Descamps4, Veronique Schneider4, Marie-Dominique Tabone5, Stephanie Blanche1, Pierre Frange1

1Necker Hosp, Paris, France; 2Trousseau Hosp, Paris, France; 3Robert Debre Hosp, Paris, France; 4Bichat Hosp, Paris, France; 5Tenon Hosp, Paris, France

813  Long-term Effects of Weekends Off ART in HIV-1 Infected Young People on EFV+2NRTI

Anna Turkova, for the BREATHER (PENTA 16) Trial Group

Univ Coll London, London, UK

814  Cost-effectiveness of Preemptive Switch to Efavirenz (EFV) in HIV-infected Children

Sophie Desmonde1, Simone C. Frank2, Ashraf Coovadia3, Désiré Lucien Dahourou4, Elaine J. Abrams5, Rochelle P. Walensky6, Kenneth Freedberg7, Louise Kuhn1, Valeriane Leroy2, Andrea L. Ciarnello2

1Univ of Bordeaux, Bordeaux, France; 2Massachusetts General Hosp, Boston, MA, USA; 3Empilweni Service and Rsr Unit, Johannesburg, South Africa; 4Cntr de Rsr Intl Pour la Santé, Ouagadougou, Burkina Faso; 5ICAP at Columbia Univ, New York, NY, USA; 6Columbia Univ, New York, NY, USA; 7INSERM, Toulouse, France

815  Predictors of Switch to Second-line ART in HIV-Positive Children: A Global Analysis

Kara K. Wools-Kaloustian1, Colette J. Smith2, Ruth Goodall2, Intira J. Collins3, Elaine J. Abrams1, Mary-Ann Davies4, Mary Paul1, Jorge Pinto5, Russell B. Van Dyke7, for the CIPHER Durability of First Line Project Team

1Indiana Univ, Indianapolis, IN, USA; 2Univ Coll London, London, UK; 3ICAP at Columbia Univ, New York, NY, USA; 4Univ of Cape Town, Cape Town, South Africa; 5Baylor Coll of Med, Houston, TX, USA; 6Univ Fed de Minas Gerais, Belo Horizonte, Brazil; 7Tulane Univ, New Orleans, LA, USA

816  Frequent Failure After Second-line ART in HIV-positive Children from Latin America

Bryan E. Shepherd1, Cathy Jenkins1, Regina Succi1, Daisy Machado1, Jorge Pinto1, Vanessa Rouzier1, Marco Luque2, Sten Vermund3, Catherine McGowan1, for the Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet)

1Vanderbilt Univ, Nashville, TN, USA; 2Univ Fed de Sao Paulo, Sao Paulo, Brazil; 3Univ Fed de Minas Gerais, Belo Horizonte, Brazil; 4Les Cntrs GHESKIO, Port-au-Prince, Haiti; 5Hosp Escuela Univ, Tegucigalpa, Honduras

817LB  HIV-infected Children with Severe Acute Malnutrition: Early vs Delayed Art Initiation

Moherndran Archary1, Benn Sartorius1, Philip La Russa2, Thobekile Sibaya1, Micheal Healy1, Raziya Bobat1

1Univ of KwaZulu-Natal, Durban, South Africa; 2Columbia Univ, New York, NY, USA
842  RACIAL DISPARITIES IN HIV PREVALENCE AND COMPOSITION OF RISK NETWORKS, HPTN 037  
Florence Momplaisir1, Mustafa Hussein2, Danielle Fiore3, Laramie Smith4, David Bennett5, Carl Latkin6, David Metzger7  
1Drexel Coll of Med, Philadelphia, PA, USA, 2Univ of Wisconsin-Milwaukee, Milwaukee, WI, USA, 3Univ of Pennsylvania, Philadelphia, PA, USA, 4Univ of California San Diego, La Jolla, CA, USA, 5Drexel Univ, Philadelphia, PA, USA, 6The Johns Hopkins Univ, Baltimore, MD, USA

843  CONCURRENCY IN THE SEXUAL NETWORKS OF Racially Diverse YMSM  
Patrick Janulis, Gregory Phillips, Brian Mustanski, Michelle Birkett  
Northwestern Univ, Chicago, IL, USA

844  HIV TRANSMISSION IN TUJUANA, MEXICO: REAL-TIME IDENTIFICATION OF A NEW CLUSTER  
Antoine Chaillon1, Patricia Gonzalez-Zuniga1, Tommi O. Gaines1, Horacio Almanza1, Jose R. Chavez2, Jesus Vera3, Thomas L. Patterson3, Davey M. Smith4, Steffanie A. Strathdee5, Sanjay R. Mehta6  
1Univ of California San Diego, San Diego, CA, USA, 2Autonomous Univ of Baja California, Tijuana, Mexico, 3Univ of California San Diego, La Jolla, CA, USA

845LB  IDENTIFYING AND INVESTIGATING A RAPIDLY GROWING HIV TRANSMISSION CLUSTER IN TEXAS  
Analise C. Monterosso1, Sydney Minnerly1, Samuel Goings1, Allyson Morris1, Anne Marie France2, Sharoda Dasgupta2, Alexandra Oster2, Miranda Fanning1  
1Texas Dept of State Hlth Services, Austin, TX, USA, 2CDC, Atlanta, GA, USA

846  SEXUAL NETWORKS OF CIS AND TRANSGENDER PEOPLE WITH & AT- RISK FOR HIV, KING COUNTY, WA  
Julia Hood1, David A. Katz2, Lindley A. Barbee2, Sara N. Glick2, Amy Bennett1, Susan Buskin1  
1Pub Hlth–Seattle & King County, Seattle, WA, USA, 2Univ of Washington, Seattle, WA, USA

847  SPATIAL CLUSTERING OF HIV IN KENYA MAY NOT MATCH WELL-KNOWN EPIDEMIC PATTER  
Anthony Waruru1, Thomas Achia1, James Nganga1, Joyce Wamicwe2, James Tobias2, Mary Mwangi1, Evelyn Muthama1, Emily Zielinski-Gutierrez2, Tom Olouoch1, Thorkild Tylleskär1  
1US CDC, Nairobi, Kenya, 2Natl Bureau of Statistics, Nairobi, Kenya, 3Natl AIDS and STI Control Prog (NASCOP), Nairobi, Kenya, 4US CDC, Atlanta, GA, 5Univ of Bergen, Bergen, Norway

848  A FRAMEWORK FOR PREDICTING PHYLOGENETIC CLUSTERS OF HIV AT HIGH RISK FOR GROWTH  
David McVea1, Richard Liang2, Jeffrey Joy2, P. Richard Harrigan2, Art Poon3  
1Univ of British Columbia, Vancouver, Canada, 2BC Cntr for Excellence in HIV/ AIDS, Vancouver, British Columbia, Canada, 3Western Univ, London, Ontario, Canada
NETWORK VIRAL LOAD: A CRITICAL METRIC FOR HIV ELIMINATION
Britt Skaathun, Aditya Khanna, Ethan Morgan, Samuel R. Friedman, John A. Schneider
1Univ of Chicago, Chicago, IL, USA, 2Natl Development & Rsr Insts, New York, NY, USA

IDENTIFYING A GEOSPATIAL RELATIONSHIP BETWEEN COMMUNITY-LEVEL RISK AND HIV PREVALENCE
Laurence Palk, Sally Blower
Univ of California Los Angeles, Los Angeles, CA, USA

STIGMA ASSOCIATED WITH HIV/STI INCIDENCE AMONG NIGERIAN MEN WHO HAVE SEX WITH MEN
Cristina Rodriguez-Hart, Rebecca G. Nowak, Rashelle Musci, Danielle German, Ifeanyi Orazulike, Uchenna Ononaku, Hongjie Liu, Trevor Crowell, Stefan Baral, Man Charurat
The Johns Hopkins Univ, Baltimore, MD, USA, 2Univ of Maryland, Baltimore, MD, USA, 3Int'l Cntr on Advocacy and Rights to Hlth, Abuja, Nigeria, 4Inst of Human Virology Nigeria, Abuja, Nigeria, 5Univ of Maryland, Coll Park, Coll Park, MD, USA, 6US Military HIV Rsr Prog, Bethesda, MD, USA

POPULATION TRENDS IN HIV STIGMA IN LUSAKA, ZAMBIA, 2004–2011
Margaret P. Kasaro, Marie Stoner, Sujit Rathod, Tessa Roberts, Jennifer Winston, Richard Banda, Thankian Kusanthan, Jeffrey S. Stringer, Benjamin H. Chi

DEPRESSION AND ART INITIATION AMONG HIGH-RISK HIV SERODISCORDANT COUPLES IN AFRICA
Jennifer Velloza, Connie L. Celum, Haberer Jessica, Kenneth Ngure, Elizabeth Irungu, Nelly Mugo, Jared Baeten, Renee Heffron, for the Partners Demonstration Project Team
1Univ of Washington, Seattle, WA, USA, 2Cntr for Global Hlth, Massachusetts General Hosp, Boston, MA, USA, 3Kenya Med Rsr Inst, Nairobi, Kenya

HIV STIGMA, DEPRESSION, ADHERENCE, AND VIRAL LOAD AMONG HIV+ AFRICAN-AMERICAN WOMEN
Lauren Lipira, Emily C. Williams, David Huh, Patrick J. Heagerty, Audrey French, Susan E. Cohn, Janet M. Turan, Michael J. Mugavero, Deepa Rao
1Univ of Washington, Seattle, WA, USA, 2Ruth M. Rothstein CORE Cntr, Chicago, IL, USA, 3Northwestern Univ, Chicago, IL, USA, 4Univ of Alabama at Birmingham, Birmingham, AL, USA

THE CAUSAL EFFECT OF DEPRESSION ON VIRAL SUPPRESSION AMONG ADULTS IN HIV CARE
Alison Hughes, Susan Scheer
San Francisco Dept of Pub Hlth, San Francisco, CA, USA
SOCIAL ECOLOGICAL FACTORS ASSOCIATED WITH SEX WORK AMONG TRANSGENDER WOMEN IN JAMAICA
Carmen H. Logie1, Ying Wang1, Nicolette Jones2, Uzma Ahmed3, Kendasi Levermore4, Tyrone Ellis1, Ava Neil1, Annecka Marshall1, Ashley A. Lacombe-Duncan1, Peter A. Newman1
1Univ of Toronto, Toronto, Canada, 2Jamaica AIDS Support for Life, Kingston, Jamaica, 3Univ of the West Indies, Mona Campus, Kingston, Jamaica

SEXUAL ORIENTATION DIFFERENCES IN HEALTH AND WELLBEING AMONG WOMEN WITH HIV IN CANADA
Carmen H. Logie1, Ashley A. Lacombe-Duncan1, Ying Wang1, Angela Kaida2, Alexandra de Pokomandy2, Kath Webster2, Tracey Conway2, Mona Loutfy2
1Univ of Toronto, Toronto, Canada, 2Simon Fraser Univ, Vancouver, Canada

HEALTH OUTCOMES ASSOCIATED WITH GENDER-BASED VIOLENCE AMONG WOMEN WITH HIV IN CANADA
Carmen H. Logie1, Angela Kaida2, Alexandra de Pokomandy2, Erin Ding4, Nadia O’Brien3, Uzma Ahmed1, Tracey Conway2, Val Nicholson3, Mona Loutfy2
1Univ of Toronto, Toronto, Canada, 2Simon Fraser Univ, Vancouver, Canada, 3McGill Univ, Montreal, Canada, 4BC Ctr for Excellence in HIV Rsr, Vancouver, Canada

TRANS WOMEN WITH HIV IN CANADA: RESULTS OF A NATIONAL COMMUNITY-BASED COHORT STUDY
Ashley A. Lacombe-Duncan1, Yasmeen Persad2, Greta R. Bauer3, Carmen H. Logie1, Angela Kaida4, Alexandra de Pokomandy2, Nadia O’Brien2, Mona Loutfy4, for the CHIWOS Research Team
1Univ of Toronto, Toronto, ON, Canada, 2The 519, Toronto, ON, Canada, 3Western Univ, London, Ontario, Canada, 4Simon Fraser Univ, Vancouver, Canada, 5McGill Univ, Montreal, Canada, 6Women’s Coll Rsr Inst, Toronto, Ontario

THE HEALTH IMPACT OF SEXUAL VIOLENCE AMONG WOMEN IN A PLATINUM MINING BELT
Meiwen Zhang1, Sarah Jane Steele1, Amir Shroufi1, Gilles van Cutsem1, Junaid Khan2, Garret Barnwell3, Julia Hill4, Kristal Duncan1
1MSF, Cape Town, South Africa, 2MSF, Rustenburg, South Africa

ASSOCIATION OF SEX AND RACE WITH HIV-/NON-HIV–RELATED DEATH IN TREATED HIV INFECTION
David B. Hanna1, Donald R. Hoover2, Quihu Shi2, Uriel Felsen3, Mark H. Kuniholm1, Mindy S. Ginsberg1, Howard D. Strickler2, Kathryn Anastos1
1Albert Einstein Coll of Med, Bronx, NY, USA, 2Rutgers, the State Univ of New Jersey, New Brunswick, NJ, USA, 3New York Med Coll, Valhalla, NY, USA, 4State Univ of New York at Albany, Rensselaer, NY, USA

IMPACT OF INJECTION DRUG USE AND SELECTED COMORBIDITIES ON HEALTHY LIFE EXPECTANCY
Robert S. Hogg, Ogenowowede Eyawo, Wendy Zhang, Paul Serada, Mark Hull, Jean A. Shovelier, Karyn Gabler, Viviane D. Lima, Julio S. Montaner, for the Comparative Outcomes And Service Utilization Trends (COAST) study BC Ctr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
LONGITUDINAL ASSOCIATION BETWEEN HIV STATUS AND MEDICALLY SIGNIFICANT FALLS

Julie A. Womack1, Terrence E. Murphy2, Harini Bathulapalli1, Jonathan Bates3, Cynthia L. Gibert1, Maria Rodriguez-Barradas4, Phyllis Tien5, Michael T. Yin6, Cynthia A. Brandt7, Amy Justice3

1VA Connecticut Healthcare System, West Haven, CT, USA, 2Yale Univ, New Haven, CT, USA, 3Washington, DC, VA Med Ctr, Washington, DC, USA, 4Baylor Coll of Med, Houston, TX, USA, 5Univ of California San Francisco, San Francisco, CA, USA, 6Columbia Univ, New York, NY, USA

VIREMIA COPY-YEARS & MORTALITY IN HIV+ MEN STARTING ART: HOW MUCH HISTORY IS NEEDED?

Ruibin Wang1, Sabina Haberlen1, Frank J. Palella2, Joseph B. Margolick1, Bernard Macatangay1, Otoniel Martinez-Maza3, Lisa Jacobson1, Alison Abraham1

1The Johns Hopkins Univ, Baltimore, MD, USA, 2Northwestern Univ, Chicago, IL, USA, 3Univ of Pittsburgh, Pittsburgh, PA, USA, 4Univ of California, Los Angeles, Los Angeles, CA, USA

LOW-LEVEL VIREMIA IS ASSOCIATED WITH VIROLOGIC FAILURE IN A LARGE MILITARY COHORT

Christie Joya1, Seung Hyun Won2, Karl Kronmann3, Jason Okulicz4, Timothy Whitman1, Robert Deiss1, Christina Schofield4, Julie Pavlin1, Brian K. Agan1, Anuradha Ganesan5

1Walter Reed Natl Military Med Ctr, Bethesda, MD, USA, 2Henry M. Jackson Fndn for Advancement of Military Med, Bethesda, MD, USA, 3Naval Med Ctr Portsmouth, Portsmouth, VA, USA, 4Brooke Army Med Ctr, San Antonio, TX, USA, 5Uniformed Services Univ of the Hlth Scis, Rockville, MD, USA, 6Madigan Army Med Ctr, Tacoma, WA, USA

LONGITUDINAL VIRAL TRAJECTORY AMONG WOMEN IN THE WOMEN’S INTERAGENCY HIV STUDY

Seble Kassaye1, Cuiwei Wang1, Jeff Collmann1, Tracey Wilson2, Kathryn Anastos1, Mardge H. Cohen3, Ruth Greenblatt6, Joel Milam6, Steven Gange7, Michael Plankey1

1Georgetown Univ, Washington, DC, USA, 2SUNY Downstate Med Ctr, Brooklyn, NY, USA, 3Albert Einstein Coll of Med, Bronx, NY, USA, 4John H.Stroger Jr. Hosp of Cook County, Chicago, IL, USA, 5Univ of California San Francisco, San Francisco, CA, USA, 6Univ of Southern California, Los Angeles, CA, USA, 7The Johns Hopkins Univ, Baltimore, MD, USA

THE EPIDEMIOLOGY OF HIV IN PEOPLE BORN OUTSIDE THE UNITED STATES, 2010–2014

Roxanne P. Kerani1, Anna S. Johnson2, Susan Buskin3, Deepa Rao1, Matthew R. Golden1, Xiaohong Hu2, Irene Hall3

1Univ of Washington, Seattle, WA, USA, 2CDC, Atlanta, GA, USA, 3Pub Hlth—Seattle & King County, Seattle, WA, USA

CHANGES IN HIV RISK FACTORS AMONG MEN WHO HAVE SEX WITH MEN AND WOMEN, 2008–2014

Wade Ivy1, Thema Chapple2, Gabriela Paz-Bailey1, for the NHBS Study Group

1CDC, Atlanta, GA, USA, 2Morehouse Coll, Atlanta, GA, USA
**ASSOCIATION BETWEEN HOUSING STABILITY AND NEW HIV DIAGNOSIS IN SEEK AND TEST STUDIES**

Bridget Whitney, Bridget Kruszka, Jennifer Lorvick, Gregory M. Lucas, Wendee Wechsberg, Irene Kuo, William E. Cunningham, Asa Clemenzi-Allen, Julie Franks, Heidi M. Crane

1 Univ of Washington, Seattle, WA, USA, 2 RTI Intl, Berkeley, CA, USA, 3 The Johns Hopkins Univ, Baltimore, MD, USA, 4 RTI Intl, Rsr Triangle Park, NC, USA, 5 George Washington Univ, Washington, DC, USA, 6 Univ of California Los Angeles, Los Angeles, CA, USA, 7 Univ of California San Francisco, San Francisco, CA, USA, 8 Columbia Univ, New York, NY, USA

---

**HIV INCIDENCE AND RISK BEHAVIORS IN THE BANGKOK MSM COHORT STUDY, THAILAND, 2006–2015**

Timothy H. Holtz, Anchalee Varangrat, Philip Mock, Warunee Thienkrupa, Wannee Chonwattana, Witas Wimonsate, Wichuda Sukwicha, Marcel Curlin, Eileen Dunne, Anupong Chitwarakorn

1 CDC, Atlanta, GA, USA, 2 Thailand Ministry of Pub Hlth–US CDC Collab, Nonthaburi, Thailand, 3 Oregon Hlth and Scis Univ, Portland, OR, USA, 4 US CDC, Nonthaburi, Thailand, 5 Thailand Ministry of Pub Hlth, Nonthaburi, Thailand

---

**CHANGES IN RISK BEHAVIORS AFTER HIV SEROCONVERSION, BANGKOK MSM COHORT STUDY**

Witas Wimonsate, Sarika Pattanasin, Pikunchai Luechai, Jaray Tongtayai, Wichuda Sukwicha, Chaiwat Ungsedhapand, Anupong Chitwarakorn, Michael Thigpen, Eileen Dunne, Timothy Holtz

1 Thailand Ministry of Pub Hlth–US CDC Collab, Nonthaburi, Thailand, 2 Thailand Ministry of Pub Hlth, Nonthaburi, Thailand, 3 US CDC, Nonthaburi, Thailand

---

**AN EMPIRIC RISK SCORE TO GUIDE PREP UPTAKE IN MSM IN COASTAL KENYA**

Elizabeth Wahome, Alexander N. Thiong’o, Oscar Chiro, Evans Gichuru, John Mwambi, Matt A. Price, Susan M. Graham, Eduard Sanders

1 KEMRI Wellcome Trust Rsr Prog, Kilifi, Kenya, 2 Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa, 3 Setshaba Rsr Cntr, Pretoria, South Africa, 4 Khakaza Mbokodo Rsr Clinic, Ladysmith, South Africa, 5 MatCH, Durban, South Africa, 6 Perinatal HIV Rsr Unit, Soweto, South Africa, 7 CONRAD, Arlington, VA, USA

---

**VALIDATION OF A RISK SCORE FOR HIV ACQUISITION IN YOUNG AFRICAN WOMEN WITH FACTS 001**

Emma K. Burgess, Sinead Delany-Moretliwe, Pedro Pisa, Khatija Ahmed, Sydney Sibuya, Cynthia Gama, Buiswes Nkala, Gustavo Doncel, Glenda Gray, Helen Rees

1 Global Hlth Fellows Internship at USAID, Arlington, VA, USA, 2 Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa, 3 Setshaba Rsr Cntr, Pretoria, South Africa, 4 Khakaza Mbokodo Rsr Clinic, Ladysmith, South Africa, 5 MatCH, Durban, South Africa, 6 Perinatal HIV Rsr Unit, Soweto, South Africa, 7 CONRAD, Arlington, VA, USA

---

**SELF-ASSESSED HIV RISK 3 YEARS AFTER HIV “TEST AND TREAT” IMPLEMENTED IN SEARCH**

James Ayieko, Dalsonse Kwarisima, Catherine A. Koss, Craig Cohen, Elizabeth A. Bukusi, Tamara D. Clark, Edwin D. Charlebois, Moses R. Kamya, Maya L. Petersen, Diane V. Havlir

1 Kenya Med Rsr Inst, Nairobi, Kenya, 2 Makerere Univ Joint AIDS Prog, Kampala, Uganda, 3 Univ of California San Francisco, San Francisco, CA, USA, 4 Makerere Univ, Kampala, Uganda, 5 Univ of California Berkeley, Berkeley, CA, USA
859 HIV RISK FACTORS AND RISK PERCEPTION AMONG ADOLESCENT GIRLS AND YOUNG WOMEN IN MALAWI
Joan T. Price1, Nora E. Rosenberg1, Bertha Maseko2, Savvy Brar2, Twambibille Phanga3, Audrey Pettifor1, Linda-Gail Bekker3
1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Univ of North Carolina Proj–Malawi, Lilongwe, Malawi, 3Univ of Cape Town, Cape Town, South Africa

860 GENDERED PATTERNS OF MOBILITY PREDICT HIV PREVALENCE IN UGANDA/KENYA IN SEARCH STUDY
Carol S. Camlin1, Tor Neilands1, Jane Kabami2, Gabriel Chami1, Elizabeth A. Bukusi1, Tamara D. Clark1, Moses R. Kamya4, Maya L. Petersen2, Diane V. Havlir3, Edwin D. Charlebois1
1Univ of California San Francisco, San Francisco, CA, USA, 2Infectious Diseases Rsr Collab, Kampala, Uganda, 3Kenya Med Rsr Inst, Nairobi, Kenya, 4Makerere Univ, Kampala, Uganda, 3Univ of California Berkeley, Berkeley, CA, USA

861 HIGH RISK BEHAVIOR IN MARRIED PEOPLE LIVING WITH HIV: IMPLICATIONS FOR PREVENTION
Zachary A. Kwena1, Catherine K. Makokha1, David O. Ang’awa1, Elizabeth A. Bukusi1

Poster P-S3 HIV AND STIs: BACK TO THE FUTURE
Poster Hall - 4 EF
2:30 PM - 4:00 PM

862 HIV AND SYPHILIS COINFECTION IN MEN WHO HAVE SEX WITH MEN, BANGKOK, 2005–2016
Chaiwat Ungsedhapand1, Kanokpan Panchroen1, Anuwat Sriporn1, Wichuda Sukwicha1, Wipas Wimonsate1, Nutthawoot Promda1, Santi Winaihart1, Anupong Chitwarakorn2, Eileen F. Dunne3, Michael Thigpen1
1Thailand MOPH–US CDC Collab, Nonthaburi, Thailand, 2Thailand MOPH, Nonthaburi, Thailand, 3US CDC, Nonthaburi, Thailand

863 SUBSEQUENT AND RECURRENT STI AMONG THAI MSM AND TG IN TEST AND TREAT COHORT
Akarin Hiransuthikul1, Supanit Pattanaachaiwit1, Nipat Teeratakulpisarn1, Parinya Chamnan1, Panita Pathipvanich1, Suchart Thongpaen1, Supabhorn Pengnonyang1, Deondara Trachunthong1, Nittaya Phanuphak1, for the Thai MSM/TG Test and Treat Study Group
1The Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 2Sanpasitthiprasong Hosp, Ubonratchathani, Thailand, 3Lampang Hosp, Lampang, Thailand, 4Mahasarakham Hosp, Mahasarakham, Thailand

Richard Novak1, Abdelhamid Ghanem1, Rachel Hart2, Douglas Ward3, Carl Armon4, Kate Buchacz5
1Univ of Illinois at Chicago, Chicago, IL, USA, 2Cerner Corp, Kansas City, MO, USA, 3Dupont Circle Physicians Group, Washington, DC, USA, 4CDC, Atlanta, GA, USA
**Poster P-S6 ACUTE AND EARLY HIV INFECTION**

**Poster Hall - 4 EF**

**2:30 PM - 4:00 PM**

**886**

**RISK- AND SYMPTOM-BASED SCREENING IMPROVES IDENTIFICATION OF ACUTE HIV INFECTION**

Maartje Dijkstra, Godelieve J. de Bree, Ineke Stolte, Udi Davidovich, Eduard Sanders, Maria Prins, Maarten F. Schim van der Loeff

1 Pub Hlth Service Amsterdam, Netherlands, 2 Academic Med Cntr, Amsterdam, Netherlands, 3 Kenya Med Rsr Inst, Kilifi, Kenya

**887**

**IMPLEMENTATION OF A RAPID TRAJECTORY TO IDENTIFY ACUTE HIV INFECTION IN AMSTERDAM**

Maartje Dijkstra, Elske Hoornenborg, Udi Davidovich, Arjan Hogewoning, Heny J.C. de Vries, Sylvia Bruisten, Maria Prins, Maarten F Schim van der Loeff, Godelieve J. de Bree

1 Pub Hlth Service Amsterdam, Netherlands, 2 Academic Med Cntr, Amsterdam, Netherlands

**888**

**COMPARISON OF SELF-REPORT TO BIOMARKERS OF RECENT INFECTION**

Katherine E. Schlusser, Shweta Sharma, Pola de la Torre, Giuseppe Tambussi, Rika Draenert, Angie N. Pinto, Julia A. Metcalf, Danielle German, James Neaton, Oliver Laeyendecker

1 The Johns Hopkins Univ, Baltimore, MD, USA, 2 Univ of Minnesota, Minneapolis, MN, USA, 3 Cooper Univ Hosp, Camden, NJ, USA, 4 Ospedale San Raffaele, Milano, Italy, 5 Klinikum der Univ Munich, Munich, Germany, 6 Kirby Inst, Sydney, Australia, 7 NIAID, Bethesda, MD, USA
889 USE OF TESTING HISTORY TO IDENTIFY HIV-INFECTED PEOPLE AT HIGH RISK OF TRANSMISSION
Laurie Linley1, Richard M. Selik1, Xiaona Qian2, Alexandra Oster1
1CDC, Atlanta, GA, USA, 2ICF Int’l, Atlanta, GA, USA

890 VIRAL LOADS NEAR HIV DIAGNOSIS: VARIATION WITH STAGE (0, 1, 2, OR 3) AT DIAGNOSIS
Richard M. Selik, Laurie Linley, Mi Chen
CDC, Atlanta, GA, USA

951 DOES THE E138A MUTATION IN ASPIRE SEROCONVERTERS AFFECT SUSCEPTIBILITY TO DAPIVIRINE?
Kerri Penrose1, Breanna J. Goetz1, Kelley C. Gordon1, Daniel W. Szydlo2, Marla J. Husnik1, Thesla Palanee-Phillips2, Jared Baeten1, John Mellors1, Urvi Parikh1, for the MTN020/ASPIRE Study Team
1Univ of Pittsburgh, Pittsburgh, PA, USA, 2Statistical Cntr for HIV/AIDS Rsr and Prevention (SCHARP), Seattle, WA, USA, 3Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa, 4Univ of Washington, Seattle, WA, USA

952 NNRTI-CONTAINING ART IS EFFECTIVE FOR DAPIVIRINE RING BREAKTHROUGH HIV-1 INFECTION
Sharon Riddler1, Jennifer Balkus1, John Mellors1, Urvi Parikh1, Carolyne Akello1, Sofia Dadabhai1, Felix Mhlanga1, Colin O’Rourke1, Jared Baeten1, John Mellors1, Urvi Parikh1, Carolyne Akello1, Sofia Dadabhai1, Felix Mhlanga1, Colin O’Rourke1, Jared Baeten1, John Mellors1, Urvi Parikh1, Carolyne Akello1, Sofia Dadabhai1, Felix Mhlanga1, Colin O’Rourke1, Jared Baeten1, John Mellors1, Urvi Parikh1, Carolyne Akello1, Sofia Dadabhai1, Felix Mhlanga1, Colin O’Rourke1, Jared Baeten1, John Mellors1, Urvi Parikh1, Carolyne Akello1, Sofia Dadabhai1, Felix Mhlanga1, Colin O’Rourke1, Jared Baeten1
1Univ of Pittsburgh, Pittsburgh, PA, USA, 2Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 3Makerere Univ-Johns Hopkins Univ Rsr Collab, Kampala, Uganda, 4The Johns Hopkins Univ, Baltimore, MD, USA, 5Univ of Zimbabwe, Harare, Zimbabwe, 6Univ of Washington, Seattle, WA, USA

953 ACUTE INFECTION WITH A WILD-TYPE HIV-1 VIRUS IN PREP USER WITH HIGH TDF LEVELS
Elske Hoornenborg1, Godelieve J. de Bree2, for the Amsterdam PrEP Project in the HIV Transmission Elimination Amsterdam Consortium (H-TEAM)
1Pub Hlth Service Amsterdam, Amsterdam, Netherlands, 2Academic Med Cntr, Amsterdam, Netherlands

954 HIV GENETIC DIVERSITY TO INFERENCE PREP ADHERENCE AT THE ESTIMATED TIME OF INFECTION
Olivia Council1, Susan Ruone1, Philip Mock2, George Khalil1, Marcel Curlin3, Walid Heneine1, Kachit Choopanya4, Michael Martin2, Gerardo Garcia-Lerma1
1CDC, Atlanta, GA, USA, 2Thailand MOPH-US CDC Collab, Nonthaburi, Thailand, 3Oregon Hlth and Scis Univ, Portland, OR, USA, 4Bangkok Tenofovir Study Group, Bangkok, Thailand

955 CHARACTERIZATION OF HIV SEROCONVERTERS IN A TDF/FTC PREP STUDY: HPTN 067
Mariya V. Sivay1, Yinfeng Zhang1, Sarah E. Hudelson1, Maoji Li1, Estelle Piwowar-Manning1, Mark A. Marzinke1, Kevin Bokoch1, Robert Grant1, Susan H. Eshleman1, for the HPTN 067 Study Team
1The Johns Hopkins Univ, Baltimore, MD, USA, 2Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 3H3I 360, Durham, NC, USA, 4Univ of California San Francisco Gladstone Insts, San Francisco, CA, USA
Poster P-U5 VOLUNTARY MEDICAL CIRCUMCISION
Poster Hall - 4 EF
2:30 PM - 4:00 PM

982 PREDICTORS OF MEDICAL MALE CIRCUMCISION UPTAKE BY MEN AGED 25-39 YEARS IN NYANZA
Donath Emusu¹, Kawango Agot², Jonathan Grund³, Paul K Musingila⁴, Frankline Onchiri², Edward Mboya², Jacob Onyango², Eunice Omanga², Elijah Odoyo-June¹, Boaz Otieno-Nunya¹
¹US CDC, Nairobi, Kenya, ²Impact Rsr and Development Org, Kisumu, Kenya, ³CDC, Atlanta, GA, USA ⁴US CDC, Kisumu, Kenya, ⁵Seattle Children’s Rsr Inst, Seattle, WA, USA

983 MALE CIRCUMCISION AND RISK COMPENSATION IN KWAZULU-NATAL, SOUTH AFRICA
Katrina F. Ortblad¹, Guy Harling¹, Joshua A. Salomon¹, Frank Tanser², Deenan Pillay³, Tinofa Mutevedzi³, Till Baernighausen⁴
¹Harvard Univ, Boston, MA, USA, ²Africa Cntr for Pop Hlth, Mtubatuba, South Africa, ³Africa Hlth Rsr Inst, Mtubatuba, South Africa, ⁴Heidelberg Univ, Heidelberg, Germany

984 RISK COMPENSATION OVER 2 YEARS AMONG MEN IN A NATIONAL VMMC ROLL-OUT IN ZIMBABWE
Daniel E. Montano¹, Danuta Kasprzyk¹, Deven T. Hamilton¹, Mufuta Tshimanga²
¹Univ of Washington, Seattle, WA, USA, ²Univ of Zimbabwe, Harare, Zimbabwe

985 WITHDRAWN

986 AGREEMENT OF SELF-REPORTED AND PHYSICALLY VERIFIED MALE CIRCUMCISION STATUS IN KENYA
Elijah Odoyo-June¹, Kawango Agot², Edward Mboya², Jonathan Grund³, Paul K. Musingila¹, Donath Emusu¹, Leonard Soo¹, Boaz Otieno-Nunya¹
¹US CDC, Nairobi, Kenya, ²Impact Rsr and Development Org, Kisumu, Kenya, ³CDC, Atlanta, GA, USA

987 VOLUNTARY MEDICAL MALE CIRCUMCISION FOR NONCOMMUNICABLE DISEASE CASE FINDING, NAMIBIA
Nikki Soboil¹, Shawn J. Rooinasie², Catherine Laube³, Abubakari Mwinyi¹, Amir Shaker⁴
¹Jhpiego, Swakopmund, Republic of Namibia, ²Ministry of Hlth and Social Services, Erongo Regional Directorate, Swakopmund, Republic of Namibia, ³Jhpiego, Baltimore, MD, USA
1024 DISTRIBUTION OF HIV TRANSMISSION BY NETWORK AND CLINICAL FACTORS AMONG US MSM
Johanna Chapin-Bardales1, Samuel Jenness2, Eli Rosenberg3, Patrick Sullivan1, Steven M. Goodreau4
1Emory Univ, Atlanta, GA, USA, 2Univ of Washington, Seattle, WA, USA

1025 HIV TRANSMISSION IN GENERALIZED, CONCENTRATED, AND MIXED EPIDEMICS IN WESTERN KENYA
Anna Bershteyn1, Vibhuti Hate2, Daniel J. Klein1, Zindoga Mukandavire3, Graham F. Medley1, Wanjiru Mukoma4, Michael K. Kiragu5, Kristine Torjesen2, Nduku Kilonzo6, Katharine Kripke7, for the OPTIONS Consortium
1Inst for Disease Modeling, Bellevue, WA, USA, 2The George Washington Univ, Washington, DC, USA, 3London Sch of Hygiene and Trop Med, London, United Kingdom, 4LVCT Hlth, Nairobi, Kenya, 5FHI 360, Durham, NC, USA, 6Natl AIDS Control Council, Ministry of Hlth, Nairobi, Kenya, 7Avenir Hlth, Washington, DC, USA

1026 ANALYZING “MISSING MEN” IN THE UK HETEROSEXUAL HIV EPIDEMIC BY DPSHIV SIMULATIONS
Emma B. Hodcroft1, Manon Ragonnet-Cronin2, Joel O. Wertheim3, Samantha Lycett4, Sergei L. Kosakovsky Pond5, Andrew Leigh Brown6
1Univ of Edinburgh, Edinburgh, Scotland, 2Univ of Edinburgh, Midlothian, Scotland, 3Univ of California San Diego, San Diego, CA, 4Temple Univ, Philadelphia, PA, USA

1027 TEMPORAL EVOLUTION OF HIV SERODISCORDANCY AMONG STABLE COUPLES IN SUB-SAHARAN AFRICA
Susanne Awad, Hiam Chemaitelly, Laith J. Abu-Raddad
Weill Cornell Med Coll in Qatar, Doha, Qatar

1040 PAST AND FUTURE IMPACT OF ART SCALE-UP IN BRAZIL: PROGRAMME DATA ANALYSIS 1996–2014
Juan F. Vesga1, Ana R. Pati Pascom2, Tara Mangal, Marcelo Freitas3, Juliana M. Givisz3, Ronaldo de Almeida Coelho3, Mariana Veloso Meirelles3, Clarissa Habkost Dutra de Barros1, Adele Benzaken5, Timothy B. Hallett1
1Imperial Coll London, London, UK, 2Ministry of Hlth, Brasilia (DF), Brazil

1041 EARLIER DIAGNOSIS AND TREATMENT REDUCES HIV TRANSMISSION IN MSM IN THE NETHERLANDS
Ard van Sighem1, Daniela Bezemer1, Eline Op de Coul1, Judith Branger2, Mark de Boer3, Peter Reiss2, for the ATHENA National Observational HIV Cohort
1Stichting HIV Monitoring, Amsterdam, Netherlands, 2Natl Inst for Pub Hlth and the Environment, Bilthoven, Netherlands, 3Flevzkienhuis, Almere, Netherlands, 4Leiden Univ Med Cntr, Leiden, Netherlands, 5Stichting HIV Monitoring and Academic Med Cntr Amsterdam, Amsterdam, Netherlands

1042 ACHIEVING THE 90-90-90 TARGET BY 2020: THE EXPERIENCE IN BRITISH COLUMBIA, CANADA
Viviane D. Lima, Martin St-Jean, Jean A. Shoveller, P. Richard Harrigan, Bohdan Nosyk, Robert S Hogg, Paul Sereda, Rolando Barrios, Julio S. Montaner
BC Cntr for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
1043 THE CLINICAL AND ECONOMIC IMPACT OF ATTAINING NHAS TREATMENT TARGETS IN THE US
Ethan D. Borre¹, Emily P. Hyle¹, Paul E Sax¹, A. David Paltiel², Anne M. Neill¹, Kenneth Freedberg¹, Rochelle P. Walensky¹
¹Massachusetts General Hosp, Boston, MA, USA, ²Brigham and Women’s Hosp, Boston, MA, USA, ³Yale Univ, New Haven, CT, USA

1044 IMPROVING THE PRISON CARE CONTINUUM REDUCES RACIAL HIV DISPARITIES: A MODELING STUDY
Brandon D. Marshall¹, Maximilian King¹, Alexandria Macmadu¹, Lauren Brinkley-Rubinstein³, M. -J. Milloy³, Curt G. Beckwith¹, Frederick Altice¹, Josiah D. Rich¹
¹Brown Univ, Providence, RI, USA, ²The Miriam Hosp, Providence, RI, USA, ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁴Univ of British Columbia, Vancouver, British Columbia, Canada, ⁵Yale Univ, New Haven, CT, USA

1045 THE COST-EFFECTIVENESS OF FINANCIAL INCENTIVES FOR VIRAL SUPPRESSION IN HPTN 065
Blythe J. Adamson¹, Deborah J. Donnell², Dobromir Dimitrov², Louis Garrison¹, Geetha Beauchamp³, Theresa Gamble³, Wafa M. El-Sadr⁴
¹Univ of Washington, Seattle, WA, USA, ²Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, ³FHI 360, Durham, NC, USA, ⁴ICAP at Columbia Univ, New York, NY, USA

1046 OPTIMIZING INTERVENTION MODALITIES TO IMPROVE 90-90-90 CONTINUUM IN SOUTH AFRICA
David Wilson¹, Andrew Shattock¹, Nicole Fraser¹, Zara Shubber³, Marelore Gorgens³, Richard Gray², Yogan Pillay⁴
¹Monash Univ, Melbourne, Australia, ²Univ of New South Wales, Sydney, Australia, ³World Bank, Washington, DC, USA, ⁴South African Natl Dept of Hlth, Pretoria, South Africa

1047 POPULATION-LEVEL IMPACT OF REACHING UNAIDS HIV PREVENTION TARGETS IN CÔTE D’IVOIRE
Mathieu Maheu-Giroux¹, Juan F. Vesga², Souleymane Dabate³, Michel Alary³, Stefan Baral³, Douaoud Diouf³, Kouame Abo³, Marie-Claude Boily²
¹Imperial Coll London, London, UK, ²Laval Univ, Quebec, Canada, ³The Johns Hopkins Univ, Baltimore, MD, USA, ⁴Enda Santé, Dakar, Senegal, ⁵Ministère de la Santé et de l’Hygiène Pub, Abidjan, Cote d’Ivoire

1048 ART RETENTION AND VIRAL SUPPRESSION KEY TO MAXIMISING TREATMENT AS PREVENTION IMPACT
Nicky McCreesh¹, Ioannis Andrianakis¹, Mark Strong², Rebecca N. Nsubuga³, Ian Vernon³, Trevelyan J. McKinley³, Jeremy E. Oakley³, Michael Goldstein⁴, Richard Hayes⁵, Richard G. White⁶
¹London Sch of Hygiene and Trop Med, London, UK, ²Sheffield Univ, Sheffield, UK, ³MRC/UVRI Rsr Unit on AIDS, Entebbe, Uganda, ⁴Durham Univ, Durham, UK, ⁵Exeter Univ, Exeter, UK
1049LB COST-EFFECTIVENESS OF A COMBINATION STRATEGY FOR THE HIV CARE CASCADE IN SWAZILAND
Elizabeth Stevens1, Kimberly Nucifora1, Qinlian Zhou1, Lingfeng Li1, Scott Braithwaite1, Margaret McNairy2, Averie B. Gachuhi2, Matthew R. Lamb2, Velephi Okello1, Wafaa M. El-Sadr3
1New York Univ, New York City, NY, USA, 2ICAP Columbia Univ, New York, NY, USA, 3Columbia Univ, New York, NY, USA, 4Swaziland Ministry of Hlth, Mbabane, Swaziland

1050 COST-EFFECTIVENESS OF SAME-DAY TREATMENT INITIATION IN SOUTH AFRICA
Lawrence Long1, Mhairi Maskew1, Alana Brennan1, Constance Mongwenyana1, Cynthia Nyoni1, Given Malete1, Ian Sanne1, Matthew Fox2, Sydney Rosen2
1Univ of the Witwatersrand, Johannesburg, South Africa, 2Boston Univ, Boston, MA, USA

1051 COST OF STREAMLINED HIV CARE IN RURAL KENyan AND UGANDAN CLINICS IN THE SEARCH STUDY
Starley B. Shade1, Thomas Osmand1, Florence Mwangwa2, Asiphas Owaraganise2, Tamara D. Clark1, Edwin D. Charlebois1, Moses R. Kamya3, Maya L. Petersen4, Diane V. Havlir4, Vivek Jain1
1Univ of California San Francisco, San Francisco, CA, USA, 2Infectious Diseases Rsr Collab, Kampala, Uganda, 3Makerere Univ Coll of Hlth Scis, Kampala, Uganda, 4Univ of California Berkeley, Berkeley, CA, USA

1052 DIFFERENTIATED HIV RNA VIRAL-LOAD MONITORING IN UGANDA: A COST-EFFECTIVENESS ANALYSIS
Diana M. Negoescu1, Zhenhuan Zhang1, Heiner C. Bucher2, Eran Bendavid1, for the Swiss HIV Cohort Study
1Univ of Minnesota, Minneapolis, MN, USA, 2Basel Inst for Clinical Epi and Biostatistics, Basel, Switzerland, 3Stanford Univ, Stanford, CA, USA

1053 PROJECTING FUTURE DONOR ASSISTANCE FOR HIV/AIDS GLOBAL FUNCTION SUPPORT
Eran Bendavid1, Marco Marco Schäferhoff2, Jessica Kraus3, Dean Jamison3, Sebastian Martinez2
1Stanford Univ, Stanford, CA, USA, 2SEEK Development, Berlin, Germany, 3Univ of California San Francisco, San Francisco, CA, USA
POSTER SESSIONS, BY CATEGORY

All poster sessions will be held in Poster Hall in Room 4 EF from 2:30 PM to 4:00 PM on the scheduled day (listed in parenthesis below).

A. VIROLOGY
P-A1 VIROLOGY TRAFFICKING (Tuesday)
P-A2 VIRUS AND CELL RNA IN HIV REPLICATION (Wednesday)
P-A3 HIV CELL INTERACTION (Thursday)
P-A4 HIV AND HOST DEFENSE (Wednesday)
P-A5 VIRUS ADAPTATION TO IMMUNITY (Thursday)

B. MOLECULAR EPIDEMIOLOGY AND HIV/SIV EVOLUTION
P-B1 UNDERSTANDING NETWORKS AND LINKED INFECTIONS: FROM LOCAL TO GLOBAL (Tuesday)
P-B2 VIRAL DIVERSITY (Wednesday)
P-B3 TIMING INFECTION AND DEFINING FOUNDER SEQUENCES AND DUAL INFECTIONS (Thursday)

C. PATHOGENESIS: HUMAN STUDIES AND ANIMAL MODELS
P-C1 PRIMARY HIV INFECTION AND SPREAD (Wednesday)
P-C2 HOW DOES THE MICROBIOME AFFECT HIV INFECTION? (Wednesday)
P-C3 HIV INFECTION AND THE MICROBIOME (Wednesday)
P-C4 ANIMAL MODELS OF HIV INFECTION (Tuesday)
P-C5 EFFECT OF ANTIRETROVIRAL THERAPY ON HIV DISEASE AND RECOVERY (Tuesday)
P-C6 CORRELATES OF HIV DISEASE (Thursday)
P-C7 INTERACTIONS OF HIV WITH OTHER INFECTIONS (Thursday)

D. HOST IMMUNE RESPONSES TO INFECTION, VACCINES, AND IMMUNOTHERAPY
P-D1 HIV-SPECIFIC ANTIBODIES AND HOW TO INDUCE THEM (Tuesday)
P-D2 INFLAMMATION AND IMMUNITY (Thursday)
P-D3 CD4 T CELLS: MORE THAN JUST HELP (Thursday)
P-D4 CD8 T CELLS: WHERE AND HOW THEY KILL (Wednesday)
P-D5 NK AND MAIT CELLS (Wednesday)

E. HIV RESERVOIRS, LATENCY, AND ALL CURATIVE STRATEGIES INCLUDING THERAPEUTIC VACCINES AND GENE THERAPY
P-E1 PERSISTENT VIREMIA AND IMMUNITY ON ART (Tuesday)
P-E2 CHARACTERIZING THE HIV RESERVOIR (Thursday)
P-E3 WHERE IS HIV HIDING? (Wednesday)
P-E4 HIV PERSISTENCE: SEND IN THE CLONES (Thursday)
P-E5 PARSING PERSISTENT PROVIRUSES (Tuesday)
P-E6 LATENCY REVERSAL (Wednesday)
P-E7 EFFECT OF TRANSPLANTATION ON THE HIV RESERVOIR (Tuesday)
P-E8 MODIFYING THE RESERVOIR: CLINICAL STUDIES (Thursday)
P-E9 NEW TREATMENTS TO MODIFY THE HIV RESERVOIR (Wednesday)
F. NEUROPATHOGENESIS AND CNS HIV COMPLICATIONS
P-F1 THE CNS AND SYSTEMATIC IMMUNE ACTIVATION (Thursday)
P-F2 CEREBROVASCULAR EVENTS AND HIV (Wednesday)
P-F3 NEUROCOGNITIVE FUNCTIONING, VIRAL SUPPRESSION, AND ASSOCIATED RISKS (Thursday)
P-F4 CNS RESERVOIRS/ESCAPE (Wednesday)
P-F5 VIROLOGY/BASIC NEUROSCIENCE (Tuesday)
P-F6 INTERVENTION-FOCUSED (Tuesday)
P-F7 HOST AND VIRAL BIOMARKERS (Tuesday)
P-F8 NEUROIMAGING AND ASSOCIATED BIOMARKERS (Wednesday)

G. CLINICAL PHARMACOLOGY
P-G1 INTRACELLULAR AND TISSUE PHARMACOLOGY (Tuesday)
P-G2 DRUG - DRUG INTERACTIONS (Wednesday)
P-G3 PHARMACOKINETICS AND PHARMACOGENETICS: NEW AND EXISTING DRUGS AND FORMULATIONS (Tuesday)
P-G4 EXPOSURE-RESPONSE RELATIONSHIPS OF ANTIRETROVIRAL DRUGS (Wednesday)
P-G5 ANTIRETROVIRAL PHARMACOKINETICS: SPECIAL PROBLEMS AND POPULATIONS (Thursday)

H. ANTIRETROVIRAL THERAPY: PRE-CLINICAL AND RANDOMIZED TRIALS
P-H1 I WANT A NEW DRUG (Wednesday)
P-H2 ANTIRETROVIRAL CLINICAL TRIALS (Tuesday)

I. ANTIRETROVIRAL THERAPY: EFFICACY AND EFFECTIVENESS STUDIES
P-I1 ART: SAFETY AND PRESCRIBING OVER THE LONG TERM (Tuesday)
P-I2 MAINTENANCE: SECOND- AND THIRD-LINE THERAPY (Tuesday)
P-I3 ART: VIRAL RESPONSE OVER THE LONG TERM (Wednesday)
P-I4 ART: PREDICTORS OF OUTCOMES (Wednesday)
P-I5 IMMEDIATE VS DELAYED ART (Thursday)

J. HIV DRUG RESISTANCE
P-J1 PREVALENCE AND INCIDENCE OF HIV DRUG RESISTANCE (Thursday)
P-J2 IMPACT OF RESISTANCE ON RESPONSE TO ART (Thursday)
P-J3 INTEGRASE STRAND TRANSFER INHIBITOR RESISTANCE (Tuesday)
P-J4 REVERSE TRANSCRIPTASE INHIBITOR RESISTANCE (Tuesday)
P-J5 RESISTANCE TO PROTEASE AND MATURATION INHIBITORS (Tuesday)

K. HIV DIAGNOSTICS
P-K1 HIV DETECTION AND RECENCY METHODS (Tuesday)

L. HEPATITIS VIRUSES AND LIVER COMPLICATIONS
P-L1 HCV TRANSMISSION: THE CASCADE IS NOT RUNNING DRY (Tuesday)
P-L2 PROGRESSION OF LIVER DISEASE IN THE HCV-INFECTED POPULATION (Tuesday)
P-L3 HCV: PROGRESSION TO CIRRHOSIS AND HEPATOCellular CARCINOMA (Tuesday)
P-L4 HCV: THE RAINBOW AT THE END OF THE CASCADE (Wednesday)
P-L5 HCV: RESISTANCE AND RETREATMENT (Wednesday)
P-L6 DAAs: TREATMENT AND ITS COMPLEXITIES (Wednesday)
P-L7 HEPATITIS IS NOT ALL C (Thursday)
P-L8 PATHOGENESIS OF HCV INFECTION (Thursday)
M. MALIGNANCIES
P-M1  ANAL CANCER: SCREENING AND HPV (Tuesday)
P-M2  AIDS-RELATED CANCER: ART, RISK, INCIDENCE, AND BURDEN (Wednesday)
P-M3  AIDS-RELATED CANCER: LYMPHOMA, KAPOSI SARCOMA, LUNG, AND LIVER (Thursday)

N. CARDIOVASCULAR COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY
P-N1  CARDIOVASCULAR RISK AND ART EFFECTS (Wednesday)
P-N2  DYSLIPIDEMIA AND HDL FUNCTION (Wednesday)
P-N3  INTERVENTIONS TO PREVENT AND TREAT CARDIOVASCULAR DISEASE (Wednesday)
P-N4  VASCULAR, CARDIAC, AND PULMONARY EVENTS (Wednesday)
P-N5  INFLAMMATION, BIOMARKERS, AND RISK FACTORS FOR VASCULAR DISEASE (Tuesday)
P-N6  INTEGRATION OF SCREENING AND TREATMENT OF NCD INTO HIV CARE IN RESOURCE-LIMITED SETTINGS (Tuesday)

Q. OTHER COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY
P-Q1  IMMUNOLOGIC PREDICTORS OF MORBIDITY AND MORTALITY (Tuesday)
P-Q2  ART TOXICITY (Tuesday)
P-Q3  PULMONARY COMPLICATIONS (Wednesday)
P-Q4  FRAILTY AND MULTIMORBIDITY (Wednesday)
P-Q5  PREDATORS OF INFLAMMATION OR ART (Thursday)
P-Q6  BONE DISEASE: RISK PREDICTION (Thursday)
P-Q7  BONE DISEASE: MECHANISMS (Thursday)
P-Q8  BONE DISEASE: INTERVENTIONS (Thursday)
P-Q9  RENAL DISEASE (Thursday)
P-Q10  ORGAN TRANSPLANTATION (Thursday)
P-Q11  METABOLIC COMPLICATIONS (Thursday)
P-Q12  OBESITY AND FATTY LIVER DISEASE (Thursday)

P. TUBERCULOSIS AND OTHER OPPORTUNISTIC INFECTIONS
P-P1  TB PREVENTION (Tuesday)
P-P2  TB PATHOGENESIS AND DIAGNOSIS (Tuesday)
P-P3  TB TREATMENT, OUTCOMES, AND MORTALITY (Tuesday)
P-P4  TB EPIDEMIOLOGY AND BURDEN OF DISEASE (Wednesday)
P-P5  TB AND CONTINUUM OF CARE (Wednesday)
P-P6  TB AND OI IRIS (Wednesday)
P-P7  TB COMORBIDITIES (Wednesday)
P-P8  OI EPIDEMIOLOGY AND PATHOGENESIS (Thursday)
P-P9  CRYPTOCOCCAL MENINGITIS AND OTHER FUNGAL OIs (Thursday)
P-P10  NEUROSYPHILIS (Thursday)
P-P11  PROTOZOAL OIs (Thursday)

Q. MATERNAL/FETAL HIV
P-Q1  PK AND SAFETY OF ARVs AND MONOCLONAL ANTIBODIES FOR PMTCT (Thursday)
P-Q2  THE PMTCT CASCADE: TRANSMISSION, TESTING, AND VIRAL SUPPRESSION (Tuesday)
P-Q3  PREGNANCY AND PREGNANCY OUTCOMES (Thursday)
P-Q4  OUTCOMES OF HIV AND ARV-EXPOSED INFANTS (Tuesday)
P-Q5  HIV DIAGNOSIS IN NEWBORNS AND INFANTS (Wednesday)
R. PEDIATRICS AND ADOLESCENTS
P-R1 HIV DETECTION AND LATENT RESERVOIR IN CHILDREN (Wednesday)
P-R2 IMMUNE RESPONSE AND ACTIVATION IN CHILDREN (Wednesday)
P-R3 PHARMACOKINETICS AND DOSING OF ARVs AND COTREATMENTS IN CHILDREN AND YOUTH (Thursday)
P-R4 ART STRATEGIES AND OUTCOMES IN CHILDREN AND YOUTH (Thursday)
P-R5 COMORBIDITIES AND COMPLICATIONS IN CHILDREN AND YOUTH (Tuesday)
P-R6 APPROACHING 90:90:90 IN ADOLESCENTS AND YOUNG ADULTS (Wednesday)

S. EPIDEMIOLOGY
P-S1 NETWORKS OF HIV RISK (Thursday)
P-S2 RISK FACTORS FOR HIV INFECTION (Thursday)
P-S3 HIV AND STIs: BACK TO THE FUTURE (Thursday)
P-S4 HIV AND SUBSTANCE USE: DOUBLE TROUBLE (Wednesday)
P-S5 MEASURING HIV INCIDENCE AND PREVALENCE (Tuesday)
P-S6 ACUTE AND EARLY HIV INFECTION (Thursday)
P-S7 HIV SELF TESTING: KNOW YOURSELF (Tuesday)
P-S8 MEASURING THE US HIV EPIDEMIC (Tuesday)
P-S9 FACTORS INFLUENCING HIV OUTCOMES (Tuesday)
P-S10 STIGMA, MENTAL HEALTH, AND SEXUAL VIOLENCE (Thursday)
P-S11 MORBIDITY, MORTALITY, AND VIRAL DYNAMICS (Thursday)

T. PREVENTION INTERVENTIONS
P-T1 FERTILITY, CONTRACEPTION, PREGNANCY, AND REPRODUCTIVE HEALTH (Wednesday)
P-T2 HOT FLASHES: HORMONAL CONTRACEPTION AND HIV RISK (Wednesday)
P-T3 GENITAL INFECTIONS: MISHAPS AT THE MUCOSA (Wednesday)
P-T4 LESSONS FROM SEROCONVERSION ON PREP AND MICROBICIDES (Thursday)

U. PREVENTION SCALE-UP
P-U1 STRATEGIES TO INCREASE HIV TESTING (Tuesday)
P-U2 PREP WITHOUT BORDERS: NEW DELIVERY OPTIONS (Wednesday)
P-U3 PREP AWARENESS, TARGETING, AND UPTAKE (Wednesday)
P-U4 PREP PERSISTENCE, ADHERENCE, AND OUTCOMES (Wednesday)
P-U5 VOLUNTARY MEDICAL CIRCUMCISION (Thursday)

W. IMPLEMENTATION AND SCALE-UP OF TREATMENT AND CARE
P-W1 MEASURING THE GLOBAL HIV CARE CASCADE (Wednesday)
P-W2 INTERVENTIONS TO IMPROVE THE CARE CASCADE (Tuesday)
P-W3 HIV, MIGRATION, AND ACCESS TO CARE (Wednesday)
P-W4 ADVANCED HIV, AND LONG-TERM CARE (Tuesday)

X. POPULATION AND COST MODELING
P-X1 MODELLING HIV TRANSMISSION (Thursday)
P-X2 COST-EFFECTIVENESS OF HIV TESTING AND SCREENING STRATEGIES (Tuesday)
P-X3 IMPROVING THE EFFECTIVENESS AND COST EFFECTIVENESS OF PREP AND OTHER PREVENTION APPROACHES (Wednesday)
P-X4 MODELLING TO GUIDE IMPROVEMENTS IN THE CARE CASCADE (Thursday)

Y. EMERGING VIRUSES: ZIKA VIRUS
P-Y1 EMERGING VIRUSES: ZIKA VIRUS (Tuesday)

Please refer to the Index of Studies Related to Women for presentations that include, among others, studies on contraceptive and reproductive health in women (Category V).
DISCLOSURE OF FINANCIAL RELATIONSHIPS WITH COMMERCIAL CONCERNS

Disclosure information is presented generally as submitted by the corresponding presenting abstract author or invited speaker. The authors and speakers below provided their relevant disclosures of financial relationships with commercial entities for themselves and their spouses or partners, as well as funding provided to their institutions.

Abu-Raddad, Laith, J.
For self, paid to my institution:
Research grant recipient from Qatar National Research Fund
Achhra, Amit, C.
Self: Employee of NCBH Hosp and JJP VA Med Ctr, Bronx, NY
Achilles, Sharon, L.
Self: Consultant of Merck & Co, Inc
Adkison, Kimberly, K.
Self: Employee of ViiV Healthcare
Althoff, Keri, N.
Self: Consultant Gilead Sciences, Inc
Ananworanich, Jintanat
Self: Honoraria from ViiV Healthcare and Merck & Co, Inc
For self, paid to my institution:
Research grant recipient from Cooperative agreements between The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of the Army
Anderson, Jenny, L.
For self, paid to my institution:
Contracted researcher Merck & Co, Inc
Anderson, Peter, L.
For self, paid to my institution:
Research grant recipient from contract work and study drug donation from Gilead Sciences, Inc
Anderson, Sarah-Jane
Self: Consultant for Bill and Melinda Gates Foundation and consultant for Avenir Health
Andrade, Adriana
Self: Board member of Ginseng Board of Wisconsin and research grant recipient Gilead Sciences, Inc
Andrew, Katende
Self: Employee of IFAKARA Health Institute
Ankrom, Wendy
Self: Employee of Merck & Co, Inc
Spouse or Partner: Contracted researcher for Certara
Anugulruengkitt, Suvaporn
Self: Research grant recipient from The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Grant Programme
Arribas, Jose, R.
Self: Research grant recipient from and speaker’s bureau for ViiV Healthcare, JanssenTherapeutics, AbbVie, Bristol-Myers Squibb, and Gilead Sciences, Inc
Barber, Tristan
Self: Consultant and speaker’s bureau for Gilead Sciences, Inc, Janssen Therapeutics, and ViiV Healthcare
Bares, Sara, H.
Self: Research grant recipient from Gilead Sciences, Inc.
Barnard, Richard
Self: Employee of Merck and Co., Inc
Bauer, Wolfgang
Self: Consultant of GlaxoSmithKline and Pharma GmbH
Bedimo, Roger
Self: Research grant recipient from and consultant for Merck & Co, Inc and Bristol-Myers Squibb
Bekker, Linda-Gail
For self, paid to my institution:
Research grant recipient from The Desmond Tutu HIV Centre
Berenguer, Juan
For self, paid to my institution:
Research grant recipient from ABBVIE, Gilead Sciences, Inc, Merck & Co, Inc, ViiV Healthcare
Self: Speaker’s bureau for ABBVIE, Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Janssen Therapeutics, and ViiV Healthcare
Bhattacharya, Debika
For self, paid to my institution:
Research grant recipient from AbbVie, Bristol Myers Squibb, and Merck & Co, Inc
Boesecke, Christoph
Self: Consultant and speaker’s bureau AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, and ViiV Healthcare
For self, paid to my institution:
Research grant recipient from Deutsches Zentrum für Infektionsforschung (DZIF), Deutsche Leberstiftung, and NEAT ID
Boffito, Marta  
Self: Consultant and speaker's bureau for Gilead Sciences, Inc, ViIV Healthcare, Bristol-Myers Squibb, Janssen Therapeutics, Mylan, Inc, and Teva

Self, For self, paid to my institution: Research grant recipient from Gilead Sciences, Inc, ViIV Healthcare, Bristol-Myers Squibb, Janssen Therapeutics, Mylan, Inc, and Teva

Bollen, Pauline  
For self, paid to my institution: Grant from ViIV Healthcare

Brehm, Jessica  
Self: Employee of GlaxoSmithKline

Brinkman, Kees  
Self: Consultant for Merck & Co, Inc, Gilead Sciences, Inc, ViIV Healthcare, Roche Diagnostics, Bristol-Myers Squibb, and Janssen Therapeutics

Brodkmeyer, Norbert, H.  
Self: Consultant Merck & Co, Inc

For self, paid to my institution: Research grant recipient from ViIV Healthcare, Bristol-Myers Squibb, and Janssen Therapeutics

Brown, Kimberly  
Self: Janssen Therapeutics

Brown, Todd  
Self: Consultant for Gilead Sciences, Bristol-Myers Squibb, Merck & Co, Inc, EMD-Serono, and Theratechnologies

Bucher, Heiner, C.  
For self, paid to my institution: Research grant recipient from Gilead Sciences, Bristol-Myers Squibb, and ViIV Healthcare

Butt, Adeel, A.  
Self: Research grant recipient from Gilead Sciences, Inc, Merck & Co, Inc, and AbbVie

Cai, Suqin  
Self: Employee of Monogram Biosciences

Calcagno, Andrea  
Self: Consultant of Abbvie, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen-Cilag, Merck & Co, Inc, ViIV Healthcare

For self, paid to my institution: Research grant recipient from Gilead Sciences, Inc, Bristol-Myers Squibb, and ViIV Healthcare

Cambiano, Valentina  
Self: Other for Merck & Co, Inc

Ceccherini Silberstein, Francesca  
Self: Research grant recipient from consultant, and speaker's bureau for AbbVie, Abbott Molecular, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, Roche Diagnostics, ViIV Healthcare

Cento, Valeria  
Self: Speaker's bureau for Abbvie, Bristol-Myers Squibb, Merck Sharp & Dohme, and Janssen Therapeutics

Chew, Kara, W.  
Self, For self, paid to my institution: Research grant recipient from Merck & Co, Inc

Christopoulos, Katerina  
Self: Other for Roche Diagnostics and Gilead Sciences, Inc

Clarke, Diana, F.  
Self: Consultant for Merck & Co, Inc

Clement, Meredith  
Spouse or Partner: Royalty holder (company not stated)

Cloherty, Gavin  
Self: Employee of Abbott Laboratories

Coller, Kelly  
Self: Employee of Abbott Laboratories

Corbin, John, A.  
Self: Employee of Gilead Sciences, Inc

Costagliola, Dominique  
Self: Consultant for Gilead Sciences, Inc and Innnavirvax

For self, paid to my institution: Research grant recipient from ViIV Healthcare, Janssen-Cilagm, Merck & Co, Inc.

Cotte, Laurent  
For self, paid to my institution: Research grant recipient from Merck & Co, Inc, ViIV

 Custodio, Joseph, M.  
Self: Employee of Gilead Sciences, Inc

Dean, Bonnie  
Self: Research grant recipient from Cerner, Inc

Dejesus, Edwin  
Self: Consultant of Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, and Vertex, Inc

For self, paid to my institution: Research grant recipient from Abbott Laboratories, Achillion Pharmaceuticals, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, LaRoche Diagnostics, Idenix, Janssen Therapeutics, Merck & Co, Inc, Pfizer, Sangamo, Taimed, Tobira, and Vertex, Inc

Devillé, Walter  
For self, paid to my institution: Research grant recipient from Orasure Company

Dolci, Giovanni,  
Self: Consultant of Gilead Sciences, Inc

Self, For self, paid to my institution: Research grant recipient from Gilead Sciences, Inc

Dunham, Richard, M.  
Self: Employee of GlaxoSmithKline

Durand, Christine  
Self: Consultant Gilead Sciences

Research grant recipient from Merck Pharmaceuticals

Consultant Bristol-Myers Squibb
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Durham, Phillip, G.</td>
<td>Self: Employee of RTI International</td>
</tr>
<tr>
<td>Eaton, Ellen, F.</td>
<td>For self, paid to my institution: Research grant recipient from Other Bristol Myer Squibb Virolgy Fellowship</td>
</tr>
<tr>
<td>Eckard, Allison, R.</td>
<td>Self: Consultant Gilead Sciences</td>
</tr>
<tr>
<td>Eckhardt, Benjamin,</td>
<td>Self: Research grant recipient from and consultant Gilead Sciences, Inc</td>
</tr>
<tr>
<td>Ellis, Ronald, J.</td>
<td>Spouse or Partner: Stockholder of Merck &amp; Co, Inc, Abbott, and Johnson and Johnson</td>
</tr>
<tr>
<td>Emu, Brinda</td>
<td>Self: Consultant for Taimed and 3V Biosciences</td>
</tr>
<tr>
<td>Erlandson, Kristine</td>
<td>Self: Research grant recipient from and consultant for Gilead Sciences, Inc and Theratechnologies</td>
</tr>
<tr>
<td>Esser, Stefan</td>
<td>Self, For self, paid to my institution: Research grant recipient from Consultant Abbvie, BMS, Gilead, Merck &amp; Co, Inc, Janssen, ViIV</td>
</tr>
<tr>
<td>Evans, Ceri</td>
<td>Self: Other for GlaxoSmithKline</td>
</tr>
<tr>
<td>Fleisher, Ilan</td>
<td>Self: Employee of MedStar Health Research</td>
</tr>
<tr>
<td>Flexner, Charles, W.</td>
<td>Self: Consultant for Merck &amp; Co, Inc, Mylan, Inc, and ViIV Healthcare</td>
</tr>
<tr>
<td>Frange, Pierre</td>
<td>Self: Research grant recipient from Gilead Sciences, Inc</td>
</tr>
<tr>
<td>Gandhi, Rajesh, T.</td>
<td>For self, paid to my institution: Grants from EBSCO Information Services, Gilead Sciences, Inc, Merck &amp; Co, Inc, and ViIV Healthcare</td>
</tr>
<tr>
<td>Gatell, Jose, M.</td>
<td>Self: Consultant of Gilead Sciences, Inc, Merck &amp; Co, Inc, ViIV Healthcare, and Janssen Therapeutics</td>
</tr>
<tr>
<td>Gaur, Aditya</td>
<td>For self, paid to my institution: Research grant recipient from Gilead Sciences, Inc</td>
</tr>
<tr>
<td>Gerstenhaber, Rodd</td>
<td>Self: Employee of Medecins Sans Frontieres</td>
</tr>
<tr>
<td>Girardi, Enrico</td>
<td>Self: Speaker’s bureau for Janssen Therapeutics, Gilead Sciences, Inc, Otsuka, and Angelini. Research grant recipient from Gilead Sciences, Inc</td>
</tr>
<tr>
<td>Golub, Sarit, A.</td>
<td>Self: Gilead provides free study drug to project participants and covers the cost of some testing</td>
</tr>
<tr>
<td>Gonzalez-Garcia, Juan</td>
<td>Self: Consultant and speaker’s bureau for ViIV Healthcare, Gilead Sciences, Inc, Abbvie, and Merck Sharp Dohme For self, paid to my institution: Research grant from ViIV Healthcare, Gilead Sciences, Inc, Merck Sharp Dhome, Abbvie, Bristol-Myers Squibb, and Janssen-Cilag</td>
</tr>
<tr>
<td>Gonzalez-Perez, Maria Paz</td>
<td>Self: Employee of company not indicated</td>
</tr>
<tr>
<td>Grattoni, Alessandro</td>
<td>Self: Stockholder of NanoMedical Systems</td>
</tr>
<tr>
<td>Grimwood, Ashraf</td>
<td>Self: Employee of Khe‘Impilo</td>
</tr>
<tr>
<td>Grinsztejn, Beatriz</td>
<td>Self: Employee of Fundação Oswaldo Cruz</td>
</tr>
<tr>
<td>Guaraldi, Giovanni</td>
<td>Self: Consultant and speaker’s bureau for Gilead Sciences, Inc, Janssen Therapeutics, Bristol-Myers Squibb, GlaxoSmithKline, Grant recipient from ViIV Healthcareand Merck &amp; Co, Inc</td>
</tr>
<tr>
<td>Gupta, Ravindra, K.</td>
<td>Self: Speaker’s bureau for Janssen Therapeutics</td>
</tr>
<tr>
<td>Hagins, Debbie</td>
<td>For self, paid to my institution: Research grant recipient from Gilead Sciences, Inc</td>
</tr>
<tr>
<td>Hamzah, Lisa</td>
<td>Self: Other from Gilead Sciences, Inc</td>
</tr>
<tr>
<td>Hayes, Richard</td>
<td>Self: Royalty holder from Chapman and Hall</td>
</tr>
<tr>
<td>Hileman, Corrilynn, O.</td>
<td>Self: Consultant for Gilead Sciences, Inc</td>
</tr>
<tr>
<td>Hill, Andrew</td>
<td>Self: Consultant for Merck &amp; Co, Inc and Janssen Therapeutics</td>
</tr>
<tr>
<td>Hillier, Sharon, L.</td>
<td>Self: Consultant for Merck &amp; Co, Inc, Cepheid, and Symbiomix, LLC</td>
</tr>
<tr>
<td>Hodder, Sally</td>
<td>Self: Consultant for Bristol-Myers Squibb, ViIV Healthcare, Gilead Sciences, Inc, and Janssen Therapeutics</td>
</tr>
<tr>
<td>Spouse or Partner: Consultant for Sanofi, Novartis, and Johnson &amp; Johnson</td>
<td></td>
</tr>
<tr>
<td>Hogan, Michael, J.</td>
<td>Self: Recipient of Intellectual Property Rights from University of Pennsylvania</td>
</tr>
</tbody>
</table>
Holzmayer, Vera  
**Self:** Employee of and stockholder of Abbott Laboratories

Hsu, Ricky,  
**Self:** Research grant recipient from consultant, speaker's bureau, and contracted researcher for Gilead Sciences, Inc. Consultant and speaker's bureau for Janssen Therapeutics, and Bristol-Myers Squibb. Consultant for ViIV Healthcare. Speaker's bureau for Merck & Co, Inc

Huang, Wei  
**Self:** Employee of Monogram Biosciences

Hultquist, Judd, F.  
**Self:** Contracted researcher for Roche Diagnostics and consultant for BlueCatBio Ltd.

Imaz, Arkaitz  
**Self:** Research grant recipient from consultant, and speaker's bureau for Gilead Sciences, Inc, ViIV Healthcare, Bristol-Myers Squibb, Janssen Therapeutics, Merck & Co, Inc, and Abbvie

Iwuji, Collins, C.  
**Self:** Speaker's bureau for Gilead Sciences, Inc

Jarvis, Joseph, N.  
**For self, paid to my institution:** Research grant recipient from for an investigator initiated award from Gilead Sciences, Inc

Keating, Sheila  
**Self:** Other for Ortho Clinical Diagnostics

Khalilieh, Sauzanne  
**Self:** Employee of Merck & Co, Inc.

Kosloski, Matthew, P.  
**Self:** Employee of and stockholder of AbbVie

Koss, Catherine, A.  
**For self, paid to my institution:** I am involved with a study for which Gilead Sciences, Inc awarded study drug to my institution.

Lansdon, Eric  
**Self:** Employee of and stockholder of Gilead Sciences, Inc

Lathouwers, Erkki  
**Self:** Employee of Janssen Therapeutics

Leal, Lorna  
**Self:** Other for Gilead Sciences, Inc

Letendre, Scott  
**Self:** Consultant for ViIV Healthcare, Gilead Sciences, Inc., Merck & Co, Inc, and Janssen Therapeutics

Levy, Itzchak  
**Self:** Speaker's bureau for Gilead Sciences, Inc and Merck & Co, Inc

**For self, paid to my institution:** Research grant recipient from Gilead Sciences, Inc

Lewis, Stanley  
**Self:** Employee of TaiMed Biologics

Li, Jonathan  
**Self:** Research grant recipient and consultant for Gilead Sciences, Inc and Merck & Co, Inc

Link, John, O.  
**Self:** Employee and stockholder of Gilead Sciences, Inc

Longenecker, Chris, T.  
**Self:** Consultant for Gilead Sciences, Inc

Macias, Juan  
**Self:** Investigator in clinical trials supported by Roche Diagnostics, Bristol-Myers Squibb and Abbott Pharmaceuticals. Lectures fees from Roche Diagnostics, Gilead Sciences, Inc, Boehringer Ingelheim, and Bristol-Myers Squibb. Consulting fees from Boehringer Ingelheim

Maddon, Paul, J.  
**Self:** Consultant and stockholder of CytoDyn Inc. Stockholder of Progenics Pharmaceuticals, Inc.

Majeed, Sophia, R.  
**Self:** Employee and stockholder for Gilead Sciences

Makadzange, Azure, T.  
**Self:** Employee and stockholder for Gilead Sciences

Maleche Obimbo, Elizabeth  
**Self:** Stockholder Nairobi Securities Exchange

Mangia, Alessandra  
**Self:** Research grant recipient from Gilead Sciences, Janssen-Cilag, Bristol-Myers Squibb, and Merck & Co, Inc

Marconi, Vincent, C.  
**Self:** Research grant recipient from ViIV Healthcare

Margolis, David, A.  
**Self:** Employee and stockholder for ViIV Healthcare

Martinez, Esteban  
**Self:** Research grant recipient from Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, and ViIV Healthcare

Matheron, Sophie  
**For self, paid to my institution:** Research grant recipient from Merck & Co, Inc

Mauss, Stefan  
**Self:** Consultant, speaker’s bureau and advisory board for: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, and ViIV Healthcare

McClelland, R. Scott  
**For self, paid to my institution:** Research grant recipient from Hologic Corporation

McFarland, Elizabeth, J.  
**For self, paid to my institution:** Research grant recipient from Gilead Sciences, Inc
Meintjes, Graeme  
**Self:** Other relationship with Gilead Sciences, Inc

Meissner, Eric, G.  
**For self, paid to my institution:** Research grant recipient from Gilead Sciences, Inc

Mills, Lisa, A.  
**Spouse or Partner:** Employee of Leidos Biomedical

Mitchell, Michael, L.  
**Self:** Employee of Gilead Sciences, Inc

Molina, Jean-Michel  
**Self:** Consultant and speaker’s bureau Gilead Sciences, Inc. Consultant for Merck & Co, Inc and ViIV Healthcare  
**For self, paid to my institution:** Research grant recipient from Gilead Sciences

Morrison, Sheldon  
**Self:** Research grant recipient from Gilead Sciences

Mosckicki, Anna-Barbara  
**Self:** Other Merck & Co, Inc

Mothe, Beatriz  
**Self:** Consultant Aelix Therapeutics, AlbaJuna Therapeutics

Murray, Jeffrey  
**Self:** Employee of Gilead Sciences, Inc

Nijhawan, Ank, E.  
**Self:** Research grant recipient from Gilead Sciences, Inc

Novak, Richard  
**Self:** Consultant for Gilead Sciences, Inc. Contracted researcher for Merck & Co, Inc and GlaxoSmithKline

Ofotokun, Igbo  
**Self:** Consultant for Accordant

Owen, Andrew  
**Self:** Consultant Merck & Co, Inc and NorGINE  
**For self, paid to my institution:** Research grant recipient from Merck & Co, Inc, ViIV Healthcare, and AstraZeneca, Inc

Palella, Frank, J.  
**Self:** Consultant and speaker’s bureau Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, Bristol-Myers Squibb

Palma, Paolo  
**For self, paid to my institution:** Research grant recipient from ViIV Healthcare

Pérez-Valero, Ignacio  
**Self:** Other relationship with ViIV Healthcare, Gilead Sciences, Inc, and Bristol-Myers Squibb

Petoumenos, Kathy  
**Self:** Research grant from Merck Sharp & Dohme; Gilead Sciences, Inc, Bristol-Myers Squibb, Boehringer Ingelheim, Janssen-Cilag and ViIV Healthcare

Picker, Louis, J.  
**Self:** Consultant Vir Biotechnology

Price, Richard, W.  
**Self:** Consultant with Merck & Co., Inc

Riddler, Sharon  
**For self, paid to my institution:** Research grant recipient from Gilead Sciences, Inc and GlaxoSmithKline

Rijnders, Bart  
**Self:** Research grant recipient from Merk & Co, Inc and Gilead Sciences, Inc. Consultant for GL-pharmaceuticals, Bristol-Myers Squibb, Merck & Co, Inc, Gilead Sciences, Inc, Janssen-Cilag, ViIV Healthcare. Contracted researcher for Gilead Sciences, Inc and ViIV Healthcare

Rodgers, Mary  
**Self:** Employee and stockholder for Abbott Laboratories

Rose, Rebecca  
**Self:** Consultant for BioInfOExperts

Rough, Kathryn  
**Self:** Consultant for Bayer Pharmaceuticals

Ruelas, Debbie, S.  
**Self:** Employee of Merck & Co, Inc

Sabin, Caroline  
**Self:** Speaker’s bureau for Gilead Sciences, Inc. Other relationship with ViIV Healthcare and Janssen-Cilag

Sax, Paul, E.  
**Self:** Research grant recipient from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, and Janssen Therapeutics

Schalkwijk, Stein  
**For self, paid to my institution:** Research grant from Bristol-Myers Squibb, Merck & Co, Inc, ViIV Healthcare and Janssen Therapeutics

Seydi, Moussa  
**For self, paid to my institution:** Research grant recipient from Gilead Sciences, Inc

Silverberg, Michael, J.  
**For self, paid to my institution:** Research grant from Merck & Co, Inc and Pfizer, Inc

Soriano, Vincent  
**Self:** Consultant and speaker’s bureau for Gilead Sciences, Inc, Merck & Co, Inc, Janssen Therapeutics, Bristol-Myers Squibb

Squillace, Nicola  
**Self:** Consultant for ViIV Healthcare. speaker’s bureau for Merck & Co, Inc and Bristol-Myers Squibb. Other relationship with Janssen Therapeutics and Gilead Sciences, Inc
Squires, Kathleen  
**Self:** Consultant for Bristol Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, and Viiv Healthcare  
For self, paid to my institution: Research grant recipient from Clinical trials research grants to Thomas Jefferson University from Gilead Sciences, Inc

Tam, Edward  
**Self:** Consultant and speaker’s bureau for AbbVie, Bristol-Meyers Squibb, Gilead Sciences, Inc, Janssen Pharmaceuticalica, Merck & Co, Inc, and Pendopharm  
For self, paid to my institution: Research grant recipient from AbbVie

Tan, Darrell, H.S.  
For self, paid to my institution: Research grant recipient from Viiv Healthcare and Gilead Sciences, Inc

Telisinghe, L  
For self, paid to my institution: Other Qiagen provided non-financial support by providing the Quantiferon®-TB Gold Plus kits free of charge to use in the study.

Thomsen, Nathan, D.  
**Self:** Employee of Gilead Sciences, Inc

Thorne, Claire  
For self, paid to my institution: Research grant recipient from AbbVie and Viiv Healthcare

Tieu, Hong Van  
**Self:** Research grant recipient from Merck & Co, Inc

Todesco, Eve  
**Self:** Speaker’s bureau for Bristol-Myers Squibb

Tort, Olivia  
For self, paid to my institution: Research grant recipient from Gilead Sciences, Inc

Tse, Winston, C.  
**Self:** Employee of Gilead Sciences

Tung, Elyse  
**Self:** Other relationship with Gilead Sciences, Inc

Ukaegbu, Chinyere  
**Self:** Research grant recipient from Gilead Sciences, Inc

Utay, Netanya, S.  
**Self:** Consultant for Gilead Sciences, Inc. Consultant and contracted researcher for Tobira Therapeutics, Inc and Entera Health, Inc

van der Heijden, Wouter, A.  
For self, paid to my institution: Research grant recipient from Merck Sharp & Dohme, Merck & Co, Inc

van Sighem, Ard  
For self, paid to my institution: Research grant from Janssen-Cilag and Viiv Healthcare

van Zoest, Rosan  
For self, paid to my institution: Research grant from Gilead Sciences, Inc

Vannappagari, Van  
**Self:** Employee of Viiv Healthcare and stockholder of GlaxoSmithKline

Volpe, Joseph, M.  
**Self:** Employee of LabCorp

Vos, Alinda,  
**Self:** Employee of University Medical Center Utrecht, The Netherlands, Department Julius Center.

Vourvahis, Manoli  
**Self:** Employee and stockholder Pfizer, Inc

Wagner, Thor  
**Self:** Research grant from Gilead Sciences, Inc

Wandeler, Gilles  
**Self:** Research grant from Gilead Sciences, Inc

Warszawski, Josiane  
For self, paid to my institution: Research grant from Viiv Healthcare and Parexel

Weinberg, Adriana  
**Self:** Research grant recipient from GlaxoSmithKline and Medimmune  
**Spouse or Partner:** Research grant recipient from and royalty holder from Merck & Co, Inc

Weinheimer, Steven  
**Self:** Employee of TaiMed Biologics USA

White, Douglas, A. E.  
**Self:** Research grant recipient from Gilead Sciences, Inc

White, Kirsten, L.  
**Self:** Employee and stockholder of Gilead

Wiley, Dorothy, J.  
**Self:** Research grant recipient from Merck Sharp & Dohme Corp, Merck & Co., Inc

Wong, Wingwai  
For self, paid to my institution: Research grant recipient from United BioPharma  
**Self,** for self, paid to my institution: Research grant from Gilead Sciences, Inc, Viiv Healthcare, Merck 7 Co, Inc, and Bristol-Meyers Squibb

Yin, Michael, T.  
**Self:** Consultant for Gilead Sciences, Inc

Zhang, Heather  
**Self:** Employee and stockholder of Gilead Sciences, Inc
### Disclosure Information

The following have no relevant financial relationships to disclose. Any updates will be reflected in the Mobile App.

<table>
<thead>
<tr>
<th>Aamer, Hadega</th>
<th>Belaunzaran-Zamudio, Pablo, F.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abasa, Andrew, M.</td>
<td>Beloukas, Apostolos</td>
</tr>
<tr>
<td>Abdel Molsen, Mohamed</td>
<td>Bendavid, Eran</td>
</tr>
<tr>
<td>Abdo, Mona</td>
<td>Bengtson, Angela</td>
</tr>
<tr>
<td>Abewe, Hosiana</td>
<td>Bershteyn, Anna</td>
</tr>
<tr>
<td>Aboulnasr, Fatma</td>
<td>Bertoli, Ada</td>
</tr>
<tr>
<td>Abutaima, Rana</td>
<td>Bhagwat, Priya</td>
</tr>
<tr>
<td>Adamson, Blythe, J.</td>
<td>Blenczak, Andrzej</td>
</tr>
<tr>
<td>Aghokeng, Avelin, F.</td>
<td>Biliotti, Elisa</td>
</tr>
<tr>
<td>Agot, Kawango</td>
<td>Billioux, Veena, G.</td>
</tr>
<tr>
<td>Agrati, Chiara</td>
<td>Birnbaum, Jeanette</td>
</tr>
<tr>
<td>Alcaide, Maria, L.</td>
<td>Bisson, Gregory</td>
</tr>
<tr>
<td>Aldámez-Echevarria, Teresia Alessandra, Sacchi</td>
<td>Blanco, José, L.</td>
</tr>
<tr>
<td>Almirol, Ellen</td>
<td>Blokhuis, Charlotte</td>
</tr>
<tr>
<td>Alvarez, Angeles</td>
<td>Boehme, Catharina, C.</td>
</tr>
<tr>
<td>Alwano, Mary Grace</td>
<td>Boerekamps, Anne</td>
</tr>
<tr>
<td>An, Qian</td>
<td>Boivin, Michael, J.</td>
</tr>
<tr>
<td>Ancona, Giuseppe</td>
<td>Bonar, Michal</td>
</tr>
<tr>
<td>Andany, Nisha</td>
<td>Bordoni, Veronica</td>
</tr>
<tr>
<td>Anderson, Albert</td>
<td>Borges, Álvaro, H.</td>
</tr>
<tr>
<td>Anderson, Elizabeth, M.</td>
<td>Borre, Ethan, D.</td>
</tr>
<tr>
<td>Angelovich, Thomas, A.</td>
<td>Bosman, Kobus</td>
</tr>
<tr>
<td>Araújo, Marília, L.</td>
<td>Boulougoura, Afroditri</td>
</tr>
<tr>
<td>Archary, Mohendran</td>
<td>Bowen-Test, Kevin, W.</td>
</tr>
<tr>
<td>Armstrong, Heather, L.</td>
<td>Bozzi, Giorgio</td>
</tr>
<tr>
<td>Arnedo, Mireia</td>
<td>Bracchi, Margherita</td>
</tr>
<tr>
<td>Arpadi, Stephen, M.</td>
<td>Bradley, Heather</td>
</tr>
<tr>
<td>Attia, Engi, F.</td>
<td>Brenner, Bluma</td>
</tr>
<tr>
<td>Avi, Radko</td>
<td>Brittain, Kirsty</td>
</tr>
<tr>
<td>Avihingson, Anchalee</td>
<td>Broekhuis, Jordan</td>
</tr>
<tr>
<td>Avila-Rios, Santiago</td>
<td>Brooks, Kristina, M.</td>
</tr>
<tr>
<td>Ayieko, James</td>
<td>Brown, Lillian</td>
</tr>
<tr>
<td>Azzoni, Livio</td>
<td>Broz, Dita</td>
</tr>
<tr>
<td>Bachanas, Pamela, J.</td>
<td>Bruce, Veronica</td>
</tr>
<tr>
<td>Bachmann, Nadine</td>
<td>Bruhl, Maria, C.</td>
</tr>
<tr>
<td>Badje, Anani, D.</td>
<td>Brunet, Laurence</td>
</tr>
<tr>
<td>Bai, Francesca</td>
<td>Buczak, Kate</td>
</tr>
<tr>
<td>Bailin, Samuel</td>
<td>Buggert, Marcus</td>
</tr>
<tr>
<td>Baker, Jason</td>
<td>Buhl, Marta, E.</td>
</tr>
<tr>
<td>Balkus, Jennifer</td>
<td>Buranapraditkun, Supranee</td>
</tr>
<tr>
<td>Balogun, Kayode</td>
<td>Burchell, Ann, N.</td>
</tr>
<tr>
<td>Banga, Riddhima</td>
<td>Burdick, Ryan, C.</td>
</tr>
<tr>
<td>Bangham, Charles, R.M.</td>
<td>Burger, Adam</td>
</tr>
<tr>
<td>Bardhi, Ariola</td>
<td>Burgess, Emma, K.</td>
</tr>
<tr>
<td>Barnabas, Ruanne, V.</td>
<td>Burke, Mark, W.</td>
</tr>
<tr>
<td>Barocas, Joshua, A.</td>
<td>Buseyne, Florence</td>
</tr>
<tr>
<td>Batavia, Ashita, S.</td>
<td>Bush, William, S.</td>
</tr>
<tr>
<td>Battalora, Linda</td>
<td>Buskin, Susan</td>
</tr>
<tr>
<td>Baxter, Amy, E.</td>
<td>Butt, Zahid, A.</td>
</tr>
<tr>
<td>Bearden, David</td>
<td>Cachay, Edward, R.</td>
</tr>
<tr>
<td>Bebell, Lisa</td>
<td>Camacho-Gonzalez, Andres</td>
</tr>
<tr>
<td>Beck, Ingrid, A</td>
<td>Camlin, Carol, S.</td>
</tr>
<tr>
<td>Becker, James, T.</td>
<td>Campbell, Ellsworth</td>
</tr>
<tr>
<td>Becfofsky, Katie</td>
<td>Cannizzo, Elvira, S.</td>
</tr>
<tr>
<td>Bekker, Adrie</td>
<td>Capoferri, Adam</td>
</tr>
<tr>
<td></td>
<td>Carrillo, Mayra, A.</td>
</tr>
<tr>
<td></td>
<td>Carroll, Makeda</td>
</tr>
<tr>
<td></td>
<td>Carryl, Heather</td>
</tr>
<tr>
<td></td>
<td>Casazza, Joseph, P.</td>
</tr>
<tr>
<td></td>
<td>Castagna, Antonella</td>
</tr>
<tr>
<td></td>
<td>Castel, Amanda, D.</td>
</tr>
<tr>
<td></td>
<td>Castelli, Francesco</td>
</tr>
<tr>
<td></td>
<td>Castillo-Mancilla, Jose, R.</td>
</tr>
<tr>
<td></td>
<td>Chaila, Mwate, J.</td>
</tr>
<tr>
<td></td>
<td>Chaillon, Antoine</td>
</tr>
<tr>
<td></td>
<td>Chaix Baudier, Marie-Laure</td>
</tr>
<tr>
<td></td>
<td>Chan, Austin, W.</td>
</tr>
<tr>
<td></td>
<td>Chan, Phillip</td>
</tr>
<tr>
<td></td>
<td>Chang, Ming</td>
</tr>
<tr>
<td></td>
<td>Chapin-Bardales, Johanna</td>
</tr>
<tr>
<td></td>
<td>Chatttergoon, Michael</td>
</tr>
<tr>
<td></td>
<td>Chen, Mi</td>
</tr>
<tr>
<td></td>
<td>Cheng, Shu-Hsing</td>
</tr>
<tr>
<td></td>
<td>Chew, Glen</td>
</tr>
<tr>
<td></td>
<td>Chi, Benjamin, H.</td>
</tr>
<tr>
<td></td>
<td>Chow, Dominic</td>
</tr>
<tr>
<td></td>
<td>Christ, Franke</td>
</tr>
<tr>
<td></td>
<td>Christoff, Quick, Aaron</td>
</tr>
<tr>
<td></td>
<td>Ciarellano, Andrea, L.</td>
</tr>
<tr>
<td></td>
<td>Cillo, Anthony, R.</td>
</tr>
<tr>
<td></td>
<td>Claassen, Mark</td>
</tr>
<tr>
<td></td>
<td>Coban, Hamza</td>
</tr>
<tr>
<td></td>
<td>Cocker, Alexander</td>
</tr>
<tr>
<td></td>
<td>Collins, Bryan, C.</td>
</tr>
<tr>
<td></td>
<td>Collins, Lauren, F.</td>
</tr>
<tr>
<td></td>
<td>Collins, Pamela</td>
</tr>
<tr>
<td></td>
<td>Connick, Elizabeth</td>
</tr>
<tr>
<td></td>
<td>Conradiade, Francesca</td>
</tr>
<tr>
<td></td>
<td>Cote, Helene, C.F.</td>
</tr>
<tr>
<td></td>
<td>Cotugno, Nicola</td>
</tr>
<tr>
<td></td>
<td>Courtney, Colleen, R.</td>
</tr>
<tr>
<td></td>
<td>Crabtreee- Ramirez, Brenda</td>
</tr>
<tr>
<td></td>
<td>Crane, Heidi, M.</td>
</tr>
<tr>
<td></td>
<td>Cremin, Ide</td>
</tr>
<tr>
<td></td>
<td>Crezap, Nicole</td>
</tr>
<tr>
<td></td>
<td>Cummins, Nathan</td>
</tr>
<tr>
<td></td>
<td>Cunningham, Coleen, K.</td>
</tr>
<tr>
<td></td>
<td>Curtis, Kelly</td>
</tr>
<tr>
<td></td>
<td>Cuzin, Lise</td>
</tr>
<tr>
<td></td>
<td>Gyktor, Joshua, C.</td>
</tr>
<tr>
<td></td>
<td>Dabydeen, Sarah</td>
</tr>
<tr>
<td></td>
<td>Dagur, Raghubendra, S.</td>
</tr>
<tr>
<td></td>
<td>Dan, Jennifer, M.</td>
</tr>
<tr>
<td></td>
<td>Danboise, Brook</td>
</tr>
<tr>
<td></td>
<td>D’Antoni, Michelle, L.</td>
</tr>
<tr>
<td></td>
<td>D’arch, Mirela</td>
</tr>
<tr>
<td></td>
<td>Dasgupta, Sharoda</td>
</tr>
<tr>
<td></td>
<td>Daskalakis, Demètre, C.</td>
</tr>
<tr>
<td></td>
<td>Davis, Arielle, P.</td>
</tr>
<tr>
<td></td>
<td>Davis, Nicole</td>
</tr>
<tr>
<td></td>
<td>Davy, Thibaut</td>
</tr>
<tr>
<td></td>
<td>de Armas, Lesley, R.</td>
</tr>
<tr>
<td></td>
<td>De Francesco, Davide</td>
</tr>
<tr>
<td></td>
<td>De La Flor, Carolina</td>
</tr>
<tr>
<td></td>
<td>Debyrzer, Zeger</td>
</tr>
<tr>
<td></td>
<td>Del Amo, Julia</td>
</tr>
<tr>
<td></td>
<td>Delagreverie, Heloise, M.</td>
</tr>
<tr>
<td></td>
<td>Delaney, Kevin, P.</td>
</tr>
<tr>
<td></td>
<td>Delelis, Olivier</td>
</tr>
<tr>
<td></td>
<td>Delviks-Frankenberg, Krista</td>
</tr>
<tr>
<td></td>
<td>Derache, Anne</td>
</tr>
<tr>
<td></td>
<td>Desimme, Belete, A.</td>
</tr>
<tr>
<td></td>
<td>Desir, Fidel, A.</td>
</tr>
<tr>
<td></td>
<td>Desmonde, Sophie</td>
</tr>
<tr>
<td></td>
<td>Dezzutti, Charlene, S.</td>
</tr>
<tr>
<td></td>
<td>Dhody, Kush</td>
</tr>
<tr>
<td>Disclosure Information</td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td></td>
</tr>
<tr>
<td>Program and Agenda</td>
<td></td>
</tr>
<tr>
<td>CROI 2017</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Khosropur, Christine, M.</td>
</tr>
<tr>
<td>Kiani, Zahra</td>
</tr>
<tr>
<td>Kinuthia, John</td>
</tr>
<tr>
<td>Kiragga, Agnes</td>
</tr>
<tr>
<td>Kirkegaard-Klitbo, Ditte, M.</td>
</tr>
<tr>
<td>Kitchen, Scott, G.</td>
</tr>
<tr>
<td>Kityo, Cissy</td>
</tr>
<tr>
<td>Koehe, John</td>
</tr>
<tr>
<td>Koullias, Yiannis</td>
</tr>
<tr>
<td>Koyous, Roger</td>
</tr>
<tr>
<td>Krapar, Astrid, R.</td>
</tr>
<tr>
<td>Krebs, Shelly, J.</td>
</tr>
<tr>
<td>Kroeeze, Stefanie</td>
</tr>
<tr>
<td>Ku, Wen-Wei</td>
</tr>
<tr>
<td>Kuhn, Louise</td>
</tr>
<tr>
<td>Kujawski, Stephanie</td>
</tr>
<tr>
<td>Kuo, Irene</td>
</tr>
<tr>
<td>Kutluay, Sebia, B.</td>
</tr>
<tr>
<td>Kvaratskhelia, Mamuka</td>
</tr>
<tr>
<td>Kwena, Zachary, A.</td>
</tr>
<tr>
<td>Lada, Steven</td>
</tr>
<tr>
<td>Laeyendecker, Oliver</td>
</tr>
<tr>
<td>Lahuerta, Maria</td>
</tr>
<tr>
<td>Lake, Jordan, E.</td>
</tr>
<tr>
<td>Lamb, Matthew, R.</td>
</tr>
<tr>
<td>Lang, Raynell</td>
</tr>
<tr>
<td>Lange, Camille</td>
</tr>
<tr>
<td>Larmarange, Joseph</td>
</tr>
<tr>
<td>Larsen, Anna</td>
</tr>
<tr>
<td>Latkin, Carl, A.</td>
</tr>
<tr>
<td>Le, Leah, T.</td>
</tr>
<tr>
<td>Le, Thuy</td>
</tr>
<tr>
<td>Lebelonyane, Refeletswe</td>
</tr>
<tr>
<td>Lechille, Kwana</td>
</tr>
<tr>
<td>Lee, Guinevere, Q.</td>
</tr>
<tr>
<td>Lee, Tia</td>
</tr>
<tr>
<td>Le, Sulgi</td>
</tr>
<tr>
<td>Leitman, Ellen, M.</td>
</tr>
<tr>
<td>Lesosky, Maia</td>
</tr>
<tr>
<td>Levy, Yves</td>
</tr>
<tr>
<td>Leyre, Louise</td>
</tr>
<tr>
<td>Li, Sam</td>
</tr>
<tr>
<td>Li, Taisheng</td>
</tr>
<tr>
<td>Liberatore, Rachel, A.</td>
</tr>
<tr>
<td>Lifson, Jeffrey, D.</td>
</tr>
<tr>
<td>Lim, So-Yon</td>
</tr>
<tr>
<td>Lin, Kuan-Yin</td>
</tr>
<tr>
<td>Lince-Deroche, Naomi</td>
</tr>
<tr>
<td>Linley, Laurie</td>
</tr>
<tr>
<td>Lipira, Lauren</td>
</tr>
<tr>
<td>Lisco, Andrea</td>
</tr>
<tr>
<td>Liu, Cindy, M.</td>
</tr>
<tr>
<td>Liu, Qingbo</td>
</tr>
<tr>
<td>Libbre, Josep, M.</td>
</tr>
<tr>
<td>Loarec, Anne</td>
</tr>
<tr>
<td>Lofgren, Sarah</td>
</tr>
<tr>
<td>Logie, Carmen, H.</td>
</tr>
<tr>
<td>Lombardi, Francesca</td>
</tr>
<tr>
<td>Long, Lawrence</td>
</tr>
<tr>
<td>López-Bernaldo, Juan Carlos</td>
</tr>
<tr>
<td>Luong Nguyen, Liem Binh</td>
</tr>
<tr>
<td>Lynch, Briana</td>
</tr>
<tr>
<td>Mabileau, Guillaume</td>
</tr>
<tr>
<td>MacBayrre, Christine, E.</td>
</tr>
<tr>
<td>Macera, Margherita</td>
</tr>
<tr>
<td>Maeda, Kenji</td>
</tr>
<tr>
<td>Maher, Andrew, D.</td>
</tr>
<tr>
<td>Makamani, Bonus</td>
</tr>
<tr>
<td>Makinson, Alain</td>
</tr>
<tr>
<td>Mallard, Jaclyn</td>
</tr>
<tr>
<td>Maman, David</td>
</tr>
<tr>
<td>Mamede, João, I.</td>
</tr>
<tr>
<td>Manasa, Justen</td>
</tr>
<tr>
<td>Manion, Maura</td>
</tr>
<tr>
<td>Mankowski, Madeleine, C.</td>
</tr>
<tr>
<td>Manne-Goehler, Jennifer</td>
</tr>
<tr>
<td>Manzardo, Christian</td>
</tr>
<tr>
<td>Martin, Alyssa, R.</td>
</tr>
<tr>
<td>Martin, Natasha</td>
</tr>
<tr>
<td>Martin-Blondel, Guillaume</td>
</tr>
<tr>
<td>Martin-Gayo, Enrique</td>
</tr>
<tr>
<td>Martinini, Salvatore</td>
</tr>
<tr>
<td>Marukutira, Tafreyi</td>
</tr>
<tr>
<td>Masciotra, Silvina</td>
</tr>
<tr>
<td>Masetti, Michela</td>
</tr>
<tr>
<td>Masia, Mar</td>
</tr>
<tr>
<td>Massanella, Marta</td>
</tr>
<tr>
<td>Mathabire, Sekai, C.</td>
</tr>
<tr>
<td>Mattingly, Aviva</td>
</tr>
<tr>
<td>Matus Nicodemos, Rodrigo</td>
</tr>
<tr>
<td>Mavigner, Maud</td>
</tr>
<tr>
<td>Mayanja, Yonia</td>
</tr>
<tr>
<td>Mayer, Kenneth, H.</td>
</tr>
<tr>
<td>Mayor, Angel</td>
</tr>
<tr>
<td>Mc Clintic, Hillary</td>
</tr>
<tr>
<td>McCreesh, Nicky</td>
</tr>
<tr>
<td>McFall, Allison, M.</td>
</tr>
<tr>
<td>McFaul, Katie</td>
</tr>
<tr>
<td>Mcgowan, Catherine</td>
</tr>
<tr>
<td>Mckibben, Rebecca</td>
</tr>
<tr>
<td>McKinnon, Lyle</td>
</tr>
<tr>
<td>Mcmahon, Vanessa</td>
</tr>
<tr>
<td>McVeA, David</td>
</tr>
<tr>
<td>Medrano, Luz, M.</td>
</tr>
<tr>
<td>Mehta, Natasha</td>
</tr>
<tr>
<td>Mehta, Sanjay, R.</td>
</tr>
<tr>
<td>Melhado, Caroline</td>
</tr>
<tr>
<td>Menego, Geoffrey</td>
</tr>
<tr>
<td>Menzaghini, Barbara</td>
</tr>
<tr>
<td>Mercante, Nicolas</td>
</tr>
<tr>
<td>Merli, Marco</td>
</tr>
<tr>
<td>Merlini, Esther</td>
</tr>
<tr>
<td>Mesplede, Thibault</td>
</tr>
<tr>
<td>Metcalfe, John, Z.</td>
</tr>
<tr>
<td>Metcalfe, Rebecca</td>
</tr>
<tr>
<td>Meyer, Laurence</td>
</tr>
<tr>
<td>Meyer-Andrieux, Isabelle, A.</td>
</tr>
<tr>
<td>Michel, Kate</td>
</tr>
<tr>
<td>Milam, Joel</td>
</tr>
<tr>
<td>Milanini, Benedetta</td>
</tr>
<tr>
<td>Miller, Melissa</td>
</tr>
<tr>
<td>Miller, Shannon</td>
</tr>
<tr>
<td>Minami, Rumi</td>
</tr>
<tr>
<td>Miro, Jose M</td>
</tr>
<tr>
<td>Mitchell, Brooks, I.</td>
</tr>
<tr>
<td>Mitchell, Julie</td>
</tr>
<tr>
<td>Mittal, Maria Luisa</td>
</tr>
<tr>
<td>Mimalane, Mompatti</td>
</tr>
<tr>
<td>Mody, Aaokie</td>
</tr>
<tr>
<td>Mohr, Erika, K.</td>
</tr>
<tr>
<td>Moir, Lorlette</td>
</tr>
<tr>
<td>Montano, Daniel, E.</td>
</tr>
<tr>
<td>Montano, Michalina, A.</td>
</tr>
<tr>
<td>Montejano, Rocio</td>
</tr>
<tr>
<td>Monterosio, Analyse, C.</td>
</tr>
<tr>
<td>Moraka, Natasha, O.</td>
</tr>
<tr>
<td>Moran, Caitlin, A.</td>
</tr>
<tr>
<td>Morand-Joubert, Laurence</td>
</tr>
<tr>
<td>Moreno, Ana</td>
</tr>
<tr>
<td>Moron-Lopez, Sara</td>
</tr>
<tr>
<td>Morse, Caryn, G.</td>
</tr>
<tr>
<td>Moscoe, Ellen</td>
</tr>
<tr>
<td>Mospele, Mosepele</td>
</tr>
<tr>
<td>Moyo, Sikhulle</td>
</tr>
<tr>
<td>Msukwa, Malango, T.</td>
</tr>
<tr>
<td>Mukui, Ijeoma</td>
</tr>
<tr>
<td>Murphy, Gary</td>
</tr>
<tr>
<td>Murphy, Robert</td>
</tr>
<tr>
<td>Musick, Andrew</td>
</tr>
<tr>
<td>Mutenda, Nicholus</td>
</tr>
<tr>
<td>Mwangi, Mary</td>
</tr>
<tr>
<td>Myers, Luke</td>
</tr>
<tr>
<td>Nyagot, Nicolas</td>
</tr>
<tr>
<td>Naidoo, Shalena</td>
</tr>
<tr>
<td>Nakanyala, Tuli</td>
</tr>
<tr>
<td>Nakazawa, Masato</td>
</tr>
<tr>
<td>Nakiyangi, Lydia</td>
</tr>
<tr>
<td>Nanfack, Aubin, J.</td>
</tr>
<tr>
<td>Nanfaka, Mastula</td>
</tr>
<tr>
<td>Navarro, Jordi</td>
</tr>
<tr>
<td>Navarro, Samuel</td>
</tr>
<tr>
<td>Ndembii, Nicaise</td>
</tr>
<tr>
<td>Ndhlouvou, Lishomwwe, C.</td>
</tr>
<tr>
<td>Ndhlouvou, ZaA</td>
</tr>
<tr>
<td>Neary, Megan</td>
</tr>
<tr>
<td>Neff, Charles, P.</td>
</tr>
<tr>
<td>Negoescu, Diana, M.</td>
</tr>
<tr>
<td>NeIlan, Anne, M.</td>
</tr>
<tr>
<td>Nelson, Aurelie</td>
</tr>
<tr>
<td>Nelson, Julie, A.E.</td>
</tr>
<tr>
<td>Nelson, Kristin, N.</td>
</tr>
<tr>
<td>Nemeth, Johannes</td>
</tr>
<tr>
<td>Neukam, Karin</td>
</tr>
<tr>
<td>Newell, Evan William</td>
</tr>
<tr>
<td>Newman, Peter, A.</td>
</tr>
<tr>
<td>Ng'Ang'a, Lucy</td>
</tr>
<tr>
<td>Ngonou Makamadop, Krystelle</td>
</tr>
<tr>
<td>Ngongondo, MceNeil</td>
</tr>
<tr>
<td>Nguyen, Nam, H.</td>
</tr>
<tr>
<td>Nguyen, Son</td>
</tr>
<tr>
<td>Nguyen, Thanh, T.</td>
</tr>
<tr>
<td>Nguyen, Thu, T.</td>
</tr>
<tr>
<td>Nkuzwe, Alliance</td>
</tr>
<tr>
<td>Norton, Thomas, D.</td>
</tr>
<tr>
<td>Novikova, Mariia</td>
</tr>
<tr>
<td>Novitsky, Vlad</td>
</tr>
<tr>
<td>Nowak, Piotr</td>
</tr>
<tr>
<td>Nowak, Rebecca, G.</td>
</tr>
<tr>
<td>Nussenzwieg, Michel</td>
</tr>
<tr>
<td>O'Brien, Meagan</td>
</tr>
<tr>
<td>Odoyo-June, Elijah</td>
</tr>
<tr>
<td>Ohainle, Molly</td>
</tr>
<tr>
<td>O'Halloran, Jane, A.</td>
</tr>
<tr>
<td>Oliayi, Oluwatosin</td>
</tr>
<tr>
<td>Oluware, Oluwasolape, M.</td>
</tr>
<tr>
<td>Olney, Jack</td>
</tr>
<tr>
<td>Omari, Habib, R.</td>
</tr>
<tr>
<td>Onorato, Lorenzo</td>
</tr>
<tr>
<td>Onoya, Dorina</td>
</tr>
<tr>
<td>Opoku, Jenevieve</td>
</tr>
<tr>
<td>Opolloy, Valarie, S.</td>
</tr>
<tr>
<td>Ortblad, Katrina, F.</td>
</tr>
<tr>
<td>Osei-Kuffour, Edmund</td>
</tr>
<tr>
<td>Osman, Nathan</td>
</tr>
<tr>
<td>Ostrowski, Mario</td>
</tr>
<tr>
<td>Ouattara, Eric, N.</td>
</tr>
<tr>
<td>Palar, Kartika</td>
</tr>
</tbody>
</table>
Weiser, Sheri
Weiss, Kevin
Wertheim, Joel, O.
Whitney, Bridget
Whitney, James
Wiche Salinas, Tomas Raul
Wijting, Ingeborg
Wimonsate, Wipas
Winckelmann, Anni
Winston, Alan
Winter, Joanne, R.
Wirunsawanya, Kamonkiat
Wong, Cherise
Wong, Chun-Shu
Wong, Sophy, S.
Woolnough, Emily
Wools-Kaloustian, Kara, K.
Wray, Tyler, B.
Wu, Vincent
Wyatt, Monique, A.
Yagura, Hiroki
Yang, Jingyan
Yebra, Gonzalo
Yee, Lynn, M.
Yen, Yung-Feng
Yonga, Gerald
Yuan, Zhe
Zaccarelli, Mauro
Zangerle, Robert
Zanoni, Brian, C.
Zash, Rebecca
Zerbato, Jennifer, M.
Zerbe, Allison
Zhang, Meiwen
Zhang, Yinfeng
Zhang, Yuwei
Zhen, Anjie
Zheng, Wenjing
Zhong, Yaoyu
Zhu, Shuntai
Zola, Courtney
Zucker, Jason
INDEX OF STUDIES RELATED TO WOMEN

The following index lists abstracts that noted women or women’s issues as the focus of the study. This index was developed for attendees with an interest in these issues. We encourage you to refer to the full program for other presentations that may address this subject.

TUESDAY, FEBRUARY 14, 2017

22 RANDOMIZED TRIAL OF LEEP VS CRYOTHERAPY TO TREAT CIN2/3 IN HIV-INFECTED WOMEN (Oral Abstract Session O-2)

23 NATURAL HISTORY OF CERVICAL INTRAEPITHELIAL NEOPLASIA-2 AMONG HIV-INFECTED WOMEN (Oral Abstract Session O-2)

24 INTEGRATION OF POSTNATAL SERVICES IMPROVES MCH AND ART OUTCOMES: A RANDOMISED TRIAL (Oral Abstract Session O-2)

242 A BROAD POLYCLONAL RESPONSE IS MEDIATED BY SUPERINFECTION WITH 2 DISTINCT VIRUSES (Poster Session P-D1)

25 ADVERSE BIRTH OUTCOMES DIFFER BY ART REGIMEN FROM CONCEPTION IN BOTSWANA (Oral Abstract Session O-2)

266 LYMPH NODE HIV-SPECIFIC CXCR5+ CTLs ARE ASSOCIATED WITH ENHANCED VIRAL CONTROL (Themed Discussion TD-1)

281 SEX-BASED DIFFERENCES IN HIV RESERVOIR ACTIVITY AND RESIDUAL IMMUNE ACTIVATION (Poster Session P-E1)

376 IFN-β REDUCES MACROPHAGE HEME OXYGENASE-1 EXPRESSION: ROLE IN HIV NEUROPATHOGENESIS (Poster Session P-F5)

421LB HPTN 076: TMC278 LA SAFE, TOLERABLE AND ACCEPTABLE FOR HIV PREEXPOSURE PROPHYLAXIS (Poster Session P-G3)

443 EFFICACY & SAFETY OF SWITCHING TO EVG/COBI/FTC/TAF IN VIROLOGICALLY SUPPRESSED WOMEN (Poster Session P-H2)

502 DRUG RESISTANCE AFTER CESSION OF EFAVIRENZ-BASED ANTIRETROVIRAL TREATMENT (Poster Session P-J4)

526 GUT EPITHELIAL DAMAGE, IMMUNE ACTIVATION & LIVER FIBROSIS IN HIV AND HCV INFECTION (Poster Session P-L2)

591 MULTIPLE-TEST SCREENING STRATEGIES IMPROVE BIOPSY-PROVEN HSIL-DETECTION IN HIV+ WOMEN (Poster Session P-M1)

627 EPICARDIAL FAT, IMMUNE ACTIVATION, AND CORONARY PLAQUE AMONG HIV+ AND HIV- WOMEN (Poster Session P-N5)

629 CRP PREDICTS SUBCLINICAL CVD PROGRESSION IN HIV- BUT NOT HIV+ WOMEN (Poster Session P-N5)

634 IMPAIRED ANTIVASCULAR CONTRACTION OF PERIVASCULAR ADIPOSE TISSUE IN HIV INDIVIDUALS (Poster Session P-N5)

646 LONGITUDINAL HIV VIRAL TRAJECTORIES AND COMORBIDITIES IN THE WIHS (Poster Session P-01)

696 RALTEGRAVIR SWITCH AND BIOMARKERS OF LIVER STEATOSIS AND METABOLIC SYNDROME IN WOMEN (Themed Discussion TD-4)

762 MISSED OPPORTUNITIES FOR REPEAT HIV TESTING AND EARLY ART INITIATION IN PREGNANCY (Poster Session P-Q2)
## Index of Studies Related to Women

### Program and Agenda

**CROI 2017**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Session Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>763</td>
<td>Low HIV Incidence in South African Pregnant Women Receiving a Prevention Intervention</td>
<td>P-Q2</td>
</tr>
<tr>
<td>764</td>
<td>HIV Incidence, Cascade, and Testing among Mothers in Western Kenya</td>
<td>P-Q2</td>
</tr>
<tr>
<td>765</td>
<td>Detection of HIV in Breast Milk Among Pregnant/Postpartum Women with Recent HIV</td>
<td>P-Q2</td>
</tr>
<tr>
<td>766</td>
<td>Uptake and Retention in Care of Pregnant Women Starting Option B+ in Maputo Province</td>
<td>P-Q2</td>
</tr>
<tr>
<td>767</td>
<td>Strategies for Viral-Load Monitoring During Pregnancy in Resource-Limited Settings</td>
<td>P-Q2</td>
</tr>
<tr>
<td>768</td>
<td>Viral Suppression Among HIV+ Pregnant Women Entering Antenatal Care in Uganda</td>
<td>P-Q2</td>
</tr>
<tr>
<td>769</td>
<td>Measures of Engagement in Routine HIV Care to Predict Elevated Viral Load on ART</td>
<td>P-Q2</td>
</tr>
<tr>
<td>770</td>
<td>Self-Report and Dry Blood Spots as Markers of Antiretroviral Adherence in Pregnancy</td>
<td>P-Q2</td>
</tr>
<tr>
<td>771</td>
<td>Unintended Pregnancy Predicts Subsequent Raised Viral Load in the Postnatal Period</td>
<td>P-Q2</td>
</tr>
<tr>
<td>879</td>
<td>Identification and Validation of an Incidence-Testing Algorithm for HIV-1 Subtype C</td>
<td>P-S5</td>
</tr>
<tr>
<td>913</td>
<td>Food Insecurity and HIV Treatment Outcomes in the Women’s Interagency HIV Study</td>
<td>P-S9</td>
</tr>
<tr>
<td>914</td>
<td>HIV Status Awareness and ART Coverage Among Female Sex Workers in Juba, South Sudan</td>
<td>P-S9</td>
</tr>
<tr>
<td>915</td>
<td>“Test and Treat” Antiretroviral Therapy Among Female Sex Workers in Kampala, Uganda</td>
<td>P-S9</td>
</tr>
<tr>
<td>958</td>
<td>Strengthening Male-Partner Testing in Antenatal Care: Findings from South Africa</td>
<td>P-U1</td>
</tr>
<tr>
<td>959</td>
<td>HPTN 071 Home-Based Testing Improves Uptake of HCT Among Pregnant Women in Zambia</td>
<td>P-U1</td>
</tr>
<tr>
<td>1006</td>
<td>Lower Retention in Care When ART is Initiated with CD4 ≥ 500 Cells/μL</td>
<td>P-W2</td>
</tr>
</tbody>
</table>

**WEDNESDAY, FEBRUARY 15, 2017**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Session Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>85</td>
<td>Daily Oral Prep Is Effective Among Women with Abnormal Vaginal Microbiota</td>
<td>O-8</td>
</tr>
<tr>
<td>86LB</td>
<td>Impact of Vaginal Microbiota on Genital Tissue and Plasma Concentrations of Tenofovir</td>
<td>O-8</td>
</tr>
<tr>
<td>88</td>
<td>Dapivirine Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception</td>
<td>O-8</td>
</tr>
<tr>
<td>209</td>
<td>Maraviroc Inhibits HIV Target T-Cell Trafficking into the Female Genital Lumen</td>
<td>P-C2</td>
</tr>
<tr>
<td>210</td>
<td>Investigating the Effect of pH on Cervicovaginal Mucus Barrier Properties to HIV</td>
<td>P-C2</td>
</tr>
<tr>
<td>266</td>
<td>Lymph Node HIV-Specific CCR5+ CTLs Are Associated with Enhanced Viral Control</td>
<td>P-D4</td>
</tr>
<tr>
<td>Page</td>
<td>Title</td>
<td>Type</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>229</td>
<td>COGNITIVE TRAJECTORIES OVER 4 YEARS AMONG HIV+ WOMEN WITH OPTIMAL VIRAL SUPPRESSION</td>
<td>Themed Discussion TD-7</td>
</tr>
<tr>
<td>350</td>
<td>AN IN VITRO—IN SILICO STUDY OF REDUCED-DOSE EFAVIRENZ INTERACTION WITH LEVONORGESTREL</td>
<td>Poster Session P-G4</td>
</tr>
<tr>
<td>423</td>
<td>TIMING OF CART INITIATION INFLUENCES CANCER RISK AMONG WOMEN LIVING WITH HIV</td>
<td>Poster Session P-M2</td>
</tr>
<tr>
<td>599</td>
<td>FACTORS ASSOCIATED WITH PULMONARY IMPAIRMENT IN HIV-INFECTED SOUTH AFRICAN ADULTS</td>
<td>Poster Session P-D3</td>
</tr>
<tr>
<td>657</td>
<td>TARGETED HIV SCREENING AT BIRTH CAN IDENTIFY THE MAJORITY OF IN UTERO TRANSMISSIONS</td>
<td>Poster Session P-Q5</td>
</tr>
<tr>
<td>790</td>
<td>DELAYED HIV DNA PCR DETECTION AMONG INFANTS WHO RECEIVED COMBINATION ART PROPHYLAXIS</td>
<td>Poster Session P-Q5</td>
</tr>
<tr>
<td>836</td>
<td>LOCAL SOCIAL NETWORKS PREDICT RETENTION &amp; SUPPRESSION IN YOUNG WOMEN IN SEARCH TRIAL</td>
<td>Poster Session P-R6</td>
</tr>
<tr>
<td>874</td>
<td>REDUCING ALCOHOL CONSUMPTION IMPROVED HIV VIRAL SUPPRESSION IN WOMEN</td>
<td>Poster Session P-S4</td>
</tr>
<tr>
<td>934</td>
<td>PREP USED IN PREGNANCY DOES NOT INCREASE POOR BIRTH OUTCOMES</td>
<td>Poster Session P-T1</td>
</tr>
<tr>
<td>935</td>
<td>PREGNANCY INCIDENCE AND OUTCOMES AMONG WOMEN USING THE DAPIVIRINE VAGINAL RING</td>
<td>Poster Session P-T1</td>
</tr>
<tr>
<td>936</td>
<td>PREFERENCE AND CHOICE OF MULTIPURPOSE PREVENTION TECHNOLOGIES IN YOUNG AFRICAN WOMEN</td>
<td>Poster Session P-T1</td>
</tr>
<tr>
<td>937</td>
<td>MODERN CONTRACEPTIVE USE AND UNPROTECTED SEX IN HIGH-RISK HIV-POSITIVE WOMEN IN KENYA</td>
<td>Poster Session P-T1</td>
</tr>
<tr>
<td>938</td>
<td>INTERACTION BETWEEN ETONOGESTREL-RELEASING IMPLANT AND 3 ANTIRETROVIRAL REGIMENS</td>
<td>Poster Session P-T1</td>
</tr>
<tr>
<td>939</td>
<td>FERTILITY AND REPRODUCTIVE OUTCOMES OF HIV+ AND HIV- WOMEN IN THE CARMA COHORT STUDY</td>
<td>Poster Session P-T1</td>
</tr>
<tr>
<td>940</td>
<td>EARLY ONSET MENOPAUSE AMONG WOMEN LIVING WITH HIV IN CANADA</td>
<td>Poster Session P-T1</td>
</tr>
<tr>
<td>941</td>
<td>COST-EFFECTIVENESS OF 2 METHODS TO TREAT CERVICAL DYSPLASIA IN HIV-POSITIVE WOMEN</td>
<td>Poster Session P-T1</td>
</tr>
<tr>
<td>944</td>
<td>DEPOT MEDROXYPROGESTERONE ACETATE INCREASES HIV-1 REPPLICATION IN MUCOSAL TISSUE</td>
<td>Poster Session P-T2</td>
</tr>
<tr>
<td>945</td>
<td>ZIM-CHIC: IMPACT OF CONTRACEPTIVE INITIATION ON IMMUNE CELLS IN THE CERVIX AND PBMCS</td>
<td>Poster Session P-T2</td>
</tr>
<tr>
<td>946</td>
<td>HIV GENITAL-TRACT SHEDDING WHILE ON PROGESTIN CONTRACEPTION</td>
<td>Poster Session P-T2</td>
</tr>
<tr>
<td>947</td>
<td>HORMONAL CONTRACEPTION DOES NOT AFFECT ART EFFECTIVENESS OR GENITAL HIV SHEDDING</td>
<td>Poster Session P-T2</td>
</tr>
<tr>
<td>949</td>
<td>MUCOSAL INFLAMMATION ABROGATES TENOFOVIR-GEL—MEDIATED PROTECTION FROM HIV INFECTION</td>
<td>Poster Session P-T3</td>
</tr>
<tr>
<td>950</td>
<td>IS SYNDROMIC DIAGNOSIS OF REPRODUCTIVE TRACT INFECTIONS ANTQUATED IN THE HIV ERA?</td>
<td>Poster Session P-T3</td>
</tr>
<tr>
<td>970</td>
<td>IDENTIFYING PREGNANT WOMEN FOR PREP USING ROUTINE ANTENATAL CARE INDICATORS IN KENYA</td>
<td>Poster Session P-U3</td>
</tr>
<tr>
<td>992</td>
<td>MISDIAGNOSED HIV INFECTION IN PREGNANT WOMEN INITIATING UNIVERSAL ART IN SOUTH AFRICA</td>
<td>Poster Session P-W1</td>
</tr>
</tbody>
</table>
MARKED MORTALITY AND RETENTION UNDER-REPORTING IN A LARGE HIV PROGRAM IN ZAMBIA (Poster Session P-W1)

COST-EFFECTIVENESS OF PREEXPOSURE PROPHYLAXIS ACROSS COUNTIES IN WESTERN KENYA (Poster Session P-X3)

THE POTENTIAL IMPACT AND COST-EFFECTIVENESS OF MULTIPURPOSE PREVENTION TECHNOLOGIES (Poster Session P-X3)

THURSDAY, FEBRUARY 16, 2017

BONE DENSITY AND TRABECULAR BONE SCORE IMPROVE FRACTURE PREDICTION IN HIV+ WOMEN (Oral Abstract Session O-12)

HIV-1 SEQUENCES FROM EARLY INFECTION PREDICT THE AGE OF THE INFECTION (Poster Session P-B3)

MARAVIROC INHIBITS HIV TARGET T-CELL TRAFFICKING INTO THE FEMALE GENITAL LUMEN (Themed Discussion TD-16)

INVESTIGATING THE EFFECT OF PH ON CERVICOVAGINAL MUCUS BARRIER PROPERTIES TO HIV (Themed Discussion TD-16)

MONOCYTE ACTIVATION IS ASSOCIATED WITH COGNITION IN SUPPRESSED HIV-INFECTED WOMEN (Poster Session P-F1)

COGNITIVE TRAJECTORIES OVER 4 YEARS AMONG HIV+ WOMEN WITH OPTIMAL VIRAL SUPPRESSION (Poster Session P-F3)

COGNITIVE COMPLAINTS AND DEVELOPMENT OF FALLS AMONG HIV+ AND HIV- WOMEN (Poster Session P-F3)

TDF TO PREVENT PERINATAL HEPATITIS B VIRUS TRANSMISSION: A RANDOMIZED TRIAL (ITAP) (Poster Session P-L7)

A RANDOMIZED TRIAL OF VITAMIN D3 (3000 VERSUS 1000 IU) IN HIV+ POSTMENOPAUSAL WOMEN (Poster Session P-O8)

PREVALENCE AND RISK FACTORS OF RENAL INJURY IN OPTION B+ DURING THE FIRST 6 MONTHS (Poster Session P-O9)

FOOD INSECURITY IS ASSOCIATED WITH POOR DIABETES CONTROL IN THE WIHS (Poster Session P-O11)

RALTIGRAVIR SWITCH AND BIOMARKERS OF LIVER STEATOSIS AND METABOLIC SYNDROME IN WOMEN (Poster Session P-O12)

WOMEN GAIN MORE WEIGHT THAN MEN FOLLOWING INITIATION OF ANTIRETROVIRAL THERAPY (Poster Session P-P012)

DOSING FOR TWO: PLACENTAL TRANSFER OF DARUNAVIR AND SIMULATION OF FETAL EXPOSURE (Poster Session P-Q1)

SUBSTANTIALLY LOWER RILPIVIRINE PLASMA CONCENTRATIONS DURING PREGNANCY (Poster Session P-Q1)

ELVITEGRAVIR/COBICISTAT PHARMACOKINETICS IN PREGNANCY AND POSTPARTUM (Poster Session P-Q1)

PROTEASE-INHIBITOR–BASED CART IS ASSOCIATED WITH HIGH ESTRADIOL LEVELS IN PREGNANCY (Poster Session P-Q1)

SUBSEQUENT PREGNANCY OUTCOMES IN WOMEN DURING FOLLOW-UP IN PROMISE 1077HS (Poster Session P-Q3)

HIV AND RISK OF POSTPARTUM INFECTION, COMPLICATIONS, AND MORTALITY IN RURAL UGANDA (Poster Session P-Q3)
774 CMV VIREMIA IN HIV-POSITIVE AND -NEGATIVE PREGNANT WOMEN IN BOTSWANA (Poster Session P-Q3)

775 PREGNANCIES IN WOMEN WHO ACQUIRED HIV PERINATALLY (Poster Session P-Q3)

776 ANTENATAL ANTIRETROVIRAL THERAPY AND ADVERSE BIRTH OUTCOMES: THE PROMISE TRIAL (Poster Session P-Q3)

778 DO HIV+ WOMEN ON PROTEASE INHIBITORS DELIVER PRETERM? FINDINGS FROM A UK STUDY (Poster Session P-Q3)

779 TDF/FTC IN PREGNANCY SHOWS NO INCREASE IN ADVERSE INFANT BIRTH OUTCOMES IN US COHORTS (Poster Session P-Q3)

836 LOCAL SOCIAL NETWORKS PREDICT RETENTION & SUPPRESSION IN YOUNG WOMEN IN SEARCH TRIAL (Themed Discussion TD-12)

857 VALIDATION OF A RISK SCORE FOR HIV ACQUISITION IN YOUNG AFRICAN WOMEN WITH FACTS 001 (Poster Session P-S2)

921 HIV STIGMA, DEPRESSION, ADHERENCE, AND VIRAL LOAD AMONG HIV+ AFRICAN-AMERICAN WOMEN (Poster Session P-S10)

924 SEXUAL ORIENTATION DIFFERENCES IN HEALTH AND WELLBEING AMONG WOMEN WITH HIV IN CANADA (Poster Session P-S10)

925 HEALTH OUTCOMES ASSOCIATED WITH GENDER-BASED VIOLENCE AMONG WOMEN WITH HIV IN CANADA (Poster Session P-S10)

927 THE HEALTH IMPACT OF SEXUAL VIOLENCE AMONG WOMEN IN A PLATINUM MINING BELT (Poster Session P-S10)

928 ASSOCIATION OF SEX AND RACE WITH HIV-/NON-HIV–RELATED DEATH IN TREATED HIV INFECTION (Poster Session P-S11)

933 LONGITUDINAL VIRAL TRAJECTORY AMONG WOMEN IN THE WOMEN’S INTERAGENCY HIV STUDY (Poster Session P-S11)

944 DEPOT MEDROXYPROGESTERONE ACETATE INCREASES HIV-1 REPLICATION IN MUCOSAL TISSUE (Themed Discussion TD-13)

945 ZIM-CHIC: IMPACT OF CONTRACEPTIVE INITIATION ON IMMUNE CELLS IN THE CERVIX AND PBMCS (Themed Discussion TD-13)

946 HIV GENITAL-TRACT SHEDDING WHILE ON PROGESTIN CONTRACEPTION (Themed Discussion TD-13)

947 HORMONAL CONTRACEPTION DOES NOT AFFECT ART EFFECTIVENESS OR GENITAL HIV SHEDDING (Themed Discussion TD-13)

951 DOES THE E138A MUTATION IN ASPIRE SEROCONVERTERS AFFECT SUSCEPTIBILITY TO DAPIVIRINE? (Poster Session P-T4)

952 NNRTI-CONTAINING ART IS EFFECTIVE FOR DAPIVIRINE RING BREAKTHROUGH HIV-1 INFECTION (Poster Session P-T4)

1025 HIV TRANSMISSION IN GENERALIZED, CONCENTRATED, AND MIXED EPIDEMICS IN WESTERN KENYA (Poster Session P-X1)
Aamer, Hadega 304
Aaron, Justin 546
Aaron, Kristal 867
Abbaasa, Andrew Max. 976
Abacassamo, Fatima 110
Abba, Chike O. 230
Abas, Mahsa 418
Abbate, Isabella 466
Abdel Mohsen, Mohamed 284, 314
Abdo, Mona 665, 666
Abdool Karim, Quarraisha 879, 949
Abdool Karim, Salim 949
Abewe, Hosiana 307
Abou-Samra, Abdul-Badi 574
Aboud, Michael 44LB, 664
Abouzid, Omar 1035
Abou-Raddad, Laith J. 1027
Abubakar, Ibrahim 736
Abuna, Felix 1032
Achut, Victoria 914
Achilles, Sharon L. 945
Achterbergh, Roel CA 519
Achut, Victoria 914
Ackerman, Daniel 334
Ackers, Marta 882
Abras, Omar 110
Abrams, Elaine J. 24, 27, 767, 769, 771, 780, 814, 815, 837, 950, 992, 1023
Abdo-Raddad, Laith J. 1027
Abubakar, Ibrahim 736
Abuna, Felix 1032
Abutaima, Rana 416
Achlapong, Jullapong 584LB
Achra, Thomas 847
Achilles, Sharon L. 945
Achterbergh, Roel CA 519
Achut, Victoria 914
Ackerman, Daniel 334
Ackerman, Margaret 253
Akers, Marta 882
Acosta, Edward 755, 757, 806
Acquistapace, Alessandra 396
Adams-Huet, Beverley 677
Adamson, Blythe J. 1045
Adel, Malika 304
Ait Moha, Daoud 470
Aitken, Celia 185
Ajaykumar, Abhinav 590
Ajibola, Gbolanke 502, 789, 790
Akama, Eliud 762
Akanbi, Maxwell 369
Akapirat, Siriwat 291
Akkari, Sadeer 952
Akgün, Kathleen 658
Aku, Ronald 1037
Akullian, Adam N. 1037
Al-Kindi, Sadeer 674
Alary, Michel 1047
Albert, Brian E. 939
Alcaide, Maria L. 770
Alđađič-Echevarría, Teresa 530, 534
Alford, Ronald 409a
Alford, Ricardo 446
Allana, Salim 77
Alland, David 76LB
Allen, Susan 200, 202
Allender, Christopher 715LB
Allic, Tiziano 379
Almannanza, Horacio 844
Almirol, Ellen 969
Almonte, Alexi 968
Alon, Leigh 969
Altet, Maria Nieves Altet 734
Althoff, Keri N. 130, 596, 619, 662, 840
Altice, Frederick 1044
Alvarado, Luisa 1055LB
Alvarado, Maria 1056LB
Alvarez, Angeles 609
Alvarez, Beatriz 572
Alverno, Carmelita 806
Alvano, Mary Grace 993, 1009, 1017
Amanyire, Gideon 1005
Amason, Maria Enrica 379
Ambegaokar, Suren A. 375
Ambinder, Richard 318
Ambrozak, David R. 61, 165
Amedee, Angela M. 217
Amendola, Alessandra 466
Amiel, Corinne 349, 520
Amor, María Emilia 203, 354, 366, 466
Anand, Santhanam 559, 883
Anastos, Kathryn 132, 237LB, 350, 514, 636LB, 646, 928, 933
Anes, Bev M. 397, 401
Ancona, Giuseppe 215
Ancuta, Petronela 204
Andaluz, Adriana 898
Andany, Nisha 940
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andersen, Nina</td>
<td>490</td>
</tr>
<tr>
<td>Andersen, Ove</td>
<td>235</td>
</tr>
<tr>
<td>Anderson, Albert</td>
<td>353</td>
</tr>
<tr>
<td>Anderson, Christy M.</td>
<td>134</td>
</tr>
<tr>
<td>Anderson, Elizabeth Marion</td>
<td>297, 303</td>
</tr>
<tr>
<td>Anderson, Hanne</td>
<td>1057LB</td>
</tr>
<tr>
<td>Anderson, Jason</td>
<td>157</td>
</tr>
<tr>
<td>Anderson, Jenny L.</td>
<td>288, 311</td>
</tr>
<tr>
<td>Anderson, Matt</td>
<td>412</td>
</tr>
<tr>
<td>Anderson, Meegan R.</td>
<td>15</td>
</tr>
<tr>
<td>Anderson, Peter L.</td>
<td>404, 405, 419, 422LB, 976, 977</td>
</tr>
<tr>
<td>Andersen, Elizabeth Marion</td>
<td>297, 303</td>
</tr>
<tr>
<td>Andersson, Lars-Magnus</td>
<td>431</td>
</tr>
<tr>
<td>Andrade, Adriana</td>
<td>669</td>
</tr>
<tr>
<td>Andrasik, Michele</td>
<td>897</td>
</tr>
<tr>
<td>Andreni, Massimo</td>
<td>564</td>
</tr>
<tr>
<td>Andrews, Jenny L.</td>
<td>288, 311</td>
</tr>
<tr>
<td>Andrews, Jason R.</td>
<td>725</td>
</tr>
<tr>
<td>Andrianakis, Ioannis</td>
<td>1048</td>
</tr>
<tr>
<td>Andrieux-Meyer, Isabelle</td>
<td>523</td>
</tr>
<tr>
<td>Andrinopoulou, Elrozy</td>
<td>451LB</td>
</tr>
<tr>
<td>Ang'awa, David Odhiambo</td>
<td>861</td>
</tr>
<tr>
<td>Angelico, Mario</td>
<td>565</td>
</tr>
<tr>
<td>Angelovich, Thomas A.</td>
<td>611</td>
</tr>
<tr>
<td>Angerstein, Aaron</td>
<td>310</td>
</tr>
<tr>
<td>Anglade, Benedict</td>
<td>835</td>
</tr>
<tr>
<td>Anglarett, Xavier</td>
<td>78, 476</td>
</tr>
<tr>
<td>Ankrom, Wendy</td>
<td>430</td>
</tr>
<tr>
<td>Ansari, M. Azim</td>
<td>272</td>
</tr>
<tr>
<td>Antinori, Andrea</td>
<td>354, 366</td>
</tr>
<tr>
<td>Anugulruengkitt, Suwaporun</td>
<td>759</td>
</tr>
<tr>
<td>Aouizerat, Bradley E.</td>
<td>237LB</td>
</tr>
<tr>
<td>Aplenc, Richard</td>
<td>384</td>
</tr>
<tr>
<td>Apollo, Tisiti</td>
<td>1036</td>
</tr>
<tr>
<td>Appelmans, Eline</td>
<td>380</td>
</tr>
<tr>
<td>Aragaw, Dossegaw</td>
<td>713</td>
</tr>
<tr>
<td>Araujo, Mariella Ladeira</td>
<td>388</td>
</tr>
<tr>
<td>Archary, Deseree</td>
<td>949</td>
</tr>
<tr>
<td>Archary, Moherendran</td>
<td>817LB</td>
</tr>
<tr>
<td>Archin, Nancie</td>
<td>123</td>
</tr>
<tr>
<td>Arduino, Roberto</td>
<td>422LB</td>
</tr>
<tr>
<td>Arends, Joop</td>
<td>136, 137LB, 587</td>
</tr>
<tr>
<td>Arendt, Marina</td>
<td>633</td>
</tr>
<tr>
<td>Arezes, Elisa</td>
<td>821</td>
</tr>
<tr>
<td>Ariansen, JL</td>
<td>810</td>
</tr>
<tr>
<td>Arias, Ana</td>
<td>562</td>
</tr>
<tr>
<td>Arkangelo, Golda Caesar</td>
<td>914</td>
</tr>
<tr>
<td>Armon, Carl</td>
<td>32, 663, 678, 864</td>
</tr>
<tr>
<td>Armstrong, Abigail</td>
<td>207, 208</td>
</tr>
<tr>
<td>Armstrong, Heather L.</td>
<td>966</td>
</tr>
<tr>
<td>Arnedo, Mireia</td>
<td>614</td>
</tr>
<tr>
<td>Arpadi, Stephen M.</td>
<td>819</td>
</tr>
<tr>
<td>Arribas, Jose R.</td>
<td>148, 400, 453, 652</td>
</tr>
<tr>
<td>Arrington-Sanders, Renata</td>
<td>968</td>
</tr>
<tr>
<td>Arrive, Elise</td>
<td>821</td>
</tr>
<tr>
<td>Arthos, James</td>
<td>64LB</td>
</tr>
<tr>
<td>Aschheim, Joshua</td>
<td>132</td>
</tr>
<tr>
<td>Asher Prince, Heather M.</td>
<td>406</td>
</tr>
<tr>
<td>Asliimwe, Stephen</td>
<td>934</td>
</tr>
<tr>
<td>Assoumou, Lambert</td>
<td>441, 703</td>
</tr>
<tr>
<td>Atacca, Sila</td>
<td>177</td>
</tr>
<tr>
<td>Atkins, Elizabeth</td>
<td>248</td>
</tr>
<tr>
<td>Atfield, Marcus</td>
<td>176</td>
</tr>
<tr>
<td>Attia, Eni Farouk</td>
<td>660</td>
</tr>
<tr>
<td>Atwine, Martha</td>
<td>1001</td>
</tr>
<tr>
<td>Aubert, Vincent</td>
<td>191</td>
</tr>
<tr>
<td>Auer, Jim</td>
<td>236</td>
</tr>
<tr>
<td>Augusto, Orvalho</td>
<td>730, 766, 818</td>
</tr>
<tr>
<td>Auld, Sara</td>
<td>77</td>
</tr>
<tr>
<td>Auletta-Young, Chloë</td>
<td>789, 790, 885</td>
</tr>
<tr>
<td>Aupribul, Linda</td>
<td>772, 820</td>
</tr>
<tr>
<td>Austin, Gregory</td>
<td>211</td>
</tr>
<tr>
<td>Austin, Michele</td>
<td>86LB</td>
</tr>
<tr>
<td>Autran, Brigitte</td>
<td>290</td>
</tr>
<tr>
<td>Avalos, Ana</td>
<td>988</td>
</tr>
<tr>
<td>Avelino-Silva, Vivian lida</td>
<td>948</td>
</tr>
<tr>
<td>Avettand-Fenoel, Veronique</td>
<td>812</td>
</tr>
<tr>
<td>Avi, Radio</td>
<td>461</td>
</tr>
<tr>
<td>Avihingsanong, Anchalee</td>
<td>443, 698</td>
</tr>
<tr>
<td>Avila-Bios, Santiago</td>
<td>182, 480</td>
</tr>
<tr>
<td>Awad, Susanne</td>
<td>1027</td>
</tr>
<tr>
<td>Aweeka, Francesca</td>
<td>414</td>
</tr>
<tr>
<td>Axelsson, Markus</td>
<td>383</td>
</tr>
<tr>
<td>Ayat, Feriel</td>
<td>821</td>
</tr>
<tr>
<td>Ayers, Colby</td>
<td>468</td>
</tr>
<tr>
<td>Ayleko, James</td>
<td>638, 836, 858</td>
</tr>
<tr>
<td>Ayles, Helen</td>
<td>711, 834, 959, 1010, 1011</td>
</tr>
<tr>
<td>Aynalem, Getahun</td>
<td>1007, 1019</td>
</tr>
<tr>
<td>Ayobua, Ahihdo</td>
<td>218</td>
</tr>
<tr>
<td>Azama, Martin S.</td>
<td>740</td>
</tr>
<tr>
<td>Aznar, Esther</td>
<td>441</td>
</tr>
<tr>
<td>Azzo, Caitlin</td>
<td>745</td>
</tr>
<tr>
<td>Azzoni, Livio</td>
<td>326</td>
</tr>
<tr>
<td>B--</td>
<td></td>
</tr>
<tr>
<td>Ba, Selly</td>
<td>440, 508</td>
</tr>
<tr>
<td>Babigumira, Joseph</td>
<td>494</td>
</tr>
<tr>
<td>Babudieri, Sergio</td>
<td>565</td>
</tr>
<tr>
<td>Bacchetti, Peter</td>
<td>170, 281, 288, 632, 978</td>
</tr>
<tr>
<td>Bachanask, Pamela L.</td>
<td>1009, 1019</td>
</tr>
<tr>
<td>Bachmann, Nadine</td>
<td>191</td>
</tr>
<tr>
<td>Badje, Anani D.</td>
<td>78</td>
</tr>
<tr>
<td>Badley, Andrew</td>
<td>273, 319</td>
</tr>
<tr>
<td>Baernighausen, Till</td>
<td>475, 639, 916, 960, 983, 991, 994</td>
</tr>
<tr>
<td>Baeten, Jared</td>
<td>85, 88, 920, 934, 935, 947, 951, 952, 967, 1003</td>
</tr>
<tr>
<td>Bagagla, Rachel</td>
<td>1060</td>
</tr>
<tr>
<td>Bagiire, Daniel</td>
<td>915</td>
</tr>
<tr>
<td>Bagny, Aklesso</td>
<td>607</td>
</tr>
<tr>
<td>Bahemana, Emmanuel</td>
<td>355</td>
</tr>
<tr>
<td>Bai, Francesca</td>
<td>357</td>
</tr>
<tr>
<td>Bailey, Heather</td>
<td>778</td>
</tr>
<tr>
<td>Bailey, Justin R.</td>
<td>141</td>
</tr>
<tr>
<td>Bailey, S.L.</td>
<td>711</td>
</tr>
<tr>
<td>Bailin, Samuel</td>
<td>229</td>
</tr>
<tr>
<td>Bailon, Lucia</td>
<td>400</td>
</tr>
<tr>
<td>Bailor, Robert</td>
<td>415</td>
</tr>
<tr>
<td>Barrey Merz, C. Noel</td>
<td>589</td>
</tr>
<tr>
<td>Basley, Kathy</td>
<td>491</td>
</tr>
<tr>
<td>Baryegunghi, Omolara</td>
<td>266</td>
</tr>
<tr>
<td>Baker, David</td>
<td>670</td>
</tr>
<tr>
<td>Baker, Jason</td>
<td>319, 608, 623</td>
</tr>
<tr>
<td>Balachandra, Shirish</td>
<td>743</td>
</tr>
<tr>
<td>Balagopai, Ashwin</td>
<td>648</td>
</tr>
<tr>
<td>Balakrishnan, Mini</td>
<td>329, 434</td>
</tr>
<tr>
<td>Baidelli, Sara</td>
<td>411</td>
</tr>
<tr>
<td>Bale, Michael J.</td>
<td>294</td>
</tr>
<tr>
<td>Baiestra, Pietro</td>
<td>354</td>
</tr>
<tr>
<td>Balkan, Suna</td>
<td>523</td>
</tr>
<tr>
<td>Balkus, Jennifer</td>
<td>85, 88, 935, 952</td>
</tr>
<tr>
<td>Ballana, Ester</td>
<td>259</td>
</tr>
<tr>
<td>Ballif, Marie</td>
<td>714</td>
</tr>
<tr>
<td>Balogun, Kayode</td>
<td>756</td>
</tr>
<tr>
<td>Balotta, Claudia</td>
<td>227, 303</td>
</tr>
<tr>
<td>Baloyi, Kabelo</td>
<td>958</td>
</tr>
<tr>
<td>Balzer, Laura B.</td>
<td>36, 726, 832</td>
</tr>
<tr>
<td>Banasiwiczik, Mary</td>
<td>867</td>
</tr>
<tr>
<td>Banda, Karen M.</td>
<td>35</td>
</tr>
<tr>
<td>Banda, Richard</td>
<td>919</td>
</tr>
<tr>
<td>Author</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Bandason, Tsitsi</td>
<td>841LB</td>
</tr>
<tr>
<td>Bandeen-Roche, Karen</td>
<td>133</td>
</tr>
<tr>
<td>Bandera, Alessandra</td>
<td>222, 306</td>
</tr>
<tr>
<td>Bandermann, Silke</td>
<td>716LB</td>
</tr>
<tr>
<td>Banga, Riddhima</td>
<td>289</td>
</tr>
<tr>
<td>Bangham, Charles R.M.</td>
<td>109</td>
</tr>
<tr>
<td>Bangirana, Paul</td>
<td>579</td>
</tr>
<tr>
<td>Bangsberg, David</td>
<td>675, 773</td>
</tr>
<tr>
<td>Banta-Green, Caleb</td>
<td>873, 967</td>
</tr>
<tr>
<td>Bao, Jing</td>
<td>717</td>
</tr>
<tr>
<td>Bapatli, William</td>
<td>993, 1017</td>
</tr>
<tr>
<td>Baral, Stefan</td>
<td>918, 997, 1047</td>
</tr>
<tr>
<td>Barbasilisca, Silvia</td>
<td>565</td>
</tr>
<tr>
<td>Barber, Tristan</td>
<td>382</td>
</tr>
<tr>
<td>Barber, Xavier</td>
<td>647</td>
</tr>
<tr>
<td>Barblu, Lucie</td>
<td>264</td>
</tr>
<tr>
<td>Bardhi, Ariala</td>
<td>328</td>
</tr>
<tr>
<td>Bares, Sara H.</td>
<td>408, 699, 963</td>
</tr>
<tr>
<td>Barlow-Mosha, Linda</td>
<td>826</td>
</tr>
<tr>
<td>Barnabas, Ruanne V.</td>
<td>107, 1032</td>
</tr>
<tr>
<td>Barnaby, Devin</td>
<td>577</td>
</tr>
<tr>
<td>Barnard, Richard</td>
<td>311, 337</td>
</tr>
<tr>
<td>Barnes, Grace</td>
<td>657, 707</td>
</tr>
<tr>
<td>Barnhart, Scott</td>
<td>111</td>
</tr>
<tr>
<td>Barnwell, Garret</td>
<td>927</td>
</tr>
<tr>
<td>Baro, Elande</td>
<td>372</td>
</tr>
<tr>
<td>Barocas, Joshua A.</td>
<td>557</td>
</tr>
<tr>
<td>Baron, Deborah</td>
<td>2</td>
</tr>
<tr>
<td>Barr, Emily</td>
<td>779</td>
</tr>
<tr>
<td>Barreiro, Pablo</td>
<td>578</td>
</tr>
<tr>
<td>Barrera-Arellano, Carlos</td>
<td>480</td>
</tr>
<tr>
<td>Barnos, Lisa C.</td>
<td>1033</td>
</tr>
<tr>
<td>Barnos, Rolando</td>
<td>875, 1042</td>
</tr>
<tr>
<td>Barth, Roos</td>
<td>656</td>
</tr>
<tr>
<td>Bartlett, Jeffrey S.</td>
<td>322</td>
</tr>
<tr>
<td>Barton, Kinston</td>
<td>293, 305</td>
</tr>
<tr>
<td>Barton, Simon</td>
<td>447</td>
</tr>
<tr>
<td>Basch, Peter</td>
<td>517, 543, 545</td>
</tr>
<tr>
<td>Bassett, Ingrid Valerie</td>
<td>773</td>
</tr>
<tr>
<td>Batavia, Ashita S.</td>
<td>471</td>
</tr>
<tr>
<td>Bateganya, Moses</td>
<td>741, 743</td>
</tr>
<tr>
<td>Bates, Jonathan</td>
<td>930</td>
</tr>
<tr>
<td>Bathulapalli, Harini</td>
<td>930</td>
</tr>
<tr>
<td>Batra, Jag</td>
<td>424, 425</td>
</tr>
<tr>
<td>Battalora, Linda</td>
<td>663, 678</td>
</tr>
<tr>
<td>Bauer, Brent</td>
<td>669</td>
</tr>
<tr>
<td>Bauer, Greta R.</td>
<td>926</td>
</tr>
<tr>
<td>Bauer, Wolfgang</td>
<td>716LB</td>
</tr>
<tr>
<td>Bauleni, Andy</td>
<td>783</td>
</tr>
<tr>
<td>Baumgarten, Axel</td>
<td>551, 576</td>
</tr>
<tr>
<td>Bavaro, Mary F.</td>
<td>358</td>
</tr>
<tr>
<td>Baxter, Amy E.</td>
<td>264</td>
</tr>
<tr>
<td>Bayon, Carmen</td>
<td>400</td>
</tr>
<tr>
<td>Bbosa, Nicholas</td>
<td>193</td>
</tr>
<tr>
<td>Bearden, David</td>
<td>827, 828</td>
</tr>
<tr>
<td>Beauchamp, Geetha</td>
<td>1045</td>
</tr>
<tr>
<td>Bebawy, Sally S.</td>
<td>644, 912</td>
</tr>
<tr>
<td>Bebelli, Lisa</td>
<td>773</td>
</tr>
<tr>
<td>Beck, Ingrid A.</td>
<td>490, 494</td>
</tr>
<tr>
<td>Beck-Wirth, Genevieve</td>
<td>495</td>
</tr>
<tr>
<td>Becker, James T.</td>
<td>356</td>
</tr>
<tr>
<td>Beckman, Lucas</td>
<td>308</td>
</tr>
<tr>
<td>Beckwith, Curt G.</td>
<td>1044</td>
</tr>
<tr>
<td>Becofsky, Katie</td>
<td>694</td>
</tr>
<tr>
<td>Bedimo, Roger</td>
<td>468, 606, 677</td>
</tr>
<tr>
<td>Beg, Subul</td>
<td>318</td>
</tr>
<tr>
<td>Behel, Stephanie</td>
<td>1017</td>
</tr>
<tr>
<td>Behrends, Czarina N.</td>
<td>547</td>
</tr>
</tbody>
</table>

**Program and Agenda**

- Behrens, Georg 703
- Beiser, Marguerite 557
- Bekele, Alemayehu 713
- Bekker, Adrie 758
- Bekker, Linda-Gail 1036, 421LB, 859
- Belaunzaran-Zamudio, Pablo Francisco 225
- Bialiakova-Bethell, Nadejda 307
- Belkaid, Yasmin 214
- Bell, Jennifer 297
- Bell, Teal 89
- Bellamy, Scarlett 384
- Bellerave, Pantxika 349
- Bellini, Giulia 531
- Bellón, José M. 533
- Bellos, Waldo 473
- Belmonte, Simone 445
- Belnap, David M. 21
- Beloukas, Apostolos 370, 549
- Belyea, Loni 692
- Ben-Farhat, Jihane 764, 792
- Benalycherif, Aïda 458
- Bendavid, Eran 494, 725, 1052, 1053
- Bender Ignacio, Rachel Ann. 446
- Benfield, Thomas 235, 314
- Bengtson, Angela 454
- Beniguel, Lydie 441
- Benitez, Laura 562, 572
- Benjapornpong, Khunthalee 125, 387
- Benki-Nugent, Sarah 796
- Benko, Erika 122, 233
- Benne, Clairese 321
- Bennett, Amy 846
- Bennett, David 842
- Bennett, Kara 502, 640
- Benoît, Anita 940
- Benson, Paul 41
- Benzekri, Noelle A. 642
- Berdasco, Maria 228
- Berenguer, Juan 530, 533, 534, 572
- Berg, Michael 583
- Berger, Florian 551, 567, 576
- Berkhout, Ben 286
- Berkley, Jay 117
- Berlacher, Kathryn 624
- Bermudez, Elkin Hernan 464
- Bernard, Nicole 274
- Bernardino, Jose L. 652, 676
- Bershehyn, Anna 1025, 1035, 1036, 1037
- Bertagnolio, Silvia 112
- Bertero, Luca 379
- Bertine, Mélanie 194, 290
- Bertisch, Barbara 596
- Bertoli, Ada 564
- Bertrand, Rachel 722, 835
- Besa, Stable 959
- Bessegghir, Amel 448, 603
- Best, Brooke 755, 810, 938
- Best, John 344
- Bessutti, Giulia 665
- Betsem, Edouard 190
- Betts, Michael R. 65, 267
- Beudeker, Boris J.B. 587
- Beura, Lalit 267
- Beyer, Nulida 1010, 1011
- Bezemmer, Daniela 1041
- Bhagani, Sanjay 9
- Bhagwat, Priya 695
- Bhardwaj, Nina 256
- Bharti, Ajay 74, 390
- Bhasi, Kavitha 427
<table>
<thead>
<tr>
<th>Author Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bhattacharya, Debika</td>
<td>9, 589</td>
</tr>
<tr>
<td>Bhattacharya, Jayanthan</td>
<td>245</td>
</tr>
<tr>
<td>Bhaumik, Siddhartha</td>
<td>1056LB</td>
</tr>
<tr>
<td>Biasin, Mara</td>
<td>222</td>
</tr>
<tr>
<td>Bibbono, Giulla</td>
<td>466</td>
</tr>
<tr>
<td>Bibollet-Ruche, Frederic</td>
<td>181LB</td>
</tr>
<tr>
<td>Bikcho, Vadim</td>
<td>452LB</td>
</tr>
<tr>
<td>Bidwell, Gabriella</td>
<td>82</td>
</tr>
<tr>
<td>Biello, Katie</td>
<td>971</td>
</tr>
<tr>
<td>Bienczak, Andrzej</td>
<td>808</td>
</tr>
<tr>
<td>Bieniasz, Paul</td>
<td>1, 160LB, 220</td>
</tr>
<tr>
<td>Bierman, Wouter</td>
<td>451LB, 620</td>
</tr>
<tr>
<td>Bila, Dulce</td>
<td>730, 766, 818</td>
</tr>
<tr>
<td>Bile, Ebi</td>
<td>93</td>
</tr>
<tr>
<td>Biliotti, Elisa</td>
<td>575</td>
</tr>
<tr>
<td>Billaud, Eric</td>
<td>135, 550</td>
</tr>
<tr>
<td>Billingsley, James M.</td>
<td>252, 62LB</td>
</tr>
<tr>
<td>Billioux, Veena Goud</td>
<td>996</td>
</tr>
<tr>
<td>Billotta, Maria Teresa</td>
<td>203</td>
</tr>
<tr>
<td>Binda, Francesca</td>
<td>579</td>
</tr>
<tr>
<td>Bini, Teresa</td>
<td>357</td>
</tr>
<tr>
<td>Binza, David</td>
<td>998</td>
</tr>
<tr>
<td>Birkett, Michelle</td>
<td>843</td>
</tr>
<tr>
<td>Birn, Rasmus</td>
<td>395</td>
</tr>
<tr>
<td>Birnbaum, Jeanette</td>
<td>900</td>
</tr>
<tr>
<td>Birungi, Josephine</td>
<td>462</td>
</tr>
<tr>
<td>Bisbal, Otilia</td>
<td>676</td>
</tr>
<tr>
<td>Bischoff, Charlotte</td>
<td>136, 137LB</td>
</tr>
<tr>
<td>Bischoff, Charlotte</td>
<td>136, 137LB</td>
</tr>
<tr>
<td>Bisset, Gregory</td>
<td>384, 710, 717</td>
</tr>
<tr>
<td>Bitchong, Raymond Aristide</td>
<td>637</td>
</tr>
<tr>
<td>Bitilinyu-Bangoh, Joseph</td>
<td>464</td>
</tr>
<tr>
<td>Bjorkman, Per</td>
<td>202</td>
</tr>
<tr>
<td>Blackburn, Justin</td>
<td>762</td>
</tr>
<tr>
<td>Blair, Elizabeth</td>
<td>444LB</td>
</tr>
<tr>
<td>Blanché, Stephane</td>
<td>775, 781, 811</td>
</tr>
<tr>
<td>Blanco, José L.</td>
<td>42</td>
</tr>
<tr>
<td>Blanks, José Ramón</td>
<td>676</td>
</tr>
<tr>
<td>Blanks, Joel</td>
<td>253</td>
</tr>
<tr>
<td>Blaser, Nello</td>
<td>596</td>
</tr>
<tr>
<td>Blaxhult, Anders</td>
<td>431</td>
</tr>
<tr>
<td>Blennow, Kaj</td>
<td>383, 389</td>
</tr>
<tr>
<td>Block, Lisa</td>
<td>1008</td>
</tr>
<tr>
<td>Block, Willem</td>
<td>470</td>
</tr>
<tr>
<td>Bolotine, Charlotte</td>
<td>825, 830</td>
</tr>
<tr>
<td>Bloom, Jesse</td>
<td>243</td>
</tr>
<tr>
<td>Blossey, Sara J.</td>
<td>873</td>
</tr>
<tr>
<td>Blower, Sally</td>
<td>489, 850</td>
</tr>
<tr>
<td>Blumenthal, Liz</td>
<td>811LB</td>
</tr>
<tr>
<td>Bobat, Raziya</td>
<td>817LB</td>
</tr>
<tr>
<td>Bochicchio, Sara</td>
<td>396</td>
</tr>
<tr>
<td>Bock, Peter</td>
<td>1011</td>
</tr>
<tr>
<td>Bocour, Angelica</td>
<td>903</td>
</tr>
<tr>
<td>Body, Barbara</td>
<td>1054</td>
</tr>
<tr>
<td>Boehme, Catharina C.</td>
<td>52, 76LB</td>
</tr>
<tr>
<td>Boender, T. Sonia</td>
<td>467</td>
</tr>
<tr>
<td>Boerekamps, Anne</td>
<td>136, 137LB</td>
</tr>
<tr>
<td>Boesch, Austin</td>
<td>253</td>
</tr>
<tr>
<td>Boesecke, Christoph</td>
<td>551, 567, 576</td>
</tr>
<tr>
<td>Boiffin, Marta</td>
<td>39, 382, 416,</td>
</tr>
<tr>
<td>Boil, Carmen</td>
<td>644</td>
</tr>
<tr>
<td>Bohlius, Julia</td>
<td>602</td>
</tr>
<tr>
<td>Boily, Marie-Claude</td>
<td>1047</td>
</tr>
<tr>
<td>Boivin, Michael Joseph</td>
<td>826</td>
</tr>
<tr>
<td>Bokoch, Kevin</td>
<td>955</td>
</tr>
<tr>
<td>Bolivar, Hector</td>
<td>350, 361</td>
</tr>
<tr>
<td>Bollen, Pauline</td>
<td>429</td>
</tr>
<tr>
<td>Bolo, Alex</td>
<td>914</td>
</tr>
<tr>
<td>Bolon, Dan</td>
<td>246</td>
</tr>
<tr>
<td>Bolton Moore, Carolyn</td>
<td>995, 1000, 1004</td>
</tr>
<tr>
<td>Bolitz, Valerie F.</td>
<td>120</td>
</tr>
<tr>
<td>Bonar, Michá</td>
<td>154</td>
</tr>
<tr>
<td>Bonfanti, Paolo</td>
<td>542LB</td>
</tr>
<tr>
<td>Bongomin, Pido</td>
<td>637</td>
</tr>
<tr>
<td>Böni, Jürg</td>
<td>191, 521</td>
</tr>
<tr>
<td>Bonnet, Fabrice</td>
<td>131, 630</td>
</tr>
<tr>
<td>Bonnet, Marion</td>
<td>263</td>
</tr>
<tr>
<td>Bonora, Stefano</td>
<td>360, 379, 565</td>
</tr>
<tr>
<td>Boojamra, Constantine</td>
<td>436</td>
</tr>
<tr>
<td>Roen, Denali</td>
<td>516</td>
</tr>
<tr>
<td>Boonstra, Andre</td>
<td>587</td>
</tr>
<tr>
<td>Boonsuk, Sarawut</td>
<td>793</td>
</tr>
<tr>
<td>Bot, Jacob</td>
<td>960</td>
</tr>
<tr>
<td>Bordoni, Veronica</td>
<td>203</td>
</tr>
<tr>
<td>Borges, Álvaro H.</td>
<td>474</td>
</tr>
<tr>
<td>Borthi, Lidia</td>
<td>357</td>
</tr>
<tr>
<td>Boritz, Eli</td>
<td>61</td>
</tr>
<tr>
<td>Borjas Howard, Jaime</td>
<td>620</td>
</tr>
<tr>
<td>Borkowsky, William</td>
<td>800</td>
</tr>
<tr>
<td>Borre, Ethan Daniel</td>
<td>476, 1043</td>
</tr>
<tr>
<td>Borrow, Persephone</td>
<td>181LB</td>
</tr>
<tr>
<td>Bosch, Marjolein</td>
<td>610</td>
</tr>
<tr>
<td>Bosch, Ronald</td>
<td>277, 279, 280, 325, 343, 803, 840</td>
</tr>
<tr>
<td>Bose, Meera</td>
<td>299LB</td>
</tr>
<tr>
<td>Bosk, Carol</td>
<td>1019</td>
</tr>
<tr>
<td>Bosinger, Steven E.</td>
<td>252</td>
</tr>
<tr>
<td>Bosman, Robus</td>
<td>320</td>
</tr>
<tr>
<td>Botana, Laura</td>
<td>752</td>
</tr>
<tr>
<td>Boucher, Charles</td>
<td>137LB, 451LB</td>
</tr>
<tr>
<td>Boucher, Marc</td>
<td>785</td>
</tr>
<tr>
<td>Boudreau, Matthew</td>
<td>694</td>
</tr>
<tr>
<td>Bouillé, Andrew</td>
<td>727, 769, 990</td>
</tr>
<tr>
<td>Boulougourou, Afroditi</td>
<td>221, 238</td>
</tr>
<tr>
<td>Boullavre, David</td>
<td>368, 742, 744</td>
</tr>
<tr>
<td>Boum, Yap</td>
<td>675, 773</td>
</tr>
<tr>
<td>Bowman, Josephine M.</td>
<td>73</td>
</tr>
<tr>
<td>Bowring, Mary Grace</td>
<td>689</td>
</tr>
<tr>
<td>Boyd, Kathryn Fortunate</td>
<td>345, 743</td>
</tr>
<tr>
<td>Bozzi, Giorgio</td>
<td>227</td>
</tr>
<tr>
<td>Braccini, Margherita</td>
<td>418</td>
</tr>
<tr>
<td>Bradley, Heather</td>
<td>737, 907, 1012</td>
</tr>
<tr>
<td>Bradley-Stewart, Amanda</td>
<td>185</td>
</tr>
<tr>
<td>Brady, Jennifer J.</td>
<td>679</td>
</tr>
<tr>
<td>Brady, Kathleen</td>
<td>479, 911</td>
</tr>
<tr>
<td>Brathwaite, Scott</td>
<td>1049LB</td>
</tr>
<tr>
<td>Brander, Christian</td>
<td>119LB, 228, 271, 541</td>
</tr>
<tr>
<td>Brandt, Peter</td>
<td>380</td>
</tr>
<tr>
<td>Brandt, Cynthia A.</td>
<td>930</td>
</tr>
<tr>
<td>Brandt, Mary-Grace</td>
<td>187</td>
</tr>
<tr>
<td>Branger, Judith</td>
<td>1041</td>
</tr>
<tr>
<td>Brar, Savvy</td>
<td>859</td>
</tr>
<tr>
<td>Brassard, Nathalie</td>
<td>264</td>
</tr>
<tr>
<td>Braun, Dominique Laurent</td>
<td>327, 521</td>
</tr>
<tr>
<td>Braunstein, Sarah</td>
<td>1013</td>
</tr>
<tr>
<td>Breen, Elizabeth</td>
<td>593</td>
</tr>
<tr>
<td>Brehm, Jessica</td>
<td>123</td>
</tr>
<tr>
<td>Breidinger, Sheila</td>
<td>493</td>
</tr>
<tr>
<td>Brenchley, Jason</td>
<td>214</td>
</tr>
<tr>
<td>Brennan, Alanah</td>
<td>1050</td>
</tr>
<tr>
<td>Brenner, Bluma</td>
<td>42</td>
</tr>
<tr>
<td>Brew, Bruce</td>
<td>351, 398</td>
</tr>
<tr>
<td>Briand, Coralie</td>
<td>812</td>
</tr>
<tr>
<td>Bridgford, Bob F.</td>
<td>903</td>
</tr>
<tr>
<td>Brieva, Teresa</td>
<td>573</td>
</tr>
<tr>
<td>Brinkley-Rubinstein, Lauren</td>
<td>912, 1044</td>
</tr>
<tr>
<td>Brinkman, Kees</td>
<td>136, 470</td>
</tr>
<tr>
<td>Brinson, Cynthia</td>
<td>442, 44LB</td>
</tr>
<tr>
<td>Brittain, Elaine L.</td>
<td>621</td>
</tr>
<tr>
<td>Brittain, Kirsty</td>
<td>24, 771, 992</td>
</tr>
</tbody>
</table>
Britto, Paula 772
Brizgys, Gediminas 434
Brockmeyer, Norbert H. 633
Brodt, H.-R. 738
Broekhuis, Jordan 963
Bronson, Heather W. 962
Brook, Jenny 592
Brockmeyer, Ronald 879
Brooks, David 254
Brooks, John T. 377, 392, 393
Brooks, Kristina M. 409, 409a
Brophy, Jason 226
Brosens, Lodewijk 320
Brown, Alison E. 186, 736
Brown, Diane M. 317
Brown, Geri 677
Brown, Kevin W. 252
Brown, Lillian 836
Brown, Nakita 943
Brown, Rachel 260LB
Brown, Sheldon T. 606, 658
Brown, Todd 237, 239, 342, 356, 593, 624, 632, 645, 669, 683, 691, 695, 700, 981
Brown, Jr. Robert S. 568LB
Bruce, Veronica 516
Brugger, Peter 362
Brühl, Maria 879
Brumback, Babette 874
Brun-Vezinet, Francoise 290, 448
Brunet, Lawrence 483
Bruns, Anke 320
Burgener, Adam 231
Burger, David M. 429, 753, 754, 807, 808
Burgess, Emma Karolina. 857
Burchell, Ann N. 601
Burchett, Sandra 938
Burdo, Tricia H. 627, 635LB
Burke, Bryan P. 322
Burke, David 171LB
Burke, Stephen 273
Bürkle, Alexander 672
Burt, Richard 873
Busch, Fabian 580
Busch, Michael R. 279, 284, 511, 512, 876
Buseyne, Florence 190
Bush, Tim 597
Bushman, Frances 377, 392, 393
Bushman, Frederick 171LB
Bushman, Lane R. 404, 405, 419
Buskin, Susan 846, 851, 973
Busza, Joanna 841LB
Butler, Emily 577
Butler, Javed 574
Butt, Adeel Aijward. 127, 574, 626, 702
Butt, Zahid Ahmad. 524, 735
Buyze, Jozefien 81LB
Bwakura-Dangarembizi, Mutsvi 826
Bwana, Bosco Mwebesa. 773
Byron, Mary Margaret 255, 385, 612
Canaan, Matthew WA. 352LB
Cabantous, Jean Marie. 857, 858, 860, 861, 934, 947
Bukusi, Elizabeth A. 85, 762, 832, 858, 860, 861, 934, 947
Bull, Marta Eileen. 224
Bullen, Cynthia Korin. 315
Bunge, Katherine 86LB, 944
Bunupuradah, Tosak 425, 807, 820
Bursztyn, Katia 320
Bvumbwi, Babette 874
Butt, Adeel Ajwad. 127, 574, 626, 702
Butt, Zahid Ahmad. 524, 735
Buyze, Jozefien 81LB
Bwakura-Dangarembizi, Mutsvi 826
Bwana, Bosco Mwebesa. 773
Byron, Mary Margaret 255, 385, 612
Canaan, Matthew WA. 352LB
Cabantous, Jean Marie. 857, 858, 860, 861, 934, 947
Bukusi, Elizabeth A. 85, 762, 832, 858, 860, 861, 934, 947
Bull, Marta Eileen. 224
Bullen, Cynthia Korin. 315
Bunge, Katherine 86LB, 944
Bunupuradah, Tosak 425, 807, 820
Bursztyn, Katia 320
Bvumbwi, Babette 874
Butt, Adeel Ajwad. 127, 574, 626, 702
Butt, Zahid Ahmad. 524, 735
Buyze, Jozefien 81LB
—C—
Caan, Matthew WA. 352LB
Cababasay, Mae 757, 758
Caballero, Gemma 201
Caballo, Alfonso 676
Cabié, André 458
Cachay, Edward Rafael. 134
Cachomba, Yolanda 818
Cahn, Pedro 447, 451LB
Caj, Ruby 434
Cai, Suqin 140
Caiphus, Cynthia 729
Caire, Mireia 535
Calado, Rodrigo 388
Calcagno, Andrea 360, 379, 416
Caldwell, Judy 727
Cai, Ruby 434
Cai, Suqin 140
Caiphus, Cynthia 729
Caire, Mireia 535
Calado, Rodrigo 388
Calcagno, Andrea 360, 379, 416
Caldwell, Judy 727
Calle, Maria Luz. 212
Calnan, Marianne 708
Calvez, Vincent 43, 499
Calvo, Katya 977
Calvo-Pulido, Jorge 540
Camacho-Sopeño, Angela 573
Camacho-Gonzalez, Andres 839
Cambiano, Valentina 112, 1030
Cameron, Paul 288
Camlin, Carol S. 860
Campbell, Andrew 413
Campbell, Angela 77
Campbell, Ellsworth 189, 477, 877, 878
Campbell, Thomas 492, 648
Campins, Antoni 659
Camus, Gregory 560LB
Canaday, David 267
Canales Santos, Raissa 525
Canestri, Ana 75
Cannizzo, Oliva Stefania. 239, 579, 680
Cantor, Scott B. 591
Cao, Huyen 427, 443
Cap, Jacqueline 703
Capetti, Amedeo 410
Capitant, Catherine 91LB
Capobianchi, Maria Rosaria. 466
Capoferri, Adam 296, 318
Capparelli, Edmund 296
Capparelli, Edmund V. 755, 755, 760, 809, 810, 938
Cardona, Sylvain 262
Cardoso, Lena 557
Cardoso, Sandra Wagner. 457, 648
Cardoso, Sandra Wagner. 457, 648
CROI 2017 237
Duarte, Wellington 388
Dube, Michael 977
Dube, Queen 783
Dubrow, Robert 257, 600
Duenas Decamp, Maria Jose 246
Duerr, Ann 380, 446
Duerr, Ralf 881
Duisenberg-van Essenberg, Marjolijn 429
Dukhovnina, Elena 369
Dumchev, Kostyantyn 884
Dumond, Julie B. 406
Dunaway, Shelia 749, 750
Dunham, Richard M. 252
Dunne, Eileen F. 854, 855, 862
Dunville, Richard 833, 1033
Dupnik, Kathryn 471
Dupon, Michel 630
Durand, Christine 317, 318, 330LB, 689
Durfee, Joshua 528
Durham, Natasha 256
Durham, Phillip G. 420
Dutterte, Marine 732
Dutta, Sandeep 413
Easley, Kirk A. 684
Eaton, Ellen F. 454, 455
Eaton, Jeffrey 115, 1031
Ebner, Hanna 66, 67
Eckard, Allison Ross. 822
Eckhardt, Benjamin 554
Edagwa, Benson 439
Edelen, Arvid 340, 431
Eden, John-Sebastian 293
Edlefsen, Paul 1004
Egbyuie, Bon 763
Egger, Matthias 581, 596, 714
Eholie, Serge 78, 476
Eichner, Allyson 961
Eilers, Grant 171LB
Elliot, Emilie 432
Elliot, Jennifer 16
Ellis, Ronald J. 343, 353, 367, 377, 386, 392, 393
Ellis, Shanon 84
Ellis, Tyrone 923
Ellison, Lucas 405
Ellner, Jerrold 709, 76LB
Else, Laura 416, 418
Elul, Batya 110, 837
Emerman, Michael 19, 172
Emery, Ann 163
Emery, Sandy 765
Emury, Sean 473, 474
Emiliizzi, Arianna 445
Emperador, Devy 33
Emu, Brinda 257, 449LB, 72
Emusu, Donath 982, 985, 986
Engelbrecht, Susan 120
Engelman, Alan N. 157, 292
Engels, Eric A. 598, 600, 661
Engelthaler, David M. 715LB
Engen, Philip A. 240, 241
Ensight, Laura 210
Enstone, Joanne 1039
Epley, Fanny 780
Erikson, Jaran 431
Erlandson, Kristine 356, 665, 666, 700
Ernest, Oscar 950
Eron, Joseph J. 73, 198, 277, 279, 280, 298, 342, 442, 454, 465, 483, 619
Esbjörnsson, Joakim 37, 202
Escola, Gere 597
Escribà, Tuixent 614
Eshelman, Susan H. 492, 879, 955, 1002
Eshun-Wilson, Ingrid 995
Esmail, Hanif 739
Espinoza, Luis 874
Esplugues, Juan V. 609
Esposito, Vincenzo 585
Esser, Stefan 633
Essex, Max 25, 184, 484
Ete, Jose A. 259
Esteller, Manel 228
Estes, Jacob D. 70, 226, 251
Esteve, Anna 651
Estrill, Janne 596, 782
Estrada, Vicente 676
Evans, Rozenn 575
Ethridge, Steven 509
Eugen-Olsen, Jesper 235
Eusuff, Jasur 364
Evuvard, Jonathan 990
Evans, Ceri 786
Evans, David 2
Evans, Denise 917
Evans, Henry W. 346, 546
Even, Sophie 290
Everitt, Daniel 80LB
Eyawo, Oghenowede 601, 619, 929
Eymard-Duvernay, Sabrina 482, 486, 654
Fabbi, Massimiliano 222, 445
Fabbi, Gabrielle 354
Fabre, Roxane 72
Fare, Shelley 511, 876
Fafi-Kremer, Samira 495
Faini, Diana 744
Falade-Nwulia, Oluwaseun 560
Fallier, Jean-Pierre 495
Fan, Li 412, 430
Fane, Othustise 729
Fang, Annie 417
Fanjul, Francisco 659
Fanning, Miranda 845LB
Farber-Eger, Eric 621
Gabaitiri, Lesego 988
Gabillard, Delphine 78, 476
Gabler, Karyn 840, 929
Gachuki, Averie B. 1049LB, 637
Gadawski, Izabelle 590
Gaddis, Nathan C. 237LB
Gadisa, Tsigereda 706
Gaines, Tommi O. 844
Gale, Michael 260LB
Galicier, Lionel 323, 603
Galindo, Maria J. 139
Gall, Astrid 272
Galli, Laura 460
Galli, Massimo 303, 410, 411
Gallien, Sébastien 448
Galvez Celada, Cristina 306
Gama, Cynthia 857
Gamble, Theresa 1045
Gandhi, Monica 277, 281, 974, 976, 978
Gandhi, Neel R. 77
Gandhi, Rajesh T. 277, 279, 280
Ganesan, Anuradha 358, 668, 865, 932
Gange, Stephen J. 130, 619, 646, 662, 933
Ganoza, Carmela 464
Ganser, Martha 592
Ganser-Pornillos, Barbie K. 95
Gantner, Pierre 495
Garfein, Richard S. 134, 870
Garland, Wendy Hayward 1014
Garner, William 427
Garnett, Geoff P. 494, 1045
Garske, Lindsay 967
Garza, Rolando 376
Gascon, Maria Rita Polo 388
Gaseitsiwe, Simani 184, 484, 774
Gaspar, Gabriel 534
Gastonguay, Marc 384
Gatchompol, Sivaporn 698
Gatell, Jose Maria 336, 614
Gates, Thomas 351, 398
Gathogo, Esther 688
Gatto, Greg 420
Gebo, Kelly 130, 662
Geboy, Alexander 517, 543, 545
Geffner, Mitchell 780
Gel, Maria 631
Gelderblom, Huub C. 1022
Geldsetzer, Pascal 475, 916, 991, 994
Geleziunas, Romas 309, 338LB
Gelman, Benjamin B. 68, 375
Gelman, Rebecca 789
Genberg, Becky L. 908, 999
Gendelman, Howard E. 219, 433
Geng, Elvin 995, 1000, 1004, 1005
George, Jimmy M. 409a
George, Kathleen 806
George, Varghese 234, 258
Gerard, Laurence 323, 603
Geretti, Anna Maria 370, 549
German, Danielle 888, 904, 918
Gerschenson, Mariana 691
Gerstenhaber, Rodd 998
Gervasoni, Cristina 396, 410, 411
Gessain, Antoine 190
Getz, Rachel 325
Ghannam, Abdelhamid 864
Ghanouris, Mahmoud 213
Ghissetti, Valeria 379
Ghova, Margaret 786
Giacobbi, Nicholas Scott. 501
Giacomelli, Andrea 411
Giacomet, Vania 804
Gianella, Sara 166, 206, 211, 240, 241, 367, 390
Giardello, Marco 39
Gil, Thomas 1034
Gil-Martin, Angela 534
Giladi, Trupti Ishwar. 446
Gill, Alexander J. 68, 375, 376, 827, 828
Gill, John 662, 866
Gil, Surinder P. 62LB
Gillespie, Scott 839
Gilmore, Hailey 111
Gilmour, Jill 202
Gingelmaier, Andrea 754
Gingich, David 414
Ginsberg, Mindy S. 928
Girard, Pierre-Marie 44LB, 487, 703
Girardi, Enrico 466, 734
Girardot, Leila Bertoni 797
Gisslen, Magnus 72, 73, 340, 364, 383, 389, 391, 431
Givisiez, Juliana Machado. 1040
Glancy, Margaret 668
Glashoff, Richard 795, 824
Glick, Sara Nelson 846, 873, 973
Glidden, David 1005
Glover, Tynisha 269
Gnanasambagam, Devasana 776
Gnatienko, Natalia 673
Gock, Christopher 318
Godfrey, Catherine 699
Godin, Odélia 75
Goedhals, Dominique 261
Goepel, Siri 738
Goercke, Irene 740
Goetz, Breanna J. 951
Goetz, Matthew Biddwell. 127, 257, 606, 626, 658
Goggin, Kathryn 912
Goh, Shih Lin 18
Goings, Samuel 845LB
<table>
<thead>
<tr>
<th>Author</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goldberg, David</td>
<td>185</td>
</tr>
<tr>
<td>Golden, Matthew R.</td>
<td>56, 89, 851, 873, 964, 973, 979, 1032</td>
</tr>
<tr>
<td>Goldhaber-Fiebert, Jeremy D.</td>
<td>725</td>
</tr>
<tr>
<td>Goldstein, Harris</td>
<td>269, 328</td>
</tr>
<tr>
<td>Goldstein, Michael</td>
<td>1048</td>
</tr>
<tr>
<td>Golovin, Sergey</td>
<td>569</td>
</tr>
<tr>
<td>Golub, Elizabeth T.</td>
<td>132, 237LB, 341, 514, 629, 632</td>
</tr>
<tr>
<td>Golub, Jonathan</td>
<td>657</td>
</tr>
<tr>
<td>Golub, Sarit A.</td>
<td>965</td>
</tr>
<tr>
<td>Gomez-Olive, Xavier</td>
<td>639, 916, 991</td>
</tr>
<tr>
<td>Gonzalez-Baeza, Alicia</td>
<td>400</td>
</tr>
<tr>
<td>Gonzalez-Garcia, Juan</td>
<td>533, 534, 572, 697</td>
</tr>
<tr>
<td>Gonzalez-Men, Alica</td>
<td>681</td>
</tr>
<tr>
<td>Gonzalez-Perez, Maria Paz</td>
<td>365</td>
</tr>
<tr>
<td>Gonzalez-Serna, Alejandro</td>
<td>590</td>
</tr>
<tr>
<td>Gonzalez-Tome, Maria Isabel</td>
<td>527</td>
</tr>
<tr>
<td>Gonzalez-Zuniga, Patricia</td>
<td>844</td>
</tr>
<tr>
<td>Gonzalo-Gil, Elena</td>
<td>236</td>
</tr>
<tr>
<td>Goodall, Ruth</td>
<td>815</td>
</tr>
<tr>
<td>Goodreau, Steven M.</td>
<td>1024, 1033, 1034</td>
</tr>
<tr>
<td>Gopal, Satish</td>
<td>602</td>
</tr>
<tr>
<td>Gorantla, Santhi</td>
<td>219, 588</td>
</tr>
<tr>
<td>Gordon, Catherine</td>
<td>685LB</td>
</tr>
<tr>
<td>Gordon, Kelley C.</td>
<td>951</td>
</tr>
<tr>
<td>Gordon, Lori A.</td>
<td>409</td>
</tr>
<tr>
<td>Gordon, Peter</td>
<td>546</td>
</tr>
<tr>
<td>Gordon, Shanlea</td>
<td>939</td>
</tr>
<tr>
<td>Gorelick, Rob</td>
<td>281, 287, 297</td>
</tr>
<tr>
<td>Gorgens, Marelize</td>
<td>1046</td>
</tr>
<tr>
<td>Gori, Andrea</td>
<td>222</td>
</tr>
<tr>
<td>Gorin, Aleksandr</td>
<td>268</td>
</tr>
<tr>
<td>Gorman, Daniel</td>
<td>337</td>
</tr>
<tr>
<td>Gosalbes, Maria José</td>
<td>802</td>
</tr>
<tr>
<td>Gosselin, Annie</td>
<td>204</td>
</tr>
<tr>
<td>Gottes, Raphael</td>
<td>265LB</td>
</tr>
<tr>
<td>Gottlieb, Geoffrey</td>
<td>440, 508, 642</td>
</tr>
<tr>
<td>Gouaux, Ben</td>
<td>367</td>
</tr>
<tr>
<td>Gouard, Cécile</td>
<td>278</td>
</tr>
<tr>
<td>Gould, Daniel</td>
<td>245</td>
</tr>
<tr>
<td>Grabowski, Kate</td>
<td>880, 996, 1015</td>
</tr>
<tr>
<td>Grabowski, Mary K.</td>
<td>34LB</td>
</tr>
<tr>
<td>Graham, Barney S.</td>
<td>59, 760</td>
</tr>
<tr>
<td>Graham, Christine</td>
<td>739</td>
</tr>
<tr>
<td>Graham, Susan M.</td>
<td>856, 893, 1022</td>
</tr>
<tr>
<td>Granados, Rafael</td>
<td>570</td>
</tr>
<tr>
<td>Grant, Igor</td>
<td>74, 390</td>
</tr>
<tr>
<td>Grant, Robert M.</td>
<td>955</td>
</tr>
<tr>
<td>Grattoni, Alessandro</td>
<td>422LB</td>
</tr>
<tr>
<td>Gravel, Catherine</td>
<td>785</td>
</tr>
<tr>
<td>Graves, Chanda</td>
<td>839</td>
</tr>
<tr>
<td>Gray, Glenda</td>
<td>857, 1036</td>
</tr>
<tr>
<td>Gray, Richard</td>
<td>1046</td>
</tr>
<tr>
<td>Gray, Ronald H.</td>
<td>1015, 34LB, 359, 87, 880, 996</td>
</tr>
<tr>
<td>Greathouse, Louise</td>
<td>275</td>
</tr>
<tr>
<td>Grebe, Eduard</td>
<td>511, 876</td>
</tr>
<tr>
<td>Grech, Christine</td>
<td>61</td>
</tr>
<tr>
<td>Green, Richard</td>
<td>260LB</td>
</tr>
<tr>
<td>Greenberg, Alan</td>
<td>872, 909</td>
</tr>
<tr>
<td>Greenblatt, Ruth</td>
<td>237LB, 632, 646, 933</td>
</tr>
<tr>
<td>Greene, Sharon A.</td>
<td>22</td>
</tr>
<tr>
<td>Greene, Stephen A.</td>
<td>406</td>
</tr>
<tr>
<td>Greene, Warner C.</td>
<td>312</td>
</tr>
<tr>
<td>Gregson, John</td>
<td>485</td>
</tr>
<tr>
<td>Gregson, Simon</td>
<td>1031</td>
</tr>
<tr>
<td>Greiner, Jared</td>
<td>616</td>
</tr>
<tr>
<td>Gres, Anna</td>
<td>18</td>
</tr>
<tr>
<td>Greupnk, Rick</td>
<td>753</td>
</tr>
<tr>
<td>Griffith, Sam</td>
<td>1010, 1011</td>
</tr>
<tr>
<td>Grignon, Jessica</td>
<td>111</td>
</tr>
<tr>
<td>Grimwood, Ashraf</td>
<td>763</td>
</tr>
<tr>
<td>Grinspoon, Steven K.</td>
<td>627, 635LB</td>
</tr>
<tr>
<td>Grinszttein, Beatriz</td>
<td>149, 447, 714, 948, 1002</td>
</tr>
<tr>
<td>Grubb, Diederick</td>
<td>113, 656</td>
</tr>
<tr>
<td>Grobler, Jay</td>
<td>435, 440</td>
</tr>
<tr>
<td>Gross, Robert</td>
<td>384, 868LB</td>
</tr>
<tr>
<td>Grube, Christina</td>
<td>521</td>
</tr>
<tr>
<td>Grudé, Maxime</td>
<td>278, 349</td>
</tr>
<tr>
<td>Grund, Birgit</td>
<td>608, 623</td>
</tr>
<tr>
<td>Grund, Jonathan</td>
<td>982, 986</td>
</tr>
<tr>
<td>Grunenberg, Nicole</td>
<td>415</td>
</tr>
<tr>
<td>Grunfeld, Carl</td>
<td>526</td>
</tr>
<tr>
<td>Gu, Diane</td>
<td>729</td>
</tr>
<tr>
<td>Guaraldi, Giovanni</td>
<td>532, 655</td>
</tr>
<tr>
<td>Guardiola, Jose Maria</td>
<td>535</td>
</tr>
<tr>
<td>Guatelli, John</td>
<td>310</td>
</tr>
<tr>
<td>Guéhi, Calixte</td>
<td>78</td>
</tr>
<tr>
<td>Guelar, Ana</td>
<td>681</td>
</tr>
<tr>
<td>Guerra, Germano</td>
<td>585</td>
</tr>
<tr>
<td>Guerri-Fernández, Robert</td>
<td>681</td>
</tr>
<tr>
<td>Guha, Anika</td>
<td>401</td>
</tr>
<tr>
<td>Gullick, Roy M.</td>
<td>473, 981</td>
</tr>
<tr>
<td>Gulinetti, Roberto</td>
<td>542LB</td>
</tr>
<tr>
<td>Günthard, Huldrych F.</td>
<td>66, 67, 191, 263, 327, 521</td>
</tr>
<tr>
<td>Guo, Jia</td>
<td>248</td>
</tr>
<tr>
<td>Guo, Yuelong</td>
<td>237LB</td>
</tr>
<tr>
<td>Gupta, Armita</td>
<td>648, 710, 717, 720, 728</td>
</tr>
<tr>
<td>Gupta, Kushal</td>
<td>171LB</td>
</tr>
<tr>
<td>Gupta, Ravindra K.</td>
<td>146, 485</td>
</tr>
<tr>
<td>Gupta, Samir</td>
<td>683</td>
</tr>
<tr>
<td>Gupthe, Akshay</td>
<td>657</td>
</tr>
<tr>
<td>Gupthe, Nikhil</td>
<td>648</td>
</tr>
<tr>
<td>Gussio, Maria</td>
<td>542LB</td>
</tr>
<tr>
<td>Gustafson, Deborah</td>
<td>132, 350</td>
</tr>
<tr>
<td>Guttbrod, Klemens</td>
<td>362</td>
</tr>
<tr>
<td>Gutiérrez, Félix</td>
<td>647</td>
</tr>
<tr>
<td>Gutierrez, Jose</td>
<td>346</td>
</tr>
<tr>
<td>Gustkind, Sarah</td>
<td>547</td>
</tr>
<tr>
<td>Guy, Rebecca J.</td>
<td>57</td>
</tr>
<tr>
<td>Guyer, William D.</td>
<td>568LB</td>
</tr>
<tr>
<td>Guzman, Monica</td>
<td>756</td>
</tr>
<tr>
<td>Guzzo, Christina</td>
<td>64LB</td>
</tr>
</tbody>
</table>

**H—H**

<p>| Ha, Hien Thuc A.                             | 747            |
| Haaland, Richard                            | 943            |
| Haas, Andreas                               | 782            |
| Haas, Bernhard                              | 453, 631       |
| Habckost Dutra de Barros, Clarissa           | 1040           |
| Haberer, Jessica E.                         | 675, 838, 920, 976 |
| Haberl, Annette Elisabeth                   | 738            |
| Haberlen, Sabina                            | 624, 632, 645, 931 |
| Habib, Jakob                                | 1056LB         |
| Hachiyi, Atsuko                             | 496            |
| Hackett, John                               | 583            |
| Hader, Shannon L.                           | 58             |
| Haddad, Lisa B.                             | 942, 943, 946  |
| Haddox, Hugh                                | 243            |
| Hadigan, Colleen                            | 409, 409a, 525, 649 |
| Haeri Mazanderani, Ahmad                    | 794            |
| Hafeez, Maria                               | 517            |
| Hafner, Richard                             | 79             |
| Hagberg, Lars                               | 340, 383, 389, 391 |
| Hager, Cindy                                | 230            |
| Hagins, Debbie                              | 443            |</p>
<table>
<thead>
<tr>
<th>Author Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hahn, Beatrice H.</td>
<td>181LB</td>
</tr>
<tr>
<td>Hahn, Judith</td>
<td>709</td>
</tr>
<tr>
<td>Hakim, Avi</td>
<td>914</td>
</tr>
<tr>
<td>Hakim, James G.</td>
<td>11, 1002</td>
</tr>
<tr>
<td>Hale, Malika</td>
<td>335</td>
</tr>
<tr>
<td>Hall, Irene</td>
<td>30, 31, 478, 851, 899</td>
</tr>
<tr>
<td>Hall, Jake</td>
<td>511</td>
</tr>
<tr>
<td>Hallet, Timothy B.</td>
<td>115, 129, 1036, 1038, 1039, 1040</td>
</tr>
<tr>
<td>Hallett, Travis R.</td>
<td>627</td>
</tr>
<tr>
<td>Halves, Elia K.</td>
<td>120</td>
</tr>
<tr>
<td>Hamers, Raph L.</td>
<td>467, 488</td>
</tr>
<tr>
<td>Hamilton, Deven T.</td>
<td>984, 1033</td>
</tr>
<tr>
<td>Hammarlund, Gustaf Olof</td>
<td>340</td>
</tr>
<tr>
<td>Hammer, Hali</td>
<td>974</td>
</tr>
<tr>
<td>Hammer, John</td>
<td>678</td>
</tr>
<tr>
<td>Hammoud, Dima A.</td>
<td>238</td>
</tr>
<tr>
<td>Hampel, Benjamin Hans</td>
<td>521</td>
</tr>
<tr>
<td>Hamscher, Maria</td>
<td>334</td>
</tr>
<tr>
<td>Hamunime, Ndapewa</td>
<td>35</td>
</tr>
<tr>
<td>Hamzah, Lisa</td>
<td>650</td>
</tr>
<tr>
<td>Han, Xiaoyan</td>
<td>384</td>
</tr>
<tr>
<td>Han, Nathan</td>
<td>810</td>
</tr>
<tr>
<td>Hanash, Samir</td>
<td>661</td>
</tr>
<tr>
<td>Hancock, Dana B.</td>
<td>237LB</td>
</tr>
<tr>
<td>Hancock, Gemma</td>
<td>271</td>
</tr>
<tr>
<td>HANDLEY, Scott</td>
<td>213</td>
</tr>
<tr>
<td>Hanes, Justin</td>
<td>210</td>
</tr>
<tr>
<td>Haneuze, Sebastien</td>
<td>463</td>
</tr>
<tr>
<td>Han, Doan Thí Hong</td>
<td>83</td>
</tr>
<tr>
<td>Hanke, Tomas</td>
<td>119LB</td>
</tr>
<tr>
<td>Hanna, Debra</td>
<td>928</td>
</tr>
<tr>
<td>Hancock, Dana B.</td>
<td>237LB</td>
</tr>
<tr>
<td>Hancock, Cardinal</td>
<td>995</td>
</tr>
<tr>
<td>Harada, Shigeyoshi</td>
<td>247</td>
</tr>
<tr>
<td>Harb, Socorro Michel</td>
<td>446</td>
</tr>
<tr>
<td>Harbers, Veroniek</td>
<td>429</td>
</tr>
<tr>
<td>Hardiman, Gary</td>
<td>586</td>
</tr>
<tr>
<td>Hare, Jonathan</td>
<td>202</td>
</tr>
<tr>
<td>Hargreaves, James R.</td>
<td>4</td>
</tr>
<tr>
<td>Harkoo, Ishaana</td>
<td>88</td>
</tr>
<tr>
<td>Harling, Guy</td>
<td>639, 916, 983</td>
</tr>
<tr>
<td>Harrigan, P. Richard</td>
<td>590, 848, 1042</td>
</tr>
<tr>
<td>Harrington, Bryna</td>
<td>686</td>
</tr>
<tr>
<td>Harris, Bob</td>
<td>685LB</td>
</tr>
<tr>
<td>Harris, Kathryn</td>
<td>801</td>
</tr>
<tr>
<td>Harris, Kendra</td>
<td>724LB</td>
</tr>
<tr>
<td>Harrison, Laura C.</td>
<td>972</td>
</tr>
<tr>
<td>Harrison, Linda J.</td>
<td>457, 584LB</td>
</tr>
<tr>
<td>Harrison, Thomas S.</td>
<td>82</td>
</tr>
<tr>
<td>Hart, Clyde</td>
<td>943</td>
</tr>
<tr>
<td>Hart, Rachel</td>
<td>663, 864</td>
</tr>
<tr>
<td>Hartman, Christine</td>
<td>539</td>
</tr>
<tr>
<td>Hartogensis, Wendy</td>
<td>170, 288</td>
</tr>
<tr>
<td>Hassan, Amin S.</td>
<td>202</td>
</tr>
<tr>
<td>Hassan, Jaython</td>
<td>513</td>
</tr>
<tr>
<td>Hasson, Hamid</td>
<td>531</td>
</tr>
<tr>
<td>Hassounah, Said</td>
<td>498</td>
</tr>
<tr>
<td>Hasty, Alyssa</td>
<td>230</td>
</tr>
<tr>
<td>Hatano, Hinoyu</td>
<td>407</td>
</tr>
<tr>
<td>Hataye, Jason M.</td>
<td>165</td>
</tr>
<tr>
<td>Hate, Vibhuti</td>
<td>1025</td>
</tr>
<tr>
<td>Hattleberg, Camilla Ingrid</td>
<td>131, 346</td>
</tr>
<tr>
<td>Hattori, Shinichiro</td>
<td>503</td>
</tr>
<tr>
<td>Hatziioannou, Theodora</td>
<td>220</td>
</tr>
<tr>
<td>Hatzold, Karin</td>
<td>895, 896, 1030</td>
</tr>
<tr>
<td>Haubrich, Richard</td>
<td>568LB</td>
</tr>
<tr>
<td>Haukoos, Jason</td>
<td>956</td>
</tr>
<tr>
<td>Haumara, Samson</td>
<td>708</td>
</tr>
<tr>
<td>Häussinger, Dieter</td>
<td>161</td>
</tr>
<tr>
<td>Havenar-Daughton, Colin</td>
<td>264</td>
</tr>
<tr>
<td>Havens, Joshua</td>
<td>408, 963</td>
</tr>
<tr>
<td>Havens, Peter Lucas.</td>
<td>685LB</td>
</tr>
<tr>
<td>Havilir, Diane V.</td>
<td>33, 36, 312, 638, 726, 768, 797, 832, 836, 858, 860, 1005, 1051</td>
</tr>
<tr>
<td>Havranek, Edward</td>
<td>528</td>
</tr>
<tr>
<td>Hawes, Stephen E.</td>
<td>642</td>
</tr>
<tr>
<td>Hawken, Mark</td>
<td>1023</td>
</tr>
<tr>
<td>Hawkins, David</td>
<td>418</td>
</tr>
<tr>
<td>Haworth, Kevin G.</td>
<td>322</td>
</tr>
<tr>
<td>Hayashi, Hironori</td>
<td>503</td>
</tr>
<tr>
<td>Hayashi, Kanna</td>
<td>590</td>
</tr>
<tr>
<td>Hayes, Richard</td>
<td>1010, 1011, 1048, 834, 841LB, 959</td>
</tr>
<tr>
<td>Hayford, Christina</td>
<td>942</td>
</tr>
<tr>
<td>Haynes, Barton F.</td>
<td>1057LB</td>
</tr>
<tr>
<td>Hayot, Maurice</td>
<td>654</td>
</tr>
<tr>
<td>Hayward, Katy</td>
<td>428</td>
</tr>
<tr>
<td>Hazen, Stanley</td>
<td>625</td>
</tr>
<tr>
<td>Haza, Rohan</td>
<td>649, 757, 806</td>
</tr>
<tr>
<td>Hazuda, Daria</td>
<td>311, 435</td>
</tr>
<tr>
<td>Heagerty, Patrick J.</td>
<td>921</td>
</tr>
<tr>
<td>Healy, Michael</td>
<td>817LB</td>
</tr>
<tr>
<td>Hearps, Anna</td>
<td>611</td>
</tr>
<tr>
<td>Heaton, Robert K.</td>
<td>74, 201, 353, 377, 390, 392, 393</td>
</tr>
<tr>
<td>Heck, Frederick</td>
<td>170</td>
</tr>
<tr>
<td>Heckman, Barbara</td>
<td>803</td>
</tr>
<tr>
<td>Hector, Jonas</td>
<td>581</td>
</tr>
<tr>
<td>Heera, Jayvant</td>
<td>417</td>
</tr>
<tr>
<td>Heffron, Renee</td>
<td>85, 920, 934, 947, 1003</td>
</tr>
<tr>
<td>Heide - Mulder, Marieke van der.</td>
<td>587</td>
</tr>
<tr>
<td>Hella, Jerry</td>
<td>721</td>
</tr>
<tr>
<td>Heller, Theo</td>
<td>525</td>
</tr>
<tr>
<td>Hellmuth, Joanna</td>
<td>339, 344, 394</td>
</tr>
<tr>
<td>Hemphill, Linda C.</td>
<td>640</td>
</tr>
<tr>
<td>Hendrickson, Cheryl</td>
<td>1021</td>
</tr>
<tr>
<td>Hendrix, Craig</td>
<td>86LB, 976</td>
</tr>
<tr>
<td>Hendrix, Jelle</td>
<td>155</td>
</tr>
<tr>
<td>Henegar, Cassidy</td>
<td>664</td>
</tr>
<tr>
<td>Heneine, Walid</td>
<td>84, 478, 954</td>
</tr>
<tr>
<td>Hennequin, William</td>
<td>116</td>
</tr>
<tr>
<td>Henry, Amy R.</td>
<td>61</td>
</tr>
<tr>
<td>Henry, Keith</td>
<td>474, 597</td>
</tr>
<tr>
<td>Hensley-McBain, Tiffany</td>
<td>216, 231</td>
</tr>
<tr>
<td>Herasimtschuk, Anna</td>
<td>275</td>
</tr>
<tr>
<td>Herdmann, Bruce</td>
<td>911</td>
</tr>
<tr>
<td>Heresi, Gloria P.</td>
<td>425</td>
</tr>
<tr>
<td>Herlihy, Therese</td>
<td>613</td>
</tr>
<tr>
<td>Hermann, David</td>
<td>723LB</td>
</tr>
<tr>
<td>Hermans, Lucas Etienne</td>
<td>113</td>
</tr>
<tr>
<td>Hermans, Sabine</td>
<td>727</td>
</tr>
<tr>
<td>Hermansson, Linn</td>
<td>383</td>
</tr>
<tr>
<td>Hernandez, Adriane</td>
<td>755</td>
</tr>
<tr>
<td>Hernandez, Angela L.</td>
<td>187, 478</td>
</tr>
<tr>
<td>Hernandez-Diaz, Sonia</td>
<td>779</td>
</tr>
<tr>
<td>Hernández-Novoa, Beatriz</td>
<td>595</td>
</tr>
<tr>
<td>Hernandez-Ramirez, Raul Ulises</td>
<td>600</td>
</tr>
<tr>
<td>Herrmann, Eva</td>
<td>738</td>
</tr>
<tr>
<td>Hesslingesser, Joseph</td>
<td>309, 313, 338LB</td>
</tr>
<tr>
<td>Hesseling, Anneke</td>
<td>728</td>
</tr>
<tr>
<td>Hessol, Nancy A.</td>
<td>910</td>
</tr>
<tr>
<td>Heydeman, Rob</td>
<td>641</td>
</tr>
<tr>
<td>Hicks, Katherine</td>
<td>1029</td>
</tr>
<tr>
<td>Hiener, Bonnie</td>
<td>293, 305</td>
</tr>
<tr>
<td>Hicero, Loreto</td>
<td>527</td>
</tr>
<tr>
<td>Higgs, Chris</td>
<td>416</td>
</tr>
<tr>
<td>Highbarger, Helene</td>
<td>368</td>
</tr>
<tr>
<td>Hijkema, Simone Helène</td>
<td>604</td>
</tr>
<tr>
<td>Author Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Hussein, Mustafa</td>
<td>842</td>
</tr>
<tr>
<td>Hussein, Sophia A.</td>
<td>839</td>
</tr>
<tr>
<td>Hutchinson, Angela B.</td>
<td>1029</td>
</tr>
<tr>
<td>Hütter, Gero</td>
<td>320</td>
</tr>
<tr>
<td>Hwang, Carey</td>
<td>45LB</td>
</tr>
<tr>
<td>Hwang, Young</td>
<td>171LB</td>
</tr>
<tr>
<td>Hyle, Emily P.</td>
<td>493, 1043</td>
</tr>
<tr>
<td>Hussein, Sophia A.</td>
<td>839</td>
</tr>
<tr>
<td>Hutchinson, Angela B.</td>
<td>1029</td>
</tr>
<tr>
<td>Hütter, Gero</td>
<td>320</td>
</tr>
<tr>
<td>Hwang, Carey</td>
<td>45LB</td>
</tr>
<tr>
<td>Hwang, Young</td>
<td>171LB</td>
</tr>
<tr>
<td>Hyle, Emily P.</td>
<td>493, 1043</td>
</tr>
<tr>
<td>―I―</td>
<td></td>
</tr>
<tr>
<td>Iannotti, Nathalie</td>
<td>680</td>
</tr>
<tr>
<td>Iannuzzi, Francesca</td>
<td>357</td>
</tr>
<tr>
<td>Ibarra, Sofia</td>
<td>538</td>
</tr>
<tr>
<td>Ibrahim, Fauz</td>
<td>893</td>
</tr>
<tr>
<td>Ibrahim, Maryanne Rose.</td>
<td>774, 789, 790</td>
</tr>
<tr>
<td>Ichikawa, David</td>
<td>64LB</td>
</tr>
<tr>
<td>Igoe, Derval</td>
<td>513</td>
</tr>
<tr>
<td>Ikediobi, Uchenna</td>
<td>236</td>
</tr>
<tr>
<td>Imami, Nesrina</td>
<td>275</td>
</tr>
<tr>
<td>Imamichi, Hiromi</td>
<td>159, 371</td>
</tr>
<tr>
<td>Imamura, Junji</td>
<td>496</td>
</tr>
<tr>
<td>Imp, Brandon M.</td>
<td>341</td>
</tr>
<tr>
<td>Imperial, Marjorie</td>
<td>723LB</td>
</tr>
<tr>
<td>Imperiale, Daniele</td>
<td>360, 379</td>
</tr>
<tr>
<td>Indravudh, Pitchaya</td>
<td>895, 896</td>
</tr>
<tr>
<td>Ingemi, Molly</td>
<td>557</td>
</tr>
<tr>
<td>Ingiliz, Patrick</td>
<td>551, 567, 576, 703</td>
</tr>
<tr>
<td>Innes, Steve</td>
<td>823, 824</td>
</tr>
<tr>
<td>Intasax, Jintana</td>
<td>270</td>
</tr>
<tr>
<td>Invernizzi, Alessandro</td>
<td>396</td>
</tr>
<tr>
<td>Inwoley, André</td>
<td>78</td>
</tr>
<tr>
<td>Izaule, Seth</td>
<td>488</td>
</tr>
<tr>
<td>Iodice, Valentina</td>
<td>537</td>
</tr>
<tr>
<td>Iribarren, Jose A.</td>
<td>647</td>
</tr>
<tr>
<td>Irlbeck, David</td>
<td>123</td>
</tr>
<tr>
<td>Irrinki, Alivelu</td>
<td>118</td>
</tr>
<tr>
<td>Irungu, Elizabeth</td>
<td>920</td>
</tr>
<tr>
<td>Issacs, Abby</td>
<td>415</td>
</tr>
<tr>
<td>Issacs, Shahieda</td>
<td>28</td>
</tr>
<tr>
<td>Isacca, Anne Laure</td>
<td>223</td>
</tr>
<tr>
<td>Ismail, Nazir</td>
<td>770</td>
</tr>
<tr>
<td>Ita, Sergio</td>
<td>178</td>
</tr>
<tr>
<td>Itindi, Janet</td>
<td>970</td>
</tr>
<tr>
<td>Iudicello, Jennifer</td>
<td>353</td>
</tr>
<tr>
<td>Ivarauskas, Emma N.</td>
<td>157</td>
</tr>
<tr>
<td>Ivy, Wade</td>
<td>852</td>
</tr>
<tr>
<td>Iwamoto, Manfred</td>
<td>412, 430</td>
</tr>
<tr>
<td>Iwasaki, Yasumasa</td>
<td>496</td>
</tr>
<tr>
<td>Iwuji, Collins</td>
<td>43, 491, 1018</td>
</tr>
<tr>
<td>Jabsari, Shahab</td>
<td>599</td>
</tr>
<tr>
<td>Jackson, Akil</td>
<td>39</td>
</tr>
<tr>
<td>Jackson, Celia</td>
<td>185</td>
</tr>
<tr>
<td>Jackson, Debra</td>
<td>763</td>
</tr>
<tr>
<td>Jackson, Elise</td>
<td>274</td>
</tr>
<tr>
<td>Jacobson, Denise</td>
<td>25, 805</td>
</tr>
<tr>
<td>Jacobson, Evin</td>
<td>1029</td>
</tr>
<tr>
<td>Jacobson, Karen</td>
<td>709</td>
</tr>
<tr>
<td>Jacobson, Lisa</td>
<td>356, 624, 645, 931</td>
</tr>
<tr>
<td>Jacobson, Mark.</td>
<td>213</td>
</tr>
<tr>
<td>Jagodzinski, Linda</td>
<td>363</td>
</tr>
<tr>
<td>Jain, Priya</td>
<td>422LB</td>
</tr>
<tr>
<td>Jain, Sonia</td>
<td>870, 977</td>
</tr>
<tr>
<td>Jain, Vivek</td>
<td>1051</td>
</tr>
<tr>
<td>Jaison, Tara</td>
<td>308</td>
</tr>
<tr>
<td>Jalbert, Emilie</td>
<td>257</td>
</tr>
<tr>
<td>Jamaloodien, Khadija</td>
<td>1020</td>
</tr>
<tr>
<td>James, Catherine</td>
<td>974</td>
</tr>
<tr>
<td>James, Augustina</td>
<td>157</td>
</tr>
<tr>
<td>Jamison, Dean</td>
<td>1053</td>
</tr>
<tr>
<td>Janetopulos, Christopher J.</td>
<td>308</td>
</tr>
<tr>
<td>Jan, Karen S.</td>
<td>506</td>
</tr>
<tr>
<td>Jani, Conred</td>
<td>834</td>
</tr>
<tr>
<td>Jani, Illes</td>
<td>26, 110</td>
</tr>
<tr>
<td>Januja, Naveed Zafar</td>
<td>524, 735</td>
</tr>
<tr>
<td>Janse van Rensburg, Anita</td>
<td>28</td>
</tr>
<tr>
<td>Janzon, Marianne</td>
<td>37</td>
</tr>
<tr>
<td>Jantarabekjenakul, Watsamon</td>
<td>759, 807</td>
</tr>
<tr>
<td>Janulis, Patrick</td>
<td>843</td>
</tr>
<tr>
<td>Jao, Jennifer</td>
<td>780</td>
</tr>
<tr>
<td>Jaoko, Walter</td>
<td>937</td>
</tr>
<tr>
<td>Jaquet, Antoine</td>
<td>607</td>
</tr>
<tr>
<td>Jara, Paloma</td>
<td>527</td>
</tr>
<tr>
<td>Jarrin, Imma</td>
<td>534</td>
</tr>
<tr>
<td>Jarvis, Joseph N.</td>
<td>82, 740, 745, 988, 993, 1008, 1017</td>
</tr>
<tr>
<td>Jaworowski, Anthony</td>
<td>611</td>
</tr>
<tr>
<td>Jayathilake, Karu</td>
<td>719</td>
</tr>
<tr>
<td>Jean Juste, Marc Antoine</td>
<td>471</td>
</tr>
<tr>
<td>Jefferys, Greg</td>
<td>569</td>
</tr>
<tr>
<td>Jefferys, Laura</td>
<td>581</td>
</tr>
<tr>
<td>Jeffrey, Jerry</td>
<td>171LB</td>
</tr>
<tr>
<td>Jen, I-An</td>
<td>348</td>
</tr>
<tr>
<td>Jenkins, Cathy</td>
<td>719, 816</td>
</tr>
<tr>
<td>Jemess, Samuel</td>
<td>1024, 1033, 1034</td>
</tr>
<tr>
<td>Jerome, Keith</td>
<td>321</td>
</tr>
<tr>
<td>Jia, Hongwei</td>
<td>509</td>
</tr>
<tr>
<td>Jia, Peilin</td>
<td>74</td>
</tr>
<tr>
<td>Jamsaksul, Awachana</td>
<td>705</td>
</tr>
<tr>
<td>Jiang, Li</td>
<td>246</td>
</tr>
<tr>
<td>Jiang, Shaping</td>
<td>443</td>
</tr>
<tr>
<td>Jibril, Hanuma</td>
<td>787</td>
</tr>
<tr>
<td>Jiménez-Miguel</td>
<td>566</td>
</tr>
<tr>
<td>Jiménez-Hernández, Nuria</td>
<td>802</td>
</tr>
<tr>
<td>Jimenez-Sousa, Maria Angeles</td>
<td>530</td>
</tr>
<tr>
<td>Jin, Chengshi</td>
<td>978</td>
</tr>
<tr>
<td>Jin, Haolun</td>
<td>497</td>
</tr>
<tr>
<td>Jinarat, Varunee</td>
<td>793</td>
</tr>
<tr>
<td>Jigeda, Ene-Ly</td>
<td>461</td>
</tr>
<tr>
<td>John, Mathius</td>
<td>686</td>
</tr>
<tr>
<td>John-Stewart, Grace</td>
<td>22, 761, 765, 796, 970</td>
</tr>
<tr>
<td>Johns, Brian A.</td>
<td>252</td>
</tr>
<tr>
<td>Johnson, Anna Satcher.</td>
<td>30, 851, 899</td>
</tr>
<tr>
<td>Johnson, Cheryl</td>
<td>895, 896, 1030, 1031</td>
</tr>
<tr>
<td>Johnson, Eric Otto.</td>
<td>237LB</td>
</tr>
<tr>
<td>Johnson, Erica L.</td>
<td>829</td>
</tr>
<tr>
<td>Johnson, Jeffrey A.</td>
<td>189, 370, 477, 478</td>
</tr>
<tr>
<td>Johnson, Leah</td>
<td>420</td>
</tr>
<tr>
<td>Johnson, R. Paul</td>
<td>62LB</td>
</tr>
<tr>
<td>Johnson, Rachel</td>
<td>1013</td>
</tr>
<tr>
<td>Johnson, Welkin E.</td>
<td>178</td>
</tr>
<tr>
<td>Johnson, R. Paul</td>
<td>62LB</td>
</tr>
<tr>
<td>Johnson, Rachel</td>
<td>1013</td>
</tr>
<tr>
<td>Johnson, Welkin E.</td>
<td>178</td>
</tr>
<tr>
<td>Johnson, James</td>
<td>735</td>
</tr>
<tr>
<td>Johnson, Liz</td>
<td>700</td>
</tr>
<tr>
<td>Johnson, Rowena</td>
<td>281</td>
</tr>
<tr>
<td>Joly, Veronique</td>
<td>458, 732</td>
</tr>
<tr>
<td>Jonas, Anna</td>
<td>35</td>
</tr>
<tr>
<td>Jones, Bradley Robert.</td>
<td>196, 561</td>
</tr>
<tr>
<td>Jones, Deborah</td>
<td>770</td>
</tr>
<tr>
<td>Jones, Jennifer</td>
<td>328</td>
</tr>
<tr>
<td>Jones, Matthew Lee.</td>
<td>301</td>
</tr>
<tr>
<td>Jones, Nicolette</td>
<td>923</td>
</tr>
<tr>
<td>Jones, R. Brad</td>
<td>122, 296</td>
</tr>
<tr>
<td>Jones, Rachael</td>
<td>650</td>
</tr>
<tr>
<td>Jones, Ren R.</td>
<td>905</td>
</tr>
<tr>
<td>Jones, Sara</td>
<td>227, 297, 649</td>
</tr>
</tbody>
</table>
Keshavarzian, Ali 240, 241
Keshinro, Babajide Keshinro 355, 481
Keuter, Monique 610
KewalRamani, Vineet 18
Khaitan, Alka 800
Khakhtina, Svetlana 308
Khalil, George 954
Khalilieh, Sauzanne 412, 430
Khamadi, Samoel 481
Khan, Junaid 927
Khan, Nealia 885
Khan, Sadiya S. 622
Khan, Shaukat 475, 994
Khanna, Aditya 288
Khawen, Michael 872
Kho, Saey 370, 416, 418, 641
Khosropour, Christine M. 964, 979
Khoury, Gabriela 849
Khem, Hans-Peter 321, 322, 332
Kiertiburanakul, Sasisopin 705, 714
Kigerman, Laura P. 73, 364
Kim, Dhohyung 250
Kim, Joon W. 658
Kim, Peggy 312
Kimata, Jason T. 422LB
Kimhofer, Torben 567
Kincer, Laura P. 308
Klase, Zachary A. 308
Klatt, Nichole 216, 231, 260LB, 321
Klein, Daniel J. 1025, 1037
Klein, Daniel B. 130
Klein, Liore 1055LB
Klein, Marina 353
Klein, Nigel 641, 801
Klein, Pamela W. 1012
Kleiner, David E. 525
Klesper, Donald 963
Klimkait, Thomas 191
Klingman, Karin 251, 772, 777
Klipstein-Grobisch, Kerstin 656
Knecht, Robert de 587
Knezovic, Andrea 353, 684
Knobel, Hernando 681
Kobe, Matthew 157
Kober, Kord 514
Koblin, Beryl A. 897
Kobrak, Paul 898
Koenig, Helen C. 975
Koenig, Serena 722
Koethe, John R. 230, 621, 644, 691
Koga, Yasunori 643
Kohto, Satoru 503
Kohlmeier, Alison Swaim 209, 943
Kohlmeier, Jacob E. 209
Kohorn, Lindsay 255, 692
Kojic, Erna M. 597
Kok, Yik Lim 327
Kolb, Kellie E. 250
Kolber, Michael 978
Kolotar, Susan L. 665, 666
Koller, Manuel 596
Kolson, Dennis L. 68, 375, 376, 827, 828
Kombo, Bernadette 893
König, Renate 161
Konigkoff, Jacob 516, 879
Koppen, Jeffrey 649
Korsnay, Jennifer 253
Korologou-Linden, Roxanna Stephanie. 569
Kosakovsky Pond, Sergei L. 200, 201, 1026
Kosikovskaia, Iryna 537, 684, 691
Koslowsky, E. 437
Kozhaya, Lina 800
Kozirev, Oleg 452LB
Kräusslich, Hans-Georg 93
Kraus, Jessica 753
Kravchenko, Alexey V. 452LB
Kraus, Emanuval 875
Kraus, Shelly L. 205, 282, 339, 344, 363, 387
Kretschmann, Regis 938
Krehlak, Georges 520
Krieh, Christian 841LB
Krarup, Astrid Raaby. 314
Kraus, Jessica 1053
Kravchenko, Alexey V. 452LB
Kredes, Emanuel 875
Kredes, Shelly L. 205, 282, 339, 344, 363, 387
Kreithmann, Regis 938
Kreplak, Georges 520
Krippel, Christian 841LB
Kripke, Katharine 1025, 1037
Kroesen, Stefanie 467
Kroon, Arne 788
Kronmann, Karl 865, 932
Kroon, Eugene 124, 125, 270, 282, 291, 339, 387
Krupitsky, Evgeny 673, 868LB
Kruszka, Bridget 853
Ku, Wen-Wei 705
Kuball, Jürgen 320
Kufa-Chakeza, Tendesayi 320
Kuhn, Louise 27, 814, 819
Kujawski, Stephanie 110
Kukolj, George 118
Kulkarni, Rima 443
Kulkarni, Sonali P. 1014
Kumar, Muniratnam S. 559, 883
Kumar, Parag 409a
Kumar, Princy 449LB, 905
Kumar, Sudeep 512
Kumarasamy, Nagalingeswaran 456, 1002
Kummer, Kim 873
Kumwenda, Johnstone 710, 717, 720
Kumwenda, Moses 895
Kuniholm, Mark H. 928
Kunze, Ursula 362
Kuo, Irene 853, 872
Kuo, Kuei-Ling 438
Kuo, Lillian 180
Kuritzkes, Daniel R. 325, 790
Kurland, Irwin J. 780
Kuruc, Joann D. 298
Kuruppu, Nishani 507
Kusanthan, Thankian 919
Kutluay, Sebla B. 16
Kutscher, Eric 722
Kvaratskhelia, Mamuka 94, 157, 160LB
Kvaratskhelia, Nina 525
La, David 179
La Grange, Heleen 28
La Rosa, Alberto M. 224, 457
La Russa, Philip 817LB
Laar, Thijs JW van de. 519
Laboune, Farida 60, 61
Lacabaratz, Christine 630
Lachowsky, Nathan J. 966
Lacombe-Duncan, Ashley A. 923, 924, 926
Lada, Steven 240, 241, 300
Laethem, Tine 412
Laevendecker, Olivier 244, 472, 515, 516, 518, 558, 879, 880, 881, 884, 900
Laferriere, Valerie-Martel 553
Lagardere, Valerie-Arocchi. 762, 861
Kwon, Douglas 232
Kwon, Mi 306
Kwong, Peter D. 14LB
Lake, Jordan E. 251, 356, 589, 696, 700
Laker, Leana 799
Lalama, Christina 279, 280, 325
Laar, Thijs JW van de. 519
Lam, Evan 178
Lama, Javier R. 380, 446
Lamarre, Valerie 785
Lamb, Matthew R. 1049LB, 110
Lambert, Caroline 190
Lambert, John 613, 754
Lam, Evan 178
Lam, Leanne 613
Lam, Rachel 667
Lam, Rachel 667
Lambert, John 613, 754
Lampiris, Harry 312
Land, Kari 161
Landau, Nathaniel R. 333
Landay, Alan 211, 240, 241, 325, 342
Landman, Roland 458
Landman, Roland 458
Landovitz, Raphael J. 500LB, 981
Lane, H. Clifford 159, 371
Lane, Sidney 234
Lang, Karl Sebastian. 161
Lang, Philipp A. 161
Lang, Raynell 866
Langat, Agnes 761, 796, 970
Langat, Deborah 720
Langat, Rither 355
Lange, Camille 287, 368
Langer, Robert 1035
Langham, Freya 687
LangKilde, Anne 235
Lansdon, Eric 434
Lapointe, Normand 785
Laruelle, Joseph 1018
Larsen, Anna 1007, 1019
Lathouwers, Erkki 505
Latini, Alessandra 445
Lattin, Carl A. 5, 842, 904
Lau, Bryan 908
Laube, Catherine 987
Laufs, Stephanie 302
Laughton, Barbara 28, 120, 823, 824, 826
Lauw, Fanny 137LB
Law, Matthew 473, 653, 670, 693
Lawler, Leo 613
Lawlor, Sidney 944
Lawson, Dana Quinn. 16
Lazar, Jason 636LB
Lazerson, Dana 882
Le, Leah T. 72
Le, Phong Thanh. 882
Le, Thuy 83, 747, 748
Le Campion, Armelle 785
Le Chenade, Jerôme 775
Le Hingrat, Quentin 194
Le Moing, Vincent 654
Le Roux, Stanzl M. 24
Leaf, David 667
Leal, Lorna 336
Learn, Gerald H. 181LB
Lebelonyane, Refletswe 1008, 1017
LeBlanc, Roger P. 442
Lechiile, Kwana 740
<table>
<thead>
<tr>
<th>Author Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author Index</td>
<td></td>
</tr>
<tr>
<td>Program and Agenda</td>
<td></td>
</tr>
<tr>
<td>CROI 2017</td>
<td></td>
</tr>
</tbody>
</table>

- **Ledergerber, Bruno** 631
- **Lederman, Michael M.** 225, 251, 276
- **Lederwood, Julie** 330LB, 415
- **Lee, Eric** 231
- **Lee, Eunok** 293
- **Lee, Guinevere Q.** 292, 495
- **Lee, Ha Yoon** 514
- **Lee, Hana** 908
- **Lee, Janice** 29LB
- **Lee, Jeanette** 591
- **Lee, Kelly K.** 242
- **Lee, KyeongEun** 18
- **Lee, Myung Hee** 471
- **Lee, Sarah** 490
- **Lee, William** 338LB
- **Ledergerber, Bruno** 631
- **Lederman, Michael M.** 225, 251, 276
- **Ledgerwood, Julie** 330LB, 415
- **Lee, Lee** 231
- **Lee, Eunok** 293
- **Lee, Guinevere Q.** 292, 495
- **Lee, Ha Yoon** 514
- **Lee, Hana** 908
- **Lee, Janice** 29LB
- **Lee, Jeanette** 591
- **Lee, Kelly K.** 242
- **Lee, KyeongEun** 18
- **Lee, Myung Hee** 471
- **Lee, Sarah** 490
- **Lee, William** 338LB
- **Leeme, Tshepo Botho.** 82, 740, 745
- **Lefebvre, Eric** 381
- **Lefever, Steve** 162
- **Leff, Jared A.** 547
- **Lehman, Dara** 796
- **Lehmann, Clara** 183, 580
- **Leidner, Jean** 502, 784, 787
- **Leierer, Gisela** 631
- **Leigh Brown, Andrew** 185, 186, 193, 1026
- **Leipsic, Jonathon** 655
- **Leitman, Ellen M.** 272
- **Lejeune, Charlotte** 475
- **Lekwape, Nametso** 82, 745
- **Lelievre, Jean Daniel** 441, 630
- **LeMarec, Fabien** 630
- **Lemmens, Veerle** 155
- **Lemmer, Darrin** 715LB
- **Lemoine, Maud** 703
- **Lemos, Maria** 897
- **Lemus, L.** 1028
- **Leng, Sean X.** 133
- **Lennox, Jeffrey J.** 242
- **Leon, Casey** 557
- **Leoprd, Catherine** 278
- **Lerma-Chipirraz, Elisabet** 681
- **LeRoith, Derek** 780
- **Leroy, Valeriane** 811, 814
- **Lesch, François-Xavier** 75
- **Lesovsky, Maia** 767, 989
- **Lester, Richard T.** 106, 964
- **Leto, Valentina** 396
- **Letang, Emilio** 744
- **Li, Danny** 126
- **Li, Guanhan** 371
- **Li, Jiean** 378
- **Li, Jin-fen** 189, 370, 477
- **Li, Jonathan** 325
- **Li, Lingfeng** 1049LB
- **Li, Maoji** 955
- **Li, Peilin** 312
- **Li, Qingsheng** 199, 326
- **Li, Sam** 207, 208
- **Li, Shuying Sue** 421LB
- **Li, Taisheng** 399
- **Li, Weizhe** 588
- **Li, Yanling** 399
- **Li, Yuan** 337
- **Li, Zhaoping** 589
- **Liang, Ben** 179
- **Liang, Richard** 848
- **Liao, Diana** 589
- **Liao, Mei-June** 450LB
- **Liberatore, Rachel A.** 220
- **Libert, Claude** 672
- **Liberty, Afaaf** 29LB
- **Libutti, Daniel** 691
- **Lichterfeld, Mathias** 292, 319, 790
- **Lieberberg, Lenine** 949
- **Liecht, Thomas** 66, 67
- **Liegler, Teri** 170, 407, 832
- **Lienhardt, Christian** 723LB
- **Lifson, Jeffrey D.** 10, 281
- **Ligabue, Guido** 655
- **Lija, Gissenge Jackson** 950
- **Lim, Joseph** 127, 702
- **Lim, So-Yon** 179, 338LB
- **Lima, Viviane Dias.** 875, 929, 1042
- **Lin, Amy** 364
- **Lin, Angel** 308
- **Lin, Haqun** 598
- **Lin, Hsi-Hsun** 438
- **Lin, Kuan-Yin** 582
- **Lin, Li** 615
- **Linas, Benjmin** 547, 557, 709
- **Lince-Deroche, Naomi** 941
- **Lindman, Jacob** 37
- **Lindsay, Joanne** 601
- **Lindsey, Jane** 803
- **Ling, John** 40
- **Link, John O.** 38, 433
- **Linley, Joanne** 889, 890
- **Lion, Albert Y.** 419, 978
- **Lipira, Lauren** 921
- **Lippman, Sheri A.** 221
- **Lisante, Antonella** 232
- **Lisco, Andrea** 221, 226
- **Lisinichia, Joshua G.** 68
- **Lisovsky, Irene** 274
- **Little, Francesca** 990
- **Little, Susan J.** 134, 206
- **Litwin, Alain H.** 544
- **Liu, Albert Y.** 419, 978
- **Liu, Chenglong** 514, 634
- **Liu, Cindy M.** 87
- **Liu, Hongjie** 918, 997
- **Liu, Jingxia** 972
- **Liu, Jun** 233
- **Liu, Qingbo** 14LB
- **Liu, Wei** 413
- **Liu, Xiaohui** 832
- **Liu, Yang** 164
- **Liu, YaPei** 683
- **Livelli, Alessandro** 360
- **Llibre, Josep M.** 441LB, 651
- **Lloyd-Jones, Donald M.** 622
<table>
<thead>
<tr>
<th>Author Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lo, Janet</td>
<td>627</td>
</tr>
<tr>
<td>Lo, Yi-Chun</td>
<td>582</td>
</tr>
<tr>
<td>Lo Re, Vincent</td>
<td>127, 702</td>
</tr>
<tr>
<td>Loarec, Anne</td>
<td>523</td>
</tr>
<tr>
<td>Locatelli, Isabella</td>
<td>362</td>
</tr>
<tr>
<td>Lockman, Shahin</td>
<td>25, 484, 502, 640, 774, 784, 787, 789, 1008, 1009</td>
</tr>
<tr>
<td>Loefgren, Sarah</td>
<td>746</td>
</tr>
<tr>
<td>Logie, Carmen H.</td>
<td>923, 924, 925, 926</td>
</tr>
<tr>
<td>Loiseau, Claire</td>
<td>223</td>
</tr>
<tr>
<td>Lombaard, Johan</td>
<td>45LB</td>
</tr>
<tr>
<td>Lombardi, Francesca</td>
<td>445</td>
</tr>
<tr>
<td>Longenecker, Chris T.</td>
<td>628, 674, 822</td>
</tr>
<tr>
<td>Looby, Sara E.</td>
<td>627</td>
</tr>
<tr>
<td>Lofgren, Sarah</td>
<td>746</td>
</tr>
<tr>
<td>Lombaraard, Johan</td>
<td>45LB</td>
</tr>
<tr>
<td>Lombardi, Francesca</td>
<td>445</td>
</tr>
<tr>
<td>Londoño, Maria Carlota</td>
<td>540</td>
</tr>
<tr>
<td>Longenecker, Chris T.</td>
<td>628, 674, 822</td>
</tr>
<tr>
<td>Love, Tanzy</td>
<td>514</td>
</tr>
<tr>
<td>Lowrance, David W.</td>
<td>35</td>
</tr>
<tr>
<td>Lozier, Jay</td>
<td>409</td>
</tr>
<tr>
<td>Lozupone, Catherine</td>
<td>207, 208</td>
</tr>
<tr>
<td>Lu, Michael T.</td>
<td>627, 635LB</td>
</tr>
<tr>
<td>Lu, Xiang</td>
<td>593</td>
</tr>
<tr>
<td>Luban, Jeremy</td>
<td>18</td>
</tr>
<tr>
<td>Lucarello, Angela</td>
<td>585</td>
</tr>
<tr>
<td>Lucas, Gregory M.</td>
<td>853, 883</td>
</tr>
<tr>
<td>Lucera, Mark</td>
<td>169</td>
</tr>
<tr>
<td>Lucero, Constanza</td>
<td>336</td>
</tr>
<tr>
<td>Lucy, Debbie</td>
<td>897</td>
</tr>
<tr>
<td>Luechai, Pikunchai</td>
<td>855</td>
</tr>
<tr>
<td>Luettekemeyer, Annie</td>
<td>568LB</td>
</tr>
<tr>
<td>Luisi, Nicole</td>
<td>90</td>
</tr>
<tr>
<td>Luk, Ka-Cheung</td>
<td>577</td>
</tr>
<tr>
<td>Lumpa, Mwansa</td>
<td>1004</td>
</tr>
<tr>
<td>Lundgren, Jens D.</td>
<td>128LB, 131, 474, 653, 693</td>
</tr>
<tr>
<td>Luo, Dajie</td>
<td>1054</td>
</tr>
<tr>
<td>Luo, Donghan</td>
<td>505</td>
</tr>
<tr>
<td>Luo, Ma</td>
<td>179</td>
</tr>
<tr>
<td>Luong Nguyen, Liem Binh</td>
<td>116</td>
</tr>
<tr>
<td>Lupo, David</td>
<td>943</td>
</tr>
<tr>
<td>Luque, Marco</td>
<td>816</td>
</tr>
<tr>
<td>Lusso, Paolo</td>
<td>14LB, 64LB</td>
</tr>
<tr>
<td>Lutsar, Irja</td>
<td>461</td>
</tr>
<tr>
<td>Lutz, Thomas</td>
<td>551, 567, 576</td>
</tr>
<tr>
<td>Lyagoba, Frederick</td>
<td>193</td>
</tr>
<tr>
<td>Lyce, Samantha</td>
<td>1026</td>
</tr>
<tr>
<td>Lynch, Briana</td>
<td>881</td>
</tr>
<tr>
<td>Lynam, Lutgarde</td>
<td>81LB</td>
</tr>
<tr>
<td>Lynn, Shugene</td>
<td>450LB</td>
</tr>
<tr>
<td>Lyons, Michael S.</td>
<td>956</td>
</tr>
<tr>
<td>Lyss, Sheryl</td>
<td>741</td>
</tr>
<tr>
<td>Ma, Fangrui</td>
<td>199</td>
</tr>
<tr>
<td>Ma, Yifei</td>
<td>526, 625</td>
</tr>
<tr>
<td>Ma, Zhong-Min</td>
<td>252</td>
</tr>
<tr>
<td>Maalof, Naif</td>
<td>468, 677</td>
</tr>
<tr>
<td>Maan, Evelyn J.</td>
<td>939</td>
</tr>
<tr>
<td>Maartens, Gary</td>
<td>1020, 81LB</td>
</tr>
<tr>
<td>Maas, Brian</td>
<td>406</td>
</tr>
<tr>
<td>Mabileau, Guillaume</td>
<td>1028</td>
</tr>
<tr>
<td>Mabunda, Nedlio</td>
<td>26</td>
</tr>
<tr>
<td>Macalino, Grace</td>
<td>865</td>
</tr>
<tr>
<td>Macatangay, Bernard</td>
<td>280, 330LB, 931</td>
</tr>
<tr>
<td>MacBayne, Christine E.</td>
<td>404</td>
</tr>
<tr>
<td>Macera, Margherita</td>
<td>585</td>
</tr>
<tr>
<td>MacGillivray, Jay</td>
<td>756</td>
</tr>
<tr>
<td>Machado, Daisy</td>
<td>816</td>
</tr>
<tr>
<td>Macias, Juan</td>
<td>532, 536, 555, 570, 697</td>
</tr>
<tr>
<td>Macio, Ingrid</td>
<td>944</td>
</tr>
<tr>
<td>Mack, Wendy</td>
<td>514</td>
</tr>
<tr>
<td>Macken, Alan</td>
<td>679</td>
</tr>
<tr>
<td>Mackman, Richard</td>
<td>436</td>
</tr>
<tr>
<td>Maclean, Rachel L.</td>
<td>476</td>
</tr>
<tr>
<td>Macleod, David</td>
<td>834, 1010</td>
</tr>
<tr>
<td>Macmadu, Alexandria</td>
<td>1044</td>
</tr>
<tr>
<td>Macacuca, Nello</td>
<td>730, 766</td>
</tr>
<tr>
<td>Maddon, Paul J.</td>
<td>437</td>
</tr>
<tr>
<td>Madhi, Shabir</td>
<td>787</td>
</tr>
<tr>
<td>Madison, Michaela</td>
<td>16</td>
</tr>
<tr>
<td>Maeda, Kenji</td>
<td>503</td>
</tr>
<tr>
<td>Mafara, Emma</td>
<td>475, 994</td>
</tr>
<tr>
<td>Mafukidze, Arnold</td>
<td>708</td>
</tr>
<tr>
<td>Magambo, Brian</td>
<td>193</td>
</tr>
<tr>
<td>Magana, Lucas</td>
<td>197</td>
</tr>
<tr>
<td>Magni, Carlo</td>
<td>542LB</td>
</tr>
<tr>
<td>Magnus, Manya</td>
<td>872</td>
</tr>
<tr>
<td>Magwaza, Sphindile</td>
<td>958</td>
</tr>
<tr>
<td>Magyar, Clara</td>
<td>251, 700</td>
</tr>
<tr>
<td>Maher, Andrew D.</td>
<td>35</td>
</tr>
<tr>
<td>Maheu-Giroux, Mathieu</td>
<td>1047</td>
</tr>
<tr>
<td>Mahiga, Hellen</td>
<td>788</td>
</tr>
<tr>
<td>Mahjoub, Nadia</td>
<td>603</td>
</tr>
<tr>
<td>Mahlon, Niail</td>
<td>613</td>
</tr>
<tr>
<td>Maidia, Paola</td>
<td>575</td>
</tr>
<tr>
<td>Maiga, Moussa</td>
<td>607</td>
</tr>
<tr>
<td>Majeed, Sophia R.</td>
<td>427</td>
</tr>
<tr>
<td>Majoingi, Nokuthula</td>
<td>1009</td>
</tr>
<tr>
<td>Makadzange, Azure Tariro</td>
<td>345, 743</td>
</tr>
<tr>
<td>Makanani, Bonus</td>
<td>935</td>
</tr>
<tr>
<td>Makarov, Edward</td>
<td>588</td>
</tr>
<tr>
<td>Makhma, Joseph</td>
<td>25, 502, 784, 789, 790</td>
</tr>
<tr>
<td>Maki, Pauline M.</td>
<td>350</td>
</tr>
<tr>
<td>Makinson, Alain</td>
<td>654</td>
</tr>
<tr>
<td>Makokha, Catherine K.</td>
<td>861</td>
</tr>
<tr>
<td>Makovore, Vongai</td>
<td>993</td>
</tr>
<tr>
<td>Malagoli, Andrea</td>
<td>655</td>
</tr>
<tr>
<td>Malatinkova, Eva</td>
<td>302</td>
</tr>
<tr>
<td>Maldarell, Frank</td>
<td>227, 287, 294, 297, 298, 303, 368</td>
</tr>
<tr>
<td>Maleche Obimbo, Elizabeth</td>
<td>103, 796</td>
</tr>
<tr>
<td>Malet, Isabelle</td>
<td>499</td>
</tr>
<tr>
<td>Malete, Given</td>
<td>1050</td>
</tr>
<tr>
<td>Malik, Sarah</td>
<td>370</td>
</tr>
<tr>
<td>Malin, Jakob</td>
<td>580</td>
</tr>
<tr>
<td>Malisita, Kennedy</td>
<td>602</td>
</tr>
<tr>
<td>Mallal, Simon</td>
<td>230</td>
</tr>
<tr>
<td>Mallard, Jaclyn</td>
<td>69</td>
</tr>
<tr>
<td>Mallewa, Jane Edith</td>
<td>117, 641</td>
</tr>
<tr>
<td>Mallolas, Josep</td>
<td>42</td>
</tr>
<tr>
<td>Mallon, Patrick W.G.</td>
<td>613, 679</td>
</tr>
<tr>
<td>Maluzi, K</td>
<td>711</td>
</tr>
<tr>
<td>Maman, David</td>
<td>116, 464, 523, 764, 792, 1006</td>
</tr>
<tr>
<td>Mamede, João L.</td>
<td>15</td>
</tr>
<tr>
<td>Manabe, Yukari C.</td>
<td>712, 742</td>
</tr>
<tr>
<td>Manasa, Justen</td>
<td>506</td>
</tr>
<tr>
<td>Mancebo, María</td>
<td>532, 697</td>
</tr>
<tr>
<td>Mandalia, Sunthiya</td>
<td>275, 382</td>
</tr>
<tr>
<td>Mandelbrot, Laurent</td>
<td>775</td>
</tr>
<tr>
<td>Manenzhe, Kghalisho</td>
<td>936</td>
</tr>
<tr>
<td>Author</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Mangal, Tara</td>
<td>1040</td>
</tr>
<tr>
<td>Mangi, Alessandra</td>
<td>9</td>
</tr>
<tr>
<td>Manika, Katerina Manika</td>
<td>734</td>
</tr>
<tr>
<td>Manion, Maura</td>
<td>221, 287, 368</td>
</tr>
<tr>
<td>Manowski, Madeleine Clare Percey</td>
<td>141</td>
</tr>
<tr>
<td>Manne-Goehler, Jennifer</td>
<td>639, 916, 991</td>
</tr>
<tr>
<td>Manon, Santhosh</td>
<td>612</td>
</tr>
<tr>
<td>Månsund, Fredrik</td>
<td>37</td>
</tr>
<tr>
<td>Manuzak, Jennifer</td>
<td>1051, 1050</td>
</tr>
<tr>
<td>Mangal, Tara</td>
<td>184, 484</td>
</tr>
<tr>
<td>Masango, Mhleli</td>
<td>29LB</td>
</tr>
<tr>
<td>Masciotra, Silvana</td>
<td>509</td>
</tr>
<tr>
<td>Mascola, John R.</td>
<td>244, 760</td>
</tr>
<tr>
<td>Maseko, Bertha</td>
<td>859</td>
</tr>
<tr>
<td>Masese, Linnet N.</td>
<td>937</td>
</tr>
<tr>
<td>Masetti, Michela</td>
<td>222, 804</td>
</tr>
<tr>
<td>Masiha, Gaerolwe</td>
<td>772</td>
</tr>
<tr>
<td>Mar, Maris</td>
<td>595, 647</td>
</tr>
<tr>
<td>Maskew, Mbhaire</td>
<td>1021</td>
</tr>
<tr>
<td>Masopust, David</td>
<td>267</td>
</tr>
<tr>
<td>Masourn, Sara</td>
<td>440</td>
</tr>
<tr>
<td>Massacci, Guido</td>
<td>167, 518</td>
</tr>
<tr>
<td>Massad, L. Stewart</td>
<td>23</td>
</tr>
<tr>
<td>Massanella, Marta</td>
<td>285</td>
</tr>
<tr>
<td>Massie, Allan</td>
<td>689</td>
</tr>
<tr>
<td>Masson, Carmen L.</td>
<td>547</td>
</tr>
<tr>
<td>Masson, Lindi</td>
<td>949</td>
</tr>
<tr>
<td>Mastrocola, Emily J.</td>
<td>220</td>
</tr>
<tr>
<td>Mastorrosa, Ilaria</td>
<td>354</td>
</tr>
<tr>
<td>Maswabi, Kenneth</td>
<td>789, 790</td>
</tr>
<tr>
<td>Matano, Tetsuro</td>
<td>247</td>
</tr>
<tr>
<td>Mattranz, Mariano</td>
<td>676</td>
</tr>
<tr>
<td>Matemo, Daniel</td>
<td>765</td>
</tr>
<tr>
<td>Mateo, Gracia</td>
<td>651</td>
</tr>
<tr>
<td>Mathabire, Sekai Chenai</td>
<td>464</td>
</tr>
<tr>
<td>Mathanga, Don</td>
<td>783</td>
</tr>
<tr>
<td>Mathema, Barun</td>
<td>77</td>
</tr>
<tr>
<td>Matheron, Sophie</td>
<td>194, 195, 290, 448, 603, 821</td>
</tr>
<tr>
<td>Mathews, W. Christopher</td>
<td>454</td>
</tr>
<tr>
<td>Mathot, Ron</td>
<td>830</td>
</tr>
<tr>
<td>Matia, Belen</td>
<td>752</td>
</tr>
<tr>
<td>Mathloeng, Katlego</td>
<td>707</td>
</tr>
<tr>
<td>Matoga, Mitch</td>
<td>720</td>
</tr>
<tr>
<td>Matsuda, Kouki</td>
<td>503</td>
</tr>
<tr>
<td>Matsu, Masakazu</td>
<td>496</td>
</tr>
<tr>
<td>Matsuzumo, Shoko</td>
<td>463</td>
</tr>
<tr>
<td>Matsuo, Hiroshi</td>
<td>173</td>
</tr>
<tr>
<td>Matthews, Philippa</td>
<td>272, 799</td>
</tr>
<tr>
<td>Mattingly, Aviva</td>
<td>649</td>
</tr>
<tr>
<td>Matabu, Allen T.</td>
<td>945</td>
</tr>
<tr>
<td>Matus Nicodemos, Rodrigo</td>
<td>175</td>
</tr>
<tr>
<td>Maurice, Fiona</td>
<td>993</td>
</tr>
<tr>
<td>Mauss, Stefan</td>
<td>551, 567, 576</td>
</tr>
<tr>
<td>Maves, Ryan</td>
<td>865</td>
</tr>
<tr>
<td>Mavigner, Maud</td>
<td>1056LB</td>
</tr>
<tr>
<td>MaWhinney, Samantha</td>
<td>63, 419, 675</td>
</tr>
<tr>
<td>Maxwell, Claire</td>
<td>750</td>
</tr>
<tr>
<td>Mayanja, Yania</td>
<td>915</td>
</tr>
<tr>
<td>Mayer, Kenneth H.</td>
<td>415, 456, 838, 971, 972, 981</td>
</tr>
<tr>
<td>Mayondi, Gloria</td>
<td>25, 774, 784, 878</td>
</tr>
<tr>
<td>Mayor, Angel</td>
<td>662</td>
</tr>
<tr>
<td>Mazzali, Cristina</td>
<td>411</td>
</tr>
<tr>
<td>Mazzotta, Valentina</td>
<td>366</td>
</tr>
<tr>
<td>Mbengue, Mouhamed Abdou Salam</td>
<td>917</td>
</tr>
<tr>
<td>Mbete, Ndileka</td>
<td>819</td>
</tr>
<tr>
<td>Mbilizi, Yamikani</td>
<td>935</td>
</tr>
<tr>
<td>Mboya, Edward</td>
<td>982, 986</td>
</tr>
<tr>
<td>Mbwanji, Gladys</td>
<td>744</td>
</tr>
<tr>
<td>McAllister-Holod, Laura</td>
<td>1013</td>
</tr>
<tr>
<td>McAuley, Andrew</td>
<td>185</td>
</tr>
<tr>
<td>McBride, Timothy</td>
<td>972</td>
</tr>
<tr>
<td>McCabe, Paul</td>
<td>557</td>
</tr>
<tr>
<td>McCaffery, Jeannine</td>
<td>694</td>
</tr>
<tr>
<td>McCallister, Scott</td>
<td>453, 683</td>
</tr>
<tr>
<td>McCarter, Martin</td>
<td>67</td>
</tr>
<tr>
<td>McCarthy, Geraldine</td>
<td>679</td>
</tr>
<tr>
<td>McCauley, Marybeth</td>
<td>981</td>
</tr>
<tr>
<td>McClelland, R. Scott</td>
<td>54, 85, 242, 937</td>
</tr>
<tr>
<td>McClintic, Hillary</td>
<td>667</td>
</tr>
</tbody>
</table>
McClure, Myra 432
McCoig, Cynthia 428
McComsey, Grace A. 617, 618, 674, 691, 695, 699, 700, 822
McCoy, Laura 798
McCray, Eugene 30
McCreesh, Nicky 1048
McGillough, John 20
McDavid, Andrew 265LB
McDonald, Cheryl 453
McDonnell, Wyatt James 230
McElrath, Julie 897
McCaffrey, Robert 716LB
Mccaffrey, Robert 637
McFarland, Elizabeth J. 425, 760
McFarland, Willi 35
McFaul, Katie 248
McGee, Charles 1057LB
McGinty, Tara 679
McGowan, Catherine 719, 816
McGowan, Ian 420
McGrath, Christine J. 761, 970
McGrath, Nuala 1018
McHale, Carolyn 435
McHugh, Cricket 419
McHugh, Grace 841LB
McIlfer, Helen 29LB, 808
McIntyre, James A. 769, 771
McKenney, Jennie 901
McKibben, Rebeccah 632
McKinley, Trevelyan J. 1048
McKinnon, Lyle 949
McKnight, Courtney 547
McLane, Mary Fran. 184
McLaughlin, Mary 409a, 632
McLaughlin, Sherry 304
McMahan, Deborah 277, 279, 280
McManus, Maryellen 409, 409a
McMaster, Sean 209
McMillan, JoEllyn 439
McNairy, Margaret 1049LB, 637, 722, 835
McNulty, Moira 969
McPherson, Tristan 912
McRobie, Ellen 115
McVeal, David 848
Mdulile, Joice 784
Mea-Assande, Véronique 811
Meda, Nicolas 781
Meditz, Amie 63
Medley, Amy Michelle. 958
Medley, Graham 1025, 5037
Medford, Benjamin 232
Meintjes, Graeme 990
Mehta, Nehal N. 612
Mehta, Sanjay R. 182, 183, 559, 560, 883
Meignin, Veronique 603
Mejia, Ken 620
Meiers, Joost CM. 825
Meintjes, Graeme 990
Meintjes, Graeme 81LB
Meissner, Eric G. 566
Meissner, Paul 544
Meier, Niels 235
Melaku, Zenebe 706, 1023
Melbourne, Kathy 683
Melfers, Fritz 716LB
Melero, Helena 408
Meliano, Caroline 686
Mellado, Maria José 527, 802
Mellgren, Åsa 340, 431
Mellins, Claude A. 24
Mellors, John W. 120, 121, 277, 279, 280, 294, 298, 303, 309, 313, 330LB, 795, 951, 952
Mena, Leandro 972
Menni, Hervé 78
Mendel, Carl 724LB, 808LB
Mendhiharat, Pierre 116
Mendoza, Maria 32
Meneghini, Giuseppe 985
Menel, Elisabeth 262
Menzaghi, Barbara 542LB
Meraviglia, Paola 411
Mercecne, Giselle 20
Merchant, Nicolaï 139, 538
Merenstein, Daniel 132, 690
Merino, Dolores 532, 536, 555, 566, 571, 697
Merino, Esperanza 139, 538
Merli, Marco 531
Merlini, Esther 215, 239, 357, 680
Meschke, Steven K. 522
Mesojednik, Taylor 335
Mesplede, Thibault 489, 495, 498
Mestdagh, Pieter 162
Metcalfe, Julia A. 472, 888
Metcalfe, John Z. 715LB
Metcaife, Rebecca 529
Metcalfe, Rebecca 529
Metcalfe, Rebecca 529
Mekler, Naomí 362
Metsch, Lisa 913
Metzger, David 842
Metzner, Karin 263, 327
Mewalal, Nikoshia 266
Meya, David 368, 742, 744, 746
Meyer, Laurence 911LB
Meyer-Andrieux, Isabelle Anne 1006
Meyerowitz, Jodi 261
Meyn, Leslie A. 86LB, 945
Mgaya, Jimson 788
Mgodi, Nyaradzo 421LB
Mhlamba, Felix 945, 952
Miah, Jalal 734
Mican, Johanna 221, 238
Michael, Denna 714
Michael, Nelson L. 124, 197, 249, 270, 282, 299LB, 70, 71
Michel, Kate 23
Michelow, Pamela 941
Migueles, Stephen A. 473
Miguez, Maria Jose. 874
Milam, Joel 646, 933
Milanini, Benedetta 355
Milazzo, Laura 411, 579
Miles, Brodie 63
Miller, Charlene 216, 231
Miller, Christopher J. 252
Miller, Melissa 479, 911
Miller, Michael D. 330LB, 436, 497
Miller, Shannon 63
Miller, William 198
Millo, Corina 238
Millroy, M. J. 590, 875, 1044
Mills, Lisa A. 184, 1008
Melaku, Zenebe 706, 1023
Melbourne, Kathy 683
Melfers, Fritz 716LB
Melero, Helena 408
Meliano, Caroline 686
Mellado, Maria José 527, 802
Mellgren, Åsa 340, 431
Mellins, Claude A. 24
Mellors, John W. 120, 121, 277, 279, 280, 294, 298, 303, 309, 313, 330LB, 795, 951, 952
Mena, Leandro 972
Menni, Hervé 78
Mendel, Carl 724LB, 808LB
Mendhiharat, Pierre 116
Mendoza, Maria 32
Meneghini, Giuseppe 985
Menel, Elisabeth 262
Menzaghi, Barbara 542LB
Meraviglia, Paola 411
Mercecne, Giselle 20
Merchant, Nicolaï 139, 538
Merenstein, Daniel 132, 690
Merino, Dolores 532, 536, 555, 566, 571, 697
Merino, Esperanza 139, 538
Merli, Marco 531
Merlini, Esther 215, 239, 357, 680
Meschke, Steven K. 522
Mesojednik, Taylor 335
Mesplede, Thibault 489, 495, 498
Mestdagh, Pieter 162
Metcalfe, Julia A. 472, 888
Metcalfe, John Z. 715LB
Metcaife, Rebecca 529
Metcalfe, Rebecca 529
Mekler, Naomí 362
Metsch, Lisa 913
Metzger, David 842
Metzner, Karin 263, 327
Mewalal, Nikoshia 266
Meya, David 368, 742, 744, 746
Meyer, Laurence 911LB
Meyer-Andrieux, Isabelle Anne 1006
Meyerowitz, Jodi 261
Meyn, Leslie A. 86LB, 945
Mgaya, Jimson 788
Mgodi, Nyaradzo 421LB
Mhlamba, Felix 945, 952
Miah, Jalal 734
Mican, Johanna 221, 238
Michael, Denna 714
Michael, Nelson L. 124, 197, 249, 270, 282, 299LB, 70, 71
Michel, Kate 23
Michelow, Pamela 941
Migueles, Stephen A. 473
Miguez, Maria Jose. 874
Milam, Joel 646, 933
Milanini, Benedetta 355
Milazzo, Laura 411, 579
Miles, Brodie 63
Miller, Charlene 216, 231
Miller, Christopher J. 252
Miller, Melissa 479, 911
Miller, Michael D. 330LB, 436, 497
Miller, Shannon 63
Miller, William 198
Millo, Corina 238
Millroy, M. J. 590, 875, 1044
Mills, Lisa A. 184, 1008
Author Index

CROI 2017

256

Author Index

Program and Agenda

Milne, Ross 490
Milosevic, Catriona 185
Milush, Jeffery 293
Milus, Jeffery 293
Mimagi, Matthew J. 971
Min, Jeong Eun 875
Minami, Rumi 643
Mingorance, Jesus 657
Minichi, Carmine 537
Minisci, Davide 411
Minkoff, Howard 23
Minnerly, Sydney 845LB
Minnis, Alexandra 936
Miro, Jose M 540, 541, 651, 751
Mirochnick, Mark 755, 757, 758, 809, 938
Mitchell, Brooks I. 385, 612, 692
Mitchell, Caroline 224
Mitchell, Hannah K. 740
Mitchell, James 84
Mitchell, Julie 125
Mitchell, Michael Lloyd. 434
Mitsuya, Hiroaki 503
Mitsuyasu, Ronald T. 592
Mittal, Maria Luisa 870
Miyahara, Sachiko 79, 342, 710, 717, 720
Mlati, Nqobile 1021
Mock, Philip 854, 954
Mocroft, Amanda 128LB, 131, 653
Modesitt, Jacob 216
Modise, Sylvia 993
Modongo, Chawangwa 729
Moody, Aaloke 1000
Moh, Raoul 78
Mohammadi, Pejman 162
Mohammed, Terence 789
Mohr, Erika K. 718
Mohr, Raphael 704
Moir, Lorlette 544
Mokaleng, Baitshepi 184
Mokomane, Margaret 745
Molefi, Mooketsi 729
Molfino, Lucas 523
Molina, Jean-Michel 55, 45LB, 91LB
Mollan, Katie 454
Mollay, Sile 82
Moltó, José 119LB, 754
Moncla, Bernard John. 86LB
Mondi, Annalisa 203, 466
Montero, Marta 139, 527, 533
Montaño, Daniel E. 936
Montano, Jesus 314
Montane, Julio SG. 599, 875, 929, 966, 1042
Monte, Luis 326
Montano, Mauricio 311
Montano, Michaelina A. 979
Montejano, Rocio 400, 652
Montes, Marisa 400, 533, 652
Mongwenyana, Constance 1050
Montana, Libia 639, 916
Montaner, Doug 599, 875, 929, 966, 1042
Monteiro, Maria 326
Montano, Daniel E. 936
Montano, Mauricio 311
Monte, Luis 326
Montano, Michaelina A. 979
Montejano, Rocio 400, 652
Monteiro, Marta 139, 527, 533
Monterosso, Analise Castellanos. 845LB
Montes, Marisa 400, 533, 652
Montgomery, Madeline C. 968
Monteiro, Maria 326
Moodley, Amber 266
Moodley, Pravi 266
Moolla, Aneesah 1021
Moon, Juhi 560
Moore, David 462, 966
Moore, David J. 353, 358, 367, 977
Moore, Janet 1009
Moore, Michael 433
Moore, Penny 142
Moore, Raelene 358
Moore, Richard D. 310, 347, 454, 560, 619, 662, 840
Moore, Teresa 677
Moorehouse, Michelle Anne. 113, 1020
Moorthy, Ganesh S. 975
Mosha, Mahomaded-Yunus 1020
Morana, Natasha Onalenna. 774
Moran, Caitlin A. 629
Moran, Joanne 513
Moran, Matthew G. 592
Mordant-Joubert, Laurence 349, 487
Morans-Amanda, Luis E. 536, 555, 570, 571
Morawski, Hotep 228
Morse, Caryn Gee. 226, 525
Morse, Deodatha 950
Moses, Carlee 695, 700
Moses, Michael 687
Moss, Darren Michael. 423
Motswere, Catherine 1009
Moulignier, Antoine 75
Mounzahr, Karem 326, 664, 975
Moy, Graeme 418, 432
Moyo, Prince 114LB
Moyo, Faith 794
Moyo, Ntozakhele 84, 480, 502, 774, 789, 790
Mpalwa, Ngole, Etiel 482, 486
Msandwiwa, Regina 657
Msika, Albans 946
Msukwa, Malangolo T. 782
Mthabo, Bryan 686
Mubiru, Frank 712
Mucunguzi, Atukunda 726
Mudenderangwa, Chishamiso 26
Mudridkova, Tania 504LB
Mugavero, Michael J. 454, 455, 838, 908, 921
Mugenyi, Mark 712
Mugisha, Daudata 950
Mungurungi, Owen 114LB
Mugyenyi, Peter 117

256 CROI 2017
<table>
<thead>
<tr>
<th>Author</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muianga, Basilio</td>
<td>766</td>
</tr>
<tr>
<td>Mui, Andrew J.</td>
<td>552</td>
</tr>
<tr>
<td>Mujib, Shariq</td>
<td>766</td>
</tr>
<tr>
<td>Mukandavire, Zindoga</td>
<td>1025, 1037</td>
</tr>
<tr>
<td>Mukim, Amey</td>
<td>1025, 1037</td>
</tr>
<tr>
<td>Mukumbwa-Mwenechanya, Mpande</td>
<td>1004</td>
</tr>
<tr>
<td>Mulato, Andrew</td>
<td>38, 433, 434</td>
</tr>
<tr>
<td>Mulenga, Fredah</td>
<td>740</td>
</tr>
<tr>
<td>Muller, Odelia</td>
<td>718</td>
</tr>
<tr>
<td>Mulligan, Kathleen</td>
<td>839, 847</td>
</tr>
<tr>
<td>Mukinda, Bezil</td>
<td>20</td>
</tr>
<tr>
<td>Name</td>
<td>Pages</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Oksenhendler, Eric</td>
<td>323, 603</td>
</tr>
<tr>
<td>Okulicz, Jason</td>
<td>358, 668, 865, 932</td>
</tr>
<tr>
<td>Olaiya, Oluwatosin</td>
<td>907</td>
</tr>
<tr>
<td>Olawore, Olusolasope M.</td>
<td>1015</td>
</tr>
<tr>
<td>Oldenbuellett, Celia</td>
<td>42</td>
</tr>
<tr>
<td>Oldenburg, Catherine E.</td>
<td>968, 972</td>
</tr>
<tr>
<td>Olender, Susan</td>
<td>682</td>
</tr>
<tr>
<td>Oliveria, Augusto Cesar Penalva</td>
<td>388</td>
</tr>
<tr>
<td>Olimedo Reneaum, Rodrigo Alejandro</td>
<td>225</td>
</tr>
<tr>
<td>Olney, Jack</td>
<td>115</td>
</tr>
<tr>
<td>Oluch, Tom</td>
<td>847</td>
</tr>
<tr>
<td>Ongando, Eunice</td>
<td>982</td>
</tr>
<tr>
<td>Omari, Habib R.</td>
<td>997</td>
</tr>
<tr>
<td>Omwooyo, Willis</td>
<td>764, 792</td>
</tr>
<tr>
<td>Onchiri, Frankline</td>
<td>982</td>
</tr>
<tr>
<td>Ondoa, Pascale</td>
<td>467</td>
</tr>
<tr>
<td>Ongubo, Dennis</td>
<td>783</td>
</tr>
<tr>
<td>Ongwande, Sumet</td>
<td>793</td>
</tr>
<tr>
<td>Ononaku, Uchenna</td>
<td>918, 997</td>
</tr>
<tr>
<td>Onorato, Lorenzo</td>
<td>537</td>
</tr>
<tr>
<td>Onya, Dorina</td>
<td>459, 917</td>
</tr>
<tr>
<td>Ongendo, Jacob</td>
<td>982</td>
</tr>
<tr>
<td>Ongendo, Mathews</td>
<td>985</td>
</tr>
<tr>
<td>Oord, Gertine van.</td>
<td>587</td>
</tr>
<tr>
<td>Oosthuizen, Christa</td>
<td>990</td>
</tr>
<tr>
<td>Op de Coul, Eline</td>
<td>1041</td>
</tr>
<tr>
<td>Ope-Opario, Don</td>
<td>892</td>
</tr>
<tr>
<td>Opoku, Jenevieve</td>
<td>872, 905</td>
</tr>
<tr>
<td>Opollo, Valarie Sarah</td>
<td>728, 764, 792</td>
</tr>
<tr>
<td>Orzuzulke, Ileanji</td>
<td>918, 997</td>
</tr>
<tr>
<td>Orden, Samuel</td>
<td>609</td>
</tr>
<tr>
<td>Orlando, Gabriella</td>
<td>635</td>
</tr>
<tr>
<td>Orlova, Nina</td>
<td>292</td>
</tr>
<tr>
<td>Orofino, Giancarlo</td>
<td>360</td>
</tr>
<tr>
<td>Orr, Cody</td>
<td>386</td>
</tr>
<tr>
<td>Orbellou, Katrina F.</td>
<td>983</td>
</tr>
<tr>
<td>Ortega, Jose</td>
<td>508</td>
</tr>
<tr>
<td>Ortiz, Geneva</td>
<td>897</td>
</tr>
<tr>
<td>Osburn, William</td>
<td>518</td>
</tr>
<tr>
<td>Osei-Kuffour, Edmund</td>
<td>161</td>
</tr>
<tr>
<td>Osier, Mark</td>
<td>434</td>
</tr>
<tr>
<td>Osier, Meg</td>
<td>990</td>
</tr>
<tr>
<td>Osman, Nathan</td>
<td>498</td>
</tr>
<tr>
<td>Osmand, Thomas</td>
<td>1051</td>
</tr>
<tr>
<td>Osna, Natalie</td>
<td>588</td>
</tr>
<tr>
<td>Oster, Alexandra</td>
<td>187, 188, 478, 845LB, 889</td>
</tr>
<tr>
<td>Ostrander, Darin</td>
<td>317</td>
</tr>
<tr>
<td>Ostrowski, Mario</td>
<td>233</td>
</tr>
<tr>
<td>Osuna, Christa</td>
<td>338LB</td>
</tr>
<tr>
<td>Oteru, Luis</td>
<td>562</td>
</tr>
<tr>
<td>Otieno-Nyunya, Boaz</td>
<td>982, 986</td>
</tr>
<tr>
<td>Otswome, Kenneth K.</td>
<td>823, 824</td>
</tr>
<tr>
<td>Ouattara, Eric Nindouagues</td>
<td>476</td>
</tr>
<tr>
<td>Ounchanum, Pradthana</td>
<td>759, 820</td>
</tr>
<tr>
<td>Oursler, Krisana</td>
<td>667</td>
</tr>
<tr>
<td>Ouyang, Zhengyu</td>
<td>250</td>
</tr>
<tr>
<td>Ovsha, Julie</td>
<td>242, 243, 765, 796</td>
</tr>
<tr>
<td>Overtor, Edgar Turner</td>
<td>213, 678</td>
</tr>
<tr>
<td>Owari, Asphas</td>
<td>638, 836, 1051</td>
</tr>
<tr>
<td>Owen, Andrew</td>
<td>39, 416, 418, 423</td>
</tr>
<tr>
<td>Owen, Christopher Leigh</td>
<td>197</td>
</tr>
<tr>
<td>Owens, Douglas K.</td>
<td>725</td>
</tr>
<tr>
<td>Owino, Frederick</td>
<td>936</td>
</tr>
<tr>
<td>Owino, George</td>
<td>762</td>
</tr>
<tr>
<td>Owiti, Preston</td>
<td>488</td>
</tr>
<tr>
<td>Ower, Maxensia</td>
<td>776, 777</td>
</tr>
<tr>
<td>Owuoth, John</td>
<td>481</td>
</tr>
<tr>
<td>Oyaro, Patrick</td>
<td>762</td>
</tr>
<tr>
<td>Oyengsa, Laura</td>
<td>764, 792</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ozunturk, Ayse Naz.</td>
<td>16</td>
</tr>
<tr>
<td>O’Cleirigh, Connoll</td>
<td>454</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pace, Craig S.</td>
<td>329</td>
</tr>
<tr>
<td>Pachankis, John</td>
<td>965</td>
</tr>
<tr>
<td>Padgett, Denis</td>
<td>719</td>
</tr>
<tr>
<td>Padian, Nancy</td>
<td>995, 1000, 1004</td>
</tr>
<tr>
<td>Padilla, Sergio</td>
<td>647</td>
</tr>
<tr>
<td>Pagani, Nicole</td>
<td>418, 432</td>
</tr>
<tr>
<td>Page, Kimberly</td>
<td>516</td>
</tr>
<tr>
<td>Pahwa, Rajendra</td>
<td>234, 258</td>
</tr>
<tr>
<td>Pahwa, Savita</td>
<td>234, 258, 798</td>
</tr>
<tr>
<td>Paiardini, Mirko</td>
<td>388</td>
</tr>
<tr>
<td>Pal, Tommy</td>
<td>640</td>
</tr>
<tr>
<td>Palanee-Phillips, Thesla</td>
<td>88, 935, 951</td>
</tr>
<tr>
<td>Pali, Kartika</td>
<td>690, 913</td>
</tr>
<tr>
<td>Palazzo, Donatella</td>
<td>575</td>
</tr>
<tr>
<td>Palefsky, Joel</td>
<td>23, 591, 597</td>
</tr>
<tr>
<td>Palella, Frank Joseph.</td>
<td>32, 130, 624, 632, 645, 665, 666, 701, 931</td>
</tr>
<tr>
<td>Palfreeman, Adrian</td>
<td>473</td>
</tr>
<tr>
<td>Palich, Romain</td>
<td>323</td>
</tr>
<tr>
<td>Palk, Laurence</td>
<td>850</td>
</tr>
<tr>
<td>Pallier, Coralie</td>
<td>349</td>
</tr>
<tr>
<td>Pallikkuth, Suresh</td>
<td>234, 258</td>
</tr>
<tr>
<td>Palm, Angelica</td>
<td>37</td>
</tr>
<tr>
<td>Palma, Anton M.</td>
<td>637</td>
</tr>
<tr>
<td>Palma, Paolo</td>
<td>798</td>
</tr>
<tr>
<td>Palmateer, Norah</td>
<td>185</td>
</tr>
<tr>
<td>Palmer, Brent E.</td>
<td>207, 208</td>
</tr>
<tr>
<td>Palmer, Sarah</td>
<td>293, 305</td>
</tr>
<tr>
<td>Palou, Elsa Y.</td>
<td>182</td>
</tr>
<tr>
<td>Paltiel, A. David</td>
<td>456, 476, 1028, 1043</td>
</tr>
<tr>
<td>Palumbo, Paul</td>
<td>826</td>
</tr>
<tr>
<td>Pan, Li</td>
<td>258</td>
</tr>
<tr>
<td>Pan, Sung-Ching</td>
<td>582</td>
</tr>
<tr>
<td>Pancharoen, Chitsanu</td>
<td>759, 807</td>
</tr>
<tr>
<td>Panchofen, Kanokpan</td>
<td>862</td>
</tr>
<tr>
<td>Paneerselvam, Nadagopan</td>
<td>245, 559</td>
</tr>
<tr>
<td>Pankau, Mark David</td>
<td>796</td>
</tr>
<tr>
<td>Panneer, Nivedha</td>
<td>187, 188</td>
</tr>
<tr>
<td>Pantaleo, Giuseppe</td>
<td>265LB, 289</td>
</tr>
<tr>
<td>Panwelker, Nina</td>
<td>378</td>
</tr>
<tr>
<td>Papadakis, Georgios Z.</td>
<td>238</td>
</tr>
<tr>
<td>Papadimitropoulos, Athanasios</td>
<td>549</td>
</tr>
<tr>
<td>Papasavvas, Emmanoulli</td>
<td>326</td>
</tr>
<tr>
<td>Papazian, Emily</td>
<td>69</td>
</tr>
<tr>
<td>Pape, Jean W.</td>
<td>471, 722, 835</td>
</tr>
<tr>
<td>Papp, Eszter</td>
<td>756</td>
</tr>
<tr>
<td>Pardi, Norbert</td>
<td>1057LB</td>
</tr>
<tr>
<td>Paredes, Roger</td>
<td>212</td>
</tr>
<tr>
<td>Parikh, Urvi</td>
<td>951, 952</td>
</tr>
<tr>
<td>Park, Chung</td>
<td>64LB</td>
</tr>
<tr>
<td>Park, Eun-Young</td>
<td>255</td>
</tr>
<tr>
<td>Park, Lawrence</td>
<td>138</td>
</tr>
<tr>
<td>Park, Lesley</td>
<td>257, 606</td>
</tr>
<tr>
<td>Park, Seo Young</td>
<td>944</td>
</tr>
<tr>
<td>Park, Sung Yong</td>
<td>514</td>
</tr>
<tr>
<td>Parker, Robert A.</td>
<td>116, 833</td>
</tr>
<tr>
<td>Parr, Jonathan</td>
<td>522</td>
</tr>
<tr>
<td>Parruti, Giustino</td>
<td>564</td>
</tr>
<tr>
<td>Partisani, Marialuisa</td>
<td>495</td>
</tr>
<tr>
<td>Pascasio, Juan Manuel</td>
<td>566</td>
</tr>
<tr>
<td>Pascoe, Sophie</td>
<td>1021</td>
</tr>
<tr>
<td>Pasipamire, Munyadarzdi</td>
<td>708</td>
</tr>
<tr>
<td>Pasquazi, Caterina</td>
<td>564</td>
</tr>
<tr>
<td>Passmore, Jo-Ann</td>
<td>949</td>
</tr>
<tr>
<td>Pasternak, Alexander</td>
<td>286</td>
</tr>
</tbody>
</table>
Author Index

CROI 2017

Pastor, Roque 614
Patel, Eshan Uday. 515, 516, 558, 881
Patel, Faeezah 27, 819
Patel, Hetal 114LB
Patel, Kunjal 779, 805
Patel, Pragna 150, 597
Patel, Raju RK. 745
Patel, Rena 947
Patel, Rupa Rajesh. 972
Patel, Sadhna V. 35
Patel, Vipulkumar N. 68
Patel, Viraj V. 1016
Pathak, Vinay K. 17, 164, 173, 227, 334
Pathipvanich, Panita 863
Pati Pascom, Ana Roberta. 1040
Patrick, Rudy 872
Pattamasavin, Suwanna 249
Pattanachaiwit, Supanit 863
Pattanasin, Sarika 855
Patterson, Thomas L. 844
Patton, Stephanie M. 377
Patts, Gregory 673
Pau, Alice K. 409a
Paul, Mary 810, 815
Paul, Robert 363, 381, 394, 395, 401
Pauk, Merit 461
Pavlin, Julie 668, 865, 932
Pawlowski, Anna 622
Pedrioli, Patrick 263
Peel, Sheila A. 481
Peeling, Rosanna W. 105
Peeters, Martine 218, 482, 486
Pelc, Rebecca S. 1057LB
Pellegrin, Isabelle 630
Peña, Alejandro 647
Peña, Jose M 578
Pena, Stephanie 965
Peñaflael, Judith 540, 541
Peñaranda, Martina 101, 809
Penazzato, Martina 647
Pereyra, Florencia 325
Perez, Alejandro 737
Perez, Ana Belen. 566
Pere, Idene 517
Perez, Janice 1055LB
Pérez-Latorre, Leire 533
Pérez-Martínez, Laura 595
Pérez-Molina, José A. 595
Pérez-Pérez, Montserrat 571
Pérez-Santiago, Josue 353, 390
Pérez-Valero, Ignacio 400, 652
Periés, Marianne 781
Perinelli, Paola 575
Perlman, David C. 547
Perlowski, Charlotte 760
Perna, Angelica 585
Perno, Carlo F. 366, 564, 565
Perona, Rosario 652
Perreau, Matthieu 289
Persad, Yasmeen 926
Persaud, Deborah 803
Person, Anna K. 912
Pertea, Mihaela 296
Peter, Trevor 26
Peters, Helen 831
Peters, Paul J. 365
Peters, Philip J. 189, 477, 878
Petersen, Maya L. 36, 638, 726, 832, 836, 858, 860, 1051
Peterson, Christopher 321, 322, 332
Peterson, James 872
Peterson, Scott N. 390
Petito, Chipo 25, 784
Petrov, Konstantinos 267
Petitferr, Audrey 859, 879
Petit, April C. 191, 912
Peytavin, Gilles 458
Pfei, Sarah 956
Phalora, Prabhjeeet 324
Pham Thi, Thanh Thuy 83, 463
Phang, Tawambille 859
Panh, Salinda 475
Phanunphak, Prapan 125, 698
Phanuphak, Nittaya 124, 205, 214, 291, 299LB, 863
Phetsouphanh, Chansavath 261
Phillips, Andrew 1030, 112, 128LB, 650, 693
Phillips, Gregory 843
Phillips, Patrick 723LB
Phillips, Tamsin 24, 769, 771, 992
Phiri, Eddy Moffo 602
Phiri, Jane 941
Phiri, Mwelwa 1010
Phiri, Sam 602, 783
Phuong, Dang 807
Phunpithak, Supalak 698
Phuc, Pham Thi Hanh. 83
Phulosa, Jacob 686
Pialoux, Gilles 654, 911B
Picarelli, Chiara 445
Pick, Neora 553, 599, 939
Pich, Louis J. 49
Pierson, Theodore C. 1057LB
Pieterman, Elise D. 620
Piggott, Damani A. 133
Pignatti, Riccardo 362
Pilgora, Cheryl 424, 425
Pic, Christophe D. 170, 284, 380, 511, 512, 876
Pillai, Satish K. 170, 208, 314, 797
Pillay, Deenan 43, 491, 960, 983, 1018
Pillay, Sandip 29LB, 648
Pillay, Yogan 1019, 1046
Pilotto, Jose H. 772
Pineda, Juan A. 139, 532, 536, 538, 555, 570, 571, 697
Pinetti, Carmela 354, 366, 466
Pinto, Angie Natalie. 472, 888
Pinto, Jorge 815, 816
Pintye, Jillian 761, 970
Pinyakorn, Suteeraporn 124, 125, 214, 249, 270
Pizzone, Marlia Rita. 283
Piovesan, Mauro 386
Piper, Jeanna 935
Pipkin, Sharon 910
Pisa, Pedro 857
Pisarski, Emily E. 1003
Pistorius, Marcel 830
Pittaluga, Stefania 221
Piwowar-Manning, Estelle 955, 1002
Planer, Michael 341, 361, 526, 629, 646, 933
Plantier, Jean-Christophe 192
Playford, Martin Playford 612
Plazy, Mélanie 1018
Pledgerleith, Lindsey J. 181LB
Plana, Montserrat 336, 614
Planelles, Vicente 311
Platner, Emily E. 1003
Pistorius, Marcel 830
Pittaluga, Stefania 221
Piwowar-Manning, Estelle 955, 1002
Plana, Montserrat 336, 614
Planelles, Vicente 311
Plankey, Michael 341, 361, 526, 629, 646, 933
Pissanter, Pedro 857
Pisarski, Emily E. 1003
Pistorius, Marcel 830
Pittaluga, Stefania 221
Piwowar-Manning, Estelle 955, 1002
Plass, Marcy 829
Planderleith, Lindsey J. 181LB
Plazy, Mélanie 1018
Plenderleith, Lindsey J. 181LB
Plenty, Albert 832
Plessis, Lorraine 278
Plitnik, Timothy 174
Plotnikova, Yulia 443
Plummer, Francis 179
Podany, Anthony 408
Podzamczer, Daniel 382, 651
Poerio, Cody 911
Poindexter, John 677
Poizot-Martin, Isabelle 550
Polacino, Patricia 321, 322
Pollack, Ross 296
Poluektova, Larisa 588
Polyak, Christina 355, 481
Pons, Amanda 605
Pons, Pau 471
Pontali, Emanuele 734
Port, Michael 244, 317, 34LB, 515, 516, 880, 881, 904
Portman, Steve 431
Porte, Eric 100
Porter, Kholoud 491
Porter, Laura 114LB
Porter, Sarah E. 477
Porterfield, Zach 236
Portilla, Joaquin 647
Post, Frank 650, 688
Post, Wendy 624, 632, 636LB, 701
Postma, Anneloes 731
Potempa, Marc 198
Potenza, Nicola 537
Potter, Clinton 14LB
Poulet, Elisabeth 1006
Poursahan, Nader 437
Powis, Kathleen M. 502, 780, 1017
Poznaniak, Anton 186, 382, 569
Pradat, Pierre 550
Pradep, Arno 558, 559
Pradier, Christian 72, 693
Preiser, Wolfgang 989
Prejean, Joseph 1012
Prendergast, Andrew 117, 786
Presslau, Claire 811
Presti, Rachel 213
Preston, Richard A. 430
Preterius Holme, Molly 1009
Price, Jennifer 526, 701
Price, Joan T. 859
Price, Kristyn A. 877, 878
Price, Lance 87
Price, Matt A. 200, 202, 856, 876, 1022
Price, Richard W. 72, 73, 364, 389, 391
Priddie, Frances 976
<table>
<thead>
<tr>
<th>Author</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ramogola-Masire, Doreen</td>
<td>152</td>
</tr>
<tr>
<td>Ramos, Jose Tomas</td>
<td>802</td>
</tr>
<tr>
<td>Ramsey, Benjamin</td>
<td>691</td>
</tr>
<tr>
<td>Rannard, Steve</td>
<td>39</td>
</tr>
<tr>
<td>Ransier, Amy</td>
<td>60</td>
</tr>
<tr>
<td>Rao, Deepa</td>
<td>851, 921</td>
</tr>
<tr>
<td>Raoof, Fahimeh</td>
<td>337</td>
</tr>
<tr>
<td>Rapoport, James</td>
<td>867</td>
</tr>
<tr>
<td>Rappold, Michaela</td>
<td>631</td>
</tr>
<tr>
<td>Rapuano, Patrick</td>
<td>Burns</td>
</tr>
<tr>
<td>Rasmussen, Sarah</td>
<td>689</td>
</tr>
<tr>
<td>Rasmussen, Thomas</td>
<td>Aagaard</td>
</tr>
<tr>
<td>Ratanshi, Rosalind Parkes</td>
<td>1001</td>
</tr>
<tr>
<td>Rathod, Sujit</td>
<td>911</td>
</tr>
<tr>
<td>Rattlhagana, Mary-Jane</td>
<td>111</td>
</tr>
<tr>
<td>Ratnaratorn, Nisakorn</td>
<td>344</td>
</tr>
<tr>
<td>Ratnaratorn, Nisakorn</td>
<td>344</td>
</tr>
<tr>
<td>Ratnaratorn, Nisakorn</td>
<td>344</td>
</tr>
<tr>
<td>Rauji, Dana</td>
<td>440, 508</td>
</tr>
<tr>
<td>Rawlings, David J.</td>
<td>335</td>
</tr>
<tr>
<td>Rawls, Anthony</td>
<td>872</td>
</tr>
<tr>
<td>Ray, Adrian</td>
<td>436</td>
</tr>
<tr>
<td>Ray, Stuart C</td>
<td>141, 518</td>
</tr>
<tr>
<td>Raymond, Stephanie</td>
<td>349</td>
</tr>
<tr>
<td>Raymond Marchand, Laurence</td>
<td>785</td>
</tr>
<tr>
<td>Read, Ron</td>
<td>866</td>
</tr>
<tr>
<td>Read, Ron</td>
<td>866</td>
</tr>
<tr>
<td>Real, Luis M.</td>
<td>532</td>
</tr>
<tr>
<td>Rebeiro, Peter F.</td>
<td>840, 912</td>
</tr>
<tr>
<td>Rebensburg, Stephanie</td>
<td>157, 160LB</td>
</tr>
<tr>
<td>Reid, Michael J.A.</td>
<td>526</td>
</tr>
<tr>
<td>Reif, Lindsey</td>
<td>722, 835</td>
</tr>
<tr>
<td>Reich, Daniel S.</td>
<td>371, 402</td>
</tr>
<tr>
<td>Reich, Daniel S.</td>
<td>371, 402</td>
</tr>
<tr>
<td>Reizes, Peter</td>
<td>1041, 128LB</td>
</tr>
<tr>
<td>Reiuliet, Véronique</td>
<td>821</td>
</tr>
<tr>
<td>Remien, Robert</td>
<td>24</td>
</tr>
<tr>
<td>Rentsch, Christopher</td>
<td>626</td>
</tr>
<tr>
<td>Requena, Mary</td>
<td>223</td>
</tr>
<tr>
<td>Resino, Salvador</td>
<td>530</td>
</tr>
<tr>
<td>Resnati, Chiara</td>
<td>396</td>
</tr>
<tr>
<td>Reutz, Julie</td>
<td>471</td>
</tr>
<tr>
<td>Revill, Paul</td>
<td>112, 1030</td>
</tr>
<tr>
<td>Revollo, Boris</td>
<td>139, 538</td>
</tr>
<tr>
<td>Rewari, Bharat Bhushan</td>
<td>456</td>
</tr>
<tr>
<td>Rey, David</td>
<td>495</td>
</tr>
<tr>
<td>Reynes, Jacques</td>
<td>135, 550, 605, 654</td>
</tr>
<tr>
<td>Reynolds, James</td>
<td>649</td>
</tr>
<tr>
<td>Reynolds, Steven J.</td>
<td>104, 34LB, 880, 996</td>
</tr>
<tr>
<td>Reynoso, David</td>
<td>696</td>
</tr>
<tr>
<td>Rezek, Valerie</td>
<td>254, 331, 332</td>
</tr>
<tr>
<td>Rhee, Martin</td>
<td>424, 425</td>
</tr>
<tr>
<td>Rhee, Soo-Yon</td>
<td>485, 506</td>
</tr>
<tr>
<td>Rhein, Josh</td>
<td>744, 746</td>
</tr>
<tr>
<td>Rheinmann, Lara</td>
<td>20</td>
</tr>
<tr>
<td>Ribas, Maria Angeles</td>
<td>659</td>
</tr>
<tr>
<td>Ribaudo, Heather</td>
<td>414</td>
</tr>
<tr>
<td>Ribeiro, Clea Elsa</td>
<td>386</td>
</tr>
<tr>
<td>Ribet, Celine</td>
<td>654</td>
</tr>
<tr>
<td>Rice, William</td>
<td>14LB</td>
</tr>
<tr>
<td>Rich, Josiah D.</td>
<td>1044</td>
</tr>
<tr>
<td>Richard, Léo</td>
<td>190</td>
</tr>
<tr>
<td>Richardson, Babara A.</td>
<td>22, 765</td>
</tr>
<tr>
<td>Richardson, Kelly</td>
<td>803</td>
</tr>
<tr>
<td>Richman, Douglas D.</td>
<td>113, 200, 201, 300, 307, 319, 326</td>
</tr>
<tr>
<td>Richmond, Gary J.</td>
<td>442, 449LB</td>
</tr>
<tr>
<td>Richter, Clemens</td>
<td>136</td>
</tr>
<tr>
<td>Rick, Fernanda</td>
<td>464</td>
</tr>
<tr>
<td>Ricciotti, Martina</td>
<td>354</td>
</tr>
<tr>
<td>Riddler, Sharon</td>
<td>330LB, 952</td>
</tr>
<tr>
<td>Riegel, Armin</td>
<td>631</td>
</tr>
<tr>
<td>Riera, Melchor</td>
<td>651, 659</td>
</tr>
<tr>
<td>Rife, Brittany</td>
<td>69</td>
</tr>
<tr>
<td>Rijnders, Bart</td>
<td>136, 137LB, 451LB, 620, 731</td>
</tr>
<tr>
<td>Riley, Laura</td>
<td>Elizabeth</td>
</tr>
<tr>
<td>Rimland, David</td>
<td>626</td>
</tr>
<tr>
<td>Rimola, Antonio</td>
<td>540, 541</td>
</tr>
<tr>
<td>Rinaldi, Stefano</td>
<td>234, 258</td>
</tr>
<tr>
<td>Rinaldo, Charles</td>
<td>280</td>
</tr>
<tr>
<td>Rinke de Wit, Tobias F.</td>
<td>467, 488</td>
</tr>
<tr>
<td>Rios, Jessica</td>
<td>380</td>
</tr>
<tr>
<td>Rios Prego, Monica</td>
<td>734</td>
</tr>
<tr>
<td>Rios-Villegas, Maria J.</td>
<td>139, 536, 570</td>
</tr>
<tr>
<td>Risch, Lorenz</td>
<td>721</td>
</tr>
<tr>
<td>Rita, Casetti</td>
<td>203</td>
</tr>
<tr>
<td>Ritz, Justin</td>
<td>330LB</td>
</tr>
<tr>
<td>Riva, Agostino</td>
<td>265LB, 396, 410</td>
</tr>
<tr>
<td>Riveira-Muñoz, Eva</td>
<td>259</td>
</tr>
<tr>
<td>Rivera, Javier</td>
<td>212</td>
</tr>
<tr>
<td>Rivera, Vanessa</td>
<td>722, 835</td>
</tr>
<tr>
<td>Rivero, Antonio</td>
<td>566, 573, 697</td>
</tr>
<tr>
<td>Rivero-Juárez, Antonio</td>
<td>139, 532, 571, 573</td>
</tr>
<tr>
<td>Ricciotti, Giuliano</td>
<td>410, 564, 565</td>
</tr>
<tr>
<td>Roan, Nadia R.</td>
<td>170</td>
</tr>
<tr>
<td>Robb, Merlin L.</td>
<td>124, 197, 249, 270, 282, 291, 299LB</td>
</tr>
<tr>
<td>Robbins, Gregory K.</td>
<td>838</td>
</tr>
<tr>
<td>Roberts, Owain</td>
<td>423</td>
</tr>
<tr>
<td>Roberts, Tessa</td>
<td>919</td>
</tr>
<tr>
<td>Robertson, Kevin</td>
<td>72, 73, 342, 343, 359, 369, 380, 665</td>
</tr>
<tr>
<td>Robichaux, Spencer</td>
<td>217</td>
</tr>
<tr>
<td>Robinson, Cameron</td>
<td>1056LB</td>
</tr>
<tr>
<td>Robinson, Nicola</td>
<td>301, 324</td>
</tr>
<tr>
<td>Roby, Gregg</td>
<td>287</td>
</tr>
<tr>
<td>Rocca, Salvatore</td>
<td>798</td>
</tr>
<tr>
<td>Rocha, Susana</td>
<td>155</td>
</tr>
<tr>
<td>Rockstroh, Jürgen K.</td>
<td>551, 576, 580, 704</td>
</tr>
<tr>
<td>Rodgers, Mary</td>
<td>510, 577</td>
</tr>
<tr>
<td>Rodriguez, Allan</td>
<td>234, 258</td>
</tr>
<tr>
<td>Rodriguez, Violeta</td>
<td>770</td>
</tr>
<tr>
<td>Rodriguez-Arrondo, Francisco</td>
<td>139, 538</td>
</tr>
<tr>
<td>Rodriguez-Barradas, Maria</td>
<td>127, 606, 626, 658, 702, 930</td>
</tr>
<tr>
<td>Rodriguez-Cano, Diego</td>
<td>573</td>
</tr>
<tr>
<td>Rodriguez-Hart, Cristina</td>
<td>918</td>
</tr>
<tr>
<td>Rogers, Anna</td>
<td>762</td>
</tr>
<tr>
<td>Rohan, Lisa C.</td>
<td>866LB</td>
</tr>
<tr>
<td>Rohr, Julia K.</td>
<td>639, 916, 991</td>
</tr>
<tr>
<td>Rojanawiwat, Archawin</td>
<td>793</td>
</tr>
<tr>
<td>Rojas, John</td>
<td>1013</td>
</tr>
<tr>
<td>Rojas, Sarah</td>
<td>548</td>
</tr>
<tr>
<td>Rojas-Castro, Daniela</td>
<td>91LB</td>
</tr>
<tr>
<td>Rokku, Casper</td>
<td>45LB, 620, 731</td>
</tr>
<tr>
<td>Rolland, Morgane</td>
<td>197, 299LB</td>
</tr>
<tr>
<td>Rolle, Charlotte-Paige Melanie</td>
<td>90</td>
</tr>
<tr>
<td>Romano Ibarra, Guillermo</td>
<td>335</td>
</tr>
<tr>
<td>Romero, Jorge</td>
<td>595</td>
</tr>
<tr>
<td>Romero, Klaus</td>
<td>723LB</td>
</tr>
<tr>
<td>Romero-Palacios, Alberto</td>
<td>538</td>
</tr>
<tr>
<td>Ronan, Agnes</td>
<td>769, 771</td>
</tr>
<tr>
<td>Roncadori, Andrea</td>
<td>460</td>
</tr>
</tbody>
</table>

262 CROI 2017
<table>
<thead>
<tr>
<th>Author Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ronchetti, Anne-Marie</td>
<td>603</td>
</tr>
<tr>
<td>Ronzi, Paola</td>
<td>579</td>
</tr>
<tr>
<td>Roinasie, Shawn Jarroth</td>
<td>987</td>
</tr>
<tr>
<td>Roon, Laura</td>
<td>405</td>
</tr>
<tr>
<td>Rossa Umbert, Miriam</td>
<td>271</td>
</tr>
<tr>
<td>Rose, Charles</td>
<td>32</td>
</tr>
<tr>
<td>Rose, Herbert</td>
<td>903</td>
</tr>
<tr>
<td>Ross, Rebecca</td>
<td>518</td>
</tr>
<tr>
<td>Rosebush, Julia C.</td>
<td>822</td>
</tr>
<tr>
<td>Rosen, Sydney</td>
<td>1050</td>
</tr>
<tr>
<td>Rosenberg, Eli</td>
<td>1024, 1033, 1034, 1055LB, 90</td>
</tr>
<tr>
<td>Rosenberg, Eric</td>
<td>292</td>
</tr>
<tr>
<td>Rosenberg, Molly</td>
<td>991</td>
</tr>
<tr>
<td>Rosenberg, Nora E.</td>
<td>859</td>
</tr>
<tr>
<td>Rosenbloom, Daniel I.S.</td>
<td>318</td>
</tr>
<tr>
<td>Rosakam-Kwint, Marieke</td>
<td>429</td>
</tr>
<tr>
<td>Ross, Christine</td>
<td>743</td>
</tr>
<tr>
<td>Ross, Jonathan</td>
<td>1016</td>
</tr>
<tr>
<td>Ross, Michael</td>
<td>653</td>
</tr>
<tr>
<td>Rossaro, Lorenzo</td>
<td>568LB</td>
</tr>
<tr>
<td>Rossi, Fiorella Patricia</td>
<td>376</td>
</tr>
<tr>
<td>Rossi, Francesca</td>
<td>531</td>
</tr>
<tr>
<td>Rossi, Paolo</td>
<td>798</td>
</tr>
<tr>
<td>Roth, David</td>
<td>735</td>
</tr>
<tr>
<td>Roth, Eric</td>
<td>966</td>
</tr>
<tr>
<td>Rothman, Richard</td>
<td>956</td>
</tr>
<tr>
<td>Rothrock, Ginger</td>
<td>420</td>
</tr>
<tr>
<td>Rotta, Indianaan</td>
<td>386</td>
</tr>
<tr>
<td>Roudiere, Laurent</td>
<td>520</td>
</tr>
<tr>
<td>Rough, Kathryn</td>
<td>779</td>
</tr>
<tr>
<td>Rouskin, Silvi</td>
<td>8</td>
</tr>
<tr>
<td>Routy, Jean-Pierre</td>
<td>123, 204, 264, 274</td>
</tr>
<tr>
<td>Rouzier, Vanessa</td>
<td>816</td>
</tr>
<tr>
<td>Rouzioux, Christine</td>
<td>775</td>
</tr>
<tr>
<td>Rowan, Sarah E.</td>
<td>528</td>
</tr>
<tr>
<td>Rowe, William</td>
<td>38</td>
</tr>
<tr>
<td>Rowland-Jones, Sarah</td>
<td>202</td>
</tr>
<tr>
<td>Rowley, Christopher</td>
<td>502</td>
</tr>
<tr>
<td>Roy, Daisy</td>
<td>512</td>
</tr>
<tr>
<td>Roy, Monika</td>
<td>1000, 1004</td>
</tr>
<tr>
<td>RoyChoudhury, Arindam</td>
<td>682</td>
</tr>
<tr>
<td>Royse, Kathryn E.</td>
<td>539</td>
</tr>
<tr>
<td>Rozera, Gabriella</td>
<td>466</td>
</tr>
<tr>
<td>Rua, Réjane</td>
<td>190</td>
</tr>
<tr>
<td>Rubin, Leah H.</td>
<td>341, 350</td>
</tr>
<tr>
<td>Rude, Eric</td>
<td>903</td>
</tr>
<tr>
<td>Ruel, Theodore</td>
<td>726, 768, 797, 806, 832</td>
</tr>
<tr>
<td>Ruelas, Debbie Sophia</td>
<td>337</td>
</tr>
<tr>
<td>Ruff, Joshua H.</td>
<td>822</td>
</tr>
<tr>
<td>Ruffner, Andrew</td>
<td>956</td>
</tr>
<tr>
<td>Ruixo, Carlos Pérez</td>
<td>427</td>
</tr>
<tr>
<td>Ruiz, Eduardo</td>
<td>380</td>
</tr>
<tr>
<td>Ruiz-Giardin, Jose Manuel</td>
<td>752</td>
</tr>
<tr>
<td>Rukobo, Sandra</td>
<td>786</td>
</tr>
<tr>
<td>Ruone, Susan</td>
<td>954</td>
</tr>
<tr>
<td>Rupert, Adam</td>
<td>126, 225, 226</td>
</tr>
<tr>
<td>Rusconi, Stefano</td>
<td>303, 396</td>
</tr>
<tr>
<td>Ruset, Peter</td>
<td>66, 67</td>
</tr>
<tr>
<td>Russel, Frans G.M.</td>
<td>753</td>
</tr>
<tr>
<td>Russell, Ronnie M.</td>
<td>181LB</td>
</tr>
<tr>
<td>Russo, Aniello</td>
<td>537</td>
</tr>
<tr>
<td>Rutledge, Brandy</td>
<td>685LB</td>
</tr>
<tr>
<td>Rüütel, Kristi</td>
<td>1028</td>
</tr>
<tr>
<td>Ruxrungtham, Kiat</td>
<td>698, 705</td>
</tr>
<tr>
<td>Ryan, Pablo</td>
<td>534</td>
</tr>
<tr>
<td>Ryom, Lene</td>
<td>128LB, 131, 653, 693</td>
</tr>
<tr>
<td>Saag, Michael</td>
<td>138</td>
</tr>
<tr>
<td>Sabi, Issa</td>
<td>788</td>
</tr>
<tr>
<td>Sabin, Caroline</td>
<td>128LB, 352LB, 650, 672, 679, 693</td>
</tr>
<tr>
<td>Sacco, Carlo</td>
<td>344</td>
</tr>
<tr>
<td>Sacktor, Ned</td>
<td>356, 359</td>
</tr>
<tr>
<td>Saduvala, Neeraja</td>
<td>478</td>
</tr>
<tr>
<td>Saeed, Sahar</td>
<td>533</td>
</tr>
<tr>
<td>Sagar, Manish</td>
<td>177</td>
</tr>
<tr>
<td>Sagnelli, Caterina</td>
<td>531</td>
</tr>
<tr>
<td>Sagnelli, Evangelista</td>
<td>531, 537</td>
</tr>
<tr>
<td>Sah Bandar, Ivo</td>
<td>255</td>
</tr>
<tr>
<td>Sahi, Sharon</td>
<td>749, 750</td>
</tr>
<tr>
<td>Sahni, Jaya</td>
<td>335</td>
</tr>
<tr>
<td>Sahoo, Debashis</td>
<td>374</td>
</tr>
<tr>
<td>Saisalutsa, Napapon</td>
<td>339, 363, 394</td>
</tr>
<tr>
<td>Sainz, Talia</td>
<td>527, 802</td>
</tr>
<tr>
<td>Saito, Suzue</td>
<td>706</td>
</tr>
<tr>
<td>Sakala, Doreen</td>
<td>895</td>
</tr>
<tr>
<td>Sakowicz, Roman</td>
<td>434</td>
</tr>
<tr>
<td>Sakr, Sameh</td>
<td>227</td>
</tr>
<tr>
<td>Salanave, Benoit</td>
<td>821</td>
</tr>
<tr>
<td>Salazar-Austin, Nicole</td>
<td>707</td>
</tr>
<tr>
<td>Salcuni, Paul M.</td>
<td>891, 898</td>
</tr>
<tr>
<td>Salemi, Marco</td>
<td>69</td>
</tr>
<tr>
<td>Salgado, Maria</td>
<td>306, 320</td>
</tr>
<tr>
<td>Salomon, Joshua A.</td>
<td>833, 983, 991</td>
</tr>
<tr>
<td>Salters, Kate</td>
<td>599, 601</td>
</tr>
<tr>
<td>Salumu, Leon</td>
<td>464, 764, 792, 1006</td>
</tr>
<tr>
<td>Samandari, Tarar</td>
<td>980</td>
</tr>
<tr>
<td>Sambucetti, Lidia</td>
<td>283</td>
</tr>
<tr>
<td>Samet, Jeffrey H.</td>
<td>673</td>
</tr>
<tr>
<td>Samileerat, Tanawan</td>
<td>793</td>
</tr>
<tr>
<td>Samoff, Erika</td>
<td>198</td>
</tr>
<tr>
<td>Sampérez, Gloria</td>
<td>659</td>
</tr>
<tr>
<td>Samir, Assia</td>
<td>290</td>
</tr>
<tr>
<td>Samuel, David C.</td>
<td>229, 377, 392, 393, 691</td>
</tr>
<tr>
<td>San Martin, Juan Victor</td>
<td>752</td>
</tr>
<tr>
<td>Sanchez, Carmen</td>
<td>752</td>
</tr>
<tr>
<td>Sanchez, Rosa</td>
<td>412, 430</td>
</tr>
<tr>
<td>Sanchez, Travis</td>
<td>90</td>
</tr>
<tr>
<td>Sanchez Mellado, Diana</td>
<td>734</td>
</tr>
<tr>
<td>Sánchez Rivas, Elena</td>
<td>504LB</td>
</tr>
<tr>
<td>Sanchez-Lopez, Anhia</td>
<td>609</td>
</tr>
<tr>
<td>Sanders, Eduard</td>
<td>202, 856, 886, 893, 976, 1022</td>
</tr>
<tr>
<td>Sanders-Buell, Eric</td>
<td>197, 299LB, 71</td>
</tr>
<tr>
<td>Sanderson, Jeremy</td>
<td>324</td>
</tr>
<tr>
<td>Sands, Bryan</td>
<td>335</td>
</tr>
<tr>
<td>Sane Schepisi, Monica</td>
<td>734</td>
</tr>
<tr>
<td>Sanford, Ryan</td>
<td>397</td>
</tr>
<tr>
<td>Sang, Norton</td>
<td>36, 832</td>
</tr>
<tr>
<td>Sangal, Neel</td>
<td>167</td>
</tr>
<tr>
<td>Sanne, Ian</td>
<td>225, 1050</td>
</tr>
<tr>
<td>Sansom, Stephanie L.</td>
<td>1029</td>
</tr>
<tr>
<td>Santana, Bárbara</td>
<td>388</td>
</tr>
<tr>
<td>Santelli, John</td>
<td>1015</td>
</tr>
<tr>
<td>Santiago, Gilberto</td>
<td>1055LB</td>
</tr>
<tr>
<td>Santiago, Mario</td>
<td>63</td>
</tr>
<tr>
<td>Santoro, Antonella</td>
<td>655</td>
</tr>
<tr>
<td>Santos, Ignacio</td>
<td>534</td>
</tr>
<tr>
<td>Sanz, Gonzalo</td>
<td>595</td>
</tr>
<tr>
<td>Sanz, Jose</td>
<td>572</td>
</tr>
<tr>
<td>Sarafianos, Stefan G.</td>
<td>18, 503</td>
</tr>
<tr>
<td>Sarah Hau, Sarah</td>
<td>549</td>
</tr>
<tr>
<td>Saravanan, Shanmugam</td>
<td>492, 559</td>
</tr>
<tr>
<td>Saricletti, Mario</td>
<td>631</td>
</tr>
<tr>
<td>Sardo, Luca</td>
<td>308</td>
</tr>
<tr>
<td>Sartorius, Benn</td>
<td>817LB</td>
</tr>
<tr>
<td>Sasco, Annie Jeanne</td>
<td>607</td>
</tr>
<tr>
<td>Sastri, Jaya</td>
<td>17</td>
</tr>
<tr>
<td>Sastry, Jagannadhra</td>
<td>422LB</td>
</tr>
<tr>
<td>Satapathy, Sanjaya</td>
<td>568LB</td>
</tr>
<tr>
<td>Author Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Author Index</td>
<td></td>
</tr>
<tr>
<td>Program and Agenda</td>
<td></td>
</tr>
<tr>
<td>CROI 2017</td>
<td></td>
</tr>
<tr>
<td>Sato, Paul</td>
<td>803</td>
</tr>
<tr>
<td>Sattar, Abdus</td>
<td>617, 618</td>
</tr>
<tr>
<td>Savatovsky, Julien</td>
<td>75</td>
</tr>
<tr>
<td>Savic, Radjoka M.</td>
<td>407, 723LB</td>
</tr>
<tr>
<td>Saw, Fredrick</td>
<td>197</td>
</tr>
<tr>
<td>Sax, Paul E.</td>
<td>1043, 325, 41, 453, 45LB, 493, 691</td>
</tr>
<tr>
<td>Sayles, Harlan</td>
<td>963</td>
</tr>
<tr>
<td>Saylor, Deanna</td>
<td>339</td>
</tr>
<tr>
<td>Sazonova, Yana</td>
<td>884</td>
</tr>
<tr>
<td>Scaglioni, Riccardo</td>
<td>655</td>
</tr>
<tr>
<td>Scarsi, Kimberly K.</td>
<td>408, 423, 963</td>
</tr>
<tr>
<td>Schaaf, H. Simon</td>
<td>53</td>
</tr>
<tr>
<td>Schaap, Ab</td>
<td>834, 959, 1010, 1011</td>
</tr>
<tr>
<td>Schackman, Bruce R.</td>
<td>547</td>
</tr>
<tr>
<td>Schackwijk, Stein</td>
<td>753, 754</td>
</tr>
<tr>
<td>Schandel, Laura</td>
<td>827, 828</td>
</tr>
<tr>
<td>Schanz, Merle</td>
<td>67</td>
</tr>
<tr>
<td>Scharenberg, Andrew M.</td>
<td>335</td>
</tr>
<tr>
<td>Schauer, Amanda</td>
<td>406</td>
</tr>
<tr>
<td>Scheeler, Susan</td>
<td>906, 910, 922, 974</td>
</tr>
<tr>
<td>Schellenberg, Gerard D.</td>
<td>74</td>
</tr>
<tr>
<td>Scherpier, Henriette J.</td>
<td>825, 830</td>
</tr>
<tr>
<td>Scherzer, Rebecca</td>
<td>526</td>
</tr>
<tr>
<td>Schewe, Knud</td>
<td>551, 567, 576</td>
</tr>
<tr>
<td>Schief, William R.</td>
<td>143</td>
</tr>
<tr>
<td>Schif, Abigail</td>
<td>232</td>
</tr>
<tr>
<td>Schim van der Loeff, Maarten F</td>
<td>519, 886, 887</td>
</tr>
<tr>
<td>Schinazi, Raymond F</td>
<td>829</td>
</tr>
<tr>
<td>Schinkel, Janke</td>
<td>519</td>
</tr>
<tr>
<td>Schlater, Daniela</td>
<td>169</td>
</tr>
<tr>
<td>Schleimann, Marianne H.</td>
<td>314</td>
</tr>
<tr>
<td>Schub, Timothy E.</td>
<td>305</td>
</tr>
<tr>
<td>Schlusser, Katherine E.</td>
<td>472, 888</td>
</tr>
<tr>
<td>Schmidt, Justin A.</td>
<td>942</td>
</tr>
<tr>
<td>Schmidt, Fabian</td>
<td>220</td>
</tr>
<tr>
<td>Schmidt, Manfred</td>
<td>302</td>
</tr>
<tr>
<td>Schmidt, Stephen</td>
<td>244</td>
</tr>
<tr>
<td>Schmied, Brigitte</td>
<td>631</td>
</tr>
<tr>
<td>Schmitz, Mary</td>
<td>761</td>
</tr>
<tr>
<td>Schnapp, Lynn M.</td>
<td>660</td>
</tr>
<tr>
<td>Schneider, Daniel</td>
<td>622</td>
</tr>
<tr>
<td>Schneider, John A.</td>
<td>849, 969</td>
</tr>
<tr>
<td>Schneider, Marie-Paule</td>
<td>671</td>
</tr>
<tr>
<td>Schneider, Veronique</td>
<td>520, 812</td>
</tr>
<tr>
<td>Schofield, Christina</td>
<td>668, 932</td>
</tr>
<tr>
<td>Schofield, Joe</td>
<td>529</td>
</tr>
<tr>
<td>Schommers, Philipp</td>
<td>176</td>
</tr>
<tr>
<td>Schott, Kerstin</td>
<td>161</td>
</tr>
<tr>
<td>Schrader, Shannon</td>
<td>449LB</td>
</tr>
<tr>
<td>Schrier, Rachel</td>
<td>206</td>
</tr>
<tr>
<td>Schuettfert, Gundolf</td>
<td>738</td>
</tr>
<tr>
<td>Schulze, Christina</td>
<td>633</td>
</tr>
<tr>
<td>Schulke zur Wiesch, Julian</td>
<td>551, 567, 587</td>
</tr>
<tr>
<td>Schumacher, Samuel G.</td>
<td>76LB</td>
</tr>
<tr>
<td>Schurink, Karin</td>
<td>451LB</td>
</tr>
<tr>
<td>Schult, Charlotte</td>
<td>81LB</td>
</tr>
<tr>
<td>Schuurman, Rob</td>
<td>504LB</td>
</tr>
<tr>
<td>Schwarck, Sandy</td>
<td>906</td>
</tr>
<tr>
<td>Schwartz, Jill</td>
<td>86LB</td>
</tr>
<tr>
<td>Schwartz, Jonathan M.</td>
<td>544</td>
</tr>
<tr>
<td>Schwartz, Jordan Ari.</td>
<td>233</td>
</tr>
<tr>
<td>Schwartz, Olivier</td>
<td>194</td>
</tr>
<tr>
<td>Schwarze-Zander, Carolynne</td>
<td>580, 704</td>
</tr>
<tr>
<td>Schwind, Marc</td>
<td>362</td>
</tr>
<tr>
<td>Scott, Hyman</td>
<td>974</td>
</tr>
<tr>
<td>Scott, Jenna</td>
<td>427</td>
</tr>
<tr>
<td>Scott, John D.</td>
<td>9</td>
</tr>
<tr>
<td>Scully, Eileen</td>
<td>281</td>
</tr>
<tr>
<td>Seaberg, Eric</td>
<td>701</td>
</tr>
<tr>
<td>Seage, George R.</td>
<td>779, 805</td>
</tr>
<tr>
<td>Seaton, Kelly</td>
<td>415</td>
</tr>
<tr>
<td>Sebikari, Dorothy</td>
<td>777</td>
</tr>
<tr>
<td>Sebogodi, Phillimon P.</td>
<td>484</td>
</tr>
<tr>
<td>Seeley, Janet</td>
<td>915</td>
</tr>
<tr>
<td>Segev, Dorry</td>
<td>317, 689</td>
</tr>
<tr>
<td>Seifert, Sharon</td>
<td>419</td>
</tr>
<tr>
<td>Seivers, Matthew</td>
<td>244</td>
</tr>
<tr>
<td>Sekaly, Raif-Pierre</td>
<td>60, 304, 321</td>
</tr>
<tr>
<td>Selik, Richard M.</td>
<td>889, 890</td>
</tr>
<tr>
<td>Selinger, Christian</td>
<td>1035, 1036</td>
</tr>
<tr>
<td>Sellers, Christopher</td>
<td>198</td>
</tr>
<tr>
<td>Semba, Richard</td>
<td>648</td>
</tr>
<tr>
<td>Semitala, Fred</td>
<td>1005</td>
</tr>
<tr>
<td>Sendagorta, Elena</td>
<td>595</td>
</tr>
<tr>
<td>SenGupta, Devi</td>
<td>427</td>
</tr>
<tr>
<td>Sent, Baraeti Winnie</td>
<td>1009</td>
</tr>
<tr>
<td>Serada, Paul</td>
<td>929</td>
</tr>
<tr>
<td>Serani, Marco</td>
<td>575</td>
</tr>
<tr>
<td>Sereda, Paul</td>
<td>966, 1042</td>
</tr>
<tr>
<td>Sereti, Irini</td>
<td>214, 221, 225, 226, 238, 287, 368, 473, 733</td>
</tr>
<tr>
<td>Serghides, Lena</td>
<td>756</td>
</tr>
<tr>
<td>Serra-Moreno, Ruth</td>
<td>168</td>
</tr>
<tr>
<td>Serrano, Miriam</td>
<td>555</td>
</tr>
<tr>
<td>Serrano-Villar, Sergio</td>
<td>595, 676, 802</td>
</tr>
<tr>
<td>Serra, Erik</td>
<td>292</td>
</tr>
<tr>
<td>Serrawadda, David</td>
<td>1015, 34LB, 87, 880</td>
</tr>
<tr>
<td>Sethiff, Ian</td>
<td>230</td>
</tr>
<tr>
<td>Severe, Patrice</td>
<td>471</td>
</tr>
<tr>
<td>Seydi, Moussa</td>
<td>440, 508, 642</td>
</tr>
<tr>
<td>Seyedkazemi, Sareh</td>
<td>505</td>
</tr>
<tr>
<td>Seyedkazemi, Star</td>
<td>381</td>
</tr>
<tr>
<td>Shade, Julie Kristin</td>
<td>210</td>
</tr>
<tr>
<td>Shade, Stanley B.</td>
<td>111, 1051</td>
</tr>
<tr>
<td>Shafer, Mark</td>
<td>428</td>
</tr>
<tr>
<td>Shafer, Robert</td>
<td>485, 494, 506</td>
</tr>
<tr>
<td>Shaffer, Ashton</td>
<td>689</td>
</tr>
<tr>
<td>Shafi, Juma</td>
<td>937</td>
</tr>
<tr>
<td>Shah, N. Sarita</td>
<td>50, 77, 728</td>
</tr>
<tr>
<td>Shah, Sanjiv J.</td>
<td>622</td>
</tr>
<tr>
<td>Shaihk, Najma</td>
<td>763</td>
</tr>
<tr>
<td>Shaker, Amir</td>
<td>987</td>
</tr>
<tr>
<td>Shalek, Alex K.</td>
<td>250</td>
</tr>
<tr>
<td>Shalit, Peter</td>
<td>961</td>
</tr>
<tr>
<td>Shally, Mahmoud</td>
<td>893</td>
</tr>
<tr>
<td>Shanabaue, Kwanue</td>
<td>834, 959, 1010, 1011</td>
</tr>
<tr>
<td>Shane, Elizabeth</td>
<td>682</td>
</tr>
<tr>
<td>Shankar, Anupama</td>
<td>189, 477</td>
</tr>
<tr>
<td>Shannon, Dylan</td>
<td>679</td>
</tr>
<tr>
<td>Shao, Wei</td>
<td>227, 294, 305</td>
</tr>
<tr>
<td>Shao, Yongwu</td>
<td>424, 427</td>
</tr>
<tr>
<td>Shapiro, David E.</td>
<td>779, 938</td>
</tr>
<tr>
<td>Shapiro, Nathan D.</td>
<td>433</td>
</tr>
<tr>
<td>Shapiro, Roger L.</td>
<td>25, 100, 502, 787, 789, 790</td>
</tr>
<tr>
<td>Sharyk, Mark</td>
<td>174</td>
</tr>
<tr>
<td>Sharma, Anjali</td>
<td>132, 361, 682</td>
</tr>
<tr>
<td>Sharma, Anjali</td>
<td>1004</td>
</tr>
<tr>
<td>Sharma, Monisha</td>
<td>1032</td>
</tr>
<tr>
<td>Sharma, Shweta</td>
<td>472, 474, 608, 623, 888</td>
</tr>
<tr>
<td>Sharp, David J.</td>
<td>352LB</td>
</tr>
<tr>
<td>Sharp, Katie</td>
<td>489</td>
</tr>
<tr>
<td>Sharp, Paul M.</td>
<td>181LB</td>
</tr>
<tr>
<td>Sharp, Tyler</td>
<td>1055LB</td>
</tr>
<tr>
<td>Shattock, Andrew</td>
<td>1046</td>
</tr>
<tr>
<td>Shearer, Kate</td>
<td>904</td>
</tr>
<tr>
<td>Shebl, Fatma</td>
<td>606</td>
</tr>
<tr>
<td>Sheehan, Gerard</td>
<td>613</td>
</tr>
<tr>
<td>Sheha, Irene</td>
<td>641</td>
</tr>
</tbody>
</table>
Spira, Bonnie 498
Spreoer, Adrian 602, 782
Sreen, William 84, 442
Springer, Gayle 350
Spudich, Serena 1, 70, 71, 72, 339, 344, 363, 364, 380, 387, 391, 394
Squillace, Nicola 222
Squires, Kathleen 443, 45LB
Srikrishnan, Aylur K. 245, 558, 559, 883
Sriram, Robert 90, 901, 1024, 1033, 1034
Summers, Angela 402
Suri, Hsin-Yun 582
Suri, Li 435
Sun, Ly Penh 705
Sun, Philena 634
Sun, Ren 268, 500LB
Sun, Xiaoming 292
Sung, Yen 870, 977
Sun, Xin 79, 710, 717, 720
Sundquist, Wes 20, 21
Suntarattiwong, Piyarat 285, 759, 820
Sunyakumthorn, Piyanate 70
Sura, Monali 412
Surie, Diya 937
Sutcliffe, Catherine 560
Suthar, Mensul 1056LB
Suttichom, Duanghathai 205, 344
Sutton, Kenneth 442
Sutton, Madeline 839
Sutton, Richard 236
Sutton, Sarah H. 469
Swadling, Leo 239
Swaminathan, Shobha 421LB
Swanstrom, Ronald 73, 163, 198, 364, 369
Swanson, Stephanie 420
Swartz, Taila 256
Swathirajan, Chinnambedu 245
Swieboda, Dominika 829
Swindells, Susan 79, 408, 728, 963
Switzer, William M. 189, 477, 877, 878
Sworay, Alice 799
Sykes, Craig 406
Symonds, Geoff 322
Szeklo, Leah 447
Szubert, Alexander J. 117
Szymula, Elisabeth 116, 464, 764, 792, 1006
Szydlowski, Daniel W. 951
Søgaard, Ole Schmeltz 305, 314

Taban, Acaga 914
Tabano, David C. 528
Tabler, Caroline 169
Tabone, Marie-Dominique 812
Tabrizi, Mohammad 337
Tachdjian, Gilda 316
Tada, Takuya 333
Tadesse, Mulualem 713
Taejemeyer, Miriam 896
Taejaroenkul, Sineenart 820
Taguchi, Ayumu 661
Tai, Vincent 123
Takaiwa, Babafemi 342, 369, 665, 666
Takayama, Seiichi 643
Takahama, Yoshihiko 503
Takata, Hiroshi 270
Takata, Matthew 160LB
Tallani, Gloria 564, 575
Tallon, Benjamin 274

Subra, Frédéric 499
Suci, Bertrand 223
Succi, Regina 816
Sudarshana, Taviyita 820
Sugandhi, Nandita 809
Sugrue, Catherine Ann 695
Sukwicha, Wichuda 854, 855, 862
Sulkowski, Mark 138, 558, 559, 560
Sullivan, Claire E. 628
Sullivan, Patrick 90, 901, 1024, 1033, 1034
Summers, Angela 402
Sun, Hsin-Yun 582
Sun, Li 435
Sun, Ly Penh 705
Sun, Philena 634
Sun, Ren 268, 500LB
Sun, Xiaoming 292
Sung, Yen 870, 977
Sun, Xin 79, 710, 717, 720
Sundquist, Wes 20, 21
Suntarattiwong, Piyarat 285, 759, 820
Sunyakumthorn, Piyanate 70
Sura, Monali 412
Surie, Diya 937
Sutcliffe, Catherine 560
Suthar, Mensul 1056LB
Suttichom, Duanghathai 205, 344
Sutton, Kenneth 442
Sutton, Madeline 839
Sutton, Richard 236
Sutton, Sarah H. 469
Swadling, Leo 239
Swaminathan, Shobha 421LB
Swan, Ashley Robb. 403
Swanstrom, Ronald 73, 163, 198, 364, 369
Swanson, Stephanie 420
Swartz, Taila 256
Swathirajan, Chinnambedu 245
Swieboda, Dominika 829
Swindells, Susan 79, 408, 728, 963
Switzer, William M. 189, 477, 877, 878
Sworay, Alice 799
Sykes, Craig 406
Symonds, Geoff 322
Szeklo, Leah 447
Szubert, Alexander J. 117
Szymula, Elisabeth 116, 464, 764, 792, 1006
Szydlowski, Daniel W. 951
Søgaard, Ole Schmeltz 305, 314

---

Taban, Acaga 914
Tabano, David C. 528
Tabler, Caroline 169
Tabone, Marie-Dominique 812
Tabrizi, Mohammad 337
Tachdjian, Gilda 316
Tada, Takuya 333
Tadesse, Mulualem 713
Taejemeyer, Miriam 896
Taejaroenkul, Sineenart 820
Taguchi, Ayumu 661
Tai, Vincent 123
Takaiwa, Babafemi 342, 369, 665, 666
Takayama, Seiichi 643
Takahama, Yoshihiko 503
Takata, Hiroshi 270
Takata, Matthew 160LB
Tallani, Gloria 564, 575
Tallon, Benjamin 274
<table>
<thead>
<tr>
<th>Author</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trastoy, Rocío</td>
<td>578</td>
</tr>
<tr>
<td>Trautmann, Lydie</td>
<td>125, 249, 270</td>
</tr>
<tr>
<td>Traverso, Carlo Giovanni</td>
<td>1035</td>
</tr>
<tr>
<td>Trebicka, Jonel</td>
<td>704</td>
</tr>
<tr>
<td>Treluyer, Jean-Marc</td>
<td>811</td>
</tr>
<tr>
<td>Tremblay, Cécile</td>
<td>204</td>
</tr>
<tr>
<td>Trenchs-Rodriguez, Marta</td>
<td>681</td>
</tr>
<tr>
<td>Treluyer, Alice</td>
<td>360</td>
</tr>
<tr>
<td>Treulinger, Carl Johan</td>
<td>431</td>
</tr>
<tr>
<td>Trevi, Janine M.</td>
<td>687</td>
</tr>
<tr>
<td>Trevi, Lydie</td>
<td>578</td>
</tr>
<tr>
<td>Treutiger, Carl Johan</td>
<td>431</td>
</tr>
<tr>
<td>Trible, Matthew</td>
<td>658</td>
</tr>
<tr>
<td>Trivino Duran, Laura</td>
<td>718, 791</td>
</tr>
<tr>
<td>Trkola, Alexandra</td>
<td>66, 67</td>
</tr>
<tr>
<td>Troyer, Zach</td>
<td>169</td>
</tr>
<tr>
<td>Tsuchida, Mugefu</td>
<td>658</td>
</tr>
<tr>
<td>Truffo, Mattia</td>
<td>360, 379</td>
</tr>
<tr>
<td>Trujillo, Marta</td>
<td>681</td>
</tr>
<tr>
<td>Turk, Teja</td>
<td>191</td>
</tr>
<tr>
<td>Turkki, Vesa</td>
<td>171LB</td>
</tr>
<tr>
<td>Tsang, Manuel</td>
<td>497</td>
</tr>
<tr>
<td>Tsibris, Atie</td>
<td>342</td>
</tr>
<tr>
<td>Tsoi, Benjamin</td>
<td>898</td>
</tr>
<tr>
<td>Tshimanga, Mufuta</td>
<td>984</td>
</tr>
<tr>
<td>Tsholo, Katlego</td>
<td>82, 745</td>
</tr>
<tr>
<td>Tsiang, Manuel</td>
<td>497</td>
</tr>
<tr>
<td>Tsoi, Hung-Chin</td>
<td>450LB</td>
</tr>
<tr>
<td>Tse, Winston C.</td>
<td>38</td>
</tr>
<tr>
<td>Tshefu, Anto</td>
<td>522</td>
</tr>
<tr>
<td>Tsilfis, Mugefu</td>
<td>658</td>
</tr>
<tr>
<td>Tumi, John</td>
<td>111, 958</td>
</tr>
<tr>
<td>Tumino, Nicola</td>
<td>203</td>
</tr>
<tr>
<td>Tumwes, James</td>
<td>781</td>
</tr>
<tr>
<td>Tung, Elyse</td>
<td>961</td>
</tr>
<tr>
<td>Tung, Nguyen Le Nhu</td>
<td>83, 747, 748</td>
</tr>
<tr>
<td>Tura, Nabil M.</td>
<td>690, 762, 921</td>
</tr>
<tr>
<td>Turk, Teja</td>
<td>191</td>
</tr>
<tr>
<td>Turkova, Anna</td>
<td>813</td>
</tr>
<tr>
<td>Turner, Diana</td>
<td>677</td>
</tr>
<tr>
<td>Turner, Megan M.</td>
<td>644, 912</td>
</tr>
<tr>
<td>Tveja, Hannock</td>
<td>602</td>
</tr>
<tr>
<td>Tyler, Shaun</td>
<td>179</td>
</tr>
<tr>
<td>Tylleskær, Thorkild</td>
<td>781, 847</td>
</tr>
<tr>
<td>Ut——</td>
<td></td>
</tr>
<tr>
<td>Uberti-Foppa, Caterina</td>
<td>531</td>
</tr>
<tr>
<td>Ubolymov, Sasvimol</td>
<td>698</td>
</tr>
<tr>
<td>Uehira, Tomoko</td>
<td>426</td>
</tr>
<tr>
<td>Ukaegbu, Chinnye</td>
<td>543, 545</td>
</tr>
<tr>
<td>Ulrich, Angela K.</td>
<td>446</td>
</tr>
<tr>
<td>Unal, Guillemette</td>
<td>192</td>
</tr>
<tr>
<td>Underwood, Jonathan</td>
<td>352LB</td>
</tr>
<tr>
<td>Ungar, Elizabeth</td>
<td>597</td>
</tr>
<tr>
<td>Ungos Pasayan, Mark Kristoffer</td>
<td>705</td>
</tr>
<tr>
<td>Ungschahapand, Cheawvat</td>
<td>855, 862</td>
</tr>
<tr>
<td>Unsal, Aylin</td>
<td>649</td>
</tr>
<tr>
<td>Unutmaz, Derya</td>
<td>800</td>
</tr>
<tr>
<td>Urano, Emiko</td>
<td>507</td>
</tr>
<tr>
<td>Ure, Victor</td>
<td>228</td>
</tr>
<tr>
<td>Usery, Gene</td>
<td>1017</td>
</tr>
<tr>
<td>Utay, Netanya Sandler</td>
<td>251, 696</td>
</tr>
<tr>
<td>V——</td>
<td></td>
</tr>
<tr>
<td>Vaartjes, Ilona</td>
<td>129</td>
</tr>
<tr>
<td>Vai, Daniela</td>
<td>360</td>
</tr>
<tr>
<td>Vaida, Florin</td>
<td>386, 401</td>
</tr>
<tr>
<td>Vaikath, Maria</td>
<td>994</td>
</tr>
<tr>
<td>Valantin, Marc-Antoine</td>
<td>135, 520, 550, 703, 732</td>
</tr>
<tr>
<td>Valdez, Rogelio Miguel</td>
<td>446</td>
</tr>
<tr>
<td>Valdez Madruga, Jose</td>
<td>447, 948</td>
</tr>
<tr>
<td>Valentine, Megan</td>
<td>760</td>
</tr>
<tr>
<td>Valin, Nadia</td>
<td>75</td>
</tr>
<tr>
<td>Vallabhaneni, Snigdha</td>
<td>743</td>
</tr>
<tr>
<td>Van, Phu</td>
<td>265LB</td>
</tr>
<tr>
<td>Van Bortel, Luc</td>
<td>412</td>
</tr>
<tr>
<td>Van Crevel, Reinoat</td>
<td>429, 610</td>
</tr>
<tr>
<td>Van Cutsen, Gilles</td>
<td>791, 927</td>
</tr>
<tr>
<td>Van de Perre, Philippe</td>
<td>781</td>
</tr>
<tr>
<td>Van de Vrijer, David</td>
<td>604</td>
</tr>
<tr>
<td>Van den Berk, Guido</td>
<td>137LB, 470</td>
</tr>
<tr>
<td>Van der Elst, Elisabeth Maria</td>
<td>893, 1022</td>
</tr>
<tr>
<td>Van der Ende, Ineke</td>
<td>604, 731, 754</td>
</tr>
<tr>
<td>Van der Heijden, Wouter Antonio</td>
<td>610</td>
</tr>
<tr>
<td>Van Der Pol, Barbara</td>
<td>867</td>
</tr>
<tr>
<td>Van der Straten, Ariane</td>
<td>420, 936</td>
</tr>
<tr>
<td>Van der Valk, Marc</td>
<td>129, 136</td>
</tr>
<tr>
<td>Van der Ven, André</td>
<td>610</td>
</tr>
<tr>
<td>Van Duyne, Gregory</td>
<td>171LB</td>
</tr>
<tr>
<td>Van Duyne, Rachel</td>
<td>156, 180</td>
</tr>
<tr>
<td>Van Dyke, Russell B.</td>
<td>815, 827, 828</td>
</tr>
<tr>
<td>Van Gorp, Eric</td>
<td>451LB</td>
</tr>
<tr>
<td>Van Hecke, Clarissa</td>
<td>162</td>
</tr>
<tr>
<td>Van Kampen, Jeroen Jacob Alexander</td>
<td>604</td>
</tr>
<tr>
<td>Van Lancker, Gret</td>
<td>412</td>
</tr>
<tr>
<td>Van Loan, Marta</td>
<td>685LB</td>
</tr>
<tr>
<td>Van Niekerk, Christo</td>
<td>80LB</td>
</tr>
<tr>
<td>Van Ommen, Clara E.</td>
<td>939</td>
</tr>
<tr>
<td>Van Oosterhout, Joep J.</td>
<td>782</td>
</tr>
<tr>
<td>Van Rensburg, Craig</td>
<td>941</td>
</tr>
<tr>
<td>Van Rompay, Koen</td>
<td>373</td>
</tr>
<tr>
<td>Van Schaik, Nienke</td>
<td>958</td>
</tr>
<tr>
<td>Van Sighem, Ard</td>
<td>1041</td>
</tr>
<tr>
<td>Van Vuuren, Coete</td>
<td>261</td>
</tr>
<tr>
<td>Van Wingenburg, Bonnie</td>
<td>239</td>
</tr>
<tr>
<td>Van Zoet, Rosan</td>
<td>129, 352LB</td>
</tr>
<tr>
<td>Van Zy, Gert U.</td>
<td>28, 120, 795</td>
</tr>
<tr>
<td>VanBelenz, Jake</td>
<td>300</td>
</tr>
<tr>
<td>Vance, David</td>
<td>350</td>
</tr>
<tr>
<td>Vandekerkhove, Linos</td>
<td>162, 302</td>
</tr>
<tr>
<td>Vandenbulcke, Alexandra</td>
<td>116, 764, 792</td>
</tr>
<tr>
<td>Vandergeeten, Claire</td>
<td>291</td>
</tr>
<tr>
<td>Vandermeulen, Kati</td>
<td>44LB</td>
</tr>
<tr>
<td>Vandesompele, Jo</td>
<td>162</td>
</tr>
<tr>
<td>Vangala, Sitram</td>
<td>593</td>
</tr>
<tr>
<td>Vannappagar, Van</td>
<td>664</td>
</tr>
<tr>
<td>VanWidenfelt, Erik</td>
<td>885</td>
</tr>
<tr>
<td>Varangrat, Anchalee</td>
<td>854</td>
</tr>
<tr>
<td>Vardhanabhuti, Saran</td>
<td>492</td>
</tr>
<tr>
<td>Varetska, Olga</td>
<td>884</td>
</tr>
<tr>
<td>Vargas, Milenka</td>
<td>206</td>
</tr>
<tr>
<td>Varghese, Vici</td>
<td>506</td>
</tr>
<tr>
<td>Varkila, Meri</td>
<td>656</td>
</tr>
<tr>
<td>Vasan, Sandhya</td>
<td>70</td>
</tr>
<tr>
<td>Vascconcelos, Ricardo de Paula</td>
<td>948</td>
</tr>
<tr>
<td>Vashishta, Deshev</td>
<td>870</td>
</tr>
<tr>
<td>Vassallo, Matteo</td>
<td>72</td>
</tr>
<tr>
<td>Vasudevan, Canjeervaram K.</td>
<td>883</td>
</tr>
<tr>
<td>Vavrek, Marissa</td>
<td>435</td>
</tr>
<tr>
<td>Vavo, Cindy</td>
<td>806</td>
</tr>
<tr>
<td>Vaz, Paula</td>
<td>730, 766, 818</td>
</tr>
<tr>
<td>Veenhuis, Rebecca</td>
<td>253</td>
</tr>
<tr>
<td>Vehreschild, Joerg Janne</td>
<td>183, 580</td>
</tr>
<tr>
<td>Veldsmann, Kirsten Abigail</td>
<td>28</td>
</tr>
<tr>
<td>Vellozo, Jennifer</td>
<td>92, 920</td>
</tr>
<tr>
<td>Veloso, Valdidea</td>
<td>719, 948</td>
</tr>
<tr>
<td>Veloso Meireilles, Mariana</td>
<td>1040</td>
</tr>
<tr>
<td>Velthuisen, Emile</td>
<td>171LB</td>
</tr>
</tbody>
</table>
Venter, Willem Daniel. 113, 1020
Vera, Jesus 844
Vera-Rojas, Jaime 432
Verbeey, Jennifer 634
Verbistkays, Elena 868LB
Verbon, Annelies 587
Verdu, Javier 659
Vergas, Jorge 572
Vergori, Alessandra 354
Vermeire, Jolien 19
Vermund, Sten 816
Vernon, Ian 1048
Vesga, Juan Fernando. 1040, 1047
Vesterbacka, Jan 212
Vezain, Myriam 192
Viani, Rolando M. 413
Vilaplana, Cristina 306
Vilchez, Helem Haydee 535, 659
Vilchez, Helem Haydee 535, 659
Villar, Judit 676, 681
Villanueva, Armando G. 38
Viquerat, Victor 135
Vishwasrao, Harshad D. 308
Vissers, Colin 204
Vivin, Louis 242
Vlad, Dragos 204
Voigt, Robin M. 240, 241
Vojnov, Lara 26
Vollbrecht, Thomas 310
Volpe, Joseph M. 1054
Volpicelli, Lorenzo 575
von Groote-Bidlingmaier, Florian 79
Von Wichmann, Miguel A. 533
Vongrad, Valentina 263, 327
Vorvah, Ernest 821
Vorvah, Ernest 821
Wadie, Alisha 639
Wadiga, Roxanne 606
Wafula, Rose 761
Wagner, Gabriel A. 200, 201
Wagner, Ryan 639, 916, 991
Wagner, Theresa 419
Wagner, Thor 335
Wahome, Elizabeth 856, 1022
Wainberg, Mark 495
Wainberg, Mark A. 42, 489, 498
Waldrop-Valverde, Drenna 350
Walensky, Rochelle P. 456, 493, 814, 833, 1028, 1043
Walker, Bruce D. 250, 266
Walker, Rowan G. 687
Walker, Sarah 117, 641, 801, 808
Wallenta, Jeanna 638, 1005
Wallis, Carole 492
Walmsley, Sharon 447, 553, 756
Walsh, Fiona 475
Walston, Jeremy D. 133
Walter, Kizito 523
Wamalwa, Dalton 796
Wamitsch, Joyce 847
Wamutti, Beatrice 1032
Wandel, John 879
Wang, Bingjie 242
Wang, Chang-Yi 450LB
Wang, Cheng 634
Wang, Chi-Chao 594
Wang, Chunhui 1023
Wang, Guwei 23, 634, 646, 933
Wang, Dan 634
Wang, Dong 199
Wang, Hui 40
Wang, Huisheng 1009
Wang, James 569
Wang, Kaiji 755, 757, 758, 938
Wang, Jianhong 434
Wang, Jing 238
Wang, Jing 879
Wang, Li-Fan 833, 1033
Wang, Linbo 885
Wang, Lu 940
Wang, Ning-Chi 438
Wang, Roland 624, 701, 931
Wang, Wei 302
Wang, Weimin 588
Wang, Xinzhu 432
Wang, Xun 865
Wang, Yangping 328
Wang, Ying 923, 924
Wang, Yujin 433
Wang, Zheng 295
Wanjala, Stephen 116, 764, 792
Wansom, Tanyaporn 560
Waynonyi, Kennedy 970
Ward, Adam 122
Ward, Andrew B. 144
Ward, Douglas 41, 663, 864
Ward, John W. 98
Ware, Norma C. 1003
Warren, Rob 715LB
Warszawski, Jaroslaw 775, 821
Warre, Anthony 847
Washington, Ida 420
Wasmuth, Jan-Christian 580, 704
Watson, Richard M. 255, 692
Watson, Richard M. 255, 692
Waterman, Stephen 1055LB
Watkins, Melynda 39
Watling, Michael 490
Watlow, Michael 490
Wawer, Maria 1015, 34LB, 359, 880, 996
Weber, Kathleen M. 361
Weber, Rainer 128LB, 263
Webster, Kath 924, 940
Webster-Cyriaque, Jennifer 213
Wechsberg, Wendee 853
Weeks, Kevin M. 164
Weeraratne, Achini 687
<table>
<thead>
<tr>
<th>Author</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wegner, Matthew</td>
<td>70</td>
</tr>
<tr>
<td>Wehmeyer, Malte</td>
<td>576</td>
</tr>
<tr>
<td>Wei, Xuelan</td>
<td>40, 41</td>
</tr>
<tr>
<td>Weinberg, Adriana</td>
<td>774, 803</td>
</tr>
<tr>
<td>Weiner, Steven</td>
<td>438, 449LB</td>
</tr>
<tr>
<td>Weinrib, Rachel</td>
<td>936</td>
</tr>
<tr>
<td>Weiser, John</td>
<td>737</td>
</tr>
<tr>
<td>Weisser, Sheri</td>
<td>690, 913</td>
</tr>
<tr>
<td>Weiss, Helen</td>
<td>841LB</td>
</tr>
<tr>
<td>Weiss, Jeffrey</td>
<td>544</td>
</tr>
<tr>
<td>Weiss, Kevin</td>
<td>1034</td>
</tr>
<tr>
<td>Weiss, Stephen</td>
<td>770</td>
</tr>
<tr>
<td>Weisser, Maja</td>
<td>744</td>
</tr>
<tr>
<td>Weissman, Drew</td>
<td>1057LB</td>
</tr>
<tr>
<td>Weitzmann, M Neale</td>
<td>684</td>
</tr>
<tr>
<td>Weymert, Cyprian</td>
<td>902</td>
</tr>
<tr>
<td>Weke, Elly</td>
<td>762</td>
</tr>
<tr>
<td>Wells, David</td>
<td>298</td>
</tr>
<tr>
<td>Wells, Quinn S.</td>
<td>621</td>
</tr>
<tr>
<td>Welte, Alex</td>
<td>511, 876</td>
</tr>
<tr>
<td>Wensig, Annemarie</td>
<td>113, 306, 320, 504LB</td>
</tr>
<tr>
<td>Wentz, Eryka</td>
<td>690, 913</td>
</tr>
<tr>
<td>Werb, Dan</td>
<td>870</td>
</tr>
<tr>
<td>Were, Kennedy</td>
<td>488</td>
</tr>
<tr>
<td>Wertheim, Joel O.</td>
<td>182, 188, 1026</td>
</tr>
<tr>
<td>Wesevich, Austin</td>
<td>783</td>
</tr>
<tr>
<td>Wesołowski, Laura</td>
<td>509</td>
</tr>
<tr>
<td>Wesson, Jennifer</td>
<td>914</td>
</tr>
<tr>
<td>Westheimer, Emily</td>
<td>189, 477</td>
</tr>
<tr>
<td>Whitcomb, Jeanette</td>
<td>140</td>
</tr>
<tr>
<td>White, Douglas A. E.</td>
<td>956</td>
</tr>
<tr>
<td>White, Elizabeth</td>
<td>506</td>
</tr>
<tr>
<td>White, Kirsten</td>
<td>436, 467, 497</td>
</tr>
<tr>
<td>Whitney, G. Richard</td>
<td>1048</td>
</tr>
<tr>
<td>Whiteside, Y. Omar</td>
<td>188</td>
</tr>
<tr>
<td>Whitman, Timothy</td>
<td>932</td>
</tr>
<tr>
<td>Whitney, Bridget</td>
<td>853</td>
</tr>
<tr>
<td>Whitney, James</td>
<td>179, 338LB</td>
</tr>
<tr>
<td>Wicher Salinas, Tomas</td>
<td>204</td>
</tr>
<tr>
<td>Widhani, Alvina</td>
<td>705</td>
</tr>
<tr>
<td>Wiegand, Ann</td>
<td>120, 294</td>
</tr>
<tr>
<td>Wiener, Jeff</td>
<td>946</td>
</tr>
<tr>
<td>Wiesner, Lubbe</td>
<td>758, 808</td>
</tr>
<tr>
<td>Wiewel, Ellen</td>
<td>1013</td>
</tr>
<tr>
<td>Wijting, Ingeborg</td>
<td>451LB, 731</td>
</tr>
<tr>
<td>Wilcox, Christopher</td>
<td>634</td>
</tr>
<tr>
<td>Wild, Carl</td>
<td>507</td>
</tr>
<tr>
<td>Wilder, Julius M.</td>
<td>552</td>
</tr>
<tr>
<td>Wiley, Dorothy Joann</td>
<td>591, 592, 593</td>
</tr>
<tr>
<td>Wilkin, Timothy</td>
<td>981</td>
</tr>
<tr>
<td>Wilkinson, Eduan</td>
<td>504LB</td>
</tr>
<tr>
<td>Wilkinson, Robert</td>
<td>739, 819LB</td>
</tr>
<tr>
<td>Wilks, Moses Q.</td>
<td>635LB</td>
</tr>
<tr>
<td>Willen, Jesse</td>
<td>220</td>
</tr>
<tr>
<td>William, Jillian</td>
<td>549</td>
</tr>
<tr>
<td>Williams, Corey</td>
<td>224</td>
</tr>
<tr>
<td>Williams, Deborah</td>
<td>650</td>
</tr>
<tr>
<td>Williams, Emily C.</td>
<td>921</td>
</tr>
<tr>
<td>Williams, Gary J.</td>
<td>903</td>
</tr>
<tr>
<td>Williams, James A.</td>
<td>242</td>
</tr>
<tr>
<td>Williams, Katherine L.</td>
<td>242</td>
</tr>
<tr>
<td>Williams, Kenneth C.</td>
<td>635LB, 69</td>
</tr>
<tr>
<td>Williams, Paige L.</td>
<td>779, 784, 827, 828</td>
</tr>
<tr>
<td>Williams, Peter E.</td>
<td>442</td>
</tr>
<tr>
<td>Wilson, Cara</td>
<td>211, 231</td>
</tr>
<tr>
<td>Wilson, Caroline</td>
<td>660</td>
</tr>
<tr>
<td>Wilson, David</td>
<td>1046</td>
</tr>
<tr>
<td>Wilson, David</td>
<td>1046</td>
</tr>
<tr>
<td>Wilson, Eleanor</td>
<td>733</td>
</tr>
<tr>
<td>Wilson, Kate</td>
<td>937</td>
</tr>
<tr>
<td>Wilson, Tracey</td>
<td>646, 690, 913, 933</td>
</tr>
</tbody>
</table>

**Author Index**

**Program and Agenda**

**CROI 2017**
Author Index
Program and Agenda
CROI 2017

Xue, Guangai 18

Y—
Yagamato, Hiroiki 426
Yamamoto, Masahiro 643
Yamamoto, Takuya 165
Yamashita, Masahiro 160LB
Yamazaki, Kunio 426
Yan, Peng 574
Yang, Hongbing 271
Yang, Huanle 133
Yang, Xiaohe 353
Yang, Z, npanah, Yazdan 116, 458, 1028
Ye, Monica 599, 601
Ye, Kelly 412, 430
Yee, Lynn M. 469
Yen, Yung-Feng 348
Yende, Nonhlanhla 949
Yi, Jungen 558
Yi, Sue 21
Yiannoutsos, Constantin 837
Yilmaz, Aylin 340, 389
Yin, Michael T. 132, 213, 346, 546, 682, 683, 819, 930
Ying, Roger 1032
Yokomaku, Yoshiyuki 496
Yonaba, Caroline 811
Yong, Gerald 151
Yoshimura, Kazuhsia 247
Yoshino, Munehiro 426
You, Chunli 780
You, Helen 329, 434, 436
You, Huyin Jae 18
You, Kimberly 544
You, Xi G. 250, 292
Yuan, Chun-Su 669
Yuan, Zhe 199
Yudin, Mark 756, 940
Yue, Fengyun 233
Yuen, Kwok-Yung 747
Yoenling, Katharine 706
Yuhas, Krista 937
Yuki, Steven A. 312

Z—
Zaccarelli, Mauro 354, 460
Zack, Jerome 332
Zadilka, Amanda 803
Zahralban-Sheeley, Melissa 184, 484
Zakhrova, Oksana 465, 483
Zang, Trinity 160LB, 220
Zang, Xiao 875
Zangari, Paola 798
Zanger, Robert 631
Zanni, Markella V. 627, 635LB
Zanoni, Brian C. 838
Zash, Rebecca 25
Zenan, Cosmina 682
Zedler, Ulrike 716LB
Zeh, Clement 488
Zellman, Hannah 911

Zerbato, Jennifer M. 298, 316
Zerbe, Allison 24, 769, 771, 992
Zetola, Nicola M. 729
Zetterberg, Henrik 72, 73, 340, 383, 389
Zevin, Alexander Simon. 216, 231
Zevo, Leonel 730
Zeymo, Alexander 517
Zhang, Chengylen 682
Zhang, Heather 40, 424, 425
Zhang, Hongliang 233
Zhang, Jennifer R. 38
Zhang, Lily 415
Zhang, Long 356, 645
Zhang, Meiwen 927
Zhang, Peng 14LB
Zhang, Tianchi 187
Zhang, Wendy 929
Zhang, Xiaodong 1056LB
Zhang, Xin Yu 274
Zhang, Xinyi C. 1002
Zhang, Yue 329
Zhang, Yinfei 955
Zhang, Yuwei 204
Zhang, Zhenguan 1052
Zhang, Zhiping 428
Zhao, Mitchell 367
Zhen, Anjie 254, 331, 332, 333
Zheng, Amy 456
Zheng, Jia-Hua 405
Zheng, Jianhua 269
Zheng, Jiayin 552
Zheng, Jim 38
Zheng, Lu 330LB, 457
Zheng, Wenjing 36, 836
Zheng, Yanan 337
Zhong, Yaoyu 1013
Zhou, Qinian 1049LB
Zhou, Shuntai 198, 369
Zhou, Tian 439
Zhou, Zhi 874
Zhu, Jun-Jia 462
Zhu, Yuan-Shan 471
Zidar, David A. 628, 674
Zielinski-Gutierrez, Emily 847
Zimmerman, Scott J. 198
Zingman, Barry S. 682, 903
Zins, Marie 654
Zinnykatira, Nesbret 727
Zlotorzynska, Maria 869, 901
Zohoun-Guidibgui, Luteica 487
Zola, Courtney 621
Zona, Stefano 655
Zoppa, Olga 452LB
Zubk, Wendy 447
Zuccotti, GianVincenzo 804
Zucker, Jason 546
Zunt, Joseph 347
Zuppa, Athena 384, 975
Zurszewske, Gerard 262
Zwozski, Sandy 262
Zürcher, Kathrin 714
Zurnic, Irena 155
Zvartaud, Edwina 868LB
Zwahlen, Marcel 721
Östergaard, Lars 305, 314

Program and Agenda
Author Index
### Conference Schedule Overview

<table>
<thead>
<tr>
<th>Time</th>
<th>Monday, February 13, 2017</th>
<th>Tuesday, February 14, 2017</th>
<th>Wednesday, February 15, 2017</th>
<th>Thursday, February 16, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 AM</td>
<td>Plenary Session Auditorium 4 AB</td>
<td>Plenary Session Auditorium 4 AB</td>
<td>Plenary Session Auditorium 4 AB</td>
<td>Plenary Session Auditorium 4 AB</td>
</tr>
<tr>
<td></td>
<td>8:30 AM THE EMERGING POTENTIAL FOR HIV CURE FOR INFANTS</td>
<td>8:30 AM (PREVENTING) THE COMING EPIDEMIC; HIV IN YOUTH</td>
<td>8:30 AM IF YOU CAN MAKE IT THERE: ENDING THE HIV EPIDEMIC IN NEW YORK</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CHILDREN, AND ADULTS</td>
<td>9:00 AM ANTIMVIRAL VACCINE DEVELOPMENT FROM A (ADBS) TO Z (ZIKA)</td>
<td>9:00 AM HTLV-1: THE OTHER HUMAN RETROVIRUS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>9:00 AM ADVANCES IN CELLULAR THERAPY IN CANCER AND HIV</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 AM</td>
<td>PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 6 AB</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td>CONCURRENT ORAL ABSTRACT SESSIONS:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0-1 GETTING HIV THROUGH THE CELL Room 611-614</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0-2 CRITICAL ISSUES IN WOMEN'S HEALTH, MTCT, AND HIV TREATMENT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IN CHILDREN Room 606-609</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0-3 HIDING IN PLAIN SIGHT: DISCOVERING THE UNDIAGNOSED AND</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>UNDERDIAGNOSED HIV EPIDEMIC Room 6 E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0-4 NEW HIV DRUGS, FORMULATIONS, COMBINATIONS, AND RESISTANCE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 6 AB</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td>LUNCH AND MARTIN DELANEY PRESENTATION FROM LAB TO LICENSURE</td>
<td>LUNCH</td>
<td>LUNCH</td>
<td>LUNCH</td>
</tr>
<tr>
<td></td>
<td>THE IMPORTANCE OF GOOD PARTICIPATORY PRACTICE IN RESEARCH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 6 AB</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 PM</td>
<td>CONCURRENT THEMED DISCUSSIONS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TD-1 CD8 T CELLS: WHERE AND HOW THEY KILL Room 615-617</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TD-2 VIRUS AND CELL RNA IN HIV REPLICATION Room 611-614</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TD-3 HIV, MIGRATION, AND ACCESS TO CARE Room 606-609</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TD-4 OBESITY AND FATTY LIVER DISEASE Room 6 C</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TD-5 PREP WITHOUT BORDERS: NEW DELIVERY OPTIONS Room 6 E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>CONCURRENT WORKSHOPS 2:15 PM TO 4:00 PM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CLINICAL TRIAL DESIGN AND ANALYSIS Room 6 C</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FRONTIERS IN LABORATORY SCIENCE Room 611-614</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:30 PM</td>
<td>POSTER SESSIONS 2:30 PM TO 4:00 PM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>POSTER HALL 4 EF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td>CONCURRENT SYMPOSIA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S-1 VISIONS OF HIV CURE Room 6 E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S-2 MULTIDRUG-RESISTANT TB (MDR-TB); THE GOOD THE BAD, AND THE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>UGLY Room 606-609</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S-3 STRANGERS IN THE NIGHT: CHALLENGES AND OPPORTUNITIES IN STI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CONTROL Room 6 C</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00 PM</td>
<td>OPENING SESSION Auditorium - 4 AB</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bernard Fields Lecture</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N’Galy-Mann Lecture</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CROI Foundation Special Event</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td>Welcome Reception</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>